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Chapter 1
General introducti on and outline of the thesis

Coronary heart disease has been the leading 
cause of death in developed countries for many 
years.1 At the same ti me, the developments in 
the fi eld of interventi onal cardiology occurred at 
an incredible speed and it took no more than 15 
years for the fi rst balloon-mounted stent by Pal-
maz et al. in 1985 to evolve into a modern fi rst 
generati on drug-eluti ng stent (DES). As early as 
1999, stenti ng comprised 84.2% of percutaneous 
coronary interventi ons (PCI).2 In the same year, 
several preclinical studies reported that sirolimus 
(rapamycin), a macrocyclic lactone that inhibits 
cytokine-mediated and growth-factor–mediated 
proliferati on of lymphocytes and smooth-muscle 
cells, reduced neointi mal proliferati on (i.e. renar-
rowing of the vascular lumen at the site of stent 
implantati on, leading to recurrence of angina 
- the largest limitati on of stenti ng thus far).3-5 In 
2002, the fi rst DES, coated with sirolimus, were 
introduced into clinical practi ce in order to re-
duce restenosis which occurred in 15% to 25% 
of pati ents receiving bare-metal stents.6, 7 Subse-
quent trials with diff erent types of DES confi rmed 
their effi  cacy in this regard.8 In 2002, the pivotal 
RAVEL trial reported that none of the pati ents 
in the sirolimus-stent group, as compared with 
26.6% of those in the standard-stent group, had 
restenosis of 50 percent or more of the luminal 
diameter (P<0.001).6
The success of DES can be refl ected by the fact 
that the enti re interventi onal cardiology com-
munity quickly embraced the DES as the ulti mate 
manner to prevent restenosis following PCI. The 
use of the fi rst generati on DES even increased up 
to 100% in some centers in Europe and the US as 
soon as 2003, no more than one year aft er their 
commercial introducti on in 2002 and despite the 
lack of long-term data on safety and effi  cacy.
To assess the performance of DES in a “real 
world” seƫ  ng, far beyond the scope of the piv-
otal randomized trials, the Thoraxcenter decided 
to implant these devices in all pati ents suitable 
for stent implantati on, irrespecti ve of clinical or 
angiographic fi ndings. From the moment of the 
commercial introducti on of the sirolimus-eluti ng 
(Cypher®, Cordis Corporati on, a Johnson and 
Johnson company, Waterloo, Belgium) stent on 
April 16, 2002, the Thoraxcenter adopted a policy 
of an unrestricted sirolimus-eluti ng stent use un-
ti l February 23, 2003, when the paclitaxel-eluti ng 
stent (TAXUS™ Express2™ or Liberté™, Boston 
Scienti fi c, Nati ck, MA) replaced the Cypher as 
the device of fi rst choice. All pati ents treated in 
this period were included in the RESEARCH and 
T-SEARCH registries respecti vely.9, 10
Despite the initi al booming success, several cave-
ats regarding the use of DES emerged. Late stent 
thrombosis, acute closure of the in-stent vascular 
lumen due to thromboti c material, was reported 
as early as 2004, typically in pati ents disconti nu-
ing dual anti platelet therapy.11 At the European 
and World Congress of Cardiology in Barcelona 
2006, a threesome of proceedings hypothesized 
that the use of DES was even associated with in-
creased rates of death and myocardial infarcti on 
as compared to bare metal stents.12-15 
The aims of the current thesis are multi ple. The 
primary goal was to study the long-term safety 
and effi  cacy of DES in real world clinical practi ce 
with specifi c aƩ enti on for high-risk pati ent and 
lesion subsets, caveats and cost-eff ecti veness. 
Part I, including chapters 1 and 2, is a preface to 
the current developments and problems in the 
DES fi eld. Part II reports on the long-term follow-
up of the RESEARCH and T-SEARCH registries. 
While Chapter 4 reports the 2-year follow-up of 
the T-SEARCH registry, the 3 and 4 follow-up of 
the RESEARCH registry are described in Chap-
ters 5 and 6 respecti vely. In Part III and IV of this 
thesis, the long-term relati ve benefi ts and limita-
ti ons of DES in specifi c pati ent and lesion subsets 
not previously described, are assessed. Chapter 
7 reports on the outcome of DES in pati ents on 
dialysis, Chapter 8 specifi cally focuses on pati ents 
presenti ng with acute myocardial infarcti on, and 
Chapter 9 and 10 deal with diabeti cs. In Part 
IV, focussing on specifi c lesion subsets, Chapter 
11 reports on the usability of sirolimus-eluti ng 
stents for comprehensive bifurcati on stenti ng. 
Additi onally, chapter 12, 13, 14 and 15 focus on 
the long-term performance of both sirolimus 
and paclitaxel-eluti ng stents in very small ves-
sels (2.25mm), chronic total occlusions, aorto 
osti al lesions, and coronary artery bypass graft s 
respecti vely.  
Following the specifi c aƩ enti on to several sub-
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group analysis, Part VI reports on the fi rst caveat 
of drug-eluti ng stents, namely stent thrombosis. 
Part IV opens with Chapter 16, which puts the 
problem into perspecti ve. Chapter 17 consists 
of the landmark paper of a collaborati ve study 
of the Thoraxcenter together with the University 
Medical Center in Bern Switserland on the long-
term incidence of stent thrombosis in real world 
clinical practi ce and is followed by Chapter 18 ex-
tending the follow-up from 3 to 4 years. Finally, 
Chapter 19 goes into further detail on the impor-
tance of thrombus burden in pati ents presenti ng 
with ST-segment elevati on myocardial infarcti on. 
Aft er having assessed the occurrence of stent 
thrombosis following DES implantati on, Part VII 
reports on the long-term safety as expressed by 
hard clinical endpoints. Chapters 20 and 21 in-
clude pati ent-level based data meta-analyses of 
the pivotal randomized controlled Cypher and 
TAXUS trials respecti vely with 4-years of follow-
up. In Chapter 22 an epidemiological analysis was 
performed with specifi c aƩ enti on to long-term 
safety in an extended RESEARCH and T-SEARCH 
populati on, including 6.219 consecuti ve all-
comers treated with bare-metal, sirolimus-elut-
ing, and paclitaxel-eluti ng stents in a sequenti al 
fashion. Closing Part VII, Chapter 23 contains the 
offi  cial ESC forum report of a meeti ng on Drug-
Eluti ng Stents held on September 27-28 2007, in 
Nice, France. 
In the spirit of the conti nuing struggle of PCI to 
compete with the golden standard for treatment 
of multi vessel coronary artery disease, coronary 
artery bypass graft  surgery (CABG), Part VIII en-
closes several chapters on the relati ve outcome of 
PCI with DES for multi vessel disease as compared 
to CABG. Chapter 24 opens Part VIII by providing 
a state-of-the-art overview of the pros and cons 
of both treatment modaliti es up to 2006. Chap-
ter 25 contains a meta-analysis of the fi ve-year 
follow-up to the pivotal randomized PCI-CABG 
trials with 5-years of follow-up. Following this 
pooled analysis, including exclusively PCI pati ents 
treated with bare-metal stents, Chapters 26-29 
focus on the outcomes of pati ents treated with 
sirolimus-eluti ng stents for multi vessel disease as 
part of the Arterial Revascularizati on Therapies 
Study (ARTS), Part II. The overall 3-year follow-up 
is covered by Chapter 26, whereas Chapter 27, 28 
and 29 reports on the impact of body mass in-
dex, diabetes and quality of life on the long-term 
outcomes. 
A specifi c topic that gathered aƩ enti on in the 
last years was the cost-eff ecti ves of DES. Chapter 
30, embedded in Part IX of this thesis, includes 
a cost-eff ecti veness analysis based on the 2-year 
results on the RESEARCH registry. 
Finally, going beyond the scope of the conven-
ti onal riskfactors, increasing aƩ enti on has gone 
to the impact of psychological factors on the 
performance of pati ents treated with PCI. Part 
X includes 3 chapters reporti ng on the infl uence 
of Type-D-personality, fati gue, depression, hope-
lessness and anhedonia on the long-term out-
come of pati ents treated with DES as part of the 
RESEARCH and T-SEARCH registries in Chapters 
31 to 33 respecti vely. 
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Drug-Eluting Stent Update 2007
Part I: A Survey of Current and Future Generation Drug-Eluting Stents:
Meaningful Advances or More of the Same?
Joost Daemen, MD; Patrick W. Serruys, MD, PhD
Analyst projections for the drug-eluting stent (DES)market estimated that the total number of DES im-
planted in 2010 would go beyond 4.5 million worldwide.
Although the initial results seemed promising, longer-term
follow-up in a broader range of patients revealed some
pitfalls. Delayed neointimal growth, enhanced platelet aggre-
gation, a local hypersensitivity reaction against the polymer
coating, stent fracture, and a failure of sirolimus-, paclitaxel-,
and tacrolimus-eluting stents to reduce neointimal hyperpla-
sia at 90 and 180 days in animals, when the drug was
completely eluted from the stent, are just several examples.1–8
The number of stents currently under investigation is
substantial. They are all loaded with drugs that interfere with
pathways in the process of inflammation and neointimal
proliferation. However, the process of restenosis is a se-
quence of complex events that has been only partly elucidated
over the last 2 decades.9 Locally acting DES provide the
opportunity to interfere with the various mechanisms respon-
sible for each step in the restenotic cascade, and a wide
variety of different agents are currently available. Although
only sirolimus-eluting stents (SES) and paclitaxel-eluting
stents (PES) have received US Food and Drug Administration
(FDA) approval to date, multiple alternative devices are
attempting to find their way to achieve the same goal, namely
a reduction of restenosis and the need for repeat interventions.
Established and Investigational Drugs
Six Limus family–related drugs are currently being studied in
DES, namely sirolimus, everolimus, biolimus A9, zotaroli-
mus, tacrolimus, and pimecrolimus. Sirolimus, everolimus,
biolimus A9, and zotarolimus all bind to the FKBP12 binding
protein, which subsequently binds to the mammalian target of
rapamycin (mTOR) and thereby blocks the cell cycle mainly
of the smooth muscle cell from the G1 to S phase. The
mechanisms of action of tacrolimus and pimecrolimus are
different. Both drugs bind to FKBP506. The tacrolimus/
pimecrolimus FKBP506 complex subsequently inhibits the
calcineurin receptor, which leads to decreased cytokine ex-
pression on the cell surface membrane and results in an
inhibition of T-cell activation and lower smooth muscle cell
selectivity (Figures 1 and 2).
A non-Limus family–related drug widely studied for its
efficacy in coronary stents is paclitaxel. Its effect has been
mainly explained by its ability to stabilize microtubules and
thereby inhibit cell division in the G0/G1 and G2/M phases.
Sirolimus
The first of the Limus family drugs used on endovascular
prosthesis was sirolimus, a natural macrocyclic lactone that is
able to inhibit mTOR.10,11 Sirolimus proved to possess potent
antiproliferative and immunosuppressive effects. Several suc-
cessive studies proved the efficacy of the SES (Cypher,
Cordis Corp, Warren, NJ), a polymer-coated bare metal Bx
Velocity (Cordis Corp) balloon expandable stent, in popula-
tions that ranged from highly selected patients with single
lesions to unselected all-comers.12–18 The Cypher stent was
the first DES to receive both Conformité Européenne (CE)-
mark and FDA approval in April 2002 and 2003, respectively
(Figure 3). Because of the polymer, 75% of the drug is slowly
released over the first 10 days. Nevertheless, the antireste-
notic properties of the SES proved to persist much longer.19
Because there was no significant change in neointimal thick-
ening between 2 and 4 years in the First in Man (FIM) trial
and given the continued clinical superiority of SES after 4
years in a pooled analysis of the 4 pivotal randomized Cypher
trials (RAndomized study with the sirolimus-eluting VElocity
balloon-expandable stent in the treatment of patients with de
novo native coronary artery Lesions [RAVEL], SIRolImUS-
coated Bx Velocity balloon-expandable stent in the treatment
of patients with de novo coronary artery lesions [SIRIUS],
Canadian [C]-SIRIUS and European [E]-SIRIUS), it seems
reasonable to rule out a late catch-up in restenosis; at least so
far, because both the clinical and angiographic end points
continue to slowly accrue over time.14,20
Everolimus
A second derivative of the Limus family is everolimus, a
sirolimus analog with a single minimal alteration in its
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molecular structure (position 40), without a chemical modi-
fication of the mTOR binding domain21 (Figures 1 and 2). Of
interest is that, when implanted in rabbit iliac arteries, a more
rapid endothelialization was observed in the everolimus-
eluting stent as compared with sirolimus-, zotarolimus-, or
paclitaxel-eluting stents, demonstrated by a complete endo-
thelialization of the struts with exhibition of cd31 (antigen
surface marker of good endothelial functionality) in the cells
at 14 days (R. Virmani, MD, unpublished data, 2006).
The Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of Patients
with de novo Native Coronary Artery Lesions First (SPIRIT)
trial proved the superiority of everolimus embedded in a
durable polymer on a cobalt chromium stent as compared
with bare metal stents (BMS).22,23 In the recently completed
SPIRIT-II trial, the everolimus-eluting XIENCE V stent
(Advanced Cardiovascular Systems, an Abbott Vascular
Company, Santa Clara, Calif) proved to be superior to the
PES for reduction of both late loss and binary restenosis.24
Subsequently, the SPIRIT-III trial has randomized 1002
patients in the US to treatment with either an everolimus
XIENCE V stent or a PES. As part of the SPIRIT-III study,
additional patients will also be enrolled in 4 registry arms in
Japan, 1 each for stents that are 38 mm, 2.25 mm, and 4.0 mm
long. Additionally, the SPIRIT-IV and SPIRIT-V studies will
provide further clinical data.
Zotarolimus
A third descendant of the Limus family, also with a change on
position 40, that is used on coronary stents is zotarolimus
(ABT-578, Abbott Pharmaceuticals, Abbott Park, Ill), which
likewise contains antiproliferative and antiinflammatory ef-
fects, but zotarolimus is suggested to have higher tissue
retention compared with the SES (Figures 1, 2). Of note,
recent data on endothelial function after stent placement in
porcine coronaries showed a normally functioning endothe-
lium 1 and 3 months after zotarolimus-eluting stent implan-
tation, whereas a dysfunctional endothelium was observed
after both Cypher and Taxus implantation.25
In the ENDEAVOR I and II trials, the phosphorylcholine
polymer-based cobalt-alloy Driver coronary stent (Medtronic
Vascular, Santa Rosa, Calif), loaded with zotarolimus, proved
to be superior to BMS in both angiographic and clinical end
points.26,27 Recently presented 2- and 3-year follow-up data
of the ENDEAVOR I and II trials proved sustained superi-
ority in the reduction of target lesion revascularization (TLR)
with remarkably low rates of total stent thrombosis (0.3%)
and no cases of stent thrombosis after 30 days. The
ENDEAVOR III trial was a prospective randomized compar-
ison of the Endeavor zotarolimus-eluting stent and the SES
(n436). At 8 months, the Endeavor stent failed to meet its
noninferiority end point in terms of late lumen loss. Of note,
the rates of death, myocardial infarction, and target vessel
Figure 1. Mechanisms of action of sirolimus, everolimus, Biolimus A9, zotarolimus, tacrolimus, and pimecrolimus. PDGF indicates
platelet-derived growth factor; FGF, fibroblast growth factor; FKBP, FK binding protein; G, growth; M, mitosis; S, synthesis; and NFAT,
nuclear factor of activated T cells.
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revascularization were equal in both groups.28 A possible
explanation for the lack of noninferiority of the Endeavor
stent might be the rate of elution. The Cypher stent elutes
75% of its drug within the first 10 days; in the Endeavor stent
this took only 2 days.
Another zotarolimus-eluting device is the Zomaxx Tri-
Maxx stent (Abbott Pharmaceuticals, Abbott Park, Ill.),
which has a trilayer pharmacoat that consists of a phospho-
rylcholine basecoat and topcoat wrapped around a zotaroli-
mus layer with elution rates comparable to the Cypher stent.
The platform used was a stainless steel/tantalum/stainless
steel triplex stent. Although the 4-month results of the
Zomaxx-IVUS trial (n40), which showed a late loss of
0.20 mm, were promising, its manufacturer Abbott recently
announced it would discontinue the Zomaxx program after
the disappointing results of the Zomaxx-I trial. At 9 months,
the Zomaxx stent was associated with a significantly higher
late loss and binary restenosis rate compared with the Taxus
stent.29
Biolimus
Biolimus A9 is a highly lipophilic sirolimus analog that
inhibits T cell and smooth muscle cell proliferation (Figures
1 and 2). The Stent Eluting A9 Biolimus Trial in Humans
(STEALTH) trial was the FIM study to assess the safety and
efficacy of the poly-lactic acid bioabsorbable-polymer-coated
Biolimus A9–eluting BioMatrix stent (Biosensors Interna-
tional, Singapore). A stainless steel S-stent was the basis for
a biodegradable polymer coating that released its drug grad-
ually over 6 to 9 months. The STEALTH-I trial randomized
120 (1:2) patients to treatment with a control bare metal
S-stent or a Biolimus A9–eluting stent. Although the 12-
month clinical event rates were similar between both groups,
treatment with the Biolimus A9 stent was associated with a
57% lower rate of binary restenosis and 65% lower rate of
late lumen loss compared with the BMS group at 6 months.30
The recently presented 9-month results of the Nobori-I trial,
which randomized (2:1) patients to either a PES (n35) or
the Biolimus-eluting stent (n85), showed significantly less
late lumen loss in the Biolimus arm as compared with the
Taxus arm.31
Pimecrolimus
Although a part of the Limus family, pimecrolimus does not
block mTOR and inhibits to a much lesser degree the
endothelial cell proliferation (Figures 1 and 2).32 The active
pharmaceutical ingredient of pimecrolimus is Elidel, an
FDA-approved drug developed by Novartis Pharmaceuticals
Corp, East Hanover, NJ) for the treatment of atopic derma-
titis. The FIM study to evaluate the safety and efficacy of a
pimecrolimus-eluting stent is currently ongoing.33
Figure 2. Molecular structure of sirolimus, everolimus, biolimus, zotarolimus, tacrolimus, and pimecrolimus.
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Tacrolimus
Tacrolimus (FK506) is a water-insoluble macrolide immuno-
suppressant produced by streptomyces tsukubaensis (Figures
1 and 2). Tacrolimus is also known as Prograf, a drug widely
used to prevent allograft rejection after organ transplantation.
Tacrolimus is a noncytotoxic T cell inhibitor, which holds
cells in the G0 or resting phase. In this situation, cells are able
to function but unable to replicate. The end result of tacroli-
mus is a reduction in activation of cytokine genes. In contrast
to sirolimus, tacrolimus demonstrates far more potent inhibi-
tion of smooth muscle cells rather than endothelial cells.4,34
The multicenter European Direct Stenting of De Novo
Coronary Artery Stenosis With Tacrolimus-Eluting Versus
Carbon-Coated Carbostents (JUPITER)–II trial (n332) was
conducted to compare the safety and effectiveness of direct
stenting with a Janus tacrolimus-eluting stent (Sorin Bio-
medica Cardio, Saluggia, Italy) versus the mechanical plat-
form with no drug-eluting capability from which the Janus
stent (Tecnic CCS coronary carbostents) was derived. In the
Janus tacrolimus-eluting stent, the drug is embedded in
reservoirs carved on the outer stent surface to release the drug
only toward the vessel wall and possesses an integral throm-
boresistant carbofilm coating on the whole stent surface.
Remarkable was that at 1 year no cases of stent thrombosis
were reported in the polymer-free tacrolimus-eluting stent
arm. However, the 6-month in-stent late lumen loss of
0.65 mm for the Janus was equal to the Tecnic carbostent;
therefore the study failed to meet its primary end point.35 The
currently ongoing 3-arm Inova trial is evaluating the efficacy
of a Janus Carbofilm–coated SRT stent platform with differ-
ent formulations of tacrolimus: (1) pure tacrolimus (3.3
g/mm2); (2) tacrolimus with 20% ascorbyl palmitate
(2.3 g/mm2); (3) tacrolimus with 20% PVP Kollidon 17 (2.3
g/mm2). Along these lines, the Japanese company Kaneka is
evaluating the efficacy of a tacrolimus when applied on a
cobalt chromium platform with a poly-DL-lactide-co-
glycolide biodegradable polymer.
Paclitaxel
Although not a member of the Limus family, the PES (Taxus,
Boston Scientific, Natick, Mass) was the second DES to
receive FDA approval, 1 year after the SES. Paclitaxel was
first found by The National Cancer Institute in a search for
naturally occurring agents with strong antiproliferative qual-
ities. Paclitaxel stabilizes microtubules and thereby inhibits
cell division in the G0/G1 and G2/M phases (Figure 1). The
randomized TAXUS-I trial (2003) was designed as a FIM
phase I feasibility study and proved that a polymer-coated
PES was superior to BMS at 6 and 12 months of follow-up.36
Thereafter, the TAXUS family trials expanded with the II, IV,
V, and VI trials and confirmed the superiority of PES as
compared with BMS in more complex patients and le-
sions.36–39 Recently, the TAXUS-V-ISR (in-stent restenosis)
trial compared the efficacy of a slow-release polymer-based
PES with brachytherapy for in-stent restenotic lesions. At 9
months, the use of PES was associated with lower rates of
clinical and angiographic restenosis and an improved event-
free survival.40 The TAXUS clinical trial program, which
assessed the TAXUS Express stent system from single to
complex lesions, was followed by the TAXUS ATLAS and
Olympia programs, which transferred the established polymer
drug combination to a new stent platform, the Liberté
stent.41,42
Another new device coated with paclitaxel is the Asian
Infinnium (Sahajanand Medical Technologies, Gujarat, India)
stent. The stent has a biodegradable hemocompatible polymer
Figure 3. CE or FDA approval of current and investigational devices.
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coating and lower strut thickness (0.084 mm compared with
0.14 mm for Cypher) designed to reduce vessel trauma. The
coating consists of slow, medium, and fast release polymer
layers. The multicenter open-label registry Safety and Effi-
cacy of Infinnium: A Paclitaxel-Eluting Stent (SIMPLE-I)
trial (n282) was the first to test the efficacy of this new
device. The SIMPLE-I trial was followed by the multicenter,
single-arm, prospective SIMPLE-II trial (n103) to further
investigate the safety and the efficacy of the Infinnium
stent.43 With little late loss at 6 months (0.38 mm) and a
binary restenosis rate of 7.3%, the device was the first
indigenously designed and evaluated “low-cost” DES from
Asia to receive CE mark approval.
New Coatings
After disappointing results with the use of carbon-, platinum-,
and gold-coated stents, the polymer was hypothesized to be
an appealing alternative carrier to reduce restenosis and
thrombosis and to guarantee controlled drug-release kinet-
ics.44 Soon, the first-generation polymer-coated SES and PES
proved to be more effective than their non–polymer-coated
counterparts.45–48 Nevertheless, a major limitation is that
many polymer coatings are not entirely inert, and hypersen-
sitivity reactions against the polymer have been frequently
reported.1,3,49 In line with this data, long-term adverse effects
such as increased inflammation of the vessel wall, a throm-
bogenic response, and induced apoptosis of smooth muscle
cells have been described.50,51
To reduce the inflammatory reaction, which is partially
caused by the polymer, Medtronic recently developed a novel
co-polymer, the “Endeavor Resolute”, for extended release of
zotarolimus in a next-generation DES. The new BioLinx
polymer system contains a C10 polymer, which is lipophilic/
hydrophobic and stimulates a controlled drug release, a C19
polymer, which is primarily hydrophilic and thus more
biocompatible and helpful in drug elution, and finally poly-
vinyl pyrrolidone, which is hydrophilic, increases the initial
drug burst, and enhances the elution rate. Porcine coronary
implants (n25) showed no difference in inflammatory
response after implantation of the Endeavor Resolute or a
control BMS and a 100% re-endothelialization. Four-month
follow-up in the first 30 patients revealed an in-stent late loss
of 0.12 mm, and no target vessel revascularization or stent
thrombosis were observed.52
In a search for more biocompatible coatings, hydroxyapa-
tite was found to be a valuable alternative as a polymer
surrogate. Hydroxyapatite is a well-known and excellent
bioceramic that closely resembles biological apatite (bone); it
is biocompatible, bioactive, and bioresorbable, and it forms
the basis of a polymer that is only 200 nm thick.53 Further-
more, its porous structure makes it an ideal drug carrier.
Likewise, a new spongious nanocarbon coating constructed
of porous, glassy, pyrolytic carbon, which guarantees extraor-
dinary elasticity, was recently developed. Lastly, the Intra-
coronary Stenting and Angiographic Restenosis–Test Equiv-
alence Between 2 Drug-Eluting Stents (ISAR-TEST) study
recently showed that a polymer-free, microporous, sirolimus-
coated Yukon stent (Translumina, The Drug-Eluting System
Company, Hechinger, Germany) was not inferior to a
polymer-based PES in the reduction of restenosis.54
Another alternative for the polymer is a heparin coating.
Heparin-coated stents proved to be superior to both balloon
angioplasty and BMS. In 1996, the Belgium Netherlands
Stent II (BENESTENT II) randomized trial proved the
superiority of heparin-coated stents as compared with balloon
angioplasty. A more recent registry even proved a significant
reduction in stent thrombosis in the heparin-coated stent as
compared with a standard BMS.55 Sahajanand Medical Tech-
nologies Pvt. Ltd. (Saiyedpura, Surat, India), recently de-
signed a dual-layer heparin-SES, which combines the anti-
proliferative action of sirolimus with the excellent
biocompatibility and hemocompatibility of the heparin coat-
ing. Both drugs elute almost simultaneously, whereas heparin
will give effect for almost 50 days and sirolimus for 60 days.
A completely new concept is heparin-coupled with poly-
L-lactic acid to create a so-called absorbable “heparinized”
polymer, which in turn can serve as a drug reservoir.
Indeed, the most commonly studied biodegradable poly-
mers are derived from lactic and glycolic acid. Biodegrada-
tion is achieved by hydrolytically unstable linkages (esters) in
the backbone of the polymer, which results in surface erosion.
The rate of erosion or biodegradation can be altered by the
molecular weight of the polymer and the number of unstable
linkages. Furthermore, the drug-release profile can be ad-
justed by alteration of the biodegradation profile of the
polymer.
New Platforms
Several limitations and side effects have been associated with
coronary stenting. First, stents cause permanent physical
irritation with the risk of long-term endothelial dysfunction or
inflammation.9 Second, stents possess a high thrombogenic-
ity.56 Third, stents create an inability for the vessel to remodel
and act in a normal physiological way.4 Finally, stents create
difficulties for possible future bypass surgery and noninva-
sive imaging. The first bioabsorbable stents were made of
poly-L-lactic acid and recently studied in porcine models.57
The first successful in-human experience with a poly-L-lactic
acid stent was described by Tamai et al in 2000.58 The study
included 15 patients treated with a monopolymer poly-L-
lactic acid Igaki-Tamai stent (Igaki Medical Planning Co,
Ltd, Kyoto, Japan) with a zigzag helical coil pattern. The
stent expanded by itself at a temperature of 37°C. Angio-
graphic restenosis rate and TLR was 10.5%, which thereby
proved that its use was feasible, safe, and effective in humans.
The 30-day results of the FIM ABSORB trial (n30) are
worth mentioning. The BVS stent (Figure 4) (Bioabsorbable
Vascular Solutions, Guidant Corp, Indianapolis, Ind), the
world’s first fully absorbable DES, which consists of a
bioabsorbable polylactic acid polymer that contains everoli-
mus (98 g/cm2 of surface area) and a bioabsorbable BVS
polylactic acid stent platform, proved to be associated with a
100% procedural success rate and a major adverse cardiac
event rate of 0%. Furthermore, the stent recoil of 6.85% was
comparable to the 4.27% seen with the XIENCE V metal
stent.59–61
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REVA Medical, Inc. (San Diego, Calif) is presently inves-
tigating a fully absorbable polymer stent with a “slide &
lock” design; sliding parts with monodirectional lockouts that
are hypothesized to result in a nearly negligible stent recoil
(Figure 5). The stent consists of a radiopaque tyrosine-
derived polycarbonate backbone. The composition of the
polymer, comprised of 3 basic components, allows the
resorption time to be varied by a change in the ratio of these
components. Both a bare and a paclitaxel-eluting version, in
which the polymer is mixed with the drug, will become
available. The Randomized Endovascular Study of the REVA
Bioresorbable Stent (RESORB) clinical trial has been re-
cently designed to assess the safety of this new platform.
Another alternative for the metallic backbone of the stent
was found in magnesium. Magnesium, with antithrombotic,
antiarrhythmic, and antiproliferative properties, is one of the
first natural body components to be used as a basis for a
bioabsorbable stent. Several experimental studies to evaluate
the efficacy of a magnesium alloy stent degradable by
biocorrosion have been performed. Heublein et al described
the use of a coronary stent prototype that consisted of the
noncommercial magnesium-based alloy AE21 (contains 2%
aluminum and 1% rare earth metals) with an expected 50%
loss of mass within 6 months in 11 domestic pigs (Figure 6).
Quantitative angiography at follow-up showed a significant
40% loss of perfused lumen between 10 and 35 days caused
by the loss of mechanical integrity of the stent.62 One year
later, the use of a bioabsorbable magnesium alloy–based stent
with a controlled corrosion in 20 patients with critical limb
ischemia was described. At 9 months, a 90% vessel patency
was observed.63 As a result of the successful FIM trial (n5)
by Erbel and colleagues, the enrollment in the larger world-
wide PROGRESS-AMS study has been recently completed.64
The 4-month results showed a late loss of 1.08 0.49 and
an ischemia-driven TLR rate of 23.8%, which was compara-
ble to those reported with the use of BMS.
New Concepts
An appealing new concept is the dual DES. In line with the
previously mentioned dual-layer heparin-SES, Abbott’s Zo-
diac program incorporates a trilayer stent that embeds both
zotarolimus and dexamethasone. Dexamethasone is a potent
antiinflammatory agent that is used for a variety of inflam-
matory and immune diseases. Glucocorticoids suppress the
production and effects of humoral factors involved in the
inflammatory response, inhibit leukocyte migration to sites of
inflammation, and have a rather low effect on endothelial
(35%) and smooth muscle cell (60%) proliferation.65–68
Although the Study of Antirestenosis With the BiodivYsio
Dexamethasone-Eluting Stent (STRIDE) trial, the FIM pilot
trial that evaluated the safety and efficacy of a dexametha-
sone-eluting stent (BiodivYsio Matrix LO stent, Biocom-
patibles, Ltd., Farnham, UK) demonstrated an acceptable
binary restenosis rate of 13.3%,69 the preliminary 6-month
results of the larger-scale Drug-Eluting Stents for In-Stent
Restenosis (DESIRE) trial showed a clinically driven target
Figure 4. The BVS fully absorbable DES. A, Bioabsorbable BVS polymer and platform. Note the radiopaque marker at the top left. B,
64-slice MSCT scan shows a significant stenosis in the LCX with 3 calcium spots. C, MSCT posttreatment with a BVS stent. Note that
only the markers are visible. D and E, OCT images show the BVS stent struts immediately after implantation (D) and covered with a
new endothelial layer at 6 months follow-up (E). BVS indicates Bioabsorbable Vascular Solutions; MSCT, multislice coronary tomogra-
phy; and OCT, optical coherence tomography.
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vessel recascularization rate of 9.5%, which was 50%
higher than the target vessel recascularization rates in the
TAXUS-IV and SIRIUS trials.70 The final results were never
published, and it is to be expected whether the simultaneous
inhibition of smooth muscle cell proliferation and endothelial
inflammation by zotarolimus and dexamethasone in the
Zodiac program will turn out to be successful.
Promising results are also expected from the Randomized,
Multicenter Study of the Pimecrolimus-Eluting (Corio) and
Pimecrolimus/Paclitaxel–Eluting Coronary Stent System
(SymBio) in Patients With De Novo Lesions of the Native
Coronary Arteries (GENESIS) trial, which will compare a
dual paclitaxel/pimecrolimus-eluting stent with a stent that
elutes only pimecrolimus. Additionally, a dual sirolimus/
genistein-eluting stent is currently under investigation (Figure
7). Genistein is a potential isoflavone, which possesses
dose-dependent antiplatelet and antiproliferative properties
and inhibits collagen-induced platelet aggregation responsi-
ble for primary thrombosis. The stent consists of 5 layers that
contain an alternating blend of sirolimus and genistein and a
drug-free top layer. The unique biodegradable heparinized
polymer blend includes poly-L-lactide, poly-DL-lactide-co-
glycolide and polyvinyl pyrrolidone. A complex elution
pattern aims to provide both smooth muscle cell proliferation
by sirolimus and short- and long-term thrombus formation by
genistein.
The Prohealing Approach
Endothelial progenitor cells have been identified as a key
factor in the reendothelialization process after stent implan-
tation.71 To accelerate the process of endothelialization and
thereby reduce the risk of thrombosis and restenosis, the
Genous Bioengineered R stent (OrbusNeich, Fort Lauderdale,
Fla) was developed. The Healthy Endothelial Accelerated
Lining Inhibits Neointimal Growth (HEALING)-FIM (n16)
was the first clinical study to evaluate the use of an endothe-
lial progenitor cell (EPC)-captured stent, which was devel-
oped with immobilized antibodies targeted at EPC surface
antigens. Six-month angiographic outcomes showed a binary
restenosis rate of 13.3% with an associated late loss of
0.630.52. Nine-month outcomes showed that its use was
safe and feasible (major adverse cardiac event and cerebro-
vascular events rate was 6.3%).72 The HEALING-II study
(n63) extended these results in a nonrandomized multi-
center trial. The initial results reported a zero incidence of
major adverse cardiac events at 30 days and 6-month in-stent
restenosis rates of 17.2% with an associated in-stent late
luminal loss 0.780.39. Of interest is the late loss at 18
months, which decreased to 0.590.06 mm.73 Of note, 2
things have to be mentioned. First, the patient’s total number
of circulating EPCs were shown to be of critical importance
for the efficacy of the EPC-captured stent. This can be
illustrated by the results of the HEALING-I; late loss in
patients found to have low levels of circulating EPCs was
more than double that of patients with normal circulating
EPC levels. Second, the total number of circulation EPCs can
be increased by an optimal usage of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins).74
Following the dual-elution trend, recent developments
have been made on an EPC-DES combination. A concept of
a stent with a biodegradable, abluminally focused drug on a
Genous-coated platform with an additional drug component
integrated throughout the polymer backbone. The stent
should be able to enhance drug delivery at the abluminal site,
to inhibit neointimal proliferation, and to simultaneously
possess CD34 endothelial cell capture activity at the endolu-
minal site to enhance reendothelialization.
New Techniques of Elution
The Conor Medstent (Conor Medsystems, Inc., Menlo Park,
Calif) was the first stent specifically designed for drug-
delivery, and it guaranteed an expanded drug capacity and
controllable release kinetics. The stent was equipped with
hundreds of laser-cut holes, and the drug could be deposited
in multilayered degradable polymer inlays.
The Paclitaxel in Stent Controlled Eluting Study (PISCES)
study was the FIM study to evaluate the safety and potential
efficacy of a 316L stainless steel Conor stent system with an
erodable polymer with complete elution of low doses of
paclitaxel. The study included 6 groups distinguished by
different paclitaxel-doses with fast or slow and unidirectional
Figure 5. A, REVA’s “slide & lock” design. Sliding parts with
monodirectional lockouts result in nearly negligible stent recoil.
B, Excellent radiopacity of the tyrosine-derived polycarbonate
backbone. Two REVA stents (left side and top right side) and
one metal control stent (bottom right side).
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or bidirectional release kinetics. At 30 days, the lowest
in-stent late loss (0.38 mm and 0.30 mm) and volume
obstruction (8% and 5%) were observed in the 10-g and
30-g doses groups, respectively, both with unidirectional
release.75,76 The PISCES study was followed by the Study of
Controlled Elution of Paclitaxel for the Elimination of Reste-
nosis (SCEPTER) trial, a safety and effectiveness study
intended to justify market clearance in the European Com-
munity and incorporate 2 arms of 130 patients.77
The Conor Cobalt Chromium Stent With Antiproliferative
for Restenosis (COSTAR)-I trial evaluated the use of an
equally effective, more flexible, and more deliverable cobalt
chromium COSTAR paclitaxel-eluting coronary stent system.
The stent uses a poly-lactic-co-glycolic acid bioabsorbable
polymer, limited to the small wells embedded in the stent
where the drug is loaded, which thereby leaves the actual
stent surface free of polymer.78 The small-scale dose-finding
COSTAR-I trial (n87) was directly followed by the Euro-
pean Cobalt Chromium Stent With Antiproliferative for
Restenosis (EuroSTAR) trial and the COSTAR-II trial. The
EUROSTAR trial showed that the Costar stent system was
highly deliverable and radiopaque, and it permitted high rates
of acute success and direct stenting. One-year clinical
follow-up data showed a 2.8% and 3.4% incidence of TLR in
the 10-g and 30-g groups, respectively, associated with an
in-stent late loss of 0.25 mm and 0.36 mm.79 On the basis of
these results, the cobalt chromium COSTAR paclitaxel-
eluting coronary stent recently received CE mark approval.
Furthermore, the deliverability of the stent has proven to be
of great importance. With the growing complexity of the
lesions treated percutaneously, there exists a need for devices
with better deliverability and higher flexibility. For that
reason, both the Taxus Liberté (Boston Scientific) and
Cypher Select (Cordis) were developed.
To improve the efficacy of stenting of specific lesions like
bifurcations, the multicenter Axxess Plus Biolimus Stent in
LMCA Bifurcations Trial (AXXENT) registry (n33), was
conducted to evaluate the safety and efficacy of the DEVAX–
AXXESS bifurcation stent (Devax, Inc., Irvine, Calif) for use
in the left main coronary artery. Procedural success rates have
been shown to be high, and with a 30-day major adverse
cardiac event rate of 6.1%, the early results looked encour-
aging.80 Recently the DIVERGE trial has been conducted to
further assess the efficacy of this specific bifurcation device.
Comparable dedicated bifurcation devices are the Multilink
Frontier (Abbott),81 which was designed to preserve side-
branch access; the Invatec system (Invatec srl, Roncadelle,
Italy) with axial and rotational self-positioning properties; the
Nile CroCo (Minvasys, Gennevilliers, France), which allows
instant poststent “kissing balloon” dilatation; the Petal (Bos-
ton Scientific) with a side aperture and deployable struts; the
Sideguard (Cappella, Inc, Auburndale, Mass), a Nitinol self-
Figure 6. Light microscopy (A) and scanning electron microscopy (B) images of the magnesium-based alloy AE21 stent.
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expanding device on a single-catheter delivery system; and
the Tryton stent (Tryton Medical, Inc, Newton, Mass).
A promising new concept is the Xtent modular system for
long lesions, multiple lesions, and multivessel disease (Figure
8). The Biolimus A9 polylactic acid bioabsorbable polymer-
coated stent (Biosensors International) has a modular design
and consists of multiple 6-mm cobalt chromium stent seg-
ments that are interdigitated, which allows for in situ cus-
tomization of stent length. The delivery system consists of a
balloon that can be shortened and reused during the proce-
dure, which may eliminate the need to use a separate
postdeployment balloon and may result in significant device
cost savings, reduced catheter exchanges, and shorter proce-
dure times. The device is currently under investigation in the
CUSTOM-II trial, which aims to extend the promising results
of the CUSTOM-I registry.
Finally, an ultralow-profile, self-expandable, thin strut
stent mounted on a guide wire (CardioMind, Sunnyvale,
Calif) is in development for specific use in small vessels.
Current Clinical Results
Although many of the investigated devices have been shown
to be effective in the reduction of restenosis and the need for
repeat revascularization, drug-coated devices like those
coated with batistimat, actinomycin, or tacrolimus, or taxol-
dipped stents failed to show superiority compared with
BMS.48,82–84 The relative efficacy of the more successful
DES cannot be easily assessed because they are most often
compared with BMS. Randomized trials such as the
Prospective, Randomized, Multi-Center Comparison of the
Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting
Stent Systems (REALITY), Paclitaxel and Sirolimus Stents in
the Real World of Interventional Cardiology (TAXI) study,
Drug-Eluting Stent for Complex Lesions: Cordoba–Las Pal-
mas Study (CORPAL), Sirolimus-Eluting Stent Compared
with Paclitaxel-Eluting Stent for Coronary Revascularization
(SIRTAX) study, Intracoronary Stenting and Angiographic
Results—Drug-Eluting Stents for In-Stent Restenosis (ISAR-
DESIRE) trial, and the ISAR-Diabetes trial directly compared
SES and PES in a wide variety of patient and lesion types.85–90
The Basel Stent Kosten Effektivita¨ts Trial (BASKET) as-
sessed the cost-effectiveness of SES and PES combined
versus BMS.91 Both the SIRTAX and ISAR-DESIRE showed
TLR rates that favored SES.88,89 However, the TAXI, REAL-
Figure 7. Design of the genistein-sirolimus dual-eluting stent.
Total drug dose: 2.51 mg/mm2 (112 mg genistein and 76 mg
sirolimus content on 16-mm stent). Unique biodegradable hepa-
rinized polymers blend includes poly-L-lactide, 50/50 poly-DL-
lactide-co-glycolide, and polyvinyl pyrrolidone. Elution profile:
Initial high dose of genistein for 2 days to prevent platelet
aggregation. (Top layer D). Concurrent release of genistein and
sirolimus from layer C between 3 to 9 days will target primary
thrombus formation and intimal cell proliferation. Slow release of
genistein and sirolimus (Layer B) between 10 to 49 days to pre-
vent mainly cell proliferation. Finally, slow release of genistein
(Layer A) from 50 to 89 days will prevent late thrombosis up to
3 months.
Figure 8. The Xtent modular system for long lesions, multiple lesions, and multivessel disease. A, 6-mm CoCr segment; 1 device con-
tains 6 to 10 segments (diameters: 2.5, 3.0, and 3.5 mm). B, The delivery system consists of a balloon that can be shortened and
reused during the procedure. C, A modular design that consists of multiple 6-mm CoCr stent segments customized to fit the lesion
length. D, Biolimus A9 elutes from a polylactic acid bioabsorbable polymer.
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ITY, ISAR-DIABETES, and CORPAL studies did not show
a significant difference between both devices.85–87,90 Of note,
because of a lack of angiographic follow-up, a large reference
vessel diameter, and only 50% of randomized patients, the
results of the TAXI trial should be interpreted with care. Two
recent meta-analyses showed that the use of SES was asso-
ciated with lower angiographic restenosis rates and a lower
incidence of target vessel recascularization as compared with
PES.92,93 Of note, no significant differences were found in the
incidence of death or myocardial infarction between both
groups. Among the PES registries, the TAXUS Stent Evalu-
ated at Rotterdam Cardiology Hospital (T-SEARCH) registry
is worth mention because it was one of the first studies to
reflect real-world clinical practice. The recently published
2-year results did not show a significant difference between
PES and SES in any of the clinical end points.94 The much
larger Strategic Transcatheter Evaluation of New Therapies
(STENT) registry also did not show a significant difference
between both devices at 6 months in 6659 patients.95
Currently, a variety of trials that compare the Taxus and
CYPHER stents to several newcomers are in progress. In the
Prospective, Multicenter, Randomized Trial of Zotarolimus-
and Paclitaxel-Eluting Stents in Patients With Coronary
Artery Disease (ZOMAXX-I) (n396), which compared the
zotarolimus-eluting Zomaxx stent to a PES, the Zomaxx stent
was shown to be associated with a significantly higher late
loss at 9 months and thereby failed to meet its primary end
point.29 The CObalt chromium STent with Anti-proliferative
for Restenosis (COSTAR)-II trial, which used the CONOR
platform, is an ongoing, prospective, randomized controlled
trial that will include 2000 patients at 85 international sites
that compare the use of the COSTAR stent to a TAXUS
stent.78,96,97 Medtronic’s Patient-Related OuTcomes with En-
deavor versus Cypher stenting Trial (PROTECT) is currently
enrolling 8000 patients to compare the safety and efficacy of
the Endeavor zotarolimus-eluting stent to the Cypher stent,
with stent thrombosis as one of its primary end points at 3
years.
Also currently ongoing are 2 prospective, randomized,
multicenter trials that compare the Biolimus A9–eluting
Biomatrix (Biolimus-eluting stent) with a Cypher SES (Li-
mus Eluted From a Durable versus Erodable Stent Coating
(LEADERS) trial; n1700) and to a Taxus PES (Nobori-I
study; n360). The recently presented 9-month results of the
Nobori-I showed significantly less late lumen loss in the
Biolimus arm as compared with the Taxus arm.31 Finally, the
large-scale SPIRIT III, which was designed for further
evaluation of the efficacy of the XIENCE V everolimus-
eluting stent, has finished enrollment of its randomized arm.
Conclusions
As with any new device in medicine, the applauded 2 pioneer
DES Cypher and TAXUS were shown to possess some side
effects as well, some of which only arose very recently.
Currently, various innovative DES types are emerging and
will become available in the coming years with the intention
to avoid the current pitfalls. Abolition of neointimal hyper-
plasia is no longer the ultimate goal and has been replaced by
the development of more biocompatible and bioabsorbable
stents that facilitate adequate endothelialization.
Recently, the FDA acknowledged a cause of concern for
late adverse events after stent implantation and called for
long-term monitoring of safety outcome. It is hoped that the
testing of possible remedies to the current deficiencies of the
first-generation DES will not be paradoxically hindered by
more stringent regulatory measures as a penalty for the late
recognition of their inherent limitations.
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None.
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Drug-Eluting Stent Update 2007
Part II: Unsettled Issues
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Restenosis has been called the Achilles heel of coronarystenting and is caused by a combination of factors,
including neointimal proliferation, elastic recoil, reorganiza-
tion of thrombus, remodeling, and inflammation.1 Long-term
follow-up (6 years) in patients with bare metal stents
(BMS) shows that tissue proliferation reaches its peak at
around 6 to 12 months and then regresses.2 This pattern fits
with the observed increase in revascularization rates up to 1
year, after which a plateau occurs. After drug-eluting stent
(DES) implantation, Carter et al3 showed a late catch-up of
restenosis in sirolimus-eluting stents (SES) in porcine mod-
els. Although a 50% reduction of restenosis was observed at
30 days, restenosis rates for SES and BMS were equivalent at
6 months.3 A similar catch-up phenomenon was observed
after implantation of paclitaxel-eluting stents (PES) and
tacrolimus-eluting stents in porcine models.4,5 Conversely, in
humans, there does not seem to be reason for concern about
late catch-up for up to 4 years on both clinical and angio-
graphic end points.6–10 However, several long-term DES
studies showed that, in contrast to BMS, the neointima
continued to grow up to 2 years as assessed by intravascular
ultrasound.11 The discrepancy between porcine and clinical
data is influenced by the temporal differences in arterial
response in humans compared with animal models but also
may be due to differences in species response to sirolimus and
paclitaxel and physiological stimuli for neointimal formation.
Trading Restenosis for Thrombosis and
Late Mortality?
The Problem of Restenosis
Restenosis has always been considered a benign and harmless
entity. However, recent studies assessing the clinical presen-
tation and long-term outcome of patients presenting with
in-stent restenosis demonstrated worrying findings, leading
some critics to ask whether restenosis had simply been traded
for long-term issues like thrombosis and mortality.12 At least
10% of all cases of BMS in-stent restenosis presented with a
myocardial infarction (MI); 0.7% died.13,14 Furthermore,
long-term survival rates proved to be significantly lower in
patients with binary restenosis.15,16
The Pros and Cons of DES Implantation
Since the clinical introduction of the first DES, the sirolimus-
eluting Cypher (r) stent, in April 2002 in Europe, SES, PES,
and many other new investigational agents like everolimus-,
zotarolimus-, and tacrolimus-eluting stents have been tested
extensively for their main purpose, namely their ability to
reduce restenosis. Recent pooled data from the pivotal
Cypher and TAXUS trials, evaluating the efficacy of both the
SES and PES, proved that both DES are associated with a
significantly lower rate of angiographic and clinical resteno-
sis compared with BMS for up to 4 years in selected
patients.17
Besides their superiority to BMS in reducing restenosis,
DES also have been associated with several unintended
consequences. First, DES proved to hamper the natural
vascular healing process. A study of 48 matched DES-BMS
postmortems (30 days after stent implantation) revealed the
following. First, re-endothelialization was observed in only
56% of the DES cases compared with 90% of the BMS cases,
illustrated by significantly higher persistent fibrin depositions
that reflect delayed healing caused by ongoing inflammation
in the DES-treated lesions; and at least 61% of the DES cases
showed signs of late stent thrombosis (ST) compared with
only 8% of the BMS cases.18 Although these results may not
accurately represent the fate of patients who receive DES and
survive, they do show that the natural healing process after
DES implantation is not as optimal as originally hypothe-
sized. Second, stent underexpansion (minimum stent area
5.0 mm2), a factor linked to restenosis, proved to be
significantly more frequent after DES implantation. Whereas
stent underexpansion is observed in 20% of all restenotic
BMS lesions, an incidence of 67% is reported in restenotic
DES lesions.19,20 These data were confirmed by a recent
intravascular ultrasound study concluding that the angio-
graphic restenosis rate was highest in lesions with stent area
5.5 mm2 and stent length 40 mm.21 In the BMS era, the
theory of “the bigger, the better” was widely advertised and
became an obsessive motto for the interventional cardiologist.
Although a large final minimum lumen area was shown to be
associated with lower repeated revascularization rates, the
superior antirestenotic properties of DES groundlessly made
optimal stent deployment less important. Nevertheless, this
could be an explanation for the substantially higher rate of
stent underexpansion in in-stent restenotic DES lesions.22
Third, DES implantation was associated with a significant
impairment in endothelial function, which in turn has been
From Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Correspondence to Professor P.W. Serruys, MD, PhD, Thoraxcenter, Ba-583, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail
p.w.j.c.serruys@erasmusmc.nl
(Circulation. 2007:116:961-968)
© 2007 American Heart Association, Inc.
DES Update 2007 Part II| Chapter 3
37
associated with a higher rate of late adverse cardiac
events.23–25 Fourth, 2 recent reports showed a significantly
lower rate of neointimal coverage with DES (13.3% to 66%)
than with BMS (90% to 100%), and subclinical thrombi
tended to more common with DES (P0.09).18,26,27 It is
exactly these issues that are hypothesized to cause higher
rates of (late) ST in patients treated with DES.
Stent Thrombosis
ST has emerged as an important safety concern after stent
implantation, although the rates have decreased from20%
after Wall stent implantation in the early 1990s to 0.2% to
1.8% after the implantation of current-generation BMS and
DES.28–36
In an attempt to identify predictors of ST, several studies
identified 15 patient- and procedure-related factors asso-
ciated with early ST. Whereas in the early days the early
pattern was hypothesized to be related mainly to technical
aspects of stent implantation such as underexpansion and
dissections, 2 recent large-scale registries showed that
patient-related factors such as age, hypertension, smoking,
renal failure, acute coronary syndrome at presentation, left
ventricular function, and female gender also were indepen-
dently associated with early ST.37,38 Unfortunately, the lack
of consistent data and the overall low number of events
make it difficult to interpret these predictors. Conversely,
the late form has been related to delayed endothelialization
and a hypersensitivity reaction to the drug or polymer.39–41
The most common predictors of late ST proved to be acute
coronary syndrome at presentation, diabetes, and stent
implantation of the left anterior descending coronary ar-
tery.37,38 A worldwide controversy is currently ongoing as to
whether (late) ST indeed occurs more frequently after DES
implantation. Two meta-analyses showed early ST rates
between 0.51% and 0.9% for patients treated with BMS.29,42
Ong et al43 published a series of 2512 unselected patients
who underwent stenting. Early ST proved to be equal in
patients treated with BMS, SES, and PES and occurred in
1% to 1.5% of all patients, depending on the definition. The
concerns for late ST (30 days) after DES implantation
originate from a report of a patient in the European
SIRolImUS-coated Bx Velocity balloon-expandable stent in
the treatment of patients with de novo coronary artery
lesions (E-SIRIUS) study, who developed late ST 18
months after SES implantation.40 Because of the presence of
polymer fragments surrounded by giant cells and eosino-
phils, the authors concluded that this might have been the
cause of the thrombotic event rather than the drug itself,
which is no longer present in the vessel wall after 60 days.
Additionally, McFadden et al44 reported 4 cases of late ST
when antiplatelet therapy was interrupted after elective
implantation of either an SES (n2) or a PES (n2).
For on-label use, pooled analyses of the randomized
Cypher and TAXUS family trials demonstrated identical ST
rates of 3.5% (using the new Academic Research Con-
sortium definitions45 that take not only angiographically
proven ST but also MI in the target region and sudden
unexplained death into consideration) in both selected BMS
and DES patients up to 4 years.46 However, a trend seems to
arise toward a higher rate of late ST (between 30 and 365
days) in patients treated with BMS that is partially related to
target lesion revascularization, reaching its peak at 6
months, which is compensated for by a higher rate of very
late (1 year) ST in the DES patients not related to repeated
interventions. An additional interesting finding from the
meta-analyses of the Cypher and TAXUS trials was the
association between intervening target lesion revasculariza-
tion and ST.46 In the Cypher trials, 6 of 15 cases (40%) of
definite or probable ST in the BMS group occurred after
repeated target lesion intervention. Conversely, in the SES
group, 13 of 13 (100%) of the ST was primary, without
intervening target lesion revascularization. In the random-
ized TAXUS trials, a similar pattern was observed; 5 of 18
cases (28%) of definite or probable ST occurred after
intervening target lesion revascularization in the BMS
group compared with 21 of 22 cases (95%) of primary ST in
the PES group. Remarkably, in pooled patient-level data of
the ENDEAVOR-I, II, and III trials, although limited to 2 to
3 years of follow-up, the occurrence of very late ST was 3
times lower after zotarolimus-eluting stent implantation
than after BMS implantation, and ST after repeated inter-
vention occurred in only 1 patient in both the DES and BMS
groups.47
Recently presented long-term follow-up data of 8146
patients treated with DES in 2 academic institutions showed
that ST, observed in 152 patients, occurred at a median of 9
days and accrued at a steady rate of 0.6% per year between
30 days and 3 years of follow-up.38 It is uncertain whether
these rates exceed those of unselected patients treated with
BMS after many years of follow-up. To settle this issue,
extremely large-scale randomized observations comparing
DES and BMS in all patients are needed. Unfortunately, the
likelihood that in the present era these trials will actually be
performed is low, and even if they were started, it would
take at least another 3 to 4 years for valid conclusions about
the long-term results to be drawn. For now, we need to rely
on large-scale registries in which the BMS control groups
often comprise lower-risk patients and lesions.
From ST to Hard Clinical End Points
Knowing that DES are able to reduce restenosis by 70%,
one could subsequently expect a long-term benefit in
survival.48,49 Instead, concerns were raised about a higher
rate of death and MI after DES implantation, and even
cancer was hypothesized to occur more frequently in DES-
treated patients.50,51
Frightened by these detrimental findings, stent manufac-
turers put complete data sets of randomized trials with
long-term patient-level–based follow-up at the disposal of
independent researchers and statisticians for further analy-
ses. After several intense scrutinizing exercises, long-term
death and MI rates appeared to be similar in pooled analyses
of the pivotal Cypher and TAXUS trials, including rela-
tively low-risk patients.17,52
In real-world registries in which the off-label DES use
accounted for up to 60% of the population, the outcomes
seem more at variance. Whereas the large DEScover and
West Denmark registries and the 3-year follow-up of the
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Rapamycin Eluting Stent Evaluated at Rotterdam Cardiol-
ogy Hospital (RESEARCH) registry showed equal survival
rates between DES and BMS, a large-scale Swedish registry
highlighted a significantly lower survival rate in the DES
group compared with the BMS group at 2.4 years of
follow-up.7,53–55 Of note, the BMS control groups in the
above-mentioned registries comprised significantly less
complex patients because of either the sequential nature of
the cohorts or substantial selection bias favoring the BMS
control groups. It remains disputed whether comprehensive
regression and propensity analyses are able to completely
account for these differences.
It is to be expected that, in the long term, higher rates of
very late ST after DES implantation will put our DES-
treated patients at higher risk for death and MI. Although
DES have been shown to be safe up to 4 years for on-label
use, the off-label long-term safety has not yet been deter-
mined, given the controversial findings of large real-world
registries and the lack of properly powered randomized
controlled trials.
DES Use for Off-Label Indications
Whereas DES seem to be not only safe and effective but
also preferable to BMS for on-label use, a lack of dedicated
research makes off-label use debatable. This issue was
reviewed at a recent panel meeting of the US Food and Drug
Administration on ST to which key opinion leaders from the
entire world were invited.
High-Risk Patient Subgroups
Two of the most widely discussed indications for DES use
are diabetes mellitus and acute MI. Although diabetic
patients make up 25% of our current population, the most
safe and effective device for this high-risk subgroup re-
mains disputed.56 Patients with diabetes are known to have
an accelerated and more aggressive form of atherosclerosis
and tend to develop substantially higher rates of restenosis
compared with nondiabetics.57–59 The latter finding can be
explained by the smaller vessel size, longer lesion length,
greater plaque burden, and a possibly different-acting reste-
notic cascade compared with patients without diabetes.60,61
To date, retrospective subset analyses in various random-
ized controlled trials and a select number of small single-
center experiences reported that both SES and PES are
effective in reducing restenosis and repeated revasculariza-
tions compared with BMS in diabetic patients for up to 1
year.59,62–64 However, in a randomized trial by Dibra et al,65
the extent of late loss and angiographic restenosis was
greater in patients treated with PES than in patients with
SES, although the difference in the clinical end points was
not statistically significant.65 Conversely, the Strategic
Transcatheter Evaluation of New Therapies (STENT) reg-
istry compared the outcome of 1680 diabetic patients treated
with either SES or PES and showed no significant differ-
ence in each of the clinical end points at 9 months.66 These
clinical findings were supported by recent results from a
retrospective subgroup analysis of 702 diabetic patients
from the RESEARCH and Taxus-Stent Evaluated at Rot-
terdam Cardiology Hospital (T-SEARCH) registry.67,68 Af-
ter propensity analysis, no significant differences in any of
the clinical end points between SES and PES were noted
after 2 years of follow-up. Finally, the Latin American
Society of Interventional Cardiology (SOLACI) and the
Taxus Express2 Stent versus Cypher Stent: What’s Your
Real-World Experience? (TC-WYRE) registry showed even
lower target vessel revascularization rates in diabetic pa-
tients treated with PES compared with those treated with
SES.69,70
In assessments of the efficacy of both DES in diabetic
patients, the different mechanisms of action of both drugs
and the theory behind insulin resistance deserve some
attention. Paclitaxel acts differently than the “limus” family
drugs, which all inhibit the mTOR (mammalian target of
rapamycin) gene. mTOR is dependent on the PI3 kinase
pathway, which is degraded in patients with non–insulin-
dependent diabetes mellitus.71 Whether these physiological
differences will result in a significant long-term clinical
difference between SES and PES remains to be determined.
A second high-risk subgroup in which the long-term
safety and efficacy are not yet unanimously proven is the
acute MI subset. A recent editorial incorporating a pooled
analysis of the first retrospective subset analyses of MI
patients treated with DES (mostly SES) concluded that the
SES was safe and effective in reducing restenosis and
repeated revascularizations in this high-risk subset.72 How-
ever, the number of patients included in these preliminary
reports was small, and the studies were underpowered to
definitively prove a beneficial effect of DES. Recently, the
randomized Trial to Assess the Use of the Cypher Stent in
Acute Myocardial Infarction Treated With Balloon Angio-
plasty (TYPHOON) and randomized Sirolimus Stent Ver-
sus Bare Stent in Acute Myocardial Infarction (SESAMI)
trial proved that SES were superior to BMS in reducing
restenosis and repeated revascularization in patients pres-
enting with acute MI.73,74 As a result of the negative
findings of the Paclitaxel-Eluting Stent Versus Conven-
tional Stent in Myocardial Infarction With ST-Segment
Elevation (PASSION) trial and the nonsignificantly differ-
ent repeated revascularization rates in the Helsinki Area
Acute Myocardial Infarction Treatment Reevaluation:
Should the Patient Get a Drug-Eluting or a Normal Stent?
(HAAMU-stent) study, it is currently unclear whether this
also holds for PES.75–77 We look forward to the results of
the upcoming Harmonizing Outcomes With Revasculariza-
tion and Stents in Acute Myocardial Infarction (HORI-
ZONS AMI) trial, which is designed to prove the efficacy of
the PES in acute MI patients.
Of note, all the above-mentioned studies showed similar
safety profiles (expressed by hard clinical end points like
death, MI, and ST) for both DES and BMS in MI patients.
However, this evidence goes no further than 1 year. Con-
sidering that very late ST was significantly more frequent
after DES implantation (11 of 2278 cases) than after BMS
implantation (1 of 2267)46 and knowing that acute MI
proved to be among the strongest predictors of ST, we
acknowledge that the long-term safety of DES in these
patients remains debatable.35,36,38,78
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Off-Label Indications
A substantial amount of randomized controlled trials proved
the efficacy of DES for off-label indications like chronic
total occlusions, in-stent restenosis, small vessels, and
bypass grafts.79–83 However, the primary end points of these
trials were most often angiographic, and the follow-up is not
reported beyond 1 year. Because of the limited number of
patients in these trials, making them underpowered for
assessing hard clinical end points, the long-term safety of
DES for off-label indications needs to be determined on the
basis of both pooled meta-analyses of these trials and
real-world registries.
Duration of Antiplatelet Therapy
Currently, product labeling recommends 3 months of clo-
pidogrel after SES implantation and 6 months after PES
implantation, accompanied by lifelong administration of
aspirin. Looking back on the rationale for these recommen-
dations brings us to the First in Man (FIM) trial and the
Randomized Study With the Velocity Balloon-Expandable
SES in the Treatment of Patients With De Novo Native
Coronary Artery Lesions (RAVEL) trial in which 2 months
of ticlopidine or clopidogrel was mandated on the basis of
the fact that the FIM was planned as a 60-day safety trial
with concomitant ticlopidine use for 60 days. Although it
would take another 2 years for the first concerns for late ST
after DES implantation to be raised,44 clopidogrel prescrip-
tion was prolonged to 3 and 6 months in the pivotal SIRIUS
and TAXUS-I trials, respectively. Unfortunately, the ratio-
nale for this prolongation remains unclear.
It has been 5 years since the introduction of the first DES,
and the optimal duration of dual antiplatelet therapy remains
to be determined. In dedicated trials in the BMS era, the
benefit of clopidogrel therapy proved to be apparent mainly
in the first 1 to 6 months after stent implantation. The
randomized Clopidogrel in Unstable Angina to Prevent
Recurrent Events (PCI-CURE) trial proved that long-term
administration of clopidogrel was associated with a 31%
reduction in cardiovascular death or MI (P0.002) in
patients presenting with a non–ST-segment elevation acute
coronary syndrome.84 However, as supported by the find-
ings of the Clopidogrel for the Reduction of Events During
Observation (CREDO) trial, which included only elective
patients, the observed benefit was already achieved in the
first month.84,85 No significant difference in death or MI
between the clopidogrel- and placebo-treated groups was
noted between 1 and 6 months.86 Given the lack of dedi-
cated randomized trials in the DES era, we are forced to rely
on indirect evidence indicating possibly severe conse-
quences after the premature discontinuation of dual anti-
platelet therapy.32,34,35,87,88 Currently, the Food and Drug
Administration and the updated American College of Car-
diology/American Heart Association/Society for Cardiovas-
cular Angiography and Interventions guidelines recommend
at least 12 months of clopidogrel in patients at low risk for
bleeding.89,90 The currently available evidence supporting
long-term clopidogrel use is controversial. On the one hand,
2 recent large-scale registries demonstrated that 25% to
50% of all late ST events occurred in patients who were still
on dual antiplatelet therapy.38,87 On the other hand, Eisen-
stein et al91 recently demonstrated a significant higher
2-year survival in patients remaining on dual antiplatelet
therapy at 6 and 12 months compared with those who
stopped clopidogrel. Unfortunately, the study does not
report on the antiplatelet use at the time the 662 censored
events in the first 6 months (156 of 1501 in the DES group
versus 506 of 3165 in the BMS group) occurred. Finally, in
the Clopidogrel for High Atherothrombotic Risk and Ische-
mic Stabilization, Management, and Avoidance (CHA-
RISMA) trial, which randomly assigned 15 603 patients
with either clinically evident cardiovascular disease or
multiple risk factors to receive clopidogrel (75 mg/d) plus
low-dose aspirin (75 to 162 mg/d) or placebo plus low-dose
aspirin and followed them up for a median of 28 months,
clopidogrel plus aspirin was not significantly superior to
aspirin alone, and additional harm such a significantly
higher risk of bleeding could not be excluded.92
Cost-Effectiveness
Although both SES and PES proved to be highly effective in
reducing restenosis and the need for reinterventions, their
cost-effectiveness is still debated. The cost-effectiveness
analyses for both RAVEL and SIRIUS showed that SES
were relatively cost-effective for simple lesions.93,94 Al-
though the cost-effectiveness analyses of the RAVEL trial
adjusted for the consequences of mandated angiographic
follow-up, the results of economical analyses based on such
trials should be interpreted with caution.
The Basel Stent Kosten Effektivitäts Trial (BASKET)
analyzed the cost-effectiveness of both eluting stents com-
bined compared with standard BMS in a real-world single-
center setting.95 Total costs at 6 months were higher with
DES (mean, €10 544; SD, €6849) than with BMS (mean,
€9639; SD, €(9067; P0.0001). At 6 months, the lower
reintervention rates did not compensate for the higher initial
costs. The incremental cost-effectiveness ratio of DES
compared with BMS to avoid 1 major event was €18 311,
and costs per quality-adjusted life-year gained exceeded
€50 000. Subgroup analyses showed that DES were more
cost-effective for elderly patients and specific high-risk
subgroups like patients with 3-vessel disease, longer le-
sions, and type B lesions (the Figure). However, several
methodological issues with this trial merit discussion. First,
the analysis was based on 6-month clinical outcome,
whereas we know from the randomized TAXUS and
SIRIUS family trials that the Kaplan-Meier curves for target
lesion revascularization for these DES compared with BMS
continue to diverge up to 12 months. This would lead to a
serious underestimation of their cost-effectiveness. In the
simple incremental cost-effectiveness ratio equation, which
expresses cost-effectiveness as change in cost divided by
change in effect, the difference in cost would be overesti-
mated, whereas the difference in effect would be
underestimated.
Second, the cost-effectiveness was based on the perfor-
mance of “DES,” in this case a combined population of both
SES and PES patients. Blending the outcomes of both stents
may affect the accuracy of the cost-effectiveness for each
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product. The 18-month cost-effectiveness results of BAS-
KET are expected soon and should be much more
informative.
As mentioned in BASKET, the possible cost-
effectiveness of DES has to be driven by the ability to
reduce the need for reinterventions because death and MI
rates proved to be comparable. Ong et al96 evaluated the
cost-effectiveness of SES in the RESEARCH study and
concluded that the SES was not cost-effective at 1 or 2 years
of follow-up compared with BMS. However, Ong et al
concluded that the incremental cost-effectiveness ratio per
target vessel revascularization avoided was €29 373 at 1
year and €22 267 at 2 years in the total cohort. On the basis
of these results, the calculated maximum cost-effective
price after 1 year of follow-up is €1336 per SES for
all-comers or €1023 to achieve cost neutrality. It is clear that
longer-term follow-up is needed to determine the number of
reinterventions that could be avoided to make DES cost-
effective. It is worth noting that an inherent trap exists when
the incremental cost-effectiveness equation is applied for all
new medical technologies that do not, for example, apply to
pharmaceuticals. The incremental cost-effectiveness ratio
will be heavily influenced by the costs of both the new and
old technology. The more successful the new technology is,
the more rapidly and farther the price of the old technology
that it is replacing is likely to fall. Thus, although initially
cost-effective, the new technology may no longer be so 1 or
2 years later according to this equation.
Conclusions
So far, DES have been proved to be safe and effective with
significantly lower rates of repeated revascularization. The
trend toward a higher incidence of very late ST in patients
treated with DES does not seem to affect the long-term hard
clinical end points like death and MI, at least for on-label
use and assuming compliance with the antiplatelet regimen.
Whether this restricted 4-year safety profile can be extended
to 5 or even 10 years and to higher-risk patients remains to
be determined, given the lack of dedicated trials sufficiently
powered for clinical safety end points like death and MI. It
is evident that DES are associated with adverse side effects
like endothelial dysfunction and a severely disturbed vas-
cular healing process. Future research has to demonstrate if,
how, and when this will affect long-term safety and
efficacy.
Although adherence to 6 months of clopidogrel in DES-
treated patients seems crucial in preventing stent thrombotic
events, dedicated large-scale randomized trials are needed
to settle the pros and cons of prolonged dual antiplatelet
therapy.
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Abstract
Aims: To investigate the medium term (2 year) clinical outcome of the use of the paclitaxel-eluting stent
(PES) compared to the sirolimus-eluting stent (SES). To date, there are no direct comparative data on the
efficacy of these stents over medium term follow-up. Furthermore, a possible late restenotic phenomenon
has not been excluded.
Methods and results: The Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry
compared 576 consecutive “all-comer” patients, exclusively treated with PES, with 508 patients who
received SES from the RESEARCH registry in the preceding period. Patients were enrolled irrespective of
clinical or angiographic features. At 2 years, major adverse cardiac event (death, myocardial infarction or
target vessel revascularisation) rates were comparable in the two groups: 15.4% in the SES group versus
18.9% in the PES group (HR 1.26, 95% CI 0.94-1.69, p=0.12). Correcting for differences in both groups
resulted in an adjusted HR of 1.11 (95% CI 0.82-1.50, p=0.51, using significant univariate variables).
Target vessel revascularisation was 8.0% in the SES group compared with 9.6% in the PES group (HR
1.23, 95% CI 0.81-1.86, p=0.33).
Conclusions: The unrestricted use of SES and PES was safe at two years of follow-up. No significant differ-
ence was found between the two devices in terms of death or MI, MACE, TVR or TLR. No late clinical
restenotic phenomenon was observed.
KEYWORDS
Sirolimus, 
Paclitaxel, stent, 
T-SEARCH, two-year
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Introduction
Several years have elapsed since the commercial introduction of
sirolimus and paclitaxel eluting stents and to date more than 3 mil-
lion drug-eluting stents have been implanted worldwide.
Both stents, loaded with antiproliferative drugs, have shown to be
highly effective in reducing restenosis in stenotic coronary arteries
compared to bare metal stents1-5. Evidence was seen from the early
days of DES with trials describing the effect of the Rapamycin cov-
ered SES in relatively simple lesions in the FIM trial6,7 and the
RAVEL trial8. Currently, randomised trials, such as the REALITY,
TAXI, CORPAL, SIRTAX, ISAR Diabetes trial and BASKET trial, are
comparing SES and PES in a wide variety of patient and lesion
types9-14. Although a recent meta-analysis has demonstrated the
efficacy of DES, and the superiority of SES to PES in reducing
restenosis and target lesion revascularisation (TLR), the randomised
REALITY trial did not show a difference in binary restenosis and nei-
ther in major adverse cardiac events (MACE) at 8 and 12 months
between both devices9,15. Of note, no difference was seen in the
rates of death and myocardial infarction after relatively short-term
follow-up in both studies.
The purpose of the present study is to report the two-year clinical
outcome of an unselected patient cohort compromising 1,084 con-
secutive patients treated with a sirolimus- or paclitaxel-eluting stent.
The study was performed for two reasons: First, to evaluate the inci-
dence of late adverse events – the importance of this issue can be
demonstrated by a variety of complications that showed up after
several years of clinical experience using multiple drug-eluting
devices such as; stent thrombosis more than one year after implan-
tation despite continuation of anti-platelet therapy16, delayed neoin-
timal growth17, and a phenomenon of late restenosis in porcine
models18. Secondly, to see whether both devices were still associat-
ed with a comparable outcome at 2 years19.
Methods
Study design and patient population
The Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-
SEARCH) registry is a single-centre prospective registry with the aim
of evaluating the safety and efficacy of the unrestricted use of PES
(PES, TAXUS, Boston Scientific Corp., Natick, Massachusetts, USA)
implantation in an unselected patient population typical of daily
practice. Its design and methodology are similar to that of the
RESEARCH registry20 and follows the dynamic registry design
described by Rothman and Greenland21.
PES was granted Conformité Européenne (CE) approval on
February 16, 2003 and replaced SES (SES, Cypher, Cordis corpo-
ration, Warren, NJ, USA) as the default strategy for every percuta-
neous coronary intervention (PCI) in our institution. Up to
September 30, 2003, a total of 576 patients with de novo lesions
were treated exclusively with PES and are included in the present
report (PES group). In this period, 84% of all patients with de novo
disease received a PES. Patients not treated purely with PES or
patients included in other drug-eluting stent trials were excluded
from the present report. This PES group was compared with a con-
trol group that comprised the active arm of the RESEARCH registry,
including 508 patients with de novo disease treated solely with SES
(SES group). Written informed consent was acquired for every patient
included. Our study fulfilled the criteria of the declaration of Helsinki
and was approved by the hospital ethics committee.
Procedures and post-intervention medications
All procedures were performed according to current standards, with
the final interventional strategy (including direct stenting, postdilata-
tion and the use of intravascular ultrasound) left to the operator’s
discretion20. Angiographic success was defined as residual stenosis
<30% by visual analysis in the presence of Thrombolysis In
Myocardial Infarction (TIMI) grade 3 flow. All patients were pretreat-
ed with 300mg clopidogrel. For patients in the SES group post pro-
cedure clopidogrel (75 mg/day) was prescribed for at least
3 months. Several exceptions were made for patients treated for
long lesions (stented segment >36 mm), chronic total occlusions,
bifurcations and patients in whom more that 3 stents were used.
These patients received at least 6 months clopidogrel. In the PES
population clopidogrel (75 mg/day) was prescribed for at least
6 months according to the protocol of several randomised clinical
trials3,5. Furthermore, all patients were advised to maintain life-long
aspirin treatment (at least 80 mg/day).
End point definitions
Our primary endpoint was MACE at 2 years. MACE was defined as
a composite of all cause death, non-fatal myocardial infarction (MI)
or target vessel revascularisation (TVR). Secondary endpoints were
target lesion revascularisation (TLR), defined as a treatment of a
lesion in-stent or within 5 mm of the stent borders, and clinically
driven repeat revascularisation, defined as any intervention motivat-
ed by a significant luminal stenosis (>50% diameter stenosis) in the
presence of anginal symptoms and/or proven myocardial ischaemia
Abbreviations and acronyms
CI: Confidence interval
HR: Hazard Ratio
MACE: Major Adverse Cardiac Event
MI: myocardial infarction
RAVEL: Randomised study with the sirolimus-eluting BxVelocity
balloon -expandable stent in the treatment of patients with de
novo native coronary artery lesions.
RESEARCH: Rapamycin-Eluting Stent Evaluated at Rotterdam
Cardiology Hospital
T-SEARCH: Taxus-Stent Evaluated at Rotterdam Cardiology
Hospital
SES: sirolimus-eluting stent
PES: paclitaxel-eluting stent
TLR: target lesion revascularisation
TVR: Target vessel revascularisation
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on the target vessel territory by noninvasive testing. Myocardial
infarction was diagnosed by a rise in creatine kinase-MB fraction
(CK-MB) of three times the upper normal limit according to
American Heart Association/American College of Cardiology guide-
lines22,23. Subacute angiographic stent thrombosis was defined as
an angiographically documented complete occlusion (TIMI grade 0
or 1 flow) or a flow-limiting thrombus (TIMI grade 1 or 2 flow) in the
first 30 days after a successful procedure. Late angiographic stent
thrombosis was defined as late – occurring at least one month after
DES implantation with acute symptoms; angiographic – stent
thrombosis confirmed angiographically; stent thrombosis – defined
as thrombosis with TIMI grade 0 or 1 flow or the presence of a flow
limiting thrombus (TIMI flow 1 or 2)24.
Two-year follow-up data
Long-term survival status was obtained by information provided by
the municipal civil registry. Subsequently, questionnaires were sent
to all living patients inquiring about new interventions (either surgi-
cal or percutaneous), myocardial infarction and medication usage.
If patients had an MI or underwent a re-intervention in another hos-
pital, discharge letters from the referring hospitals were requested
and analysed for additional information. In cases of doubt, the local
cardiologist or general practitioners were contacted. All information
was prospectively collected in a dedicated database. We were not
able to retrieve complete follow-up information on 30 patients,
mostly due to emigration or due to an illegal status in the
Netherlands. Finally, follow-up was available for 97% of the patients
in both groups.
In both groups, follow-up coronary angiography was clinically driv-
en by symptoms or signs suggestive of myocardial ischaemia or
mandated by the operator at the end of the index procedure pre-
dominantly for complex procedures. In the PES group 18.4%
underwent angiographic follow-up, as part of three specific complex
subgroups: left main stenting, crush-bifurcation procedures, and
patients who were part of a vulnerable plaque substudy. Of the SES
patients, 36.0% underwent angiographic follow-up, as part of the
following complex subgroups: bifurcation lesions, chronic total
occlusions, very small vessels, left main stenting, long stent length
(36 mm), and acute MI.
Statistical analysis
Continuous variables are presented as mean ±SD and were com-
pared by Student’s t-test. Categorical variables are presented as
counts and percentages and compared by Fisher’s exact test. All
statistical tests are 2-tailed and a p-value <0.05 was considered sig-
nificant. The cumulative incidence of adverse events was estimated
according to the Kaplan-Meier method, and Cox proportional haz-
ards models were used to assess differences between the two
strategies. Curves were compared by log-rank test. Separate Cox
proportional hazards models were performed to identify independ-
ent predictors of adverse events, using clinical, angiographic, and
procedural variables contained in Tables 1 and 2. The Cox propor-
tional hazards regression models were used to control for differ-
ences between groups, and the final results are presented as
Table 1. Baseline characteristics of patients treated with SES or PES
SES Group PES Group P- value
(n=508) (n=576)
Male,% 68 74 0.04
Age, years ±SD 61±11 62±11 0.4
Diabetes,% 18 18 0.8
Non-insulin dependent,% 12 13 0.5
Insulin-dependent,% 6 5 0.2
Hypertension,% 41 42 0.9
Hypercholesterolaemia,% 56 62 0.03
Current smoking,% 31 29 0.6
Previous myocardial infarction,% 30 45 0.13
Previous angioplasty,% 19 18 0.8
Previous coronary bypass surgery,% 9 6 0.05
Single-vessel disease,% 46 44 0.5
Multivessel disease,% 54 56 0.5
Clinical presentation <0.001
Stable angina,% 45 45
Unstable angina,% 37 27
Acute myocardial infarction,% 18 28
Cardiogenic shock,%* 10 13
* Relative to patients with acute myocardial infarction.
Table 2. Angiographic and procedural characteristics of patients
treated with SES or PES
SES Group PES Group P- value
(n=508) (n=576)
Treated Vessel
Left anterior descending,% 59 55 0.3
Left circumflex,% 32 33 0.6
Right coronary,% 39 38 0.9
Left main coronary,% 3 4 0.3
Bypass graft,% 3 3 1.0
Lesion type*
Type A or B1% 47 32 <0.001
Type B2 or C% 76 87 <0.001
Multivessel treatment,% 32 29 0.3
Glycoprotein IIb/IIIa inhibitor,% 19 28 0.002
Clopidogrel prescription,
months ±SD 6±0 <0.05
Bifurcation stenting,% 16 16 0.9
Number of stented 
segments ±SD 2.0±1.0 1.7±0.9 <0.001
Number of stented 
vessels ± SD 1.3±0.6 1.3±0.6 0.8
Number of implanted 
stents ± SD 2.1±1.4 2.2±1.5 0.09
Total stented length 
per patient, mm ± SD 38.7±23.7 42.9±31.2 0.02
Nominal stent 
diameter <2.5 mm,% 36 35 0.7
Total stented length >33mm,% 45 48 0.5
Angiographic success 
of all lesions,% 97 97 0.9
* Percentage of patients with at least 1 lesion type within the category.
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adjusted hazard ratios (HRs). Patients lost to follow-up were consid-
ered at risk until the date of last contact, at which point they were
censored.
Results
Baseline and procedural characteristics
Both baseline and procedural characteristics are shown in Tables 1
and 2. In summary, patients were predominantly male and slightly
more frequent in the PES group, PES patients had more myocardial
infarctions (MIs) and cardiogenic shock as their presenting symp-
tom and hypercholesterolaemia was more often present.
Furthermore, PES patients had more complex lesions, received
longer total stent lengths and glycoprotein IIb/IIIa inhibitors were
administered more frequently (28% versus 19%; p=0.002).
Furthermore, fewer PES patients had a history of previous coronary
bypass surgery, and fewer segments per patients were stented,
although the number of vessels treated per patient was identical.
Other baseline and procedural characteristics were similar.
Two-year follow-up
The one-year results of our study have been published previously19.
At two years of clinical follow-up there was no significant difference
in mortality between the SES- and PES-groups, (5.8% versus 7.7%
respectively, HR 1.35, 95% CI 0.84 - 2.16, p=0.21) (Figure 1a). No
difference was found in the combined endpoint of death or MI in
the SES- versus PES-group (9.8% versus 11.9%, HR 1.23, 95% 
CI 0.85-1.78, p=0.26) (Figure 1b). TLR and TVR rates were similar
in both groups. Cumulative incidence of TLR was 6.8% versus
6.3% in the SES group versus the PES group respectively (HR 0.94,
95% CI 0.58-1.51, p=0.79) and TVR was 8.0% in the SES-group
versus 9.6% in the PES-group (HR 1.23, 95% CI 0.81-1.86,
p=0.33) (Figure 1c). Clinically driven TVR was performed in 7.2%
of the SES group compared with 9.4% in the PES group (HR 1.34,
95% CI 0.87-2.06, p=0.18). The two-year cumulative incidence of
combined MACE was 15.4% in the SES-population versus 18.9%
in the PES-population (unadjusted HR 1.26, 95% CI 0.94-1.69,
p=0.12) (Figure 1d). Late stent thrombosis at 2 years occurred in
0.3% of the PES group compared with 0.2% in the SES group. Total
rate of stent thrombosis was 1.6% in the PES group versus 0.6% in
the SES group (p=0.15).
Events between one and two years
In this period a total of 48 events occurred. Twelve patients died in
the SES group, two died of a cardiac cause, 6 patients died of a
non-cardiac cause, 2 patients died suddenly of unknown cause and
of 2 patients the cause of death was unknown. Twelve patients died
also in the pre-SES group, 5 of a cardiac cause, 3 patients died of
non-cardiac causes and the cause of death of 4 patients was
unknown. Three MI’s occurred (two in the SES group versus one in
the PES group). Furthermore, 13 patients received a TVR in the SES
group versus 9 in the PES group, all of them were clinically driven.
Eleven patients treated with SES underwent a target lesion revascu-
larisation and only 4 out of the PES population (p=0.065).
Additionally, 13 patients treated with SES and 5 with PES required
a repeat intervention in a different vessel. One case of late-stent
thrombosis was reported between one- and two-years.
Predictors of adverse events
In order to identify independent predictors of MACE at two years of
follow-up, Cox regression analysis was performed for all baseline
characteristics listed in Tables 1 and 2. The following variables were
significant in predicting MACE at two years of follow-up: age > 65,
female gender, diabetes mellitus, multivessel disease, left main
stenting, bifurcation stenting, lesion type B2 or C and total stented
length (per 10 mm increment) (Table 4). A second analysis was
performed to determine independent predictors of TVR. Diabetes
mellitus, lesion type B2 or C, bifurcation stenting and total stented
length per 10 mm increment were found to be significant.
Subanalyses were performed in several subgroups according to
baseline and procedural characteristics (Figure 2). In patients of
normal weight, defined as body mass index (BMI) <25, patients
Table 3. Events between one and two year of clinical follow-up,
additional to one-year events
SES Group PES Group P- value*
(n=508) (n=576)
Death, n (%) 12 (2.4) 12 (2.1) 0.84
Myocardial infarction, n (%) 2 (0.4) 1 (0.2) 0.60
TLR, n (%)# 11 (2.2) 4 (0.7) 0.065
TVR (including TLR), n (%)‡ 13 (2.6) 9 (1.6) 0.28
Non TVR, n (%) 13 (2.6) 5 (0.9) 0.03
# target lesion revascularisation; ‡ target vessel revascularisation
* by Fisher exact test
Table 4. Independent predictors of MACE and TVR by COX separate
regression analysis. Population tested, includes all patients#
Major Adverse Events* HR 95% CI
Cardiogenic Shock 3.67 2.09-6.46
Left Main treatment 3.44 2.12-5.60
Lesion type B2 or C 2.96 1.72-5.10
Multivessel disease 1.92 1.40-2.62
Diabetes Mellitus 1.87 1.36-2.59
Female gender 1.64 1.22-2.20
Bifurcation stenting 1.62 1.15-2.30
Total stented length 
(per 10 increment) 1.13 1.07-1.21
Age 1.01 1.00-1.03
Target Vessel Revascularisation HR 95% CI
Lesion type B2 or C 4.17 1.69-10.28
Bifurcation stenting 2.00 1.25-3.19
Diabetes 1.73 0.98-2.76
Total stented length
(per 10mm increment) 1.18 1.08-1.28
* Including death, myocardial infarction and target vessel revascularisation
# Stent type was not an independent predictor when entered into the
model
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Figure 1. Two-year adverse events in patients treated with sirolimus- and paclitaxel-eluting stents (SES and PES). Cumulative risk of death (A); death
or myocardial infarction (MI) (B); target vessel revascularisation (C); death, myocardial infarction or target vessel revascularisation (MACE) (D).
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treated with SES had a significantly lower rate of TVR compared to
the PES group (p=0.02). In all other subgroups no superiority was
noticed between SES and PES.
Adjustment for differences between both groups
The Cox proportional hazards regression model was used to adjust
the two groups by correcting for multiple potential confounders in the
baseline and procedural characteristics. First, a model was built forc-
ing stent type and all independent predictors listed in Table 4. All pre-
viously significant variables remained significant except for bifurcation
treatment, age and total stented length. The adjusted HR for use of
PES became even less significant, decreasing from HR 1.26 (95% CI
0.94-1.69, p=0.12) to HR 1.12 (95% CI 0.83-1.51, p=0.44), after
controlling for the increased complexity in the PES group.
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A second model was then built forcing stent type and significant
univariate variables (independent predictors plus number of stents),
and the adjusted outcome of MACE at two year was similar between
SES and PES (adjusted HR 1.11, 95% CI 0.82 to 1.50, p=0.51).
Finally, stent type was also not a significant predictor of TVR when
adjusted for lesion type, bifurcation stenting, diabetes and total
stented length (adjusted HR 1.09, 95% CI 0.72-1.66, p=0.68).
Discussion
The present study reports on the 2-year clinical outcome of the use
of SES and PES in a real world patient cohort and confirms that nei-
ther one of both devices is superior to the other in preventing MACE.
Additionally, no differences were found in the occurrence of death
and MI, TLR and TVR between both groups.
Death and MI occurred in a similar amount in both groups, which is
in accordance with randomised trials15. Additionally, there was a
trend towards a higher incidence of stent thrombosis in the PES
group. It has to be mentioned that in the second year, 2 patients in
the SES group and 3 patients in the PES group died of sudden death
of unknown cause or of a fatal out-of-hospital cardiac arrest. It can-
not be excluded these patients also suffered late thrombotic events.
Whether the SES is superior to PES in terms of late luminal loss and
the ability to reduce the need for re-interventions, is still a topic of
debate. In terms of target lesion revascularisation, both the SIRTAX
and ISAR-DESIRE showed TLR rates favouring SES12,25. However,
the TAXI, REALITY, ISAR-DIABETES and CORPAL studies did not
show a difference between both devices9,10,13,26. In terms of angio-
graphic restenosis, both the SIRTAX and ISAR-DIABETES showed
results favouring the SES. Although, it has to be mentioned that in
the SIRTAX trial the incomplete angiographic follow-up may have
resulted in an overestimation of the difference owing to attrition
bias. However, the medium to long-term difference remains
unknown. The present study reports the 2-year clinical follow-up of
the use of the sirolimus- and paclitaxel- eluting stents in a real world
patient cohort and confirms that neither one of the devices is supe-
rior to the other in preventing the need for revascularisations or the
occurrence of overall MACE. The incidence of baseline characteris-
tics with a predictive value towards a worse outcome was higher in
the PES cohort and the lesions treated in the PES patients were
more difficult overall. This is reflected in the adjusted MACE rate, in
which the difference becomes even smaller. Additionally it has to be
mentioned that between one and two years, the TLR rate is in favour
of the paclitaxel-eluting stent (2.2% versus 0.69%; p=0.065).
When compared to the PES patients, a significantly higher amount of
SES patients underwent angiographic follow-up. Of all patients with
angiographic follow-up, only 6 (6.6%) underwent a TVR because of a
significant (>50% stenosis) without “documented” anginal symp-
toms. Of note, 2 were because of severe proximal stenosis with large
areas of myocardium at risk. Thereby, all TVRs performed in the sec-
ond year were clinically driven. It is for this reason, that we did not
choose clinically driven TVR as a primary endpoint.
An additional rebound phenomenon, as seen in porcine models
and brachytherapy, does not seem to occur, at least after two years
of follow-up. This latter is supported by the FIM study with 4 years
of angiographic follow-up, which demonstrated the absence of a
catch-up phenomenon of restenosis in a small patient population7.
Although both sirolimus- and paclitaxel-eluting stents have been
shown to reduce neointimal proliferation, their mechanisms of
action are different. Both devices modify the healing process after
stent injury, which is the most likely explanation for the reduction in
Figure 2. Hazard ratios (HR) of stent type at two-year follow-up for target vessel revascularisation in subgroups of patients according to base-
line and procedural characteristics. MI=myocardial infarction.
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1.34 (0.60- 3.02) 0.48
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restenosis27. Nevertheless, both drugs interfere with a different part
of the cell cycle and both stents have different polymer coatings and
dissimilar drug-release kinetics28,29. The clinical implications in the
differences between both devices still have to be determined.
Looking at the independent predictors of MACE (table 4), it can be
concluded that patients treated for left main stenosis or complex
lesions (type B2/C) had a significantly higher risk of adverse events
at 2 years. Several trials, like the FREEDOM, COMBAT, SYNTAX and
CARDIA trial, are currently ongoing to see whether these patients
would benefit more from coronary artery bypass surgery30,31.
In the subgroup analyses, we found that patients with a BMI <25
treated with SES had a superior outcome with respect to the need for
TVR when compared to PES. A paradox in the relationship between
BMI and late mortality after PCI with bare-metal stents has been pre-
viously described, however, repeat revascularisation rates were not
shown to be affected by body mass32. Whether the “obesity paradox”
will extend to repeat revascularisations in the DES-era and will be
influenced by the type of DES needs further investigation.
We realize this is an observational, non-randomised cohort study
and thus suffers from its design. For instance, the two sequential
cohorts are separated by a 4-month interval, resulting in several dif-
ferences in both baseline and procedural characteristics. In gener-
al, the PES population was more complex overall. More primary
PCIs were performed, because of the implementation of a pre-hos-
pital protocol that triaged more patients to primary PCI. More com-
plex (Type B2/C) lesions were treated and more stents were
implanted. This latter is likely due to the growing confidence in the
superior properties of DES compared to BMS.
However, our study comprises an all-inclusive unrestricted patient
population which is able to represent the daily clinical practice of a
large catheterisation laboratory and thus may possess a greater
generalisability than has been possible with randomised trials.
Conclusion
The medium term follow-up of the T-SEARCH registry shows that
the unrestricted use of SES and PES was still safe at two years. No
significant difference was found in the adjusted outcome of both
devices in terms of death or MI, TLR, TVR or MACE. The inferior
trend in crude outcome seen in PES was, in part, due to its higher-
risk population. A trend towards less TLR in the PES group between
one and 2 years was also observed. No late clinical restenotic phe-
nomenon was seen in either group and stent thrombosis after one
year occurred in only one patient.
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Three-Year Clinical Follow-Up of the Unrestricted Use of Sirolimus-Eluting
Stents as Part of the Rapamycin-Eluting Stent Evaluated at Rotterdam
Cardiology Hospital (RESEARCH) Registry
Joost Daemen, MD, Andrew T.L. Ong, MBBS, Giulio G. Stefanini, MD,
Keiichi Tsuchida, MD, PhD, Helle Spindler, BSc, Georgios Sianos, MD, PhD,
Peter P.T. de Jaegere, MD, PhD, Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD*
Sirolimus-eluting stents (SESs) have been shown to decrease restenosis compared with bare
metal stents (BMSs). Currently, there are limited data on the long-term efficacy of these
devices in a real-world patient population. Furthermore, the potential of a late restenotic
phenomenon has not yet been excluded. From April to October 2002, 508 consecutive
patients with de novo lesions exclusively treated with SESs were enrolled and compared
with 450 patients treated with BMSs in the preceding 6 months (control group). Patients in
the SES group more frequently had multivessel disease and type C lesions, received more
stents, and had more bifurcation stenting. After 3 years, the cumulative incidence of major
adverse cardiac events (comprising death, myocardial infarction, and target vessel revas-
cularization) was significantly lower in the SES group compared with the pre-SES group
(18.9% vs 24.7%, hazards ratio 0.73, 95% confidence interval 0.56 to 0.96, p  0.026). The
3-year risk of target lesion revascularization was 7.5% in the SES group versus 12.6% in the
pre-SES group (hazards ratio 0.57, 95% confidence interval 0.38 to 0.87, p  0.01). In
conclusion, the unrestricted use of SESs is safe and superior to the use of BMSs. The
beneficial effects, reported after 1 and 2 years in reducing major adverse cardiac events,
persisted with no evidence of a clinical late restenotic “catch-up” phenomenon. © 2006
Elsevier Inc. All rights reserved. (Am J Cardiol 2006;98:895–901)
Sirolimus-eluting stents (SESs) have been shown to mark-
edly decrease neointimal hyperplasia compared with bare
metal stents (BMSs).1–7 Although there was no significant
change in neointimal thickness at 2 to 4 years of follow-up
in the first-in-human trial,8 other data have suggested a
possible delayed healing response that might result in a late
restenotic phenomenon. Examples of this phenomenon are a
few reports of delayed neointimal growth, a local hypersen-
sitivity reaction with late in-stent thrombosis, and some
cases of stent fracture with local tissue proliferation.9–12
Although a recent meta-analysis demonstrated the efficacy
of drug-eluting stents in general in decreasing restenosis,13
no difference was seen in rates of death and myocardial
infarction after relatively short-term follow-up. This study
presents the 3-year clinical outcome of the unrestricted use
of the SES compared with a BMS in a real-world patient
population that was treated for de novo lesions. Our objec-
tives were to investigate whether the positive 2-year results
were still present after 3 years and to describe the events
that occurred between the second and third years.14
Methods and Results
Methods of the Rapamycin-Eluting Stent Evaluated at Rot-
terdam Cardiology Hospital (RESEARCH) registry have
been previously reported.15 Briefly, the RESEARCH is a
single-center registry evaluating the safety and efficacy of
SES implantation in patients treated in daily practice. On
April 16, 2002, our institution commenced the use of SESs
(Cypher, Cordis Corporation, Warren, New Jersey) as the
default strategy for every percutaneous coronary interven-
tion, with the aim of including a patient population repre-
senting the “real world.” In the first 6 months of enrollment,
508 patients with de novo lesions were treated exclusively
with SESs (SES group) and compared with a group of 450
consecutive patients treated with BMSs for de novo lesions
in the preceding 6 months (pre-SES group) matched for
stent diameter.16 This protocol was approved by the hospital
ethics committee and was in accordance with the Declara-
tion of Helsinki. Written informed consent was obtained
from every patient.
All procedures were performed according to current
standard procedural guidelines, and their details have been
previously reported.17 Angiographic success was defined as
residual stenosis30% by visual analysis in the presence of
Thrombolysis In Myocardial Infarction grade 3 flow. All
patients were advised to maintain lifelong aspirin. At least
1-month of clopidogrel treatment (75 mg/day) was recom-
mended for patients treated in the pre-SES phase. For pa-
tients treated with SESs, clopidogrel was prescribed for 3
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months, unless 1 of the following was present: multiple SES
implantation (3 stents), total stented length 36 mm,
persistent total occlusion, and bifurcations. In these cases,
clopidogrel was maintained for 6 months.
Our primary end point was major adverse clinical events
(MACEs) at 3-year follow-up. MACEs were defined as a
composite of all-cause death, nonfatal myocardial infarc-
tion, or target vessel revascularization. Target vessel revas-
cularization was defined as a reintervention driven by any
lesion located in the same coronary vessel. A secondary end
point was target lesion revascularization, defined as treat-
ment of a lesion in the stent or within 5 mm of the stent
borders. Myocardial infarction was diagnosed by an in-
crease in creatine kinase-MB fraction of 3 times the upper
limit of normal, according to American Heart Association/
American College of Cardiology guidelines.18,19 Late stent
thrombosis was defined as angiographically defined throm-
bosis with Thrombolysis In Myocardial Infarction grade 0
or 1 flow or the presence of a flow-limiting thrombus,
occurring 1 month after drug-eluting stent implantation
accompanied by acute symptoms.20 Hypercholesterolemia
was defined as a fasting serum cholesterol level5.5 mmol/L
or use of lipid-lowering therapy at the time of the procedure.
Patients were contacted at 6 months and at 1, 2, and 3
years. Follow-up will continue yearly until 5 years. Survival
status was obtained through municipal civil registries.
Health questionnaires inquiring about postdischarge repeat
coronary interventions (surgical or percutaneous), myocar-
dial infarction, and medication usage were subsequently
sent to all living patients. Follow-up information was pro-
spectively entered into a dedicated database. If a patient had
a myocardial infarction or reintervention at another center,
medical records or discharge letters were requested and
systematically reviewed. Local cardiologists or general
practitioners were also contacted as necessary. Follow-up
was available for 97.5% of our patients at a mean time of
1,095  265 days.
Continuous variables are presented as mean  SD and
were compared by Student’s t test. Categorical variables are
presented as counts and percentages and were compared by
Fisher’s exact test. The cumulative incidence of adverse events
was estimated according to the Kaplan-Meier method, and
curves were compared using log-rank test. Separate Cox
regression analyses were performed to identify independent
predictors of adverse events using clinical, angiographic,
and procedural variables listed in Tables 1 and 2. Cox
proportional hazards regression models were used to control
for differences between groups and independent predictors
of outcome. Final results are presented as adjusted hazard
ratios. Patients lost to follow-up were considered at risk
until the date of final contact, at which point they were
censored.
Baseline and procedural characteristics have been previ-
ously described and are presented in Tables 1 and 2. Ap-
proximately 50% of patients in the 2 groups were admitted
with acute coronary syndromes, and diabetes was present in
16%. Patients treated with SESs had significantly more mul-
tivessel disease, more type C lesions, more bifurcation stent-
ing, more segments stented, and more stents used (p 0.01).
Table 1
Baseline clinical characteristics
Variable Pre-SES Group SES Group p
Value(n  450) (n  508)
Men 72% 68% 0.4
Age (yrs), mean  SD 61  11 61 11 0.7
Diabetes mellitus 15% 18% 0.3
Non–insulin-dependent mellitus 11% 12% 0.7
Insulin-dependent mellitus 4% 6% 0.2
Hypertension 48% 41% 0.2
Hypercholesterolemia* 55% 56% 1.0
Current smoking 34% 31% 0.3
Previous myocardial infarction 40% 30% 0.01
Previous angioplasty 18% 19% 0.8
Previous coronary bypass surgery 8% 9% 0.5
Single-vessel disease 52% 46% 0.05
Multivessel disease 48% 54% 0.05
Clinical presentation — — 0.7
Stable angina pectoris 48% 45% —
Unstable angina pectoris 35% 37% —
Acute myocardial infarction 18% 18% —
Cardiogenic shock† 12% 10% 0.7
* Defined as a fasting cholesterol level 5.5mmol/L or use of lipid-
lowering therapy.
† Compared with patients with acute myocardial infarction.
Table 2
Angiographic and procedural characteristics
Pre-SES Group SES Group p
Value(n  450) (n  508)
Treated coronary vessel*
Left anterior descending artery 59% 59% 0.8
Left circumflex artery 33% 32% 0.7
Right artery 34% 39% 0.2
Left main artery 2% 3% 0.6
Bypass graft 2% 3% 0.2
Lesion type
A 20% 22% 0.4
B1 32% 31% 0.7
B2 50% 49% 0.8
C 30% 43% 0.01
Glycoprotein IIb/IIIa inhibitor 33% 19% 0.01
Clopidogrel prescription (mo) 2.9  2.0 4.0 2.0 0.01
Bifurcation stenting 8% 16% 0.01
No. of stented segments 1.8  0.9 2.0 1.0 0.01
No. of implanted stents 1.9  1.2 2.1  1.4 0.01
Individual stent length 33 mm 10% 35% 0.01
Total stented length per patient
(mm)
30.1 19.6 38.7  28.7 0.01
Nominal stent diameter 2.5
mm
23% 36% 0.01
Postdilatation with a balloon
0.5 mm larger
19% 55% 0.01
Angiographic success of all
lesions
97% 97% 1.0
Values are numbers (percentages) or means  SDS.
* Expressed as percentage of patients with vessel type treated. Total
exceeds 100%.
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Further, in the SES group, long stents and stents with
smaller diameters were more frequently used. Periproce-
dural administration of glycoprotein IIb/IIIa inhibitors was
more frequent in the pre-SES phase (33% vs 19%;
p 0.01). The angiographic success rate was similar in the
2 groups.
The 1-, 2-, and 3-year results are shown in Figure 1. At
1 year, the cumulative risk of MACEs (a composite of
death, myocardial infarction, or target vessel revasculariza-
tion) was significantly decreased in the SES group (9.7% vs
14.8% in the pre-SES group, hazard ratio 0.62, 95% confi-
dence interval 0.44 to 0.89, p  0.008). This difference
remained significant after 2 years, with an incidence of
15.4% in the SES group versus 22% in the pre-SES group
(hazard ratio 0.68, 95% confidence interval 0.50 to 0.91,
p  0.01). The difference in outcomes between groups was
mainly due to a decreased need for target vessel revascu-
larization in the SES group. The cumulative incidence of
death and death or myocardial infarction remained similar
between groups after 1 and 2 years of follow-up.
At 3 years, there were no significant differences in cu-
mulative mortality between the SES and pre-SES groups
(8.7% vs 7.9%, hazard ratio 1.09, 95% confidence interval
0.70 to 1.71, p  0.69; Figure 2). The combined end point
of death or myocardial infarction was also similar at 12.9%
in the SES group versus 12.6% in the pre-SES group (haz-
ard ratio 1.02, 95% confidence interval 0.71 to 1.45, p 
0.93; Figure 2). The 3-year incidence of the combined end
point of MACEs remained lower in the SES group com-
pared with the pre-SES group (18.9% vs 24.7%, unadjusted
hazard ratio 0.73, 95% confidence interval 0.56 to 0.96, p
0.026; Figure 2) and was driven by a significantly lower
incidence of target vessel revascularization in the SES
group (9.4% vs 16.6% respectively, hazard ratio 0.54, 95%
confidence interval 0.37 to 0.78, p  0.001; Figure 2).
Similarly, the difference in target lesion revascularization
remained significantly lower at 7.5% in the SES group
compared with 12.6% in the pre-SES group (hazard ratio
0.57, 95% confidence interval 0.38 to 0.87, p  0.01).
Between 2 and 3 years, 31 events occurred (Table 3).
Fourteen patients in the SES group died: 3 were classified as
cardiac and 6 as noncardiac. Four patients died suddenly of
unknown causes and in 1 case the cause of death was
unknown. Seven patients in the pre-SES population died: 4
died of cardiac death and 3 died from an unknown cause.
Three myocardial infarctions occurred in the SES group
compared with 2 in the pre-SES group. Further, in the SES
group, 6 target vessel revascularizations occurred compared
with 7 in the pre-SES group. Target lesion revascularization
occurred in 3 patients in the SES group versus 5 in the
pre-SES group. Overall, MACE rates were 18 versus 12 in
the SES and pre-SES groups, respectively, between 2 and 3
years of follow-up. In addition, 2 patients in the SES group
versus 3 in the pre-SES group underwent revascularization
in a different vessel. There was no significant difference
between groups for any of these different event rates. Two
cases of angiographically documented late stent thrombosis
occurred in the SES group. The first patient, a 60-year-old
woman, was admitted 36 months after a procedure with
acute myocardial infarction. Clopidogrel was contraindi-
cated because of gastrointestinal bleeding of unknown ori-
gin after the procedure. The second patient, a 71-year-old
man, was admitted with cardiogenic shock 26 months after
the procedure and died.
Figure 1. Cumulative incidence of adverse events at 1, 2, and 3 years in patients treated with SESs (black bars) and BMSs (gray bars). MI  myocardial
infarction; TVR  target vessel revascularization.
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To identify independent predictors of MACEs and target
vessel revascularization at 3 years, Cox regression analyses
were performed for all baseline and procedural characteris-
tics listed in Tables 1 and 2 (Table 4). Age, diabetes, hyper-
tension, previous angioplasty, multivessel disease, cardiogenic
shock at presentation, lesion type B2 or C, treatment of the
left main coronary artery, and total stented length (per
10-mm increment) were significant predictors of MACEs at
3 years. In addition, saphenous graft treatment and the use
of SESs were protective. Further, diabetes, hypertension,
previous percutaneous coronary intervention, acute coro-
nary syndrome at presentation, lesion type B2 or C, and
total stented length (per 10-mm increment) were significant
predictors of target vessel revascularization, whereas acute
coronary syndrome at entry and the use of SESs were
protective.
When adjusted for these independent predictors of
MACE and target vessel revascularization, the use of SESs
remained significantly protective for MACEs (hazard ratio
0.61, 95% confidence interval 0.46 to 0.81, p  0.001) and
target vessel revascularization (hazard ratio 0.44, 95% con-
fidence interval 0.30 to 0.65, p 0.001) at 3 years of
follow-up.
Discussion
Currently, there are no long-term results of the unrestricted
use of SESs in a real-world patient population. The present
report shows that SESs remain superior to BMSs in decreas-
ing the need for reinterventions in the long term, even after
adjustment for independent predictors of adverse events. At
3 years, the use of SESs resulted in a relative decrease of
Figure 2. Three-year adverse events in patients treated with BMSs (pre-SES) and SESs: (A) cumulative risk of death, (B) death or myocardial infarction
(MID), (C) target vessel revascularization, (D) death, myocardial infarction, or target vessel revascularization. CI  confidence interval; other abbreviations
as in Figure 1.
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39% in MACEs, whereas target vessel revascularization
was decreased by 56% compared with the use of BMSs.
No difference was found between groups in terms of
death and myocardial infarction. These findings are par-
ticularly noteworthy because patients treated with SESs
generally had more complex disease than those treated
with BMSs; however, they are in accordance with the
findings of a large meta-analysis on drug-eluting stents
and many other publications that showed no difference in
long-term survival outcome, not even compared with
medical therapy.13,21,22
Between 2 and 3 years of follow-up, relatively few non-
target vessel revascularizations occurred in the 2 groups (3
in the pre-SES group vs 2 in the SES group). Twenty-one
patients died. Whether the 4 patients in the SES group who
died suddenly of an unknown cause between 2 and 3 years
died of stent thrombosis remains an important question.
However, because of the low frequency of postmortems, a
detailed analysis of the exact causes of death was not fea-
sible. In terms of overall causes of death, our results concur
with those of several trials, which reported an almost equal
incidence of cardiac and noncardiac causes of death after
2 years of follow-up in this type of population.1–5
Patients treated for left main stenosis or complex lesions
(type B2/C) were independently associated with a worse
MACE outcome at 3 years. Several trials, such as the Future
Revascularization Evaluation in patients with Diabetes
mellitus: Optimal management of Multivessel disease
(FREEDOM), COMparison of Bypass Surgery and Angio-
plasTy Using Sirolimus-eluting Stent in Patients With Un-
protected Left Main Coronary Artery Disease (COMBAT),
Synergy between Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery (SYNTAX), and Coronary Ar-
tery Revascularisation in Diabetes (CARDIA) trials, are
currently ongoing to investigate whether these patients
would benefit more from coronary artery bypass sur-
gery.23,24
Several post hoc subanalyses were performed and, al-
though they concern relatively small numbers of patients,
the results give an impression of the outcome of different
patient groups treated with SES after 3 years of follow-up
(Figure 3). In patients treated for acute coronary syndromes
at entry, the use of SESs demonstrated a decrease of 70%
in clinically driven target vessel revascularization (p 
0.006) at 1 year.16 At 3 years, we found a risk decrease in
target vessel revascularization of 38%, with only a trend
toward a more favorable outcome with the use of SESs
(p  0.1; Figure 3). The same finding was observed in
patients presenting with an acute myocardial infarction
and patients treated for multivessel disease and bifurca-
tion lesions. Further, the benefit of SESs was not statis-
tically significant after 1 year or at 3 years in women and
diabetic patients. Although limited to 1 year of follow-
up, previous studies showed that diabetic patients treated
with SESs had a better outcome than those treated in a
conventional way.25 This was a post hoc subgroup anal-
ysis with small numbers of patients, and the results jus-
tify larger, longer term, and more detailed studies with
these subpopulations.
With MACE rates remaining constant between 1 and 3
years, no late clinical restenotic phenomenon was observed.
It is clear that the long-term beneficial effects of SESs are
mainly due to the marked decrease in restenosis rates in the
first year. After 1 year, the Kaplan-Meier curves for target
vessel revascularization and MACEs remain essentially par-
allel, but, more importantly, the beneficial results are sus-
tained. These findings are in accordance with the 2-year
angiographic follow-up data after SES implantation and
with the recently published 3-year results of the Random-
ized study with the sirolimus-eluting Velocity balloon-ex-
pandable stent in the treatment of patients with de novo
native coronary artery Lesions (RAVEL) trial.6,26,27 The
present study extends these observations to a population that
is representative of 1 treated in a tertiary intervention center
with the unrestricted use of SESs.
Table 3
Events between two and three years of clinical follow-up
Variable Pre-SES Group SES Group p
Value(n  450) (n  508)
Death 7 (1.6%) 14 (2.8%) 0.27
Myocardial infarction 2 (0.4%) 3 (0.6%) 1.00
TLR 5 (1.1%) 3 (0.6%) 0.48
Target vessel revascularization
(including TLR)
7 (1.8%) 6 (1.2%) 0.78
Nontarget vessel revascularization 3 (0.7%) 2 (0.4%) 0.67
MACEs 12 (2.7%) 18 (3.5%) 0.46
TLR  target lesion revascularization.
Table 4
Independent predictors of major adverse cardiac events and target vessel
revascularization by Cox separate regression analysis
HR 95% CI
MACEs
Cardiogenic shock 3.61 1.91–6.82
Left main treatment 2.70 1.47–4.95
Diabetes mellitus 2.08 1.53–2.84
Lesion type B2 or C 1.74 1.22–2.47
Multivessel disease 1.63 1.23–2.16
Previous angioplasty 1.57 2.14–2.16
Hypertension 1.38 1.05–1.81
Total stented length (per 10-mm increment) 1.10 1.05–1.15
Age 1.02 1.00–1.03
Use of SESs 0.73 0.56–0.96
Saphenous graft treatment 0.41 0.23–0.74
Target vessel revascularization
Diabetes mellitus 2.21 1.48–3.31
Lesion type B2 or C 1.69 1.06–2.69
Previous intervention 1.55 1.02–2.36
Hypertension 1.49 1.04–2.15
Total stented length (per 10-mm increment) 1.11 1.05–1.18
Acute coronary syndrome at presentation 0.60 0.41–0.86
Use of SESs 0.54 0.37–0.78
CI  confidence interval; HR  hazard ratio.
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Although the safety of drug-eluting stents has been under considerable scrutiny, limited
real-world follow-up data extending up to 4 years are available. The randomized clinical
trials carefully selected patients and are not reflective of everyday practice. From April to
October 2002, 508 consecutive patients treated with sirolimus-eluting stents (SES) were
enrolled. The control group consisted of 450 patients treated with bare-metal stents during
the preceding 6 months. After 4 years of follow-up, the incidence of composite major
adverse clinical events (all-cause death, myocardial infarction, or target vessel revascular-
ization) was found to be significantly lower in the SES group (23.0% vs 28.7%, adjusted
hazard ratio 0.66, 95% confidence interval 0.51 to 0.86), as were rates of target vessel
revascularization (12.2% vs 17.8%, adjusted hazard ratio 0.57, 95% confidence interval 0.39
to 0.83). There were no differences in all-cause mortality (10.5% for SES vs 10.6% for
bare-metal stents, p  0.9) or in the rates of cardiac death (4.5% vs 6.9%, p  0.1).
Although there was no difference in overall stent thrombosis (2.3% vs 2.2%, p  1.0), SES
had a higher rate of very late stent thrombosis (1.4% vs 0%, p  0.02), balanced by a lower
rate of early stent thrombosis (0.4% vs 1.8%, p  0.05). In conclusion, after 4 years, SES
were found to remain safe and effective compared with bare-metal stents. Nevertheless, the
higher rate of very late stent thrombosis remains a concern. Longer term follow-up will be
required to determine the extent of this problem. © 2008 Elsevier Inc. All rights reserved.
(Am J Cardiol 2008;101:1105–1111)
Long-term analyses of randomized trials of drug-eluting stents
(DES) show a persisting benefit of DES on restenosis and
target lesion revascularization, whereas mortality rates with
DES and bare-metal stents (BMS) are equivalent, despite con-
cerns regarding late stent thrombosis.1–5 Inevitably, these ran-
domized trials have selective inclusion criteria, but in the real
world, DES are often used beyond their labeled indications, for
example, in bifurcation lesions, coronary artery bypass grafts,
chronic total occlusions, long lesions requiring multiple over-
lapping stents, and acute myocardial infarction (MI).6 Despite
using sirolimus-eluting stents (SES) for “off-label” indications
in a considerable number of cases, we have previously
reported an ongoing benefit of SES after 3 years of
follow-up in real-world consecutive patients.7 Here, we
present the clinical outcomes after 4 years.
Methods
The Rapamycin-Eluting Stent Evaluated at Rotterdam Cardi-
ology Hospital (RESEARCH) registry has already been de-
scribed.8 On April 16, 2002, our institution commenced the use
of SES (Cypher; Cordis Corporation, Miami Lakes, Florida) as
the default strategy for every percutaneous coronary interven-
tion. In the first 6 months of enrollment, 508 patients with de
novo lesions were treated exclusively with SES (the SES
group) and compared with a group of 450 consecutive patients
treated with BMS for de novo lesions in the preceding 6
months (the pre-SES group), matched for stent diameter.9 The
protocol was approved by the hospital’s ethics committee and
is in accordance with the Declaration of Helsinki. Written
informed consent was obtained from every patient.
All procedures were performed following current stan-
dard procedural guidelines as previously reported.10 Angio-
graphic success was defined as residual stenosis 30% by
visual analysis in the presence of Thrombolysis In Myocar-
dial Infarction (TIMI) grade 3 flow. All patients were ad-
vised to maintain lifelong aspirin. At least 1 month of
clopidogrel treatment (75 mg/day) was recommended for
patients treated in the pre-SES phase. For patients treated
with SES, clopidogrel was prescribed for3 months, unless
1 of the following was present: multiple SES implantation
(3 stents), total stented length 36 mm, chronic total
occlusion, or bifurcation treatment. In these patients, clopi-
dogrel was maintained for 6 months.
The prespecified primary end point was major adverse
clinical events (MACEs), defined as a composite of all-
cause death, nonfatal MI, or target vessel revascularization
(TVR).8 MI was diagnosed by an increase in creatine ki-
nase-MB fraction of 3 times the upper limit of normal,
according to American Heart Association and American
College of Cardiology guidelines.11,12 Stent thrombosis was
defined as angiographically documented thrombus with
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TIMI grade 0 or 1 flow, accompanied by acute symptoms
(consistent with the definition of definite stent thrombosis as
recommended by the Academic Research Consortium).13,14
The timing of stent thrombosis was categorized into early
(30 days after implantation), late (30 days to 1 year), or
very late (1 year).14
Follow-up survival data for all patients were obtained from
municipal civil registries. The causes of death were classified
according to the International Classification of Diseases and
Related Health Problems, 10th Revision. A health question-
naire was subsequently sent to all living patients with specific
inquiries on rehospitalization and MACEs. Because ours is the
principal regional cardiac referral center, repeat procedures
(percutaneous and surgical) are normally performed at our
institution and recorded prospectively in our database. For
patients who had adverse events at other centers, medical
records or discharge summaries from the other institutions
were systematically reviewed. General practitioners, referring
cardiologists, and patients were contacted as necessary if fur-
ther information was required.
Continuous variables were compared using Student’s t
test and are presented as mean  SD. Categorical variables
were compared using either Fisher’s exact test or Pearson’s
chi-square test (both 2-sided) and are presented as counts
and percentages. The cumulative incidence of adverse
events was estimated according to the Kaplan-Meier
method, and curves were compared using the log-rank test.
Patients lost to follow-up were considered at risk until the
date of last contact, at which point they were censored.
Separate Cox regression analyses were performed to iden-
tify predictors of adverse events, using the clinical, angio-
graphic, and procedural variables listed in Tables 1 and 2.
Variables with a significance of p 0.05 were entered into
a Cox multivariate regression analysis; the final results are
presented as adjusted hazard ratios (HRs) with 95% confi-
dence intervals (CIs).
Results
Complete follow-up was available for 95.5% of patients.
The baseline clinical characteristics of the 2 groups were
similar except for a higher prevalence of multivessel disease
in the SES group (54.2% vs 47.8%, p  0.05) and a lower
incidence of previous MI (30.2% vs 39.7%, p  0.02). Full
baseline and procedural details are listed in Tables 1 and 2.
Overall, patients treated with SES underwent more complex
treatment (more type C lesions, more bifurcations, more
stents used, longer total stent length, and smaller average
stent diameter). As previously reported, overall 38% of SES
group underwent repeat coronary angiography in the first
year, while none of the BMS group underwent a scheduled
restudy.9 After the first year, all cases of repeat angiography
were clinically mandated.
Table 1
Baseline characteristics
Variable BMS
(n  450)
SES
(n  508)
p Value
Men 70.4% 67.9% 0.4
Age (yrs) 60.8  11.0 61.1  11.0 0.7
Body mass index (kg/m2) 26.6  3.6 27  4 0.1
Previous MI 39.7% 30.2% 0.02
Previous coronary bypass
surgery
8.0% 9.3% 0.5
Previous percutaneous
intervention
18.0% 18.8% 0.8
Multivessel coronary disease 47.8% 54.2% 0.05
Hypercholesterolemia* 55.3% 55.3% 1.0
Hypertension‡ 37.6% 41.3% 0.2
Family history of coronary
disease
28.2% 32.5% 0.2
Current smoker 34.0% 30.7% 0.3
Diabetes mellitus 14.9% 17.7% 0.2
Clinical presentation 0.6
Stable angina pectoris 47.6% 44.7%
Unstable angina pectoris 34.7% 37.2%
Acute MI 17.8% 18.1%
Cardiogenic shock† 11.3% 9.8% 0.7
Data are expressed as mean  SD or percentages.
* Defined as fasting total cholesterol 5mmol/L (193 mg/dl) or the use
of lipid-lowering therapy.
† Refers to patients with acute MIs.
‡ Defined as blood pressure 140/90 mm Hg or treatment for
hypertension.
Table 2
Procedural characteristics
Variable BMS
(n  450)
SES
(n  508)
p Value
Coronary vessel treated*
Left anterior descending 59.3% 58.7% 0.8
Right 34.0% 38.6% 0.1
Left circumflex 33.1% 31.7% 0.6
Saphenous vein graft 2.0% 3.3% 0.2
Left main 2.2% 3.0% 0.5
ACC/AHA lesion type
A 19.6% 21.9% 0.4
B1 31.8% 30.7% 0.7
B2 49.6% 48.6% 0.8
C 29.8% 42.5% 0.01
Bifurcation 7.8% 15.7% 0.01
Nominal stent length 33 mm 9.8% 35.0% 0.01
No. of stents 1.8  1.1 2.2  1.4 0.01
Total stent length (mm) 30.1  19.6 38.8  27.9 0.01
Glycoprotein IIb/IIIa inhibitor
used
33.3% 19.3% 0.01
Average stent diameter (mm) 3.15  0.31 2.85  0.21 0.01
Angiographic success 97.3% 97.2% 0.9
Clopidogrel duration (mo) 1  0.1 4.2  2 0.01
Data are expressed as mean  SD or percentages.
* Patients with each vessel type, hence total 100%.
ACC  American College of Cardiology; AHA  American Heart
Association.
Table 3
Cumulative incidence of adverse events
Variable BMS SES p Value
Death 48 (10.6%) 53 (10.5%) 0.9
MI 23 (5.2%) 21 (4.2%) 0.5
TVR 78 (17.8%) 60 (12.2%) 0.02
Composite MACEs 127 (28.7%) 115 (23.0%) 0.05
Stent thrombosis 10 (2.2%) 12 (2.3%) 1.0
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Figure 1. Kaplan-Meier survival curves for (A) freedom from death, (B) freedom from TVR, (C) freedom from composite MACEs (defined as
or TVR), and (D) freedom from stent thrombosis.
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Figure 1. (continued).
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The clinical outcomes after 3 years of follow-up have
already been reported.7 The event rates after 4 years are
listed in Table 3. The cumulative survival rates for death,
TVR, overall MACEs, and stent thrombosis are displayed in
Figure 1. As indicated in Table 4, there were no statistically
significant differences in the occurrence of any clinical end
point between 3 and 4 years of follow-up, although there
was a trend toward a higher rate of TVR in the SES group.
The cause of death was ascertained in all cases. Analysis of
the causes of death showed no significant differences be-
tween the 2 groups during 4 years of follow-up, as demon-
strated in Figure 2.
Further examination of patients with stent thrombosis
revealed that despite no statistically significant difference in
overall stent thrombosis rates between the 2 groups, the
BMS group had a higher incidence of early stent thrombo-
sis, whereas the SES group had a higher incidence of very
late stent thrombosis, as listed in Table 5. The status of
antiplatelet therapy at the time of stent thrombosis was
available for 18 of the 21 patients. One BMS patient with
early stent thrombosis and 1 DES patient with very late stent
thrombosis had recently stopped clopidogrel (within 1
week). The details of antiplatelet therapy at the time of stent
thrombosis are shown in Figure 3.
The independent predictors of mortality were cardio-
genic shock (HR 5.79, 95% CI 2.46 to 13.6), left main
coronary artery treatment (HR 2.17, 95% CI 1.00 to 4.17),
diabetes mellitus (HR 1.78, 95% CI 1.11 to 2.85), age (per
10-year increment HR 1.42, 95% CI 1.16 to 1.74), and
angiographic success (HR 0.43, 95% CI 0.19 to 0.98). The
only independent predictors of definite stent thrombosis
were the presence of insulin-dependent diabetes (HR
3.87, 95% CI 1.13 to 13.3), acute MI at presentation (HR
2.58, 95% CI 1.03 to 6.44), and treatment of the left
anterior descending artery (HR 0.33, 95% CI 0.11 to
0.99). The presence of diabetes was the only independent
predictor of MI (HR 2.16, 95% CI 1.12 to 4.15). All
independent predictors for TVR or composite MACEs
are listed in Table 6. Treatment with SES did not predict
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Figure 2. Causes of death expressed as percentages of all deaths in each
group. There were no statistically significant differences for any of the
categories.
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Figure 3. Antiplatelet therapy at the time of stent thrombosis.
Table 4
Events between 3 and 4 years of follow-up
Variable BMS SES p Value
Death 11 (2.4%) 10 (2.0%) 0.66
MI 1 (0.2%) 2 (0.4%) 1.0
TVR 5 (1.1%) 10 (2.0%) 0.31
Composite MACEs 13 (2.9%) 19 (3.7%) 0.48
Stent thrombosis 0 (0%) 1 (0.1%) 1.0
Other revascularization 2 (0.4%) 4 (0.8%) 0.69
Table 5
Timing of definite stent thrombosis
Variable BMS SES p Value
Early 8 (1.8%) 2 (0.4%) 0.05
Acute 4 (0.9%) 1 (0.2%) 0.2
Subacute 4 (0.9%) 1 (0.2%) 0.2
Late 2 (0.4%) 2 (0.4%) 1.0
Very late 0 (0%) 7 (1.4%) 0.02
Total 10 (2.2%) 11 (2.2%) 1.0
Early stent thrombosis was defined as occurring within 30 days of the
index procedure, acute stent thrombosis within 24 hours, subacute stent
thrombosis from 24 hours to 30 days, late stent thrombosis from 30 days
to 1 year, and very late stent thrombosis 1 year after the index
procedure.
Table 6
Independent predictors of target vessel revascularization and major
adverse clinical events
Variable HR 95% CI
TVR
Diabetes mellitus 1.80 1.18–2.77
AHA/ACC lesion type B2 or C 1.78 1.08–2.95
Previous percutaneous intervention 1.62 1.06–2.46
Treatment with SES 0.57 0.39–0.83
Prespecified composite MACEs
Cardiogenic shock 3.59 1.81–7.14
Left main treatment 1.98 1.06–3.73
Diabetes mellitus 1.81 1.34–2.43
Previous percutaneous intervention 1.52 1.12–2.05
Total stent length (per 10-mm increment) 1.11 1.00–1.23
Treatment with SES 0.66 0.51–0.86
Abbreviations as in Table 2.
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death (adjusted HR 0.88, 95% CI 0.59 to 1.31), MI
(adjusted HR 0.67, 95% CI 0.36 to 1.23), or overall stent
thrombosis (adjusted HR 0.97, 95% CI 0.41 to 2.29) but
was protective against TVR (adjusted HR 0.57, 95% CI
0.39 to 0.83) and composite MACEs (adjusted HR 0.66,
95% CI 0.51 to 0.86).
Discussion
In this report, we have described long-term clinical out-
comes after the use of SES in an all-comers, real-world
registry. We have previously reported results after 1, 2, and
3 years of follow-up, all of which have demonstrated no
difference in mortality but a continued benefit of SES with
respect to TVR and overall MACEs.7,9,15 To date, there
appears to be no diminution of the protective effect of SES
treatment with time; after 2 years, the HR for TVR was 0.53
(95% CI 0.36 to 0.79), and the HR for composite MACEs
was 0.68 (95% CI 0.50 to 0.91), while after 4 years, these
values were 0.57 (95% CI 0.39 to 0.83) and 0.66 (95% CI
0.51 to 0.86), respectively.15 Thus, after 4 years, the bene-
ficial treatment effect of SES on TVR and composite
MACEs was maintained, with no evidence of any late
“catch-up” effect of restenosis. Although 4-year follow-up
data are available for the randomized trials of SES, our data
provide the longest possible follow-up for more complex
patients because we used SES as a default treatment
strategy for all patients as soon as they became commer-
cially available.
There have been several recent reports addressing the
safety of DES, particularly with regard to mortality and
stent thrombosis.1–5,16 Two analyses examined 1,748 pa-
tients enrolled in the 4 main randomized SES trials (the
Randomized Study With the Sirolimus-Eluting Velocity
Balloon-Expandable Stent [RAVEL], Sirolimus-Eluting
Stent in Coronary Lesions [SIRIUS], Canadian Sirolimus-
Eluting Stent in Coronary Lesions [C-SIRIUS], and
European Sirolimus-Eluting Stent in Coronary Lesions
[E-SIRIUS]).3,4 They found no significant differences in
4-year rates of mortality or stent thrombosis between SES
and BMS. Another meta-analysis of 4,958 patients enrolled
in randomized trials, including some complex patients such
as those presenting with acute MI and those who underwent
saphenous vein or chronic total occlusion treatment, also
found no difference in the rate of death or stent thrombosis
between SES and BMS patients after a maximum of 5 years
of follow-up.1 A recently reported network analysis of
18,000 patients enrolled in 38 randomized DES trials
(including 6,771 patients treated with SES and 4,921 pa-
tients treated with BMS) also found no differences between
SES and BMS with regard to mortality or stent thrombosis
after up to 4 years of follow-up.5 However, treatment with
SES was protective against MI (HR 0.81, 95% CI 0.66 to
0.97).
The findings in this report are consistent with these
recent meta-analyses: we also found no difference in mor-
tality or stent thrombosis, although our overall mortality
rates were higher than those reported in the meta-analyses
of the randomized trials.1,3,4 In our patients, we found no
significant differences in mortality between the BMS and
SES groups, although the SES patients underwent more
complex treatment. Reassuringly, there was a trend toward
a reduced rate of cardiac death with SES compared with
BMS (4.5% vs 6.9%, p  0.1).
Similarly, the rate of definite stent thrombosis (2.3% for
SES vs 2.2% for BMS) was higher in our cohort than in a
meta-analyses of the randomized trials (1.2% for SES vs
0.6% for BMS using the trial definitions for stent thrombo-
sis and 1.5% for SES vs 1.7% for BMS using the Academic
Research Consortium definitions for definite and probable
stent thrombosis).16 An analysis of 8,000 patients treated
with DES (paclitaxel-eluting stents and SES) demonstrated
an overall stent thrombosis rate of 2.9% after 3 years, with
an ongoing incidence of late stent thrombosis of 0.6% per
year.2 Among the 3,875 patients treated with SES, the stent
thrombosis rate was 2.7% after 4 years of follow-up.17 In the
present cohort, the early stent thrombosis rate was lower in
the DES group, despite the DES patients’ receiving glyco-
protein IIb/IIIa antagonists less frequently and having un-
dergone treatment of smaller vessels and longer lesions.
Although early stent thrombosis is associated with subop-
timal angiographic and intravascular ultrasound findings,18
the pathophysiologic mechanisms of late stent thrombosis
are quite different (related to delayed healing and incom-
plete endothelialization19,20); late stent thrombosis was more
common in our DES cohort, although there were no signif-
icant differences in overall stent thrombosis. Most patients
with stent thrombosis were on some form of antiplatelet
therapy at the time of the event, but our patient numbers
were too small to draw any conclusions from this. It remains
unclear whether prolonged dual-antiplatelet therapy would
have prevented these adverse events.
Data are available from several large registries from
across the globe, all of which demonstrate decreased mor-
tality with DES compared with BMS.21–25 The Swedish
Coronary Angiography and Angioplasty Registry (SCAAR)
initially reported on 19,771 patients and found that after 3
years, treatment with DES was associated with a 32% in-
crease in mortality.26 However, subsequent data from
SCAAR conformed to those found by the other registries,
namely, that DES are associated with improved survival
(although not reaching statistical significance in all).23,27
Although these registries included much larger numbers
of patients, they tended to investigate patients treated at
institutions at which DES and BMS were used concomi-
tantly, raising the possibility of selection bias. Furthermore,
only approximately 1/3 of these patients were treated with
DES, and the maximum published follow-up data are for 3
years. As such, the mortality rates in our 2 patient groups
were higher than in the other registries, whose outcomes
data reflect the randomized trials more closely.
Our study also highlights the particular risk endured by
diabetic patients: diabetes was an independent predictor of
all clinical events, serving a reminder that these patients
need aggressive risk factor and lifestyle management. Fur-
thermore, treatment of the left main stem was associated
with an increased 4-year risk for overall MACEs and death,
suggesting that coronary artery bypass surgery should re-
main the preferred strategy for such patients. Ongoing ran-
domized multicenter studies will shed further light on this
issue.
In conclusion, after 4 years, therefore, it appears that the
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safety of SES is maintained in real-world patients. Mortality
rates for the BMS and SES groups were higher than those
reported in the randomized trials; presumably, this reflects
the higher risk and more complex nature of our series of
consecutive all-comers as opposed to carefully selected ran-
domized trial patients.
The major weakness of this study is that it was a single-
center registry using a historically lower risk BMS control
group. Furthermore, the patient numbers may have been too
small to detect small differences in mortality.
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Chapter 7
Treatment of coronary artery disease of dialysis 
pati ents with sirolimus-eluti ng stents: 1-year 
clinical follow-up of a consecuti ve series of cases
Daemen J, Lemos PA, Aoki J, Arampatzis C, Hoye A, McFadden E,        
Serruys PW 
 J Invasive Cardiol. 2004;16(12):685-7

ABSTRACT: From April 16, 2002 to October 16, 2002, 10consec-
utive patients with coronary disease on chronic dialysis were treated
with sirolimus-eluting stents. Diabetes was present in 30% and half of
the patients had multivessel coronary disease. On average, patients had
been on dialysis for 5 years prior to the procedure (range: 2–15 years).
Five patients were on hemodialysis and 5 patients were on peritoneal
dialysis. Overall, 18 lesions were treated with 1.9 ± 1.1 sirolimus-eluting
stents per patient. At a mean follow-up of 403 days, there were no cases
of death, myocardial infarction, or target lesion revascularization.
J INVAS CARDIOL 2004;16:xxx–xxx
Key words: renal failure, dialysis, coronary disease, stent,
restenosis, drug-eluting stent
In this preliminary series, sirolimus-eluting stent implanta-
tion appeared safe and effective for the treatment of dialysis
patients with coronary artery disease. Dialysis patients are well
known to be a high-risk population for cardiovascular morbidity
and mortality, especially due to coronary atherosclerotic disease.
However, the management of coronary disease in patients with
end-stage renal failure is often problematic due to the presence of
multiple co-morbidities and frequent limitations to drug pre-
scription.1 Moreover, these patients have been reported to be at a
higher risk for short- and long-term complications after invasive
treatment compared to non-dialysis patients.2,3
The overall impact of invasive coronary treatment in dialysis
patients is an ongoing debate. In a recent report, coronary
bypass surgery was associated with superior outcomes compared
to conventional stenting, with in-stent restenosis being suggest-
ed as a possible contributor to the impaired outcomes after per-
cutaneous treatment.4
Sirolimus-eluting stents (SES) have been recently shown in
randomized studies to markedly decrease neointimal growth and
in-stent restenosis in comparison with conventional stents.5-7 How-
ever, all clinical trials conducted to date excluded patients with
decreased renal function, and therefore the impact of SES implan-
tation in patients with renal failure is currently unknown. The pre-
sent study aimed to report on the 1-year clinical outcomes of a
consecutive series of patients on chronic dialysis treated with SES.
Since April 2002, SES (Cypher; Johnson & Johnson-Cordis
unit, Cordis Europa NV, Roden, the Netherlands) have been
routinely utilized as the device of choice for all patients treated
with percutaneous coronary intervention in our institution.8
During the first 6 months of this policy, SES implantation was
performed in ten consecutive patients on chronic dialysis, who
comprise the present study population. All patients on either
chronic haemodialysis or peritoneal dialysis at the time of the
procedure were included.
Methods
Percutaneous interventions were performed utilizing standard
techniques, with the final strategy entirely left at the discretion of
the operator aiming to achieve a residual stenosis < 30% by visual
analysis with TIMI 3 antegrade flow. All patients were advised to
maintain lifelong aspirin and clopidogrel was prescribed for at least
3 months.
Patients were prospectively evaluated during follow-up for
the occurrence of death, non-fatal myocardial infarction, or tar-
get lesion revascularisation (TLD). Myocardial infarction was
diagnosed by a rise in the creatine kinase level to more than
twice the upper normal limit with an increased creatine kinase-
MB. TLD was defined as a repeat intervention (surgical or per-
cutaneous) to treat a luminal stenosis within the stent or in the
5-mm distal or proximal segments adjacent to the stent. This
protocol was approved by the local ethics committee and is in
accordance with the Declaration of Helsinki. Written, informed
consent was obtained from every patient.
Clinical, procedural, and follow-up characteristics of the 10
patients included in the present report were detailed in Table 1.
Mean age was 55 years, and 5 patients (50%) were male. Dia-
betes was present in 3 patients (30%) and most were hyperten-
sives (70%). Half of the patients had multivessel coronary
disease. On average, patients were on dialysis for 5 years prior to
the procedure (range: 2–15 years). Five patients were on
hemodialysis and 5 patients were on peritoneal dialysis. Two
patients had had kidney transplantation prior to the procedure.
Patient 5 underwent kidney transplantation 12 years ago and
lost his transplant 1 year after the transplantation, while patient
6 underwent kidney transplantation twice, 24 and 18 years ago,
but lost the last graft 14 years ago.
Overall, 18 lesions (range 1–4 lesions per patient) were treat-
ed with 1.9 ± 1.1 SES per case (range 1–4), and an average
stented length of 38 ± 26 mm per patient (range 8–87 mm).
The left anterior descending artery was stented in 5 patients
(50%) and the left main coronary in one patient. All treated
lesions were de novo lesions and moderate to severe coronary
Treatment of Coronary Artery Disease of Dialysis Patients With
Sirolimus-eluting Stents: 1-year Clinical Follow-up of a
Consecutive Series of Cases
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angiographic calcification was observed in 4 patients (40%).
Glycoprotein IIbIIIa inhibitors were not utilized in any
patient (Table 1).
Complete clinical follow-up was available for all patients at
an average of 403 days (range: 338–463). There were no cases of
death, myocardial infarction, or target lesion revascularization.
One patient (patient 4), was admitted with unstable angina 8
months after the procedure. Coronary angiogram showed widely
patent SES but severe lesion progression in other vessel seg-
ments. The patient was referred to surgical treatment. Another
patient (patient 5) underwent balloon dilatation in a side branch
at 6 months, with no evidence of restenosis at the previously
stented site. Four of our patients underwent kidney transplanta-
tion during follow-up, at 8 months (patient 1), 5 months
(patient 2), 6 months (patient 4), and 3 months post-procedure
(patient 7) (Table 1).
Results
In the present study, SES implantation for patients on dialy-
sis appeared to be safe and associated with an extremely low inci-
dence of adverse events at 1-year follow-up, with no cases of
repeat intervention due to restenosis.
Table 1. Baseline, procedural, and follow-up characteristics of 10 dialysis patients treated with sirolimus-eluting stents
Patient no. 1 2 3 4 5 6 7 8 9 10
Age, years 54 62 52 59 48 57 46 41 82 44
Male sex 0 + 0 + 0 + + 0 + 0
Risk factors
Diabetes mellitus 0 0 0 0 + 0 0 + 0 +
Systemic hypertension + 0 + 0 + + 0 + + +
Hypercholesterolemia + + + 0 + + 0 0 0 +
Current smoking 0 0 0 0 0 0 + 0 0 0
Previous coronary surgery 0 0 0 0 0 0 0 0 + 0
Previous angioplasty 0 0 0 0 0 0 0 0 0 0
Previous myocardial infarction 0 + 0 0 0 0 0 0 0 0
Previous renal transplantation 0 0 0 0 + + 0 0 0 0
Dialysis
Duration at procedure, years 4 5 3.5 4 15 5 0.5 3 6 2
Route perit           perit        Hemod      hemod       hemod        perit            perit           perit        hemod        hemod
Clinical presentation SAP           UAP SI SI AP         UAP SI           AUP AP UAP
Coronary vessel disease 1 2 2 1 3 1 1 2 2 1
Vessels treated RCA      RCA, LAD  LAD, LCx   RCA     RCA, LM    RCA          RCA      LAD, LCx   RCA, LAD   LAD
Number of SES implanted 1 3 2 1 4 1 1 3 2 1
Total stented length, mm 8 59 66 18 87 18 18 49 41 18
Clinical Follow-up
Duration, days 445             463            388            446            374           368            393            392           380 379
Renal transplantation during follow-up at 8 mo.     at 5 mo. 0            at 6 mo. 0 0            at 3 mo. 0 0 0
Death 0 0 0 0 0 0 0 0 0 0
Myocardial infarction 0 0 0 0 0 0 0 0 0 0
Target lesion revascularization 0 0 0 0 0 0 0 0 0 0
hemod = hemodialysis; LAD = left anterior descending; LCx = left circumflex artery; LMC = left main coronary; perit = peritoneal; RCA = right coronary artery;
SAP = stable angina pectoris; SES = sirolimus-eluting stents; SI = silent ischemia; UAP = unstable angina pectoris.
Table 2. Previous studies with end stagerenal disease patients treated with percutaneous coronary intervention.
Author Year Follow-Up (months) No. Death Repeat revascularization MACE
Hang16 2000 14 31 65% NA NA
Kahn9 1990 20 17 41% 67% NA
Ahmed10 1994 12 21 33% NA NA
Rinehart11 1995 24 24 49% NA NA
Marso13 1996 24 23 63% 52% NA
Herzog15 1999 24 6887 47% NA NA
Herzog4* 2002 42 4280 71% NA NA
Hase21* 2001 12 23 5% 13% 28%
Malanuk20* 2001 18 10 30% 0% 30%
Simsir14 1998 18 19 31% NA 40%
Le Feuvre17* 2000 12 27 15% 33% 41%
Agirbasli18 2000 12 122 23% 16% 44%
Azar19* 2000 9 34 18% 39% 50%
Le Feuvre22 2003 48 112 27% 44% 51%
Koyanagi12 1996 5 20 10% 75% 82%
RESEARCH 2003 12 10 0 20% 20%
*Numbers shown to patients treated with stent implantation. NA = not available; MACE = death, myocardial infarction, or any repeat revascularization.
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Discussion
Our favourable results clearly contrasts with the previously
reported high rate of late complications following angioplasty in
dialysis patients, as shown in Table 2.2,4,9–22 Although the present
study did not include an angiographic re-evaluation, the
uneventful late clinical outcomes observed were consistent with a
marked reduction in the incidence of restenosis, as seen in non-
dialysis patients.5–7
Coronary surgery has been associated with better clinical out-
comes than percutaneous intervention in patients on chronic
dialysis.4 However, the impact of restenosis as a contributor to
the worse outcomes after angioplasty is still to be clarified.4 Five
out of ten patients in the present series had undergone multives-
sel SES implantation. In all of these patients, the interventional
treatment included stenting of lesions located in the left anterior
descending artery or left main coronary, an anatomical scenario
typically referred to surgical treatment. Whether SES constitutes
an effective therapeutic option for dialysis patients with multi-
vessel disease will have to be determined in further studies incor-
porating larger number of patients.
The SES decrease restenosis by locally delivering the antipro-
liferative drug, which eventually inhibits neointimal formation
and prevents late lumen renarrowing. The interaction between
the local administration of sirolimus and the systemic immuno-
suppression therapy in patients undergoing renal transplantation
is currently unclear. In our series, renal transplantation was per-
formed in 4 patients during the follow-up period. None of these
patients presented any clinical complication that could be associ-
ated with increased drug toxicity. However, importantly, in all
cases the transplantation was performed at least 3 months after
the coronary procedure and, based on the known drug kinetics
of SES, most of the drug should have been released by 1 month
after the implantation. 
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Comparison of Three-Year Clinical Outcome of Sirolimus- and
Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients
With ST-Segment Elevation Myocardial Infarction
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Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs)
in decreasing the need for repeat revascularization in patients with ST-segment elevation
myocardial infarction (STEMI) at 1 year. Whether this also holds for paclitaxel-eluting
stents (PESs) is currently unclear and the long-term relatively efficacy of the 2 drug-eluting
stents is currently unknown. We investigated the 3-year efficacy of SESs and PESs versus
BMSs in patients with STEMI. Primary angioplasty was performed in a consecutive group
of 505 patients (BMSs in 183, SESs in 186, PESs in 136). At 3 years, the cumulative
mortality rate was comparable in the 3 groups: 13.3% in the BMS group, 11.5% in the SES
group, and 12.4% in the PES group (nonsignificant for all). The rate of target vessel
revascularization (TVR) was 12.0% in the BMS group compared with 8.0% and 7.7% in the
SES and PES groups, respectively (p  0.12 for BMS vs SES, 0.30 for BMS vs PES, 0.62
for SES vs PES). The cumulative incidence of death, MI, or TVR was 25.5% in the BMS
group compared with 17.9% and 20.6% in the SES and PES groups, respectively (p  0.06
for BMS vs SES, 0.32 for BMS vs PES, 0.45 for SES vs PES). Angiographic stent thrombosis
occurred in 2.4% of all patients (BMS 1.6%, SES 2.7%, PES 2.9%). In conclusion, in this
relatively small consecutive patient cohort, the use of SESs and PESs was no longer
associated with significantly lower rates of TVR and major adverse cardiace events in
patients with STEMI after 3 years of follow-up. A high frequency of stent thrombosis was
observed in the 2 drug-eluting stent groups. © 2007 Elsevier Inc. All rights reserved. (Am
J Cardiol 2007;99:1027–1032)
Primary percutaneous coronary intervention, with or with-
out stenting, has been shown to result in superior long-term
outcome compared with thrombolytic therapy in patients
with acute myocardial infarction (MI).1 Recently, several
studies have reported that sirolimus-eluting stents (SESs)
and paclitaxel-eluting stents (PESs) are more effective in
decreasing restenosis and the frequency of repeat interven-
tions than are bare metal stents (BMSs), which rapidly
resulted in an unrestricted use of drug-eluting stents also in
patients with ST-segment elevation MI (STEMI).2–4 Shortly
after the introduction of SESs in 2002 the first studies
appeared, hypothesizing that the therapeutic range of SESs
could be extended to use in patients presenting with MI.
Compared with BMSs, SESs were associated with less
restenosis and target vessel revascularization (TVR) up until
1 year of follow-up.3,5 Currently it is unclear whether this
also holds for PESs.4,6 To date, there are no data on the
long-term outcome of the use of SESs and PESs in patients
with STEMI, a growing high-risk subgroup that is becom-
ing a substantial recipient of the total number of percutane-
ous coronary interventions in many centers all over the
world. For that reason, we evaluated the 3-year clinical
outcomes of a series of consecutive patients with STEMI
treated with BMSs, SESs, or PESs as part of a primary
percutaneous coronary intervention strategy.
Methods
On April 16, 2002, our institution commenced the use of
SESs (Cypher, Cordis Corp., Warren, New Jersey) as the
default strategy for every percutaneous coronary interven-
tion, with the aim of including a patient population repre-
senting the “real world.”7 Up until January 2003, 186 con-
secutive patients were treated with primary angioplasty
using exclusively SESs for STEMI. In February 2003 the
PES replaced the SES as the device of choice for all per-
cutaneous coronary interventions. Until September 2003,
136 primary percutaneous coronary interventions were per-
formed using exclusively PESs for STEMI. A control group
of 183 consecutive patients with STEMI treated with BMSs
immediately before April 2002 was retrospectively selected.
Of note, the 2 study groups were part of the Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
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(RESEARCH) and Taxus-Stent Evaluated at Rotterdam
Cardiology Hospital (T-SEARCH) registries, respectively.
All patients were enrolled in the analysis including patients
in cardiogenic shock (defined as systolic blood pressure
persistently90 mm Hg or the need for inotropic support or
intra-aortic balloon pump implantation to maintain a blood
pressure 90 mm Hg with evidence of organ end failure
and increased left ventricular filling pressures). Patients
who underwent rescue percutaneous coronary intervention
after failed thrombolysis or who had previous brachyther-
apy were not included in this study. This protocol was
approved by the hospital ethics committee and is in accor-
dance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
All procedures were performed according to current
standard procedural guidelines and their details have been
reported previously.8,9 Baseline and postprocedural flows
were evaluated offline according to the Thrombolysis In
Myocardial Infarction criteria by cardiologists blinded to
stent group and clinical outcomes. All patients were advised
to maintain lifelong aspirin. At least 1 month of clopidogrel
treatment (75 mg/day) was recommended for patients
treated in the BMS group. In the 2 drug-eluting stents
groups, clopidogrel was prescribed for 3 months unless
multiple SES implantation (3 stents), total stented length
36 mm, persistent total occlusion, or bifurcations was
present. In these cases clopidogrel was prescribed for 6
months.
Patients were prospectively followed for the occurrence
of major adverse cardiac events (defined as a composite of
all-cause death, nonfatal MI, or TVR). Reinfarction was
diagnosed by recurrent symptoms and/or new electrocardio-
graphic changes in association with increases in creatine
kinase and creatine kinase myoglobin levels of 1.5 times
the previous value, if within 48 hours, or3 times the upper
normal limit, if 48 hours after the index infarction.10,11 TVR
was defined as a reintervention driven by any lesion located
in the same coronary artery. A secondary end point was
Table 1
Baseline and procedural characteristics of patients treated with bare metal, sirolimus, or paclitaxel-eluting stents
Variable BMS Group SES Group PES Group p Value
(n  183) (n  186) (n  136)
Men 79% 75% 84% 0.2
Age (yrs) 57 12 60  12 59  12 0.1
Diabetes mellitus 12% 12% 6% 0.1
Hypercholesterolemia* 34% 37% 46% 0.1
Hypertension 26% 27% 24% 0.8
Current smoker 48% 47% 42% 0.5
Previous MI 24% 14% 11% 0.006
Previous coronary angioplasty 9% 7% 6% 0.6
Previous coronary bypass grafting 3% 2% 2% 0.6
No. of coronary arteries narrowed 50% 0.6
1 48% 55% 52%
2 29% 27% 29%
3 24% 18% 19%
Cardiogenic shock 10% 13% 12% 0.6
Time from symptom onset to angioplasty (h) 3.5  3.8 3.3  2.1 3.2  2.4 0.8
Infarct-related coronary vessel 0.7
Left anterior descending 57% 53% 52%
Left circumflex 10% 8% 9%
Right coronary 30% 37% 36%
Left main 1% 2% 2%
Bypass graft 2% — 2%
TIMI flow at baseline 0.8
Grade 0/1 73% 73% 78%
Grade 2 15% 17% 11%
Grade 3 13% 10% 10%
TIMI flow after angioplasty 0.6
Grade 0/1 4% 2% 2%
Grade 2 17% 15% 12%
Grade 3 79% 83% 86%
Bifurcation lesion 4.4% 9.1% 9.6% 0.13
No. of implanted stents 1.7  1.0 1.9  1.2 1.8  1.1 0.1
Total stented length (mm) 30.3  20 34.7  24 35.9  23 0.055
Clopidogrel prescription (mo) 2.3  1.6 4.2  2.0 5.7  1.0 0.001
Glycoprotein IIb/IIIa inhibitor 56% 37% 55% 0.001
Peak creatinine kinase (U/L) 3,957  5,135 3,126  3,126 2,875  2,713 0.1
Peak creatinine kinase-MB (IU/L) 319  230 296  255 320  306 0.7
Values are percentages of patients or means  SDs.
* Defined as a fasting total serum cholesterol level 5.5 mmol/L (210 mg/dl) or use of lipid-lowering therapy.
TIMI  Thrombolysis In Myocardial Infarction.
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target lesion revascularization, defined as treatment of a
lesion in stent or within 5 mm of the stent borders. Subacute
stent thrombosis was defined as an angiographically docu-
mented complete occlusion (Thrombolysis In Myocardial
Infarction grade 0 or 1 flow) or a flow-limiting thrombus
(Thrombolysis In Myocardial Infarction grade 1 or 2 flow)
in the first 30 days after a successful procedure. Late stent
thrombosis was defined as angiographically defined throm-
bosis with Thrombolysis In Myocardial Infarction grade 0
or 1 flow or the presence of a flow limiting thrombus
occurring 1 month after drug-eluting stent implantation
accompanied by acute symptoms.12
Three-year survival status was obtained through munic-
ipal civil registries. Health questionnaires were subse-
quently sent to all living patients and inquired about post-
discharge repeat coronary interventions (surgical or
percutaneous) and MI. If a patient had an MI or a reinter-
vention at another center, medical records or discharge
letters were requested and systematically reviewed. Local
cardiologists or general practitioners were contacted if nec-
essary. Follow-up was available for 98% of patients with
BMSs, 98% of patients with SESs, and 97% of patients with
PESs.
Continuous variables are presented as mean  SD. Cat-
egorical variables are expressed as percentages. Compari-
sons across the 3 groups were performed by the F test from
an analysis of variance for continues variables and Pearson
chi-square test for categorical variables. The cumulative
incidence of adverse events was estimated according to the
Kaplan-Meier method. Patients were censored at 1, 2, and 3
Figure 1. Kaplan-Meier survival curves of (A) TVR and (B) combined cumulative incidence of major adverse cardiac events (MACE; death, MI, and TVR).
  change.
Table 2
Major adverse cardiac events at one year and two and three years
Variable BMS Group SES Group PES Group p Value
(n  183) (n  186) (n  136)
Events in first year
All-cause mortality 17 (9.3%) 15 (8.1%) 11 (8.1%) 0.89
MI 6 (3.3%) 2 (1.1%) 6 (4.4%) 0.17
TVR (all) 14 (7.7%) 3 (1.6%) 9 (6.6%) 0.021
Stent thrombosis 3 (1.6%) 1 (0.5%) 4 (2.9%) 0.22
Hierarchical MACEs 34 (18.6%) 18 (9.7%) 21 (15.4%) 0.048
Events in second year
All-cause mortality 5 (2.7%) 4 (2.2%) 3 (2.2%) 0.92
MI — 1 (0.5%) — 0.42
TVR (all) 4 (2.2%) 5 (2.7%) 1 (0.7%) 0.45
Stent thrombosis — 1 (0.5%) — 0.423
Hierarchical MACEs 8 (4.4%) 9 (4.8%) 4 (2.9%) 0.69
Events in third year
All-cause mortality 2 (1.1%) 2 (1.1%) 2 (1.5%) 0.94
MI — 3 (1.6%) — 0.075
TVR (all) 2 (1.1%) 4 (2.2%) — 0.21
Stent thrombosis — 3 (1.6%) — 0.075
Hierarchical MACEs 4 (2.2%) 6 (3.2%) 2 (1.5%) 0.76
MACEs  major adverse cardiac events.
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years to report the cumulative incidence of major adverse
cardiac events and TVR in the 2 Kaplan-Meier curves.
Overall incidences were tested using log-rank test. Cox
proportional hazards regression analyses were performed to
correct for independent predictors of adverse events and
differences across groups. Independent predictors were de-
termined for each end point in the 3 compared groups (SES
vs BMS, SES vs PES, PES vs BMS) by using all univariate
significant (p 0.1) baseline and procedural characteristics
listed in Table 1. Independent predictors of outcome were
forced into the model, together with stent type used. The
final results are presented as adjusted hazard ratios. Patients
lost to follow-up were considered at risk until the date of
final contact, when they were censored.
Results
Clinical baseline characteristics were comparable among
groups, with the exception of previous MI, which was more
frequent in the BMS group (24%) than in the SES and PES
groups (14% and 11%, respectively, p  0.006; Table 1).
There were few differences in procedural characteristics
among groups: Glycoprotein IIb/IIIa inhibitor use was
higher in the BMS (56%) and PES (55%) groups than in the
SES group (37%, p 0.001), and as defined by the study
protocol clopidogrel prescription was longer in the 2 drug-
eluting stent groups than in the BMS group.
Thirty-day and 1-year outcome have been reported pre-
viously.8,9 At 3 years, the cumulative mortality rate was
comparable in the 3 groups (13.3% in the BMS group,
11.5% in the SES group, and 12.4% in the PES group;
log-rank p  0.63 for BMS vs SES, 0.78 for BMS vs PES,
0.86 for SES vs PES). Cause of death was cardiac in 62%,
unknown in 18%, and noncardiac in 20% of patients. In the
BMS group 3.5% developed a new MI compared with 4.0%
in the SES group and 4.7% in the PES group (log-rank p 
0.99 for BMS vs SES, 0.62 for BMS vs PES, 0.52 for SES
vs PES). Target lesion revascularization was performed in
8.4% of patients in the BMS group compared with 6.2% in
the SES group and 6.1% in the PES group (log-rank p 
0.27 for BMS vs SES, 0.56 for BMS vs PES, 0.58 for SES
vs PES). There was a trend toward a higher incidence of
TVR in the BMS group (12.0%) compared with the SES
(8.0%) and PES (7.7%) groups (Figure 1). The combined
cumulative incidence of major adverse cardiac events was
25.5% in the BMS group compared with 17.9% in the SES
group and 20.6% in the PES group (Figure 1). Events
occurring in the second and third years of follow-up are
presented in Table 2.
At 3 years, 12 patients (2.4%) presented with angio-
graphically documented stent thrombosis. Three patients
(1.6%) in the BMS group developed stent thrombosis com-
pared with 5 (2.7%) in the SES group and 4 (2.9%) in the
PES group (p  0.72 for SES vs BMS, 0.46 for PES vs
BMS). Stent thrombosis occurred relatively soon after the
index percutaneous coronary intervention at a mean of 8.7
days (range 6 to 11) and 3.5 days (range 0 to 6) in the BMS
and PES groups, respectively. In contrast, in the SES group
stent thrombosis occurred much later, at a mean of 685 days
(range 18 to 1,074). Three of 4 patients with stent throm-
bosis after 1 year were on single antiplatelet therapy with
aspirin and 1 stopped using aspirin 2 days before the event.
Two patients presented with unstable angina and 2 with MI.
One patient in the PES group had 3 recurrent thrombotic
events at 4, 8, and 11 days after the procedure and died
during the third event of a subsequent MI despite being on
dual antiplatelet therapy. Although beyond the scope of the
present analysis, it is worth mentioning that 1 patient in the
PES group developed stent thrombosis at 1,100 days after
the procedure, 2 days after stopping dual antiplatelet ther-
apy, because of an elective surgical procedure. All cases of
stent thrombosis were treated using balloon angioplasty
with 100% glycoprotein IIb/IIIa use and additional stents
were used in 4 cases.
In Cox multivariate analysis performed in the total pop-
ulation, bifurcation treatment (in which 2 stents were used
in 92% of patients) proved to be the strongest predictor of
stent thrombosis (hazard ratio 7.84, 95% confidence interval
2.12 to 29.03) followed by female gender, which had a
cardioprotective effect (hazard ratio 0.17, 95% confidence
interval 0.05 to 0.58). Cox multivariate regression models
were also used to correct for differences and independent
predictors of adverse events between each pair of groups
(SES vs BMS, PES vs BMS, and PES vs SES; Table 3).
After adjustment, no significant differences were seen in the
3 comparisons in any clinical end point (death, nonfatal MI,
TVR, and major adverse cardiac events).
Discussion
The main findings of the present analysis of 505 consecutive
patients presenting with STEMI are (1) the superiority of
Table 3
Major adverse cardiac events up to three years
Variable BMS Group
(n  183)
SES Group
(n  186)
PES Group
(n  136)
Relative Risk (95% CI)
SES vs BMS PES vs BMS PES vs SES
Mortality at 1 yr 9.4% 8.1% 8.1% 0.81 (0.36–1.81) 1.01 (0.66–1.53) 1.24 (0.52–2.95)
Mortality at 3 yrs 13.3% 11.5% 12.4% 0.78 (0.41–1.51) 1.08 (0.77–1.52) 1.62 (0.80–3.27)
Nonfatal MI at 1 yr 3.5% 1.2% 4.7% 0.30 (0.06–1.53) 1.11 (0.62–1.99) 5.40 (1.07–27.6)
Nonfatal MI at 3 yrs 3.5% 4.0% 4.7% 0.95 (0.30–2.98) 1.11 (0.62–1.99) 2.03 (0.63–6.51)
TVR at 1 yr 8.2% 1.7% 6.9% 0.23 (0.06–0.85) 1.11 (0.72–1.72) 10.45 (1.76–62.2)
TVR at 3 yrs 12.0% 8.0% 7.7% 0.65 (0.30–1.37) 0.98 (0.66–1.46) 1.69 (0.70–4.07)
MACEs (death, MI, and TVR) at 1 yr 18.7% 9.7% 15.5% 0.57 (0.32–1.03) 0.99 (0.75–1.31) 1.49 (0.79–2.82)
MACEs (death, MI, and TVR) at 3 yrs 25.5% 17.9% 20.6% 0.77 (0.48–1.23) 0.97 (0.76–1.24) 1.17 (0.69–1.97)
CI  confidence interval; other abbreviation as in Table 2.
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SESs in decreasing TVR compared with BMSs and PESs at
1 year was no longer present at 3 years, (2) PESs were not
superior to BMS in decreasing the incidence of adverse
cardiac events at 1, 2, and 3 years of follow-up, and (3) stent
thrombosis in this high-risk subgroup occurred with an
overall incidence of 2.4% at a mean of 289 days after the
procedure (median 10 days, interquartile range 4.5 to 757)
and did not differ significantly across the 3 groups.
Previous (non)randomized studies have reported that the
use of the 2 types of drug-eluting stent result in similar rates
of death and MI compared with BMSs.13,14 A recent meta-
analysis of randomized trials comparing SESs with PESs
also showed no significant difference in these end points.15
The results of the present study concur with those of the
previously mentioned studies and are supported by a recent
meta-analysis of the results of SES implantation in patients
with acute MI.5
The success of drug-eluting stents is primarily driven by
their capability to decrease restenosis and the need for
repeat interventions, but the currently available long-term
follow-up is based on randomized studies, which excluded
patients with STEMI.14 At 1 year, we observed a relative
decrease of 80% in the risk for TVR with the use of SESs
compared with BMSs (p  0.006). However, at 2 and 3
years, the relative decreases were 59% (p 0.003) and 44%
(p 0.12), respectively. PESs showed no significant benefit
in decreasing TVR compared with BMSs at 1 years or 2 or
3 years. These 1-year results concur with those of the Trial
to Assess the Use of the Cypher Stent in Acute Myocardial
Infarction Treated with Balloon Angioplasty (TYPHOON)
trial, which randomized 700 patients and showed that
SESs were superior to BMSs in patients presenting with
acute MI.3 With regard to PESs, the randomized Paclitaxel-
Eluting Stent versus Conventional Stent in Myocardial In-
farction with ST-Segment Elevation (PASSION) trial con-
firmed our findings that PESs were not superior to BMSs in
each clinical end point at 1 year of follow-up.4 The favor-
able results of the SESs in the TYPHOON trial might have
been influenced by the high TVR rate in the BMS control
arm and the angiographic follow-up in a considerable num-
ber of patients.
The loss of the superiority of SESs compared with BMS
after 1 year of follow-up might be partly explained by the
occurrence of late stent thrombosis, which occurred in 4
patients (2.1%) in the SES group in the third year of fol-
low-up compared with a 0% incidence in the BMS group.
These 4 cases of late stent thrombosis comprised 50% of the
total number of TVRs performed in the third year of fol-
low-up and accounted for 100% of all MIs occurring be-
tween the first and third year. The increased incidence in
very late stent thrombosis in the SES group is in accordance
with a recent report by Togni et al,16 which showed a trend
toward a higher incidence of very late stent thrombosis in
patients treated with SESs. Although stenting in the setting
of MI proved to be a consistent predictor of stent thrombo-
sis, current reports about the occurrence of stent thrombosis
after 1 year and especially after 2 years are still scarce.17–19
The total incidence of stent thrombosis in this high-risk
patient population was 2.4% and was, although mostly due
to the longer follow-up, higher than that in previous reports
in which stent thrombosis rates were 1.0% to 1.7%.12,20,21
The incidence of stent thrombosis in the BMS group in the
present study was 1.6% and in is agreement with that in
previous reports.22 Stent thrombosis occurred in 2.9% of
patients in the PES group, all within the first week after the
index percutaneous coronary intervention. No late stent
thrombosis was observed from 1 year to 3 years. This latter
observation does not concur with a previous study, which
reported late stent thrombosis rates of 	0.8% in patients
treated with PESs.23 However, the occurrence and rate of
early stent thrombosis in the PES group was comparable to
that in the BMS group, occurring mainly within the first 2
weeks after stent implantation.24 It is unknown whether the
late deaths of unknown cause were due to stent thrombosis.
Dual antiplatelet therapy was not able to prevent the 10
early thrombotic events. Whether it would have prevented
the late cases of stent thrombosis remains unclear. Thus, the
relative efficacy of dual antiplatelet therapy remains un-
known, even when taking into account the increased costs,
higher bleeding risk, and possibility of aspirin and/or clo-
pidogrel resistance.25–28
A limitation of the present study is that the results are
based on a nonrandomized patient population without com-
pletely identical groups. An example of this is glycoprotein
IIb/IIIa prescription, which was lower in the SES group.
However, its use did not prove to be protective against
adverse events and short- and long-term outcomes in the
present study, which is in accordance with the current lit-
erature.29 Further, the results are based on a relatively small
patient cohort and therefore may have lack of power. Nev-
ertheless, the present study is the first in the world to
complete longer-term follow-up of this high-risk patient
subset because Europe was the first to grant Conformité
Européenne mark approval for the 2 types of drug-eluting
stent, whereas approval by the US Food and Drug Admin-
istration was granted 1 year later.
The recently published 1-year results of the randomized,
controlled PASSION and TYPHOON trials showed dis-simi-
lar outcomes with respect to the different drug-eluting stents
used.3,4 However, until they are able to present longer-term
follow-ups, the present single-center prospective registry,
which aims to represent a real-world patient population, shows
that the “unrestricted” use of SESs and PESs might not be
justified in patients presenting with STEMI when taking into
account the long-term adverse events.
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The long-term value of sirolimus- and paclitaxel-eluting
stents over bare metal stents in patients with diabetes
mellitus
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Aims To investigate the outcome of a real world diabetic patient cohort treated with bare metal stents
(BMS), sirolimus-, or paclitaxel-eluting stents (SES and PES, respectively). Due to the different mechan-
isms of action of both drugs it is currently unknown which device is the best option to treat these high-
risk patients.
Methods and results The study compares the 2-year clinical outcome of 708 consecutive diabetic
patients (25% insulin treated) treated with either a BMS (n ¼ 252), a SES (n ¼ 206), or a PES
(n ¼ 250), as part of the RESEARCH and T-SEARCH registries. Target vessel revascularization was
19.5% in the BMS group, vs. 15.3% in the SES group and 9.7% in the PES group. PES (21.2%), but not
SES (28.9%), were superior to BMS (29.7%) in reducing major adverse cardiac events. After propensity
analyses, none of the differences remained significant. The incidence of stent thrombosis (ST) was
high in both DES groups.
Conclusion There was a trend towards a more favourable outcome associated with the use of PES over
BMS. There was no significant difference between SES and PES in each of the clinical endpoints, and
neither in the NIDDM patients, which are hypothesized to be better-off with PES.
KEYWORDS
Diabetes;
Sirolimus-eluting stent;
Paclitaxel-eluting stent;
Restenosis
Introduction
Patients with diabetes mellitus (DM) are known to have a
higher incidence of mortality and cardiovascular disease
compared with non-diabetic patients.1 Major reasons are
the more diffuse and accelerated form of atherosclerosis,
accompanied by longer lesion lengths, smaller vessel size,
and greater plaque burden.2–5 Insulin-requiring diabetics
are, especially, more susceptible to adverse cardiac events.6
Several trials that pre-date the drug-eluting stent (DES)
era showed that the event-free survival was significantly
higher in patients treated with coronary artery bypass
surgery over percutaneous coronary intervention (PCI) with
balloon angioplasty or bare metal stents (BMS), mainly due
to the high restenosis rates, inability to fully revascularize
multiple ischaemic areas, and the rapid progression of
atherosclerosis.7–11 To date, both sirolimus- and paclitaxel-
eluting stents (SES and PES) proved to be more effective in
reducing restenosis and target vessel revascularization
(TVR) in diabetic patients when compared with BMS up
until 1 year of follow-up in several retrospective subset
analysis of randomized controlled trials and small single-
centre experiences.12–16 Whether besides these benefits,
the long-term hard clinical endpoints as mortality and
myocardial infarction (MI) remain comparable between
both groups remains questionable.17,18.
Of interest is that patients with type II diabetes exhibit a
breakdown in the PI3-kinase insulin signal transduction
pathway, the pathway in which mammalian target of rapa-
mycin (mTOR) is involved.19 It can be hypothesized that in
this situation, inhibiting protein synthesis by blocking
mTOR with rapamycin may be less effective. Paclitaxel con-
versely, inhibits signalling downstream, independent of
insulin resistance. Whether this hypothesis can be translated
into clinical practice remains puzzling and is currently
illustrated by various studies focusing on differences
between SES and PES in selected patients up to 1 year of
follow-up.20–22 Our goal is to present the 2-year clinical
outcome of 708 consecutive diabetic patients treated with
a BMS, SES, or a PES.
Methods
Study design and patient population
In April 2002, our institution began to use SES (Cypherw; Cordis
Corporation, Warren, NJ, USA) as a default strategy for all patients
undergoing PCI. In February 2003, the PES (Taxus, Boston Scientific
Corp., Natick, MA, USA) replaced the SES as the default treatment.
* Corresponding author. Tel: þ 31 10 4635260; fax: þ 31 10 4369154.
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From April 2002 to February 2003, 206 consecutive patients were
treated exclusively with SES. From February 2003 to April 2004, 250
consecutive DM patients received a PES. A group of 252 consecutive
diabetic patients treated with BMS immediately before April 2002
were retrospectively selected as a control group. The present diabetic
population (n ¼ 708) comprises 20% of the patients treated within the
framework of the consecutive and similarly designed RESEARCH and
T-SEARCH registries, which are described elsewhere.23,24 Patients
were eligible for inclusion if they were undergoing pharmacological
treatment with either insulin or hypoglycaemic agents at the time
of the index procedure and patients with transient hyperglycaemia
were not included in the present analysis.
The protocol was approved by the hospital Ethics Committee and
is in accordance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
Procedures and post-intervention medications
All procedures were performed according to standard clinical guide-
lines.24 Angiographic success was defined as a residual stenosis 30%
by visual analysis in the presence of Thrombolysis In Myocardial
Infarction (TIMI) grade 3 flow. All patients were pretreated with
300 mg of clopidogrel. At least 1-month of clopidogrel treatment
(75 mg/day) was recommended for patients treated in the BMS
phase. Patients who received a PES were prescribed 6 months of
clopidogrel (75 mg/day), and those who received an SES were pre-
scribed clopidogrel for 3 or 6 months depending on the complexity
of the procedure.25 All patients were advised to maintain aspirin
(80 mg/day) lifelong.
Endpoint definitions and clinical follow-up
DM was defined by the presence of therapy: patients taking solely
oral medication were classified as non-insulin dependent diabetes
mellitus (NIDDM) and those on insulin therapy as insulin-dependent
diabetes mellitus (IDDM).
The primary endpoint was the occurrence of major cardiac
events, defined as a hierarchical composite of all-cause death, non-
fatal MI, or TVR. MI was diagnosed by an increase in creatine
kinase-MB fraction of greater than three times the normal upper
limit.26 Target lesion revascularization (TLR) was defined as a
repeat intervention (surgical or percutaneous) to control a luminal
stenosis within the stent or in the 5-mm proximal or distal segments
adjacent to the stent. TVR was defined as a re-intervention of a
lesion in the same epicardial vessel. Subacute angiographic stent
thrombosis was defined as an angiographically documented com-
plete occlusion (TIMI grade 0 or 1 flow) or a flow-limiting thrombus
(TIMI grade 1 or 2 flow) in the first 30 days after a successful pro-
cedure. Late-stent thrombosis was defined as angiographically
defined thrombosis (TIMI grade 0 or 1 flow or the presence of a flow-
limiting thrombus) occurring at least 1 month after DES implan-
tation accompanied by acute symptoms.27 Creatinine clearance
was used as the measure of renal function with the baseline creati-
nine clearance calculated from most recent preprocedural creati-
nine value according to the formula proposed by Cockcroft and
Gault.28 Hypercholesterolaemia was defined as a fasting serum
cholesterol level .5.5 mmol/L or use of lipid-lowering therapy at
the time of the procedure.29
Two-year follow-up data
Survival data for all patients were obtained frommunicipal civil regis-
tries. A health questionnaire was subsequently sent to all living
patients with specific questions on re-hospitalization and major
adverse cardiac events. Patients treated with BMS or SES were con-
tacted at 6 months, 1 year, and 2 years post-procedure, whereas
patients treated with PES were contacted at 1 and 2 year(s) post-
procedure. All repeat interventions and re-hospitalizations were
prospectively collected during follow-up and entered into a dedi-
cated database. When needed, referring physicians and institutions
were contacted for additional information. Finally, follow-up was
available for 98% of the patients in both DES groups and for 97% in
the BMS group.
Statistical analysis
Continuous variables are presented as mean+ SD. Categorical vari-
ables are expressed as counts and percentages. Comparisons among
the three groups were performed by the F-test from an analysis of
variance for continues variables and Pearson’s x2 test for categori-
cal variables. The cumulative incidence of adverse events was esti-
mated according to the Kaplan–Meier method and the log-rank test
was used to evaluate differences between groups. Cox proportional
hazards regression analysis was performed to correct for indepen-
dent predictors of adverse events. Independent predictors, using
all the baseline and procedural characteristics listed in Tables 1
and 2, were determined for each of the endpoints in the three com-
pared groups (SES vs. BMS; SES vs. PES; PES vs. BMS). Independent
predictors of outcome (P, 0.1), were forced into the model,
together with the stent-type (¼crude hazard ratios) and the
assumptions of the proportional hazards model were tested using
Omnibus tests of model coefficients. In order to avoid chance pre-
dictors, all predictors were carefully evaluated and none of them
was in contrast to previously known risk factors. Control of potential
confounders was attempted by constructing a propensity score using
logistic regression.30 The propensity score was the probability that a
patient would receive either a BMS, an SES, or a PES, and was com-
puted using an extensive, non-parsimonious, logistic regression
model including the following variables: age, gender, clinical pres-
entation, previous PCI, previous MI, previous coronary artery
bypass surgery, multivessel disease, hypertension, dyslipidaemia,
family history of coronary artery disease, smoking, diabetes, creati-
nine clearance, body mass index (BMI), glycoprotein IIb/IIIa inhibitor
use, bifurcation treatment, vessel treated (RCA, LAD, LCX, LM,
bypass graft), lesion type, chronic total occlusion, average stent
diameter, number of stents, and total stented length. The selection
of the variables was made so as to get the best discriminating model
as assessed by the C-statistics. Covariate interactions and higher-
order terms for the continuous variables proved unnecessary for
the balance of baseline characteristics across quintiles. In the PES
vs. BMS comparison, the propensity score became significant in
the model for which we deleted the first quintile. In the PES vs.
SES comparison, we deleted the fifth quintile. The resulting propen-
sity score was then included in the Cox proportional hazards model
as a continuous variable. The final results are presented as adjusted
HRs. Patients lost to follow-up were considered at risk until the date
of last contact, at which point they were censored. In all cases,
P , 0.05 was considered significant. Statistical analysis were per-
formed with SPSS 12.0.2 for Windows (SPSS Inc., Chicago IL, USA).
Results
Baseline and procedural characteristics
Baseline, angiographic, and procedural characteristics are
included in Tables 1 and 2. There were more patients requir-
ing insulin treatment in both DES groups: 31% (SES), 28%
(PES), than in the BMS group (18%), P, 0.002. Both hyper-
tension and hypercholesterolaemia increased over time
and so was the presence of multivessel disease and the
duration of clopidogrel prescription. The complexity of the
procedures also increased over time, reflected by the treat-
ment of type C lesions, incidence of multivessel treatment,
number of stented vessels, number of implanted stents,
total stented length, average stent diameter, and treatment
of chronic total occlusions.
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Two-year follow-up
Two-year cumulative incidence of mortality was comparable
among the three groups: 9.8% in the BMS group vs. 13.3% and
11.5% in the SES and PES groups, respectively (Figure 1A).
However, a significantly higher number of patients in the
SES group died in the second year: 12 (5.8%) when compared
with only three (1.2%) in the PES group (P ¼ 0.007). Eight
patients (3,2%) died in the second year in the BMS group.
MI was more frequent in the BMS (7.7%) and SES (5.1%)
groups when compared with the PES group (3.4%)
(P ¼ 0.048 PES vs. BMS). The cumulative incidence of the
combined endpoint of death and MI occurred in 15.4% of
Table 1 Baseline clinical characteristics
Bare (n ¼ 252) SES (n ¼ 206) PES (n ¼ 250) P-value
Male, n (%) 162 (64) 136 (66) 82 (67) 0.78
Age (years+ SD) 62.7+ 10 62.0+ 10 63.8+ 11 0.2
NIDDM, n (%) 208 (82) 142 (69) 180 (72) 0.002
IDDM, n (%) 44 (18) 64 (31) 70 (28) 0.002
Hypertension, n (%) 135 (54) 142 (69) 176 (70) ,0.001
Hypercholesterolaemia, n (%) 150 (60) 145 (70) 207 (83) ,0.001
Current smoking, n (%) 55 (22) 41 (20) 47 (19) 0.69
Previous myocardial infarction, n (%) 92 (37) 74 (36) 102 (41) 0.49
Previous angioplasty, n (%) 69 (27) 65 (32) 67 (27) 0.49
Previous coronary bypass surgery, n (%) 40 (16) 21 (10) 40 (16) 0.14
Multivessel disease, n (%) 151 (60) 139 (67) 177 (71) 0.03
Clinical presentation
Stable angina, n (%) 125 (50) 100 (49) 116 (47) 0.77
Unstable angina, n (%) 99 (39) 73 (35) 93 (37) 0.70
Acute myocardial infarction, n (%) 28 (11) 33 (16) 41 (16) 0.18
Creatinine clearance (mL/min) 107.6+ 72.4 96.2+ 35.2 89.5+ 40.0 0.02
BMI (kg/m2) 29.5+ 6 29.0+ 5 29.1+ 11 0.76
Table 2 Angiographic and procedural characteristics
Bare (n ¼ 252) SES (n ¼ 206) PES (n ¼ 250) P-value
Treated coronary vessela
Left anterior descending, n (%) 145 (58) 126 (61) 135 (54) 0.31
Left circumflex, n (%) 83 (33) 74 (36) 87 (35) 0.79
RCA, n (%) 88 (35) 82 (40) 160 (64) ,0.001
LM coronary, n (%) 14 (6) 13 (6) 12 (5) 0.78
Bypass graft, n (%) 19 (7.5) 6 (3) 23 (9) 0.024
Lesion type b
Type A, n (%) 41 (16) 42 (20) 22 (9) 0.002
Type B1, n (%) 82 (32) 76 (37) 56 (22) 0.002
Type B2, n (%) 122 (48) 107 (52) 125 (50) 0.75
Type C, n (%) 100 (40) 86 (42) 132 (53) 0.007
Number of coronary vessels treated,
n (%)
,0.001
1 166 (66) 124 (60) 137 (55)
2 71 (28) 68 (33) 63 (25)
3 15 (6) 14 (7) 50 (20)
Multivessel treatment, n (%) 85 (34) 82 (40) 114 (46) 0.025
Bifurcation stenting, n (%) 20 (8) 38 (18) 30 (12) 0.003
No. of stented vessels 1.4+ 0.6 1.5+ 0.6 1.7+ 0.8 ,0.001
Number of implanted stents+ SD 1.9+ 1.2 2.3+ 1.4 2.3+ 1.4 ,0.001
Total stented length per patient (mm+ SD) 30.5+ 22.4 44.1+ 29.2 48.8+ 32.9 ,0.001
Average stent diameter (mm+ SD) 3.27+ 0.49 2.82+ 0.25 2.91+ 0.37 ,0.001
Nominal stent diameter 2.5 mm, n (%) 21 (8.4) 31 (15.1) 52 (20.6) 0.001
Chronic total occlusion (.3 months), n (%) 14 (6) 20 (10) 54 (22) ,0.001
Glycoprotein IIb/IIIa inhibitor, n (%) 80 (32) 41 (20) 64 (26) 0.02
Clopidogrel prescription (months)+ SD 3.17+ 3.23 4.68+ 2.73 6.32+ 2.58 ,0.001
Angiographic success of all lesions, n (%) 244 (97) 190 (92) 235 (94) 0.1
Values are means+ SD or percentages.
aExpressed as percentage of patients with vessel type treated. Total exceeds 100%.
bExpressed as percentage of patients with lesion type. Total exceeds 100%.
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the BMS patients, vs. 18.2% and 14.7% of the SES and PES
patients, respectively (P ¼ 0.33 SES vs. PES). TLR was per-
formed in a remarkably low percentage of PES patients
(5.3%) when compared with the BMS (15.6%) and SES
(13.2%) patients (P ¼ 0.0037 SES vs. PES; P ¼ 0.0004 PES
vs. BMS). Also, TVR was significantly lower in the PES
group (9.7%) when compared with the BMS group (19.5%)
(P ¼ 0.0034). The cumulative incidence of TVR in the SES
group was 15.3% and was neither inferior to PES (P ¼ 0.06)
nor superior to BMS (P ¼ 0.97) (Figure 1B). The composite
endpoint of MACE was found in 29.7% of the BMS patients,
almost comparable with the SES group, in which a 28.9%
incidence of MACE was found. MACE rates in the PES group
(21.2%) were significantly lower when compared with the
BMS group (29.7%), P ¼ 0.04 (Figure 1C). Of interest was
the high incidence of ST, which occurred in 4.4% of the SES
patients (3.4% early ST) compared with 2.4% in the PES
group (2.0% early ST) and only 0.8% in the BMS group (0.8%
early ST) (P-values: SES vs. BMS, 0.015; PES vs. BMS, 0.18;
SES vs. PES, 0.29). Of the total 17 patients with ST, two
died, seven presented with an MI, and 12 patients were
still on dual-antiplatelet therapy at the time of the event.
When patients were classified with respect to the use of
insulin, the cumulative incidence of mortality was signifi-
cantly higher in IDDM patients (16.7%) compared with the
NIDDM patients (9.6%); (P ¼ 0.013). TVR was performed in
a comparable number of IDDM patients (17.1%) as in NIDDM
patients (14.1%); (P ¼ 0.36). Comparing TVR rates in the
NIDDM patients (Figure 1D), the outcomes remained com-
parable to those of the overall population, showing no sig-
nificant superiority of PES to SES.
Cox multivariable regression models were used to correct
for differences and independent predictors of adverse
events between each pair of groups (SES vs. BMS; PES vs.
BMS; and PES vs. SES) (Table 3). After correcting for inde-
pendent predictors of adverse events, the use of PES
remained significantly superior to BMS in terms of TVR at
both 1 (HR 0.66; 95% CI 0.49–0.89) and 2 years (HR 0.69;
95% CI 0.53–0.89), and MACE at 2 years (HR 0.75; 95% CI
0.60–0.94). The use of SES was neither significantly superior
Figure 1 Two-year cumulative incidence of mortality (A), TVR (B), major adverse cardiac events (C), and TVR in NIDDM (D), in patients treated with BMS, SES, or
PES, respectively.
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to BMS nor significantly inferior to PES. Of interest was that
when the propensity score was added to the models, none of
the comparisons remained significant although a trend
remained towards a better outcome with PES when com-
pared with both BMS and SES.
Discussion
The present study, comprising a series of 708 consecutive
diabetic patients, showed that in contrast to the SES-
treated patients, the crude relative risk for both TVR and
MACE was significantly lower in the PES group over the
BMS group, at 2 years of clinical follow-up. However, after
propensity analyses, these differences did not remain signifi-
cant. Although hypothesized, PES was not superior to SES in
the NIDDM subset in reducing TVR or MACE. When compared
with IDDM, NIDDM was associated with a better long-term
survival.
The 2-year event-free survival rate in this diabetic subset
was 24.8%, irrespective of the stent type used, and was sub-
stantially lower than reported in DES trials including a
general population.31–33 This latter confirms again the detri-
mental effect of DM on the prognosis following PCI, despite
the use of DES in the majority of our patients.34
Both SES and PES have been shown to be superior to BMS in
patients with DM up until 1 year of follow-up.15,16 In a ran-
domized trial by Dibra et al., there was no significant differ-
ence between both devices in any of the clinical endpoints
at 9 months of follow-up, despite the superiority of SES in
reducing late lumen loss and binary restenosis.20 A
meta-analyses of randomized trials comparing either SES
or PES to BMS showed that when the diabetic subsets were
pooled, the use of SES was associated with a 65% reduction
in in-stent restenosis compared with PES, albeit there was
again no significant difference between both SES and PES
in reducing TVR and MACE.35 Because of its clinical
approach, the present report is not completely comparable
to these previous studies with angiographic primary end-
points, which show that inconsistencies between clinical
and angiographic endpoints are far from being resolved.
Nevertheless, our results are in line with other registries.
The STENT registry, including 1680 diabetic patients, con-
firmed the comparable results achieved with both devices
at 9 months of follow-up and the SOLACI registry showed
even lower TVR rates in diabetics treated with PES, com-
pared to those treated with SES.21,36
Stent thrombosis in both DES arms was high (SES: 4.4%,
PES: 2.4%) when compared with the BMS patients (0.8%).
Studies focusing on the incidence of ST following treatment
with DES in a general population, reported ST rates of
1.0–1.6% and depicted diabetes as an independent predictor
of ST.27,37 The present report emphasizes the need for
longer-term follow-up and confirms that ST, mainly in the
DES-treated patients, continues to occur after 6–12
months of follow-up.38 As 78% of the patients with ST were
still on dual-antiplatelet therapy, lifelong prescription of
clopidogrel, additionally associated with higher bleeding
risks, higher costs, and a potential of clopidogrel resistance,
does not seem warranted.39–41 Nevertheless, we feel that
these numbers should encourage researchers to continue
to follow their patients and not to stop their follow-up
when the initial (1 year) results look promising.
Of interest are the mechanisms of action of both drugs.
Sirolimus is a natural macrocyclic lactone that is capable
of inhibiting the mTOR and blocking the cell-cycle during
the transition from G1 to S phase.42 mTOR is dependent of
the PI3-kinase pathway, which is hypothesized to be
degraded in insulin-resistant diabetics.19 This latter suggests
SES to be less effective in diabetic patients (comprising
70% NIDDM). Paclitaxel on the other hand stabilizes micro-
tubules, which are known to be responsible for cell division,
and acts completely independent of the PI3-kinase pathway.
This hypothesis is partly supported by the results of the
present study. We observed an almost identical occurrence
of MACE in the SES and BMS groups, providing some evidence
for the non-superiority of SES in diabetics. Although many
would refer to previously published studies, which did
prove this superiority, one has to realize that these studies
Table 3 Multivariable predictors of major adverse cardiac events at 2 years (Cox proportional hazards model)
BMS
(n ¼ 252)
SES
(n ¼ 206)
PES
(n ¼ 250)
SES vs. BMS,
relative risk
(95% CI)
PES vs. BMS,
relative risk
(95% CI)
PES vs. SES,
relative risk
(95% CI)
Mortality at 1 year (%)a 6.5 7.3 10.2 0.59 (0.23–1.5)] 0.95 (0.61–1.47) 1.72 (0.75–4.00)
Including propensity score 0.65 (0.20–2.14) 1.31 (0.64–2.69) 1.89 (0.69–5.21)
Mortality at 2 years (%)a 9.8 13.3 11.5 1.32 (0.76–2.29) 0.89 (0.61–1.31) 0.93 (0.48–1.82)
Including propensity score 1.55 (0.77–3.14) 1.08 (0.58–1.99) 2.31 (0.81–6.58)
Death or non-fatal MI at 1 year (%)a 10.9 12.2 12.6 1.04 (0.60–1.78) 0.85 (0.61–1.20) 1.24 (0.66–2.34)
Including propensity score 1.13 (0.58–2.19) 0.92 (0.57–1.51) 1.53 (0.70–3.39)
Death or non-fatal MI at 2 years (%)a 15.4 18.2 14.7 1.01 (0.62–1.63) 0.80 (0.59–1.08) 0.78 (0.50–1.24)
Including propensity score 1.20 (0.66–2.19) 0.90 (0.64–1.26) 0.89 (0.44–1.80)
TVR at 1 year (%)a 14.1 13.6 6.9 0.99 (0.59–1.65) 0.66 (0.49–0.89) 0.57 (0.29–1.14)
Including propensity score 0.98 (0.52–1.83) 0.69 (0.46–1.03) 0.66 (0.26–1.67)
TVR at 2 years (%)a 19.5 15.3 9.7 0.77 (0.48–1.24) 0.69 (0.53–0.89) 0.73 (0.40–1.35)
Including propensity score 0.83 (0.47–1.47) 0.73 (0.51–1.05) 0.65 (0.29–1.47)
MACE (Death, MI, and TVR) at 1 year (%)a 21.5 21.4 16.7 0.95 (0.64–1.42) 0.82 (0.65–1.02) 0.75 (0.49–1.15)
Including propensity score 0.97 (0.60–1.58) 0.77 (0.58–1.03) 0.55 (0.32–0.95)
MACE (Death, MI, and TVR) at 2 years (%)a 29.7 28.9 21.2 0.99 (0.70–1.40) 0.75 (0.60–0.94) 0.70 (0.49–1.02)
Including propensity score 1.11 (0.72–1.70) 0.77 (0.55–1.07) 0.68 (0.36–1.30)
aCrude HRs without propensity scores.
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included only highly selected patients not reflecting daily
clinical practice. Not only patients presenting with acute cor-
onary syndrome, chronic total occlusions, and (un)protected
left main (LM) stenosis, but also the typical diabetics with
diffuse disease in multiple vessels, requiring extensive revas-
cularization were often excluded.12,14,15 In this study, these
high-risk patients comprised60% of the present population.
Although we were not able to show a superiority of PES over
SES, there were two interesting findings. First, MACE rates
were significantly higher in the SES group when compared
with the PES group at 1 year (propensity analysis), which is
in agreement with NIDDM arm, the large-scale STENT regis-
try.43 Secondly, there was a significantly higher mortality
rate during the second year in the SES group. Although this
difference could be due to ST, focusing on the combined end-
point of death and MI revealed comparable rates in all three
groups, especially when correcting for independent predic-
tors. Moreover, it has to be commented that the overall
mortality rate (11.4%) in the present population was higher
than reported in previous trials and is most likely related to
the high complexity of the present population. Excluding
patients presenting with multivessel disease, LM lesions and
presentation with acute myocardial infarction resulted in a
2-year mortality rate of only 7.6%.
The present study suffers from the inherent limitations of
a non-randomized trial. The compared groups were not com-
pletely identical, which was mainly due to the relatively
large inclusion period in which the complexity of the pro-
cedures increased. In order to partly compensate for the
differences in baseline characteristics, with an increasing
risk over time, we performed a multivariable analysis and
a propensity analysis. Thereby, the TLR rate might be less
accurate in predicting clinical restenosis compared with a
non-diabetic population, since diabetic patients are known
to have a significantly greater incidence of silent ischaemia
than non-diabetics and the lack of an angiographic
follow-up.44 Finally, ST related only to angiographically
document ST, using a definition consistent with previous
reports on ST either after DES or BMS implantation. This
latter may have led to an underestimation of the actual inci-
dence of ST, particularly, in patients suffering from sudden
cardiac death or silent stent occlusion.
Nevertheless, this report focuses on the 2-year ‘clinical’
outcome of the unrestricted use of BMS, SES, and PES in
diabetic patients in a ‘real world’ setting and demonstrates
the importance of longer-term follow-up. More larger scale
and randomized trials are needed to elucidate the best
treatment for patients with DM and the possible superiority
of one DES compared to another, also taking into account
the long-term adverse events like ST.
Conclusion
Although there was a trend towards lower MACE rates in the
PES group at 2 years of clinical follow-up, the superiority of
both SES and PES over BMS in diabetic patients remains
questionable. There was no significant difference between
SES and PES in the NIDDM patients, who are hypothesized
to be better-off with PES, and ST was more frequent in
both DES groups.
Conflict of interest: none declared.
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Chapter 11
Multi -lesion culoƩ e and crush bifurcati on stenti ng 
with sirolimus-eluti ng stents: long-term angiographic 
outcome
Daemen J, Lemos PA, Serruys PW 
J Invasive Cardiol. 2003 Nov;15(11):653-6

Case Report. A 63-year-old man, an ex-smoker with a history
of hypertension and previous myocardial infarction, was admitted
with stable angina (Canadian Cardiovascular Society Class 1) for
elective percutaneous coronary intervention. Pre-procedure coro-
nary angiogram revealed diffuse disease in the proximal and mid
segments of the left circumflex artery (LCx) that was totally occlud-
ed in its distal portion (Fig. 1A). The first obtuse marginal branch
(OM) presented a severe ostial stenosis (Fig. 1A). Also, the left ante-
rior descending artery (LAD) presented a long stenosis in its mid
portion, involving the origin of the first and second diagonal
branches (Fig. 2A). The right coronary artery (RCA) showed mild
irregularities without any localized significant stenosis.
The left coronary was cannulated with a 7 French (Fr) Vista
Brite Amplatz Left guiding catheter (Johnson & Johnson, Cordis
Corporation, Miami Lakes, Florida). The ostial lesion in first
OM was crossed with a PT Graphix Intermediate 0.014˝
guidewire. Another PT Graphix Intermediate 0.014˝ guidewire
was inserted in the LCx, but the total occlusion in its distal seg-
ment could only be partially recannalized. A 2.5 x 18 mm
sirolimus-eluting Cypher stent (Cordis Corp.) was deployed (14
atm) in a stenotic lesion in the LCx just proximal to the site of
the vessel occlusion in an attempt to facilitate further measures to
recannalize the vessel; the stent was deployed covering the origin
of the first marginal branch (Fig. 1B). A 3.0 X 18 mm sirolimus-
eluting Cypher stent (Johnson & Johnson, Cordis Corp.) was
then implanted in the LCx-OM using the “culotte” technique
(20 atm) (Figs. 1C and 1D). A residual stenosis in the proximal
LCx was treated with an additional 3.0 x 18 mm sirolimus-elut-
ing Cypher stent overlapping the distal stent (20 atm). Further
attempts to recannalize the distal LCx were unsuccessful. The
final result is depicted in Figure 1E.
Two PT Graphix Intermediate 0.014˝ guidewires were insert-
ed in the LAD and second diagonal branch. A “crush” stent
implantation was performed: a 2.25 x 8 mm sirolimus-eluting
stent and a 3 x 33 mm sirolimus-eluting stent (Cypher) were con-
comitantly positioned in the second diagonal and mid LAD,
respectively (Figure 2B). The 2.25 x 8 mm sirolimus-eluting stent
was deployed (12 atm) with its proximal portion partially placed
through the LAD (Figure 2B). Importantly, the LAD-diagonal
stent was implanted while the undeployed 3 x 33 mm sirolimus-
eluting-stent was already positioned in the LAD in the site of its
future implantation (covering the origin of the diagonal branch)
(Fig. 2B). Subsequently, the balloon-catheter was retrieved from
the diagonal branch and the LAD stent was deployed (22 atm)
(Fig. 2B). After implantation of the LAD stent, a residual stenosis
was noted in the proximal stent edge together with ostial compro-
mise of the first diagonal branch, possibly due to plaque shiften-
ing towards its origin (Fig. 2C). Additional “crush” stenting was
performed to treat the LAD-first diagonal bifurcation (Fig. 2D).
Following the same strategy as describe above, a 2.25 x 8 mm
Multi-Lesion “Culotte” and “Crush” Bifurcation Stenting with
Sirolimus-Eluting Stents: Long-Term Angiographic Outcome
Joost Daemen,  Pedro A. Lemos, MD,  Patrick W. Serruys, MD, PhD
From the Dept. of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam.
A B C
Figure 1. (A) Left
coronary angiogram
(caudal right anterior
oblique projection)
showing diffuse dis-
ease with distal occlu-
sion of the left
circumflex artery and
severe ostial stenosis
in first obtuse mar-
ginal branch.  
D E
(B) Stent deployed covering the origin of the first
marginal branch. A guidewire was placed in the
marginal branch through the struts of the circumflex
stent. (C) Residual stenosis in the ostium of the first
marginal branch after implantation of the stent in
the circumflex.(D) implantation of a 3.0 X 18 mm
sirolimus-eluting stent in the LCx-OM using the
“culotte” technique. (E) final angiographic result.
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sirolimus-eluting Cypher stent was implanted in the first diagonal
(12 atm) with its proximal portion partially deployed in the LAD
(Fig. 2D) while an undeployed 3 x 8 mm sirolimus eluting-stent
was already placed in the LAD (along the diagonal ostium) (Fig.
2D). The LAD stent was then deployed (20 atm) covering the
ostium of the first diagonal branch (Fig. 2D). A small gap
between the two LAD stents was noted and a 3 x 8 mm
sirolimus-eluting Cypher stent was implanted (20 atm) to accom-
plish complete lesion coverage (Fig. 2E). Final high-pressure post-
dilatation (22 atm) was performed in the mid LAD (Maverick
balloon 3.0 x 9 mm, Boston Scientific, Natick, Massachusetts).
Care was taken to inflate the balloon inside the stented area in
order to avoid vessel injury in the non-stented edges. Excellent
final angiographic result was achieved with TIMI 3 grade flow
and minimal residual stenosis in all treated lesions (Fig. 2F).
The patient was included in the Rapamycin Eluting-Stent
Evaluated At Rotterdam Cardiology Hospitals (RESEARCH)
registry and agreed to undergo late angiographic follow-up.1 After
208 days, the patient remained asymptomatic and a stress test was
negative. No adverse events had occurred. At coronary angiogra-
phy, the RCA was unchanged. All stents were widely patent with
no angiographic evidence of stenosis (Figs. 3A and 3B). 
References
1. Lemos PA, Lee C, Degertekin M, et al. Early outcome after sirolimus-eluting stent
implantation in patients with acute coronary syndromes. Insights from the Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J
Am Coll Cardiol 2003;41:2093–2099.
How Would you Manage this Case?
Bernhard Meier, MD
Swiss Cardiovascular Center Bern
Bern, Switzerland
The approach to this 60-year-old man with stable angina
after a MI (presumably in the region of the posterolateral mar-
ginal branch of the left circumflex coronary artery) selected by
the authors shows virtuosity and fantasy in the use of coronary
stents. It can be condoned as exclusively drug-eluting stents
(DES) with a low restenosis potential used. Also, the excellent
long-term result proves the strategy right. The costs, however,
are of concern and a far less expensive simple approach as
described below would also have had a good chance of good
long-term patency of all important branches.
Figure 2. (A) Left anterior descending artery (cranial right anterior oblique projection) presenting a long stenosis in its mid portion, involving the origin of
the first and second diagonal branches. (B) “Crush” stenting: a 2.25 X 8 mm sirolimus-eluting stent and a 3 X 33 mm sirolimus-eluting Cypher stent
(Johnson & Johnson, Cordis Corporation) concomitantly positioned in the second diagonal and mid LAD, respectively. Note that the proximal portion of
the stent placed in the diagonal is protruding into the LAD. (C) Residual stenosis noted in the proximal LAD together with ostial compromise of the first
diagonal branch after implantation of the distal stent in the LAD. (D) “Crush” stenting in the LAD-first diagonal bifurcation: a 2.25 X 8 mm sirolimus-
eluting Cypher stent (Johnson & Johnson, Cordis Corporation) in first diagonal branch is positioned with its proximal portion partially located though the
LAD. An undeployed 3 X 8 mm sirolimus eluting-stent was concomitantly positioned in the LAD along the diagonal ostium. (E) A 3 x 8 mm SES
deployed at a small gap between the two LAD SES. The radiopaque stents implanted in the 2 previously treated bifurcations are noted. (F) Final angio-
graphic result of the treatment of the LAD with a TIMI 3 grade flow and minimal residual stenosis in all treated lesions. 
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Working exclusively with 5 Fr coronary catheters (often
inserted without an introducer thereby keeping the puncture hole
smaller than that of a 4 Fr introducer), kissing balloon techniques
are out of the question. The same holds true for “crush” stenting.
I would have used a left Amplatz II catheter exactly like the
authors, but 2 Fr smaller. I would then have first tried to recanal-
ize the posterolateral marginal branch of the LCx. The authors
failed on that, so would have I presumably. This would have
reduced the bifurcation lesion in the LCx to a single vessel lesion,
which I would have dilated with a 3 mm balloon and stented
with a DES if the result had not been pleasing. Given the initial
lesion, this would have been the case with a 60% probability.
I would have used the LAD approach second, because you
want a virgin coronary guidewire and balloon catheter to tackle a
chronic occlusion and you also want the potential benefit of
reversed collaterals from an initially recanalized LCx if problems
arise in the LAD. I would have dilated the segment of the LAD
encompassing the 2 involved diagonal branches. With a proba-
bility of about 30%, I would have found a need to stent the
entire segment again using a DES. After this, I would have
turned my attention to the 2 diagonal branches. I would have
first tried to cross them with the wire and 3 mm balloon used for
all dilatations so far. if they looked significantly stenosed. Only if
a take-off stenosis of more than 50% of these diagonal branches
had persisted, I would have tried to stent one or both take-offs
with a short 2.5 mm stent, again using drug-eluting stents. The
likelihood of this need can be guessed at 30% each. After such
diagonal stenting, almost unvariably the 3 mm balloon would
have had to be reinserted into the LAD for a final dilatation of
this main axis, still using the same guidewire.
In a follow-up angiogram, the chances of the LAD or the
only important branch of the LCx to be restenosed would have
been the same as with the technique described by the authors.
The risk of a restenosis in one or both of the diagonal branches is
projected at about 50%, if they had not been stented, and about
20% if they had been stented. The risk of an abrupt closure of
an important vessel with the frugal approach should not have
been increased (it might even have been decreased), as stents
harbor overall an equal or even higher risk for acute or subacute
closure than balloon angioplasty with an acceptably looking
result. My tab at the end of the day would have shown one
coronary guidewire, one 3.0 mm balloon, and 1–3 DES, rather
than 2 coronary guidewires, two balloons, and about 7 or 8 (I
lost count) DES. The thriftiness would have carried a risk of
about 30% to wind up with one or two take-off restenoses of
diagonal branches, unlikely to be clinically apparent. The other
risks would have been the same as with the authors approach. 
The 5 Fr catheter without an introducer could have been
pulled at the end, requiring only a 10–15 minute manual com-
pression, rather than a closure device or a mechanical compres-
sion device, usually used in conjunction with a 7 Fr guiding
catheter inserted through an introducer (about 8.5 Fr outer
diameter). I failed to mention the reduced amount of x-ray and
contrast medium used, and the shorter occupation of the
catheterization laboratory with the simple approach (perhaps
even if you include the remote possibility of a redilatation later).
Howard Cohen, MD
Cardiovascular Institute - UPMCHS
Presbyterian University Hospital 
Pittsburgh, Pennsylvania 
Bifurcation lesions continue to represent a difficult technical
challenge for the interventional cardiologist because of side or
main branch compromise due to the problem of plaque shift and
the “snowplow effect.” Prior to the advent of stenting, the “kiss-
ing balloon” technique or debulking with directional atherecto-
my was advocated to avoid these problems. With the advent of
stenting, attempts to solve this problem with “bifurcation stent-
ing” with the culotte, Y, T or kissing stent techniques were
attempted with excellent acute angiographic results and proce-
dural outcomes, but were ultimately abandoned as a primary
strategy because of the high rates of restenosis that were encoun-
tered. Now, with DES, there is renewed hope that the routine
use of these stents in bifurcation lesions will result in superior
long-term outcomes.
In this issue of the Journal, Dr. Daemon et al. present a dra-
matic case of the use of DES to treat 3 bifurcations in a patient
in a single setting. Eight stents were employed to achieve excel-
lent angiographic results acutely as well as at 6-month follow-up.
At a cost of approximately $3,000/stent, this amounts to
$24,000 for the stents alone. This is clearly a costly strategy,
although it conceivably might be cost effective in the long term
if it avoids repeated PCI for restenosis. I suspect that the stents
used in this reported case were available on a “research” basis and
Figure 3. (A) Angiograph-
ic follow-up of the LCx-
OM ostial lesions. No
restenosis has occurred. (B)
Excellent result after 6
months angiographic follow-
up of the LAD. 
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Chapter 12
Two-Year clinical outcome aft er coronary stenti ng 
of very small vessels using 2.25mm sirolimus- and 
paclitaxel-eluti ng stents: Insight into the RESEARCH 
and T-SEARCH registries
Tanimoto S, Daemen J, Tsuchida K, García-García HM, de Jaegere P,    
van Domburg RT, Serruys PW
Catheter Cardiovasc Interv. 2007; 69(1):94-103

Two-Year Clinical Outcome After Coronary Stenting
of Small Vessels Using 2.25-mm Sirolimus- and
Paclitaxel-Eluting Stents: Insight Into the
RESEARCH and T-SEARCH Registries
Shuzou Tanimoto, MD, Joost Daemen, MD, Keiichi Tsuchida, MD, PhD,
He´ctor M. Garcı´a-Garcı´a, MD, Peter de Jaegere, MD, PhD, Ron T. van Domburg, PhD,
and Patrick W. Serruys,* MD, PhD
Objectives: To evaluate long-term outcomes after drug-eluting stents (DES) implanta-
tion in small coronary vessels. Background: Sirolimus-eluting stents (SES) and pacli-
taxel-eluting stents (PES) have been reported to improve both the angiographic and
clinical outcomes compared with bare metal stents even in ‘real world’ settings.
Currently, no data is available on long-term outcomes after DES implantation in small
vessels. Methods: Since April 2002, our institution has implanted DES, either SES or
PES, as a default strategy in all patients irrespective of their clinical presentation.
Between October 2002 and September 2003, 197 consecutive patients were enrolled:
107 consecutive patients received at least one 2.25-mm SES (SES group) and 90 con-
secutive patients received at least one 2.25-mm PES (PES group). Results: The two
cohorts presented with high-risk characteristics. At 2 years, the cumulative incidence
of major adverse cardiac events (MACE) in the SES group was significantly lower
than that in the PES group (10.3% vs. 23.3%, P = 0.02). There were two subacute
angiographic stent thromboses in the PES group and none in the SES group. By multi-
variate analysis, PES utilization (HR 2.37, 95% CI 1.07–5.26), presentation with acute
coronary syndromes (ACS) (HR 3.34, 95% CI 1.44–7.70) and multi-vessel disease
(MVD) (HR 3.91, 95% CI 1.27–12.0) were identified as independent predictors of
MACE. Conclusions: In an unselected population treated for small vessel disease, SES
were associated with significantly better 2-year clinical outcomes than PES. The use of
PES and the presentation with ACS and MVD were identified as independent predictors
of MACE. ' 2006 Wiley-Liss, Inc.
Key words: coronary artery disease; drug-eluting stents; sirolimus; paclitaxel
INTRODUCTION
Percutaneous coronary intervention (PCI) is a major
treatment strategy for patients with ischemic heart disease,
and currently coronary stents are widely used [1]. Bare
metal stents (BMS) reduce coronary restenosis and signifi-
cantly improve the angiographic and clinical outcomes in
vessels with a reference diameter (RD) more than 3 mm
by their ability to prevent both early elastic recoil and late
vascular remodeling, as compared to balloon angioplasty
[2–4]. On the other hand, several randomized trials have
failed to show an advantage of BMS over balloon angio-
plasty in vessels with a RD less than 3 mm [5,6]. There-
fore, whether stent implantation in small vessels improves
outcomes compared to balloon angioplasty alone still
remains controversial. At present, however, PCI in small
vessels of less than 3 mm accounts for almost 50% of all
revascularization procedures and leads to a higher inci-
dence of restenosis and adverse cardiac events [7].
In the last 3–4 years, drug-eluting stents (DES), ei-
ther sirolimus-eluting stents (SES) or paclitaxel-eluting
stents (PES), have revolutionized the interventional
cardiology practice by reducing restenosis and the need
for repeat revascularizations as compared to BMS. Se-
veral multicenter randomized trials have evaluated the
efficacy of DES for the treatment of vessels with a RD
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less than 3 mm and shown a significant reduction in
both restenosis and clinical events [8–11]. More re-
cently, several trials comparing SES with PES were
performed [12–17]. The general conclusion from a
meta-analysis of these trials is that SES are signifi-
cantly better at reducing neointimal hyperplasia and
confer an advantage over PES in terms of clinical out-
comes [18]. However, there is limited information on
the relative safety and efficacy of SES compared to
PES in patients with small vessel disease [19,20].
Some recent studies have also cautioned that either
SES or PES could increase thrombotic complications
compared to BMS, especially late stent thrombosis
[21,22], due to decreased endothelial function [23], de-
layed vascular healing [24], and/or hypersensitivity
reactions to the polymer coating of the DES and the
drug itself [25,26]. Although BMS implantation in
small vessels had been previously cited as a risk factor
for stent thrombosis [27], improved techniques of opti-
mal stent deployment and dual antiplatelet regimens
appear to have largely resolved this problem so that
the risk of stent thrombosis in small vessel stenting
now seems to be similar to that in larger vessel stent-
ing [28]. But, DES implantation in small vessels may
increase the risk of stent thrombosis because of their
features as mentioned earlier. Therefore, long-term fol-
low-up as well as short- and medium-term follow-up
are needed to determine whether DES implantation is
safe in the subset of patients with small vessel disease.
To the best of our knowledge, there is currently no
available publication comparing the long-term efficacy of
SES and PES for the treatment of small coronary arteries.
The present study, which is derived from our previous
study population [19], is conducted to compare clinical
outcomes in terms of safety and efficacy at 2 years after
implantation of 2.25-mm diameter SES and PES.
MATERIALS AND METHODS
Study Design and Patient Population
Since April 2002, SES (Cypher1; Cordis Corpora-
tion, Warren, NJ) have been implanted as the default
strategy for every PCI in our institution as part of the
Rapamycin-Eluting Stent Evaluated At Rotterdam Car-
diology Hospital (RESEARCH) registry [29]. This
strategy continued until February 2003, when PES
(TaxusTM; Boston Scientific Corporation, Galway, Ire-
land) implantation became the default strategy for all
patients with coronary artery disease as part of the
Taxus-Stent Evaluated At Rotterdam Cardiology Hos-
pital (T-SEARCH) registry [30]. The methods and
design of both studies have been described previously
[29,30]. Both trials evaluated the safety and efficacy of
SES and PES implantation for patients treated in daily
practice. All patients were included irrespective of
their clinical presentation and lesion characteristics.
Between October 2002 and September 2003, a total of
197 consecutive patients were enrolled: 107 patients
received at least one 2.25-mm diameter SES (SES group)
and 90 patients received at least one 2.25-mm diameter
PES (PES group). The study protocol was approved by
the institutional ethics committee, and all patients pro-
vided written informed consent.
Procedures and Postinterventional Medications
All procedures were performed in accordance with
standard techniques. The interventional strategy and use of
glycoprotein IIb/IIIa inhibitors were left entirely to the dis-
cretion of the operator. All patients were advised to take
aspirin lifelong (at least 80 mg/day). A loading dose of
300 mg clopidogrel was given before the intervention.
Postprocedural clopidogrel treatment (75 mg/day) differed
between the two groups. For patients treated with SES,
clopidogrel was prescribed for at least 3 months, unless
one of the following was present (in which case clopidog-
rel was maintained for at least 6 months): multiple SES
implantation (3 stents), total stent length 36 mm,
chronic total occlusion, and bifurcations. Patients treated
with PES were prescribed at least 6 months of clopidogrel
in accordance with the product labeling and instructions
for use, based on existing data from randomized, con-
trolled trials [31]. The methodology of quantitative coro-
nary angiography (QCA) evaluation has been described
previously [19].
Definition and Follow-Up
Patients were prospectively followed-up for the inci-
dence of major adverse cardiac events (MACE), which
included all-cause mortality, nonfatal myocardial infarc-
tion, and target lesion revascularization (TLR) or target
vascular revascularization (TVR). Myocardial infarction
(MI) was diagnosed by a rise in the creatine kinase-MB
fraction (CK-MB) of more than three times the upper
limit of normal, according to the American Heart Asso-
ciation/American College of Cardiology guidelines [32].
TLR was defined as a repeat intervention (surgical or
percutaneous) to treat a luminal stenosis within the stent
or in the 5-mm distal or proximal segments adjacent to
the stent. TVR was defined as a reintervention driven by
any lesions located in the same treated epicardial vessel.
Stent thrombosis was defined as angiographically docu-
mented complete occlusion (TIMI flow grade 0 or 1) or
flow-limiting thrombus (TIMI flow grade 1 or 2) in pre-
viously successfully treated artery. Information about the
in-hospital outcomes was derived from our institutional
electronic clinical database and by review of the hospital
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records of those discharged to referring hospitals. Postdi-
scharge survival status was obtained from the municipal
civil registries. Health questionnaires were subsequently
sent to all living patients, inquiring about postdischarge
repeat coronary interventions (either surgical or percuta-
neous) and the occurrence of MI. All repeat interven-
tions and rehospitalizations were prospectively collected
during follow-up. Referring physicians and institutions
were contacted for additional information if required.
Statistical Analysis
Continuous variables were presented as mean 6 SD
and were compared by means of the Student’s un-
paired t test. Categorical variables were presented as
counts and percentages and compared by means of the
v2 test or Fisher’s exact test. The cumulative incidence
of adverse events was estimated according to the
Kaplan–Meier method and compared by the log rank
test. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were
censored. Multivariate analyses were performed to
identify independent predictors of adverse events,
using all clinical, angiographic, and procedural varia-
bles included in Tables I and II. Cox proportional haz-
ards survival models were used to assess risk reduction
of adverse events. The hazard ratio (HR) and its 95%
confidence intervals (CI) were computed for outcome
measures. A P value of <0.05 was considered statisti-
cally significant.
RESULTS
Patient Characteristics
Table I shows baseline characteristics of the study
population. No significant differences were observed be-
tween both groups apart from a higher prevalence of
smoking and family history of coronary artery disease in
the PES group. A large number of patients with previous
history of MI (38.1%), multi-vessel disease (MVD)
(71.1%), and acute coronary syndromes (ACS) (42.6%)
were enrolled. The number of implanted stents and total
stent length per patient were similar in both groups.
Baseline Angiographic and Procedural
Characteristics
Baseline angiographic and procedural data are dis-
played in Table II. There were 127 lesions in the
SES group and 97 lesions in the PES group. A larger
stent, in addition to 2.25-mm stent, was deployed in
76.6 and 85.6% of SES and PES patients (P ¼ 0.11).
The reasons for stenting with a 2.25-mm device were
reported in detail in a previous paper [19]. A high
TABLE I. Baseline Characteristics
SES (n ¼ 107) PES (n ¼ 90) P value
Age (years 6 SD) 61.3 6 11.1 62.9 6 12.4 0.34
Male, n (%) 75 (70.1) 59 (65.6) 0.54
Diabetes mellitus, n (%) 20 (18.7) 20 (22.2) 0.6
Type I, n (%) 6 (5.6) 6 (6.7) 0.77
Type II, n (%) 14 (13.1) 14 (15.6) 0.68
Hypertension, n (%) 47 (43.9) 44 (48.9) 0.57
Hypercholesterolemia, n (%) 72 (67.3) 55 (61.1) 0.38
Family history, n (%) 35 (32.7) 48 (53.3) 0.004
Current smoking, n (%) 20 (18.7) 28 (31.3) 0.047
Previous myocardial infarction, n (%) 35 (32.7) 40 (44.4) 0.11
Previous angioplasty, n (%) 28 (26.2) 25 (27.8) 0.87
Previous coronary bypass surgery, n (%) 9 (8.4) 6 (6.7) 0.79
Vessel disease 0.91a
1-vessel disease, n (%) 33 (30.8) 24 (26.7)
2-vessel disease, n (%) 42 (39.3) 44 (48.9)
3-vessel disease, n (%) 32 (29.9) 22 (24.4)
Multivessel disease, n (%) 74 (69.2) 66 (73.3) 0.53
Clinical presentation 0.86a
Stable angina, n (%) 61 (57.0) 52 (57.8)
Unstable angina, n (%) 33 (30.8) 28 (31.1)
Acute myocardial infarction, n (%) 13 (12.1) 10 (11.1)
Acute coronary syndrome, n (%) 46 (43.0) 38 (42.2) 1.00
Left ventricular ejection fraction (%) 50.4 6 9.70 51.2 6 9.50 0.61
Number of implanted stents/patients 6 SD 1.40 6 0.69 1.31 6 0.57 0.32
Total stent length/patient (mm 6 SD) 23.4 6 14.5 21.6 6 11.1 0.35
Number of lesions/patient 6 SD 1.50 6 0.71 1.63 6 0.77 0.19
Glycoprotein IIb/IIIa use, n (%) 33 (30.8) 30 (33.3) 0.76
aAcross all groups.
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prevalence of bifurcation lesions was observed in the
entire cohort (25.0%). The prevalence of target
lesions located at an ostium was significantly higher
in the SES group than in the PES group (28.3% vs.
15.5%, P ¼ 0.025). The mean maximal pressure at
stent deployment was significantly higher in the SES
group (16.0 6 3.3 atm vs. 14.9 6 3.0 atm in the
PES group, P ¼ 0.046). The number of implanted
stents and total stent length per lesion were compara-
ble between the two groups. By QCA analysis, the
minimal lesion diameter both pre- and post-PCI was
smaller in the SES group (0.47 6 0.38 mm and
1.73 6 0.31 mm vs. 0.57 6 0.38 mm and 1.82 6 0.36
mm in the PES group; P ¼ 0.06 and 0.06, respectively),
whereas lesion length was significantly longer in the
PES group than in the SES group (16.4 6 10.4 mm vs.
13.0 6 8.5 mm; P ¼ 0.02).
Clinical Outcome
Two-year follow-up data were obtained for 105
patients (98.1%) in the SES group and 89 patients
(98.9%) in the PES group. MACE was analyzed at 1
month (30 days), 1 year (365 days), and 2 years (730
days) (Table III).
One-Month (30 Days) and One-Year (365 Days)
Follow-Up
The 1-month and 1-year clinical outcomes have been
previously reported [19]. Briefly, three patients died in
the first month (2 PES and 1 SES); all these patients pre-
sented with MVD and ACS on their admission and died
of cardiac cause. There were two episodes of angio-
graphically documented subacute thrombosis in the PES
group (2.2%) and none in the SES group (P ¼ 0.21).
These two patients who presented with stent thrombosis
were alive at 2-year follow-up.
At 1 year, one patient (0.9%) died in the SES group,
and four patients (4.3%) died in the PES group (P ¼
0.18): their causes of death were cardiac. The inci-
dence of TLR, TVR, and TVR-MACE was more fre-
quent in the PES group, but it did not reach statistical
significance (11.1, 12.2, and 18.9% vs. 6.5, 7.5, and
9.3% in the SES group; P ¼ 0.31, 0.33, and 0.06,
respectively). TLR-MACE rate was significantly lower
TABLE II. Angiographic and Procedural Characteristics
SES (n ¼ 127) PES (n ¼ 97) P value
Treated vessel
Right coronary artery, n (%) 20 (15.7) 9 (9.3) 0.17
Left anterior descending, n (%) 29 (22.8) 25 (25.8) 0.64
Diagonal, n (%) 31 (24.4) 18 (18.6) 0.33
Left circumflex, n (%) 35 (27.6) 25 (25.8) 0.88
Obtuse or intermediate marginal, n (%) 12 (9.4) 18 (18.6) 0.07
Bypass graft, n (%) 0 (0) 2 (2.1) 0.19
ACC/AHA modified lesion classification
Type A or B1, n (%) 58 (45.7) 38 (39.2) 0.34
Type B2 or C, n (%) 69 (54.3) 59 (60.8) 0.34
Calcification (moderate/severe), n (%) 15 (11.8) 7 (7.2) 0.37
Thrombus, n (%) 10 (7.9) 8 (8.2) 1.00
Ostial, n (%) 36 (28.3) 15 (15.5) 0.025
Bifurcation, n (%) 32 (25.2) 24 (25.3) 1.00
Total occlusion, n (%) 33 (26.0) 22 (22.7) 0.64
TIMI grade 3 flow post procedure, n (%) 122 (96.0) 95 (97.9) 0.70
Number of stent/lesion 6 SD 1.17 6 0.42 1.21 6 0.48 0.58
Total stent length/lesion (mm 6 SD) 19.8 6 10.9 19.8 6 9.5 0.99
Direct stenting, n (% 6 SD) 65 (51.2) 58 (60.4) 0.22
Postdilatation, n (% 6 SD) 30 (23.6) 18 (18.6) 0.41
Max. pressure (atm 6 SD) 16.0 6 3.3 14.9 6 3.0 0.046
Quantitative coronary angiography analysis
Pre
Reference diameter (mm 6 SD) 1.86 6 0.37 1.95 6 0.38 0.15
Minimal lesion diameter (mm 6 SD) 0.47 6 0.38 0.57 + 0.38 0.06
Diameter stenosis (% 6 SD) 74.8 6 20.1 70.3 6 19.3 0.10
Lesion length (mm 6 SD) 13.0 6 8.5 16.4 6 10.4 0.02
Post
Minimal lesion diameter (mm 6 SD) 1.73 6 0.31 1.82 6 0.36 0.06
Diameter stenosis (% 6 SD) 12.3 6 10.0 14.0 6 9.80 0.19
ACC, American College of Cardiology; AHD, American Heart Association; TIMI, Thrombolysis In
Myocardial Infarction.
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in the SES group (8.4% vs. 18.9% in the PES group;
P ¼ 0.04). Angiographic late stent thrombosis, which
was defined as occurring 30 days after stent implanta-
tion, was not seen during the first year.
Two-Year (730 Days) Follow-Up
At 2 years, there were two deaths (1.9%) in the SES
group and seven deaths (7.6%) in the PES group (P ¼
0.08). The combined endpoint of death and MI was sig-
nificantly different between the two groups (4.7% in the
SES group and 13.3% in the PES group; P ¼ 0.04). An
event-free survival rate of this composite endpoint is
shown in Fig. 1 (log rank P ¼ 0.031, by Kaplan–Meier
estimate). The prevalence of TLR and TVR was lower
in the SES group compared to the PES group, but did
not achieve statistical significance (P ¼ 0.22 and 0.24,
respectively). The 2-year incidence of TVR-MACE was
significantly higher in the PES group (23.3% vs. 10.3%
in the SES group; P ¼ 0.02), with a MACE-free sur-
vival rate of 76.6 and 89.7% in patients treated with
PES and SES, respectively (log rank P ¼ 0.012, by
Kaplan–Meier estimate) (Fig. 2).
Events From One (365 Days) to Two Years
(730 Days)
Between 1 and 2 years, five events occurred. There
was one death in the SES group and three deaths in
the PES group (P ¼ 0.33); noncardiac death was
observed in one patient in the SES group, the causes
of death in the PES group were one cardiac and two
unknown. No patient in either group experienced MI
or late angiographic stent thrombosis during this period.
Including TLR, there was only one additional TVR
in the PES group and none in the SES group (P ¼
0.46).
Multivariate Predictors of Outcomes
Cox regression analysis was performed to identify
independent predictors of MACE and the composite
endpoint of death and MI at 2 years (Table IV). PES
utilization (HR 2.37, 95% CI 1.07–5.26; P ¼ 0.03),
the presentation with ACS (HR 3.34, 95% CI 1.44–
7.70; P ¼ 0.005) and MVD (HR 3.91, 95% CI 1.27–
12.0; P ¼ 0.017) were found to be significant inde-
pendent predictors of the 2-year MACE rate. Signifi-
cant predictors of the 2-year composite endpoint of
death or MI included PES utilization (HR 4.48, 95%
CI 1.19–16.79; P ¼ 0.03), the presentation with ACS
(HR 4.46, 95% CI 1.14–17.46; P ¼ 0.03) and diabetes
mellitus (HR 5.54, 95% CI 1.65–18.62; P ¼ 0.006).
Hypercholesterolemia was found to be a protective fac-
tor for the 2-year composite endpoint of death or MI
(HR 0.16, 95% CI 0.04–0.59; P ¼ 0.006).
DISCUSSION
The main findings of this study were (1) SES im-
plantation significantly reduced the incidence of MACE
at 2 years as compared to PES implantation, (2) the use
of PES and the presence of ACS and MVD were inde-
pendent factors of 2-year MACE, and (3) the efficacy of
the SES was maintained up to 2 years in a very challeng-
ing real world population.
Study Population
It is noteworthy that the overall population included
in this study had a markedly increased risk of adverse
outcomes. We included clinical and procedural subsets
commonly excluded from most studies such as patients
with acute MI, totally occluded vessels, left ventricular
TABLE III. Major Adverse Cardiac Events
Events
SES
(n ¼ 107)
PES
(n ¼ 92) P valuea
30 days Death, n (%) 1 (0.9) 2 (2.2) 0.59
MI, n (%) 3 (2.8) 6 (6.7) 0.31
TLR, n (%) 3 (2.8) 5 (5.6) 0.47
TVR, n (%) 3 (2.8) 5 (5.6) 0.47
Death or MI, n (%) 4 (3.7) 7 (7.8) 0.35
TLR MACE, n (%) 5 (4.7) 11 (12.2) 0.07
TVR MACE, n (%) 5 (4.7) 11 (12.2) 0.07
Stent thrombosisb 0 (0) 2 (2.2) 0.21
365 days Death, n (%) 1 (0.9) 4 (4.3) 0.18
MI, n (%) 3 (2.8) 7 (7.8) 0.19
TLR, n (%) 7 (6.5) 10 (11.1) 0.31
TVR, n (%) 8 (7.5) 11 (12.2) 0.33
Death or MI, n (%) 4 (3.7) 9 (10.0) 0.09
TLR MACE, n (%) 9 (8.4) 17 (18.9) 0.04
TVR MACE, n (%) 10 (9.3) 17 (18.9) 0.06
Stent thrombosisb 0 (0) 2 (2.2) 0.21
730 days Death, n (%) 2 (1.9) 7 (7.6) 0.08
MI, n (%) 3 (2.8) 7 (7.6) 0.19
TLR, n (%) 7 (6.5) 11 (12.2) 0.22
TVR, n (%) 8 (7.5) 12 (13.3) 0.24
Death or MI, n (%) 5 (4.7) 12 (13.3) 0.04
TLR MACE, n (%) 10 (9.3) 21 (23.3) 0.01
TVR MACE, n (%) 11 (10.3) 21 (23.3) 0.02
Stent thrombosisb 0 (0) 2 (2.2) 0.21
366–730 days Death, n (%) 1 (0.9) 3 (3.3) 0.33
MI, n (%) 0 (0) 0 (0)
TLR, n (%) 0 (0) 1 (1.1) 0.46
TVR, n (%) 0 (0) 1 (1.1) 0.46
Death or MI, n (%) 1 (0.9) 3 (3.3) 0.33
TLR MACE, n (%) 1 (0.9) 4 (4.3) 0.18
TVR MACE, n (%) 1 (0.9) 4 (4.3) 0.18
Stent thrombosisb 0 (0) 0 (0)
MI, myocardial infarction; TLR, target lesion revascularization; TVR,
target vessel revascularization; MACE, major adverse cardiac events.
aBy Fisher’s exact test or the v2-test.
bAngiographically documented stent thrombosis.
SES for smal vessels | Chapter 12
123
dysfunction, and thrombotic and calcified lesions.
Indeed, there was a marked high prevalence of patients
with MVD (71.1%), ACS (42.6%), and chronic total
occlusion (24.4%) in the present study. In addition,
mean RD of the target vessels was particularly small
(1.90 6 3.8 mm).
Fig. 1. Survival free of the composite of death or myocardial infarction of patients treated
with sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) by Kaplan–Meier
estimate up to 2 years.
Fig. 2. Survival free of major adverse cardiac events (MACE) of patients treated with siroli-
mus-eluting stents (SES) versus paclitaxel-eluting stents (PES) by Kaplan–Meier estimate up
to 2 years.
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Clinical Results
Small vessel size is known to be an independent
predictive factor of restenosis after PCI [33]. It
remains controversial whether BMS placement in small
vessels less than 3 mm in diameter is actually superior
to balloon angioplasty. The latest meta-analysis on
small vessel stenting reported that rates of restenosis
and MACE in patients treated with BMS were 27.8
and 17.6%, respectively [34]. This high restenosis rate
is due to the fact that absolute late lumen loss after
stenting in small vessels is similar to that in large ves-
sels so that even a small volume of neointimal hyper-
plasia induce a diameter stenosis more than 50% in
small vessels more easily than in large vessels [28].
The high incidence of angiographic restenosis could
lead to high MACE rates in this clinical setting.
The advent of DES, which markedly inhibited neo-
intimal hyperplasia and reduced restenosis, created the
expectation of reducing restenosis substantially in
patients with small vessels. Indeed, several randomized
studies have demonstrated that both DES resulted in
remarkably low angiographic restenosis rates (0–6%)
and revascularization rates (3–4%) as compared to
BMS for the treatment of vessels with a RD of less
than 3 mm [8–11]. But in some trials, which focused
on DES implantation in small vessels (mean RD less
that 2.5 mm), the incidence of cardiac events was rela-
tively high and differed between SES and PES utiliza-
tion (Table V). The SES-SMART trial [35], which
enrolled patients with small vessels (mean RD
was 2.2 mm), showed that the incidence of TLR and
MACE in the SES arm was 7.0 and 9.3%, respec-
tively. The subanalysis of TAXUS V trial [36], in
which patients treated with 2.25-mm diameter PES
were included and mean RD was 2.08 mm, indicated
that the TLR and MACE rates were 10.4 and 18.9%,
respectively. The most important conclusion of the
subanalysis of TAXUS V was that there was no signif-
icant difference between the MACE rates in the PES
and BMS arms despite considerably lower rates of
angiographic restenosis and TLR in the PES arm when
compared with the BMS arm. The ISAR-SMART 3
study [20] was a head-to-head comparative trial (SES
vs. PES) for patients with small vessel disease (mean
RD was about 2.4 mm), and reported that SES was
more effective in reducing restenosis and TLR when
compared with PES (8.0 and 6.6% in the SES group
vs. 14.9 and 14.7% in the PES group; P ¼ 0.04 and
0.008, respectively). Interestingly, our clinical results
TABLE IV. Independent Predictors of MACE and the Composite Endpoint of Death or MI at 2-Year Follow-Up
MACE at 2 years Death or MI at 2 years
HR P value HR P value
PES utilization 2.37 (1.07–5.26)a 0.03 4.48 (1.19–16.79) 0.03
Acute coronary syndrome 3.34 (1.44–7.70) 0.005 4.46 (1.14–17.46) 0.03
Multivessel disease 3.91 (1.27–12.0) 0.02 2.32 (0.46–11.74) 0.31
Diabetes mellitus 1.56 (0.66–3.68) 0.31 5.54 (1.65–18.62) 0.006
Hypercholesterolemia 0.55 (0.25–1.19) 0.13 0.16 (0.04–0.590) 0.006
MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stents; HR, hazard ratio; CI, confidence intervals.
aValues in parentheses are 95% CI.
TABLE V. Published Papers on Drug-Eluting Stent Implantation in Patients With Very Small Vessels
Study
SES-SMART [35]
TAXUS V
subanalysis [36] ISAR-SMART 3 [20] The present study
Trial design Randomized trial Randomized trial Randomized trial Nonrandomized
Clinical follow-up (month) 8 9 12 24
Angiographic follow-up 8 9 6–8 NA
Stent SES BMS P value PES BMS P value SES PES P value SES PES P value
No. of patients, n 129 128 108 95 198 204 107 92
Reference diameter (mm) 2.22 2.17 0.15 2.07 2.10 0.46 2.44 2.40 0.34 1.86 1.95 0.15
Lesion length (mm) 13.0 10.7 <0.01 16.6 16.4 0.91 12.9 11.7 0.12 13.0 16.4 0.02
In-stent restenosis (%) 4.9 49.1 <0.01 24.7 44.7 <0.01 8.0 14.9 0.04 NA NA NA
TLR (%) 7.0 21.1 <0.01 10.4 21.5 0.03 6.6 14.7 0.008 6.5 12.2 0.22
MACE (%) 9.3 31.3 <0.01 18.9 26.9 0.23 NA NA NA 10.3 23.3 0.02
Stent thrombosis (%) 0.8 3.1 0.21 1.0 1.1 >0.99 NA NA NA 0.0 2.2 0.21
TLR, target lesion revascularization; MACE, major adverse cardiac events; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; BMS, bare
metal stents; NA, not available.
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in the two arms at 1 year were comparable to these
three trials, though the mean RD of the entire cohort
was smaller (mean RD 1.90 mm) and the present pop-
ulations were at higher risk of clinical events as men-
tioned above. In addition, our results, like those in the
ISAR-SMART 3 trial, also indicated that the SES
tended to have a lower 1-year TLR rate as compared
to the PES (6.5% vs. 11.1%; P ¼ 0.31). Moreover, by
multivariate analysis, the use of SES rather than PES
was found to be an independent protective factor for
the prevention of MACE at 2 years in the present
study.
Considering these results, it can be said that the
SES is likely to be more effective than the PES in this
clinical setting. This propensity was verified by the
results of recent large head-to-head, randomized con-
trolled trials [13–15,17,18], which indicated that SES
was significantly better at reducing neointimal hyper-
plasia and had a slight advantage in clinical outcomes
when compared with PES. Different drug-release
kinetics and mechanisms of inhibiting neointimal hy-
perplasia between SES and PES presumably accounts
for the observed difference in their performance. How-
ever, it is difficult to directly compare previous trials
with the present study because the inclusion criteria
and endpoints of each study were different. In addi-
tion, the number of enrolled patients in each study was
too small and underpowered to definitely assess the
effect of DES on the rate of TVR or MACE in this
patient population. Moreover, it is worth emphasizing
that to date the ISAR-SMART 3 trial is the only
randomized controlled prospective study comparing the
efficacy of SES with that of PES in patients with small
vessels. Further investigations are needed to identify
which DES is more effective than the other in this par-
ticular clinical setting.
Safety Concerns of DES Implantation
in Small Vessels
After DES were approved, these devices were im-
planted in a large number of patients with coronary ar-
tery disease and many trials indicated the use of them
to be feasible and safe. Recently, however, certain
potential issues with their use have been raised. One
of the problems was delayed restenosis, which was
usually called a \late catch-up phenomenon" and
noticed as a complication following brachytherapy.
This concern has been fueled by findings in the por-
cine model [37,38]. In humans, continued hyperplastic
growth of neointima during the follow-up period was
noted in some trials in which serial intravascular ultra-
sound analyses were performed [39–41]. The precise
reason for this observation is still unclear. Delayed
neointimal hyperplasia could cause a high incidence of
TLR and MACE with long-term follow-up. The pres-
ent study showed only one patient treated with PES
presented with TLR in the second year of follow-up.
This result might suggest an absence of the late catch-
up phenomenon within these small vessels. All we can
mention with certainty in the present study is that the
efficacy of DES, especially SES, was maintained up to
2 years.
Late stent thrombosis is another topical issue follow-
ing DES deployment. Our result demonstrated that in
the entire cohort the overall angiographic stent throm-
bosis rate was 1.0% and no late stent thromboses were
seen. This incidence rate seems acceptable. However,
it should be mentioned that not all patients suffering
from stent thrombosis underwent coronary angiogra-
phy. Indeed, as indicated in the results section, three
patients in our study who died suddenly during the
first month after stent implantation were suspected of
having subacute stent thrombosis but they could not be
confirmed as having stent thrombosis in the absence of
coronary angiography. To assess this rare and unex-
pected late complication precisely, a much larger sam-
ple size and long-term follow-up are needed. Neverthe-
less, this study provides some reassurance about this
safety concern for both DES in the small vessel sub-
sets.
Independent Factors of Late Cardiac Events
Besides the use of PES, the presence of ACS and
MVD were also independent predictive factors of 2-
year TVR-MACE. These factors are well known to be
predictors of restenosis and late cardiac adverse events.
The patients receiving small vessel stenting, who pre-
sented with ACS and MVD on admission, should be
attended and followed-up carefully. ACS as well as di-
abetes mellitus, in addition to the use of PES, were
also significant predictive factors for the composite
endpoint of death or MI. To prevent the onset of ACS,
detecting vulnerable patients early is very important. It
is imperative that intensive glucose control physically
and pharmaceutically is implemented to reduce late
cardiac events. Curiously, in our multivariate analysis,
the presence of hypercholesterolemia was a protective
factor for the composite endpoint of death or MI. This
result is not easy to explain.
Study Limitation
This study presents several limitations related to its
small sample size, nonrandomized nature, and lack of
a true control group. The fact that a large percentage
of the population enrolled in the present study were
simultaneously treated with larger stent size DES
(more than 2.25 mm) might have influenced the accu-
racy of our result. Another potential limitation is that
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each group was treated in different time periods. This
might lead to some bias in terms of patient selection
and affect procedural characteristics, as treatment strat-
egy has evolved over time. However, it should be
noted that this study enrolled consecutive patients
treated in daily practice: we enrolled all comers and
had no exclusion criteria. To definitively address the
efficacy and safety of each DES in patients with small
coronary arteries, larger head-to-head randomized trials
are needed.
CONCLUSIONS
In an unselected population treated for small vessel
disease, SES was associated with significantly better 2-
years clinical outcomes, especially MACE, when com-
pared with PES. The use of PES and the presence of
MVD and ACS were independent predictors of 2-year
MACE. The efficacy and safety of SES utilization was
maintained up to 2 years.
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Three-Year Clinical Outcomes After
Coronary Stenting of Chronic Total Occlusion
Using Sirolimus-Eluting Stents:
Insights From the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology
Hospital—(RESEARCH) Registry
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Ron T. van Domburg, PhD, and Patrick W. Serruys,* MD, PhD
Background: We previously reported that the 1-year survival-free from target lesion re-
vascularization was 97.4% in patients with chronic total occlusion (CTO) treated with siro-
limus-eluting stents (SES). There are currently no long-term results of the efficacy of SES
in this subset of lesions. We assessed the 3-year clinical outcomes of 147 patients with
CTO treated with either SES or bare metal stents (BMS). Methods and Results: A total of
147 (BMS 5 71, SES 5 76) patients were included. Four patients died in the BMS group
while five patients died in the SES group, P 5 0.8; two myocardial infarctions occurred in
both groups, P 5 0.9; and target vessel revascularization was performed in nine patients
in the BMS and seven in the SES group, P 5 0.5. The cumulative event-free survival of
MACE was 81.7% in BMS group and 84.2% in SES group, P5 0.7. Two patients of the SES
group had a coronary aneurism at 3-year angiographic follow-up. Conclusions: The use
of SES was no longer associated with significantly lower rates of target vessel revascu-
larization and major adverse cardiac events in patients with CTOs after 3 years of follow-
up compared with BMSs. ' 2007 Wiley-Liss, Inc.
Key words: drug-eluting stents; angiography; coronary; total occlusions; percutaneous
coronary intervention; restenosis
INTRODUCTION
Drug-eluting stents (DES) are superior in terms of
clinical outcomes and restenosis rate to bare-metal
stents (BMS) in every angiographic and patient sub-
set [1–3]. In particular, in patients with chronic total
occlusion (CTO) DES have shown a significant
decrease in need for repeat revascularization and re-
stenosis rate [4–7], although this subset remains still
in the DES era a predictor of restenosis [8]. Our
group has previously reported the 6-month angio-
graphic and clinical outcomes of sirolimus-eluting
stent (SES) in patients with CTOs [9]. In this study,
we showed a marked reduction in restenosis rate and
major adverse cardiac events (MACE) compared with
BMS. This observation was confirmed in the PRISON
II study [10], a prospective, randomized trial that
included a total of 200 patients treated either with a
SES or BMS with both clinical and angiographical
follow-up at 6 months. However, among the interven-
tionalists, the clinical and angiographic long-term fol-
low-up of the DES is still a major concern, especially
in high-risk populations. We therefore investigated
the 3-year clinical and angiographic follow-up of
patients with CTO in a consecutive series of 147
patients, with comparison between the bare metal
stents and SESs.
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MATERIALS AND METHODS
From April 2002 to February 2003, 76 patients with
CTOs were treated solely with SES. In this period
SES (Cypher1; Cordis Corporation, Warren, NJ) was
the device of first choice for every PCI performed
in our institution as part of the rapamycin eluting
stent evaluated at rotterdam cardiology hospital
(RESEARCH) registry, a prospective single center
study set-up with the aim of evaluating the safety and
efficacy of SES in a ‘‘real world’’ scenario, following
the dynamic registry design described by Rothman and
coworkers [11,12]. Except for contraindications to clo-
pidogrel treatment, no exclusion criteria were made.
All consecutive patients treated successfully were en-
rolled irrespective of clinical presentation and CTO
lesion characteristics. Those patients treated with SES
implantation were compared with all those treated for
a CTO in the preceding 1 year with bare metal stents
(BMS), identified from the departments’ dedicated
database. The same operators utilizing standard techni-
ques treated all groups; the only difference being the
type of stent.
This protocol was approved by the hospital ethics
committee and is in accordance with the principles of
Good Clinical Practice for Trials of Medicinal Products
in the European Community and the Declaration of
Helsinki. Written informed consent was obtained from
every patient.
CTO Definition
CTO was defined as a complete occlusion on angi-
ography with no antegrade filling of the distal vessel
other than via collaterals. All the occlusions in a native
vessel with at least 3-month duration based on the
clinical history or a previous coronary angiogram were
included [9].
Angiographic Analysis
Quantitative coronary analysis in those patients with
angiographic follow-up was performed as previously
described [9]. Briefly, three segments were analyzed:
(1) stent segment; (2) the 5 mm proximal to the stent;
and (3) the 5 mm distal to the stent. The target lesion
comprised the in-stent plus the proximal and distal
edge segments. Binary restenosis was considered as
>50% diameter stenosis within the target lesion.
All patients were pretreated with 300 mg of clopi-
dogrel, which was then prescribed at a dose of 75 mg/
day for 6 months. All patients were advised to main-
tain aspirin (80 mg/day) lifelong.
Our primary endpoints were the 3-year incidence of
MACE, a compound endpoint of all-cause mortality,
nonfatal myocardial infarction and target-vessel revas-
cularization, in both groups. Secondary endpoints were
target vessel revascularization (TVR) and myocardial
infarction (MI). MI was defined by a rise in creatine
kinase-MB fraction (CK-MB) of three times the upper
limit of normal, according to American Heart Associa-
tion/American College of Cardiology guidelines [13].
TVR was defined as a percutaneous reintervention or
coronary artery bypass grafting (CABG) of a lesion in
the same epicardial vessel. Subacute angiographic stent
thrombosis was defined as an angiographically docu-
mented complete occlusion (TIMI grade 0 or 1 flow)
or a flow-limiting thrombus (TIMI grade 1 or 2 flow)
in the first 30 days after a successful procedure. Late
stent thrombosis was defined as angiographically
defined thrombosis with (TIMI grade 0 or 1 flow or
the presence of a flow limiting thrombus), occurring at
least 1 month after DES implantation accompanied by
acute symptoms. Angiographic follow-up was per-
formed in a subset of 30 patients in the SES group.
Three-Year Follow-Up Data
Patients were followed-up prospectively and eval-
uated for MACE-free survival of using both municipal
civil registries and health questionnaires inquiring
about postdischarge repeat coronary interventions (ei-
ther surgical or percutaneous) and MI. Since our hospi-
tal is a tertiary referral center for our region, with a
catchment area of 1.3 million people, most of the
repeat interventions were performed at our institution.
Follow-up information was prospectively entered into a
dedicated database. If a patient had an MI or a reinter-
vention at another center, medical records or discharge
letters were requested and systematically reviewed.
Local cardiologists or general practitioners were also
contacted as necessary. Patients lost to follow-up were
considered at risk until the date of last contact, at
which point they were censored.
Statistical Analysis
Continuous variables are presented as mean 6 SD
and were compared by the Student’s t test. Categorical
variables are presented as counts and percentages and
compared by Fisher’s exact test. The cumulative inci-
dence of adverse events was estimated according to
the Kaplan–Meier method and curves were compared
using the log-rank test. Separate Cox regression analy-
ses were performed to identify independent predictors
of adverse events. Preselected variables were: age, gen-
der, hypertension, diabetes, renal impairment, previous
intervention, old MI, smoking, treatment of the left
main coronary artery, and previous CABG. The final
results are presented as adjusted hazard ratios (HRs).
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RESULTS
Baseline and Procedural Characteristics
A total of 71 and 76 patients were included in the
BMS group and in the SES group, respectively. There
were no significant differences between the groups
with respect to baseline patient characteristics
(Table I). In the BMS group 76.1% and in the SES
group 65.8% were male (P ¼ 0.1) and the mean age
was 60.9 6 10.5 and 61.1 6 10.6 years, respectively
(P ¼ 0.9). Although not statistically significant, in the
SES group the number of diabetic patients and patients
treated in the LAD were higher. Glycoprotein IIb/IIIa
inhibitor use was low in both the BMS group (21.9%)
and SES group (18.4%) (P ¼ 0.08); as defined by pro-
tocol, clopidogrel prescription was longer in SES
group (6 months) as compared with the BMS group (1
month).
Three-Year Clinical Follow-Up
Both 6-month and 1-year outcomes have been
reported previously [9,14]. At 3 years, follow-up was
available in 87.3% of the patients in the BMS group
and in 96% of the SES group. Four patients died in
the BMS group, two of unknown cause, one of noncar-
diac cause, and one of cardiac death; while five
patients died in the SES group, P ¼ 0.8; in this group,
three deaths were of cardiac cause, one patient died of
cancer, and the cause of one patient was unknown.
Two MI’s occured in both groups, P ¼ 0.9; and
TVR was performed in nine patients in the BMS and
seven in the SES group, P ¼ 0.5. The cumulative sur-
vival-free of MACE was 81.7% in BMS group and
84.2% in SES group, P ¼ 0.7 (Table II and Fig. 1).
No cases of late stent thrombosis were identified in
these two groups.
In the multivariate analysis the only variable that
was an independent predictor of MACE was age, HR
1.04 (95%CI, 1.01, 1.07).
Three-Year Angiographic Follow-Up
Thirty patients underwent angiography at 3-year; the
in-stent minimum lumen diameter was 1.9 6 0.6 mm,
the in-stent diameter stenosis was 30.5%, and the late
loss 0.35 6 0.50; four patients had binary restenosis;
out of this four, two CTOs were found to be reoc-
cluded (Fig. 2). One of these patients with reocclusion
TABLE I. Baseline Patient Characteristics
BMS n ¼ 71 SES n ¼ 76 P value
Mean age (years) 60.9 6 10.5 61.1 6 10.6 0.9
Male sex (%) 76.7 65.8 0.1
Current smoker (%) 27.4 18.4 0.2
Diabetes mellitus (%) 5.5 14.5 0.07
Hypertension (%) 35.6 42.1 0.3
Hypercholesterolemia (%) 57.5 67.1 0.3
Previous myocardial
infarction (%)
50.7 51.3 0.8
Previous CABG (%) 0 3.9 0.2
Glycoprotein IIb/IIIa
inhibitor usage (%)
21.9 18.4 0.8
Target vessel 0.1
LAD (%) 27.5 46.1
LCX (%) 27.5 19.7
RCA (%) 44.9 36.8
Mean number of stents 1.9 6 0.8 2.2 6 1.2 0.9
Mean diameter of
the stent (mm)
3.1 6 0.58 2.8 6 0.3 <0.001
Mean length of stent (mm) 21.7 6 6.3 22.5 6 6.1 0.5
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, CABG: cor-
onary artery bypass grafting, PCI: percutaneous coronary intervention,
LAD: left anterior descending artery, LCX: circumflex artery, RCA: right
coronary artery.
TABLE II. Clinical Events at Three-Year Follow-Up
BMS, n ¼ 71 SES, n ¼ 76 P value
Death, n(%) 4(5.6) 5(6.6) 0.8
MI, n(%) 2(2.8) 2(2.6) 0.9
TLR, n(%) 8(11.3) 6(7.9) 0.5
TVR, n(%) 9(12.7) 7(9.2) 0.5
TLR/Death, n(%) 12(16.9) 11(14.5) 0.7
TVR/Death, n(%) 13(18.3) 12(15.8) 0.7
MI/Death, n(%) 4(5.7) 6(8.1) 0.6
MACE, n(%) 13(18.3) 12(15.8) 0.7
MI, myocardial infarction; TLR, target lesion revascularization; MACE,
major adverse cardiac events.
Fig. 1. Three-year cumulative incidence of major adverse car-
diovascular events.
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was treated due to the presence of symptoms, while
the other patient was left untreated due to the absence
of symptoms and it is awaiting noninvasive ischemia
testing. Two patients had a coronary aneurism.
DISCUSSION
This report describes the 3-year clinical and angio-
graphic follow-up of patients with CTO treated with
either BMS or sirolimus stents.
There have been some publications comparing BMS
vs. DES treatment for CTOs with 6-month follow-up
[7,9,15], and recently the first randomized trial in the
DES era that included exclusively CTO patients was
published [10]; pooling these studies despite the differ-
ent nature of data (e.g. registries vs. randomized trial),
the analysis showed a decrease in TVR and MACE
with DES, OR 0.25 (95%CI, 0.16, 0.40) and OR 0.36
(95%CI, 0.24, 0.53), respectively. Three 1-year follow-
up studies have been published [5,6,14], (all registries),
which also showed a sustained benefit of DES in terms
of TVR and MACE, OR 0.1 (95%CI, 0.05, 0.20) and
OR 0.17 (95%CI, 0.07, 0.43), respectively. Clinical
reports including up to 1-year clinical follow-up, nei-
ther individually or globally, showed a decrease in
terms of all cause death or MI.
Although due to the study design some baseline
characteristics are different between the two groups
such the presence of diabetes, treatment of the LAD
(no statistically significant), and diameter of the stent,
in the 6-month [9] and 1-year [14] reports in patients
treated with SES a marked reduction in restenosis rate
and MACE was observed compared with BMS. In
turn, this 3-year follow-up report showed no difference
whatsoever in any of the MACE components. This is
in agreement with other two long-term follow-up sub-
studies of the RESEARCH registry, patients with dia-
betes mellitus and acute MI [16]. The former report
compared the 2-year clinical outcome of 708 consecu-
tive diabetic patients treated with either a BMS (n ¼
252), a SES (n ¼ 206), or a PES (n ¼ 250). TVR
rates were 19.5% in the BMS group, vs. 15.3% in the
SES group and 9.7% in the PES group. PES (21.2%)
but not SES (28.9%), were superior to BMS (29.7%)
in reducing MACEs. However, after propensity analy-
ses, none of the differences remained significant. The
second report where primary angioplasty was per-
formed in a consecutive group of 505 patients (BMS,
n ¼ 183; SES, n ¼ 186; PES, n ¼ 136), showed that
the cumulative incidence of death or MI was compara-
ble in the three groups: 16.6% in the BMS group,
14.6% in the SES group, and 16.9% in the PES group.
At 3 years, TVR was 12.0% in the BMS group, com-
pared with 8.0 and 7.7% in the SES and PES groups,
respectively. The cumulative incidence of death, MI or
TVR was 25.5% in the BMS group compared with
17.9 and 21.4% in the SES and PES groups, respec-
tively. In light of these results, it seems that a late
clinical restenotic phenomenon is observed in specific
subsets of patients, and that the beneficial effects in re-
stenosis rates of DES observed in the first year might
drop over the time.
The present study has all the intrinsic limitations of
a registry. Although in our center only in a limited pe-
riod of time all comers were treated with sirolimus
eluting stent and the number of CTO patients treated
was relatively small, all consecutively treated CTO
patients were included in this registry. A word of cau-
tion in interpreting the present findings as confirmative
must be given, since the sample size is small. However,
so far, in this subset of patients, this is the only registry
with clinical and angiographic long-term follow-up.
CONCLUSIONS
Despite clinical benefit after 1 year, the use of siro-
limus stent was no longer associated with significantly
lower rates of TVR and MACEs in patients with
Fig. 2. A patient with a chronic total occlusion in the distal
right coronary artery (panel A) was treated with four sirolimus
stent (SES), in panel B the final result. Seventeen months later
the patient underwent coronary angiogram due to stable an-
gina and focal stent restenosis was seen in the gap between
SES 3 and 4 (panel C). In addition, mild intimal hyperplasia
was observed in the body of the SES number 4. Patient was
treated with a PES (panel D). In the three-year angiographic
follow-up an increase was seen in the intimal hyperplasia
(panel E).
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CTOs after 3 years of follow-up compared with bare
metal stents.
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Abstract
Background: Percutaneous treatment of stenoses involving aorto-ostial lesions is technically demanding and has been associated with lower
procedural success and poorer clinical and angiographic outcomes when compared with non-ostial lesions. This study evaluated the
immediate and long-term (2-year) outcome of aorto-ostial stenoses treated with paclitaxel-eluting stents (PES).
Methods: From February 2003 to December 2004, a total of 76 consecutive patients with 76 lesions underwent percutaneous intervention
with PES for aorto-ostial lesions (right coronary artery, 37; left main, 26; saphenous vein graft, 13). All patients were clinically followed for
the occurrence of major adverse cardiac events (MACE), defined as cardiac death, non-fatal myocardial infarction (MI), target lesion
revascularization (TLR) or target vessel revascularization (TVR).
Results: All stents (1.7/lesion) were successfully deployed. Three lesions (3.9%) were pre-treated with debulking devices. Thirty-seven
lesions (48.7%) were post-dilated with non-compliant balloons (balloon/artery ratio, 1.2). Stents were positioned protruding into the aortic
lumen in 29 lesions (38.2%). Cumulative 2-year event-free survival was 68.4%. There was one angiographically-proven stent thrombosis
occurring 427 days after TLR for restenosis after the index procedure. The restenosis rate at 7 months (median) was 20.0% and in-stent late
lumen loss was 0.48 mm in 40 patients with angiographic follow-up.
Conclusions: Utilization of PES in this complex lesion subset is feasible and associated with favorable angiographic results at 7 months.
However, the gradual increase in later events up to 2 years suggests that aorto-ostial disease remains problematic even in the era of drug-
eluting stents.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Aorto-ostial lesion; Paclitaxel-eluting stent; Percutaneous coronary intervention; Aorto-ostial lesion; Paclitaxel-eluting stent
1. Introduction
Percutaneous treatment of stenoses involving aorto-ostial
lesion is a technically demanding procedure for interven-
tionalists and has been associated with lower procedural
success, and poorer clinical and angiographic outcomes
when compared with treatment of non-ostial lesion [1,2].
The extremely sclerotic and calcified nature of this lesion site
[3–5] has contributed to suboptimal immediate and long-
term results after balloon angioplasty as a stand-alone
strategy [6]. Debulking strategies with directional coronary
atherectomy (DCA) or rotational atherectomy (rotablator)
were assumed to alter outcomes for this particular lesion
subset, but their efficacies have not been determined. To
counter the ostial elasticity resulting in high restenosis rates
(enhanced recoil), stent implantation is a reasonable strategy
for lesion scaffolding, and bare metal stents have resulted
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in better outcomes than conventional balloon angioplasty
[7–9]. However, in addition to acute and chronic stent recoil,
excessive neointimal growth after stenting in this location
has been documented [10]. Although drug-eluting stents
(DES) have shown even better clinical and angiographic
results than bare metal stents, data on the efficacy of DES for
ostial lesions are still limited, mostly due to the exclusion of
these high risk lesions in the majority of the published
randomized trials [11–14]. Percutaneous treatment with
sirolimus-eluting stent (SES) for aorto-ostial lesions has
already been reported to improve short-term clinical and
angiographic outcomes [15]. Polymer-based paclicaxel-
eluting stent (PES, TAXUS™ Express2™, Boston Scientific
Corp., Natick, MA) is another FDA-approved drug-eluting
stent that has been shown to reduce clinical events in simpler
lesions [13]. To date, few reports are available on the
treatment of ostial stenoses using PES. In addition, little is
known about the long-term results of percutaneous treatment
of aorto-ostial lesions using DES. This study was made to
evaluate both the 7-month angiographic and 2-year clinical
outcomes of the use of PES for aorto-ostial narrowings.
2. Methods
From February 2003 to December 2004, a total of 93
consecutive patients underwent percutaneous intervention
for 93 aorto-ostial lesions in our institution. All the eligible
lesions were primary culprit lesions for each patient and
therefore stenting due to dissection, extended stenting from
non-ostial lesions, or spasm induced by catheter tip were
excluded. Seventeen patients were excluded from this study
because of deployment of SES (Cypher™, Cordis/Johnson
& Johnson, Warren, NJ) in 7, bare metal stents in 5,
angioplasty without stenting in 2, unsuccessful guidewire
crossing in 2 (chronic total occlusions), and PES with a
different type of platform (Infinium™, Sahajanand Medical
Technologies Pvt. Ltd., Gujarat, India) in 1. Thus, the study
population consisted of 76 consecutive patients treated with
TAXUS™ Express2™ stents. The study population is a
constitutive part of Taxus-Stent Evaluated at Rotterdam
Cardiology Hospital (T-SEARCH) registry of which the
design and goals have been described previously [16]. An
aorto-ostial lesions were defined as being located less than
3 mm (as measured by quantitative angiographic analysis) of
the orifice of the right coronary artery, left main coronary
artery, or saphenous venous graft when visualized in an
angiographic projection without foreshortening [6]. The
study protocol was approved by the local ethics committee
and is in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all patients.
2.1. Medications and interventional procedures
Elective patients were all pre-treated with aspirin and
clopidogrel. A loading dose of 300 mg of clopidogrel was
adopted in emergency cases. Post-interventional prescription
of antiplatelet was life-long aspirin and 6-month clopidogrel
with daily dose of 75 mg. PESs were available in diameters
of 2.25, 2.5, 2.75, 3.0 and 3.5 mm. Usage of debulking
devices (DCA or rotablator), distal protection devices and
administration of glycoprotein IIb/IIIa inhibitors was left to
the discretion of each physician. Slight stent protrusion into
the aortic lumen was determined in the least foreshortened
angiographic projection. Angiographic success was defined
as residual diameter stenosis b30% in the presence of
Thrombolysis in Myocardial Infarction (TIMI) flow grade 3.
2.2. Clinical follow-up and definitions
Adverse events were assessed at 30 days, 1 and 2 years.
The primary endpoint was the occurrence of major adverse
cardiac events (MACE), defined as a composite of cardiac
death, non-fatal myocardial infarction (MI), target lesion
revascularization (TLR), and target vessel revascularization
(TVR). All deaths were regarded as those of cardiac origin
unless a noncardiac origin was proven either clinically or by
autopsy. Non-fatal MI was defined as the occurrence of an
elevated creatine kinase-MB fraction (CK-MB) N3 times the
upper limit of normal [16]. TLR was defined as either
surgical or percutaneous reintervention driven by significant
(≥50%) luminal narrowing either within the stent or the
borders 5 mm proximal and distal to the stent that was
undertaken in the presence of either anginal symptoms or
objective evidence of ischemia. TVR was defined as
reintervention in the treated vessel outside the target lesion.
Stent thrombosis was defined as angiographically-documen-
ted complete occlusion (TIMI flow grade 0 or 1) or flow-
limiting thrombus (TIMI flow grade 1 or 2) in a previously
treated artery. Stent thrombosis was categorized according to
its timing relative to the index procedure as early (within
30 days) or late (N30 days) thrombosis.
All patients were clinically followed for the occurrence of
MACE. Information about in-hospital outcomes was
obtained from an electronic clinical database maintained at
our institution and by review of patients' records. Post-
discharge survival status was examined from the Municipal
Civil Registries. Occurrence of MI or revascularization at
follow-up was collected by consulting our institutional
electronic patient database and by contacting referring
physicians and institutions.
2.3. Quantitative angiographic analysis
Quantitative angiographic analysis was performed using
the computer-based validated QCA system (CAAS II, Pie
Medical Imaging, Maastricht, the Netherlands). Quantitative
measurements included the diameter of the reference vessel,
the minimal luminal diameter, percentage (%) diameter
stenosis, and late luminal loss (the difference between the
minimal luminal diameter after the procedure and the
minimal luminal diameter at follow-up). Binary restenosis
was defined as a stenosis of at least 50% of the minimal
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luminal diameter in the target lesion at angiographic follow-
up. In most cases, reference vessel diameter was obtained
only from a point distal to the lesion. Angiographic patterns
of restenosis were also determined [17].
2.4. Statistical analysis
Values in the text and tables are presented as mean±SD,
or frequency (percentage) for descriptive purposes. The
cumulative incidence of adverse events was estimated
according to the Kaplan–Meier analysis. Statistical analyses
were performed with SPSS 12.0.1 for Windows (SPSS Inc.,
Chicago, IL). A p value b0.05 was considered statistically
significant.
3. Results
3.1. Baseline characteristics
Baseline patient, lesion, and procedural characteristics are
shown in Tables 1 and 2. Multivessel disease was observed
in 72.4% of the patients. More than half of the cases
underwent index PCI for an acute coronary syndrome
(unstable angina, 42.1%; acute myocardial infarction,
15.8%). There was no documentation of non-atherosclerotic
etiologies associated with aorto-ostial disease such as
syphilitic cardiovascular disease, Takayasu's arteritis, etc.
[18].
The seventy-six target vessels in the present study
consisted of 37 right coronary arteries, 26 left main coronary
arteries, and 13 venous grafts. These lesions included seven
restenotic lesions following bare metal stent implantation
(9.2%). Moderate to severe calcification was documented in
19 lesions, presence of thrombus in 13, restenosis of bare
metal stent in 7, chronic total occlusion (an occlusion period
more than 3 months) in 1.
3.2. Procedural results
Target lesions were treated using 1.69±0.97 stents (total
stent length per lesion, 32.11±26.58 mm) that were post-
dilated using balloons 3.6±0.44 mm diameter (mean
balloon–artery ratio, 1.24). Lesion modification by debulk-
ing devices or cutting balloon was made in 7 patients. Stent
placement with slight protrusion of the proximal edge into
the ascending aorta was performed in 38.2% of the cases.
Two patients were complicated by aorto-coronary dissection
involving in the sinus of Valsalva, which regressed
conservatively over a short period. Thirty-five patients
(46.1%) underwent concomitant treatment of non-ostial
lesions either in the same or different vessels.
3.3. Clinical outcome up to 2 years
Thirty-day, one-year as well as 2-year outcomes in terms
of clinical events are reported in Table 3.
Table 1
Baseline clinical and angiographic characteristics (n=76)
Age, years 66.0±10.9
Male gender, n (%) 51 (67.1)
Smoking:
current, n (%) 15 (19.7)
Former, n (%) 14 (18.4)
Diabetes:
type I, n (%) 13 (17.1)
Type II, n (%) 4 (5.3)
Hypertension, n (%) 31 (40.8)
Hypercholesterolemia, n (%) 44 (57.9)
Renal insufficiency, n (%) 9 (11.9)
Family history, n (%) 28 (36.8)
Prior myocardial infarction, n (%) 26 (34.2)
Previous intervention, n (%) 18 (23.7)
Previous bypass surgery, n (%) 17 (22.4)
Multivessel disease, n (%) 55 (72.4)
Stable angina pectoris, n (%) 31 (42.1)
Unstable angina pectoris, n (%) 32 (42.1)
Acute myocardial infarction, n (%) 13 (15.8)
Cardiogenic shock, n (%) 4 (5.3)
Table 2
Baseline lesion and procedural characteristics (n=76)
Lesion characteristics
Lesion location
Right coronary artery, n (%) 37 (48.7)
Left main coronary artery, n (%) 26 (34.2)
Venous graft, n (%) 13 (17.1)
In-stent restenosis of bare metal stent, n (%) 7 (9.2)
Chronic total occlusion, n (%) 1 (1.3)
Thrombus-containing lesion, n (%) 13 (17.1)
Moderate to severe calcification, n (%) 19 (25.0)
Eccentric lesion, n (%) 24 (31.6)
TIMI flow grade ≤2:
Baseline, n (%) 18 (23.7)
After procedure, n (%) 3 (3.9)
Procedural characteristics
Number of stents/lesion, n 1.69±0.97
Total stent length/lesion, mm 32.11±26.58
Maximal balloon size, mm 3.64±0.44
Balloon/artery ratio 1.24±0.23
Maximal inflation pressure, atm 20.18±2.65
Debulking, n (%) 3 (3.9)
Cutting balloon, n (%) 4 (5.3)
Direct stenting, n (%) 33 (43.4)
Post-dilatation, n (%) 37 (48.7)
Use of glycoprotein IIb/IIIa inhibitors, n (%) 10 (13.2)
Distal protection device, n (%) 12 (15.8)
Intra-aortic balloon pump, n (%) 4 (5.3)
Left ventricular assist device (LVAD), n (%) a 1 (1.3)
Periprocedural stent thrombosis, n (%) 0 (0.0)
Stent protrusion, n (%) 29 (38.2)
Aorto-coronary dissection after procedure, n (%) 2 (2.6)
Concomitantly treated lesion, n (%) 35 (46.1)
Angiographic success, n (%) 73 (96.1)
a The Impella LVAD Recover LP 2.5 (Impella Cardiotechnik, Aachen,
Germany).
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3.3.1. 30-day outcome
In the first month, 6 patients died, four of whom exhibited
fatal MI resulting in refractory cardiogenic shock as a
baseline clinical presentation, although stents were success-
fully deployed in each of the target lesions (1 right and 3 left
main coronary arteries). One patient with stable angina
underwent elective stenting for ostial left main disease, but
died due to a rapid hemodynamic collapse resulting from
compromised blood flow to the jailed left circumflex artery.
One patient died 21 days after concomitant stenting in 2
target lesions (ostial right coronary artery and left anterior
descending artery). This case was strongly suspected of
having early stent thrombosis either in the territory of the
right coronary artery or left anterior descending artery as the
cause of sudden death, which was not angiographically-
documented.
Out of the 4 MIs, 3 were MIs during the index procedures
and the other was a subacute stent thrombosis in a
concomitantly-treated different vessel (left anterior descend-
ing artery) 21 days after the index procedure. There were no
cases of TLR or TVR in the first 30 days.
3.3.2. 1-year outcome
Neither further death nor MI was documented after
30 days up to 1 year. TVR was required in 8 patients (TLR,
3/8), all of which were treated percutaneously.
3.3.3. 2-year outcome
There was a gradual increase in MACE throughout
2 years (Fig. 1). There were 3 more deaths identified between
1 and 2 years. One patient who died 465 days after stenting
was strongly suspected of having late stent thrombosis in the
territory of the right coronary artery as the cause of sudden
Table 3
Major adverse cardiac events
30-day outcome
Death 6 (7.9)
Non-fatal myocardial infarction 4 (5.3)
Target vessel revascularization 0
Target lesion revascularization 0
MACE 10 (13.2)
Stent thrombosis⁎ 1 (1.3)
1-year outcome
Death 6 (7.9)
Non-fatal myocardial infarction 4 (5.3)
Target vessel revascularization 8 (10.5)
Target lesion revascularization 3 (3.9)
MACE 18 (23.7)
Stent thrombosis⁎ 1 (1.3)
2-year outcome
Death 9 (11.8)
Non-fatal myocardial infarction 6 (7.9)
Target vessel revascularization 11 (14.5)
Target lesion revascularization 3 (3.9)
MACE 24 (31.6)
Stent thrombosis† 3 (3.9)
⁎Subacute stent thrombosis in a concomitantly-treated non-ostial target
vessel (left anterior descending) 21 days after the index PCI; †One is
subacute thrombosis in a non-ostial target vessel (left anterior descending)
2 days after stenting and the other is late thrombosis in the right coronary
ostial lesion 427 days after TLR. MACE = major adverse cardiac events.
Fig. 1. Kaplan–Meier event-free survival at 2 years for major adverse
cardiac events (MACE).
Table 4
Quantitative coronary angiography (n=76)
Baseline
Reference vessel diameter, mm 3.04±0.56
Minimum luminal diameter, mm 0.92±0.51
Diameter stenosis, % 69±16
Lesion length, mm 14.24±15.06
Post procedure
Reference vessel diameter, mm 3.30±0.51
Minimum luminal diameter, mm 2.73±0.52
Diameter stenosis, % 17±9
Follow-up (n=40) at 7 monthsa
Reference vessel diameter, mm 3.26±0.54
Minimum luminal diameter, mm 2.23±0.94
Diameter stenosis, % 34±26
In-stent late lumen loss, mm 0.48±0.88
Restenosis, n (%)b 8 (20%)
Focal — articulation 1
Focal — margin 1
Focal — body 2
Diffuse — intrastent 1
Diffuse — proliferative 1
Diffuse — total occlusion 2
aMedian of follow-up period.
bRestenosis patterns were adopted from the classification by Mehran et al.
(Ref. [17]).
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death, though this was not angiographically confirmed.
Additional 3 clinically-driven TVRs were performed. The 2-
year cumulative incidence of MACE was 31.6%. There were
two additional stent thromboses (early and late) identified.
One occurred 2 days after stenting a non-ostial lesion (left
anterior descending) and the other was a late thrombosis
427 days after the index PCI for the right coronary ostial
lesion.
3.4. Angiographic results
Quantitative coronary angiographic analysis is summa-
rized in Table 4. The mean reference vessel diameter was
3.04 mm. Angiographic follow-up data were obtained in 40
patients (52.6%) at the median timing of 7 months after the
index stenting. Binary in-stent restenosis rate was 20.0% (8/
40). Focal patterns of restenosis were found in 50% (4/8). In-
stent late lumen loss of PES in this lesion subset was
0.48 mm.
4. Discussion
The present study provides the 7-month angiographic and
2 year clinical outcomes of PES in aorto-ostial lesions in a
larger consecutive population than that of earlier studies
[1,9,15,19]. The results of the present study suggest the
following two main findings: 1) PES utilization is a feasible
treatment option in this complex lesion setting by keeping
the restenosis rate to 20.0% and thereby TLR rate to 5.3%; 2)
The long-term efficacy of PES, however, in overall clinical
outcome still remains to be determined due to the subsequent
increase in later events.
Aorto-ostial disease can be a critical cause of fatal
myocardial infarction or sudden cardiac death due to the
relatively large myocardial territory exposed to risk [3].
Lesions in this location are distinctive from branch ostial
lesions because of their specific histopathological character-
istics such as highly increased fibrous cellularity, calcifica-
tion and sclerosis [3–5]. Reflecting this lesion background,
Tsunoda et al. reported that excessive neointimal growth and
chronic stent recoil might be two important etiologic factors
for stent restenosis at this particular location [10]. With
regards to the former factor, stents coated with antiprolifera-
tive agents are reasonable devices of choice and PES
demonstrated successful reduction of neointimal growth
after stenting (late loss, 0.48 mm),. To overcome another
potential factor for restenosis, the combination of debulking
and DES may be a particularly optimal approach. Plaque
modification prior to stent implantation has been initially
embraced as a preferred treatment strategy for this lesion
subset [4]. However, since the role of debulking in the era of
DES has not been clarified, we performed adjunctive
debulking in only 3 patients. Instead of using atherectomy
devices, we aggressively post-dilated by adopting a
relatively large-sized non-compliant balloon (balloon–artery
ratio, 1.24) in order to achieve a satisfactory angiographic
result. Because of the delayed healing response of injured
vessel wall after implantation of DES [20], it might be
speculated that the relatively high mechanical injury
resulting from atherectomy further delayed healing process
following DES placement. Furthermore, atherectomy of
aorto-ostial lesions is technically demanding because of the
need to pull the guiding catheter from the coronary ostium
while leaving the atherectomy catheter in position for
debulking. Additionally, when performing DCA or rotabla-
tion for aorto-ostial lesions, great care should be taken to
avoid excision of guiding catheter material [21,22].
Slight stent protrusion into the aorta is usually associated
with a benign clinical course. However, unapposed protrud-
ing stent struts may theoretically promote platelet activation,
thrombosis, and/or distal embolization. In addition, protrud-
ing stent struts may not only pose an inability to easily re-
engage the ostium with either diagnostic or guiding
catheters, but also can complicate future interventional as
well as surgical procedures [23–26]. We encountered only
one angiographically-documented stent thrombosis related
to the target vessel and stent protrusion was not implicated in
this case. Of the 2 possible stent thrombosis cases, stent
placement with slight protrusion was performed in one
(465 days after stenting) and not in the other (21 days after
stenting). The 2 cases with very late stent thrombosis
occurring beyond 1 year suggest that current US Food and
Drug Administration-approved indications for 6-month
clopidogrel use following TAXUS implantation may not be
sufficient to prevent late stent thrombosis. Eisenstein et al.
showed that longer-term clopidogrel use may be associated
with more favorable clinical outcome for patients receiving
DES [27]. However, the small number of patients evaluated
in this analysis do not allow for any definitive statement with
respect to the safety profile of this stenting technique. So far,
it appears that positioning of PES with protrusion of only a
short segment of stent into the aorta might instead contribute
to lower restenosis by adequately covering the lesion.
Despite the low incidence of TLR at 2 years, the limited
role of PES on overall long-term outcome was also indicated
because of the gradual increase in TVR rate. Obstruction at
the origin of a coronary artery is most often associated with
more generalized coronary atherosclerosis and the presence
of multivessel coronary artery disease (72.4%). It may be
helpful for long-term favorable outcome to prevent and
adequately detect the progression of other non-ostial lesions
that are not significant at time of treatment of ostial lesions in
the same vessel. Long-term evaluation of non-ostial lesions
in the target vessels should be considered.
4.1. Study limitations
There were several limitations in this study. First, this was
a single-center's experience with implantation of PES in
aorto-ostial stenoses. Second, no control group was used to
compare the long-term efficacy of PES with other devices. In
this regard, direct comparison between PES and bare stent/
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SES would have been interesting to address whether a
different drug and different stent platform might influence
the incidence of restenosis. Third, the rate of follow-up
angiography was limited to 52.6% of 76 patients. Finally,
since each treatment strategy was not prespecified, the
results may reflect our bias toward our treatment technique.
However, this study more likely represents “real-life” prac-
tice of PES utilization.
5. Conclusions
In conclusion, our findings suggest that PES in aorto-
ostial lesions is safe and feasible in light of the low incidence
of restenosis at 7 months. However, the increase in later
events, especially the TVR rate, may attrite the long-term
benefit of PES in patients with this complex lesion subset.
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Abstract
Objectives: Recently, concerns were raised about the relative long-term safety and efficacy of drug-eluting
stents (DES) in saphenous vein bypass grafts (SVG). Our objective was to assess the 4-year relative safety
and efficacy of the unrestricted use of drug-eluting stents (DES) as compared to bare metal stents (BMS)
in saphenous vein bypass grafts (SVG).
Methods: Between April 16, 2002 and December 2005 a total of 122 consecutive patients were treated
with either sirolimus- or paclitaxel-eluting stents for saphenous vein graft disease. These patients were
compared with 128 consecutive patients treated with BMS in the immediate preceding period (January 1,
2000 to April 2002).
Results: At 4-years the cumulative survival rate in the DES group was 77.5% versus 73.0% in the BMS
group (adjusted HR 1.09; 95% CI 0.63-1.90, Logrank p=0.65). The cumulative survival free of major
adverse cardiac events (MACE: death, myocardial infarction and target vessel revascularisation) was
61.5% vs. 46.8% in the DES and BMS groups respectively (adjusted HR 0.77, 95% CI; 0.51-1.16) due to
a higher event free survival of clinically driven target vessel revascularisation in the DES group as compared
to the BMS group (81.6% vs. 69.0%; adjusted HR 0.53; 95% CI 0.27-1.05).
Conclusions: In the present study, the use of DES for SVG PCI was associated a similar safety profile and
there was a trend towards lower rates of TVR and MACE at four years as compared to BMS.
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Bypass graft, 
drug-eluting stent,
bare-metal stent, 
long-term safety
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Introduction
Saphenous vein grafts are the commonest conduit in coronary
artery bypass graft surgery (CABG).1 However, the lifespan of
saphenous vein grafts (SVG) proved to be limited – at 10 years, 50%
of such grafts contain at least one significant stenosis with a total
occlusion rate of up to 40%.2,3
Currently the use of drug eluting stents (DES) for off-label
indications is frequent (up to 60 % in our centre) and PCI has
surpassed CABG as the treatment of first choice for treating
coronary artery bypass graft disease.4,5 Still, event-free survival after
stent implantation remains low due to restenosis at the lesion site.6-8
The use of DES in SVG lesions has led to a decrease in restenosis
and the need for repeat revascularisation at one year as compared
to bare metal stents (BMS).9-11
Currently there is still scarce evidence about the long-term safety
and efficacy of DES when used in coronary artery bypass grafts. The
recently published 32-months follow-up of the Delayed Reduction
of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-
Eluting Stent (RRISC) trial showed a catch-up in the repeat
revascularisation rates in patients treated with sirolimus-eluting
stents (SES).12 Moreover, the authors reported a significant increase
in late mortality in patients treated with SES as compared to those
treated with bare metal stents (BMS).12
The current study was performed to assess the long-term outcome
of a consecutive series of patients treated with BMS, sirolimus- or
paclitaxel-eluting stents (SES and PES respectively) for lesions in
venous bypass grafts.
Methods
Patient selection
Between January 1, 2000 and December 31, 2005 a total of 387
percutaneous interventions were performed in our institution using
BMS, SES or PES in coronary bypass-graft lesions (arterial or
venous bypass grafts) (Figure 1). A total of 62 procedures were
excluded due to treatment restricted to balloon angioplasty (n=35)
or the use of (previous) brachytherapy (n=27). Two patients
received a Symbiot™ Covered Stent and were also excluded. Out of
323 procedures selected, 298 involved the treatment of saphenous
vein grafts and in 25 procedures arterial grafts were treated. From
January 2000 until April 16th 2002, 144 PCI procedures in a venous
bypass-graft were performed using exclusively BMS, from April 16,
until December, 2005, 154 procedures were performed using either
sirolimus-eluting stents (Cypher®, Cordis Corp., Johnson & Johnson,
Warren, NJ, USA) or using paclitaxel-eluting stents (TAXUS™
Express2™ or Liberté™, Boston Scientific, Natick, MA, USA).
Patients initially enrolled in one of the sequential cohorts (BMS or
DES) were maintained for analytical purposes throughout the follow-
up period in their original cohort, even if a repeat intervention was
performed using a different type of stent at a later stage. Finally, 250
patients fulfilled these criteria.
This study was approved by the local ethics committee and
performed in accordance with the Declaration of Helsinki. Written
informed consent was obtained from all patients.
Procedural and baseline definitions
All procedures were performed following previously defined current
standard procedural guidelines.13 The use of distal embolisation
protection devices and periprocedural glycoprotein IIb/IIIa inhibitors
were left to the operator’s discretion. Finally, the use of distal
protection devices was low (4.7% in the BMS group vs. 1.6% in the
DES group; p=0.28).
Patients were prescribed aspirin plus clopidogrel 75 mg/day (after
a loading dose of 300 mg) before or during baseline coronary
interventions. Patients treated with bare metal stents received at least
one month of clopidogrel (median, three months, IQR: 2-6 months).
Patients treated with DES received at least three months of
clopidogrel (median, six months, IQR: 6-6 months). All patients
were advised to remain on aspirin indefinitely.
Hypertension was defined as a blood pressure > 140 systolic or
> 90 mm Hg diastolic or based on the current use of
antihypertensive treatment. Dyslipidaemia was classified as a total
serum cholesterol level of > 6.2 mmol/l or the use of lipid lowering
drugs. Diabetes was defined as treatment with either oral
hypoglycaemic agent, insulin or through diet. Complete procedural
success was defined by the achievement of <50% diameter
stenosis (visual assessment) and Thrombolysis in Myocardial
Infarction (TIMI) grade flow 3 in all lesions intended to treat. Clinical
success was defined as procedural success without death or re-
infarction during the index hospitalisation.
Endpoint definitions and clinical follow-up
Our primary endpoint was MACE (major adverse cardiac events;
defined as a composite of all-cause death, myocardial infarction
[MI] and target vessel revascularisation [TVR]) at 4-years.
Secondary endpoints included the itemised outcomes all-cause
Figure 1. Inclusion flow chart of study population.
387 PCI procedures in
by-pass graft
Brachytx n=27
no stent n=35
Different DES n=2
323 procedures with
by-pass stenting
298 procedures with
venous graft
N=2 no graft info available
N=23 arterial graft
250 patients, venous
by-pass grafts
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death, MI and TVR at 4-years. MI was defined as creatinine kinase-
MB enzyme elevation > 3 times the upper limit of normal. TVR was
defined as a clinically driven (presence of clinical symptoms and/or
signs of ischaemia) repeat revascularisation procedure (either
percutaneous or surgical) of the index graft. Stent thrombosis (ST)
was defined as angiographically defined thrombosis with TIMI grade 0
or 1 flow or the presence of a flow limiting thrombus, accompanied
by acute symptoms, resembling the ARC definite criteria.14,15
Survival status was obtained from municipal registries. Cause of
death was acquired via the central bureau of statistics, The Hague,
The Netherlands and classified according to the international
Classification of Diseases and Related Health Problems, 10th
revision (ICD-10).16 Questionnaires inquiring about patients current
health status, and medication use were subsequently sent to all
living patients. Events (MI, TVR) that occurred outside our
institution were verified by contacting the peripheral hospital.
Finally, follow-up was available for 98.4% of the BMS patients and
95.9% of the DES patients.
Statistical analysis
Summary statistics for all continuous variables are presented as
medians together with the interquartile range (IQR). Categorical
data are summarised as frequencies and percentages. Continuous
variables were compared using the Mann-Whitney U test.
Categorical variables were tested for significance using the Chi-
square or Fisher’s exact test. Survival and event-free survival
analysis were presented using Kaplan-Meier survival curves and
tested for difference using the log-rank test. Cox proportional
hazards regression models were used to control for differences
between groups and independent predictors of outcome. First, all
baseline, clinical and procedural variables were put in a univariate
cox proportional hazards regression model for the different
endpoints. Second, all significant predictors of outcome (p<0.1)
were forced into a second model along with stent type (BMS or
DES) and tested for significance. Final results are reported as
adjusted Hazard ratios (HR) with their respective 95% confidence
intervals (CI). All statistical tests were two-tailed. A value of p < 0.05
(unless reported otherwise) was used for all tests to indicate
statistical significance. All statistical analyses were performed using
SPSS version 12 (SPSS Inc., Chicago, Illinois).
Results
Baseline and procedural characteristics are presented in Tables 1
and 2 respectively. Baseline characteristics were similar between
the two groups, except for a significantly higher incidence of family
history of coronary artery disease and dyslipidaemia in the DES
group as compared to the BMS group. Procedural characteristics
differed in terms of a smaller average stent diameter and a longer
total stented length in the DES group. The use of glycoprotein
IIb/IIIa inhibitors decreased over time, from 41% in the BMS group
to 21% in the DES group, p=0.001). At 4-years, the cumulative
survival free of MACE was 61.5% versus 46.8% in the DES and
BMS groups respectively (adjusted HR 0.77, 95% CI; 0.51-1.16).
[Figure 2, Table 3] A total of 57 patients died (23 in the DES group
and 34 in the BMS group). The cause of death was cardiac in 15/23
Table 1. Baseline characteristics.
Bare metal Drug-eluting P-value
stent group n=128 stent group n=122
Age (years)
median 69.3 68.3 0.19
IQR 62.4-77.2 62.4-74.7
Male gender 80% (102/128) 84% (103/122) 0.33
BMI 0.15
Median 25.8 26.5
IQR 23.9-28.1 24.5-29.0
Diabetes mellitus 21% (27/128) 31% (38/122) 0.07
Dyslipidaemia 45% (57/128) 66% (81/122) 0.001
Hypertension 43% (55/128) 49% (60/122) 0.33
Family history of CAD 17% (22/128) 28% (34/122) 0.043
Current smoker 16% (21/128) 8% (10/122) 0.049
Renal impairment 2% (2/128) 5% (6/122) 0.13
Previous MI 46% (59/128) 50% (61/122) 0.23
Previous PCI 27% (34/128) 30% (36/122) 0.77
Enrolment diagnosis 0.37
Stable angina 33% (42/128) 41% (50/121)
Unstable angina 53% (68/128) 50% (60/121)
Acute MI 14% (18/128) 8% (10/121)
Shock 0% (0/128) 1% (1/121)
Table 2. Lesion and procedural characteristics.
Bare metal stent Drug-eluting stent P-value
group n=128 group n=122
Revascularisation territory
LAD 49% (49/127) 33% (37/111) 0.40
LCX 53% (67/127) 49% (54/111) 0.53
RCA 31% (39/127) 34% (38/111) 0.56
Native vessels treated
LAD 10.9% (14/128) 13.1 (16/122) 0.70
LCX 10.2% (13/128) 12.3% (15/122) 0.43
RCA 12.5% (16/128) 18% (22/122) 0.38
LM 2.3% (3/128) 1.6% (2/122) 1.00
In stent restenosis 8% (10/128) 8% (10/122) 0.91
Lesion type
A 9% (11/128) 10% (12/122) 0.73
B1 27% (34/128) 25% (30/122) 0.72
B2 37% (47/128) 40% (49/122) 0.58
C 49% (63/128) 59% (72/122) 0.12
Clinical success 97% (124/128) 98% (117/122) 0.46
Number of lesions successfully treated 0.97
Median 1.00 1.00
IQR 1.0-2.0 1.0-2.0
Number of treated grafts 0.92
Median 1.0 1.0
IQR 1.0-1.0 1.0-1.0
Number of stents per lesion 0.21
Median 2.00 2.00
IQR 1.0-2.0 1.0-3.0
Total stent length, mm 0.02
Median 31.9 32.0
IQR 18.0-40.3 18.0-58.5
Average stent diameter, mm <0.001
Median 3.5 3.1
IQR 3.3-4.0 3.0-3.5
Distal protection device used 4.7% (6/128) 1.6% (2/120) 0.28
Glycoprotein IIb/IIIa inhibitors 41% (53/128) 21% (26/122) 0.001
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(65.2%) in the DES patients and 22/34 (64.7%) in the BMS patients.
the cumulative survival rate in the DES group was 77.5% versus
73.0% in the BMS group (p=0.65). When adjusting for independent
predictors the HR for death in the DES group was 1.09; 95% CI
0.63-1.90). [Figure 3, Table 3] The cumulative event free survival for
the combined endpoint death/MI was 70.6 % in the DES group vs.
65.8% in the BMS group (adjusted HR 1.11 95% CI; 0.68-1.81).
Cumulative survival free of clinically driven TVR was higher in the
DES group as compared to the BMS group (81.6% vs. 69.0%
respectively; adjusted HR 0.53; 95% CI 0.27 - 1.05). [Figure 4,
Table 3] A total of five (4.0%) patients treated with BMS suffered
from stent thrombosis occurring at a median of 176 days (IQR
134-731) versus only 1 (0.8%) in the DES group occurring at 606
days.
Figure 2. Kaplan Meier event free survival of major adverse cardiac events
(MACE, the primary combined endpoints of all-cause mortality, myocardial
infarction, and clinically driven target vessel revascularisation). DES stands
for drug-eluting stent, BMS for bare metal stent.
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Table 3. Event rates: total, in hospital and after 4 years.
Total population (n=250) Crude event rates Kaplan Meier estimates Hazard rate [95% confidence interval]
Variables BMS DES BMS DES
(128 patients) (122 patients) (128 patients)(122 patients)
In Hospital events
Total death 2.3% (3/128) 1.6% (2/122) 2.4% 1.7%
Cardiac death 2.3% (3/128) 1.6% (2/122) 2.4% 1.7%
Non-cardiac death 0.0% (0/128) 0.0% (0/122) – – –
Myocardial infarction 3.1% (4/128) 2.6% (3/122) 3.2% 2.5%
Target vessel revascularisation 1.6% (2/128) 0.0% (0/122) 1.6% – –
Major adverse cardiac events 7.0% (9/128) 4.1% (5/122) 7.1% 4.2%
Events at 4 years
Death 26.6% (34/128) 18.9% (23/122) 27.0% 22.5% 1.09; 95% CI 0.63-1.90*
Cardiac 17.2% (22/128) 9.0% (15/122) 18.6% 15.1% 1.02; 95% CI 0.52-1.04*
Non-cardiac 9.4% (12/128) 6.6% (8/122) 10.4% 8.6% 1.27; 95% CI 0.50-3.17*
Total myocardial infarction 10.2% (13/128) 5.7% (7/122) 11.1% 7.6% 0.71; 95% CI 0.27-1.82**
Target vessel revascularisation 28.1% (36/128) 13.9% (17/122) 31.0% 18.4% 0.53; 95% CI 0.27-1.05***
Major adverse cardiac events 52.3% (67/128) 33.6% (41/122) 53.2% 38.5% 0.77; 95% CI 0.51-1.16¶
* Adjusted for, diabetes, revascularisation territory LAD, indication acute coronary syndrome, positive family history of coronary artery disease and age
** Adjusted for, hypercholesterolaemia, revascularisation territory LAD
*** Adjusted for, hypertension, average stent diameter, number of treated grafts, number of stents, total stented length, diabetes, age and sex
¶ Adjusted for revascularisation territory LAD, gender, hypercholesterolemia, and indication acute coronary syndrome.
Figure 3. Kaplan Meier event free survival. DES stands for drug-eluting
stent, BMS for bare metal stent, TVR for target vessel revascularisation,
MI for myocardial infarction and MACE for major adverse cardiac events.
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Discussion
The present study demonstrates that the use of DES in SVG remains
safe and effective as compared to BMS up to four years of follow-
up, illustrated by similar survival rates and a trend towards
significantly lower rates of TVR in patients treated with DES. At four
years, the use of DES tended to result in lower MACE rates, mainly
caused by lower repeat revascularisation rates in the first year in
patients treated with DES – even though definite conclusions cannot
be drawn, this is a risk reduction comparable to that observed in
both the general PCI population and in SVG stenting.9,11,17-19
The 32-months results of the randomised Delayed RRISC trial
showed a catch-up in the repeat revascularisation rates in patients
treated with SES along with a significant increase in late-mortality as
compared to BMS.12 Unfortunately, the sample size of the latter
study was calculated based on in-stent late loss, which explains the
sample size of only 75 patients and the highly selected patient
population. Patients presenting with MI, with impaired renal
function, distal graft lesions, chronic total occlusions were excluded,
along with those presenting with aorto-ostial or calcified lesions
making the results difficult to apply in real-world clinical practice.
Yet, it was difficult to question these findings given the lack of long-
term data regarding the safety of DES in SVG and the presence of
previously raised concerns about a catch-up in the reintervention
rates in diabetics and patients presenting with ST-segment elevation
myocardial infarction treated with DES.20,21 Thus far, individual
patient level data meta-analyses of the pivotal randomised Cypher
and TAXUS trials were not able to address this issue given the lack of
high-risk patients and larger (network) meta-analyses simply
precluded subgroup analyses due to the lack of the individual patient
data.17,18,22,23 To date, large-scale registries have not yet reported on
the long-term outcome in this specific patient subset.24,25
The present study included a total of 250 real world consecutive
patients treated for SVG disease of which the vast majority did not
undergo routine angiographic follow-up. At four years, both all-
cause and cardiac survival were identical between the BMS and
DES group and there was no sign of a catch-up in TVR rates
following DES use. The importance of detailed analyses of high-risk
subgroups can be demonstrated by several recent studies
suggesting that DES perform best in high-risk patients, like those
presenting with small vessels, long-lesions, diabetes and SVG.24,26
Thus far, the overall benefit of DES has been widely adopted, but
concerns regarding their long-term safety17,25,27 prompted
investigators to further scrutinise their data for cost-effectiveness
and heterogeneity of the treatment effect. While thus far, the safety
concerns seem to be unfounded, a proper patient selection might
become of crucial importance given the unfavourable cost-
effectiveness profile of the DES.26
The steep drop in the TVR-free survival in the BMS group forced us
to scrutinise the indications leading to the re-interventions occurring
between 100 and 260 days. Only clinically driven cases of TVR
were taken account into the present analysis. Out of the 14 TVR
procedures occurring at six months in the BMS group, only two
were due to angiographic follow-up and were not counted in the
present analysis. Out of the remaining 12 patients who underwent a
repeat intervention within this time frame, eight presented with
unstable angina, three with stent thrombosis and one patient
presented with stable angina and had a positive stress test.
Although patients treated with DES received clopidogrel for a longer
period of time, the prescribed duration of clopidogrel did not seem
to impact on any of the endpoints, even when adjusting for
independent predictors.
The present study has several limitations. Firstly, although the DES
and BMS groups in the present study were reasonably well matched
in terms of baseline and procedural characteristics, it remains
uncertain whether the use of extensive regression analyses was able
to fully correct for the dissimilarities between the groups.
Nevertheless, the overall risk profile was greater in the DES group.
Large-scale randomised trials are needed to prove the long-term
benefit advantage of DES over BMS in SVG. Secondly, the drug-
eluting stent cohort contained both patients treated with SES and
PES. However, no heterogeneity in the treatment effect was found
regarding the use of either SES or PES.
Conclusions
In the present real world patient cohort, the use of DES for SVG
lesions appeared safe and effective after 4-years of clinical follow-
up. At 4-years, the use of DES tended to results in lower MACE rates
as compared to BMS, due to similar survival rates and a trend
towards lower rates of TVR.
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Are drug-eluting stents associated with a higher
rate of late thrombosis than bare metal stents?
Late Stent Thrombosis
A Nuisance in Both Bare Metal and Drug-Eluting Stents
Patrick W. Serruys, MD, PhD; Joost Daemen, MD
Late stent thrombosis (ST) is for us an old foe that we havetracked repeatedly throughout the history of interven-tional cardiology. In 1991, we made headlines by pub-
lishing in the New England Journal of Medicine a rate of early
and late ST of 20% among the first 151 patients having received
a wall stent.1 A few years later, when some believed that they
had discovered the universal panacea for restenosis (vascular
brachytherapy), we were the first to report in the literature 6
cases of late ST in 100 patients having undergone brachytherapy
after stent implantation.2 At that time, this seminal observation
triggered a wave of observations; the cases of late ST after
brachytherapy accrued month after month until the pioneer in the
field, Ron Waksman, courageously admitted in an editorial that
we were “sitting on a time bomb.”3 Five years later (2004), in the
beginning of the drug-eluting stent (DES) era, we reported,
together with Waksman’s group, the first 4 cases of late ST.4 In
the following 2 years, the incidence of late ST, scrutinized by
alerted clinicians, was publicized in reports that included
25 000 patients treated with DES; the incidence ranged from
0.2% in a postmarketing surveillance trial to 1.8% in a small
series of multivessel stenting.5–10 Around this period, we realized
that Bern and Rotterdam had somewhat diverging incidences of
late ST, 0.4% and 0.9%, and we joined efforts to retrospectively
assess the rate of late ST over a period of 4 years. A steady rate
of 0.6% per year was detected without abatement over a
follow-up period of 3 years.11 What makes the experience of
these 2 groups unique is that both tertiary institutions embraced
the technology of eluting stents at the time of their commercial
introduction and decided to treat all comers with this new
promising therapeutic approach. Of 8146 patients, we saw
61 patients coming back to our catheterization laboratory
with symptoms and angiographic signs of late ST. Of these
61 patients, 3 died in hospital from late ST, and 44
sustained a myocardial infarction (MI). At the 6-month
follow-up, an additional 2 patients had died and 2 sus-
tained a reinfarction. In summary, 5 of 8146 patients died
as a result of this dreadful complication of ST. These
numbers were largely confirmed by the 3 years of
follow-up of the Arterial Revascularization Therapies
Study Part II, showing a similar annual increase of definite
ST of 1.7%, 0.6%, and 0.4% at 1, 2 ,and 3 years,
respectively, in a population with a majority of 3-vessel
treatment and with an average stented length of 73 mm. By
reporting these figures, we are not trying to minimize the
phenomenon, and we recognize that we are describing only
the tip of the iceberg by disregarding fatal MI and
unexplained death as clinical surrogates of ST, but we do
not believe that 0.6% per year could, by any means, be
compared with the 6% late ST seen after vascular brachy-
therapy. In other words, we are not facing a new “vascular
brachytherapy syndrome.”
Response by Camenzind et al p 1439
After this introduction on the history of ST, we will
analyze more judiciously the contentions by Camenzind et al
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that DES increase deaths, as headlined by the European
Society and World Congress of Cardiology (ESC) newsletter
at the congress in Barcelona 2006.12
Are There Physiopathological Reasons to
Have Late ST?
Camenzind and coauthors referred to the classic triad of
Virchow (altered blood constituents, flow pattern, and endo-
thelial lining). This is without a doubt appealing to the
readers, but let us analyze critically their arguments and the
validity of their analogical comparison when they equate a
stenotic lesion covered by a DES to an atherothrombotic
phenomenon in the general circulation.
Their first argument suggests that implantation of DES
with concomitant but transient administration of dual platelet
therapy would generate at the time of the discontinuation a
thrombogenic milieu. Using common sense, we have to point
out that 99% of the patients worldwide discontinue their
thienopyridine medication without experiencing ST within
days. We were the first to link the interruption of aspirin with
ST in DES.4 In that respect, the relationship between platelet
therapy and thrombosis is not unique to DES. In a study
reporting on 1236 patients hospitalized for acute coronary
syndrome, those who stopped aspirin presented significantly
more often with ST-segment elevation acute coronary syn-
drome. Twenty percent of these cases involved a bare metal
stent (BMS) thrombosis on an average of 15.5 months.13 In
fact, interruption of aspirin is a risk factor for every patient
with atherosclerosis.14 “Noncompliance or withdrawal of
aspirin treatment has ominous prognostic implications in
subjects with or at moderate-to-high risk for coronary artery
disease. Aspirin discontinuation in such patients should be
advocated only when bleeding risk clearly overwhelms that
of atherothrombotic events.” These are the conclusions of a
recently published meta-analysis on the hazards of discon-
tinuing or not adhering to aspirin among 50 279 patients at
risk for coronary artery disease.14 Similarly, clopidogrel
withdrawal is associated with proinflammatory and pro-
thrombotic effects in patients with diabetes mellitus and
coronary artery disease.15 The concern in trials has not been
the discontinuation of the antiplatelet therapy but its prema-
ture discontinuation, and this concept of premature discon-
tinuation has to be critically discussed.
It is relevant to note that the patients included in the FIM
(First in Man) and the RAVEL (Randomized Study with the
Sirolimus-Coated Bx Velocity Balloon Expandable Stent in
the Treatment of Patients With De Novo Native Coronary
Artery Lesions) trials were prescribed 2 months of ticlopidine
or clopidogrel. The rationale for the 2-month prescription is
that initially (July 1999, trial discussion at the headquarters of
Cordis) the First in Man trial was planned as a 60-day safety
trial with concomitant use of 60 days of ticlopidine. Later, the
protocol was converted into a 4- and 6-month study with
quantitative coronary angiography and intravascular
ultrasound.
After completion of the European pivotal trial, the Amer-
ican pivotal trial, SIRIUS (Sirolimus-Eluting Stent in De
Novo Native Coronary Lesions), was initiated, and for
reasons unknown to the authors, the prescription of clopi-
dogrel was prolonged to 3 months, although no thrombotic
issue was observed in the RAVEL trial in the first 5 years of
follow-up. The decision to prescribe 6 months of clopidogrel
in the TAXUS-I trial (and in the subsequent trials) was not
discussed in the original report. In other words, the duration
of prescription of clopidogrel does not seem to be validated
by scientific arguments; consequently, the concept of prema-
ture discontinuation is arbitrary as well. So far, there is no
evidence-based medicine that prolonged dual-antiplatelet
therapy could reduce late ST in DES-treated patients. Of note,
one quarter of our patients with late or very late ST were on
dual-antiplatelet therapy.11 The only evidence of a preventive
effect of dual-antiplatelet therapy on late ST stems from the
experience with brachytherapy in which prolongation of
dual-antiplatelet therapy was effective in preventing late ST,
although a rebound phenomenon in ST was observed after
cessation of clopidogrel. At 15 months, the incidence of
thrombotic occlusion was 15.9% in the Washington Radiation
for In-Stent Restenosis Trial plus 6 months of clopidogrel
(WRIST-PLUS) versus 13.5% in WRIST.12,16,17
The postmortem findings in patients with a DES constitute
dramatic and compelling evidence that stented arteries show,
in a limited number of patients, impaired reendothelialization
with uncovered stent struts as a consequence. However, the
eminent pathologist Dr Renu Virmani is the first to admit that
in postmortem studies there is no common denominator and
that the number of patients treated with DES in whom
“uncovered stent struts” do not lead to ST is unknown but
undoubtedly very large. Still today, the relative impact of the
stent platform with a variety of strut thicknesses, polymers,
and drugs on ST remains unclear. In her most recent presen-
tation, Dr Virmani demonstrated a complete endothelializa-
tion of the struts with cells exhibiting cd31 (antigen surface
marker of good endothelial functionality) at 14 days in rabbit
iliac arteries stented with a DES eluting everolimus, a
sirolimus analog with a sole and minimal alteration of the
molecular structure of sirolimus in the binding domain,
without any chemical modification of the mTOR binding
domain. With such a subtle difference between sirolimus and
everolimus, it becomes unclear whether we have to blame the
drug, the polymer, or even the platform for the difference in
reendothelialization.18
We are aware that DES may induce complex interactions
between shear stress and inhibition of neointimal growth,
resulting in a peculiar rheological profile that we described
early on in Circulation,19 and we have attempted to differen-
tiate delayed neointimal growth (delayed restenosis) from
adaptive shear stress–induced growth, which is a long-term
physiological process.20,21
But before discussing in more detail the impact of vessel
wall remodeling on late ST, we should clarify that late
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acquired malapposition and stent underexpansion are 2 dif-
ferent entities with different possible consequences. In the
early days of BMS, Colombo et al22 convinced the world that
incorrect deployment and incomplete apposition of stents
were major contributors to subacute ST. This older generation
of interventional cardiologists was painstakingly educated to
postdilate the stent to avoid this incomplete deployment.
Today, the lesson of the past seems to have been forgotten by
a new generation of interventional cardiologists who rely too
much on the antirestenotic properties of DES and do not care
enough for correct mechanical deployment of the “metallic
endoprosthesis.” In an extensive and retrospective analysis of
BMS patients treated in the previous decade, stent underex-
pansion (minimum stent area 5.0 mm2) was present in 20%
of all restenotic lesions.23 In a comparable but smaller
analysis of DES-treated patients, stent underexpansion (using
the same definition) was observed in at least 67% of all
cases.24
Incorrect deployment with early thrombosis in (non) elut-
ing stents will remain an actuality.25 Although late acquired
malapposition also is observed with BMS, this phenomenon
has been documented more frequently in patients with DES.26
The question remains whether late acquired malapposition
has an unfavorable prognosis with respect to late ST. Hoff-
man et al have compiled the intravascular ultrasound studies
performed in the randomized trials (RAVEL, SIRIUS and
E-SIRIUS) (personal communication). Intravascular ultra-
sound was available in 325 patients and the incidence of
incomplete stent apposition at 6 months was 25% in the SES
group versus 8.3% in the BMS group. The authors were
unable to demonstrate any prognostic impact of incomplete
stent apposition on death (2.2% with incomplete stent appo-
sition versus 5.2% without incomplete stent apposition) and
major adverse cardiac events (8.9% with incomplete stent
apposition versus 12.6% without incomplete stent apposition)
in patients treated with sirolimus-eluting stents. Late ST was
observed in only 1 of 45 patients with incomplete stent
apposition at a 6- to 8-month follow-up. Considering the fact
that the era of trials comparing BMS and DES is coming to an
end, such a comparison between DES and BMS on that topic
might not be obtainable in the future.
The ESC Firestorm
At the ESC Barcelona 2006, some of us were caught off
guard by a plenary session combining 3 critical presentations
by Edoardo Camenzind, Salim Yousouf, and Alain Nord-
mann. After having pooled the published data from the 4
pivotal randomized controlled trials assessing the safety and
efficacy of the Cypher stent (RAVEL, SIRIUS, E-SIRIUS,
and C-SIRIUS), Camenzind and colleagues disclosed a rate
of total death and Q-wave MI of 6.3% in the Cypher group
versus 3.9% in the control group, with a value of P0.03. It
did not take too long for the lay media to report with
sensationalism that DES were increasing the incidence of
death and Q-wave MI by 66%. However, what was over-
looked is that this meta-analysis was derived from data
published in the literature at different time points of follow-
up. Camenzind took 2 hard clinical end points, total death and
Q-wave MI, and disregarded the non–Q-wave MI incidences,
which were substantially lower in the Cypher group, did not
fit with the general contention, and would have ruined the
statistical foundation (a probability value would not have
been reached with a composite of Q- and non–Q-wave MI).
The TAXUS results of the perennial competitor Boston
Scientific were not questioned because a meta-analysis de-
rived from the randomized TAXUS family trial data in the
literature did not show an alarming incidence of death and
Q-wave MI.
In contrast to these data, we had access to the patient-level–
based data for all 4 trials (RAVEL, SIRIUS, E-SIRIUS, and
C-SIRIUS) with a complete follow-up of 4 years.26a These
data had been transferred to 2 independent academic statisti-
cians for verification. Previously, the data management had
been performed by 2 independent central research organiza-
tions located in Rotterdam and Harvard. In these trials, the
clinical events had been adjudicated by independent clinical
event committees, whereas the incidence of ST had been
readjudicated by the Harvard Central Research Institute
according to new definitions of ST (Table 1). The definitions
were formulated before the ESC congress by a consortium of
interventional cardiologists from both sides of the Atlantic,
representatives of the Food and Drug Administration, aca-
demic central research organizations (Harvard Central Re-
search Institute, Duke Clinical Research Institute, Cardiovas-
cular Research Foundation, and Cardialysis), and
representatives from major stent manufacturers. Two meet-
ings held in Washington in March 2006 and in Dublin in June
2006 aimed to reach a consensus on the new standard and to
promote consistency for reporting to guarantee the transpar-
ency of the data. In the past, inappropriate comparisons and
conclusions were based on various definitions with the
potential to bias results by choosing definitions most favor-
able to those conducting analyses. In contrast to the data
presented by Camenzind and colleagues, the actual rate of
total death and all MI at 4 years was 11.4% in the Cypher
group and 10.1% in the control group, with a value of P0.4.
Not being “P valuists,” we recognized that the Kaplan-Meier
curves were nevertheless slightly diverging over time. Al-
though not completely correct from a methodological point of
view, Camenzind’s report at the ESC became a wakeup call
for everybody (the device industry, principal investigators,
clinical research organizations, The European Agency for the
Evaluation of Medical Products, and the US Food and Drug
Administration).
Puzzled by these observations, we started looking for
heterogeneity of the treatment effect and discovered that the
slight excess in mortality in the total population was due
exclusively to the diabetic population. In the 428 diabetic
patients enrolled in the 4 pivotal randomized trials, the 3-year
survival was 96% in the BMS control group and 87.8% in the
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Cypher group, with a value of P002. Because the nondia-
betic Kaplan-Meier curves were nicely superimposed, our
first reflex was to analyze the incidence of ST in these
diabetic patients as a specific cause of mortality. The rate of
definite or probable ST was 1.0% (2 of 195 patients) in the
Cypher group versus 2.1% (5 of 233) in the control group.
However, there was an imbalance between the Cypher (5.6%,
10 of 195) and control (1.7%, 4 of 233) groups in possible ST
defined as any unexplained death from 30 days after the
procedure. This intense scrutinizing exercise in comparing
the death rate in these 428 diabetic patients boiled down to a
difference of 6 unexplained deaths in the Cypher group and
an excess of 3 cases of definite or probable ST in the control
group, whereas the 3 categories of ST were very well
balanced in the total population (Table 2).
However, a chronological analysis of the occurrence of
these thromboses revealed some subtle differences in timing.
In the DES group, the incidence of very late (n23) primary
ST (not a sequela of reintervention) was prominent, and the
occurrence of ST after target lesion revascularization was not
observed mainly because of the very low incidence of target
lesion revascularization in the DES group. In the BMS group,
TABLE 1. Academic Research Consortium Definitions of Stent Thrombosis
Timing
Acute stent thrombosis: 0–24 h after stent implantation
Subacute stent thrombosis: 24 h–30 d after stent implantation
Late ST*: 30 d–1 y after stent implantation
Very late ST*: 1 y after stent implantation
Three categories of evidence in defining stent thrombosis
Definite stent thrombosis
Angiographic confirmation of stent thrombosis
TIMI flow grade 0 with occlusion originating in the stent or in the segment 5 mm proximal or distal to the stent region in the presence of a thrombus*
TIMI flow grade 1, 2, or 3 originating in the stent or in the segment 5 mm proximal or distal to the stent region in the presence of a thrombus* and at
least one of the following criteria has been fulfilled within a 48-h time window: new onset of ischemic symptoms at rest (typical chest pain with
duration 20 min), new ischemic ECG changes suggestive of acute ischemia, or typical rise and fall in cardiac biomarkers (refer to definition
non–procedure-related MI
Confirmation of stent thrombosis
Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved after thrombectomy
Probable stent thrombosis
Considered to have occurred after intracoronary stenting in the following cases: any unexplained death within the first 30 d and, regardless of the time
after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of
stent thrombosis and in the absence of any other obvious cause
Possible ST
Clinical definition of possible ST is considered to have occurred with any unexplained death from 30 d after intracoronary stenting until end of trial
follow-up
TIMI indicates Thrombolysis In Myocardial Infarction.
*Including primary and secondary late ST; secondary late ST is an ST after a target segment revascularization.
TABLE 2. Academic Research Consortium Definitions of ST in a Pooled Meta-Analysis of the
Randomized RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS Trials
Variables
Crude Event Rates, %
P
Sirolimus-Eluting Stent
(N878 patients)
BMS
(N870 patients)
Any thrombosis by Academic Research Consortium
definitions, % (n/N)
3.4 (30/878) 3.2 (28/870) 0.89
Acute ST (within 24 h) 0.0 (0/878) 0.0 (0/870)   
Subacute ST (between 1 and 30 d) 0.5 (4/878) 0.3 (3/870) 1.00
Late ST (between 30 d and 1 y) 0.3 (3/878) 1.3 (11/870) 0.034
Very late ST (after 1 y) 2.6 (23/878) 1.6 (14/870) 0.18
Definite ST 1.1 (10/878) 0.8 (7/870) 0.63
Probable ST 0.3 (3/878) 0.9 (8/870) 0.14
Possible ST 1.9 (17/878) 1.5 (13/870) 0.58
Total population: n1748.
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9 late and 6 very late ST events were documented, of which
10 occurred after reintervention. These incidences of late ST
in BMS are not uncommon and have been previously docu-
mented in the literature in 9000 patients, with rates of late
ST (30 days) ranging from 0.4% and 0.8%.27–29
These numbers emphasize the fact that restenosis with
BMS is not just a nuisance but has potentially severe
consequences. In 2006, Chen and colleagues30 reported on the
clinical presentation of 1186 consecutive episodes of in-stent
restenosis in patients treated with BMS. Whereas 26.4% of
the patients required hospitalization for unstable angina, an
additional 9.5% presented with MI, and 0.7% died. Nayak et
al31 reported a similar 10% incidence of MI resulting from
in-stent restenosis, and an additional 12% presented with a
2-fold increase in troponin. Additionally, 2 recent studies
proved a close correlation between the extent of restenosis
and late mortality.32,33 In other words, by preventing 100
restenoses per 1000 patients (clinical restenosis reduced from
20% to 10%), DES could prevent 10 restenosis-related MIs
(9.5% of 100 prevented restenosis), and we could surmise
that a reduction of 10 per 1000 cases of restenosis-related MIs
would be sufficient to offset an increase of 5 per 1000 in very
late ST–related MIs, leading to similar late death and MI rates
for DES and the BMS control.
How Do We Interpret the Data in Light of the
Academic Research Consortium Definitions?
We have 3 options: there is a new problem, and the use of
DES results in more (very) late thrombosis than BMS; there
is no new problem, and the rate of (very) late ST after DES
is similar to that of BMS; and there is a problem, and early
and (very) late ST should be abolished. In the near future, we
may consider 3 strategies (the Figure).
1. Pharmacological and long-term randomized trials will
test the antithrombotic properties of current or novel dual-
antiplatelet therapy in trials with death and MI as their
primary end points and ST as their secondary end point.
2. Certain current active and passive coated stents claim to
have lower rates of ST and will be compared in dedicated
randomized trials with long-term follow-up with as a sole
primary end point difference in ST with as secondary end
point death and MI (eg, REVOLUTION, PROTECT [Pro-
spective Reinfarction Outcomes in Thrombolytic Era
Cardizem CD Trial], and TRIAS).
3. The current technology is viewed as imperfect, and the
deficiencies should be amended by introducing more biocom-
patible absorbable coatings and new drugs with biological
targets other than smooth muscle cell duplication (eg, throm-
botic and inflammatory mechanisms) using dual elution of
drugs or a prohealing approach such as the capture of
endothelial progenitor cells with or without drug elution.
It is clear that abolishing neointimal hyperplasia is no
longer the ultimate goal. Development of more biocompatible
and bioabsorbable stents facilitating adequate endothelializa-
tion is expected in the near future.
Conclusions
Late ST exists in both DES and BMS. In an all-comer
population, angiographic ST in DES seems to occur at a
steady rate of 0.4% to 0.6% per year. Clinicians, regulators,
and the device industry now realize that clinical surrogates
for ST (death and MI) have to be incorporated into the
long-term follow-up of the patient to capture late and very
late ST patients who do not reach the catheterization labora-
tory to have their thrombosis angiographically confirmed.
Fortunately, a first consensus on these angiographic and
Future directions of clinical trials. RT indi-
cates randomized trials; ASA, acetylsalicyl-
ic acid; EPC, endothelial progenitor cell;
and gen, generation.
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clinical end-point definitions has been reached under the
umbrella of the Academic Research Consortium. Retrospec-
tive analysis of ST, applying the Academic Research Con-
sortium definitions in randomized controlled trials, does not
disclose a different rate of late ST between BMS and DES up
to 4 years. However, the chronology and circumstances of
occurrence seem quite different. In DES, late ST occurs later
than in BMS and seems to appear as primary thrombosis,
whereas in BMS, a certain number of late thromboses are
related to repeat interventions of the target lesion. Dedicated
research is warranted to further elucidate the role of endothe-
lial dysfunction, malapposition, and prolonged antiplatelet
therapy. Currently, the second generation of DES is attempt-
ing to resolve the issues discovered so far with the first
generation of DES.
Disclosures
None.
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Early and late coronary stent thrombosis of sirolimus-
eluting and paclitaxel-eluting stents in routine clinical 
practice: data from a large two-institutional cohort study
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Summary 
Background Stent thrombosis is a safety concern associated with use of drug-eluting stents. Little is known about 
occurrence of stent thrombosis more than 1 year after implantation of such stents. 
Methods Between April, 2002, and Dec, 2005, 8146 patients underwent percutaneous coronary intervention with 
sirolimus-eluting stents (SES; n=3823) or paclitaxel-eluting stents (PES; n=4323) at two academic hospitals. We 
assessed data from this group to ascertain the incidence, time course, and correlates of stent thrombosis, and the 
diff erences between early (0–30 days) and late (>30 days) stent thrombosis and between SES and PES. 
Findings Angiographically documented stent thrombosis occurred in 152 patients (incidence density 1·3 per 100 
person-years; cumulative incidence at 3 years 2·9%). Early stent thrombosis was noted in 91 (60%) patients, and late 
stent thrombosis in 61 (40%) patients. Late stent thrombosis occurred steadily at a constant rate of 0·6% per year up 
to 3 years after stent implantation. Incidence of early stent thrombosis was similar for SES (1·1%) and PES (1·3%), 
but late stent thrombosis was more frequent with PES (1·8%) than with SES (1·4%; p=0·031). At the time of stent 
thrombosis, dual antiplatelet therapy was being taken by 87% (early) and 23% (late) of patients (p<0·0001). 
Independent predictors of overall stent thrombosis were acute coronary syndrome at presentation (hazard ratio 2·28, 
95% CI 1·29–4·03) and diabetes (2·03, 1·07–3·83).
Interpretation Late stent thrombosis was encountered steadily with no evidence of diminution up to 3 years of follow-
up. Early and late stent thrombosis were observed with SES and with PES. Acute coronary syndrome at presentation 
and diabetes were independent predictors of stent thrombosis.
Introduction
Drug-eluting stents signifi cantly reduce rates of 
restenosis and target lesion revascularisation compared 
with bare metal stent. Since the publication of pivotal 
randomised trials on the two DES approved by the US 
Food and Drug Administration (polymer-based 
sirolimus-eluting stents [SES] and polymer-based 
paclitaxel-eluting stents [PES]),1–4 these devices have 
been widely used in the percutaneous treatment of 
coronary artery disease worldwide.5–8 However, several 
pre-clinical and clinical safety concerns9–15 related to the 
use of drug-eluting stents have been expressed since 
then. One of the most important issues raised is stent 
thrombosis, a catastrophic, albeit infrequent, 
complication that results in abrupt coronary artery 
closure, which can lead to myocardial infarction or 
sudden cardiac death. This problem is not restricted to 
drug-eluting stents, and its incidence does not seem to 
exceed that seen with bare metal stents up to 1 year of 
follow-up.16–22 However, case reports and observational 
studies have noted that some patients develop stent 
thrombosis unusually late after implantation of drug-
eluting stents.23–25
To date, no large-scale study has focused on late stent 
thrombosis later than 1 year after drug-eluting stent 
implantation. Although variables such as acute coronary 
syndromes, bifurcation stenting, diabetes, discontinu-
ation of antiplatelet therapy, renal failure, and stent 
length seem to be consistently associated with overall 
stent thrombosis,19,26–28 predictors specifi c for late stent 
throm bosis have not yet been identifi ed. We therefore 
assessed all angiographically documented stent throm-
bosis following unrestricted use of SES and PES in 
routine clinical practice at two academic referral hospitals 
between April, 2002, and December, 2005. The purposes 
of this investigation were to: estimate the incidence and 
time course of stent thrombosis with drug-eluting stents 
in routine clinical practice; identify predictors of stent 
thrombosis; identify diff erences between early and late 
stent thrombosis; and assess diff erences between SES 
and PES.
Methods
Study group and design 
Between April 16, 2002, and Dec 31, 2005, a total of 
8146 consecutive patients underwent percutaneous 
coronary intervention with SES or PES at two academic 
referral hospitals in the Netherlands and Switzerland. 
3823 patients were treated with SES (Cypher, Cordis 
Corporation, Johnson and Johnson, Warren, NJ, USA) 
and 4323 patients with PES (TAXUS, Express2, or Liberté, 
Boston Scientifi c, Natick, MA, USA). In the Dutch 
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institution, SES have been used as a default strategy for 
PCI as part of the Rapamycin-Eluting Stent Evaluated At 
Rotterdam Cardiology Hospital (RESEARCH) registry7 
since April, 2002. From the fi rst quarter of 2003, PES 
became commercially available and replaced SES as 
default device for such procedures, as part of the Taxus 
Stent Evaluated At Rotterdam Cardiology Hospital 
(T-SEARCH) registry.5 In the Swiss institution, SES have 
been used since April, 2002, and PES since March, 2003. 
Between April, 2003, and May, 2004, a randomised trial 
was done to compare the devices.6 Between June, 2004, 
and March, 2005, the use of SES and PES was alternated 
on a daily basis. Since April, 2005, the use of PES has 
been abandoned and SES have been used as the default 
device. Patients treated with both types of stents (SES 
and PES) in one lesion, and lesions previously treated 
with brachytherapy, were excluded from the study 
population. The study was designed during a conference 
between the Bern and Rotterdam investigators. Baseline 
clinical and angiographic variables, procedural 
characteristics, and endpoints of interest were identifi ed, 
and a template with all variables of interest for this study 
was supplied to the two study sites. Data from both sites 
were then entered into a database, held at the 
Thoraxcenter, Rotterdam, The Netherlands, generating 
all analyses presented in this manuscript.
This study was approved by the local ethics committee 
at both hospitals and was done in accord with the 
Declaration of Helsinki. Written informed consent was 
obtained from all patients. 
Procedures
All interventions were done according to current practice 
guidelines for percutaneous coronary intervention.29 The 
operator was responsible for the decision to choose a 
specifi c treatment strategy. Patients were prescribed aspirin 
plus clopidogrel 75 mg per day (after a loading dose of 300 
mg or 600 mg) before or during baseline coronary 
3823 treated with sirolimus-eluting stent
2775 patients from Bern
1048 patients from Rotterdam
3378 30 days follow-up available
77 died within 30 days
368 to be contacted
3193 6 months follow-up available
115 died within 6 months
515 to be contacted
2605 1-year follow-up available
147 died within 1 year
1071 to be contacted
1712 2-year follow-up available
208 died within 2 years
1903 to be contacted
920 3-year follow-up available
237 died within 3 years
2666 to be contacted
4323 treated with Paclitaxel-eluting stent
1365 patients from Bern
2958 patients from Rotterdam
3399 30 days follow-up available
126 died within 30 days
798 to be contacted
3075 6 months follow-up available
186 died within 6 months
1062 to be contacted
2857 1-year follow-up available
231 died within 1 year
1235 to be contacted
1163 2-year follow-up available
292 died within 2 years
2868 to be contacted
84 3-year follow-up available
305 died within 3 years
3934 to be contacted
8146 enrolled
Figure 1: Study profi le
Overall (n=8146) SES (n=3823) PES (n=4323) p
Age (years) 62·6 (11·6) 62·5 (11·5) 62·7 (11·6) 0·31
Male 6065/8146 (75%) 2859/3823 (75%) 3206/4323 (74%) 0·53
Hypertension 3745/8144 (46%) 1965/3821 (51%) 1780/4323 (41%) <0·0001
Family history 2279/8144 (28%) 1112/3821 (29%) 1167/4323 (27%) 0·04
Current smoking 2993/8144 (37%) 1721/3821 (45%) 1272/4323 (29%) <0·0001
Dyslipidaemia 4079/8144 (50%) 2087/3821 (55%) 1992/4323 (46%) <0·0001
Diabetes 1315/8144 (16%) 697/3821 (18%) 618/4323 (14%) <0·0001
Renal failure 134/3309 (4%) 97/2253 (4%) 37/1056 (4%) 0·30
Left ventricular ejection fraction (%) 55 (12) 54 (12) 55 (11) 0·01
Acute coronary syndrome at presentation 2853/4859 (59%) 795/1481 (54%) 2058/3378 (6 1%) <0·0001
Bifurcation treatment 781/4889 (16%) 267/1488 (18%) 514/3401 (15%) 0·01
Number of stents per patient 1·96 (1·23) 1·87 (1·13) 2·03 (1·31) <0·0001
Total stent length per patient (mm) 35·9 (25·3) 33·6 (22·6) 37·9 (27·4) <0·0001
Average stent diameter per patient (mm) 2·93 (1·4) 2·90 (2·1) 2·95 (0·5) 0·11
Duration of clopidogrel prescription (months)* 5·94 (3·1) 4·72 (4·0) 6·36 (2·6) <0·0001
Data are mean (SD) or n/total with data available (%). *Based on Rotterdam cohort.
Table 1: Clinical and procedural characteristics of study population stratifi ed by stent type
Early and late stent thrombosis aft er DES 
166
interventions. After the procedure, all patients were advised 
to maintain lifelong use of aspirin. In the Dutch institution, 
patients treated with PES were prescribed at least 6 months 
of clopidogrel (75 mg per day), on the basis of existing data 
from a randomised controlled trial.30 For patients treated 
with SES, clopidogrel was prescribed for at least 3 months, 
unless one of the following was present, in which case 
clopidogrel was maintained for at least 6 months: multiple 
SES implantation (≥3 stents), total stent length 36 mm or 
longer, chronic total occlusion, and bifurcations.5 In the 
Swiss institution, 12 months of clopidogrel was prescribed 
irrespective of the stent type used.6 In a few patients who 
were on oral anticoagulation therapy, doctors recommended 
a shorter duration of clopidogrel (eg, 3-month triple 
therapy with aspirin, clopidogrel, and warfarin).
Patients were contacted according to follow-up 
schedules specifi c for each institution for the occurrence 
of major adverse cardiac events, including all-cause 
death, myocardial infarction, and repeat revascularisa-
tion. Survival data for all patients were obtained from 
municipal civil registries. A health questionnaire was 
subsequently sent to all living patients with specifi c 
questions on re-admission and major adverse cardiac 
events. For patients who had an adverse event at another 
centre, medical records or discharge summaries from 
other institutions were systematically reviewed. General 
practitioners, referring cardiologists, and patients were 
contacted as necessary for additional information. Data 
were based on a registry at two institutions entered into 
a database. There was no independent or external 
monitoring of data entry. However, data were carefully 
verifi ed and adjudicated by clinicians. Mean follow-up 
was 1·73 years. Figure 1 shows fl ow of patients during 
various follow-up times. 
Myocardial infarction was defi ned as increased creatine 
kinase by twice the upper limit of normal value and three 
times the upper limit of normal value of creatine kinase-
MB fraction. Repeat revascularisation included target 
lesion revascularisation (TLR) and non-TLR, irrespective 
of whether the procedure was clinically or angiographically 
driven.    
Only patients with angiographically proven stent 
thrombosis were included in the present study. Stent 
thrombosis was judged to have occurred if thrombolysis 
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Figure 3: Kaplan-Meier survival curve showing cumulative incidence of stent thrombosis in patients with SES 
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in myocardial infarction (TIMI) fl ow was grade 0 with 
occlusion originating in the peri-stent region, or grade 1, 
2, or 3 in the presence of a thrombus originating in the 
peri-stent region. Angiographic evidence of thrombus 
was defi ned as a discrete, intraluminal fi lling defect with 
defi ned borders and separated from the vessel wall.31 
Additionally, at least one of the following criteria had to be 
met: acute ischaemic symptoms (typical chest pain with 
duration >20 min); ischaemic ECG changes (ST-segment 
elevation in territory of implanted stent, ST-segment 
depression or T-wave inversion in territory of implanted 
stent); typical rise and fall in cardiac biomarkers.32 
All cases of angiographically proven stent thrombosis 
were reviewed independently by two experienced 
interventional cardiologists. In case of disagreement, a 
consensus was established between the two reviewers, or 
a third interventional cardiologist was consulted.
Stent thrombosis was categorised dependant on the 
timing of emergence into early (within 30 days) and late 
(>30 days). 
Risk factors and co-morbidities in each patient were 
determined as classifi ed by the treating physicians. Acute 
coronary syndrome was defi ned as the group of clinical 
symptoms, electrocardiographic changes, and elevation 
of cardiac biomarkers that is compatible with acute 
myocardial ischaemia and encompasses an acute 
myocardial infarction (ST-segment elevation and non-ST 
segment elevation myocardial infarction) as well as 
unstable angina.32 Hypertension was defi ned as blood 
pressure of 140 mm Hg or greater systolic or 90 mm Hg 
or greater diastolic, or current use of antihypertensive 
treatment. Dyslipidaemia was classifi ed as a concentration 
of cholesterol in serum of 6·2 mmol/L or greater, or the 
use of lipid-lowering drugs. 
Angiographic success was defi ned as: achievement of 
30% or less residual diameter stenosis within the 
stented segment by visual assessment; no evidence of 
residual dissection; no evidence of thrombus; and 
achievement of fi nal TIMI fl ow grade 3. For the 
quantitative angiographic analysis, in-segment analysis 
was defi ned as the stented segment plus the adjacent 
proximal and distal 5-mm peri-stent regions. Premature 
discontinuation of antiplatelet therapy was characterised 
as cessation of either aspirin or clopidogrel before the 
end of the recommended duration of prescription. 
ST (n=152)  No ST (n=7994) p 
Age (years) 60·3 (12·0) 62·5 (11·5) 0·01
Male 115/152 (76%) 5950/7994 (74%) 0·78
Hypertension 63/152 (41%) 3682/7992 (46%) 0·29
Family history 44/152 (29%) 2235/7992 (28%) 0·79
Current smoking 57/152 (38%) 2936/7992 (37%) 0·87
Dyslipidaemia 74/152 (49%) 4005/7992 (50%) 0·74
Diabetes 29/152 (19%) 1286/7992 (16%) 0·32
Renal failure 9/152 (6%) 132/3242 (4%) 1·00
Left ventricular ejection fraction (%) 52 (12) 55 (12) 0·07
Acute coronary syndrome at presentation 67/95 (71%) 2786/4764 (59%) 0·02
Bifurcation treatment 27/96 (28%) 754/4793 (16%) 0·003
Number of stents per patient 2·35 (1·73) 1·95 (1·22) <0·0001
Total stent length per patient (mm) 42·3 (34·0) 35·8 (25·1) 0·002
Average stent diameter per patient (mm) 2·83 (0·35) 2·93 (1·44) 0·48
Data are mean (SD) or n/total with data available (%). ST=stent thrombosis. 
Table 2: Comparison of clinical and procedural characteristics between patients with and without stent 
thrombosis
Hazard ratio (95% CI)
Bern Rotterdam
Univariate Multivariate Univariate Multivariate
Overall stent thrombosis
Age 0·99 (0·97–1·00) 0·98 (0·96–1·01) 0·98 (0·96–1·00) 0·97 (0·95–1·00)
Male sex 1·06 (0·63–1·79} 1·32 (0·65–2·66) 1·05 (0·62–1·75) 0·90 (0·51–1·58)
Family history 0·74 (0·44–1·25) 0·67 (0·35–1·28) 1·25 (0·77–2·02) 1·23 (0·74–2·15)
Diabetes 1·04 (0·58–1·85) 1·30 (0·67–2·51) 1·43 (0·81–2·53) 2·03 (1·07–3·83)
Hypertension 0·83 (0·54–1·30) 0·78 (0·45–1·34) 0·72 (0·44–1·19) 0·68 (0·38–1·21)
Smoking 1·05 (0·67–1·63) 0·87 (0·50–1·51) 0·89 (0·51–1·55) 0·78 (0·43–1·44)
Dyslipidaemia 0·77 (0·50–1·20) 0·76 (0·44–1·30) 0·93 (0·58–1·47) 1·07 (0·63–1·82)
Left ventricular ejection fraction 0·98 (0·96–0·99) * ‡ ‡
Renal failure† 1·00 (0·24–4·10) 0·96 (0·23–3·99) ‡ ‡
Acute coronary syndrome at presentation ‡ ‡ 1·80 (1·07–3·05) 2·28 (1·29–4·03)
Bifurcation treatment ‡ ‡ 1·87 (1·04–3·37) 1·47 (0·79 –2·72)
Paclitaxel-eluting stents 1·26 (0·80–1·97) 1·25 (0·73–2·12) 1·47 (0·86–2·51) 1·38 (0·79–2·44)
Number of stents per patient 1·21 (0·97–1·51) 1·11 (0·74–1·67) 1·27 (1·12–1·43) 1·27 (0·98–1·64)
Total stent length per patient 1·01 (1·00–1·02) 1·01 (0·98–1·03) 1·01 (1·01–1·02) 1·00 (0·99–1·01)
Average stent diameter per patient 0·64 (0·26–1·60) ‡ 0·70 (0·46–1·07) 0·72 (0·42–1·22)
Absence of clopidogrel ‡ ‡ 0·59 (0·77–4·48) 0·77 (0·09–6·24)
(Continues on next page)
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A creatinine value of 150 μmol per L or chronic 
haemodialysis qualifi ed for the defi nition of renal 
impairment.
Statistical analysis
Continuous variables are described as mean and SD or 
median values with IQR. Dichotomous variables are 
described as counts and percentages. Continuous 
variables were compared between SES and PES and 
between early and late thrombosis with Student’s t test 
(for parametric variables) or Mann-Whitney U test (for 
non-parametric variables) as appropriate in terms of the 
clinical, angiographic, and procedural demo graphics. 
The incidence of stent thrombosis was calculated as 
incidence density and as cumulative incidence. 
Incidence density was defi ned as the number of patients 
with stent thrombosis divided by the total number of 
patient-years, and expressed as a number per 100 
patient-years of observation.33,34 Cumulative incidence 
was estimated by the Kaplan Meier method and 
diff erences were assessed with the log-rank test. A Cox 
proportional hazards model was used to identify 
independent predictors of stent thrombosis, with these 
variables: age, sex, family history of cardiovascular 
disease, diabetes, hypertension, current smoking, 
dyslipidaemia, renal impairment, left ventricular 
ejection fraction, acute coronary syndrome at 
presentation, stent type (SES or PES), number of stents, 
total stent length, average stent diameter, bifurcation 
treatment, and prescribed duration of clopidogrel. Data 
(Continued from previous page)
Early stent thrombosis
Age 1·01 (0·98–1·04) 1·00 (0·97–1·04) 0·98 (0·96–1·01) 0·96 (0·94–0·99)
Male sex 1·02 (0·50–2·08) 1·04 (0·44–2·49) 0·82 (0·45–1·52) 0·70 (0·35–1·39)
Family history 0·50 (0·22–1·12) 0·41 (0·14–1·18) 0·94 (0·50–1·78) 0·83 (0·40–1·70)
Diabetes 1·43 (0·70–2·90) 2·03 (0·91–4·52) 1·94 (1·01–3·73) 2·29 (1·07–4·90)
Hypertension 0·51 (0·28–0·94) 0·40 (0·19–0·86) 0·97 (0·54–1·76) 0·80 (0·39–1·63)
Smoking 0·76 (0·41–1·38) 0·85 (0·41–1·78) 0·40 (0·16–1·01) 0·37 (0·14–0·97)
Dyslipidaemia 0·68 (0·37–1·24) 0·82 (0·39–1·68) 1·03 (0·59–1·82) 1·29 (0·66–2·56)
Left ventricular ejection fraction 0·98 (0·95–1·00) * ‡ ‡
Renal failure† 1·64 (0·39–6·82) 1·23 (0·29–5·28) ‡ ‡
Acute coronary syndrome at presentation ‡ ‡ 1·64 (0·86–3·14) 2·29 (1·16–4·52)
Bifurcation treatment ‡ ‡ 3·17 (1·66–6·05) 2·52 (1·26–5·02)
Paclitaxel-eluting stents 1·11 (0·60–2·05) 1·28 (0·63–2·59) 0·93 (0·49–1·76) 0·86 (0·44–1·71)
Number of stents per patient 1·32 (1·00–1·74) 1·39 (0·85–2·26) 1·34 (1·17–1·55) 1·18 (0·85–1·63)
Total stent length per patient 1·01 (1·00–1·03) 1·00 (0·98–1·03) 1·02 (1·01–1·02) 1·01 (0·99–1·02)
Average stent diameter per patient 0·63 (0·20–1·95) ‡ 0·70 (0·45–1·11) 0·66 (0·35–1·24)
Absence of clopidogrel ‡ ‡ ¶ *
Late stent thrombosis
Age 0·96 (0·94–0·99) 0·96 (0·92–0·99) 0·97 (0·94–1·01) 0·99 (0·95–1·03)
Male sex 1·11 (0·50–2·43) 1·93 (0·56–6·63) 1·93 (0·66–5·63) 1·52 (0·51–4·56)
Family history 1·06 (0·51–2·15) 1·04 (0·45–2·43) 2·07 (0·95–4·55) 2·40 (1·03–5·58)
Diabetes 0·61 (0·22–1·73) 0·67 (0·20–2·27) 0·69 (0·20–2·30) 1·22 (0·34–4·34)
Hypertension 1·53 (0·77–3·06) 1·75 (0·75–4·09) 0·36 (0·14–0·98) 0·43 (0·15–1·24)
Smoking 1·52 (0·78–2·97) 0·92 (0·40–2·11) 2·13 (0·97–4·70) 1·70 (0·70–4·11)
Dyslipidaemia 0·88 (0·46–1·70) 0·72 (0·32–1·62) 0·80 (0·37–1·76) 0·89 (0·37–2·04)
Left ventricular ejection fraction 0·98 (0·96–1·01) * ‡ ‡
Renal failure† .. .. ‡ ‡
Acute coronary syndrome at presentation ‡ ‡ 2·34 (0·94–5·87) 2·46 (0·87–7·00)
Bifurcation treatment ‡ ‡ 0·31 (0·04–2·30) 0·22 (0·03–1·72)
Paclitaxel-eluting stents 1·39 (0·72–2·70) 1·21 (0·54–2·75) 2·43 (0·96–6·17) 2·36 (0·92–6·04)
Number of stents per patient 1·07 (0·75–1·54) 0·73 (0·35–1·56) 1·14 (0·90–1·45) 1·57 (1·00–2·46)
Total stent length per patient 1·00 (0·99–1·02) 1·01 (0·98–1·05) 1·00 (0·99–1·01) 0·99 (0·96–1·01)
Average stent diameter per patient 0·63 (0·13–3·00) ‡ 0·85 (0·33–2·15) 0·82 (0·33–2·06)
Absence of clopidogrel ‡ ‡ 0·74 (0·07–7·42) 1·03 (0·08–13·03)
*Not used for multivariate analysis because of colinearity problems. †Defi ned as creatinine >150 μmol/L. ‡Not used in analysis, <75% of variables available. ¶Could not 
be estimated. 
Table 3: Univariate and multivariate Cox proportional hazards analysis  
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on acute coronary syndrome, bifurcation treatment, and 
average stent diameter in the Bern cohort, and on left 
ventricular ejection fraction and renal impairment in 
the Rotterdam cohort, were available in less than 75% of 
the patients; therefore, we stratifi ed univariate and 
multivariate Cox regression analysis by centre. Statistical 
analyses were done with SPSS 12.0.1 for Windows. All 
p values were two-sided and values less than 0·05 were 
judged statistically signifi cant.
Role of the funding source
There was no industry involvement in the study design, 
data collection, data analysis, or writing of the report. 
The study was supported by research grants from the 
two institutions; data from both institutions were 
entered into a common database held at the 
Thoraxcenter, Rotterdam, the Netherlands. As principal 
investigators, PWS and SW had full access to the data 
and take fi nal responsibility for the data as presented in
the manuscript. 
Results
Between April, 2002, and December, 2005, 8146 patients
underwent percutaneous coronary intervention with SES
(3823 patients) or PES (4323 patients) at the two academic
hospitals. Table 1 summarises clinical and procedural
characteristics of the overall study population. Compared
with patients treated with PES, those who received SES
were more likely to have hypertension, a family history of
coronary heart disease, dyslipidaemia, and diabetes, and
were more frequently smokers. Left ventricular ejection
fraction was somewhat lower in the SES group than in
the PES group. By contrast, patients treated with PES
presented more often with an acute coronary syndrome,
and received more and longer stents than SES patients. 
Angiographically proven stent thrombosis was recorded
in 152 of 8146 patients at a median of 9 days (IQR 3–342)
after DES implantation during a follow-up period of
more than 3 years (mean 1·73 years, SD 0·99). The
incidence density of stent thrombosis was 1·3 per 100
person-years. Stent thrombosis occurred early (at 0–30
Overall ST 
(n=152)
Early ST 
(n=91)
Late ST 
(n=61)
p
PCI for stent thrombosis 148 (97%) 87 (96%) 61 (100%) 0·51
Additional stenting 59 (39%) 30 (33%) 29 (48%) 0·13
Adjunctive thrombolysis 9 (6%) 5 (6%) 4 (7%) 0·83
Adjunctive thrombectomy 18 (12%) 11 (12%) 7 (12%) 9·85
In-hospital outcome
Death 11 (7%) 8 (9%) 3 (5%) 0·53
Periprocedural myocardial 
infarction*
106 (70%) 62 (68%) 44 (72%) 0·99
Reinfarction 2 (1%) 1 (1%) 1 (2%) 0·77
Repeat revascularisation 5 (3%) 3 (3%) 2 (3%) 0·97
Emergency bypass surgery 3 (2%) 2 (2%) 1 (2%) 1·00
Recurrent stent thrombosis 2 (1%) 1 (1%) 1 (2%) 0·77
30-day outcome
Death 13 (9%) 9 (10%) 4 (7%) 0·40
Reinfarction 3 (2%) 2 (2%) 1 (2%) 1·00
Repeat revascularisation 7 (5%) 4 (4%) 3 (5%) 1·00
Recurrent stent thrombosis 3 (2%) 2 (2%) 1 (2%) 1·00
6-month outcome
Death 17 (11%) 12 (13%) 5 (8·2%) 0·24
Reinfarction 3 (2%) 2 (2%) 1 (1·6%) 1·00
Repeat revascularisation 10 (7%) 5 (6%) 5 (8·2%) 0·52
Recurrent stent thrombosis 3 (2%) 2 (2%) 1 (1·6%) 1·00
Hierarchical MACE† 117 (76%) 70 (77%) 47 (75·4%) 0·99
PCI=percutaneous coronary intervention. ST=stent thrombosis. MACE=major 
adverse cardiac events (defi ned as the composite of death, periprocedural 
myocardial infarction, reinfarction, and repeat revascularisation). *Myocardial 
infarction due to stent thrombosis. †Including periprocedural myocardial 
infarction due to stent thrombosis.
Table 4: Periprocedural and postprocedural clinical outcomes of patients 
with stent thrombosis  
Figure 4: Kaplan Meier survival curves showing (A) all-cause mortality and (B) all-cause mortality or 
myocardial infarction in overall population 
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days) in 91 of 152 (60%) patients, and late (after 30 days) 
in 61 of 152 (40%) patients. The cumulative incidence of 
early ST was 1·1% (91 events), whereas late ST occurred 
at a rate of 0·6 per 100 person-years of observation 
(61 events). The median time to occurrence of early stent 
thrombosis was 4 days (IQR 1–6). Of the 61 late ST cases, 
36 (59%) patients developed stent thrombosis 1 year or 
later after stent implantation (median 451 days; IQR 
211–665; fi gure 2). The cumulative incidence of stent 
thrombosis over time showed an initial steep rise with 
50% of cases occurring within 9 days, followed by an 
almost linear increase in the remaining events up to 
3 years. The cumulative incidence of stent thrombosis 
was 1·2% at 30 days, 1·7% at 1 year, 2·3% at 2 years, and 
2·9% at 3 years. The slope of the linear portion of the 
cumulative incidence curve between 30 days and 3 years 
was 0·6% per year (fi gure 3).
Patients with stent thrombosis were younger, presented 
more often with an acute coronary syndrome, and were 
treated more frequently for bifurcation lesions, compared 
with those without stent thrombosis (table 2). The 
number of stents and total stent length were greater in 
patients with stent thrombosis than in those without 
(table 2).
Table 3 summarises the results of Cox proportional 
hazards analysis. In the Bern group, no independent 
predictors of overall stent thrombosis emerged. 
Hypertension was the only independent predictor of 
early stent thrombosis, and age was the only independent 
predictor of late stent thrombosis. In the Rotterdam 
group, acute coronary syndrome at presentation and 
diabetes were independent predictors of overall stent 
thrombosis. Age, hypertension, smoking, acute coronary 
syndrome at presentation, and bifurcation treatment 
were independently associated with early stent 
thrombosis. Family history of coronary heart disease was 
an independent predictor of late stent thrombosis in the 
Rotterdam group. Absence of clopidogrel treatment did 
not seem to be associated with an increased risk of total 
and late stent thrombosis.
In the overall group (n=8146), 3-year cumulative 
incidences were 10·3% for all-cause mortality, 13·7% for 
death or myocardial infarction (fi gure 4), 4·1% for 
myocardial infarction, 11·7% for target vessel 
revascularisation, and 22·3% for major adverse cardiac 
events (ie, death, periprocedural myocardial infarction, 
reinfarction, and repeat revascularisation). Percutaneous 
coronary intervention was the initial treatment strategy 
in almost all patients who developed stent thrombosis 
(table 4). The majority of patients who presented with 
stent thrombosis developed myocardial infarction. 
Notably, recurrent stent thrombosis in two patients and 
multiple stent thromboses in a diff erent vessel in another 
patient caused three reinfarctions within 6 months after 
treatment of stent thrombosis. We noted no diff erences 
in clinical outcome between patients with early and late 
stent thrombosis.
Table 5 shows baseline clinical, angiographic, and 
procedural characteristics stratifi ed for early or late stent 
thrombosis. Compared with patients who had late stent 
thrombosis, patients with early stent thrombosis were 
slightly younger, more frequently diabetic, less frequently 
smokers, and had more bifurcation lesions treated, smaller 
reference vessel diameter, smaller fi nal minimum luminal 
diameter, and a higher residual diameter stenosis. 
Clinical, procedural, and angiographic characteristics of 
the 152 patients with stent thrombosis are shown in 
table 6, along with the comparison between SES and PES. 
More than 70% of stent thrombosis cases occurred in 
patients who underwent the index percutaneous coronary 
intervention in the context of acute coronary syndromes. 
Patients’ characteristics, apart from sex and hypertension, 
were similar for both stent types. The groups were also 
similar in terms of time course (table 6), 3-year cumulative 
incidence of total stent thrombosis (SES 2·5%, PES 3·2%, 
p=0·07; fi gure 5), and cumulative incidence of early stent 
thrombosis (SES 1·1%, PES 1·3%, p=0·49). Late stent 
thrombosis, however, occurred later in the SES group than 
in the PES group (table 6) and cumulative incidence at 
3 years was signifi cantly higher in the PES group (1·9%) 
than in the SES group (1·4%; p=0.031).
Of patients who had early stent thrombosis, 79 (87%) 
were on dual antiplatelet therapy, eight (9%) were on a 
Early ST Late ST p 
Baseline clinical characteristics
n 91 61
Age (years) 61·9 (11·7) 58·0 (12·2) 0·05
Male sex 66/91 (73%) 49/61 (80%) 0·34
Clinical presentation
Stable angina 28/91 (31%) 15/61 (25%)
Acute myocardial infarction 41/91 (45%) 28/61 (50%) 1·00
Unstable angina 22/91 (24%) 18/61 (30%) 0·57
Cardiogenic shock 8 (9%) 5 (8%) 1·00
Hypertension 35/91 (39%) 28/61 (46%) 0·40
Family history 20/91 (22%) 24/61 (39%) 0·03
Current smoking 25/91 (28%) 32/61 (53%) 0·002
Dyslipidaemia 41/91 (45%) 33/61 (54%) 0·32
Diabetes 25/91 (28%) 5/61 (8%) 0·003
Non-insulin-dependent 18/91 (20%) 4/61 (7%) 0·03
Insulin-dependent 7/91 (7%) 1/61 (2%) 0·15
Renal insuffi  ciency 8/91 (9%) 1/61 (2%) 0·09
Multivessel disease 55/91 (60%) 33/61 (54%) 0·50
Multivessel stenting 31/91 (34%) 17/61 (28%) 0·48
Left ventricular ejection fraction (%) 51 (12) 53 (12) 0·41
Number of stents per patient 2·52 (1·85) 2·08 (1·51) 0·12
Total stent length per patient (mm) 46·4 (37·5) 36·1 (27·2) 0·07
Average stent diameter per patient (mm) 2·82 (0·37) 2·85 (0·32) 0·72
Timing of ST (days)
Mean (SD) 5·5 (6·5) 459·4 (274·7) ..
Median (IQR) 4·0 (1–6) 442·0 (235–652) ..
(Continues on next page)
Early and late stent thrombosis aft er DES | Chapter 17
171
single antiplatelet drug, and four (4%) were not on 
antiplatelet therapy. By contrast, late stent thrombosis 
occurred during dual antiplatelet therapy in 14 (23%) 
patients, during single-drug therapy in 31 (51%), and in 16 
(26%) who were not on antiplatelet therapy (p<0·0001 for 
the comparison of early vs late). Stent thrombosis occurred 
late in 31 patients on aspirin monotherapy, and 97% 
(30 of 31) experienced the event after the recommended 
prescription period of clopidogrel had ended. 23 patients 
prematurely discontinued one or both of the two 
antiplatelet drugs (seven of 91 early, 16 of 61 late, p=0·008). 
The reasons for premature discontinuation were poor 
compliance in 11 patients (48%), surgery in 7 (30%), 
bleeding in four (17%), and allergy in one (4%).
Discussion
Our fi ndings from a large cohort of patients with stent 
thrombosis after implantation of drug-eluting stents add 
to the evidence about late stent thrombosis23–28,35 with the 
following observations: stent thrombosis occurred with 
an incidence density of 1·3 per 100 person-years and a 
cumulative incidence of 2·9% at 3 years; the incidence of 
late stent thrombosis did not diminish, but continued at 
a steady rate of 0·6% per year during the fi rst 3 years; 
acute coronary syndrome at presentation and diabetes 
were independent predictors of overall stent thrombosis; 
and early and late stent thrombosis occurred with both 
types of drug-eluting stent, but late stent thrombosis was 
more frequently observed with PES than with SES.
The principal aim of this study was to assess the 
incidence of stent thrombosis during a follow-up period 
of up to 3 years in a large group of patients treated with 
the unrestricted use of drug-eluting stents. Previous data 
on stent thrombosis after drug-eluting stent implantation 
were derived from randomised trials and registries, in 
which low rates of events were reported and early stent 
thrombosis seemed to occur with similar frequency in 
drug-eluting and bare metal stents.17,19–22,36 Similarly, a 
recent meta-analysis reported similar event rates for 
drug-eluting and bare metal stents up to 1 year of follow-
up.18 The incidence of early stent thrombosis (1·2%) and 
the median time to stent thrombosis (9 days) in the 
present study were similar to rates previously reported in 
patients treated with bare metal stents.16,35
Of more interest are adverse events during long-term 
follow-up and the occurrence of late stent thrombosis 
encountered with drug-eluting stents. Late stent 
thrombosis has also been shown in the long-term follow-
up results of early trials comparing SES and PES with 
bare metal stents. A pooled analysis of RAVEL, SIRIUS, 
C-SIRIUS, and E-SIRIUS revealed fi ve cases of late stent 
thrombosis between 1 year and 4 years of follow-up with 
SES, but no such case with bare metal stents (survival 
free from stent thrombosis at 3 years: 98·8% vs 99·4%, 
p=0·20).37 Similarly, a pooled analysis of TAXUS II, IV, V, 
and VI showed eight cases of late stent thrombosis 
between 9 months and 3 years with PES and only one 
case with bare metal stents (survival free from stent 
thrombosis at 3 years 98·7% vs 99·2%, p=0·36).22 
However, concerns have been raised as to whether these 
data are truly applicable to everyday clinical practice, 
because of the small number of patients, and the 
exclusion of acute coronary syndromes and complex 
lesions in randomised controlled trials. The complexity 
of the present population is refl ected in the high mortality 
rates. The cumulative incidence of all-cause mortality 
was 10·3% in the present study, which is higher than the 
mortality rates reported in previous studies. However, 
the results of the present study suggest that late stent 
thrombosis with drug-eluting stents occurs more 
frequently than expected19–22,36 and that rates increase 
steadily during long-term follow-up. The sustained 
occurrence over a long-term period might be explained 
in part by the delayed healing response after implantation 
of drug-eluting stents, as indicated by delayed re-
(Continued from previous page)
Lesion and procedural characteristics 
n* 98 63
Pre-procedure
Treated vessel
Left main coronary artery 0/98 (0%) 1/63 (2%) ..
Left anterior descending artery 53/98 (54%) 34/63 (54%) 0·989
Left circumfl ex artery 19/98 (19%) 6/63 (10%) 0·092
Right coronary artery 26/98 (27%) 21/63 (33%) 0·378
Saphenous vein graft 0 1 (2%) ..
ACC/AHA lesion class B2/C 81/89 (91%) 51/63 (81%) 0·089
Bifurcation lesions 34/95 (36%) 8/63 (13%) 0·002
Diameter stenosis (%) 81 (17) 82 (19) 0·740
Lesion length (mm) 20·11 (13·36) 20·30 (13·83) 0·940
MLD (mm) 0·49 (0·41) 0·55 (0·57) 0·465
MLD, excluded total occlusion (mm) 0·68 (0·33) 0·77 (0·53) 0·332
RVD (mm) 2·70 (0·53) 2·87 (0·43) 0·041
Periprocedure or postprocedure
Number of stents per lesion 1·59 (0·87) 1·63 (1·04) 0·746
Average stent diameter per lesion (mm) 2·95 (0·32) 2·94 (0·29) 0·902
Total stent length per lesion (mm) 32·39 (23·05) 31·08 (23·11) 0·729
Maximum balloon infl ation pressure (atm) 16·9 (3·7) 16·2 (3·7) 0·250
Periprocedural bolus heparin (units) 7·4 (3·5) 7·3 (2·9) 0·753
In-stent diameter stenosis (%) 14 (14) 10 (8) 0·046
In-stent MLD (mm) 2·39 (0·52) 2·58 (0·40) 0·024
In-segment diameter stenosis (%) 18 (12) 13 (10) 0·030
In-segment MLD (mm) 2·14 (0·51) 2·38 (0·45) 0·006
Ratio of SES to PES 0·8 (43:55) 0·8 (27:36) 0·899
Direct stenting 29/98 (30%) 17/63 (27%) 0·653
Stent overlap 41/98 (42%) 24/63 (38%) 0·392
Use of glycoprotein IIb/IIIa inhibitors 38/98 (39%) 19/63 (30%) 0·218
Data are mean (SD) or n/total with data available (%), unless otherwise specifi ed. MLD=minimum lumen diameter. 
PCI=percutaneous coronary intervention. RVD=reference vessel diameter. ACC/AHA=American College of Cardiology/
American Heart Association. *Multiple lesions in the same patient counted separately.
 Table 5: Clinical, procedural, and angiographic characteristics for patients with early and late stent 
thrombosis (ST)
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endothelialisation38 and hypersensitivity reactions to the 
antiproliferative drugs or, more probably, to the synthetic 
polymers.12,13
Stent thrombosis is a multifactorial occurrence that 
has been attributed to a range of angiographic, lesion-
related and vessel-related, technical and clinical factors.39 
Acute coronary syndrome, bifurcation treatment, diabetes 
and premature discontinuation of anti-platelet therapy 
were the strongest predictors of overall ST in several 
previous studies.19,26–28,40 The present study confi rms the 
predictive value of diabetes and acute coronary syndrome 
at presentation. 
Several clinical risk factors were predictive for 
development of early stent thrombosis. The increased risk 
in diabetic patients might be related to the more diff use 
and aggressive nature of atherosclerosis, accompanied by 
longer lesion lengths, smaller vessel size, and greater 
plaque burden, which might incur less optimal procedural 
results.41–44 Additionally, the detrimental eff ects of smoking 
on endothelial function45,46 and the long-term impairment 
of peri-stent vasoreactivity after drug-eluting stent 
implantation14,15 are well known. However, the fact that 
smoking was independently associated with lower rates of 
early stent thrombosis might be related to the high 
number of patients with acute coronary syndrome in the 
present population. Smokers are likely to stop smoking 
immediately after such an event, which might remove 
from their risk-factor profi le one of the major determinants 
of atherosclerosis.47,48 The fact that the use or 
implementation of an antihypertensive treatment at the 
time of percutaneous coronary intervention was suffi  cient 
to qualify patients as hypertensive might have resulted in 
the so-called protective predictive value of hypertension 
for early stent thrombosis and the trend towards a lower 
risk for late stent thrombosis. However, overall, late stent 
thrombosis seemed diffi  cult to predict and its cause 
remains largely unknown.  
 Although the cumulative incidence of overall and early 
stent thrombosis was similar for the two types of drug-
eluting stent, late stent thrombosis occurred more 
frequently in patients treated with PES than in those 
treated with SES during the 3-year observation period. 
Up to 90% of paclitaxel remains indefi nitely sequestered 
within the polymer, while 10% of the drug is released in a 
bimodal manner during a 2-week period. In contrast, 
sirolimus is completely released from the polymer and 
slowly elutes over a 90-day period. Whether the 
diff erences in drug-release kinetics,49 distribution within 
the vessel wall, mechanisms of action,50 or design of the 
stent platforms51 aff ect the incidence and time course of 
late stent thrombosis remains unclear. PES were 
implanted in more complex lesions in this study group, 
 Overall (n=152) SES (n=69) PES ( n=83) p 
Age (years) 60·3 (12·0) 61·3 (13·4) 59·5 (10·8) 0·37
Male sex 115/152 (76%) 46/69 (67%) 69/83 (83%) 0·02
Hypertension 63/152 (41%) 40/69 (58%) 23/83 (28%) <0·0001
Family history 44/152 (29%) 23/69 (33%) 21/83 (25%) 0·29
Current smoking 57/152 (38%) 27/69 (39%) 30/83 (36%) 0·74
Dyslipidaemia 74/152 (49%) 33/69 (48%) 41/83 (49%) 0·87
Diabetes 29/152 (19%) 16/69 (23%) 13/83 (16%) 0·30
Renal insuffi  ciency 9/143 (6%) 6/68 (9%) 3/84 (4%) 0·30
Left ventricular ejection fraction (%) 52 (12) 53 (12) 51 (13) 0·61
Acute coronary syndrome at presentation 67/95 (71%) 24/35 (69%) 43/60 (72%) 0·82
Multivessel disease 88/149 (59%) 42/65 (65%) 45/83 (54%) 0·24
Bifurcation treatment 27/96 (28%) 9/36 (25%) 18/60 (30%) 0·65
Timing of early ST (days)
Mean (SD) 5·5 (6·5) 5·9 (6·3) 5·1 (6·4) 0·58
Median (IQR) 4·0 (1–6) 4·0 (2–8) 4·0 (1–5)
Timing of late ST (days)
Mean (SD) 459·4 (274·7) 564·8 (310·1) 375·7 (212·5) 0·007
Median (IQR) 442·0 (235–652) 585 (381–801) 343·5 (214–509)
Recommended duration of clopidogrel (months)
Mean (SD) 7·9 (3·5) 8·1 (4·1) 7·9 (3·1) 0·84
Median (IQR) 6·0 (6·0–12·0) 6·5 (3·8–12·0) 6·0 (6·0–12·0)
Number of stents per patient 2·35 (1·73) 2·20 (1·64) 2·47 (1·80) 0·35
Average stent diameter per patient (mm) 2·83 (0·35) 2·75 (0·28) 2·89 (0·39) 0·051
Total stent length per patient (mm) 42·3 (34·0) 38·5 (28·0) 45·5 (38·2) 0·22
Data are mean (SD) or n/total with data available (%), unless otherwise specifi ed.
Table 6: Clinical, procedural, and angiographic characteristics of patients with stent thrombosis (ST) overall and by type of stent
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whereas SES had been used from an earlier time than 
had PES, and subsequently the length of follow-up 
diff ered between the two devices. Only randomised 
clinical trials will be able to fairly address potential 
diff erences in safety between the two stent types.
In this study, 30 of 31 patients who had late stent 
thrombosis while on single antiplatelet therapy received 
lifelong aspirin. Although absence of clopidogrel was not 
associated with a higher risk of stent thrombosis, 80% of 
patients with late stent thrombosis developed the problem 
after completion of the recommended duration of 
clopidogrel treatment. The question of whether extended 
or indefi nite adjunctive clopidogrel treatment, if well 
tolerated, might be considered for patients who undergo 
drug-eluting stent implantation remains open. The eff ect 
of antiplatelet treatment on the pathophysiology of stent 
thrombosis is well established. Platelet aggregation 
studies have shown that an impaired response to 
antiplatelet treatment52 and high post-treatment platelet 
reactivity53 are associated with stent thrombosis. 
Furthermore, late stent thrombosis after cessation of 
clopidogrel has been reported in several studies.23,25–27,35 In 
particular, the withdrawal of antiplatelet treatment in 
patients undergoing non-cardiac procedures seems 
problematic, because perioperative stress enhances 
platelet aggregation and thus the risk of thrombotic stent 
occlusion.23,54 In this study, seven patients (one early; six 
late) discontinued both aspirin and clopidogrel before 
elective dental work or non-cardiac surgery. However, 
further evidence of the limited ability of clopidogrel to 
prevent all stent thrombosis is provided in our study, in 
which 13 of 61 of patients had late stent thrombosis 
despite dual antiplatelet therapy with aspirin and 
clopidogrel. Despite the longer duration of clopidogrel 
prescription (12 months) in the patients from Bern 
compared with those in Rotterdam (6 months), the 
incidence of both early and late stent thrombosis was 
similar in both centres. Additionally, the increased risk of 
bleeding complications and the economic burden 
imposed by long-term clopidogrel administration must 
be carefully weighed in light of these fi ndings. 
Eff ective antiplatelet treatment has a key role in the 
prevention of stent thrombosis and randomised controlled 
trials should be appropriately designed to prospectively 
address the following questions: which drugs are essential 
and for how long, what is the role of platelet function tests 
in patients undergoing drug-eluting stent implantation, 
and what are the therapeutic consequences? 
Our study has several limitations. First, this was a non-
randomised cohort study, with the decision about stent 
type and antiplatelet therapy largely determined by local 
institutional practice. The main purpose of the present 
study was to investigate the incidence and time course of 
stent thrombosis in unselected patients treated with drug-
eluting stents. A comparison with stent thrombosis after 
bare metal stent implantation was beyond the scope of the 
present manuscript. The study was observational in nature 
and has the same disadvantages as any other observational 
study, including confounding by indication.55 SES and PES 
have been used in both centres at diff erent times, and PES 
were available for commercial use 1 year later than were 
SES. This diff erence in follow up might have biased our 
results. Nevertheless, results from comparisons of these 
two stent types should be viewed as hypothesis-generating 
and have to be confi rmed in long-term follow-up of 
randomised controlled trials directly comparing these 
devices. Longer-term follow-up of the group of patients we 
studied will be needed to better understand the time course 
and incidence of this overall rare problem. 
Second, our data provide an estimate of the incidence 
of stent thrombosis after drug-eluting stent implantation 
during routine clinical practice at two tertiary care 
centres. In this study we recorded a high number of 
stents per patient, small average stent diameter, and 
overall long total stent length, so our fi ndings might not 
apply to institutions with more restricted use of drug-
eluting stents. Nevertheless, previous randomised trials 
certainly underestimated the true incidence of stent 
thrombosis because of their less complex population of 
patients. Some stent thrombosis might have been 
undetected in our study despite our attempts at an active 
surveillance of harms.56 
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Additionally, we only reported angiographically 
documented cases, using a defi nition consistent with our 
previous reports on stent thrombosis after drug-eluting 
or bare metal stent implantation.16,17,19–22,36 This practice 
might have led to an underestimation of the actual 
incidence of stent thrombosis—for example, if patients 
had sudden cardiac death or silent stent occlusion. 
Because of resource limitations it was impossible to 
ascertain retrospectively characteristics of patients and 
procedures that were not prospectively collected as part of 
routine procedures. Therefore, some variables were 
unavailable. In particular, the actual use of clopidogrel at 
each time point was not available for a substantial 
proportion of patients and therefore was not used in the 
fi nal analysis. By contrast, the duration of clopidogrel 
prescription was available for all patients in Rotterdam 
and was included in the fi nal Cox regression models. The 
value of clopidogrel in preventing stent thrombosis needs 
to be established in suffi  ciently powered dedicated trials. 
Intravascular ultrasound examination was not routinely 
done and the underlying mechanism contributing to the 
occurrence of stent thrombosis was not specifi cally 
investigated.
In conclusion, our data suggest that late stent 
thrombosis occurs at a steady rate during follow-up up 
to 3 years, tends to be more frequent with PES than 
with SES, and can unpredictably occur at any time point 
despite antiplatelet therapy. Late stent thrombosis 
complicating the use of drug-eluting seems to be a 
distinct entity with pathophysiological factors that diff er 
from those of early stent thrombosis.
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Incidence and Correlates of Drug-Eluting
Stent Thrombosis in Routine Clinical Practice
4-Year Results From a Large 2-Institutional Cohort Study
Peter Wenaweser, MD,* Joost Daemen, MD,‡ Marcel Zwahlen, PHD,† Ron van Domburg, PHD,‡
Peter Jüni, MD,† Sophia Vaina, MD, PHD,‡ Gerrit Hellige, MD,* Keiichi Tsuchida, MD,‡
Cyrill Morger, MD,* Eric Boersma, PHD,‡ Neville Kukreja, MBBS, MRCP,‡ Bernhard Meier, MD,*
Patrick W. Serruys, MD, PHD,‡ Stephan Windecker, MD*
Bern, Switzerland; and Rotterdam, the Netherlands
Objectives We sought to determine the risk of late stent thrombosis (ST) during long-term follow-up beyond 3 years,
searched for predictors, and assessed the impact of ST on overall mortality.
Background Late ST was reported to occur at an annual rate of 0.6% up to 3 years after drug-eluting stent (DES) implantation.
Methods A total of 8,146 patients underwent percutaneous coronary intervention with a sirolimus-eluting stent (SES)
(n  3,823) or paclitaxel-eluting stent (PES) (n  4,323) and were followed up to 4 years after stent implanta-
tion. Dual antiplatelet treatment was prescribed for 6 to 12 months.
Results Definite ST occurred in 192 of 8,146 patients with an incidence density of 1.0/100 patient-years and a cumula-
tive incidence of 3.3% at 4 years. The hazard of ST continued at a steady rate of 0.53% (95% confidence
interval [CI]: 0.44 to 0.64) between 30 days and 4 years. Diabetes was an independent predictor of early ST
(hazard ratio [HR]: 1.96; 95% CI: 1.18 to 3.28), and acute coronary syndrome (HR: 2.21; 95% CI: 1.39 to
3.51), younger age (HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR: 1.67; 95% CI: 1.08 to 2.56) were
independent predictors of late ST. Rates of death and myocardial infarction at 4 years were 10.6% and
4.6%, respectively.
Conclusions Late ST occurs steadily at an annual rate of 0.4% to 0.6% for up to 4 years. Diabetes is an independent predic-
tor of early ST, whereas acute coronary syndrome, younger age, and PES implantation are associated with late
ST. (J Am Coll Cardiol 2008;52:1134–40) © 2008 by the American College of Cardiology Foundation
Drug-eluting stents (DES) reduce angiographic restenosis
and the clinical need for repeat revascularization procedures
(1,2). Recent systematic reviews and large-scale registries
observed similar rates of death and myocardial infarction
(MI) for patients treated with either a DES or bare-metal
stent (BMS) during long-term 4-year follow-up (3–5).
However, very late stent thrombosis (ST) has emerged as a
distinct entity overshadowing the use of DES, and concerns
persist as to whether this phenomenon might jeopardize the
long-term outcome after DES implantation, particularly
after discontinuation of dual antiplatelet therapy (6–11).
Drug-eluting stents delay healing and impair endotheli-
alization as evidenced in necropsy studies and clinical
investigations (12,13). Vessel remodeling (14) in concert
with local drug release enhancing endothelial tissue factor
expression (15,16) after DES implantation might result in a
prothrombotic milieu predisposing to late ST. Previously,
we reported on the frequency and timing of ST after the
unrestricted use of DES implantation in a cohort of 8,146
consecutive patients treated at 2 academic institutions (10).
Late and very late ST was encountered steadily at an annual
rate of 0.6% with no evidence of diminution up to 3 years of
follow-up. During extension of the follow-up period to 4
years in the current study, we investigated whether the risk
of very late ST would change beyond 3 years, identified
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correlates of early as opposed to late ST, and assessed the
impact of ST-related mortality after DES implantation on
overall mortality in the entire cohort.
Methods
Study cohort, design, and follow-up. Between April
16, 2002, and December 31, 2005, a total of 8,146
consecutive patients underwent percutaneous coronary
intervention with the 2 Food and Drug Administration–
approved DES at 2 academic referral hospitals in Swit-
zerland and the Netherlands, comprising 3,823 patients
treated with sirolimus-eluting stents (SES) (Cypher,
Cordis Corp., Johnson & Johnson, Warren, New Jersey)
and 4,323 patients treated with paclitaxel-eluting stents
(PES) (TAXUS Express2 or Liberté, Boston Scientific,
Natick, Massachusetts). The use of the respective stent
platforms at the 2 institutions has been reported previ-
ously (10). For the present extended 4-year follow-up,
patients were again contacted 1 year after the last contact
with specific questions addressing repeat hospital stay
and major adverse cardiac events (MACE) with a health
questionnaire. Patients who did not return the question-
naire were contacted by phone, at which time the
questionnaire was completed. Moreover, survival data
were obtained from municipal civil registries. If neces-
sary, medical records and discharge summaries from
other institutions were systematically reviewed and pri-
mary care physicians were contacted for additional or
missing information. The median follow-up was 2.53
years/patient, and a complete clinical follow-up was
achieved in 96.4% (n  7,857). The common database
was held and analyzed at the Institute of Social and
Preventive Medicine, University of Bern, Bern, Switzer-
land. There was no industry involvement in the design,
conduct, or analysis of the study.
This study was approved by the local ethics committee in
both hospitals and is in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all
patients.
Definitions. Definite ST was defined as follows:
1. Presence of Thrombolysis In Myocardial Infarction
(TIMI) flow:
a. Grade 0 with occlusion originating in the peri-stent
region
b. Grade 1, 2, or 3 in the presence of a thrombus
originating in the peri-stent region. Angiographic
evidence of thrombus was defined as a discrete,
intraluminal filling defect with defined borders and
separated from the vessel wall.
And at least 1 of the following criteria had to be met:
1. Acute ischemic symptoms (typical chest pain with dura-
tion 20 min)
2. Ischemic electrocardiographic changes
a. ST-segment elevation in territory of implanted stent
b. ST-segment depression or
T-wave inversion in terri-
tory of implanted stent
3. Typical rise and fall in cardiac
biomarkers (17).
All cases of definite ST were
reviewed independently by 2
experienced interventional cardi-
ologists, and in case of disagree-
ment, a consensus was estab-
lished between the 2 reviewers or
a third interventional cardiologist
was consulted. Moreover, ST
was categorized into early (within
30 days), late (30 days and365
days), and very late (365 days)
depending on the timing of oc-
currence of the event. For the
definition of probable ST, the
Academic Research Consor-
tium (ARC) criteria were ap-
plied (18).
The diagnosis of MI was based on the presence of new
Q waves in at least 2 contiguous leads with an elevated
creatine kinase-myocardial band fraction. In the absence
of pathologic Q waves, the diagnosis of MI was based on
an elevation in creatine kinase to more than twice the
upper limit of normal with an elevated creatine kinase-
myocardial band fraction of more than 3 times the upper
limit of normal. Premature discontinuation of antiplatelet
therapy was referred to as cessation of acetylsalicylic acid
(ASA) or clopidogrel or both before the recommended
duration of prescription. A creatinine value 150 mol
or chronic hemodialysis qualified as definition of renal
impairment.
Interventional procedure and antiplatelet prescription.
All interventions were performed according to current
practice guidelines for percutaneous coronary intervention.
The decision to choose a specific treatment strategy was left
to the discretion of the operator. Patients were prescribed
ASA 100 mg once daily plus clopidogrel 75 mg/day (after a
loading dose of 300 or 600 mg) before or during baseline
coronary interventions. After the procedure, all patients
were advised to maintain ASA 100 mg once daily lifelong.
In the Swiss institution, 12 months of clopidogrel therapy
was prescribed irrespective of the stent type used. In the
Dutch institution, PES-treated patients received at least 6
months of clopidogrel (75 mg/day), whereas patients treated
with SES were prescribed clopidogrel for at least 3 months,
unless 1 of the following was present (in which case
clopidogrel was maintained for at least 6 months): 3
SES implantations, total stent length36 mm, chronic total
occlusion, and bifurcations. In a minority of patients under oral
anticoagulation therapy, a shorter duration of clopidogrel (e.g.,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ARC  Academic Research
Consortium
ASA  acetylsalicylic acid
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarction
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3-month triple therapy with ASA, clopidogrel, and warfarin)
was recommended.
Statistical analysis. Continuous variables are expressed as
mean  SD or median values with the corresponding
interquartile range. Dichotomous variables are expressed as
counts and percentages. For comparison of continuous
variables between SES and PES as well as early and late
thrombosis, a Student t test for continuous variables was
used.
The incidence of ST was calculated in 2 different ways:
1) incidence density, defined as the number of patients
with ST divided by the total number of patient-years
under observation (expressed as a number of events/100
patient-years); and 2) cumulative incidence, estimated
according to the Kaplan-Meier method and the log-rank
test for the differences in survival curve. Univariable and
multivariable Cox proportional hazards models were used
to assess predictors of ST, with the following variables:
age, gender, family history of cardiovascular disease,
diabetes, hypertension, current smoking, dyslipidemia,
renal impairment, left ventricular ejection fraction, acute
coronary syndrome (ACS) at presentation, stent type,
number of stents, total stent length, average stent diam-
eter, bifurcation treatment, and prescribed duration of
clopidogrel. Statistical analyses were performed with
Stata version 9 for Windows (Stata Corp., College
Station, Texas). All p values were 2-sided and values
0.05 were considered statistically significant.
Results
Baseline clinical and procedural characteristics of patients
with and without ST are summarized in Table 1. Compared
with patients without ST, those suffering from definite ST
were younger (59.4  12.1 years vs. 62.9  11.5 years, p 
0.001), had a lower left ventricular ejection fraction (52 
12% vs. 55  12%, p  0.035) and more often an ACS
(67.7% vs. 54.9%, p  0.001) at the time of stent implan-
tation, and had received longer (total stent length: 44.0 
38.8 mm vs. 36.1  25.5 mm, p  0.001) and more stents
(number of stents: 2.33  1.71 vs. 1.95  1.21, p  0.001),
which were smaller in diameter (2.88 0.32 mm vs. 2.94
0.38 mm, p  0.048). The status of antiplatelet therapy as
recorded during early and late and very late ST is summa-
rized in Figure 1.
Incidence and time course of ST. During a follow-up
period of 4 years, definite ST was encountered in 192 of
8,146 patients after a median of 56 (interquartile range 4 to
593) days (Fig. 2). Early ST was observed in 92 (48%), late
ST in 31 (16%), and very late ST in 69 (36%) of 192
patients. Definite ST occurred with an incidence density of
1.0/100 patient-years and a cumulative incidence of 3.3% at
4 years of follow-up. The hazard of late ST (between 30
days and 1 year) amounted to 0.46% (95% confidence
interval [CI]: 0.32% to 0.65%), the hazard of very late ST
(between 1 and 4 years) to 0.57% (95% CI: 0.45% to
Figure 1 Status of Antiplatelet Treatment
at Time of Definite Stent Thrombosis
Proportion of patients with early and late stent
thrombosis treated with dual, single, or no antiplatelet therapy.
Clinical and Procedural Characteristics of Patients With and Without Definite ST
Table 1 Clinical and Procedural Characteristics of Patients With and Without Definite ST
Overall Population (n  8,146) ST (n  192) No ST (n  7,954) p Value
Age (yrs), mean SD 62.8 11.5 59.4 12.1 62.9 11.5 0.001
Male gender, % 74.5 75.0 74.5 0.88
Hypertension, % 46.5 42.2 46.6 0.23
Current smoking, % 36.8 41.7 36.7 0.16
Family history of CAD, % 28.1 29.2 28.1 0.75
Dyslipidemia, % 50.9 50.0 50.9 0.81
Diabetes, % 16.3 20.8 16.2 0.09
Left ventricular ejection fraction (%), mean  SD 55 12 52 12 55 12 0.035
Renal impairment, % 4.1 2.6 4.2 0.48
ACS at presentation, % 55.2 67.7 54.9 0.001
Bifurcation treatment, % 11.8 17.9 11.6 0.06
Sirolimus-eluting stent, % 47.9 43.2 48.0 0.19
Total stent length/patient (mm), mean  SD 36.3 25.9 44.0 38.8 36.1 25.5 0.001
Number of stents/patient, mean  SD 1.96 1.23 2.33 1.71 1.95 1.21 0.001
Average stent diameter/patient (mm), mean  SD 2.94 0.38 2.88 0.32 2.94 0.38 0.048
ACS  acute coronary syndrome; CAD  coronary artery disease; ST  stent thrombosis.
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0.72%), and the hazard of the combined rate for late and
very late ST (between 30 days and 4 years) was 0.53% (95%
CI: 0.44% to 0.64%)/year. The rate of definite and probable
ST after 4 years amounted to 5.7% (95% CI: 5.15% to
6.39%) with an incidence of 3.68% (95% CI: 3.29% to
4.12%) after 30 days and 4.09% (95% CI: 3.67% to 4.55%)
after 1 year (Fig. 2).
Baseline demographic data for SES- and PES-treated
patients differed widely (Table 2). The cumulative incidence
of ST up to 3.5 years amounted to 2.7% for SES-treated
and 3.6% for PES-treated patients (HR: 0.7; 95% CI: 0.53
to 0.95, p  0.02) (Fig. 3A). Whereas early ST occurred
with similar frequency in SES- (1.0%) and PES-treated
Figure 2 Cumulative Incidence of Definite ST in
8,146 Patients During a 4-Year Follow-Up Period
PCI  percutaneous coronary intervention; ST  stent thrombosis.
Figure 3 Cumulative Incidence of Definite ST Stratification
(A) Cumulative incidence of definite stent thrombosis (ST) stratified by stent
type. (B) Cumulative incidence of definite ST stratified by stent type and treat-
ment site. PCI  percutaneous coronary intervention; PES  paclitaxel-eluting
stent(s); SES  sirolimus-eluting stent(s).
Clinical and Procedural Characteristics of Patients Stratified by Stent Type
Table 2 Clinical and Procedural Characteristics of Patients Stratified by Stent Type
SES (n  3,823) PES (n  4,323) p Value
Age (yrs), mean  SD 62.6 11.4 63.0 11.5 0.31
Male gender, % 74.9 74.2 0.51
Hypertension, % 41.9 51.6 0.0001
Current smoking, % 44.9 29.5 0.0001
Family history of CAD, % 29.0 27.3 0.09
Dyslipidemia, % 55.8 47.3 0.0001
Diabetes, % 18.3 14.6 0.0001
Left ventricular ejection fraction (%), mean SD 54 12 55 12 0.01
Renal impairment, % 4.3 3.9 0.58
ACS at presentation, % 52.1 58.0 0.0001
Bifurcation treatment, % 10.3 12.3 0.09
Total stent length/patient (mm), mean  SD 33.8 23.0 38.6 28.1 0.0001
Number of stents/patient, mean  SD 1.87 1.14 2.03 1.30 0.0001
Average stent diameter/patient (mm), mean  SD 2.86 0.32 3.00 0.40 0.0001
Duration of clopidogrel prescription (days), mean  SD 144 120 194 80 0.0001
PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); other abbreviations as in Table 1.
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(1.3%) patients (HR: 0.76; 95% CI: 0.50 to 1.15, p 0.19),
late and very late ST occurred with an annual rate of 0.44%
(95% CI: 0.33% to 0.59%) after SES and 0.63% (95% CI:
0.49% to 0.83%) after PES implantation (HR: 0.66; 95%
CI: 0.44 to 0.99, p  0.047). A stratified analysis according
to treatment site revealed a similar frequency and time
course of definite ST after SES (Bern: 2.9% vs. Rotterdam:
2.4%, p  0.49) and PES (Bern: 3.1% vs. Rotterdam: 3.9%,
p  0.83) implantation at both institutions (Fig. 3B).
Predictors of ST. The results of multivariate analyses to
identify overall, early, and late definite ST are summarized
in Table 3. Acute coronary syndrome at the time of stent
implantation (HR: 1.81; 95% CI: 1.32 to 2.49), diabetes
(HR: 1.61; 95% CI: 1.11 to 2.33), younger age (HR: 0.98;
95% CI: 0.96 to 0.99), and use of PES (HR: 1.51; 95% CI:
1.10 to 2.04) were independent predictors of overall ST.
Diabetes (HR: 1.96; 95% CI: 1.18 to 3.28) was the only
predictor of early ST, whereas ACS at time of stent
implantation (HR: 2.21; 95% CI: 1.39 to 3.51), younger age
(HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR:
1.67; 95% CI: 1.08 to 2.56) were independently associated
with an increased risk of late ST.
Long-term clinical outcome. Mortality after definite ST
amounted to 15.6% at 2 years and tended to be higher in
patients suffering from early (20.3%) as opposed to late and
very late ST (10.4%) (Fig. 4). At 4 years of follow-up, rates
of death, MI, and the composite of death or MI were
10.6%, 4.6%, and 14.6%, respectively, in the overall popula-
tion (Fig. 5). During the entire observation period of 4 years,
27 patients suffering from definite ST subsequently died.
Death after the diagnosis of definite ST occurred in 0.4% of
the entire population and accounted for 3.9% of all 702 deaths.
Discussion
The results of the present study indicate a continuous hazard of
late and very late ST at an annual rate of 0.4% to 0.6%
extending to 4 years after DES implantation. The only
independent predictor of early ST was diabetes, whereas ACS,
younger age, and use of PES were independently associated
with an increased risk of late ST. Mortality due to definite ST
accounted for only a small fraction of overall mortality.
Autopsy studies and clinical investigations using angios-
copy and assessment of endothelial function indicate that DES
delay healing and impair endothelialization (12,13,
19–22). Intravascular ultrasound studies demonstrate a higher
incidence of stent malapposition and evidence of vessel remod-
eling after DES implantation in patients with very late ST
(14). Furthermore, drugs released from the drug-polymer
combination might be thrombogenic on their own, because
both sirolimus and paclitaxel enhance endothelial tissue factor
expression, the principal activator of the coagulation cascade
that activates factors IX and X (15,16). Therefore, it has been
suggested that DES might create a prothrombotic milieu
predisposing to thrombotic stent occlusion.
Previously, we reported the phenomenon of late ST after
DES implantation occurring continuously without diminu-
Figure 4 Cumulative Incidence of Death in Patients With
Definite ST Stratified According to Early and Late ST
ST  stent thrombosis.
Figure 5 Cumulative Incidence of Ischemic Adverse Events
in 8,146 Patients During 4 Years of Follow-Up
MI  myocardial infarction; PCI  percutaneous
coronary intervention; ST  stent thrombosis.
Hazard Ratio and 95% CI for Risk FactorsAssociated With Definite ST During the EntireFoll w-Up Per od From Multivariable C x Regression
Table 3
Hazard Ratio and 95% CI for Risk Factors
Associated With Definite ST During the Entire
Follow-Up Period From Multivariable Cox Regression
Variables Hazard Ratio 95% CI
ACS at presentation 1.8 1.3–2.5
Diabetes 1.6 1.1–2.3
Number of stents/patient 1.2 0.95–1.4
Current smoking 1.1 0.78–1.5
Family history of CAD 1.0 0.73–1.4
Total stented length/patient 1.0 1.00–1.01
Age 0.98 0.96–0.99
Dyslipidemia 0.95 0.70–1.28
Female 0.89 0.63–1.25
Hypertension 0.85 0.62–1.16
Use of PES 1.67 1.08–2.56
CI  confidence interval; other abbreviations as in Tables 1 and 2.
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tion up to 3 years of follow-up in a large cohort of
consecutive patients treated with the unrestricted use of
DES (10). The present study extends these findings to a
longer-term follow-up and shows that the steady annual rate
of 0.4% to 0.6% remains unchanged between 3 and 4 years
of follow-up. A continuous linear hazard of late ST com-
parable to the present study has been corroborated more
recently in the extended follow-up of 21,717 DES-treated
patients included in the SCAAR (Swedish Coronary An-
giography and Angioplasty Registry) with an annual rate of
ST of 0.5% during a follow-up of 2 years (23,24). Moreover,
several systematic reviews reported a significantly higher
rate of very late ST in disfavor of both SES and PES
compared with BMS, although the overall rate of ST was
not different between the different stent types (3,4,25).
Accordingly, very late ST is a distinct entity complicating
the use of DES, and arterial healing remains incomplete up
to 4 years after DES implantation in humans.
Although late and very late ST complicated the clinical
course of both DES types, it was more frequent with PES
than SES, and use of PES emerged as independent of late
ST. Of note, PES was implanted in more complex lesions in
this cohort, whereas SES had been used earlier than PES,
and subsequently the length of follow-up was different
between the 2 devices, which might have biased the results
in disfavor of PES. Yet, Bavry et al. (7) made a similar
observation and found the risk of very late ST more
pronounced with PES (5.9 of 1,000 patient-years) than SES
(3.6 of 1,000 patient-years) in a meta-analysis of 14 trials
with 6,675 patients. A meta-analysis directly comparing
SES (4,391 patients) with PES (4,304 patients) also re-
ported a higher risk of protocol-defined ST with PES
(1.9%) than SES (1.2%; HR: 0.66, 95% CI: 0.46 to 0.94,
p  0.02) (26). Finally, a network meta-analysis of 38 trials
comparing BMS, SES, and PES reported an increased risk
of late ST with PES compared with BMS (HR: 2.11; 95%
credibility interval: 1.2 to 4.2, p  0.02), whereas the risk
was less pronounced with SES (HR 1.1; 95% credibility
interval: 0.6 to 2.3, p  0.71) (5). It can only be speculated
whether the different drug-release kinetics, distribution
within the vessel wall, mechanisms of action, inhomogene-
ity of strut coverage, or design of the stent platforms impact
on the incidence and time course of late ST.
Previous studies identified clinical characteristics such as
premature discontinuation of antiplatelet therapy (27–29),
ACS (10,30), diabetes (10,27,30), and renal failure (27,28)
as independent risk factors of DES-associated ST. In
addition, lesion characteristics including smaller reference
vessel diameter, stent length (29), thrombus burden (31),
and bifurcation lesions (27,28) were identified as predictive
of ST. The present study not only confirms the hazard
related to diabetes and ACS in the largest cohort of patients
with definite ST to date but also identifies diabetes as a
predictor of early ST and ACS as a predictor of late ST. The
reasons for a predisposition of diabetic patients to early ST
might be related to smaller vessel size (32), longer lesion
length, a higher rate of residual dissections, and an increased
platelet aggregation (11,33). Conversely, patients with ACS
might be predisposed to late and very late ST due to a higher
thrombus burden at the time of stent implantation (31), which
upon dissolution might result in late acquired stent malappo-
sition and altered flow dynamics around stent struts (14).
The contribution of definite ST to overall mortality was
small in the present study (5%). A similar observation has
been made in a pooled analysis of pivotal trials comparing
DES with BMS (25), where mortality due to ST accounted
for 10% of overall mortality. It might be speculated that
the overall outcome regarding death or MI of patients
treated by percutaneous coronary interventions might be
determined in large part by causes other than target lesion
revascularization or ST. Along this line, a pooled analysis of
4 randomized trials comparing SES with BMS in 1,748
patients found that the majority of death or MI in both
stent groups was unrelated to either target lesion revascu-
larization or ST, suggesting another etiology, such as disease
progression (34). However, it is important to note that the
definition of definite ST requiring angiographic or autopsy
confirmation of thrombotic stent occlusion leads to a
considerable underestimation of the true incidence of ST-
related mortality. Because only those patients reaching the
catheterization laboratory alive qualify for the diagnosis of
definite ST, all deaths before angiographic or autopsy
confirmation are missed and not classified as “definite
ST”–related. In other words, the presented data only reflect
the mortality toll of definite ST after initial survival.
Study limitations. The findings of this study have to be
interpreted in light of several limitations. First, the study
was nonrandomized, with the decision regarding stent type
and antiplatelet therapy largely determined by local institu-
tional practice. The principal purpose was to investigate the
incidence and time course of definite ST in unselected
patients treated with DES during long-term follow-up
rather than a comparison of ST as encountered after BMS
implantation. This is an observational study, which suffers
from confounding by indication. The SES and PES were
used in both centers during different time periods, and PES
was available for commercial use 1 year later than SES. This
might have resulted in bias due to differences in follow-up.
Due to the continuous enrollment of patients into this
registry between 2002 and 2005, not all patients had
completed the 4-year follow-up. Accordingly, estimates of
the risk of ST are less precise during later time points, and
the data should be carefully interpreted by considering the
corresponding CIs. Second, the data were obtained from a
patient population at 2 tertiary care centers with a high
number of stents/patient, a small average stent diameter,
and an overall long total stent length, which might not apply
to institutions with a more restricted DES use. Third, it is
possible that some ST went undetected in our study despite
our attempts at an active surveillance of harms. In addition,
the focus of the present study was on definite ST, which
might have led to an underestimation of the actual incidence
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of ST as well as mortality related to definite ST. The latter
requires angiographic or autopsy confirmation of throm-
botic stent occlusion and therefore ignores any death with-
out these prerequisites. However, the definition is in line
with previous reports from our group on ST either after
DES or BMS implantation and allows for appropriate
comparisons. Moreover, the composite of definite and
probable ST, suggested as a useful parameter to avoid
underestimation and overestimation of ST, is provided in
the present study as are the ischemic end points of death
and MI. Finally, only the prescribed duration of anti-
platelet therapy was available in the present study,
whereas the exact duration of dual antiplatelet therapy
could not reliably be ascertained in the whole patient
population. Therefore, it cannot be excluded that we
missed an important relation between the actual duration
of thienopyridine therapy and ST.
Conclusions
Late ST is a distinct entity complicating the use of DES and
occurs steadily at an annual rate of 0.4% to 0.6% for up to
4 years of follow-up. Diabetes is an independent predictor
of early ST, whereas ACS, younger age, and use of PES are
associated with late ST.
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Angiographic Stent Thrombosis After
Routine Use of Drug-Eluting Stents in
ST-Segment Elevation Myocardial Infarction
The Importance of Thrombus Burden
Georgios Sianos, MD, PHD, Michail I. Papafaklis, MD, Joost Daemen, MD, Sofia Vaina, MD,
Carlos A. van Mieghem, MD, Ron T. van Domburg, PHD, Lampros K. Michalis, MD, MRCP,
Patrick W. Serruys, MD, PHD, FACC
Rotterdam, the Netherlands
Objectives This study sought to investigate the impact of thrombus burden on the clinical outcome and angiographic
infarct-related artery stent thrombosis (IRA-ST) in patients routinely treated with drug-eluting stent (DES) implan-
tation for ST-segment elevation myocardial infarction (STEMI).
Background There are limited data for the safety and effectiveness of DES in STEMI.
Methods We retrospectively analyzed 812 consecutive patients treated with DES implantation for STEMI. Intracoronary
thrombus burden was angiographically estimated and categorized as large thrombus burden (LTB), defined as
thrombus burden 2 vessel diameters, and small thrombus burden (STB) to predict clinical outcomes. Major
adverse cardiac events (MACE) were defined as death, repeat myocardial infarction, and IRA reintervention.
Results Mean duration of follow-up was 18.2  7.8 months. Large thrombus burden was an independent predictor of
mortality (hazard ratio [HR] 1.76, p  0.023) and MACE (HR 1.88, p  0.001). The cumulative angiographic
IRA-ST was 1.1% at 30 days and 3.2% at 2 years, and continued to augment beyond 2 years. It was significantly
higher in the LTB compared with the STB group (8.2% vs. 1.3% at 2 years, respectively, p  0.001). Significant
independent predictors for IRA-ST were LTB (HR 8.73, p  0.001), stent thrombosis at presentation (HR 6.24, p
 0.001), bifurcation stenting (HR 4.06, p  0.002), age (HR 0.55, p  0.003), and rheolytic thrombectomy (HR
0.11, p  0.03).
Conclusions Large thrombus burden is an independent predictor of MACE and IRA-ST in patients treated with DES for
STEMI. (J Am Coll Cardiol 2007;50:573–83) © 2007 by the American College of Cardiology Foundation
Journal Club 
Selection
www.jaccjc.org
Primary percutaneous coronary intervention
(PCI) with bare metal stent (BMS) implanta-
tion is established as the treatment of choice for
ST-segment elevation myocardial infarction
(STEMI) (1,2). There are limited data regard-
ing the use of drug-eluting stents (DES) in a
STEMI setting. Initial small registries showed superiority
of sirolimus-eluting stents (SES) compared with BMS up to
1 year of follow-up (3–8). Two randomized trials confirmed
these results (9,10). The findings regarding paclitaxel-
eluting stents (PES) are less clear with positive small
single-center reports (11,12), but a negative randomized
trial (13). There are no data on the routine use of DES for
STEMI with midterm outcomes.
The etiology of stent thrombosis is multifactorial,
involving stent thrombogenicity and procedure-, lesion-,
and patient-related factors (14). Acute coronary syn-
dromes have been recognized as a factor of increased rates
of stent thrombosis both for BMS (15–17) and DES
(18–20). Limited data exist regarding the incidence
and predictors of DES thrombosis during STEMI
(9,10,13,18).
In patients with acute coronary syndromes, angiographic
presence of thrombus increases the incidence of in-hospital
major adverse cardiac events (MACE) (21,22). Mechanical
treatment of thrombotic lesions, by means of thrombectomy
and distal protection devices, has been proposed to prevent the
complications caused by thrombus and improve clinical out-
comes, but randomized trials failed to show any beneficial
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effect of routine use in “all comers”
on myocardial reperfusion or clin-
ical outcome during STEMI
(23,24). There is no angiographic
thrombus classification validated
to predict clinical outcomes.
In a large unselected cohort of
consecutive patients with STEMI
treated with PCI and DES, we
propose a simple angiographic
thrombus classification, and we re-
port the 2-year clinical outcome
and incidence and predictors of
infarct-related artery stent throm-
bosis (IRA-ST).
Patients and Methods
Patients and procedure. From
April 2002, when DES were in-
troduced, until December 2004,
900 consecutive patients pre-
sented with STEMI and under-
went PCI (primary or rescue)
within 12 h after the onset of
chest pain; 37 (4.1%) were
treated with balloon angioplasty,
51 (5.7%) with BMS, and 812
(90.2%) with DES. The BMS
were implanted because of un-
availability of all DES sizes
(length or diameter) in the ini-
tial period of their approval.
This analysis focuses on patients treated exclusively with
DES. All patients were pretreated with 250 mg aspirin
and 300 mg clopidogrel. Preprocedural intracoronary
nitrates were systematically administered. A PCI was
performed according to standard clinical practice. The
use of rheolytic thrombectomy (RT) (Possis Medical,
Inc., Minneapolis, Minnesota), the only thrombectomy
or aspiration system used, and periprocedural pharmaco-
logical treatment (e.g., glycoprotein IIb/IIIa antagonists)
were at the operator’s discretion. All patients received
dual antiplatelet therapy: aspirin 325 mg/day indefinitely
and clopidogrel 75 mg/day for 3 and 6 months after SES
and PES implantation, respectively.
Clinical follow-up. Information regarding baseline clinical
characteristics, procedural details, and in-hospital events
was obtained from electronic databases maintained at Eras-
mus Medical Center. Postdischarge survival status was
obtained from the Municipal Civil Registry. A question-
naire was mailed to all living patients focusing on rehospi-
talization and MACE. Referring cardiologists, general
practitioners, and patients were contacted when necessary
for additional information. All patients provided written
informed consent.
Angiographic analysis. Intracoronary thrombus was an-
giographically identified and scored in 5 grades as previously
described (25). According to this classification, in thrombus
grade 0 (G0), no cineangiographic characteristics of throm-
bus are present; in thrombus grade 1 (G1), possible throm-
bus is present, with such angiography characteristics as
reduced contrast density, haziness, irregular lesion contour,
or a smooth convex meniscus at the site of total occlusion
suggestive but not diagnostic of thrombus; in thrombus
grade 2 (G2), there is definite thrombus, with greatest
dimensions 1/2 the vessel diameter; in thrombus grade 3
(G3), there is definite thrombus but with greatest linear
dimension 1/2 but 2 vessel diameters; in thrombus
grade 4 (G4), there is definite thrombus, with the largest
dimension 2 vessel diameters; and in thrombus grade 5
(G5), there is total occlusion (unable to assess thrombus
burden due to total vessel occlusion).
In patients presenting with an open IRA, thrombus was
scored in the preintervention angiographic sequence more
clearly depicting its size. In patients presenting with an
occluded IRA (G5; essentially no flow and not thrombus
classification), thrombus was reclassified into one of the
other categories after flow achievement with either guide-
wire crossing or a small (diameter 1.5 mm) deflated balloon
passage or dilation. After reclassification of the G5 group,
thrombus burden was stratified in 2 categories, scored as a
small thrombus burden (STB) for thrombus G4 and a
large thrombus burden (LTB) for thrombus G4, based on
clinical outcomes.
Thrombosis In Myocardial Infarction (TIMI) flow and
myocardial blush were assessed as previously reported
(26,27). No reflow was defined as reduced antegrade flow
(TIMI flow grade 2) in the absence of occlusion at the
treatment site or evidence of distal embolization. Distal
embolization was defined as migration of a filling defect to
distally occlude the infarct-related vessel or one of its
branches, or a new abrupt cutoff of the distal vessel/branch.
Stent thrombosis was defined as a complete or partial
occlusion within the stented segment with evidence of
thrombus and reduced antegrade flow (TIMI flow grade
3) with a concurrent acute clinical ischemic event.
The stent thrombosis cases were categorized according to the
timing of occurrence into acute (from the end of the procedure
up to 24 h), subacute (from 24 h up to 30 days), late
(between 30 days and 6 months), and very late (6
months).
All procedural parameters, including thrombus classifica-
tion, were assessed by 2 experienced interventional cardiol-
ogists reviewing the angiograms together. Both reviewers
were blinded to clinical outcomes. Consensus was achieved
in all patients. Half of the films were randomly selected and
reanalyzed by the same analysts for intraobserver variability,
and by a third experienced interventional cardiologist for
interobserver variability of the proposed LTB and STB
classification.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
IRA-ST  infarct-related
artery stent thrombosis
LTB  large thrombus
burden
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stents
PCI  percutaneous
coronary intervention
RT  rheolytic
thrombectomy
SES  sirolimus-eluting
stent(s)
STB  small thrombus
burden
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombosis In
Myocardial Infarction
TLR  target lesion
revascularization (of the
infarct-related artery)
TVR  target vessel
revascularization (of the
infarct-related artery)
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Definitions. Repeat myocardial infarction (MI) (nonfatal)
was defined as new clinical symptoms or electrocardiogram
changes associated with an increase in the creatine kinase
level to more than twice the upper normal limit with an
increased creatine kinase-MB. In cases in which the creatine
kinase level had not returned to normal values after the
index event, a second peak was defined as repeat MI. Target
lesion revascularization (TLR) was defined as any repeat
revascularization of the IRA involving the stent and/or its
5-mm proximal or distal edges.
Target vessel revascularization (TVR) was defined as any
repeat revascularization of the IRA. A MACE was defined
as death, repeat MI, and TVR.
Statistics. Categorical variables (presented as counts and
percentages) were compared using the chi-square test or
Fisher exact test where the expected value in any cell was
5. The unpaired t test was used for comparing continuous
variables (presented as the mean  SD). Cumulative event
rates were estimated using the Kaplan-Meier method, and
differences between groups were assessed by the log-rank
test of significance. Variables associated with event rates on
univariate analysis at a level of p  0.2 were entered in a
multivariate Cox model with a stepping algorithm, and then
the variables referring to thrombus burden and RT were
forced into the model to estimate their independent effect
along with the other predictors of clinical outcome (mor-
tality, MACE, stent thrombosis). In-hospital events were
included in the survival analysis. All tests were 2-tailed,
and a value of p  0.05 was considered significant. The
SPSS statistical software package (version 12.0 for Win-
dows, SPSS Inc. Chicago, Illinois) was used for the
analysis.
Baseline Clinical, Angiographic, and Procedural Characteristics
Table 1 Baseline Clinical, Angiographic, and Procedural Characteristics
Characteristic Total Population (n  792) STB (n  567) LTB (n  225) p Value*
Age (yrs) 59.4 11.5 59.6 11.6 58.8 11.1 0.38
Female 166 (21%) 122 (21.5%) 44 (19.6%) 0.54
Diabetes 80 (10.1%) 50 (8.8%) 30 (13.3%) 0.057
Hypertension 215 (27.1%) 148 (26.1%) 67 (29.8%) 0.294
Hypercholesterolemia 240 (30.3%) 177 (31.2%) 63 (28.0%) 0.374
Smoking 299 (37.8%) 223 (39.3%) 76 (33.8%) 0.146
Family history of CAD 207 (26.1%) 144 (25.4%) 63 (28.0%) 0.452
Previous MI 80 (10.1%) 54 (9.5%) 26 (11.6%) 0.392
Previous PCI 46 (5.8%) 24 (4.2%) 22 (9.8%) 0.003
MI presentation
Infarct duration (h)† 4.5 11.3 4.3 8.5 4.9 14.9 0.659
Peak CK-MB (IU/l) 314.5 303.6 305.3 292.4 335.9 328.2 0.699
Primary PCI 712 (89.9%) 503 (88.7%) 209 (92.9%) 0.079
Rescue PCI 80 (10.1%) 64 (11.3%) 16 (7.1%) 0.079
Cardiogenic shock 76 (9.6%) 50 (8.8%) 26 (11.6%) 0.238
Stent thrombosis 22 (2.8%) 6 (1.1%) 16 (7.1%) 0.001
Prehospital resuscitation 21 (2.7%) 15 (2.6%) 6 (2.7%) 0.987
Multivessel disease 309 (39.0%) 229 (40.4%) 80 (35.6%) 0.209
Infarct-related artery 0.007
Left main stem 11 (1.4%) 10 (1.8%) 1 (0.4%)
Left anterior descending 404 (51%) 299 (52.7%) 105 (46.7%)
Right coronary artery 297 (37.5%) 199 (35.1%) 98 (43.6%)
Circumflex coronary artery 75 (9.5%) 58 (10.2%) 17 (7.6%)
Vein or IMA graft 5 (0.6%) 1 (0.2%) 4 (1.8%)
Multivessel PCI 85 (10.7%) 69 (12.2%) 16 (7.1%) 0.038
Pacemaker 107 (13.5%) 46 (8.1%) 61 (27.1%) 0.001
IABP 91 (11.5%) 57 (10.1%) 34 (15.1%) 0.044
Inotropes 90 (11.4%) 59 (10.4%) 31 (13.8%) 0.177
Glycoprotein IIb/IIIa antagonists 401 (50.6%) 251 (44.3%) 150 (66.7%) 0.001
Distal protection device 15 (1.9%) 2 (0.4%) 13 (5.8%) 0.001
Drug-eluting stent type 0.004
Sirolimus-eluting stent 200 (25.3%) 159 (28.0%) 41 (18.2%)
Paclitaxel-eluting stent 592 (74.7%) 408 (72.0%) 184 (81.8%)
Bifurcational stenting 51 (6.4%) 33 (5.8%) 18 (8.0%) 0.26
Direct stenting 442 (55.8%) 321 (56.6%) 121 (53.8%) 0.469
Rheolytic thrombectomy 63 (8.0%) 4 (0.7%) 59 (26.2%) 0.001
*STB versus LTB group. †Infarct duration was available in 531 patients (361 in the STB and 170 in the LTB group).
CAD coronary artery disease; CK creatine kinase; IABP intra-aortic balloon pump; IMA internal mammary artery; LTB large thrombus burden; MImyocardial infarction; PCI percutaneous
coronary intervention; STB  small thrombus burden.
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Kappa statistics were calculated for estimating the in-
traobserver (kappa  0.95) and interobserver (kappa 
0.91) variability of the proposed thrombus classification
after selecting randomly and reanalyzing half of the films.
Results
Complete follow-up information was obtained in 798
(98.3%) patients treated with DES (mean duration 18.2 
7.8 months), and both clinical follow-up and thrombus
burden classification was available in 792 (97.5%) patients.
Minimum follow-up for patients who survived the index
hospitalization was 12 months. Baseline demographic and
procedural characteristics of the total population and ac-
cording to thrombus burden are presented in Table 1.
Angiographic classification of thrombus burden. Throm-
bus burden grading is presented in Table 2. More than half
of the patients (57%) presented with an occluded IRA (G5).
Reclassification into a thrombus category (G0 to G4) was
achieved in 449 (98.7%) patients; in 305 (67.9%) after some
flow achievement with guidewire crossing, and in 144
(32.1%) after a deflated 1.5-mm balloon passage or dilation
(mean dilation pressure was 6.8 atm and mean duration of
dilation was 16.6 s). An example of thrombus reclassifica-
tion after wire crossing is presented in Figure 1. In 2
patients, thrombus G5 was sustained (no flow achievement),
and in 4 patients reclassification was not possible because of
inadequate angiographic documentation. Finally, thrombus
burden was estimated in 792 (99.2%) patients.
In the reclassified G5 group, there were more G4 patients
compared with the group with open IRA (33.0% vs. 22.4%,
p  0.001).
Clinical outcome. The 2-year cumulative clinical out-
comes of the total population are presented in Figure 2, and
2-year cumulative mortality and MACE rate according to
thrombus score after G5 reclassification are depicted in
Figures 3A and 3B. Patient groups G1, G2, and G3 had
similar 2-year cumulative mortality (7.8% vs. 9.6% vs. 7.9%,
respectively, p  0.95) and MACE rates (15% vs. 13.8% vs.
12.8%, respectively, p  0.78), whereas groups G0 and G4
had higher rates (mortality 14.6% and 13%, respectively, p
 0.22; MACE rate 24.4% and 24.9%, respectively, p 
0.001) compared with the former groups. The G0 group
compared with G1 to G3 had more multivessel PCI (20.6%
vs. 11.1%, p 0.029) and more left main stem and less right
coronary artery involvement (4.8% vs. 1.4% and 19% vs.
37.1%, respectively, p  0.001).
Based on the aforementioned results, we stratified throm-
bus burden in 2 groups of patients with STB, combining
Classification of Thrombus Burden
Table 2 Classification of Thrombus Burden
Thrombus Score
Thrombus Burden*
Reference
(n  798)
Reference
Non-G5†
(n  343)
G5
Reclassified†
(n  455)
Reclassified
Final
(n  798)
G5 455 (57.0) 0 (0) 2 (0.4) 2 (0.3)
G4 77 (9.6) 77 (22.4) 148 (32.5) 225 (28.2)
G3 61 (7.6) 61 (17.8) 80 (17.6) 141 (17.7)
G2 95 (11.9) 95 (27.7) 113 (24.8) 208 (26.1)
G1 68 (8.5) 68 (19.8) 87 (19.1) 155 (19.4)
G0 42 (5.3) 42 (12.2) 21 (4.6) 63 (7.9)
Not available‡ 0 (0) 0 (0) 4 (0.9) 4 (0.5)
Data are presented as n (%). *Reference is the classification that includes patients with occluded
vessels at presentation (G5), and reclassified is the one after thrombus evaluation in this group
following minimal intervention. †p  0.001 for the comparison of G0, G1, G2, G3, G4 between
“Reference Non-G5” and “G5 Reclassified” groups. ‡In 4 patients, reclassification was not possible
because of inadequate angiographic documentation.
Figure 1 Thrombus Burden Evaluation in a Patient
Presenting With an Occluded Infarct-Related Artery
(A) An occluded left anterior descending coronary artery (arrow) after the take-
off of the first diagonal branch (D1) in a patient who presented with anterior
myocardial infarction. (B) After crossing the occlusion with an angioplasty
guidewire (arrowheads) and without further intervention, Thrombolysis In Myo-
cardial Infarction flow grade 1 was restored, allowing the visualization of a
large thrombus (arrows).
Figure 2 Overall Clinical Outcomes
Two-year cumulative mortality, repeat nonfatal myocardial infarction (MI),
infarct-related artery lesion repeat revascularization (TLR), infarct-related artery
repeat revascularization (TVR), and major adverse cardiac event (MACE) (death,
MI, TVR) rates of patients treated with drug-eluting stents.
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groups G0 to G3, and LTB, same as G4. The LTB group
had higher in-hospital mortality (7.6% vs. 5.1%, p  0.18).
Two-year mortality and MACE rate were increased in LTB
patients compared with the STB patients (Figs. 3C and
3D). The difference in mortality became evident early, at 30
days (Fig. 4A), and there was no difference beyond 30 days
between the 2 groups (Fig. 4B). An LTB was an indepen-
dent predictor of 30-day mortality (hazard ratio 1.96, 95%
confidence interval 1.12 to 3.43, p  0.019), as well as
2-year mortality and MACE (Table 3).
Procedural outcome. There were 7 (0.9%) procedural
deaths (procedural mortality: LTB group 1.8% vs. STB
group 0.5%, p  0.1). Patients with LTB had a worse final
TIMI flow grade, myocardial blush, and complete thrombus
removal, as well as more cases of no reflow and distal
embolization compared with STB patients (Table 4).
Incidence and predictors of stent thrombosis. Two-year
cumulative stent thrombosis, IRA-ST (Fig. 5), and non–
IRA-ST rates were 3.8  0.7% (26 events), 3.2  0.7% (22
events), and 0.6  0.3% (4 events), respectively.
IRA-ST. The 2-year cumulative IRA-ST rate was signif-
icantly higher in LTB (16 events) compared with STB (6
events) patients (Fig. 5). An LTB was the most hazardous
independent predictor of IRA-ST (Table 5). The LTB
patients treated with RT had a lower 2-year cumulative
IRA-ST (0% vs. 11.3%, p  0.001) compared with LTB
patients without RT.
In relation to antiplatelet medication, 9 (40.9%) IRA-
STs occurred under dual antiplatelet therapy, 4 (18.2%)
shortly (30 days) and 9 (40.9%) long (30 days) after
clopidogrel discontinuation. Chronologically, 4 (18.2%) pa-
tients had acute, 5 (22.7%) subacute, 2 (9.1%) late, and 11
(50%) very late IRA-ST. There were 3 additional events
beyond the 2 years at 884, 1,067, and 1,074 days; 2 of them
with LTB at baseline procedure.
There was no difference in the 2-year cumulative
IRA-ST rate between PES and SES both for the total
population (PES 3.7  0.9% [18 events] vs. SES 2.1 
1.06% [4 events], p  0.314) and the LTB group (PES
7.5  2.1% [12 events] vs. SES 10.5  4.9% [4 events],
p  0.598).
In patients presenting with stent thrombosis at the index
procedure, the 2-year cumulative IRA-ST rate was 20.5 
9.2% (4 events), all with LTB. Stent thrombosis at presen-
tation was an independent predictor of IRA-ST (Table 5).
Impact of IRA-ST on clinical outcome. Of the 22
IRA-ST patients, 4 (18.2%) presented with unstable angina,
16 (72.7%) suffered a nonfatal repeat MI, and there were 2
(9.1%) deaths; all underwent TLR. Two-year cumulative
mortality attributable to IRA-ST was only 0.3%.
The LTB patients had increased 2-year cumulative repeat
MI (Fig. 6A) and TLR (Fig. 6C) rates compared with STB
patients. The 2-year cumulative repeat MI rate attributable
to IRA-ST (2.4%, 16 events) accounted for 40.7% of the
Figure 3 Mortality and MACE According to Thrombus Burden
Two-year cumulative mortality and MACE (death, repeat nonfatal myocardial infarction, or infarct-related artery repeat revascularization) rates according to the reclassified
thrombus grades before (A, B) and after stratification in large thrombus burden (LTB) and small thrombus burden (STB) (C, D). Other abbreviations as in Figure 2.
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total 2-year cumulative repeat MI rate (5.9%, 36 events).
The 2-year cumulative TLR rate attributable to IRA-ST
(3.2%, 22 events) accounted for 67.3% of the total 2-year
cumulative TLR rate (4.9%, 34 events). After excluding
patients with IRA-ST, there was no significant difference
between LTB and STB patients in the 2-year cumulative
repeat MI and TLR rates (Figs. 6B and 6D).
The LTB patients had a worse 2-year and post-30-days
cumulative MACE rate compared with STB patients
(Figs. 7A and 7B). The 2-year cumulative MACE rate
attributable to IRA-ST (3.2%, 22 events) accounted for
17.7% of the total 2-year cumulative MACE rate (18.1%,
132 events). The post-30-days cumulative MACE rate
attributable to IRA-ST (1.2%, 13 events) accounted for
21.9% of the total post-30-days cumulative MACE rate
(9.6%, 58 events). After excluding patients with IRA-ST,
there was no significant difference in the post-30-days
cumulative MACE rate between LTB and STB patients
(Fig. 7C). The LTB patients treated with RT had a lower
MACE rate compared with LTB patients without RT
(10.7% vs. 30% at 2 years, p  0.006) but similar to that of
STB patients (10.7% vs. 15.3% at 2 years, p  0.5).
Discussion
We report our experience on a large cohort of consecutive
patients presenting with STEMI and treated with PCI and
DES. This is the first report accounting for thrombus
burden. An LTB is a fundamental factor for adverse clinical
outcomes because it is related to increased 30-day mortality
and very high rates of IRA-ST, which account for the
majority of the post-30-days MACE.
Thrombus burden. Almost 60% of the patients with
STEMI presented with an occluded IRA (G5). This is
essentially a flow classification (TIMI flow grade 0), and
consequently excludes these patients from any analysis
focusing on thrombus burden. We propose a method that
allows thrombus burden estimation in almost 99% of these
patients after flow restoration with minimal intervention.
Minimal antegrade flow (even TIMI flow grade 1) allowing
contrast penetration beyond the occlusion is adequate to
allow thrombus evaluation.
There was no difference in the clinical outcome of
patients with thrombus G1 to G3, both in the univariate
and the multivariate analysis. This was the rationale for
stratifying these groups as a single category defined as STB.
Patients with no thrombus (G0) at presentation showed
worse outcomes compared with G1 to G3 patients and
similar outcomes compared with G4 patients. Despite their
increased risk, these patients were included in the STB
group because it is obvious that therapeutic strategies to
improve their clinical outcome should not target thrombus.
Incidence of stent thrombosis during STEMI. Random-
ized trials of elective BMS implantation using dual anti-
platelet therapy reported stent thrombosis rates of 0.4% to
1.3% (28,29). Stent thrombosis rates were reported to be
similar (around 0.6%) between BMS and DES in a meta-
analysis of 10 randomized trials of elective angioplasty (30).
Concerns were recently raised that DES might be more
thrombogenic compared with BMS in the long-term, espe-
cially when implanted in more complex patient subsets (31).
Acute coronary syndromes have been associated with
increased rates of stent thrombosis. In registries represent-
ing “real world” practice, which included patients with acute
coronary syndromes and STEMI treated either with BMS
(16,17) or DES (18,32,33), higher rates of stent thrombosis
(1.2% to 1.9%) were reported. In 4,607 patients treated with
BMS for acute coronary syndromes, an even higher rate of
2.9% of stent thrombosis was observed (15). In the
TYPHOON (Trial to Assess the Use of the Cypher Stent
in Acute Myocardial Infarction Treated With Angioplasty)
trial, which randomized STEMI patients to SES or BMS,
the nonangiographic stent thrombosis was 3.4% and 3.6%,
Figure 4 Impact of Thrombus Burden on Mortality
Two-year (A) and post-30-days cumulative mortality (B) according to the pres-
ence of large thrombus burden (LTB) or small thrombus burden (STB) at the
index procedure.
Stent thrombosis in STEMI pati ents
194
whereas the angiographic stent thrombosis was 2.0% and
3.4%, respectively, at 1 year (10). Similarly, in the SESAMI
(Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute
Myocardial Infarction) trial, 1-year stent thrombosis rates
were 3.1% and 3.7% for SES and BMS, respectively (9).
We observed an incidence of angiographically docu-
mented stent thrombosis of 3.2% at 2 years. The angio-
graphically documented stent thrombosis underestimates
the true incidence of stent thrombosis because sudden
deaths and repeat MIs also may be related to this compli-
cation. Moreover, patients continued to present with stent
thrombosis beyond the 2-year time window. Similar cases of
very late DES thrombosis in STEMI patients recently have
been reported (34,35).
Mechanisms of early and late stent thrombosis during
STEMI. Stent underexpansion, malapposition, residual
dissections, and inflow/outflow disease have been well
established by intravascular ultrasound as mechanical causes
related to early stent thrombosis for BMS (16,36–39) and
DES (40).
Independent Predictors of Clinical Outcomes
Table 3 Independent Predictors of Clinical Outcomes
Outcome Variable Hazard Ratio 95% Confidence Interval p Value
2-yr mortality* Age (per 10-yr increase) 1.76 1.4–2.22 0.001
Cardiogenic shock 9.47 5.87–15.28 0.001
Prehospital resuscitation 4.28 1.99–9.2 0.001
Infarct-related artery 0.024
Right coronary artery (reference) 1.00
Left anterior descending coronary artery 1.66 0.97–2.82 0.064
Circumflex coronary artery 2.07 0.94–4.55 0.069
Left main coronary artery 4.06 1.64–10.03 0.002
Graft 3.9 0.51–29.76 0.189
Large thrombus burden 1.76 1.08–2.87 0.023
Thrombus burden‡ 0.168
Grade 4 (reference) 1.00
Grade 3 0.51 0.25–1.05 0.066
Grade 2 0.62 0.34–1.16 0.135
Grade 1 0.47 0.23–0.95 0.034
Grade 0 0.78 0.35–1.73 0.543
2-yr major adverse cardiac event† Age (per 10-yr increase) 1.19 1.01–1.4 0.036
Female 1.68 1.13–2.48 0.01
Cardiogenic shock 6.31 4.28–9.28 0.001
Stent thrombosis presentation (at index procedure) 3.95 1.95–7.98 0.001
Bifurcational stenting 2.24 1.33–3.77 0.002
Prehospital resuscitation 2.84 1.46–5.52 0.002
Rheolytic thrombectomy 0.37 0.17–0.78 0.009
Large thrombus burden 1.88 1.3–2.72 0.001
Thrombus burden‡ 0.005
Grade 4 (reference) 1.00
Grade 3 0.5 0.29–0.88 0.016
Grade 2 0.45 0.27–0.73 0.001
Grade 1 0.52 0.31–0.87 0.014
Grade 0 0.91 0.5–1.66 0.755
*Additional variables entered in the multivariate model but not found to be significant were: female gender, hypercholesterolemia, smoking, multivessel disease, multivessel percutaneous coronary
intervention, intra-aortic balloon pump, glycoprotein IIb/IIIa antagonists, bifurcational stenting, direct stenting, final Thrombolysis In Myocardial Infarction flow grade, and stent type. †Additional variables
entered in the multivariate model but not found to be significant were: hypercholesterolemia, previous myocardial infarction, previous percutaneous coronary intervention, infarct-related artery, multivessel
disease, multivessel percutaneous coronary intervention, intra-aortic balloon pump, glycoprotein IIb/IIIa antagonists, direct stenting, final Thrombolysis In Myocardial Infarction flow grade, and stent type.
‡Similar results in the multivariate analysis (data not provided for the other predictors) were also shown when thrombus burden was inserted as a variable with 5 categories (grade 0, grade 1, grade 2, grade
3, grade 4) instead of 2 (large and small).
Procedural Outcome
Table 4 Procedural Outcome
Outcome
Total
(n  792)
STB
(n  567)
LTB
(n  225) p Value*
Final Thrombolysis In
Myocardial Infarction
flow grade 3
726 (91.7) 538 (94.9) 188 (83.6) 0.001
Myocardial blush
grade 3†
290 (47.6) 222 (53.2) 68 (35.4) 0.001
Complete thrombus
removal
757 (95.6) 556 (98.1) 201 (89.3) 0.001
No reflow 12 (1.5) 3 (0.5) 9 (4.0) 0.001
Distal embolization 59 (7.4) 20 (3.5) 39 (17.3) 0.001
Data are presented as n (%). *Small thrombus burden (STB) versus large thrombus burden (LTB)
group. †Myocardial blush assessment was achieved in 609 patients (417 in the STB and 192 in the
LTB group).
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Primary stenting during acute MI has been recognized as
an independent predictor of late stent malapposition both
after BMS (41) and DES (42) with an incidence 2- to
3-fold higher compared with elective stenting. Thrombus
compression/displacement by the stent struts in the acute
phase with abluminal thrombus resolution in the long term
has been proposed as a potential mechanism. However, its
incidence with DES was 31.8%, 3 times higher compared
with BMS (11.5%). These intravascular ultrasound obser-
vations may well explain the negative late loss observed in
STEMI trials with DES implantation and angiographic
follow-up (3,6). An LTB was the strongest predictor of
stent thrombosis, and LTB patients experienced an ex-
tremely high IRA-ST rate of 8.2%. It is rational that the
larger the thrombotic burden, the higher will be the inci-
dence of incomplete stent apposition that might account for
the higher rates of late stent thrombosis in LTB patients in
the long term. Moreover, the presence of thrombus has been
clearly identified as a factor predisposing to stent thrombosis
(14,36,39). Persistence of thrombus was an independent
predictor of early repeat MI in the PAMI (Primary Angio-
plasty in Myocardial Infarction) trials (43). Patients with
STB had an IRA-ST rate of 1.3%, similar to that reported
during elective stenting (14,28,29).
Mechanical reasons may be inadequate to explain the
stent thrombosis rates during STEMI; their incidence is
common but the incidence of stent thrombosis remains
relatively low. Increased platelet activity and aspirin resis-
tance have been shown during STEMI (44). Furthermore,
stent thrombosis has been associated with an impaired
response to antiplatelet therapy, particularly in ACS pa-
tients (45). There is evidence that preintervention plaque
composition resembling that of a STEMI setting predis-
poses to stent thrombosis (46).
Procedural and periprocedural factors related to stent
thrombosis. Discontinuation of dual antiplatelet therapy
after DES implantation has been related to an increased risk
for stent thrombosis (32,33). In our study, 59% of our
patients experienced IRA-ST while on aspirin mono-
therapy; 18% within the first 30 days after discontinuation
of clopidogrel. Stent thrombosis occurred in patients while
stable for very long on antiplatelet monotherapy. Dual
antiplatelet therapy was not able to prevent 41% of the
events. Whether it would have prevented the late cases of
stent thrombosis remains unclear. The efficacy of dual
antiplatelet therapy and its duration remains unclear in a
STEMI setting.
Bifurcation stenting has been recognized previously as a
risk factor for stent thrombosis in stable patients treated
with DES (18,32). It was the second strongest independent
predictor of stent thrombosis in our study, and therefore it
should be avoided if not absolutely necessary.
The worse procedural outcomes observed in LTB com-
pared with STB patients were translated into increased
short-term mortality. Mortality after 30 days was compara-
ble between the 2 groups. Similar results were recently
reported in a large cohort of patients (47).
The use of thrombectomy devices during STEMI re-
mains controversial. There were positive results reported
when surrogate markers, such as ST-segment resolution,
TIMI flow, or left ventricular remodeling (48–50), were
used as end points, but there are no randomized studies
reporting positive outcomes in hard clinical end points such
as survival and MACE (23,24). The majority of these trials
were underpowered for clinical outcomes, a fact that is
indicative of the relative paucity of evidence, and thrombus
burden was not considered. Safety issues were recently
raised regarding routine application of thrombectomy in all
comers with STEMI (24). Based on the current results, the
potential of thrombectomy devices in STEMI should be
explored selectively in patients at higher risk, such as those
with LTB, in a prospective randomized fashion.
Efficacy of DES and thrombus burden. The rate of TVR
with BMS implantation for STEMI has been reported to be
8% to 10% (51–53). Experience with DES for STEMI
Independent Predictors offarct-Rela ed Artery Stent Thrombosis
Table 5 Independent Predictors ofInfarct-Related Artery Stent Thrombosis
Variable* Hazard Ratio
95% Confidence
Interval p Value
Age (per 10-yr increase) 0.55 0.37–0.82 0.003
Stent thrombosis at
presentation
6.24 2.06–18.92 0.001
Bifurcational stenting 4.06 1.64–10.02 0.002
Rheolytic thrombectomy 0.11 0.01–0.81 0.03
Large thrombus burden 8.73 3.39–22.47 0.001
*Additional variables entered in the multivariate model but not found to be significant were
diabetes mellitus, previous myocardial infarction, previous percutaneous coronary intervention,
and direct stenting.
Figure 5 Infarct-Related Artery Stent Thrombosis
Two-year cumulative infarct-related artery stent thrombosis (IRA-ST) rate for the
total population and according to the existence of large thrombus burden (LTB)
or small thrombus burden (STB) at the index procedure.
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showed lower TLR rates, around 2% to 4% (3,4,7,8,11,12).
In our patients the 2-year TLR rate was 4.9%, and it was
significantly higher in LTB compared with STB patients. It
has been reported that thrombus can modulate stent-based
drug elution and significantly alter vessel wall drug levels
and potentially efficacy (54). Such concerns do not seem to
be confirmed because excluding reintervention caused by
IRA-ST, which is not related to restenosis, the overall TLR
rate was very low (1.7%) and was comparable in LTB and
STB patients.
Study limitations. This is a retrospective analysis with all
of the limitations arising from such an approach. Potential
thrombus burden modification related to preprocedural
pharmacotherapy cannot be excluded. Angiography has
inherent limitations for assessing thrombus burden, and
there is no gold standard method to be compared with.
However, it is the imaging modality used for decision
making during PCI for STEMI, and in that respect this
classification is clinically relevant. The poor outcome of G0
patients is poorly understood and should be further ex-
plored. Established parameters related to clinical outcomes
such as infarct duration and myocardial blush were not
available for all patients and were not included in the
multivariate analysis model. No quantitative angiographic
analysis was performed, and parameters such as lesion
characteristics and stent length also were not accounted for.
Discontinuation of antiplatelet medication is a well-
established risk factor for stent thrombosis. In our analysis,
the antiplatelet medication status of the patients who
developed stent thrombosis was well established, but no
reliable information was possible to be obtained for patients
who did not experience stent thrombosis, and therefore this
parameter also was not included in the multivariate analysis.
Of note, 6 months of double antiplatelet medication, the
maximum prescribed in our patients, is regarded as inade-
quate today. All patients who developed stent thrombosis
beyond 6 months were on aspirin monotherapy. We cur-
rently prescribe 12 months of double antiplatelet medication
in all STEMI patients treated with DES.
Conclusions
In patients presenting with STEMI, minimal intervention
with either guidewire crossing or a small (diameter 1.5 mm)
deflated balloon passage or predilation restores flow enough
to allow intracoronary thrombus estimation in angiographi-
cally occluded vessels. Thrombus stratification in LTB (2
vessel diameters) and STB has prognostic value.
Patients with STEMI treated with PCI and DES expe-
rience a high 2-year rate (3.2%) of IRA-ST, which contin-
ues to occur even beyond that time window. An LTB is a
predictor of MACE. This is because of increased 30-day
Figure 6 Impact of Thrombus Burden and IRA-ST on Repeat MI and TLR
Two-year cumulative (A) repeat myocardial infarction (MI) and (C) infarct-related artery lesion repeat revascularization (TLR) rates in relation to large thrombus burden
(LTB) or small thrombus burden (STB) at the index procedure. The corresponding rates after excluding patients with infarct-related artery stent thrombosis (IRA-ST) are
presented in (B) and (D), respectively. After excluding IRA-ST, the total 2-year cumulative repeat MI and TLR rates are 3.3% and 1.7%, respectively.
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mortality related to worse procedural outcome and very high
rates of early and late IRA-ST in LTB patients. An LTB
does not influence the clinical antirestenotic efficacy of
DES.
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Background
Although randomized studies have shown a beneficial effect of drug-eluting stents 
in reducing the risk of repeated revascularization, these trials were underpowered to 
compare rates of death and myocardial infarction. The long-term safety of drug-elut-
ing stents has been questioned recently.
Methods
We performed a pooled analysis of 1748 patients in four randomized trials evaluating 
the safety of sirolimus-eluting stents as compared with bare-metal stents. Patient-
level data were obtained and analyzed at independent statisticians at two academic 
institutions. The primary safety end point was survival at 4 years. We tested for het-
erogeneities in treatment effect in patient subgroups.
Results
The survival rate at 4 years was 93.3% in the sirolimus-stent group, as compared with 
94.6% in the bare-metal–stent group (hazard ratio for death, 1.24; 95% confidence 
interval [CI], 0.84 to 1.83; P = 0.28). In the 428 patients with diabetes, a significant 
difference in the survival rate was observed in favor of the bare-metal–stent group 
over the sirolimus-stent group (95.6% vs. 87.8%; hazard ratio for death in the siro-
limus-stent group, 2.9; 95% CI, 1.38 to 6.10; P = 0.008). The lower survival rate among 
patients with diabetes who were treated with sirolimus-eluting stents was due to in-
creased numbers of deaths from both cardiovascular and noncardiovascular causes. 
No difference in survival rate was detected among the patients without diabetes. Rates 
of myocardial infarction and stent thrombosis were similar in the two groups.
Conclusions
In a pooled analysis of data from four trials comparing sirolimus-eluting stents and 
bare-metal stents, no significant differences were found between the two treatments 
in rates of death, myocardial infarction, or stent thrombosis. (ClinicalTrials.gov num-
bers, NCT00233805, NCT00381420, NCT00232765, and NCT00235144.)
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Since april 2002, randomized trials and registries have shown that drug-eluting stents, as compared with bare-metal stents, 
reduce the need for subsequent revasculariza-
tion procedures.1-6 As a result, the use of drug-
eluting stents has increased rapidly, with current 
rates up to 80% of all stenting procedures in some 
countries. However, two recent meta-analyses have 
suggested that rates of death and myocardial in-
farction may be increased in patients who have 
received drug-eluting stents.7,8 Impaired reendo-
thelialization, late endothelial dysfunction, hyper-
sensitivity reactions to the stent or its coating, and 
stent thrombosis have been suggested as poten-
tial causes.9-17 The consequences of even a slight 
increase in the rates of death and myocardial in-
farction would be dramatic, considering the cur-
rent high rate of use of drug-eluting stents.
The early and pivotal randomized studies that 
led to approval of stents for marketing were in-
dividually not adequately powered to detect differ-
ences in the rates of death, myocardial infarction, 
or stent thrombosis. However, reliable long-term 
data, including information about these end points, 
are now available and can be pooled to conduct 
analyses with greater power than those in the 
original trials. We therefore performed a safety 
analysis of patient-level data collected, in four ran-
domized trials comparing sirolimus-eluting stents 
and bare-metal stents, during a follow-up period 
of 4 years for 1748 patients.
Me thods
Original Trials
Our analysis is based on pooled patient-level data 
from the Randomized Study with the Sirolimus-
Coated Bx Velocity Balloon Expandable Stent in 
the Treatment of Patients with De Novo Native 
Coronary Artery Lesions (RAVEL), the Sirolimus-
Eluting Balloon-Expandable Stent in the Treatment 
of Patients with De Novo Native Coronary-Artery 
Lesions (SIRIUS) trial, the European SIRIUS (E-
SIRIUS) trial, and the Canadian SIRIUS (C-SIRIUS) 
trial, all of which were performed between August 
2000 and April 2002. Each of these four trials com-
pared a sirolimus-eluting stent (Cypher, Cordis, 
a Johnson & Johnson company) with a bare-metal 
stent of identical design (Bx Velocity, Cordis), but 
without polymer and drug coatings, implanted in 
single, previously untreated lesions in native cor-
onary arteries, using a double-blind study design 
with a 1:1 randomization process.
The designs of these trials, as well as short-
term angiographic and clinical outcomes, have 
been reported previously.1-4 In summary, RAVEL 
included patients in clinically stable condition 
with relatively low-risk lesions, whereas the three 
SIRIUS trials involved patients with higher-risk 
and more complex lesions. Patients with acute 
myocardial infarction were excluded in all four tri-
als. A total of 428 patients with diabetes (treated 
through diet, with an oral hypoglycemic agent, or 
with insulin) were included.
Dual antiplatelet therapy with aspirin and clo-
pidogrel or ticlopidine was prescribed per proto-
col for a minimum of 2 months in RAVEL and the 
E-SIRIUS and C-SIRIUS trials and for a minimum 
of 3 months in the SIRIUS trial. Aspirin was pre-
scribed indefinitely; doses ranged from 81 to 
325 mg daily.
The protocols called for complete angiographic 
follow-up at 6 months (in RAVEL) or at 8 months 
(in the SIRIUS, E-SIRIUS, and C-SIRIUS studies) 
and clinical follow-up yearly. The primary end 
points differed among the studies and included 
purely angiographic end points (in-stent late loss 
in RAVEL and in-stent minimal lumen diameter 
at 8 months in the E-SIRIUS and C-SIRIUS trials) 
as well as the clinical end point of target-vessel 
failure (a composite of death, myocardial infarc-
tion, and target-vessel revascularization) in the 
SIRIUS trial. Secondary end points included death, 
myocardial infarction, and repeated revascular-
ization.
The study protocols were approved by the ethics 
committee at each participating institution and 
were conducted according to the principles of the 
Declaration of Helsinki. All patients gave written 
informed consent before enrollment. The studies 
were sponsored and monitored by Cordis.
The design of each trial specified in advance 
that data would be collected for up to 5 years, 
with adjudication of events by the independent 
end-points committee of the original trial. Four-
year follow-up data are currently available from all 
four studies. All clinical follow-up information was 
collected at the investigating centers in a blind 
fashion.
Current Analysis
The databases of the individual studies were ob-
tained from Cordis. Study coordination and data 
management were performed at two independent 
central research organizations (Cardialysis, Rotter-
dam, the Netherlands, for RAVEL, and Harvard 
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Clinical Research Institute, Boston, for the SIRIUS, 
E-SIRIUS and C-SIRIUS studies). The patient-level 
data were pooled and then analyzed by one inde-
pendent statistician at Harvard Clinical Research 
Institute and another at Erasmus University Med-
ical Center, Rotterdam. The authors were given un-
restricted access to the data by Cordis and made 
all decisions about analysis and publication inde-
pendently of the company.
Study End Points
The primary safety end point was death from any 
cause. Information on the circumstances of all 
deaths was obtained from each of the sites, and 
narratives were developed. These narratives were 
reviewed by the clinical events committees for the 
trials and, for the conduct of our analysis, by three 
of the authors.
Secondary safety end points were death from 
cardiovascular causes and noncardiovascular 
causes, death from any cause or Q-wave myocar-
dial infarction, and death from any cause or any 
type of myocardial infarction. The following defi-
nitions of events were used in all four trials.
Death from cardiovascular causes was defined 
either as death due to acute myocardial infarction, 
cardiac perforation or pericardial tamponade, ar-
rhythmia or conduction abnormality, cerebrovas-
cular accident within 30 days or related to the 
procedure, or a complication of the procedure or as 
any death in which a cardiovascular cause could 
not be ruled out. Death from noncardiovascular 
causes was defined as any death not due to a car-
diovascular cause.
Q-wave myocardial infarction was defined as 
the development of new, pathologic Q-waves in 
two or more contiguous leads as assessed by the 
electrocardiography core laboratory, with creatine 
kinase or creatine kinase MB levels elevated above 
the upper limit of the normal range. Non–Q-wave 
myocardial infarction was defined as an elevation 
of the creatine kinase MB level to three times the 
normal value in the absence of new, pathologic 
Q-waves; if no assay for creatine kinase MB was 
performed, elevation of the creatine kinase level 
to a value that was twice the normal value in the 
absence of new Q-waves was also considered a 
non–Q-wave myocardial infarction.
In the study protocols, stent thrombosis was 
defined as acute if it occurred within 24 hours 
after the index procedure, subacute if it occurred 
between 1 and 30 days after the procedure, and 
late if it occurred more than 30 days after the pro-
cedure. Acute and subacute stent thromboses were 
classified on the basis of vessel occlusion on an-
giography, any recurrent Q-wave myocardial in-
farction in an area irrigated by the stented vessel, 
or death from cardiac causes. Late stent thrombo-
sis was diagnosed on the basis of any recurrent 
myocardial infarction with vessel occlusion on 
angiography. In the original trial protocols, sec-
ondary stent thrombosis — stent thrombosis in a 
patient who had previously undergone target-lesion 
revascularization — was not considered to be a 
stent thrombosis.
Stent thrombosis was reclassified in a blind 
fashion by an independent research organization 
(Harvard Clinical Research Institute) according to 
a set of definitions developed during summer 2006 
by an academic research consortium (ARC) of aca-
demic investigators, regulators, and industry rep-
resentatives. These definitions were proposed to 
serve as standard criteria for stent thrombosis for 
the comparison of event rates across different tri-
als and studies. According to the ARC definitions, 
stent thrombosis was classified as acute if it oc-
curred within 24 hours after the index procedure, 
subacute if it occurred between 1 and 30 days af-
ter, late if it occurred between 31 days and 1 year 
after, and very late if it occurred more than 1 year 
after the procedure.
Furthermore, stent thrombosis was considered 
definite if there was angiographic confirmation of 
thrombus, with or without vessel occlusion, asso-
ciated with clinical or electrocardiographic signs 
of acute ischemia or elevation of creatine kinase 
levels to twice the normal value within 48 hours 
of angiography. Stent thrombosis was classified as 
probable if unexplained death occurred within 30 
days after the index procedure or if a myocardial 
infarction, occurring at any time after the index 
procedure, was documented in an area irrigated by 
the stented vessel in the absence of angiographic 
confirmation of stent thrombosis. Stent thrombo-
sis was classified as possible if unexplained death 
occurred more than 30 days after the index proce-
dure. During the readjudication of stent thrombo-
sis according to the ARC definitions, events occur-
ring after repeated target-lesion revascularization 
were included.
Statistical Analysis
The effectiveness analysis and safety evaluation 
were both performed in a modified intention-to-
treat population, including all patients who actu-
ally underwent stent placement (whether the pro-
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Table 1. Baseline Clinical and Angiographic Characteristics.*
Characteristic Sirolimus-Stent Group
Bare-Metal–  
Stent Group P Value
Age — yr
Median 61 62 0.91
IQR 54–70 54–70
Range 24–92 32–89
Male sex — no./total no. (%) 629/878 (71.6) 622/870 (71.5) 0.95
Diabetes mellitus — no./total no. (%) 195/878 (22.2) 233/868 (26.8) 0.02
Insulin-dependent diabetes mellitus — no./total no. (%) 51/195 (26.2) 62/233 (26.6) 0.92
Previous MI — no./total no. (%) 287/865 (33.2) 308/862 (35.7) 0.26
Previous PCI — no./total no. (%) 201/878 (22.9) 184/869 (21.2) 0.39
Previous coronary-artery bypass graft — no./total no. (%) 66/878 (7.5) 64/870 (7.4) 0.90
Hyperlipidemia — no./total no. (%) 613/866 (70.8) 617/859 (71.8) 0.63
Hypertension — no./total no. (%) 557/873 (63.8) 548/866 (63.3) 0.82
Current smoker — no./total no. (%) 183/862 (21.2) 210/858 (24.5) 0.11
Congestive heart failure — no./total no. (%) 36/869 (4.1) 49/861 (5.7) 0.14
CCS angina classification III or IV — no./total no. (%)† 344/831 (41.4) 344/831 (41.4) 1.00
Silent ischemia — no./total no. (%) 152/783 (19.4) 155/793 (19.5) 0.95
Ejection fraction — %
Median 59 60 0.55
IQR 50–64 50–65
Range 25–91 25–89
Coronary artery disease — no./total no. (%)
Single-vessel 538/876 (61.4) 531/868 (61.2) 0.92
Double-vessel 216/876 (24.7) 236/868 (27.2) 0.23
Triple-vessel 122/876 (13.9) 101/868 (11.6) 0.15
Procedure success — no./total no. (%) 858/877 (97.8) 852/868 (98.2) 0.63
Target vessel — no./total no. (%)
LAD 408/878 (46.5) 407/870 (46.8) 0.98
LCx 210/878 (23.9) 207/870 (23.8) 0.90
RCA 254/878 (28.9) 254/870 (29.2) 0.96
LMCA 3/878 (0.3) 3/870 (0.3) 1.00
SVG 0 1/870 (0.1) 0.31
Severe calcification — no./total no. (%) 37/755 (4.9) 26/754 (3.4) 0.16
Total occlusion — no./total no. (%) 25/875 (2.9) 20/870 (2.3) 0.46
Disease of branch vessel — no./total no. (%) 55/755 (7.3) 46/755 (6.1) 0.35
Modified ACC–AHA lesion class — no./total no. (%)‡
A 61/875 (7.0) 61/870 (7.0) 0.98
B1 297/875 (33.9) 317/870 (36.4) 0.28
B2 320/875 (36.6) 332/870 (38.1) 0.50
C 197/875 (22.5) 161/870 (18.5) 0.04
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cedure was successful or not). Patients who were 
randomly assigned to treatment but who did not 
undergo a procedure were not included in the 
analysis.
Summary statistics for all continuous variables 
are presented as medians and interquartile rang-
es. Categorical data are summarized as frequen-
cies and percentages. Differences in baseline char-
acteristics between the sirolimus-stent group and 
the bare-metal–stent group were analyzed using 
the Wilcoxon–Mann–Whitney test or Fisher’s ex-
act test.
The incidence of events over time was studied 
with the use of the Kaplan–Meier method, where-
as log-rank tests and Cox proportional-hazards 
regression analyses were applied to evaluate dif-
ferences between the two groups. In the main 
analysis, hazard ratios and 95% confidence inter-
vals (CIs) were adjusted for differences in outcome 
between trials. Follow-up at 1, 2, and 3 years was 
completed for 99.1%, 97.8%, and 96.3% of the 
patients, respectively. Because follow-up data for 
the period between 1441 and 1460 days were lack-
ing in 675 patients, we decided to count events 
through 1440 days, which was interpreted as 
4 years of follow-up. This 4-year follow-up was 
completed in 90.7% of patients (90.5% of those 
who received sirolimus-eluting stents and 90.9% of 
those who received bare-metal stents).
Exploratory analyses (not prespecified) were 
performed to evaluate possible heterogeneities in 
treatment effects on mortality according to the 
trial in which the patient was enrolled and the fol-
lowing 10 clinically relevant characteristics: age, 
sex, diabetes, dyslipidemia, hypertension, prior 
myocardial infarction, heart failure, angina clas-
sification by the Canadian Cardiovascular Society, 
number of diseased vessels, and left ventricular 
ejection fraction.5 Since a clinically relevant dif-
ference in treatment effect on mortality was ob-
served in relation to diabetes status, we decided to 
study other end points in patients with and those 
without diabetes. Treatment effects were evaluat-
ed with the use of Cox regressions that included 
a term for the interaction between each character-
istic of interest and the assigned treatment, ad-
justed for differences in outcome between trials. 
More extensive regression models incorporating 
predictive baseline characteristics were applied to 
estimate the adjusted treatment effects.18
All statistical tests were two-sided, without cor-
rection for multiple testing. P values of less than 
0.05 and less than 0.01 were considered to indi-
cate statistical significance for the results of non-
heterogeneity tests and tests for heterogeneity in 
treatment effect, respectively. All statistical anal-
yses were performed with the use of SAS software, 
version 8.2 (SAS Institute).
R esult s
A total of 1748 patients were included in this anal-
ysis (238 in RAVEL, 1058 in the SIRIUS study, 100 
in the C-SIRIUS study, and 352 in the E-SIRIUS 
Table 1. (Continued.)
Characteristic Sirolimus-Stent Group
Bare-Metal– 
Stent Group P Value
Reference-vessel diameter — mm
Median 2.7 2.7 0.98
IQR 2.4–3.0 2.4–3.0
Range 1.5–4.5 1.7–5.4
Lesion length — mm
Median 12.7 13.1 0.96
IQR 10.0–16.6 9.8–16.5
Range 3.2–41.5 3.4–48.9
* Data for some characteristics were missing for some patients. IQR denotes interquartile range, MI myocardial infarc-
tion, PCI percutaneous coronary intervention, LAD left anterior descending coronary artery, LCx left circumflex coronary 
artery, RCA right coronary artery, LMCA left main coronary artery, and SVG saphenous-vein graft.
† Canadian Cardiovascular Society (CCS) angina classifications III and IV are defined as angina on mild exertion and an-
gina at any level of physical exertion, respectively.
‡ Modified American College of Cardiology (ACC) and American Heart Association (AHA) lesion classes A, B1, B2, and  
C are defined as a low-risk lesion, a moderate-risk lesion with one or with two or more risk factors, and a high-risk  
lesion, respectively.
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study). In total, 878 patients underwent placement 
of a sirolimus-eluting stent, and 870 patients un-
derwent placement of a bare-metal stent. The clin-
ical and angiographic characteristics of the study 
patients are summarized in Table 1. Complex le-
sions were more frequent in patients with siroli-
mus-eluting stents than in patients with bare-metal 
stents (22.5% vs. 18.5%, P = 0.04), and diabetes was 
more common in the bare-metal–stent group than 
in the sirolimus-stent group (26.8% vs. 22.2%, 
P = 0.02).
Results for all patients are shown in Table 2 
and Figure 1. The 4-year cumulative survival rate 
was slightly, but not significantly, lower in the 
sirolimus-stent group than in the bare-metal–stent 
group (93.3% and 94.6%, respectively; hazard ra-
tio for death in the sirolimus group, 1.24; 95% CI, 
0.84 to 1.83; P = 0.28). Narratives of all patient 
deaths revealed that mortality from both car-
diovascular and noncardiovascular causes was 
slightly, but not significantly, higher in the siroli-
mus-stent group (Table 2 and the Supplementary 
Appendix, available with the full text of this ar-
ticle at www.nejm.org). Rates of myocardial in-
farction overall were similar between the two 
groups. Rates of Q-wave myocardial infarction 
were also slightly, but not significantly, higher in 
the sirolimus-stent group.
Table 2. Incidences of Death, Myocardial Infarction, and Stent Thrombosis after 1440 Days of Follow-up.*
End Point
Sirolimus-  
Stent Group  
(N = 878)
Bare-Metal– 
Stent Group  
(N = 870)
Adjusted Hazard Ratio 
(95% CI) P Value
number (percent)
Death 57 (6.7) 46 (5.4) 1.24 (0.84–1.83) 0.28
Cardiovascular cause 29 (3.5) 23 (2.7) 1.26 (0.73–2.18) 0.40
Noncardiovascular cause 28 (3.3) 23 (2.8) 1.22 (0.70–2.11) 0.49
MI 55 (6.4) 53 (6.2) 1.03 (0.71–1.51) 0.86
Q-wave 18 (2.1) 11 (1.3) 1.64 (0.78–3.47) 0.20
Non–Q-wave 37 (4.3) 43 (5.0) 0.85 (0.55–1.33) 0.48
Death or Q-wave MI 70 (8.2) 55 (6.5) 1.28 (0.90–1.82) 0.17
Death or any MI 100 (11.6) 90 (10.5) 1.11 (0.83–1.47) 0.48
Stent thrombosis as defined in 
protocols†
Acute 0 0 —
Subacute 4 (0.5) 1 (0.1) 4.02 (0.45–35.98) 0.21
Late 6 (0.7) 4 (0.5) 1.50 (0.42–5.30) 0.53
Stent thrombosis as defined by 
the ARC‡
Acute 0 0 —
Subacute 4 (0.5) 3 (0.5) 1.34 (0.30–5.93) 0.70
Late 3 (0.3) 11 (1.3) 0.18 (0.04–0.81) 0.03
Very late 23 (2.8) 14 (1.7) 1.65 (0.85–3.20) 0.14
Definite 10 (1.2) 7 (0.8) 1.43 (0.54–3.76) 0.47
Definite or probable 13 (1.5) 15 (1.8) 0.87 (0.41–1.82) 0.70
Any 30 (3.6) 28 (3.3) 1.07 (0.64–1.79) 0.80
* All percentages are based on Kaplan–Meier estimates. Numbers of patients for death or Q-wave myocardial infarction 
(MI) and death or any MI do not total the sums for each end point alone because some patients had both end points. 
CI denotes confidence interval.
† Definitions of stent thrombosis according to the study protocols were as follows: acute, within 24 hours after the proce-
dure; subacute, within 1 to 30 days after; and late, more than 30 days after.
‡ Definitions of stent thrombosis according to the academic research consortium (ARC) were as follows: acute, within 24 
hours after the procedure; subacute, within 1 to 30 days after; late, between 31 days and 1 year after; and very late, more 
than 1 year after. See text for details on stent-thrombosis adjudication per protocol and per ARC definitions.
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According to the protocol definitions, there 
were 10 stent thromboses in the sirolimus-stent 
group and 5 in the bare-metal–stent group (Ta-
ble 2). Five of the thromboses in the sirolimus-
stent group, but none in the bare-metal–stent 
group, occurred after 1 year. In contrast, according 
to the ARC definitions, there were 30 stent throm-
boses in the sirolimus-stent group and 28 in the 
bare-metal–stent group (Fig. 2). Stent thrombosis 
was more frequent in the bare-metal–stent group 
in the first year (14, vs. 6 in the sirolimus-stent 
group), whereas very late stent thrombosis (oc-
curring after the first year) was more frequent in 
the sirolimus-stent group (23, vs. 14 in the bare-
metal–stent group).
Significant heterogeneity in the treatment ef-
fects was not found for any of the prespecified 
subgroups except patients with diabetes (P value 
for interaction = 0.008) (see the Supplementary 
Appendix). The 4-year cumulative survival rates 
among patients without diabetes did not differ 
significantly between the two groups. However, 
the survival rate for patients with diabetes was 
significantly lower in the sirolimus-stent group 
(87.8%, vs. 95.6% in the bare-metal–stent group; 
hazard ratio for death, 2.90; 95% CI, 1.38 to 6.10; 
P = 0.008) (Fig. 3 and the Supplementary Appen-
dix). A large heterogeneity in the causes of death 
of the patients with diabetes precluded the identifi-
cation of a clear pattern of mortality (see the Sup-
plementary Appendix). Among the patients with 
diabetes, there was a small excess of very late stent 
thrombosis as defined by the ARC (occurring more 
than 1 year after the procedure) in the sirolimus-
stent group (11 patients, vs. 3 in the bare-metal– 
stent group) (see the Supplementary Appendix).
Discussion
In this study, we performed a pooled analysis of 
four randomized trials comparing sirolimus-elut-
ing stents and bare-metal stents in 1748 patients 
with 4 years of follow-up. We did not find evidence 
of a significantly higher rate of death, myocardial 
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Figure 1. Kaplan–Meier Survival Curves for Patients 
Who Received a Sirolimus-Eluting Stent and Those 
Who Received a Bare-Metal Stent.
Panel A shows overall survival; Panel B shows freedom 
from death or myocardial infarction (MI). The survival 
rates at 1440 days are shown in parentheses. P values 
were calculated with the use of the log-rank test.
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Figure 2. Kaplan–Meier Curves for the Survival  
of Patients without Stent Thrombosis as Defined  
by the Academic Research Consortium.
All first episodes of stent thrombosis were counted,  
including those that occurred after revascularization  
of the target lesion. The survival rates at 1440 days are 
shown in parentheses. The P value was calculated with 
the use of the log-rank test.
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infarction, or stent thrombosis in the patients 
treated with sirolimus-eluting stents. The diver-
gence of the Kaplan–Meier survival curves over 
time could be interpreted as a growing trend to-
ward a lower survival rate among patients treated 
with sirolimus-eluting stents as compared with 
those treated with bare-metal stents, although a 
larger number of patients, a longer follow-up peri-
od, or both would be necessary to confirm this in-
terpretation.
In our study, we analyzed rates of stent throm-
bosis adjudicated according to the definitions in 
the original protocols and those of the ARC. We 
believe that this provides a more accurate picture 
of the incidence of stent thrombosis with either 
type of stent, for two reasons. First, late events 
such as unexplained death, which were not consid-
ered in the original protocols, were adjudicated as 
possible stent thrombosis. Second, all episodes of 
stent thrombosis, including those occurring after 
target-lesion revascularization, were included in 
the readjudicated event rates.
A significant heterogeneity of the treatment 
effect was found with respect to diabetes. A sig-
nificantly reduced survival rate was found among 
patients with diabetes (but not patients without 
diabetes) treated with sirolimus-eluting stents. 
Deaths from cardiovascular and noncardiovas-
cular causes were more frequent in the sirolimus-
stent group. In the subgroup of patients with dia-
betes, very late stent thrombosis was adjudicated 
more frequently among the patients with siroli-
mus-eluting stents than among those with bare-
metal stents. Owing to the low number of events, 
these findings should be interpreted with caution; 
it does not appear that they adequately explain the 
observed difference in survival among patients 
with diabetes in the two groups.
Previous studies have reached different conclu-
sions regarding the benefit of drug-eluting stents 
in patients with diabetes. The 9-month results of 
a dedicated randomized trial of patients with dia-
betes showed that sirolimus-eluting stents were 
superior to bare-metal stents in reducing rates of 
both restenosis and repeated revascularization.19 
Mortality at 9 months was only 1% in the siro-
limus-stent group, as compared with 2% in the 
bare-metal–stent group. Conversely, the 2-year fol-
low-up of 708 patients with diabetes from a large 
registry on the use of drug-eluting stents revealed 
a mortality of 13.3% among patients treated with 
sirolimus-eluting stents, as compared with 9.8% 
among patients treated with bare-metal stents.20 
Although the difference in mortality was not sig-
nificant, a hazard ratio for death of 1.55 remained 
after a propensity analysis. In addition, the rate of 
angiographically proven stent thrombosis in that 
study was 4.4% in the sirolimus-stent group but 
only 0.8% in the bare-metal–stent group. Finally, 
diabetes has been shown to be a consistent inde-
pendent predictor of stent thrombosis in patients 
treated with drug-eluting stents.21,22
Several limitations of our study should be con-
sidered. The analysis was underpowered to detect 
a clinically significant difference in mortality; 
more than 11,000 patients would have been need-
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Figure 3. Kaplan–Meier Survival Curves for Patients  
with Diabetes (Panel A) and Those without Diabetes 
(Panel B).
The survival rates at 1440 days are shown in parenthe-
ses. P values were calculated with the use of the log-
rank test.
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ed for such an analysis. Patients included in the 
four randomized trials were highly selected and 
are representative of only about 25% of patients 
currently treated with drug-eluting stents. Treat-
ment with clopidogrel was required for at least 
2 or 3 months, according to the original trial pro-
tocols, but no information on actual use by indi-
vidual patients, even by those who had adverse 
events, was available. Thus, we cannot provide any 
specific insight into the question of whether pro-
longing dual antiplatelet therapy further would 
reduce the risk of such events. We performed mul-
tiple subgroup analyses that were not prespecified, 
including one for diabetes. The number of fatal 
events in patients with diabetes was small, so the 
related findings may be due to chance. Finally, 
lower-than-expected mortality was noted among 
the patients with diabetes in the bare-metal–stent 
group, for reasons that remain unclear.
In summary, in our pooled analysis of data 
from four randomized trials, we compared the 
effects of sirolimus-eluting stents with those of 
bare-metal stents on clinical events at 4 years. No 
significant differences in the rates of death, myo-
cardial infarction, or stent thrombosis were found.
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Abstract
Background: Randomised studies have demonstrated the beneficial effect of drug-eluting stents in
reducing repeat revascularisation at one year. However, they were individually underpowered to assess
long-term safety endpoints such as death and myocardial infarction. The long-term safety of drug-eluting
stents has been recently questioned.
Methods and results: We performed a pooled analysis of 2,797 patients included in four randomised trials
to assess the safety of slow-release paclitaxel-eluting stents as compared with bare metal stents. Patient
level data were obtained and analysed by two independent academic statistical institutions. The primary
safety endpoint was survival at four years. Secondary endpoints were myocardial infarction and stent
thrombosis. Heterogeneities in treatment effect were tested in subgroups.
Survival at four years was 93.4% in the paclitaxel-eluting stent group versus 93.0% in the bare-metal stent
group (Hazard ratio for survival 0.95; 95% confidence interval [CI] 0.96 - 1.30; P=0.75). Myocardial
infarction occurred at a similar rate between both treatment groups. Whereas the total rates of stent
thrombosis were equal between the two groups, there was a trend towards a higher rate of stent thrombosis
occurring after repeat target lesion revascularisation in the bare-metal stent group. No heterogeneity of
treatment effect was found in the subgroups, including diabetic patients and complex lesions.
Conclusions: In a pooled analysis of four trials comparing paclitaxel-eluting stents with bare metal stents, no
significant differences were found in the rates of death, myocardial infarction or stent thrombosis.
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paclitaxel-eluting
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Introduction
Pivotal randomised clinical trials and registries have shown that
drug-eluting stents reduce the need for subsequent
revascularisation procedures when compared with bare metal
stents1-10. More than four million patients have been treated
worldwide with drug-eluting stents. However, the pivotal randomised
trials were individually underpowered to detect differences in death
and myocardial infarction. Recently, several meta-analyses of
published randomised trials with three to four years of follow-up have
shown a small, albeit consistent increase in the rates of death,
myocardial infarction and late stent thrombosis in patients receiving
drug-eluting stents11-13. To specifically address the long-term safety
of the paclitaxel-eluting stent, we performed a safety meta-analysis of
patient level data derived from four randomised controlled trials
comparing a slow-release paclitaxel-eluting stent with a bare-metal
stent during a follow-up period of four years in 2,797 patients.
Methods
The original studies
The present analysis is based on pooled patient level data from the
TAXUS I, II, IV, and V trials, all comparing a polymer-based, slow-
release paclitaxel-eluting stent to a bare metal stent in lesions in
native coronary arteries using a double-blind study design with a 1:1
randomisation process. The design of these trials, as well as short-
term angiographic and clinical outcomes, have been reported
previously7-10,14. Patients treated with the moderate-release
paclitaxel-eluting stent, which was never commercialised, were
excluded from the present analysis. For this reason, patients treated
with the moderate-release paclitaxel-eluting stent and their control
group of cohort II of TAXUS II and patients included in TAXUS VI
were excluded. Acute myocardial infarction was an exclusion criteria
in all trials. A total of 715 patients with diabetes (defined as patients
which were medically treated and/or insulin treated) were included.
Angiographic inclusion criteria were variable: TAXUS I, II and IV
included patients with low risk lesions whereas TAXUS V included
prespecified subgroups of patients with lesions in small vessels
(< 2.25 mm), long lesions (> 26 mm), and lesions treated with large
diameter stents. In both TAXUS IV and V, randomisation of diabetics
was stratified by group. TAXUS I and II compared the paclitaxel
TAXUS NIR™ stent to the bare metal NIR™ stent and TAXUS IV and
V compared the TAXUS Express™ stent to a bare metal Express™
stent (all from Boston Scientific, Natick, Mass, USA). The primary
endpoints for TAXUS I as a Phase I feasibility study was 30-day
MACE (a composite endpoint of all-cause death, q-WAVE myocardial
infarction and stent thrombosis at 30 days). The primary endpoint for
TAXUS II as a Phase II study was % in-stent net volume obstruction
measured by intravascular ultrasound at six months. TAXUS IV and
V as Phase III and Phase IIIb studies were powered for nine-month
target vessel revascularisation as primary endpoints. Cardiac death
and myocardial infarction were collected as secondary endpoints in
all studies. All-cause death and stent thrombosis by protocol
definition were also collected in all studies.
Dual antiplatelet therapy with aspirin and clopidogrel or ticlopidine
was mandated per protocol for a minimum of six months in all
studies. Aspirin was mandated indefinitely. Aspirin doses ranged
from 81 to 325 mg daily.
The protocol called for angiographic follow-up at six months (for all
patients in TAXUS I and II), at nine months for all patients in
TAXUS V and for a prespecified subgroup of patients in TAXUS IV,
and clinical follow-up data up to five years was prespecified. Clinical
status was checked yearly and five year follow-up is currently
available for TAXUS I, four-year for TAXUS II and IV and Two years
for TAXUS V. Median follow-up was 1,430 days (IQR 1,072 to
1,452) The study protocols were approved by the ethics committee
at each participating institution and were conducted according to
the principles of the Declaration of Helsinki. All patients gave written
informed consent before enrolment. The studies were performed
between October 2000 and December 2002.
Current analysis
All studies were sponsored and monitored by the Boston Scientific
Corporation. Follow-up was performed by the investigating centres
in a blinded fashion. Core lab analysis for angiographic and
intravascular ultrasound was performed by independent research
organisations (Cardialysis, Rotterdam, The Netherlands, for the
TAXUS II trial, and by Harvard Clinical Research Institute, Boston, MA,
for the TAXUS I, IV and V trials). Independent clinical event
committees adjudicated the events. For this specific post-hoc
analysis, the patient level based data were pooled and than
analysed by two independent academic statisticians. The authors
had unrestricted access to the data and made all decisions about
publication independently of the sponsor or the principal
investigators of the studies.
Study endpoints
The primary safety endpoint was all cause death. Secondary safety
endpoints were cardiovascular and non-cardiovascular death, stent
thrombosis, and all cause death or Q-wave myocardial infarction
and all cause death or all myocardial infarction. The same
definitions of events given below were used for all four trials.
Cardiovascular death was defined as death due to any of the
following: 1) acute myocardial infarction, 2) cardiac perforation or
pericardial tamponade, 3) arrhythmia or conduction abnormality,
4) cerebrovascular accident within 30 days or related to the
procedure, 5) complication of the procedure or 6) any death in
which a cardiac cause cannot be excluded. Non-cardiovascular
death was defined as any death not due to a cardiovascular cause.
Q-wave myocardial infarction was defined as the development of
new, pathological Q-waves in two or more contiguous leads as
assessed by the ECG core laboratory with creatine kinase (CK) or
CKMB levels elevated above the upper limit of normal. Non-Q-wave
myocardial infarction was defined as an elevation of CK two times
the normal value with positive CKMB in the absence of new
pathological Q-waves.
In the study protocols stent thrombosis was defined as an acute
coronary syndrome with angiographic documentation of either
vessel occlusion or thrombus within or adjacent to a previously
successfully stented vessel or, in the absence of angiographic
confirmation, either acute myocardial infarction in the distribution of
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the treated vessel or death from cardiac causes within 30 days.
A thrombotic occlusion subsequent to a repeat target lesion
intervention did not quality as stent thrombosis in these definitions.
Stent thrombosis was re-classified in a blinded fashion by an
independent research organisation (Harvard Clinical Research
Institute, Boston, MA, USA) according to a set of definitions
developed during the summer of 2006 by a consortium of
academic investigators, regulators and industry representatives.
These definitions (referred to as the Academic Research
Consortium or ARC definitions) were proposed to serve as standard
criteria for stent thrombosis for the comparison of event rates across
different trials and studies. Using the ARC definitions, stent
thrombosis was classified as acute if it occurred within 24 hours
after the index procedure, subacute if it occurred between one and
30 days, late between 30 days and one year and very late after one
year. Furthermore, stent thrombosis was considered definite if there
was angiographic proof of thrombus with or without vessel occlusion
associated with clinical or electrocardiographic signs of acute
ischaemia, or a rise of CK twice the normal value within the 48
hours of the angiogram. Stent thrombosis was classified as probable
if unexplained death occurred within 30 days of the index
procedure or if a myocardial infarction, irrespective of the time after
the index procedure, was documented in the territory of the
implanted stent without angiographic confirmation of stent
thrombosis. Stent thrombosis was classified as possible in the
presence of any unexplained death occurring after 30 days of the
index procedure. Stent thrombotic events occurring after the index
procedures were classified as primary stent thrombosis and events
occurring after repeat target lesion revascularisations were
adjudicated as secondary stent thrombosis.
Statistical analysis
All analyses were based on the intention-to-treat principle.
Summary statistics for continuous variables are presented as
medians and interquartile ranges. Categorical data are summarised
as frequencies and percentages. Differences in baseline
characteristics between patients randomised to paclitaxel-eluting
stents versus bare metal stents were analysed using Wilcoxon-
Mann-Whitney tests or Fisher’s exact tests, as appropriate.
The incidence of events over time was with the use of the Kaplan-
Meier method, whereas log-rank tests and Cox proportional-hazards
regression analyses were applied to evaluate differences between
the two groups. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were censored. In
the main analysis, hazard ratios and 95% confidence intervals (CIs)
were adjusted for differences in outcome between trials. Owing to
the differences in the follow-up per study with a mean of 1,762,
1,384, 1,345 and 690 days in TAXUS I, II, IV and V respectively we
decided to count events through 1,440 days for TAXUS-I, II and IV
and through 730 days for TAXUS-V. Finally, two-year follow-up was
available for 95.2% of the patients in TAXUS-V, and four-year follow-
up was available for 100%, 96.1% and 94.1% in the TAXUS-I, II
and IV respectively. No events occurred beyond 1,440 days.
Exploratory analyses (not prespecified) were performed to evaluate
possible heterogeneities in treatment effects according to the trial-
of-enrolment and the following clinically and angiographic relevant
characteristics: age, gender, diabetes, dyslipidaemia, hypertension,
prior MI, clinical presentation, diseased vessel, left ventricular
ejection fraction, AHA/ACC lesion type and number of implanted
stents. Treatment effects were evaluated by Cox’ PH regressions
that included a characteristic times allocated treatment interaction
term, with adjustment for between-trial outcome differences. More
extensive regression models were applied to estimate adjusted
treatment effects15.
All statistical tests were two-sided, without correction for multiple
testing. P values of less than 0.05 and less than 0.01 were
considered to indicate statistical significance for the results of non-
heterogeneity tests and tests for heterogeneity in treatment effect,
respectively. All statistical analyses were performed with the use of
SAS software, version 8.2 (SAS Institute).
Results
A total of 2,797 patients were included in this analysis (TAXUS I: 61
patients, TAXUS II cohort I comparing the slow release formulation
and its respective control: 266, TAXUS IV: 1,314, TAXUS V: 1,156).
In total, 1,400 patients received a paclitaxel-eluting stent, and
1,397 patients were treated with a bare metal stent. The clinical and
angiographic characteristics of the study patients are summarised
in Table 1. Except for silent ischaemia at presentation, which was
slightly more frequent in the bare metal stent group as compared
with the paclitaxel-eluting stent group (18.4% versus 14.9%;
P=0.015), there were no significant differences in baseline clinical
and procedural characteristics between both treatment groups.
Results for all patients are shown in Table 2. The four-year
cumulative survival rate was similar in the paclitaxel-eluting stent
group as compared to the bare metal stent group (92.9% vs. 92.6%
respectively; hazard ratio for survival for the paclitaxel-eluting stent
group 0.95, 95% CI 0.70 -1.31; p=0.77). Subsequently, there were
no differences in both cardiovascular and non-cardiovascular
mortality. There were no differences in the occurrence of myocardial
infarction and total stent thrombosis between the two treatment
groups. Using the protocol definitions, stent thrombosis occurred in
16 patients in the paclitaxel-eluting stent group and 10 patients in
the bare metal stent group (Table 2). When the ARC definitions
were applied, stent thrombosis (either definite, probable or
possible) was noted in 39 patients in the paclitaxel-eluting stent
group and 41 patients in the bare metal stent group. Events
occurring after repeat revascularisation for restenosis accounted for
stent thrombosis in three patients with paclitaxel-eluting stents and
eight patients with bare-metal stents. Of note, all these events
occurred after 30 days. In the bare-metal stent group five definite or
probable stent thrombotic events occurred following repeat target
lesion intervention versus one on the paclitaxel-eluting stent group.
Worth mentioning was that in four out of five cases brachytherapy
was used whereas a new bare-metal stent was implanted in only
one case. In the sole event occurring post repeat intervention in the
paclitaxel-eluting stent group, brachytherapy was used as well.
No significant heterogeneity in the treatment effects was observed
in any of the prespecified characteristics, including complex lesions
and diabetes (Figure 2). While in the overall population diabetics
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Table 1. Baseline clinical and angiographic characteristics*.
Paclitaxel-eluting Bare-metal P-value
stent group stent group
(1,400 patients) (1,397 patients)
Age (years)
Median 63 62 0.15
IQR 55 - 71 55 - 70
Range 31 - 92 34 - 88
Men 71.4% (1,011/1,400) 71.7% (1,002/1,397) 0.30
Diabetes mellitus 25.4% (356/1,400) 25.7% (359/1,397) 0.90
IDDM 30.1% (107/356) 31.7% (114/359) 0.63
Previous MI 31.4% (440/1400) 29.6% (414/1397) 0.30
Previous PCI # 33.0% (406/1,232) 31.9% (390/1,222) 0.60
Previous CABG # 10.0% (137/1,369) 10.1% (138/1,365) 0.95
Hyperlipidaemia 70.1% (978/1,396) 70.1% (978/1,395) 1.00
Hypertension 72.1% (1,009/1,400) 70.6% (984/1,393) 0.40
Current smoker 23.8% (333/1,397) 22.2% (310/1,397) 0.32
Clinical presentation
Stable angina 54.4% (743/1,367) 54.4% (743/1,366) 1.00
Unstable angina 33.9% (464/1,369) 31.5% (430/1,366) 0.18
Silent ischaemia 14.9% (202/1,356) 18.4% (249/1,355) 0.015
Ejection fraction
Median 55 55 0.31
IQR 50-60 50-60
Range 25 - 90 10 - 88
Number of diseased vessels 0.39
1 82.1% (1,150/1,400) 83.4% (1,165/1,397)
2 17.9% (250/1,400) 16.6% (232/1,397)
Target vessel
LAD 40.2% (558/1,389) 39.8% (554/1,391) 0.88
LCX 27.2% (378/1,389) 26.4% (367/1,391) 0.67
RCA 32.6% (453/1,389) 33.8% (470/1,391) 0.49
Modified ACC-AHA Lesion Class §, #
A 9.4% (118/1,262) 7.9% (99/1,255) 0.20
B1 27.5% (347/1,262) 27.0% (339/1,255) 0.79
B2 35.8% (452/1,262) 36.6% (459/1,255) 0.71
C 27.3% (345/1,262) 28.5% (358/1,255) 0.54
Reference vessel diameter (mm)
Median 2.7 2.7 0.81
IQR 2.4 - 3.1 2.4 - 3.1
Range 1.2 - 4.8 1.2 - 4.5
Lesion length (mm)
Median 12.5 12.5 0.64
IQR 9.5 - 18.0 9.2 - 17.9
Range 2.4 - 58.2 2.0 - 67.3
Number of stents
Median 1 (1 - 1) 1 (1 - 1) 0.45
IQR 1 - 1 1 - 1
Range 0 - 5 0 - 5
Total stented length (mm)
Median 20 16 0.30
IQR 16 -32 16 - 32
Range 8 - 84 8 - 76
* Data for some characteristics were missing for some patients. IQR
denotes interquartile range, MI myocardial infarction, PCI percutaneous
coronary intervention, CABG coronary-aortic bypass graft, LAD left anterior
descending coronary artery, LCx left circumflex coronary artery, and RCA
right coronary artery.
§ Modified American College of Cardiology (ACC) and American Heart
Association (AHA) lesion classes A, B1, B2, and C are defined as a low-risk
lesion, a moderate-risk lesion with one B1 or with two or more B2 risk
factors, and a high-risk lesion, respectively.
# Information on previous CABG/PCI was not collected in TAXUS I and
previous PCI and AHA/ACC lesion type were not collected in TAXUS II.
Figure 1. Kaplan Meier survival curves for patients who received a
paclitaxel-eluting stent and those who received a bare-metal stent.
Survival rates at 1,440 days are shown in parenthesis. P-values were
calculated with the use of the log-rank test.
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had a worse overall survival as compared with the non-diabetic
patients, overall survival in both the bare-metal stent group and
paclitaxel-eluting stent group was comparable in both the diabetic
and non-diabetic subset (hazard ratio for survival for paclitaxel-
eluting stent treated diabetics 0.82, 95% CI 0.54-1.23; P for
interaction 0.71) (Figure 3). Additionally, in the diabetic patients
stent thrombosis occurred at an identical rate between the diabetic
patients receiving a bare-metal stent and a paclitaxel-eluting stent
(11 versus 13 events respectively according to the ARC definitions).
Discussion
In this pooled analysis of four randomised trials comparing
paclitaxel-eluting stents to bare metal stents in 2,797 patients with
four years of follow-up, we found similar rates of death, myocardial
infarction and stent thrombosis in both groups. No heterogeneity of
the treatment effect was found in the higher risk subsets, such as
diabetics or patients treated for complex lesions.
Recent concerns were raised about the long-term safety of drug-
eluting stents. Meta-analysis using published data and registries
suggested that their use would lead to marked increases in death,
myocardial infarction, stent thrombosis and even cancer. Shortly
after, physician derived independent patient level based meta-
analysis of randomised trials tempered these premature contentions
and a dedicated two-day Food and Drug Administration panel
meeting undermined the concept that the hypothesised safety
concerns outweighed the benefits of drug-eluting stents for on-label
use.16,17 The panelists’ opinions were more divided, and left open
the possibility that death and myocardial infarction due to stent
thrombosis might be increased in patients with off-label drug eluting
stent use.
In this analysis, angiographically proven stent thrombosis occurred
at a yearly rate of 0.2%. Similar results were noted in a pooled
analysis of randomised trials, which assessed the sirolimus-eluting
stent17. In contrast, the rate was 0.6% per year in a two-centre all-
Table 2. Rates of death and myocardial infarction at four-year follow-up*.
Paclitaxel-eluting stent group Bare-metal stent group Adjusted HR P-value
(1,400 patients) (1,397 patients) (95% CI)
N % N %
Death 75 7.1 79 7.4 0.95 (0.70 - 1.31) 0.77
Cardiac 31 2.7 35 3.1 0.89 (0.55 - 1.44) 0.63
Non-cardiac 44 4.4 44 4.4 1.00 (0.66 - 1.53) 0.98
Myocardial infarction 82 6.9 80 6.4 1.03 (0.75 - 1.39) 0.87
Q wave MI 13 1.0 12 1.1 1.09 (0.50 - 2.39) 0.83
Non-Q wave MI 71 6.1 70 5.5 1.01 (0.73 - 1.41) 0.94
Death or Q-wave MI 86 7.9 89 8.3 0.97 (0.72 - 1.31) 0.86
Death or any MI 148 13.0 149 12.7 1.02 (0.75 - 1.39) 0.89
Thrombosis by Protocol definition# 16 1.3 10 0.8 1.60 (0.73 - 3.54) 0.24
Acute ST (within 24 hours) 2 0.1 1 0.1 2.00 (0.18 - 22.03) 0.57
Subacute ST (within 1 - 30 days) 5 0.4 6 0.4 0.83 (0.25 - 2.73) 0.76
Late ST (after 30 days) 9 0.8 3 0.3 3.03 (0.82 - 11.20) 0.096
Thrombosis by Dublin definitions§
Acute ST (within 24 hours) 2 0.1 1 0.1 2.00 (0.18 - 22.03) 0.57
Subacute ST (within 1 - 30 days) 5 0.4 6 0.4 0.83 (0.25 - 2.73) 0.76
Late ST (within 30 days - 1 year) 12 0.9 13 0.9 0.92 (0.42 - 2.03) 0.84
Very late ST (after 1 year) 20 2.0 21 2.2 0.96 (0.52 - 1.77) 0.90
Definite ST 16 1.3 14 1.1 1.15 (0.56 - 2.35) 0.71
Definite or probable ST 22 1.9 18 1.5 1.23 (0.66 - 2.29) 0.52
Any ST 39 3.5 41 3.6 0.96 (0.62 - 1.48) 0.84
Primary thrombosis by Dublin definitions ¶
Acute ST (within 24 hours) 2 0.1 1 0.1 2.00 (0.18 - 22.03) 0.57
Subacute ST (within 1 - 30 days) 5 0.4 6 0.4 0.83 (0.25 - 2.73) 0.76
Late ST (within 30 days - 1 year) 11 0.8 11 0.8 1.00 (0.43 - 2.31) 1.00
Very late ST (after 1 year) 18 1.9 15 1.6 1.21 (0.61 - 2.41) 0.58
Definite ST 15 1.2 10 0.8 1.50 (0.68 - 3.35) 0.32
Definite or probable ST 21 1.8 13 1.1 1.62 (0.81 - 3.24) 0.17
Any ST 36 3.2 33 2.9 1.10 (0.68 - 1.76) 0.70
* All percentages are based on Kaplan-Meier estimates. Numbers of patients for death or Q-wave myocardial infarction (MI) and death or any MI do not total
the sums for each endpoint alone because some patients had both endpoints. CI denotes confidence interval.
# Definitions of stent thrombosis according to the study protocols were as follows: acute, within 24 hours after the procedure; subacute, within one to 30 days
after; and late, more than 30 days after.
§ Definitions of stent thrombosis of the academic research consortium (ARC) were as follows: acute, within 24 hours after the procedure; subacute, within one
to 30 days after; late, between 31 days and one year after; and very late, more than one year after. See text for details on stent-thrombosis adjudication per
protocol and per ARC definitions.
¶ Stent thrombosis events occurring post target-lesion revascularisation were censored.
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comers registry with a three-year follow-up.18 Careful selection and
follow-up of patients in randomised trials may account for this
difference. Primary angioplasty for acute myocardial infarction,
stent length, diabetes, bifurcation treatment and premature
antiplatelet discontinuation proved to be the strongest predictors of
stent thrombosis following drug-eluting stent implantation6,18-25.
Despite the inclusion of more complex patients in the more recent
TAXUS studies, these characteristics were absent or less frequently
Figure 2. All-cause mortality in selected subgroups. Exploratory analy-
ses to evaluate possible heterogeneity in treatment effects on mortal-
ity according to the trial of enrolment and the following clinically
relevant characteristics: age, gender, diabetes, dyslipidaemia, hyper-
tension, prior MI, clinical presentation, diseased vessel, left ventricu-
lar ejection fraction, AHA/ACC lesion type and number of implanted
stents. The size of the squares corresponds to the amount of statisti-
cal information. For the continuous variables (age and left ventricular
ejection fraction), medians were used as cut-off. Results of tests for
heterogeneity in treatment effect were considered significant if P was
<0.01. MI=myocardial infarction, LVEF=left ventricular ejection frac-
tion, RVD=reference vessel diameter.
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Figure 3. Kaplan Meier curve showing freedom from stent thrombosis
according to the Dublin definitions. Survival rates at 1,440 days are
shown in parenthesis. P-values were calculated with the use of the
log-rank test.
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observed in the present analysis. Therefore, extrapolation of our
findings to a real world patient population might be far-fetched.
To better define the relative contribution of stent thrombosis to the
mortality rate in both groups, the events were adjudicated according
to definitions recently developed by a consensus group.
Classification in three categories (definite, probable, and possible)
allows uniform description and reliable comparison of stent
thrombosis rates between studies and registries. Late events such
as unexplained death, which were not considered in the initial
protocol definitions, were adjudicated as possible stent thrombosis.
Thrombotic occlusion occurring after repeat revascularisation were
also adjudicated as thrombosis of the original stent. In the bare
metal stent group, 28% (5/18) of the definite or probable stent
thrombosis occurred following a target lesion revascularisation
compared with 5% (1/22) in the paclitaxel-eluting stent group. The
validity of adjudicating events occurring after repeat
revascularisation to stent thrombosis of the original stent is
debatable, and it is worth mentioning that a thrombotic occlusion
following a repeat target lesion intervention was not considered a
stent thrombosis in the initial per protocol definitions. However,
stent thrombosis following repeat revascularisation emphasises the
potentially severe consequences of restenosis, which is still often
considered as a purely benign process. Dedicated studies of
hospitalisation for in-stent restenosis showed that up to 10% of
these patients presented with a myocardial infarction or sudden
death26,27. Additionally, two studies demonstrated a close
correlation between the rate of restenosis and late mortality.28,29 One
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could therefore expect to find a decrease in the rates of death and
myocardial infarction in the long-term follow-up of drug-eluting
stents due to a reduction in repeat revascularisation. However, our
analysis and data from large-scale real world registries shows that
there is no benefit at four years on these hard clinical endpoints. It
remains to be determined whether the long-term restenosis
reduction gained with DES use, outweighs a possibly slightly higher
incidence of late stent thrombosis5,30-32.
Recent concerns were raised about the long-term safety of
sirolimus-eluting stents in patients with diabetes mellitus. In a
pooled analysis of the pivotal randomised sirolimus-eluting stent
trials, a significantly reduced survival rate was found among
diabetic (but not nondiabetic) patients treated with sirolimus-eluting
stents17. Analysis of the causes of death and the occurrence of stent
thrombosis in this high-risk subset could not adequately explain the
observed difference in survival, and the four-year survival rate of
diabetic patients receiving bare-metal stents was surprisingly high
as compared to previous studies or the present analysis (95.6%
versus 90.1% respectively). Nevertheless, in the present analyses,
the overall survival was similar between the bare metal and
paclitaxel-eluting stent group and although larger trials with long-
term follow-up in diabetics are needed to settle this issue, there
seems so far no cause of concern for a reduced safety of drug-
eluting stents in diabetics.
The present analysis exclusively studied the slow-release PES,
which is the only commercially available TAXUS stent. In the TAXUS
II trial, the moderate-release PES, characterised by an three-fold
greater amount of in vivo drug release over the first 30 days, proved
to have a similar efficacy as the slow-release PES and the authors
thereby suggested that the dosing threshold for prevention of
restenosis had already been reached with the slow release version,
at least for low-risk lesions8.
Several limitations need to be addressed. The present analysis was
underpowered to detect a clinically significant difference in mortality,
however, it is worth mentioning that ten thousand patients would be
needed based on the results of the present study. Treatment with
clopidogrel was required for at least six months by the original trial
protocols, but no information on actual individual patient use was
available, especially in patients with adverse events. Thus, we cannot
provide any specific insight into the question of whether further
prolonging dual antiplatelet therapy would reduce the risk of such
events. We performed multiple subgroup analyses, including those
for diabetes and complex lesions, which were not pre-specified. The
number of fatal events in these subgroups was numerically small, so
that the findings may still be due to the play of chance.
In summary, in this pooled analysis of four randomised trials, we
compared the effects of paclitaxel-eluting stents with those of bare
metal stents on clinical events at four years. No significant
differences in the rates of death, myocardial infarction or stent
thrombosis were demonstrated.
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Abstract
Background: Sirolimus- and paclitaxel- eluting stents (SES and PES respectively) have been shown to
produce a sustained reduction in restenosis and repeat revascularisations as compared to bare-metal
stents (BMS) up to four years. There is still limited data about the long-term safety and efficacy of DES in
high-risk subgroups.
Methods and results: A total of 6,129 consecutive patients were treated during three sequential periods with
BMS (n=2,428; January, 2000 to April, 2002), SES (n=866; April 2002 to February 2003) or PES
(n=2,835; February 2003 to December 2005). A stratified analysis (including age, gender, diabetes,
clinical presentation, treated vessel, multivessel disease, AHA lesion class, bifurcation, in-stent restenosis,
average stent diameter <2.5 mm and total stented length <30 mm) was performed to evaluate possible
heterogeneities in treatment effect. At four years, all-cause mortality was identical between the drug-eluting
stent (DES) and BMS cohorts (13.5% vs. 13.4%, respectively; Adjusted HR 1.10, 95% CI 0.90 - 1.34)
without evidence of heterogeneity in the high-risk patient subsets. Both DES significantly reduced the risk
for target vessel revascularisation (TVR) as compared to BMS (TVR: 11.9% vs. 15.7% respectively;
Adjusted HR 0.69, 95% CI 0.58 - 0.82) along with a reduced risk for post-operative MI (adjusted HR 0.75,
95% CI 0.57 - 0.98), but counterbalanced by a non-significantly higher risk for stent thrombosis (3.1% vs.
1.6%; adjusted HR 1.26, 95% CI 0.82 - 1.95). DES failed to show superiority to BMS in patients with acute
myocardial infarction (TVR 10.5% vs. 9.2% respectively; Adjusted HR 1.26, 95% CI 0.82 - 1.93).
Conclusions: In a real world patient population, after four years, the overall use of DES was associated with
similar all-cause mortality rates and a significantly reduced risk for post-operative MI and TVR as compared
to BMS.
KEYWORDS
Sirolimus-eluting stent, 
paclitaxel-eluting
stent, long-term safety
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Introduction
While the superior anti-restenotic properties of drug-eluting stents
(DES) have been extensively demonstrated, their impact on hard
clinical endpoints like death and myocardial infarction (MI) was
never appropriately studied. Although pivotal randomised controlled
trials and meta-analyses demonstrated similar rates of death, post-
operative MI and stent thrombosis in DES as compared to bare-
metal stents (BMS), they were underpowered to detect meaningful
differences in these hard clinical endpoints, particularly when the
relative safety and efficacy were questioned in high-risk
subgroups.1-4 Although the randomisation was a key feature, the
main limiting factors in the pivotal randomised trials were the highly
selected patient populations (approximately 40% of the daily clinical
practice) and the use of angiographic primary endpoints in many of
them. These constraints limited the ability to generalise the
conclusions to an all-comer population and precluded proper
subgroup analysis. Meta-analyses of randomised controlled trials,
including trials in higher risk patients, using aggregate data rather
than patient-level data, partially resolved the long-term safety
concerns but were again unable to study high-risk subgroups.
Registries including higher risk patients have recently shown
a consistent trend towards an increased rate of late stent
thrombosis, but an improved survival rate when DES are used.5-9
However, the majority of the registries suffer from a severe selection
bias due to concomitant non-randomised use of DES and BMS.
Thereby, the “DES” cohorts in these studies were often a mixture of
different types of DES (often mixed with BMS), and ignored the fact
that there is a clear difference in the safety and efficacy of different
types of DES.4,10-12
In the present study, we analysed the relative safety and efficacy of
three sequential cohorts of all-comers (n=6.129) treated with either
BMS, sirolimus- or paclitaxel-eluting stents (SES and PES
respectively). In particular, we performed a stratified analysis to study
the efficacy of both types of DES among high-risk patient subsets.
Methods
Study design and patient population
Between January 1, 2000 and December 31, 2005, a total of 7,217
percutaneous coronary interventions were performed in our
institution using BMS, SES or PES. From January 2000 until April 16th
2002, 2,681 percutaneous coronary interventions were performed
using exclusively bare metal stents, from April 16, 2002, until
February 23, 2003, 1,035 interventions were performed using SES
(Cypher®, Cordis Corp., Johnson & Johnson, Warren, NJ, USA), as
part of RESEARCH registry13, and from February 23, 2003 to
December 31, 2005, 3,339 interventions using PES (TAXUS™
Express2™ or Liberté™, Boston Scientific, Natick, MA, USA), as
part of the T-SEARCH registry.14 Procedures in which two different
types of stents (BMS and either SES or PES; SES and either BMS or
PES; PES and either SES or BMS) were used were excluded
(n=162).
Although a total of 784 patients underwent multiple procedures,
only patients initially enrolled in one of the sequential cohorts (BMS,
SES or PES group) were maintained for analytical purposes
throughout the follow-up period in their original cohort, even if
a repeat intervention was performed using a different type of stent.
A total of 6,129 patients fulfilled these criteria. (Figure 1)
This study was approved by the local ethics committee and
performed in accordance with the Declaration of Helsinki. Written
informed consent was obtained from all patients.
Procedures and post-intervention medications
All procedures were performed following previously defined current
standard procedural guidelines.15 Baseline, clinical and procedural
patient characteristics were prospectively entered into a dedicated
database.
Patients were prescribed aspirin plus clopidogrel 75 mg/day (after
a loading dose of 300 mg) before or during baseline coronary
interventions. Patients treated with BMS received at least one
month of clopidogrel (mean 2.4±2.3 months). Patients treated with
SES, received at least three months of clopidogrel (mean 4.5±3.2
months), and patients treated with PES received at least six months
of clopidogrel (mean 6.4±3.4 months). All patients were advised to
remain on aspirin indefinitely.
Planned angiographic follow-up was performed in 12.0%, 25.9%
and 14.3% in the BMS, SES and PES groups respectively.
Baseline definitions
Angina was categorised according to the Canadian Cardiovascular
Society (CCS) classification for stable angina and according to the
Braunwald classification for unstable angina.16,17 Hypertension was
defined as a blood pressure >140 systolic or > 90 mmHg diastolic
or based on the current use of antihypertensive treatment.
Dyslipidaemia was classified as a total serum cholesterol level
> 6.2 mmol/l or the use of lipid lowering drugs. Diabetes was
defined as treatment with either an oral hypoglycaemic agent,
insulin, or through diet. Complete procedural success was defined
as the achievement of <50% diameter stenosis (visual assessment)
and Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow in all
Figure 1. Flowchart depicting the number of procedures in the three
sequential periods and the number of patients fulfilling the inclusion
criteria in each cohort. Primary cases indicates the number of patients
undergoing their first intervention in the study period (2000-2005).
SES indicates sirolimus-eluting stent, BMS bare metal stent, PES
paclitaxel-eluting stent, PCI percutaneous coronary intervention.
Jan 2000 Apr 2002 Feb 2003 Dec 2005
7217 PCIs
6129 patients
7055 PCIs
BMS=2681 SES=1035 PES=3339
BMS=2428 SES=866 PES=2835
Restricting to primary cases
Excluding 162 procedures with combined use of either BMS, SES or PES
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lesions intended to treat. Clinical success was defined as
procedural success without death or (re) infarction during the index
hospitalisation.
Endpoint definitions and clinical follow-up
The primary safety endpoint was all-cause death and post-operative
MI and the primary efficacy endpoint was target vessel
revascularisation (TVR) at 4-years of follow-up. Secondary
endpoints were the itemised outcome parameters: all-cause death,
cardiac death and death from cancer, post-operative MI, TVR and
stent thrombosis. Survival data for all patients were obtained from
municipal civil registries on a yearly basis for each of the three
patient cohorts. The most recent follow-up was performed in
October 2007. Causes of death were obtained from the Central
Bureau of Statistics, The Hague, The Netherlands. Causes of death
were classified according to the International Classification of
Diseases and Related Health Problems, 10th Revision (ICD-10).18
For the present analysis, death from ischaemic heart disease (I-20 - I-
25), sudden cardiac death (I-46), sudden death undefined (R-96),
or death from heart failure (I-50) were considered to be cardiac.
Death from cancer was defined as any death from malignant
neoplasms (C-00 - C-97). All the remaining deaths were classified
as being due to other causes and no further distinctions were made.
Follow-up was complete for 98.7% of the BMS patients, 100% of
the SES patients and 98.4% of the PES patients. Target vessel
revascularisation was defined as a re-intervention driven by any
lesion located in the same epicardial vessel.19 Myocardial infarction
at follow-up was diagnosed by a rise in creatine kinase-MB fraction
(CK-MB) of three times the upper limit of normal, according to
American Heart Association/American College of Cardiology
guidelines.20 Stent thrombosis (ST) was defined as angiographically
defined thrombosis with TIMI grade 0 or 1 flow or the presence of a
flow limiting thrombus, accompanied by acute symptoms,
irrespective of whether there had been an intervening
reintervention.21 The timing of ST was categorised as early (within
30 days after implantation), late (between 30 days and 1 year) or
very late (more than 1 year).22 Additionally, a difference was made
between primary stent thrombosis (occurring directly after the index
procedure) and secondary stent thrombosis (stent thrombosis
occurring following a repeat target vessel revascularisation).
Statistical analysis
Continuous variables are presented as mean ±standard deviation.
Categorical variables are expressed as percentages. Comparisons
among the three groups were performed by the F-test from an
analysis of variance for continuous variables and Pearson’s Chi-
Square test for categorical variables. All statistical tests are 2-tailed.
The incidence of events over time was studied with the use of the
Kaplan-Meier method, whereas log-rank tests were applied to
evaluate differences between the treatment groups. Patients lost to
follow-up were considered at risk until the date of last contact, at
which point they were censored. Cox proportional-hazards
regression analyses were applied to further study treatment effects,
adjusting for potential confounders listed in Table 1. The number of
co-variables in the final model was limited to variables (p<0.10) in
Cox multivariable regression, and variables considered clinically
relevant for each specific endpoint. Final results are presented as
adjusted hazard ratios with 95% confidence interval. Subsequent
analyses were performed to evaluate possible heterogeneities in
treatment effects on mortality and TVR according to the following
clinically relevant characteristics: age, gender, diabetes, clinical
presentation, treated vessel, multivessel disease, AHA lesion class,
bifurcation, in-stent restenosis, average stent diameter≤2.5 mm and
total stented length >30 mm. Treatment effects were evaluated with
the use of Cox regressions that included a term for the interaction
between each characteristic of interest and the assigned treatment,
adjusted for the previously defined clinically relevant characteristics.
Given the differential follow-up in the three treatment cohorts,
additional stepwise logistic regression analyses were performed on
the 2-year endpoints of all-cause mortality and TVR to check
whether these results were in line with the Cox proportional hazards
regression analyses on the 4-year endpoints.
Results
Baseline and procedural characteristics
Both baseline and procedural characteristics are depicted in
Table 1. Mean age increased slightly over time from 61.5±11.8 in
the BMS group to 62.2±11.5 in the PES group (p=0.04). Treatment
for acute MI increased from 22.4% in the BMS group to 36.1% in
the PES group (P<0.001). Procedural complexity increased over
time, illustrated by an increase in the treatment of type C lesions,
bifurcations and left main stem lesions. Over time, total stented
length and number of stents increased, while the average stent
diameter decreased.
Clinical outcomes
At thirty days, the cumulative incidence of all-cause mortality was
3.5% in both the DES and BMS groups (adjusted HR 0.84, 95% CI
0.63 - 1.13). However, there was a trend towards a lower 30-day
mortality rate in the SES group (2.2%) compared to the PES group
(4.0%) (adjusted HR 0.73, 95% CI 0.44 - 1.22). At four years, the
mortality rates in the DES and BMS group remained remarkably
similar (13.5% vs. 13.4% respectively; adjusted HR 1.10, 95% CI
0.90 - 1.34); however, a trend remained towards a lower mortality
rate in the SES group as compared to the PES group (11.2% vs.
14.0% respectively; adjusted HR 1.16, 95% CI 0.88 - 1.53)
(Table 2, Figure 2).
The majority (57%) of all deaths were due to cardiac causes, 15%
were due to cancer and 28% of the patients died of other causes.
While cardiac mortality was similar in the overall DES group as
compared with the BMS group, the cardiac mortality rate was
significantly lower in the SES group as compared with the PES
group (5.8% vs. 8.0% respectively, adjusted HR 0.69 95% CI 0.49
- 0.97). Death due to cancer occurred at a similar rate in both DES
groups as in the BMS group (Table 2).
Although the cumulative incidence of post-operative MI was similar
among the DES and BMS groups (4.8% vs. 4.9% respectively)
DES in low- and high-risk pati ents | Chapter 22
225
adjusting for independent predictors resulted in a significantly lower
risk for post-operative MI in the DES group (adjusted HR 0.75, 95%
CI 0.57 - 0.98). No statistically significant differences were observed
between the SES and PES group (adjusted HR 0.84, 95% CI 0.57 -
1.24). (Table 2)
The cumulative incidence of angiographic stent thrombosis was
significantly higher in the DES group as compared to the BMS group
(3.1% vs. 1.6%; HR 1.80, 95% CI 1.23 - 2.64)(Figure 3). Cox
multivariable regression analysis revealed that in the BMS group
previous brachytherapy and MI at presentation were significant
Table 1. Clinical and procedural characteristics of the study population stratified according to stent type.
Variables Bare metal stent Drug-eluting stent Sirolimus-eluting Paclitaxel-eluting  p*
(n=2428) (n=3701) stent (n=866) stent (n=2835) value
Age, years (SD) 61.5 (11.8) 62.1 (11.4) 61.5 (11.0) 62.2 (11.5) 0.04
Male gender 1768/2428 (72.8) 2767/3701 (72.3) 609/866 (70.3) 2067/2835 (72.9) 0.30
Indication SA 1005/2428 (41.4) 1444/3701 (39.0) 373/862 (43.3) 1071/2832 (37.8) 0.003
Indication UA 878/2428 (36.2) 1043/3701 (28.2) 303/862 (35.2) 740/2832 (26.1) <0.001
Indication MI 545/2428 (22.4) 1207/3701 (32.6) 186/862 (21.6) 1021/2832 (36.1) <0.001
Cardiogenic shock 24/2428 (1.0) 75/3701 (2.0) 24/862 (2.8) 51/2832 (1.8) <0.001
DM 320/2428 (13.2) 619/3701 (16.7) 150/866 (17.3) 469/2835 (16.5) 0.001
IDDM 32/2428 (1.3) 155/3701 (4.2) 47/866 (5.4) 108/2835 (3.8) <0.001
NIDDM 288/2428 (11.9) 471/3701 (12.7) 104/866 (12.0) 367/2835 (12.9) 0.46
Hypertension 793/2428 (32.7) 1944/3701 (33.0) 357/866 (41.2) 1172/2835 (41.3) <0.001
Hypercholesterolaemia 1057/2428 (43.5) 1944/3701 (52.5) 479/866 (55.3) 1465/2835 (51.7) <0.001
Family history 523/2428 (21.5) 1220/3701 (33.0) 267/866 (30.8) 953/2835 (33.6) <0.001
Current smoking 588/2428 (24.1) 997/3701 (26.9) 254/866 (27.9) 743/2835 (25.7) 0.011
Previous PCI 384/2422 (15.9) 416/3675 (11.2) 102/864 (11.8) 314/2811 (11.2) <0.001
Previous CABG 289/2425 (11.9) 286/3675 (7.7) 61/865 (7.1) 225/2810 (8.0) <0.001
Previous MI 847/2403 (35.2) 965/3636 (26.1) 269/859 (31.3) 696/2777 (25.1) <0.001
Treated vessel
RCA 957/2428 (39.4) 1415/3701 (38.2) 351/866 (40.5) 1064/2835 (37.5) 0.18
LAD 1291/2428 (53.2) 2009/3701 (54.3) 514/866 (59.4) 1495/2835 (52.7) 0.002
LCX 732/2428 (30.1) 115/3701 (30.1) 283/866 (32.7) 832/2835 (29.3) 0.17
LM 86/2428 (3.5) 174/3701 (4.7) 27/866 (3.1) 147/2835 (5.2) 0.003
Bypass graft 135/2428 (5.6) 118/3701 (3.2) 17/866 (2.0) 101/2835 (3.6) <0.001
AHA Lesion class
Type A 432/2428 (17.8) 421/3701 (11.4) 162/866 (18.7) 259/2835 (9.1) <0.001
Type B1 814/2428 (33.5) 978/3701 (26.4) 295/866 (34.1) 683/2835 (24.1) <0.001
Type B2 1109/2428 (45.7) 1610/3701 (43.5) 426/866 (49.2) 1184/2835 (41.8) <0.001
Type C 883/2428 (36.4) 1556/3701 (42.0) 372/866 (43.0) 1184/2835 (41.8) <0.001
Bifurcation 87/2428 (3.6) 437/3701 (11.8) 88/866 (10.2) 349/2835 (12.3) <0.001
Multivessel disease 1280/2426 (52.8) 1911/3692 (51.6) 40/866 (54.3) 1441/2826 (51.0) 0.18
Multivessel treatment 690/2428 (28.4) 1014/3701 (27.4) 284/866 (32.8) 730/2835 (25.7) <0.001
ISR 164/2417 (6.8) 132/3605 (3.6) 43/864 (5.0) 89/2741 (3.2) <0.001
Previous brachytherapy 150/2428 (6.2) 23/3701 (0.6) 11/866 (1.3) 12/2835 (0.4) <0.001
Number of stents (SD) 1.8 (1.1) 2.2 (1.4) 2.2 (1.5) 2.2 (1.4) <0.001
Average stent diameter 3.3 (0.6) 2.9 (0.5) 2.8 (0.3) 2.9 (0.6) <0.001
Total stented length 28.3 (20.0) 42.7 (31.0) 42.8 (30.1) 42.7 (31.1) <0.001
Clinical success rate 2377/2424 (98.1) 3467/3541 (97.9) 838/859 (97.6) 2629/2682 (98.0) 0.64
Complete procedural success rate 2314/2425 (95.4) 3373/3547 (95.1) 819/862 (95.0) 2554/2685 (95.1) 0.84
IIb/IIIa Inhibitor 791/2428 (32.6) 371/3701 (19.8) 184/866 (21.2) 547/2835 (19.3) <0.001
Duration of clopidogrel in months (SD) 2.4 (2.3) 6.1 (3.5) 4.5 (3.2) 6.6 (3.4) <0.001
Planned angiographic follow-up 280/2330 (12.0) 602/3521 (17.1) 221/854 (25.9) 381/2667 (14.3) <0.001
Figures are represented as absolute numbers and percentages or means and standard deviations as appropriate. SD indicates standard deviation; IDDM:
insulin dependant diabetes mellitus; NIDDM: Non-insulin dependent diabetes mellitus; SA: stable angina; UA: unstable angina; MI: myocardial infarction;
PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; LAD: left anterior descending coronary artery; LCx: left circumflex coronary
artery; RCA: right coronary artery: LM: left main coronary artery; SVG: saphenous vein bypass graft; AHA: American Heart Association and ISR in-stent
restenosis. * P-values are based on comparison BMS, SES and PES.
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in the DES group (p=0.016).
TVR was performed significantly more often in the BMS group
(15.7%) as compared to the two DES groups (12.2% vs. 12.0% in
the SES and PES groups, respectively)(Table 3, Figure 4). The use
of DES was associated with a 31% lower risk for TVR at 4-years
compared to BMS (adjusted HR 0.69, 95% CI 0.58 - 0.82). As
compared to PES, the use of SES was associated with an equal risk
for TVR at 4-years (adjusted HR 0.99, 95% CI 0.77 - 1.28).
Finally, given the differential follow-up between the three treatment
cohorts, a stepwise logistic regression analyses with follow-up
truncated at two years was used to test the estimated 4-year
treatment effect using Cox proportional hazards regression
analyses. At two years, the adjusted HR for all-cause mortality in the
DES group was 0.92, 95% CI 0.77 - 1.10, which was comparable to
initial adjusted HR of 1.04, 95% CI 0.80 - 1.34 derived from a Cox
proportional hazards regression model including all univariate
significant (p<0.1) predictors of all-cause mortality. Similarly, for
TVR, the adjusted HR at two years was 0.55, 95% CI 0.46 - 0.65,
which was comparable to initial adjusted HR of 0.60, 95% CI 0.50 -
0.73 derived from a Cox proportional hazards regression model
including all univariate significant (p<0.1) predictors of TVR.
- 5 -
predictors of stent thrombosis while in the DES group, MI at
presentation, diabetes, treatment of the LAD and age significantly
increased the risk for stent thrombosis (Table 3). When correcting for
independent predictors of stent thrombosis, the adjusted risk for
stent thrombosis in the DES group decreased to 1.26 (95% CI 0.82 -
1.95). Additionally, there were no significant differences in the
occurrence of stent thrombosis between both DES groups (adjusted
HR 0.82, 95% CI 0.50 - 1.34). Among patients with stent thrombosis,
secondary stent thrombosis (stent thrombosis occurring after
a target lesion revascularisation) occurred in 10.8% of the BMS
patients compared to the 4.3% of the DES patients (p=0.22). None
(0%) of the patients in the BMS group vs. one (0.1%) patient in the
SES group and eight (0.3%) patients in the PES group experienced
a second episode of stent thrombosis. In the BMS group 22/111
(19.8%) post-operative MIs were due to ST versus 59/153 (38.6%)
Figure 2. Kaplan Meier all-cause mortality curves for all patients
receiving bare-metal stents (BMS), sirolimus-eluting stents (SES) or
paclitaxel-eluting stents (PES).
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Figure 3. Chart depicting the cumulative incidence of early
(<30 days), late (>30 days, <365 days) and very late (>365 days)
angiographic stent thrombosis in the bare-metal stent group (BMS),
sirolimus-eluting stent (SES) group, paclitaxel-eluting stent group
(PES) and drug-eluting stent (DES) group (combined SES and PES). P
values are based on the Logrank test.
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Table 2. All cause and specified mortality rates at 4 years.
Bare metal Drug-eluting Sirolimus-eluting Paclitaxel-eluting Drug-eluting Sirolimus- 
stent (n=2428) stent (n=3701) stent (n=866) stent (n=2835) vs. bare-metal stent vs. Paclitaxel-eluting stent
N % N % N % N % Adjusted HR [95% CI] Adjusted HR [95% CI]
All-cause death 318 13.4 400 13.5 93 11.2 307 14.0 1.10 [0.90-1.34] 1.16 [0.88-1.53]
Cardiac death 176 7.5 233 7.5 48 5.8 185 8.0 1.00 [0.80-1.25] 0.69 [0.49-0.97]
Death due to cancer 50 2.3 58 2.3 16 2.1 42 2.4 1.16 [0.77-1.75] 0.98 [0.53-1.81]
Myocardial infarction (MI) 111 4.9 153 4.8 34 4.1 119 5.1 0.75 [0.57-0.98] 0.84 [0.57-1.24]
Cardiac death or MI 274 11.7 370 11.7 79 9.5 291 12.4 0.90 [0.75-1.07] 0.76 [0.58-0.90]
Angiographic stent 
thrombosis 37 1.6 93 3.1 22 2.7 71 3.2 1.26 [0.82-1.95] 0.82 [0.50-1.34]
Target vessel 
revascularisation (TVR) 355 15.7 356 11.9 99 12.2 257 12.0 0.69 [0.58-0.82] 0.99 [0.77-1.28]
All-cause death, MI or TVR 676 28.4 778 25.3 189 22.4 589 26.6 0.83 [0.74-0.94] 0.85 [0.71-1.01]
SES: sirolimus-eluting stent; BMS: bare metal stent; PES: paclitaxel-eluting stent; HR: hazard ratio; CI: confidence interval. Percentages are based on Kaplan
Meier estimates. All hazard ratios are adjusted hazard ratios considering potential confounders listed in Table 1.
DES in low- and high-risk pati ents | Chapter 22
227
Stratified analysis among subgroups
When more specifically analysing the heterogeneity of the treatment
effect (DES vs. BMS) on the 4-year TVR rates, a trend towards
heterogeneity was observed among patients presenting with MI (p
heterogeneity 0.086).(Figure 5a) When assessing the treatment
effect of SES vs. PES, which was remarkably similar in the overall
population (Figure 4), significant heterogeneity was observed in
patients with diabetes (p heterogeneity 0.045), and bifurcation
lesions (p heterogeneity 0.036).(Figure 5b)
A stratified analysis to detect heterogeneity in the treatment effect
between DES vs. BMS and SES vs. PES did not reveal any
significant differences in the 4-year all-cause mortality rates.
ST segment elevation MI subgroup
While in patients presenting with stable or unstable angina, the risk
for TVR at 4-years was 38% lower in patients treated with DES as
compared to BMS (adjusted HR 0.62, 95% CI 0.51 - 0.75), the risk
for TVR in patients presenting with MI was 26% higher (adjusted
HR 1.26; 95% CI 0.82 - 1.93) in patients treated with DES as
compared with BMS (p heterogeneity 0.086). There was no
difference between SES and PES at four years (Figure 5b). The
cumulative incidence of all-cause mortality was 16.9% in the DES
group vs. 18.7% in the BMS group (Adjusted HR 1.15, 95% CI
0.76 - 1.74) with no significant difference between the SES and PES
groups (14.8% vs. 17.0% respectively; adjusted HR 0.82, 95% CI
0.53 - 1.29). Furthermore, there was no difference in the combined
endpoint of cardiac death or post-operative MI in DES (18.6%) and
BMS (17.9%) group (Adjusted HR 1.05, 95% CI 0.60 - 1.84). Stent
thrombosis however, occurred in 5.0% of the DES (SES: 4.9%, PES
4.7%) patients as compared to 2.4% of the BMS patients (p=0.06)
and very late stent thrombosis (>1 year) was significantly more
frequent in the DES as compared to the BMS group (2.7% vs. 0%
respectively; p=0.0007).
Diabetes subgroup
Although the 4-year cumulative incidence of TVR in the diabetic
subset was significantly lower in the overall DES group as compared
to the BMS group (16.2% vs. 24.6%; Adjusted HR 0.53, 95% CI
0.36 - 0.78) significant heterogeneity in the treatment effect was
found between SES and PES.(Figure 5b) While in the non-diabetics,
the risk for TVR in the SES group was 11% lower than in the PES
group (adjusted HR 0.89, 95% CI 0.67 - 1.19), the risk was 41%
Table 3. Univariate and multivariate predictors of stent thrombosis at 4 years in the bare metal- and drug-eluting stent groups.
BMS DES
Univariate HR [95% CI] Adjusted HR [95% CI] Univariate HR [95% CI] Adjusted HR [95% CI]
Age – – 0.97 [0.95-0.98] 0.97 [0.95-0.99]
Clinical presentation
Stable angina (ref) – – – –
Unstable angina 2.46 [1.06-5.70] 2.54 [1.08-5.97] 1.86 [1.07-3.24] 2.04 [1.17-3.57]
Myocardial infarction 3.00 [1.23-7.35] 3.56 [1.40-9.09] 2.62 [1.57-4.39] 3.45 [1.99-5.97]
Diabetes – – 1.50 [0.92-2.44] 1.83 [1.10-3.00]
Family history – – 1.42 [0.94-2.14] 1.44 [0.94-2.19]
Previous brachytherapy 2.84 [1.18-6.80] 3.70 [1.48-9.29] – –
Treatment of RCA 0.24 [0.09-0.61] 0.42 [0.14-1.23] – –
Treatment of LAD 2.11 [1.04-4.26] 2.01 [0.80 -5.03] 2.15 [1.36-3.38] 1.92 [1.20-3.05]
Treatment of bypass graft 2.65 [1.03-6.79] 3.22 [0.99-10.4] – –
Bifurcation treatment – – 1.77 [1.06-2.96] 1.33 [0.77-2.31]
Number of stents 0.69 [0.45-1.03] 1.01 [0.50-2.05] 1.22 [1.09-1.37] 1.19 [0.89-1.61]
Total stented length 0.98 [0.95-1.00] 0.98 [0.98-1.02] 1.01 [1.00-1.01] 1.00 [0.99-1.02]
AHA lesion type B2/C – – 1.97 [1.10-3.54] 1.48 [0.81-2.70]
BMS: indicates bare-metal stent; DES: drug-eluting stent; RCA: right coronary artery; LAD: left anterior descending coronary artery; AHA: American Heart
Association
Figure 4. Kaplan Meier curves for target vessel revascularisation up to
4 years for all patients receiving bare-metal stents (BMS), sirolimus-
eluting stents (SES) or paclitaxel-eluting stents (PES).
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higher in the patients with diabetes (adjusted HR 1.41, 95% CI 0.85 -
2.35) (p heterogeneity 0.045). In diabetics, the cumulative incidence
of TVR at 4-years was 20.9% in the SES patients as compared with
13.9% in the PES group (Logrank p-value 0.048). There were no
significant differences in the hard clinical endpoints between SES and
PES treated patients: four-year all-cause mortality was 19.4% in the
SES group as compared to 18.4% in the PES group (Adjusted HR
1.38, 95% CI 0.86 - 2.19), whilst the cumulative incidence of cardiac
death or post-operative MI was 17.7% in the SES group as compared
to 14.6% in the PES group (Adjusted HR 1.09 95% CI 0.64 - 1.83)
and stent thrombosis occurred in 6.5% of the SES patients as
compared to 4.1% of the PES patients (adjusted HR 1.41; 95% CI
0.56 - 3.56).
Bifurcation lesions
Finally, significant heterogeneity in the 4-year TVR rates between
SES and PES was observed in patients treated for bifurcation
lesions. While in patients without bifurcations there was no
difference between the TVR rates in both DES groups (12.7% in the
SES group vs. 11.7% in the PES group; adjusted HR 1.04, 95% CI
0.80 - 1.36), in patients with bifurcation lesions conversely, there
was a strong trend towards a lower TVR risk in patients treated with
SES as compared to PES (7.1% vs. 14.3% respectively; adjusted
HR 0.56, 95% CI 0.23 - 1.36) (p heterogeneity 0.036).(Figure 5b)
The difference in all-cause mortality did not reach statistical
significance (SES: 6.2% vs. PES: 15.2%; adjusted HR 0.62, 95% CI
0.21 - 1.84). However, the cumulative incidence of cardiac death or
post-operative MI was significantly lower in the SES group as
compared to the PES group (4.5% vs. 14.2%; adjusted HR 0.30,
95% CI 0.10 - 0.88). Additionally, the cumulative incidence of stent
thrombosis was lower in the SES group (1.3%) than in the PES
group (5.2%) (adjusted HR 0.21, 95% CI 0.03 - 1.67).
Discussion
The results of the present study show that in a real world patient
population, after four years, the overall use of DES was associated
with similar all-cause mortality rates and a significantly reduced risk
of post-operative MI and TVR as compared to BMS. As compared to
patients treated with PES, the use of SES was associated with a
significantly lower cardiac mortality and a strong trend towards
Figure 5. Exploratory analyses to evaluate possible heterogeneity in treatment effects on 4-year target vessel revascularisation rates according to
drug-eluting vs. bare-metal stent cohort (A) and according to the sirolimus- vs. paclitaxel-eluting stent treatment cohort (B) and the following
clinically relevant characteristics: age, gender, diabetes, clinical presentation, treated vessel, multivessel disease, AHA lesion class, bifurcation,
in-stent restenosis, average stent diameter≤2.5 mm and total stented length≤30 mm. The size of the squares corresponds to the amount of
statistical information. For the continuous variables (age, average stent diameter and total stented length), medians were used as cut-off. Results
of tests for heterogeneity in treatment effect were considered significant if P was <0.05. SES indicates sirolimus-eluting stent, BMS bare metal
stent, PES paclitaxel-eluting stent, AHA American Heart Association, LAD left anterior descending coronary artery, LCx left circumflex coronary
artery, RCA right coronary artery.
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lower all-cause mortality as compared to PES. Although the
cumulative incidence of stent thrombosis was significantly higher in
the DES group, adjustment for confounders resulted in a non-
significant 26% increased risk for stent thrombosis at four years in
the DES group.
The findings of the present study need to be interpreted in the
context of a tertiary referral centre that decided to adopt a policy of
default DES use for all-comers (including acute MI at presentation,
post-CABG, in-stent restenosis etc.) since the first day of
commercial availability of the first approved drug-eluting (Cypher®)
stent in Europe on April 16, 2002. On February 23, 2003, for
financial reasons, our institution replaced the Cypher® stent by the
second CE-mark approved drug-eluting stent (TAXUS™).23 These
two sequential cohorts were complemented by an equally sized
cohort of consecutive patients treated with BMS in the two years
preceding the commercial introduction of the Cypher® stent.
With the exception of a slightly longer follow-up in the pivotal
randomised trials of the two DES24, the follow-up of the present
registry (mean 3.8 years) exceeds that of previously reported
registries.5,6,25-28 Another unique feature of this registry is that it was
conducted in a small European country with a sedentary population
and a very accurate registration of the vital status and cause of death
of its citizens by a well-organised governmental administration.
These features reinforce the strength of our observations.
Comparing our results to a recently performed network meta-
analyses of 38 drug-eluting stent trials revealed a significantly lower
absolute risk reduction for TVR at four years in the present study
(3.8% vs. approximately 12% in the meta-analysis). Additionally,
a higher overall mortality rate was observed in the present study as
compared to the network meta-analysis (13.3% vs. approximately
7.5%, without significant differences between DES and BMS).4 Yet,
it is difficult to compare our results to other published meta-
analyses and registries for three reasons. First, meta-analyses using
patient level data of the pivotal randomised trials included only
highly selected patients, and are representative of only ~40% of the
clinical population of a tertiary medical centre.29 Secondly, in
comparable registries, the use of either a DES or BMS was often
operator and procedure dependent, resulting in an even greater
degree of heterogeneity of the patients treated with DES or BMS,
thereby introducing a major potential for selection bias. For
example, whereas diabetics would be likely to receive a DES
because they are at increased risk of restenosis following BMS
placement, patients presenting with acute MI are generally more
likely to receive a BMS. It is unlikely that extensive regression and
propensity analyses can completely compensate for this inherent
type of bias. Thirdly, the vast majority of these registries pooled the
outcomes of different devices into one “DES” group, despite the widely
acknowledged differences between different types of DES.4,10-12
Recently, at least six large-scale real world registries demonstrated
similar to significantly lower mortality rates in patients treated with
DES compared to BMS.5-8,30,31 Considering the different features of
the present study, our findings demonstrated a similar safety profile
for DES and BMS with a significantly lower risk of cardiac death (or
post-operative MI) in patients treated with SES compared to PES.
The survival benefit in patients treated with SES was already
apparent at one week and remained so at one month. Exploring
clinical- and procedural success rates, including mortality due to
cardiogenic shock at presentation could not account for this
difference, and clopidogrel was mandated for at least one month in
all patients. Of note, both the short- and long-term survival in the
PES group was remarkably similar to the BMS. Several other large-
scale registries have also found a similar survival benefit with DES in
the first six months which sustained in the longer term.6,7,25 Our
sequential registry analysis does not eliminate the possibility of
confounders, but sheds additional light on the late survival after
BMS, SES and PES implantation in all comers and demonstrates
that pooling the outcomes of different types of DES may not always
be appropriate. This is an important lesson as new DES, eluting
different drugs form different polymers over different periods of
time, enter the market.
We performed a stratified analysis to assess the relative safety of
DES. The safety of DES appeared to be consistent among several
pre-selected high-risk patient subsets, without a significantly
superior safety profile, as expressed by all-cause mortality, between
SES and PES. However, we found a strong trend towards
heterogeneity in the 4-year TVR rates between DES and BMS in
patients presenting with MI. As compared to BMS, the adjusted risk
for TVR was 26% higher in patients treated with DES. Although this
difference in performance did not reach statistical significance, the
observation was in clear contrast to the non-MI population, in which
the adjusted risk for TVR in the DES group was significantly (38%)
lower. Pivotal randomised controlled trial data revealed that the use
of SES was equally safe and more efficacious in reducing TVR in
this setting as compared to BMS at 1-year, however, PES failed to
demonstrate a superior performance as compared to BMS at one
and two years.32-34 These latter controversial findings, together with
the fact that MI at presentation appeared to be a strong predictor of
stent thrombosis in patients treated with DES12,27,35,36, inevitably
leading to repeat revascularisations, together with the results of the
present study including 1,752 MI patients (DES group with over
80% PES use), makes the use of DES in this high-risk patient
subset disputable.
There was significant heterogeneity in the 4-year TVR risk between
SES and PES in patients with diabetes and bifurcation treatment.
While both drug-eluting devices had a similar safety profile, there
was a trend towards a 41% higher risk for TVR in diabetic patients
treated with SES. Several smaller subgroup analyses of randomised
controlled trials and registries concur with our findings. In the 1-year
results from the SOLACI and MILAN registry and the REALITY trial,
the use of PES was associated with non-significantly lower rates of
target lesion revascularisation as compared to SES in diabetics.37,38
The Kaiser Permanente and TC-Wyre registries conversely, even
demonstrated a significant difference between SES and PES in
reducing target lesion revascularisation in diabetics, in favour of
PES.39,40 Indirect evidence of a possible superiority of paclitaxel as
compared to the -limus family drugs was derived from a pooled
analysis of the randomised SPIRIT-II and III trials, which showed
a strong trend towards lower major adverse cardiac events rates in patients
treated with PES as compared to the Everolimus-eluting XIENCE V
stent. [FDA Executive Summary Memo. FDA Panel 29 November
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2007; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-
4333b1-00-index.html] The sole randomised ISAR-Diabetes trial
did not show any significant differences in the clinical endpoints
with SES and PES.41 Large-scale randomised controlled trials are
needed to assess the possible superiority of PES as compared to
SES in diabetics. The randomised controlled FREEDOM trial (using
PES and SES) vs. coronary artery bypass surgery will shed additional
light on this issue. 42
Finally, significant heterogeneity in the treatment effect was
observed in patients treated for bifurcation lesions, in which there
was a strong trend towards a lower TVR risk and a significantly lower
risk (70%) to suffer from cardiac death or post-operative MI when
treated with SES as compared to PES. These findings confirm the
results of a randomised trial by Pan et al evaluating the safety and
efficacy of SES vs. PES in bifurcation lesions.43 The authors
concluded that the overall system of the SES is better than the PES
in terms of main vessel restenosis rates, late loss, and neointimal
proliferation assessed using intravascular ultrasound.
The present single centre study has several limitations. First, the
clinical and procedural complexity increased over time, which
resulted in substantial differences in clinical and procedural
characteristics between the sequential patient cohorts. Despite the
use of extensive regression models, it remains uncertain whether
we were able to completely adjust for the differences between the
groups. However, the likelihood of a randomised trial comparing
BMS with DES in an all-comer population is already remote and will
become even more unlikely with the advent of the second and third
generation of DES.
A substantial amount of pivotal experiences with DES in several high
risk patient and lesion subsets were reported based on the RESEARCH
and T-SEARCH registries. Subsequently, late angiographic evaluation
was eventually obtained from “complex” patients, typically with DES
implanted in bifurcations, left main coronary, chronic total occlusions,
very small vessels, long stented length (>36 mm), and acute
myocardial infarction (in total, 25.9% patients in the SES group had
angiographic follow-up between six and 12 months).44-50 In the BMS
and PES groups, planned angiography was performed in 12.0% and
14.3% respectively. In all other cases, coronary angiography during
follow-up was obtained as clinically indicated by symptoms or
documentation of myocardial ischaemia. Of note, planned
angiographic re-evaluation was used as a co-variable in the Cox
proportional hazards regression models.
Due to the sequential nature of the three patient cohorts in the
present study, the follow-up in the PES group was shorter than the
follow-up in both the BMS and SES groups resulting in a lower
number of patients at risk at three years in the PES group. Kaplan
Meier survival analyses were performed to reconcile this limitation.
The per patient clinical- and procedural risk profile was linearly
associated with time. Given the sequential nature of the three
patient cohorts in our study, propensity analyses were considered
inappropriate. However, the overall risk profile was more favourable
for the BMS group than for either DES group and might even
underestimate the real difference.
Finally, the findings derived from the stratified analyses to detect
possible heterogeneity in the treatment effect of the different
devices should be seen as hypothesis generating. The non-
randomised nature of our study precludes any definite statements
about the true superiority of one DES above the other in several
high-risk subgroups. However it was remarkable that our findings
concurred with the few comparative data available in these high-risk
subgroups, despite the longer follow-up and subsequent higher
event rates in the present study. With the exception of the
FREEDOM trial, there are currently no comparative randomised
controlled trials ongoing comparing either SES or PES or one of both
with BMS in patients with acute MI, bifurcations and/or diabetes
properly powered for hard clinical endpoints to confirm our findings.
Conclusion
The results of the present study show that in a real world patient
population, after four years, the overall use of DES was associated
with similar all-cause mortality rates and a significantly reduced risk
for post-operative MI and TVR as compared to BMS. This finding
appeared to be consistent among several high-risk patient subsets,
with the exception of patients presenting with MI. Furthermore, the
use of SES resulted in significantly lower rates of cardiac death and
post-operative MI as compared to PES.
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INTRODUCTION 
Drug  eluting  stents  (DES)  were  introduced 
into  clinical  practice  in  2002  in  order  to 
reduce restenosis which occurred in 15% to 
25% of patients receiving bare‐metal stents 
(BMS).(2, 3) Subsequent trials with different 
types of DES confirmed their efficacy in this 
regard.(4)  However,  late  stent  thrombosis 
was  reported  as  early  as  2004,  typically  in 
patients  discontinuing  dual  antiplatelet 
therapy.(5)  At  the  European  and  World 
Congress  of  Cardiology  in  Barcelona  2006, 
alarming  data were  presented  on  a worse 
long‐term  prognosis  following  DES 
implantation as compared to BMS.(6‐8) As a 
result both randomized controlled trials and 
registry  data  were  scrutinized  to  validate 
these  concerns,  bearing  in  mind  the 
differential values of both  types of  studies. 
Furthermore,  the  worldwide  discussion  on 
the  long‐term  safety  and  efficacy  of  DES 
triggered  the  European  Society  of 
Cardiology  together  with  the  European 
Association for Percutaneous Cardiovascular 
Interventions  to  organize  a  forum  on  DES. 
On September 27 and 28, 2007, key opinion 
leaders  in  (interventional)  cardiology  and 
representatives  from  industry  and 
regulatory bodies gathered in the European 
Heart House with the intention to review: 1) 
the  most  recent  data  on  the  long‐term 
efficacy  (reduction  of  restenosis,  re‐
intervention and possibly improved survival) 
and  safety  (late  stent  thrombosis, 
myocardial  infarction, mortality)  of DES;  2) 
specific  indications  for  DES;  3)  health 
economical  analyses  currently  performed 
with DES; 4) the DES registration process  in 
Europe; 5)  current and possible  future  trial 
designs.  The  overall  goal  was  to  provide 
general  recommendations  to  the  medical 
community  for  the  use,  clinical 
development and future assessment of DES. 
SAFETY 
In  several  randomized  controlled  trials 
comparing  sirolimus‐eluting  stents  or 
paclitaxel‐eluting  stents  and  bare‐metal 
stents, no significant differences were found 
in  the  rates  of  death  or  myocardial 
infarction, although RAVEL  showed a  trend 
towards more death and MI at 5 year follow 
up.(9‐12)  The  overall  similar  safety  was 
confirmed  in  several  pooled  analyses  of 
individual  patient  level  data  from  these 
trials.(13‐15)  The  long‐term  safety  of  DES 
was  further  assessed  in  a  network  meta‐
analysis  including 38 randomized controlled 
ESC DES meeti ng report | Chapter 23
237
Meeti ng Report
ESC Forum on Drug Eluti ng Stents
European Heart House Nice, 27 – 28 September 2007
Daemen J, MD; Simoons M.L. , MD, PhD; Wijns W., MD, PhD; Bagust A. ; Bos G. ; 
Boam, A., MD; Bowen J.M., MSc; Braunwald E., MD; Camenzind E., MD; Farb, A. MD; 
Chevalier B., MD; DiMario C, MD; Fajadet J., MD; Ghislain J.C.; GiƩ  A., MD; Guagliu-
mi G., MD; Hillege H., MD, PhD; James S., MD; Jüni P. MD; Kastrati  A., MD; Kloth S. 
MD, PhD;  Kristensen S.D., MD; Krucoff  M., MD;  Legrand V., MD; Lekehal M. ; Pfi s-
terer M, MD; Raveau-Landon C. ; Rothman M., MD; Serruys P.W., MD, PhD; Silber S., 
MD; Steg P.G., MD, PhD; Tariah I. ; Wallenti n L, MD, PhD; Windecker S.W., MD, PhD.
European Heart Journal; in press
31'*2 ', -5"1 \cC[[[ /3'",32C L\aM &'*"
3&"1"62,-!'$$"1", "',+-13*'384/3-_
8"12',/3'",32','3'**831"3"!6'3&"'3&"1
@ 2'1-*'+42I"*43',% 23",32 LM -1
/ *'37"*I"*43',% 23",32 LM@ 3&"  62
22- '3"! 6'3&  \dg *-6"1 1'2) $-1
+8- 1!'* ',$1 3'-, L
M 2  -+/1"! 3-
,!\bg2 -+/1"!3-C

, 3&" *3"23 1"/-13 -$ 3&" 6"!'2& 
1"%'2318 L,h^`C]a]M /1"2",3"! 3 3&" 
 -,%1"22 ', '",, ][[b@ 3&" ', '!", " -$
!"3&,!
622'+'*1"36"",,!
 4/ 3- $-41 8"12CL\bM 	-6"5"1@ 3&"
2415'5* 415"22&-6"!2&-13I3"1+2415'5*
","$'36'3&4/3-Q\8"1$-**-6"!8
*3"  3 &I4/CLcM &42 3&" //1",3 "1*8
","$'3 '2 *-23 8 , "7 "22 -$ 242"04",3
"5",32C 
3 '2 ,-3"6-13&8 3&3 3&" '+/'1"!
-5"1**-43 -+"6'3&3&3621"/-13"!
"1*'"1 8 3&"  ',5"23'%3-12 ',
/3'",32 31"3"!4/ 3-][[_@62,- *-,%"1
/1"2",3 ', 3&"+-1" 1" ",3 ,*82'2@ 6&' &
', *4!"! /3'",32 31"3"! ', ][[`CL\cM
!!'3'-,**8@ 3&""23"1,I",+1) 1"%'2318
L,h\]C^d`M@ ,31'- 1"%'2318 !3
L,h\^C^`^M@ ,! !3 $1-+ 3&" 233" -$
22 &42"332 !"+-,2313"!  31",!
3-61!2  *-6"1 +-13*'38 13" $-**-6',%
 ', 3&" $'123 +-,3&2@ 6&' & 62
+',3',"!4/3-]8"12CL\dI]\M
/33"1,-$*-6"1','3'*,!', 1"2"!*3"
+-13*'38 13"2 $-**-6',%  42" 62 *2-
1"/-13"! 8 3&" 2"* 3",3 -23",
$$")3'5'3321'*LIAB,h`_`A
B,h]c\M',5"23'%3-12C&'*"3&"1"62
%', ,- !'$$"1", " ', !"3& ,! 
 3 ^
8"12@ 3&'262 3&","3 1"24*3 -$  &'%&"1 a
+-,3&2 2415'5* ,!  &'%&"1 ', '!", " -$
*3" Lj\+-,3&M!"3&-1
 $-**-6',%C
  -1!',% 3- 3&" 43&-12@ 3&'2 *33"1 +'%&3
" 3&"  -,2"04", " -$ 3&" !'2 -,3',43'-,
-$  *-/'!-%1"* 3 a +-,3&2CL]]M 
, ,
,*82'2-$aC\]d -,2" 43'5"/3'",32 $1-+
-33"1!+@3&""3&"1*,!2@3&"42"-$
62 22- '3"! 6'3&  2'%,'$' ,3*8 &'%&"1
2415'5* 2  -+/1"! 3- CL]^M &"
2415'5* ","$'3 6'3&  " +" //1",3
2"1*82^+-,3&2@$',!',%6&' &62',
*'," 6'3& 3&" ,'2& 1"%'2318 ,! 3&" *23
$-**-6I4/ -$ 3&"  ,!22 &42"332
1"%'231'"2CL\b@ ]\M &"/1-%1+@
"5*43',%  9-31-*'+42I"*43',% 23",3
2&-6"! 2'%,'$' ,3*8 *-6"1  1!'  !"3&
,!
13"2$-13&"2 -+/1"!6'3&
4/3-^8"12CL\\M

3 2&-4*! " //1" '3"! 3&3 $-**-6 4/ ',
!'$$"1",331'*2@+"3I,*82"2,!1"%'231'"2
51'"2 $1-+-,"-1 36- 8"12 3- $'5" 8"12C
&"2" !'$$"1", "2 2&-4*! " 3)", ',3-
 -,2'!"13'-, 6&",  -+/1',% 3&"2"
234!'"2C
$3&"31",!-$,"1*8","$'36'3&
2-+"@6'3& *3"1"7 "22-$!"3&,!

 2 -2"15"! ', 2-+" 234!'"2@ 6-4*!
/"12'23@ *-,% 3"1+ -43 -+" "8-,! $'5"
8"12+'%&3%1!4**8 $5-1C&'2 '2@-$
 -412"@&'%&*82/" 4*3'5">"5"13&"*"226"
!-&-/"3&33&"',5"23'%3-126'** -,3',4"
3- /1-5'!" 24 & 5"18 *-,% 3"1+ $-**-6I4/
!3C
	

3",33&1-+-2'2&2"",*',)"!3-6'!"
51'"38 -$ /3&-/&82'-*-%' * +" &,'2+2
,!  *',' * ,! /1- "!41* 1'2) $ 3-12CLa@
]_I]bM
3&2"",22- '3"!6'3&+-13*'38
13"2518',%"36"",\`g,!_`gCL]c@]dM
3 $1-+ 1"%'231'"2 ,! +"3I,*82"2
',!' 3"! 3&3 3&"1" '2 ,- !'$$"1", " ', 3&"
1'2) -$ "1*8 Li^[ !82M ,! *3" Lj^[ !82@
i^a` !82M 23",3 3&1-+-2'2 "36"", 
,! @ 43 3&3 , "7 "22 1'2) "+"1%"2
$3"1+-1"3&,-,"8"1-$$-**-6I4/L5"18
*3" 23",3 3&1-+-2'2MC &" ', '!", " -$
!"$','3" 23",3 3&1-+-2'2 ', 3&"  -+',"!
"1,I-33"1!+ "7/"1'", " 6'3&  ,!
62[Cag/"18"1@6'3&-43,82'%,-$
1"!4 3'-, 4/ 3- _ 8"12 $3"1 23",3
'+/*,33'-,@ ,!6'3& 2*'%&3*8 &'%&"1 13"2
$-13&,CL]d@^[M -+/1*"13"
-$[C`g62-2"15"!',3&"1"%'2318C
&'2 24%%"232 3&3 ",!-3&"*'* &"*',%
1"+',2 '+/'1"! 4/ 3- _ 8"12@ 3 *"23 ',
2-+"/3'",32C$',3"1"236"1"3&"1" ",3*8
/1"2",3"! ]I ,! ^I8"1 $-**-6I4/ -$ 3&"
 
@ 

 ,! 


 31'*2@6&' & 2&-6"!
1"+1)*8 *-6 13"2 -$ 23",3 3&1-+-2'2
L[C[g 3- [C^gM ,! ,-  2"2 -$ 23",3
3&1-+-2'2$3"1^[!82CL\\M$,-3"@3&"2"
ESC DES meeti ng report
238
/'5-3*234!'"2"5*43',%3&"1"*3'5"2$"38
,!"$$'  8-$3&"9-31-*'+42I"*43',%23",3
6"1" 1"231' 3"! 3- 1"*3'5"*8 2'+/*" *"2'-,2
,!/3'",32C&"1"24*32-$3&"*1%"I'5"
1"%'2318 ,! 3&" c[[[ /3'",3 1,!-+'9"!
31'*1""%"1*86'3"!C

32&-4*!"//1" '3"!3&3;!"$','3";23",3
3&1-+-2'2 4,!"1"23'+3"2 3&" 1"*
', '!", " -$ 24 & "5",3@ 2', " 2-+"-$ 3&"
/3'",32 6'3& 23",3 3&1-+-2'2 !"5"*-/
+8- 1!'* ',$1 3'-,@ -1 !'" 6'3&-43
,%'-%1/&'  !- 4+",33'-, -$ 23",3
3&1-+-2'2C - !!1"22 3&'2 '224"@ ,"6
!"$','3'-,2 6"1" $-1+4*3"! 8 
 -,2-13'4+ -$ ',3"15",3'-,*  1!'-*-%'232
$1-+ -3& 2'!"2 -$ 3&" 3*,3' @
1"/1"2",33'5"2 -$ 3&" --! ,! 14%
!+','2313'-,@  ",31* 1"2"1 &
-1%,'93'-,2@ ,! 1"/1"2",33'5"2 $1-+
+(-123",3+,4$ 341"12CL^\M


&"  *',' * 31'*2 2 6"** 2 1"%'231'"2
 -,2'23",3*8  -,$'1+ *-6"1 L31%"3 *"2'-,M
1"52 4*1'93'-, 13"2 3 $-**-6I4/ 6'3&
  -+/1"!6'3&CLd@ \[@\`@\b@\d@
][M 	-6"5"1@ 3&" 1"!4 3'-, -$ 242"04",3
1"52 4*1'93'-, ', 1"%'231'"262 *"22 3&,
',  *',' * 31'*2C &" 2-*43" 1"!4 3'-, ',
31%"3 5"22"* 1"52 4*1'93'-,3_ 8"12 ',
,"36-1)+"3I,*82'2-$^c *',' * 31'*2
62-43\]g5"1242]J_g',3&"6"!'2&
 1"%'2318 3 ^ 8"12CL\aM &'*" 3&"
31%"3 *"2'-, 1"52 4*1'93'-, LM 13" ',
 L6"!'2& -1-,18 ,! ,%'-/*238
"%'2318M!'!,-31" &ag3^8"12 ',3&"
 1+LcM@ 3&" ,"36-1) +"3I,*82'2L\aM
2&-6"! 13"24/ 3-dg3^8"126'3&
@  !'2 1"/, 8 3&3 62 "5", +-1"
//1",3 ', /3'",32 31"3"!6'3&,!
'2 +-23 /1-*8 "7/*',"! 8 2823"+3' 
,%'-%1/&'  $-**-6I4/ ', +,8 31'*2@ ,!
3&" * ) -$ 24 & ,%'-%1/&8 ', 3&" :1"*
6-1*!: 1"%'231'"2C &"1"8@ !3 04*'38 ',
3&"1"%'231'"2+8" *'+'3"!82", "-$
"5",3 !(4!' 3'-, 8 *',!"! -43 -+"
22"22-12 ,! * ) -$ !3 04"18 ,!
5"1'$' 3'-,C 413&"1+-1"@ /3'",3 ,!
!"5' " 2"*" 3'-, '2 -$3", -/"13-1
!"/",!",3C &'2 /&",-+",-, '2 $413&"1
",&, "! 8 3&" 1'3118 **- 3'-, -$
/3'",32 31"3"!6'3& 3 *"23 -," ',3-
3&" -&-131"%1!*"22-$3&",4+"1-$
2'+4*3,"-42*8 -1 /1"5'-42*8 '+/*,3"!
C *',' * "5",32 ', 3&" +'7"!  -&-13
+8"1"*3"!3-"'3&"123",338/"C
,+,8
1"%'231'"2@ 3&"  %1-4/ '2  +'7341" -$
+,8!'$$"1",338/"2-$1"+"3*!"5' "2@
6'3& !'$$"1",3 -43 -+"2C &'2 62
'**42313"! $1-+ 3&"  1"%'2318
1"/-13',% 1"23",-2'2 13"2 /"1 ',!'5'!4*
38/"21,%',%$1-+b3-\\g3^8"12C
N'%41" \O -1 !'$$"1",3  ^ 8"1
1"23",-2'2 13"2 51'"! "36"", ^ ,! _C`
gC ',**8@ 3&" ',3"1/1"33'-, -$ *-,%I3"1+
$-**-6I4/!3 '2 &+/"1"!8  1-22I-5"12B
/3'",326&-1" "'5"$'123-,"38/"-$23",3
,!,-3&"138/"-$23",33*3"1/-',3',
3'+"@$-1"7+/*"$-1 ',I23",31"23",-2'2C 
,
3&"-1'%',* 31'* /1-3- -*2@ 2" -,!18 23",3
3&1-+-2'2K23",33&1-+-2'2',/3'",3
6&-&!/1"5'-42*84,!"1%-,"31%"3I*"2'-,
1"52 4*1'93'-,K 62 ,-3 1"/-13"! 2 
23",33&1-+-2'2C*"1 -,2",2422&-4*!"
1" &"! -, &-6 3&"2" "5",32 2&-4*! "
 *22'$'"!,!1"/-13"!C
   
 

 



, ',3"15",3'-,*  1!'-*-%8@ 2 6"** 2 ',
-3&"1$'"*!2-$+"!' ',"@/-23I&- 24%1-4/
,*82"22&-4*!"',3"1/1"3"!6'3& 43'-,C
&"2"+8/1-5'!" '+/-13,3!'1" 3'-,2$-1
!!'3'-,* 1"2"1 &@ 43 3&"  -, *42'-,2
+8 -,*8 "   "/3"! '$ 3&"2" 1" 5"18
231-,%@  -,2'23",3 +-,% ** 234!'"2@ ,!
2"! -, /*42'*" /3&-/&82'-*-%8 ,!
"7/"1'+",3* !3C 
, %","1*@ 3&"
31"3+",3"$$" 32 ',24%1-4/26'3& *'+'3"!
,4+"12 -$ /3'",32 ,! "5",32@ 1" "23
"23'+3"!83&"-5"1**"$$" 32',3&"31'*2C
"3@$"624%1-4/22&-4*!"!'2 422"!',
3&'21"/-13C
5 
 




6-I8"1 $-**-6I4/ -$ 3&" 
  -&-13 -$
3&"  1"%'2318 2&-6"!  *-6"1 ',I
ESC DES meeti ng report | Chapter 23
239
&-2/'3* +-13*'38 ', 3&"   -&-13@ 
2'+'*1 +-13*'38 13" $1-+ 3&" 3'+" -$
!'2 &1%"4/3-aI+-,3&2@432'%,'$' ,3*8
&'%&"1 +-13*'38 13" $1-+ aI+-,3&2 3- ]
8"12 ', /3'",32 31"3"! 6'3&  L,h`adM
2  -+/1"! 3-  L,h\Cb]dM L	 aCad@
d`g 
 ]C[` J ]\CcMCL^]M 415'5* 13"2
$-**-6',%  -1 6"1" 2'+'*1 ', -3&
3&"-5"1**/-/4*3'-,,!',3&",-,I

%1-4/C  1" ",3 +"3I,*82'2 -$ 31'*2
', *4!',% /3'",32 /1"2",3',% 6'3& 
2"%+",3 "*"53'-, 
 Lc 31'*2 J ]Cbca
/3'",32M 2&-6"!,-!'$$"1", " ', 3&"&1!
 *',' * ",!/-',32-$ !"3& ,!
 ', 3&"2"
&'%&I1'2) /3'",32C 	-6"5"1@ +-23 -$ 3&"
31'*2&!$-**-6I4/*'+'3"!3-\8"1CL^^M



&"1" ",3*8/1"2",3"!^I8"11"24*32-$3&"
13"1'* "52 4*1'93'-, &"1/'"2 34!8
LI

M1"/-13"!-,3&"2$"38,!"$$'  8
-$ 
 42',%  L,ha[bM 2  -+/1"!6'3&
3&" 1,!-+'9"! 241%' * L,ha[`M ,!
/"1 43,"-42 1+2 L,ha[[M -$ I
 $-1
/3'",32 6'3& +4*3'5"22"*  -1-,18 13"18
!'2"2"CL^_M &" 43&-12  -, *4!"! 3&3
!"2/'3" 3&"&'%&"1 *',' *,!,%'-%1/&' 
1'2) /1-$'*" -$ 3&" I

 /-/4*3'-,@ 3&"
', '!", "-$!"3&HH
622'%,'$' ,3*8
*-6"13&,',3&"I

1+,!2'+'*1
3- 3&" I
  1+C "2/'3" 3&"
2'%,'$' ,3*8*-6"11"/"3',3"15",3'-,13"2
',I

2 -+/1"!3-I

@
1"+',"! 22- '3"! 6'3& 3&" *-6"23
1"',3"15",3'-, 13"2  -+/1"! 6'3& -3&

%1-4/2C&"2"$',!',%26"1"',*',"6'3&
3&" ^I8"1 1"24*32 -$ 3&" 1%",3',"
,!-+'9"! 34!8 -1-,18 ,%'-/*238
5"1242-1-,188/2241%"18 ',4*3'/*"
"22"* '2"2"  L
I


 31'*A ,hab`M
2&-6',%2'+'*113"2-$!"3&@,!

4/ 3- 3&1"" 8"12 ', /3'",32 31"3"! 6'3&
2 -+/1"!3-"'3&"1-1
6'3&
 ,! 2'%,'$' ,3*8 *-6"1 1"/"3
1"52 4*1'93'-, ', 3&"  %1-4/ 2
 -+/1"!3--3&
1+2CL^`M
1
1



	"3"1-%","'38 -$ 3&" 31"3+",3 "$$" 3 62
24%%"23"!8,,*82'2-$3&"1,!-+'9"!
I 31'*@ -2"153'-,* !3 $1-+
,31'-@ ,! L,h\aC_dcML^aM@ ,! !3
$1-+   -,3',4-42 1"%'2318 -$ ** 
E2 ',
"*%'4+ L,h\`C]^bMC 
, 3&"2" 234!'"2 3&"
 ","$'3 62 //1",3 /13' 4*1*8 ',
2+** 5"22"*2@ *-,% *"2'-,2@ !'"3' 2 ,!
8/22 %1$32C +-,% /3'",32 6'3&
!'"3"2@  /1-5"! "$$" 3'5" ', 1"!4 ',%
3&" ,""! $-1 1"52 4*1'93'-, ', *+-23 **
*"2'-, 38/"2 ,! 1"%1!*"22 -$ 1" ",3 

23342C +-,% ,-,I!'"3'  /3'",32@ 3&"
","$'3 -$  62 +-1" *'+'3"! 43 62
//1",3 ', *-,% *"2'-,2@ 2+** 5"22"*2 ,!
/13' 4*1*86&",-3&!5"12"$"341"2 -I
"7'23"!C  *2- ', 3&" +"3I,*82'2 3&"
,4+"1 ,""!"! 3- 31"3 3- /1"5",3 31%"3
*"2'-, 1"52 4*1'93'-, 62 *-6"1 ',
!'"3'  /3'",32 2  -+/1"! 3- ,-,I
!'"3'  /3'",32CL\aMC $ ,-3"@ ',  +"3I
,*82'2 -$ /'5-3* 1,!-+'9"!  -,31-**"!
8/&"1 31'*2@ 2'%,'$' ,3 &"3"1-%","'38 ',
3&" 31"3+",3 "$$" 32 62 $-4,! $-1
/3'",32 6'3& !'"3"2C &" _I8"1
 4+4*3'5" 2415'5* 13"2 +-,% /3'",32
6'3&-43!'"3"2!'!,-3!'$$"1 2'%,'$' ,3*8
"36"", 3&" 23",3 38/"2C 	-6"5"1@ !"3&2
$1-+ -3&  1!'-52 4*1 ,! ,-,I
 1!'-52 4*1  42"2 6"1" +-1" $1"04",3
', 3&" I%1-4/ ,! 3&" 2415'5* 13" $-1
/3'",32 6'3& !'"3"2 62 2'%,'$' ,3*8
*-6"1 ', 3&"  %1-4/ L h [C[[cMC 
, 3&"
24%1-4/ -$ /3'",32 6'3& !'"3"2@ 5"18
*3"23",33&1-+-2'262!(4!' 3"!+-1"
$1"04",3*8 +-,% 3&" /3'",32 6'3&
2'1-*'+42I"*43',% 23",32 3&, +-,% 3&-2"
6'3& C 6',% 3- 3&" *-6 ,4+"1 -$
"5",32@3&"2"$',!',%22&-4*!"',3"1/1"3"!
6'3&  43'-,A '3 !-"2 ,-3 //"1 3&3 3&"8
!"043"*8"7/*', 3&"-2"15"!!'$$"1", "
', 2415'5* +-,%/3'",326'3&!'"3"2 ',
3&" 36- %1-4/2CL\^M -,5"12"*8@ ', 3&"
*1%"1 2 *" ,"36-1) +"3I,*82'2@ ,-
2'%,'$' ,3 !'$$"1", " ', **I 42" +-13*'38
62-2"15"!',/3'",326'3&!'"3"2CL\aM
ESC DES meeti ng report
240

1 
 

 



 @ 6&",  -+/1"! 6'3&  2 ,
','3'* 31"3+",3 2313"%8 1" 22- '3"!
6'3& *-6"1 242"04",3 1"52 4*1'93'-,
13"2@ 43 , "7 "22 1'2) -$ *3" 23",3
3&1-+-2'2@6&' &3&42$1@!-"2,-32""+
3- '+/ 3 -, 3&" -  411", " -$ &1!
 *',' * ",!/-',32 *')" !"3& ,!
+8- 1!'*',$1 3'-,4/3-_8"12C
 &42 $1 3&" -5"1** 1"*3'5" ! 
! -$   -+/1"! 6'3& 
//"12 3- "  -,2'23",3  1-22 !'$$"1",3
%1-4/2-$/3'",32@*"'3351'-42 *"5"*2
-$2-*43"","$'3,!1'2)C&"*-,%I3"1+
2$"38 -$  ', !'"3' 2 ,! /3'",32
/1"2",3',% 6'3& +8- 1!'* ',$1 3'-,
1"+',23-""23*'2&"!C
 3 -43 3&" *-,%I3"1+ 2$"38 ,!
"$$'  8-$ ',&'%&I1'2) 24%1-4/2 *')"
!'"3' 2@ ,! /3'",32 6'3& L,-,M 
2"%+",3"*"53'-,
1"+',*'+'3"!C&'2
&2 '+/*' 3'-,2 $-1  -23I"$$" 3'5","22
,*82"22'**42313"!"*-6C
 &"1" 1" '+/-13,3 !'$$"1", "2 "36"",
3&"51'-4238/"2-$23",32@6'3&!'22'+'*1
+" &,' * ,! /&1+ -*-%' *
/1-/"13'"2 ,! 242"04",3 !'$$"1", "2 ',
 *',' * -43 -+"C -3 **  1" "04*@
,-11"C
 
,3"1/1"33'-,-$*-,%I3"1+$-**-6I4/!3
'2&+/"1"!8 1-22I-5"12,!+'7"!
,!  42"B /3'",32 6&- 1" "'5" $'123
-," 38/" -$ 23",3 ,! ,-3&"1 38/" -$
23",33 *3"1/-',3 ', 3'+"@ $-1"7+/*"
$-1',23",31"23",-2'2C
 &"2" ,"6 $',!',%2 33",43" 3&" ','3'*
1"/-1326&' &&5" *"! 3- 3&"  1"3'-,-$
3&'2 2) -1 " ,!  ** $-1 %1"3"1
33",3'-,3-2 '",3'$' 2 143',8,! 43'-,
', 3&"  -++4,' 3'-, 3- 3&" /4*'  -$
2",2'3'5" 2 '",3'$'  ',$-1+3'-,C 	-6"5"1@
3&"  411",3  -, *42'-,2 1"%1!',% 3&"
2$"38 ,! "$$'  8 -$  2&-4*! ,-3
!'5"13 3&" 33",3'-, $1-+ 3&" '+/-13, "
3-  -,3',4" !"5"*-/+",3 -$ *"22I -1 ,-,I
3&1-+-%",' 23",32C
		


'3& 1"2/" 3 3- 3&" !'2 422'-,2 -43
"$$" 3'5","22 ,! 1'2)2 -$ @ ,! 3&"
&'%&"1  -232 -$   -+/1"! 6'3& @
&"*3& " -,-+' * ,*82"2 &5" "",
','3'3"! ', !'$$"1",3  -4,31'"2C &1""
,*82"2 6"1" /1"2",3"!@ 2&-6',%
 -,2'23",31"24*32C

,,31'-@,!@2', "][[^@3&"','2318
-$	"*3&S-,%I"1+1"&2**- 3"!
$4,!',% -$ V\] '**'-, $-1  ,,4**8
"36"",3&"\]1!' 1"",31"2',3&3
/1-5', "CL^aM -23I"$$" 3'5","22 62
,*89"! 42',% !3 $1-+ \aC_dc /3'",32
6'3&  *"23 \]+-,3&2 $-**-6I4/ 1" "'5',%
-,*8-1$1-+" \@][[^J1 &
^\@ ][[`CL][M5"1** 3&" ', 1"+",3*  -23I
"$$" 3'5","22 13'-2 L
M -$  52C @
6"1" F$'1*8 &'%&G L
 1,%',% $1-+
V]Ca^[@I$-15"18*-,%,!,11-6*"2'-,23-
V\^^Cd^b@I $-1 2&-13 *"2'-,2 ', *1%"1
5"22"*2MC  2'%,'$' ,3 ","$'3 L1"!4 3'-, -$
1"/"31"52 4*1'93'-,M3  "/3*" -232
//"1"!',*'+'3"!%1-4/-$/3'",326'3&
!5"12" *"2'-,  &1 3"1'23' 2 L*-,% *"2'-,2@
2+**5"22"*2M,!H-1!'"3"2C

, '32 $'123 //1'2* -$  1"/-13"! ',
 3-"1][[^@3&",%*'2&3'-,*
,23'343"
$-1 *',' * 	"*3& ,! 7 "**", " LC
CCCM
1"231' 3"! 3&" 42" -$  3- 2+** 5"22"*2
Li^++M,!*-,%*"2'-,2Lj\`++M2"!-,
 -23"$$" 3'5","2222"22+",342',%I
2"! 
, 1"+",3* -23I$$" 3'5","22
+"3&-!-*-%8C &" "7/" 3"! 42" -$  3
3&3 3'+"62 //1-7'+3"*8 ^[g@6&'*" ',
/1 3' " 3&" 42%" ', 1"2"! 4/ 3- +-1"
3&,a[g-$/3'",32',3&"C
,4*8][[b
C
CCC '224"! '32 ],! //1'2* -$  ',
!1$3 $-1+,!  -, *4!"! 3&3 1",-3
 -23I"$$" 3'5" ',,8/-/4*3'-,,! ,,-3
"1" -++",!"!$-1/3'",326'3& -1-,18
13"18 !'2"2"C &'2 1" -++",!3'-, 62
!1'5", 8  *-6"1 3&, "7/" 3"! ,""! $-1
1"/"3 1"52 4*1'93'-, 6'3&  ',
4,2"*" 3"! /3'",3 /-/4*3'-,2@ +1)"!*8
*-6"1 3&, ', 3&" 1,!-+'9"!  -,31-**"!
31'*2@ -,3123',%6'3&3&"5"18&'%&/1' "-$
 6&' & !'! ,-3 $** 2 "7/" 3"!C
ESC DES meeti ng report | Chapter 23
241
413&"1+-1"@ 3&"  -, *42'-,62 !1'5", 8
,', 1"2"',3&" -23!'$$"1",3'*"36"",
 ,! C &'2 1" -++",!3'-, &2
"",  &**",%"! 8 /1-$"22'-,* 2- '"3'"2
,!',!42318*')"@,!&2"",3&"24(" 3
-$ "73",2'5" !"3"C 
3 2&-4*! "
//1" '3"! 3&3 3&" +-1" 24  "22$4* 3&"
,"6 3" &,-*-%8@ 3&" +-1" 1/'!*8 ,!
$413&"13&"/1' "-$3&"-*!3" &,-*-%83&3
'3 '2 1"/* ',% '2 *')"*8 3- $**C &'2 +8
1"!4 "3&"1"*3'5" -23H"$$" 3'5","22-$3&"
,"6 3" &,-*-%8@4,*"22 '32/1' " '2 2'+'*1*8
1"!4 "!C
&" //1'2*  -++'33"" 1"5'"6"! 3&"'1
!1$3%4'!"*',"2', 3-"1][[b,!C
CCC
242"04",3*8+!"3&"'1^8"11"5'"66'3&
3&"*3"23!1$3!- 4+",3'224"!',,][[c
L2"" 3"73-7 "*-6M ,! 6'** '224" $',*
%4'!"*',"2 ', 4," ][[cC 
, 3&" \cI+-,3&
!3 /1"2",3"! $1-+ 3&"  31'*@
$-**-6I4/  -232 6"1" 2'+'*1 $-1 -3& 
,!,! 1"*3'5"*8 *-6-5"1**C4" 3-
&'%&"1 23",3  -232@ 3&" 42" -$  62
22- '3"! 6'3& , ', 1"+",3*  -23I
"$$" 3'5","22 13'- L
M -$ Ta_Cb^]C 
,
3"1+2 -$  *',' * ",!/-',32@  /1-5"!
+-23 "$$" 3'5" ', &'%&I1'2) /3'",32 ,!
*"2'-,2@ 6&'*" 3&" 234!8 2&-6"! ,-
'+/1-5"!-43 -+" ', *-6I1'2) /3'",32 ,!
*"2'-,2 ', 3"1+2 -$ "$$'  8C 4%1-4/
,*82"2 1"5"*"! 3&3 3 \c +-,3&2@ 3&"

 $-1  62 $5-1*" '$ 3&" 42" 62
*'+'3"! 3- &'%&I1'2) /3'",32 6'3& 2+**
5"22"*H8/22%1$323",3',%L-,*8-,"3&'1!
-$3&"/3'",32$**',3-3&"2"%1-4/2MCC
,% "3 *C "5*43"! 3&"  -23I"$$" 3'5","22
-$  ', 3&" /+8 ', *43',% 3",3
5*43"!3-33"1!+1!'-*-%8	-2/'3*
L	M1"%'2318,! -, *4!"!3&33&"
 62 ,-3  -23I"$$" 3'5" 3 -,"@ -1 36-
8"12 $-**-6I4/ 6&",  -+/1"! 3-
CL^bM &" ', 1"+",3*  -23I
"$$" 3'5","22 13'- /"1 31%"3 5"22"*
1"52 4*1'93'-,5-'!"!6-4*!"T]dC^b^
3\8"1@,!T]]C]ab3]8"12',3&"3-3*
 -&-13C 2"! -, 3&"2" 1"24*32@ 3&"
 * 4*3"! +7'+4+  -23I"$$" 3'5" /1' "
$3"1 \I8"1 -$ $-**-6I4/ '2 T\C^^a /"1 
$-1 **I -+"12@ -1 T\C[]^ 3-  &'"5"  -23I
,"431*'38',3&""3&"1*,!2C
&" $',!',%2 -$ 3&"2" &"*3&I" -,-+' 
,*82"21"  -,2'23",3@ ',!' 3',% 3&3
1" ,-3  -23I"$$" 3'5" 3 3&"  411",3 /1' "
*"5"*2 $-1+-23 /3'",32 4,!"1%-',% 
 $-1
23*" ,%',@6&'*" 3&" 42" -$   , "
 -23I"$$" 3'5"',242"3-$/3'",323&'%&
1'2)$-11"23",-2'2C
362!'2 422"!3&3
6-4*! " -+"  -23I"$$" 3'5" $-1 +-23
/3'",32 '$ 3&" /1' "I/1"+'4+@ 1"*3'5" 3-
@6-4*! ,-3 "7 ""! T^[[ I T_`[ LX^[[
-4,!223"1*',%MC- -23I"$$" 3'5","22!3
-, 3&" 42" -$  $-1 3&" *'$"I25',%
',!' 3'-,2-$
 L4,23*",%',@

-1
M2 -+/1"!3-"'3&"142"-1
 -,5",3'-,* 31"3+",3 1"  411",3*8
5'**"C
	



 1"  -+',3'-, /1-!4 32 3&3  -,2'23
-$  +"!' * !"5' " 6'3&  +"!' ',*
2423, " 2 , ',3"%1* /13C  6"1"
 *22'$'"! 2  *22 


 +"!' * !"5' "2 ,!
1"04'1"   -,24*33'-,6'3& 3&" -+/"3",3
43&-1'3'"2-$3&"+"+"1233"2/1'-13-
 "13'$' 3'-, 8 3&" -3'$'"! -!8C
&"1"$-1"@ 3&" -+/"3",3 43&-1'38 6'**
22"22 3&"  *',' * !3 1"*3"! 3- 04*'38@
2$"38 ,! 42"$4*,"22 -$ 3&" +"!' ',*
2423, "C &" /-2'3'5" 22"22+",3 1"/-13
-$ 3&" -+/"3",3 43&-1'38 '2 3&" /1"I
1"04'2'3" $-1 3&"  "13'$' 3'-,-$8 3&"
-3'$'"!-!8C

, ][[b@ 3 *"23 \d !'$$"1",3  &5"
1" "'5"!-,$-1+'3#41-/#",," LM+1)
//1-5*@ 6&'*" 3 3&" 3'+" -$ 3&"
 -,$"1", " -,*8 3&" $'123 36-  L8/&"1
,! 742M 6"1" //1-5"! 8 3&"  
$-1  -++"1 '* 42"C $ ,-3"@ 3&"  --!
,!14%!+','2313'-,&2 1" ",3*8%'5",
 /-2'3'5" 1"5'"6 $-1 3&" ,!"5-1 ,!
'", "IC

,  1" ",3 /4*' 3'-, $1-+ 3&" "1+,
- '"38 -$ 1!'-*-%8 3&" !3 6"1"
1"5'"6"! 24//-13',% \d 6'3& +1)@
1"/-13"!',ba1,!-+'9"! -,31-**"!31'*2C
 !'23', 3'-, 62 +!" "36"", 234!'"2
ESC DES meeti ng report
242
ESC DES meeti ng report | Chapter 23
243
CONCLUSIONS, PERSPECTIVES AND RECOMMENDATIONS ON COST‐EFFECTIVENESS 
 Cost-effectiveness analyses are essential to fully understand the value of BMS versus DES 
and enlighten health care policies. However, careful interpretation is needed when 
analyzing specific patient subsets derived from clinical trials which might not reflect real 
world clinical practice.  
At the current price level, DES can be cost-effective when applied in high-risk patients. 
Alternatively, DES would be cost-effective in the majority of patients undergoing 
percutaneous coronary intervention at a price premium around €450 (£300  Pounds 
sterling) above the price of comparable BMS, or less. 
It is worth noting that the ICER will be heavily influenced by the costs of both the new and 
old technology. The more successful the new technology, the more rapidly and further the 
price of the old technology is likely to fall. This may reduce the relative cost/effectiveness 
of the new technology, unless its price is similarly reduced.  
 Importantly, the available cost-effectiveness analyses do not pertain to high-risk patients 
such as NSTEMI and STEMI. Under those circumstances, PCI with BMS was shown to 
portend a survival benefit over non-interventional conventional therapy.(1) It is unknown 
whether this survival benefit will be amplified by the use of DES. 
UPDATE: NICE APPRAISAL JAN 2008       NOT DISCUSSED AT THE MEETING 
 The recommendation continues to support the use of DES in small vessels and long lesions, 
with no recommendation for the volume of DES that can be implanted. There has been 
some debate about the cost-effectiveness and relative pricing of BMS and DES in the UK. 
NICE used price differentials between £300 and £600 as input in their model to determine 
the cost per QALY.  Considering a differential of £300 is the subject of a current  appeal to 
NICE, the outcome of which will become public in mid 2008. 
 
with angiographic or clinical primary 
endpoints.  The authors used a predefined 
decision tree to assess the level of evidence 
gained with the individual trials. Although 
the used score was not an internationally 
validated assessment tool for clinical studies 
and disregarded the fact that several studies 
were also powered for secondary 
endpoints, the authors concluded that only 
3, or at best 5 out of the 19 CE marked DES 
had adequate clinical documentation 
supporting their use. They concluded that 
there is significant heterogeneity in the 
requirements that are set for obtaining a  
CE-mark certificate.(38)  
With the intention to harmonize the views 
and interests of the notified bodies on the 
one hand and the medical profession on the 
other hand, speakers from KEMA, BSI, TÜV 
SÜD Product Service, CETF, EMEA and the 
FDA presented their views on the current 
approval process and their thoughts for 
modification of the process for assessment 
of next generation devices. There was 
agreement that novel stent technologies 
will be developed, and should be made 
available for patient use in Europe, but also 
that more extensive pre-marketing (pre-
clinical and clinical) as well as post-
marketing studies might be required. A 
balance should be found between pre-
marketing and post-marketing evaluation 
with differential follow-up timescales, also 
accounting for the expected relatively short 
lifetime of the drug-device combination 
products. Additional guidance documents 
are required to achieve uniformity and 
consistency on the type of ‘short term’ (pre-
approval) data needed to receive CE Mark 
decision and ‘long term’ (post-approval) 
data that are needed. Such documents are 
under development both by the Notified 
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Opti mal revascularizati on strategies for multi -
vessel coronary artery disease
Daemen J, Serruys PW
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Optimal revascularization strategies for multivessel coronary
artery disease
Joost Daemen and Patrick W. Serruys
Purpose of review
The aim of this article is to review the current status of
optimal revascularization strategies in patients presenting
with multivessel coronary artery disease.
Recent findings
Coronary artery bypass surgery is the gold standard for
patients with multivessel disease. Recent developments in
the interventional field, like drug-eluting stents, which
significantly reduced restenosis and the need for repeat
revascularizations, have cut back one of the largest
limitations of percutaneous coronary intervention.
Summary
There is currently little evidence to believe that in a general
population, opting for either coronary artery bypass surgery
or percutaneous coronary intervention would imply a better
long-term survival. Coronary artery bypass surgery is still
associated with higher rates of complete revascularization
and a higher durability than percutaneous coronary
intervention, resulting in lower rates of repeat
revascularization. The current evidence, however, is based
on sub-optimal inconclusive data from single center or
multicenter registries. Until the results of several dedicated
ongoing randomized trials are presented, the choice for a
revascularization strategy should be made not only on the
basis of feasibility but also by taking into account each
patient’s co-morbidities and risk factors. Careful monitoring
of glycemic control and lipid concentrations and an optimal
pharmacological treatment are at least as important in
achieving an optimal outcome.
Keywords
complete revascularization, coronary artery bypass
surgery, coronary artery disease, multivessel disease,
percutaneous coronary intervention
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ARTS Arterial Revascularization Therapy Study
BARI Bypass Angioplasty Revascularization Investigation
CABG coronary artery bypass grafting
CTO chronic total occlusion
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Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel
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MI myocardial infarctions
PCI percutaneous coronary intervention
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Introduction
In the predrug-eluting stent era, in-stent restenosis and
the need for repeat revascularizations have been shown to
be the major limitations of the percutaneous treatment of
multivessel coronary artery disease [1,2]. Drug-eluting
stents (DESs) have been shown to reduce both angio-
graphic and clinical restenosis, resulting in a significant
reduction in the need for repeat revascularizations
[3–8,9,10]. Evidence stemmed from the use of DESs
in low-risk patients presenting with relatively simple
lesions, but soon afterwards, their use was extended to
higher-risk populations and lesions. Currently, the pre-
sence of diabetes, severely calcified lesions, left main or
multivessel disease, chronic total occlusions, bifurcation
lesions, acute myocardial infarctions (MIs) and in-stent
restenotic lesions do not hold back the interventionalist
from using DES [11,12]. Like percutaneous coronary
revascularization, coronary artery bypass surgery has also
been optimized in the last decade, illustrated by a less
invasive approach, the use of off-pump coronary artery
bypass grafting (CABG), the improvement of periopera-
tive care and the extensive use of longer-lasting arterial
grafts instead of saphenous vein grafts. Traditionally,
CABG is the gold standard for the patient with multi-
vessel disease, albeit repeatedly challenged by various
percutaneous coronary intervention (PCI) modalities
(balloon angioplasty, bare stents, and DESs). Several
dedicated randomized trials are ongoing, but until their
results are presented we have to rely on sub-optimal
inconclusive evidence from single-center or multicenter
registries.
Coronary artery bypass grafting or
percutaneous coronary intervention?
Let us imagine two patients with multivessel disease
(Fig. 1). Patient 1 has a right dominant system with
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three-vessel disease consisting of four focal lesions, two
in the right coronary, one in the mid-left anterior des-
cending and one in the proximal circumflex. Patient 2
conversely, whilst also having a right dominant system
with three-vessel disease, has a significant left main
stenosis, a proximal left anterior descending stenosis,
and a totally occluded right coronary and circumflex.
There is no argument that patient 2 forms a much
greater challenge for the interventionalist than patient
1. Whether patient 2 would be better off with CABG is
disputable, however, and depends also on the individual
patient characteristics like age and comorbidity.
Regarding the risks of long-term mortality or MI, no
differences have been found between CABG and PCI.
This latter can be illustrated by many trials from the past
like Randomized Intervention Treatment of Angina
(RITA; 1993) [13], Emory Angioplasty versus Surgery
Trial (EAST; 1994) [14], Coronary Angioplasty versus
Bypass Revascularisation Investigation (CABRI; 1995)
[15], Bypass Angioplasty Revascularization Investigation
(BARI; 1996) [16], Argentine Randomized Trial of Per-
cutaneous Transluminal Coronary Angioplasty Versus
Coronary Artery Bypass Surgery in Multivessel Disease
(ERACI; 1996) [17], Arterial Revascularization Therapy
Study (ARTS; 2001) [1], ERACI-II (2001) [18] and Stent
or Surgery (SOS; 2002) [19]. Even when patients were
followed for many years, no difference in these endpoints
could be noticed [20,21]. Nevertheless, PCI was associ-
ated with a significantly higher risk for subsequent
revascularization.
With the introduction of DESs in 2002, the parameters of
the PCI–CABG equation changed. With significantly
lower rates of clinical and angiographic restenosis as
compared with bare metal stents, DES partly cut back
themajor limitation of PCI [3–8,9,10,21]. Soon after the
disclosure of the amazingly low revascularization needs
following PCI with DESs, the first PCI–CABG trials
started to add DES arms to previously published trials.
One of the first to do so was the ARTS-II trial, which
added a prospectively collected arm of 607 consecutive
patients to the ARTS-I study [22]. The ARTS-I trial
randomized 1205 patients with stable or unstable angina
or silent ischemia presenting with two or three-vessel
disease to CABG or PCI with bare stents [23]. The
ARTS-II 1-year results showed that PCI with DES
was not inferior to CABG in terms of the combined
endpoint of major adverse cardiac and cerebrovascular
events. The need for repeat revascularizations, however,
was still significantly higher than in the CABG arm of
ARTS-I [22]. Shortly after the ARTS-II trial, the smaller
ERACI-III study was conducted maintaining a similar
approach as ARTS-II by adding a group of 225 DES
patients to the ERACI-II trial [24]. At 1 year, the need for
repeat PCI was significantly higher in the DES arm than
in the ERACI-II CABG arm. Due to the significantly
lower incidence of death and MI, however, the overall
major adverse cardiac or cerebrovascular events rate was
significantly lower in the DES arm than in the CABG arm
(P¼ 0.047). Another study worth mentioning is that of
Hannan and colleagues [25], who evaluated the 3-year
outcome of 59 314 patients with multivessel disease from
New York’s cardiac registries treated with either PCI or
CABG. The authors concluded that both the risk-
adjusted survival rates and the rates of revascularization
were significantly higher among the CABG patients.
Remarkable was that there were almost no significant
differences in the unadjusted survival rates. Thereby,
this observational report attempts to equalize the two
Figure 1 Two types of three-vessel disease
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groups by using risk-adjusted survival methods. This
methodology attempts to adjust an unadjustable charac-
teristic, namely the judgment of the treating physi-
cian regarding the revascularization strategy that is not
correctable by adjusting for clinical variables. Given the
results of the contemporary randomized trials, these
results have to be interpreted with caution and could
be misleading. In conclusion we can say that there is no
evidence to believe that the PCI-treated multivessel-
diseased patient would be at higher risk for future
mortality and MI than their surgical counterparts. This
leaves us with the problem of the need for repeat
revascularization, which is potentially connected to an
initially less complete revascularization. In fact, PCI is a
local, topical, endoluminal treatment, which does not
preclude the progression of the disease proximal or distal
to the treated focus, whereas bypass surgery inherently
prevents reintervention for most of the disease pro-
gression upstream to the bypass.
The optimal method for complete
revascularization
Although essential for comparing modalities of revas-
cularization, a clear demonstration of the completeness
of revascularization is lacking. Differences have been
pointed out between anatomical and functional
revascularization, depending on whether the reperfused
ischemic myocardial territory is taken into consideration
[26]. Other definitions also looked at the size or type
(main vessel or side branch) of the revascularized coron-
ary arteries. Furthermore, scoring systems have been
used, weighing the different vessels and locations [26].
Of note, these definitions are based on immediate pro-
cedural success rates and in contrast to PCI patients,
CABG patients will seldom undergo routine angiographic
restudy, and functional failure following an initially suc-
cessful revascularization cannot be measured.
CABG is still associated with higher rates of complete
revascularization and a higher durability than PCI
[27–29]. It is mainly because of this durability that
the difference in long-term outcome is found largely in
the need for repeat revascularization.
Whether a more complete revascularization automati-
cally implies a better survival remains controversial. In
the BARI trial, complete revascularization was achieved
in 91% of the CABG patients versus only 51% of the
PCI patients. The 5-year results, however, showed that
the excess mortality in angioplasty patients occurred
solely in the diabetic subgroup; the overall and cardiac
survival rates were similar among nondiabetic CABG
and angioplasty patients. Of interest was that when
Vander Salm and colleagues [26] applied four defi-
nitions of complete revascularization to the BARI trial
results, no independent advantage existed from com-
plete revascularization by either the traditional or func-
tional definitions.
The ARTS trial confirmed that randomization to stenting
in patients with incomplete revascularization was not
associated with a worse late mortality [29]. Hannan
et al. [30], however, when evaluating the impact of
complete revascularization on the long-term outcome
following PCI, found that complete revascularization
was associated with significant short and long-term sur-
vival benefit as compared with incomplete revasculari-
zation. Although the study is based on a population of
almost 22 000 patients, it suffers from several limitations.
Only in-hospital information is entered in the database,
there is no outcome data collection, no monitoring, and
the causes of death are unknown. Furthermore, the
registry does not comprise a surgical arm, so it is unclear
whether these patients would have benefited from bypass
surgery, also given the increased risk profile of the
patients with incomplete revascularization.
Another item that has to be taken into consideration is the
cost-effectiveness of both therapeutic strategies.
Recently, the 10–12-year follow-up of the BARI study
revealed that in patients with multivessel disease, the
cost-effectiveness of PCI relative to CABG becomes less
unfavorable at long-term. The initial revascularization
costs of the PCI arm were 35% lower than in the CABG
arm, but after 5 years, this benefit shrank to no more than
5% due to the higher frequency of repeat revasculariza-
tions in the PCI arm [31]. Ten years after randomization,
the differences between PCI and CABG in the economic
and quality-of-life outcomes were no longer significant.
Nevertheless, the study was limited by the fact that the
patients were included before the introduction of coron-
ary stents. Although many thought that with the intro-
duction of DESs this item would be resolved by a shift
fromCABG to PCI, several studies provided inconclusive
results [24,25,26–29,30,31,32,33–35].
Coronary artery bypass grafting or
percutaneous coronary intervention for
chronic total occlusions?
In a registry of 8004 patients presenting for diagnostic
catheterization, at least 52% of the patients with a ste-
nosis of 70% or greater had a chronic total occlusion
(CTO), which illustrates the incidence of this challenging
lesion [36]. Indeed, the presence of a CTO remains the
major hurdle in achieving complete revascularization
although successful recanalization of the CTO has been
shown to result in a relief of clinical symptoms, and
improvement of left ventricular function and long-term
survival [37–40].
Although bare metal stents significantly reduced
the need for repeat revascularizations in CTOs when
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compared with balloon angioplasty, Kastrati et al. [41,42]
showed that even when bare metal stents were used, the
treatment of a CTO was highly predictive of developing
restenosis. Hoye et al. [43] reported on the 10-year
single-center percutaneous CTO experience and showed
that the procedural success rates did not improve over
time. Nevertheless, many new devices and techniques to
successfully recanalize the CTO followed each other
rapidly and proved to be of variable efficacy. Laser-tipped
guidewires resulted in disappointing success rates [44].
Catheters capable of locally delivering thrombolytic
therapy [45] and retrograde recanalization using septal
collaterals, on the other hand, proved more promising.
Of note, higher rates of technical success donot necessarily
result in higher rates of procedural success, which also
includes the avoidance of complications.
Additionally, much is to be expected from further devel-
opments in the field of noninvasive coronary imaging.
Multislice computed tomographic scan and magnetic
guidance have already been shown to facilitate the reca-
nalization of the CTO [46]. In terms of improving the
outcome of successfully recanalized CTOs, both siroli-
mus and paclitaxel-eluting stents proved to be associated
with lower clinical and angiographic restenosis rates
[47,48]. Despite all progress, PCI of CTOs still remains
a predictive factor for the development of restenosis,
irrespective of the use of DES [49]. Thereby, the
CTO success rates still do not approximate those for
nonocclusive disease.
For many operators with a limited experience in the
treatment of CTOs, CABG is probably still the procedure
of first choice, definitely in patients with multivessel
disease. For those who do feel confident enough to treat
the CTO percutaneously, however, it is important to
keep in mind several drawbacks. The lack of a tapered
stump, a CTO in close vicinity of a sidebranch, bridging
collaterals, lengths of more than 15mm and severe calci-
fication have all proved to result in a substantial amount
of failures [50]. Besides these percutaneous limits, the
choice for the optimal treatment strategy should again
depend not only on the feasibility of re-opening the CTO
but also on the patient’s individual risk factors and
comorbidities.
Coronary artery bypass grafting or
percutaneous coronary intervention for
diabetic patients?
Diabetic patients are known to have an accelerated and
more aggressive form of atherosclerosis and they showed
high restenosis rates and less favorable long-term survi-
val following both PCI and CABG as compared with
nondiabetic participants [51–54]. Due to their smaller
vessel size, longer lesion length, greater plaque burden
and a possibly differently acting restenotic cascade as
compared to nondiabetic individuals they are inextric-
ably connected to multivessel disease [55,56].
Selection of the most optimal revascularization strategy
has been controversial. Confirming the results of the
randomized BARI trial, Niles and colleagues [54] showed
that after 5 years of follow-up, diabetics undergoing initial
PCI were significantly more likely to die during follow-up
than patients treated with CABG. Conversely, in the
BARI registry, all-cause survival was not significantly
different between both groups [57]. The ARTS-I trial,
which in contrast to the BARI trial included patients
treated with bare metal stents, showed that in the sub-
group of diabetic patients (n¼ 208), patients treated with
stenting had a significantly lower event-free survival
(63.4%) than those treated with CABG (84.4%), again
due to the higher need for repeat revascularizations in the
PCI arm [58]. The separate endpoints of death and MI
did not differ significantly between both groups. The
more recent nonrandomized diabetes subgroup of the
ARTS-II trial, which included patients with sirolimus-
eluting stents, showed that the 1-year event-free survival
was equal in the CABG arm (85.4%) and ARTS-II arm
(84.3%). The need for repeat revascularization, however,
was still in favor of the CABG-treated patients (4.2%
ARTS-I CABG versus 12.6% ARTS-II; P¼ 0.027) [59].
The above mentioned results are disputable since they
are all derived from indirect comparisons and subgroup
analyses of randomized controlled trials. There seems
reason, however, to believe that due to the rapid disease
progression and greater atherosclerotic burden of the
diabetic patient with multivessel disease, CABG should
be the preferred treatment, mainly because of its ability
to bypass this large amount of plaque burden, which
could make repeat revascularizations necessary.
Currently, the first randomized controlled trials, specifi-
cally designed to compare the outcomes of diabetic
patients treated with either CABG or PCI with DESs,
are ongoing. The Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management
of Multivessel Disease (FREEDOM) trial, a randomized
unblinded two-sided superiority trial, is enrolling 2400
diabetic patients with multivessel disease to treatment
with PCI with sirolimus-eluting stent (SES) or paclitaxel-
eluting stent (PES) versus CABG. Another ongoing trial
is the Coronary Artery Revascularisation in Diabetes
(CARDIA) study, a prospective, randomized, multicenter
UK investigation of 600 diabetes mellitus patients,
designed to address the hypothesis that PCI with SES
is not inferior to CABG as a revascularization strategy.
Until the results of these trials are published the choice
for either strategy should be based on the patient’s
individual risk profile and anatomy. Additionally, it is
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imperative to say that carefully monitoring glycemic
control and lipid concentrations is at least as important
in achieving an optimal outcome [60].
Adjunctive pharmacological treatment
Recent developments in periprocedural and postproce-
dural adjunctive drug therapy have led to a significant
improvement in both short and long-term survival follow-
ing PCI. In a recent meta-analysis of 19 randomized trials
evaluating the impact of the use of IIb/IIIa inhibitors in a
total of 20 137 patients, mortality was significantly
reduced by 31% at 30 days (RR 0.69; 95% CI 0.53–
0.90) and 21% at 6months (RR 0.79; 95% CI 0.64–
0.97) [61]. Additionally, there was no excessive risk of
bleeding if heparin was discontinued. Regarding the use
of clopidogrel, the randomized PCI–CURE trial showed
that long-term administration of clopidogrel after PCI
was associated with a lower rate of cardiovascular death,
MI, or any revascularization (P¼ 0.03), and of cardiovas-
cular death or MI (P¼ 0.047). Overall (including events
before and after PCI) there was a 31% reduction in
cardiovascular death or MI (P¼ 0.002) [62]. What has
to be remarked is that the PCI–CURE trial, supported by
the Clopidogrel for the Reduction of Events During
Observation (CREDO) trial, showed that clopidogrel
given before a PCI is effective and cost-effective in
reducing major adverse cardiac events up to 1month
[62,63]. There was, however, no significant difference
in death or MI between the clopidogrel and placebo-
treated groups between 1 and 6months [64]. Herewith,
the long-term continuation of clopidogrel and the pro-
tective effect on stent-thrombosis remains controversial
when also taking into account the increased costs, the
higher bleeding risk and the possibility of aspirin or
clopidogrel resistance [64–66]. Additionally, worth men-
tioning is the Lescol Intervention Prevention Study
(LIPS), which randomized PCI patients to treatment
with fluvastatin or a placebo [67]. The presence of multi-
vessel disease markedly increased the risk of cardiac
atherosclerotic events compared with single-vessel dis-
ease among patients allocated to placebo (RR 1.67; 95%
CI 1.24–2.25). In patients treated with fluvastatin, how-
ever, no significant differences in long-term outcomes
were observed between patients with multivessel disease
and single-vessel disease (RR 1.28; 95% CI 0.90–1.81)
[68,69]. The additional cost-effectiveness of fluvastatin
following successful first PCI was shown to be US$13 505
per life–year (US$15 454 per quality adjusted life–year)
saved [70].
Conclusion
As outlined above there is little evidence to believe that
opting for either CABG or PCI would imply a better
survival in the general population. What we do know is
that the interventionalist should try to strive for a com-
plete revascularization, which has proved to be the
surgeon’s best asset. This implies that improving one’s
skills in the treatment of chronic total occlusions is
essential and is a goal that might be difficult to achieve
for many interventionalists operating in a smaller-scale
setting with limited access to high-tech tools and tech-
niques. It is noteworthy that new scoring systems and
reports of surgeon-based procedural mortality rates tend
to cause a shift of high-risk patients from surgery towards
a percutaneous approach.
Taken all together, surgical coronary revascularization
remains a valuable technique that will certainly not
disappear and does not have to be restricted to the
severely diseased diabetic patient or the patient with
CTOs.
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Long-Term Safety and Efficacy of Percutaneous Coronary
Intervention With Stenting and Coronary Artery Bypass
Surgery for Multivessel Coronary Artery Disease
A Meta-Analysis With 5-Year Patient-Level Data From the ARTS,
ERACI-II, MASS-II, and SoS Trials
Joost Daemen, MD; Eric Boersma, PhD; Marcus Flather, MBBS; Jean Booth, MSc;
Rod Stables, MA, DM, FRCP; Alfredo Rodriguez, MD; Gaston Rodriguez-Granillo, MD, PhD;
Whady A. Hueb, MD; Pedro A. Lemos, MD, PhD; Patrick W. Serruys, MD, PhD
Background—Randomized trials that studied clinical outcomes after percutaneous coronary intervention (PCI) with bare
metal stenting versus coronary artery bypass grafting (CABG) are underpowered to properly assess safety end points like
death, stroke, and myocardial infarction. Pooling data from randomized controlled trials increases the statistical power
and allows better assessment of the treatment effect in high-risk subgroups.
Methods and Results—We performed a pooled analysis of 3051 patients in 4 randomized trials evaluating the relative
safety and efficacy of PCI with stenting and CABG at 5 years for the treatment of multivessel coronary artery disease.
The primary end point was the composite end point of death, stroke, or myocardial infarction. The secondary end point
was the occurrence of major adverse cardiac and cerebrovascular accidents, death, stroke, myocardial infarction, and
repeat revascularization. We tested for heterogeneities in treatment effect in patient subgroups. At 5 years, the
cumulative incidence of death, myocardial infarction, and stroke was similar in patients randomized to PCI with stenting
versus CABG (16.7% versus 16.9%, respectively; hazard ratio, 1.04, 95% confidence interval, 0.86 to 1.27; P0.69).
Repeat revascularization, however, occurred significantly more frequently after PCI than CABG (29.0% versus 7.9%,
respectively; hazard ratio, 0.23; 95% confidence interval, 0.18 to 0.29; P0.001). Major adverse cardiac and
cerebrovascular events were significantly higher in the PCI than the CABG group (39.2% versus 23.0%, respectively;
hazard ratio, 0.53; 95% confidence interval, 0.45 to 0.61; P0.001). No heterogeneity of treatment effect was found in
the subgroups, including diabetic patients and those presenting with 3-vessel disease.
Conclusions—In this pooled analysis of 4 randomized trials, PCI with stenting was associated with a long-term safety
profile similar to that of CABG. However, as a result of persistently lower repeat revascularization rates in the CABG
patients, overall major adverse cardiac and cerebrovascular event rates were significantly lower in the CABG group at
5 years. (Circulation. 2008;118:1146-1154.)
Key Words: bypass  coronary disease  prognosis  stents  surgery
Coronary artery bypass grafting (CABG) has been con-sidered the gold standard for treating multivessel coro-
nary artery disease, mainly because of its higher rate of
complete revascularization, reflected by a lower need for
repeat revascularizations compared with percutaneous coro-
nary intervention (PCI).1–4
Clinical Perspective p 1154
Whereas the risk difference of CABG versus balloon
angioplasty for repeat revascularization in a large-scale meta-
analysis proved to be 34% at 3 years, this difference de-
creased to 15% when coronary stents were used.1 In terms of
clinical safety end points, the recently reported 5-year
follow-up of the Arterial Revascularization Therapies Study
(ARTS),5 Argentine Randomized Trial of Coronary Angio-
plasty With Stenting Versus Coronary Bypass Surgery in
Patients With Multiple Vessel Disease (ERACI-II),6 and the
Medicine, Angioplasty or Surgery Study for Multi-Vessel
Coronary Artery Disease (MASS-II)7 reported no difference
in death rates between the 2 revascularization strategies.
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Conversely, the Stent or Surgery (SoS) trial recently demon-
strated a significantly lower survival in patients treated with
PCI compared with CABG at 6 years.7a
In the present study, patient-level data of the above-
mentioned randomized trials were pooled to make a more
precise estimate of the relative long-term safety and efficacy
of PCI with stenting and CABG for multivessel coronary
artery disease, to assess the relative treatment effect in several
high-risk subgroups, and to assess the heterogeneity of the
treatment effect.
Methods
Study Design and Patient Population
The methodology of the present meta-analysis has been described
previously.8 In brief, a MEDLINE search using the keywords
coronary stenting, coronary artery bypass surgery, and multisystem/
multivessel disease was performed with the intention of selecting and
including all randomized clinical trials comparing PCI with stenting
and CABG in patients with multivessel coronary artery disease. Four
trials were selected: ARTS,9 SoS,10 ERACI-II,11 and MASS-II.12
Principal investigators of each study group were contacted, and
individual patient data were requested on a broad range of baseline
characteristics, medication usage, procedural results, and clinical
outcome at 5 years. Clinical outcome included data on death, stroke,
myocardial infarction (MI), and repeat revascularization (either PCI
or CABG) at 5 years for ARTS, MASS-II, and ERACI-II. For the
SoS trial, 5-year follow-up data were restricted to survival data. Data
on the occurrence of stroke, MI, and repeat revascularization
between 1 and 5 years were not collected by the SoS investigators.
Clinical events were adjudicated by independent clinical event
committees. The patient-level–based data were subsequently trans-
ferred to Erasmus University Medical Center (Rotterdam, the Neth-
erlands; E.B.) to 2 researchers (J.D., P.W.S.) who analyzed and
interpreted the data.
Definitions and Clinical End Points
No attempt was made to readjudicate the events in the different trials
to compensate for the differences in the individual end-point defini-
tions. Given the randomized design of the 4 trials, no bias was
expected. The primary end point was the composite end point of
death, stroke, or MI at 5 years. The secondary end points included
major adverse cardiac and cerebrovascular events (defined as the
occurrence of major adverse cardiac and cerebrovascular accidents:
all-cause death, stroke, MI, and repeat revascularization); the com-
bined end point of all-cause death, MI, or repeat revascularization;
and the itemized end points of death, stroke, MI, and repeat
revascularization (PCI or CABG).
Statistical Analysis
All analyses were performed on an intention-to-treat population.
Most continuous variables had nonnormal distribution (as evaluated
by Kolmogorov-Smirnov tests). For reasons of uniformity, summary
statistics for all continuous variables are therefore presented as
medians and 25th and 75th percentiles. Categorical data are summa-
rized as frequencies and percentages. Differences in baseline char-
acteristics between patients randomized to PCI with stenting versus
CABG were analyzed with Wilcoxon–Mann–Whitney tests or Fish-
er’s exact tests as appropriate.
The incidence of events over time was studied by the Kaplan–
Meier method, and log-rank tests were applied to evaluate differ-
ences between patients allocated to PCI with stenting or CABG.
Additionally, Cox proportional-hazards regression models were
applied to further evaluate the effects of allocated treatment on the
incidence of events over time. Because aggregated estimates of
treatment effect that are based on small numbers of studies are
sensitive to the chosen pooling method, we applied a variety of such
methods, which showed quite consistent results. First, hazard ratios
(HRs) for study end points were determined from the proportional-
hazards model stratified by trial with a single fixed effect according
to the Yusuf–Peto13 approach. Subsequently, nonstratified models
were fitted with study membership as a covariate in the model,
allowing for the adjustment of trial effects and variations in the
standards of practice across participating institutions.14 Then, trial-
by-treatment interaction terms were added to evaluate heterogeneity
in treatment effect across trials. Interaction terms also were added to
study heterogeneities in treatment effects according to clinically
relevant characteristics, including age, gender, diabetes, dyslipid-
emia, hypertension, prior MI, number of diseased vessels, left
ventricular ejection fraction, and peripheral vascular disease. Be-
cause the 2 log likelihood of the regression models was not
improved by adding interaction terms (except for death in relation to
trial; see the Results section), we decided to stick to the fixed-effects
approach and to remove any interaction term from further models.
The HRs that are finally reported (together with the 95% confidence
intervals [CIs]) are based on regression models with allocated
treatment as the main effect and with the above-mentioned clinical
characteristics as covariates.15
All tests are 2 sided with a significance level of 0.05. All statistical
analyses were performed with the SAS System version 8.2 (SAS
Institute Inc, Cary, NC).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Patients, Baseline, and Procedural Characteristics
A total of 3051 patients were included in this analysis
between June 1995 and June 2000 (1205 in ARTS, 450 in
ERACI-II, 408 in MASS-II, and 988 in SoS). In total, 1533
were randomized to CABG, and 1518 were randomized to
PCI. Eighty-nine percent of patients allocated to PCI under-
went the assigned treatment compared with 96% of those
assigned to CABG.
Baseline and procedural characteristics are summarized in
Table 1. Although 3-vessel disease was more frequent in the
CABG group compared with the PCI group (40.0% versus
36.1%, respectively; P0.017), complete revascularization
was performed in 89.4% of the CABG patients compared
with 62.0% of the PCI patients (P0.001). The hospital stay
was significantly longer in the CABG group (median, 8 days;
interquartile range, 1 to 4 days) compared with the PCI group
(median, 3 days; interquartile range, 6 to 11) (P0.001).
Clinical Outcome
Clinical event rates are summarized in Table 2 and Figure 1.
Five-year follow-up was complete for 97% of all patients
(100% in ARTS and ERACI-II, 97.5% in MASS-II, and
91.6% in SoS). At 5 years, the cumulative incidence of death,
MI, and stroke was similar in patients randomized to PCI with
stenting versus CABG (16.7% versus 16.9%, respectively;
HR, 1.04; 95% CI, 0.86 to 1.27; P0.69). Repeat revascu-
larization, however, occurred significantly more frequently
after PCI compared with CABG (29.0% versus 7.9%, respec-
tively; HR, 0.23; 95% CI, 0.18 to 0.29; P0.001). Because of
the substantial difference in the repeat revascularization rates
between both treatment modalities, major adverse cardiac and
cerebrovascular event rates were significantly higher in the
PCI group than in the CABG group (39.2% versus 23.0%,
respectively; HR, 0.53; 95% CI, 0.45 to 0.61; P0.001).
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Table 1. Baseline and Procedural Characteristics and Medications
PCI With Stenting
(n1518 Patients)
CABG
(n1533 Patients) P
Age, y
Median 61.6 61.6 0.37
IQR 53.5–68.0 54.6–68.3
Range 30.2–85.4 31.9–86.0
Men, % 76.5 (1162/1518) 77.1 (1182/1533) 0.73
Diabetes mellitus, % 18.1 (275/1518) 17.5 (268/1533) 0.67
Hyperlipidemia, % 60.1 (910/1515) 56.5 (866/1532) 0.051
Hypertension, % 50.5 (766/1518) 51.7 (792/1533) 0.52
Family history of CAD, % 38.1 (498/1307) 38.7 (514/1327) 0.75
Current smoker, % 28.3 (429/1516) 26.5 (406/1533) 0.27
Previous MI, % 42.8 (650/1518) 41.4 (635/1533) 0.44
Peripheral vascular disease, % 7.0 (107/1518) 8.2 (126/1533) 0.25
Aspirin, % 93.5 (1419/1518) 90.2 (1382/1533) 0.001
-Blockers, % 79.4 (1205/1518) 81.7 (1252/1533) 0.11
Calcium channel blockers, % 37.3 (566/1518) 40.2 (617/1533) 0.095
Nitrates, % 68.1 (1033/1518) 69.7 (1068/1533) 0.35
Statins, % 40.9 (621/1517) 39.5% (606/1533) 0.44
Enrollment diagnosis, %*
Stable angina 68.2 (1036/1518) 68.9 (1057/1533) 0.70
Unstable angina 28.5 (432/1518) 27.3 (418/1533) 0.47
Silent ischemia 3.5 (48/1358) 2.6 (34/1330) 0.15
Ejection fraction, % 0.91
Median 60 60
IQR 52–68 51–67
Range 27–92 26–91
Segments with 50% stenosis, n 0.92
Median 3 3
IQR 2–3 2–3
Range 1–9 1–8
Diseased vessels, n 0.017
1 4.6 (70/1518) 3.0 (46/1533)
2 59.3 (900/1518) 57.0 (874/1533)
3 36.1 (548/1518) 40.0 (613/1533)
Vessel territory with stenosis, %
RCA 74.2 (1127/1518) 78.0 (1195/1533) 0.017
LAD 89.9 (1364/1518) 91.8 (1408/1533) 0.06
LCx 63.2 (959/1518) 67.7 (1038/1533) 0.009
LMCA 1.0 (15/1518) 0.7 (10/1533) 0.32
Length of hospital stay, d 0.001
Median 3 8
IQR 1–4 6–11
Range 1–70 1–110
Complete revascularization, % 62.0 (809/1304) 89.4 (1180/1320) 0.001
IQR indicates interquartile range; CAD, coronary artery disease; RCA, right coronary artery; LAD, left
anterior descending artery; LCx, left circumflex artery; and LMCA, left main coronary artery. Values
are meanSD when appropriate. The difference between the total number in each group and the
denominator used to calculate the percentages for each variable is due to missing data.
*Stable angina was defined according to the Canadian Cardiovascular Society system; unstable
angina was classified according to the Braunwald classification.
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Heterogeneity
As far as the composite end point of death, stroke, and MI is
concerned, there was no evidence of heterogeneity in the
treatment effect between the 4 trials. However, we found
significant heterogeneity in the treatment effect for death at 5
years between SoS and the other trials (P0.0074; Figure
2A). In SoS, CABG was associated with a 44% reduction in
5-year mortality rate compared with PCI with stenting (cu-
mulative survival, 95.5% versus 92.1%, respectively; HR,
0.56; 95% CI, 0.33 to 0.95), whereas no such reduction was
observed in the remaining trials (91.2% versus 90.0%, re-
spectively; HR, 1.15; 95% CI, 0.86 to 1.52). No heterogeneity
was observed between SoS and ARTS with respect to the
effects of CABG versus PCI with stenting on 5-year mortality
rate (P0.09). Furthermore, no significant heterogeneity for
the composite end point of death, stroke, and MI was found
for any of the clinical and anatomic subgroups of interest
shown in Figures 2B and 3.
Patients With Diabetes
For the composite end point of death, stroke, and MI, no
heterogeneity in treatment was found between patients with
diabetes and those without diabetes (Figure 3). In patients
with diabetes, the cumulative incidence of death was 12.4%
in the PCI group compared with 7.9% in the CABG group
(P0.09). In patients without diabetes, the cumulative inci-
dence of death was 7.7% in the PCI group compared with
8.3% in the CABG group (P0.55). The cumulative inci-
dence of death, stroke, or MI in diabetics was similar after
PCI with stenting and CABG (21.4% versus 20.9%, respec-
tively; P0.9). However, the HR for repeat revascularization
in the diabetic subgroup was 0.18 (95% CI, 0.11 to 0.29) as
a result of a 3-fold-higher cumulative incidence of repeat
revascularization in the PCI group (29.7% versus 9.2%;
P0.001).
2-Vessel Versus 3-Vessel Disease
The cumulative 5-year incidence of death was similar be-
tween PCI and CABG in both the 2-vessel disease (7.6%
versus 7.3%, respectively; P0.87) and the 3-vessel disease
(10.2% versus 9.5%, respectively; P0.71) subgroups. The
cumulative incidence of death, stroke, and MI was similar
between PCI and CABG in both the 2- and 3-vessel sub-
groups. However, repeat revascularization rates were signif-
icantly higher in the PCI group in patients with 2-vessel and
in those with 3-vessel disease (29.0% versus 7.2%, P0.001;
and 28.9% versus 7.8%, P0.001, respectively), resulting in
a significantly lower incidence of the combined major ad-
verse cardiac and cerebrovascular events in the CABG cohort
for both 2- and 3-vessel disease.
Discussion
The present study was conducted using individual patient-
based data with complete follow-up until 5 years. We
demonstrated that at 5 years PCI and CABG were associated
with a similar safety profile, expressed by hard clinical end
points like death, stroke, and MI. These results confirm the
previous findings of a large-scale review of 23 PCI (with and
without stenting) versus CABG trials by Bravata et al,16
which demonstrated no difference in the 5-year survival rates
between both treatment modalities. No differences in survival
rates between PCI and CABG were noted even up to 13
years.17–20
A nonrandomized study that reached different conclusions
was a large-scale registry (n59 314) by Hannan and col-
leagues.21 Risk-adjusted survival rates in this study were
significantly higher in patients treated with CABG than in
those treated with PCI with stenting. Bearing in mind that all
baseline characteristics collected in this study were signifi-
cantly different between the PCI and CABG groups and the
unadjustable characteristic “judgment of the treating physi-
cian to chose for either PCI or CABG,” we must interpret
these results with caution. Furthermore, the shorter follow-up
and the higher-risk profile (higher age, higher incidence of
diabetes, lower ejection fraction) of patients included in the
study by Hannan and colleagues compared with the present
meta-analysis make it difficult to put the results into
perspective.
Table 2. Event Rates at 5 Years
Variables
Crude Event Rates, %
P
Kaplan–Meier Estimates, %
HR (95% CI)* P
PCI
(n1518 Patients)
CABG
(n1533 Patients)
PCI
(n1518 Patients)
CABG
(n1533 Patients)
Death 8.5 (129/1518) 8.2 (125/1533) 0.74 8.5 8.2 0.95 (0.73–1.23) 0.69
Stroke 2.5 (38/1518) 2.9 (45/1533) 0.51 3.1 3.6 1.16 (0.73–1.83) 0.54
MI 6.6 (100/1518) 6.1 (94/1533) 0.66 7.3 7.6 0.91 (0.68–1.23) 0.54
Repeat revascularization 25.0 (379/1518) 6.3 (96/1533) 0.001 29.0 7.9 0.23 (0.18–0.29) 0.001
Repeat PCI 18.3 (278/1518) 5.4 (83/1533) 0.001 21.5 6.9 0.29 (0.22–0.37) 0.001
Repeat CABG 9.1 (138/1518) 1.2 (18/1533) 0.001 10.4 1.5 0.12 (0.07–0.21) 0.001
Death, stroke, or MI 14.2 (215/1518) 14.6 (224/1533) 0.76 16.7 16.9 1.04 (0.86–1.27) 0.69
Death, MI, or repeat
revascularization
32.5 (494/1518) 17.5 (268/1533) 0.001 37.1 20.4 0.50 (0.43–0.58) 0.001
Death, stroke, MI, or repeat
revascularization
34.2 (519/1518) 19.6 (301/1533) 0.001 39.2 23.0 0.53 (0.45–0.61) 0.001
*Adjusted for between-trial outcomes and the following predetermined clinical characteristics: age, gender, diabetes, dyslipidemia, hypertension, prior MI, number
of diseased vessels, left ventricular ejection fraction, and peripheral vascular disease.
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All 4 randomized trials included in the present meta-anal-
ysis studied the safety and effectiveness of PCI with bare
metal stents. Since 2002, drug-eluting stents have been shown
to halve repeat reinterventions rates without affecting the
short- and long-term safety of the treatment.22–25 Moreover,
because of their significantly lower revascularization rates,
sirolimus-eluting stents proved to be capable of narrowing the
gap in major adverse cardiac event rates between PCI and
CABG, as demonstrated by the ARTS-II and ERACI-III
studies.26,27 In contrast to the ARTS-I study, the recently
presented 3-year results of the ARTS-II study showed similar
major adverse cardiac event rates after PCI with sirolimus-
eluting stents and CABG. However, the need for repeat
revascularization was still significantly lower after CABG.28
Although both ERACI-III and ARTS-II showed a clear
impact of drug-eluting stents on the relative efficacy of PCI
and CABG, it must be noted that both studies were nonran-
domized comparisons. Along these lines, a recent registry by
Javaid et al29 reported significantly higher mortality rates and
a trend toward higher MI rates in patients treated with PCI
with drug-eluting stents compared with those treated with
CABG at 1 year regardless of the amount of vessels diseased
and the presence of diabetes.29 It is worth mentioning that the
1-year results of none of the 4 randomized trials in the present
study concurred with these latter findings.9–12 Given the
similar, if not superior, safety profile of drug-eluting stents
compared with bare metal stents, it is unlikely that the use of
drug-eluting stents in this study accounted for this dissimi-
larity.22,23,30 Several large-scale randomized trials such as
Future Revascularization Evaluation in Patients With Diabetes:
Optimal Management of Multivessel Disease (FREEDOM),
Coronary Artery Revascularization in Diabetics (CARDIA), and
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Figure 1. Kaplan–Meier event-free survival analysis of death (A); death, stroke, or MI (B); repeat revascularization (C); and major
adverse cardiac and cerebrovascular events (death, stroke, MI, and repeat revascularization (D).
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Synergy Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery (SYNTAX) are currently comparing
the safety and effectiveness of CABG and PCI with drug-eluting
stents.31
Of note, despite the improvement in durability of more
contemporary PCI with (drug-eluting) stents, long-term sur-
vival rates do not seem to improve in a similar fashion and
remain equal between PCI and CABG. This finding recalls a
major goal of treating (multivessel) coronary artery disease:
the relief of angina. Despite the fact that at 1 year after CABG
significantly more patients were free of angina compared
with PCI in all 4 trials,9–12 5-year reports of the ARTS,
ERACI-II, and MASS-II demonstrated similar incidences of
angina at 5 years after CABG and PCI.5–7 Additionally, the
final results from the Bypass Angioplasty Revascularization
Investigation (BARI) trial proved that even up to 10 years,
angina rates were still equal between both treatment modal-
ities.17 However, in the PCI group, these similar angina rates
were achieved only after a significantly higher rate of repeat
revascularizations compared with the CABG group.
Significant heterogeneity in treatment effect was noted
between SoS and the remaining trials with respect to survival
at 5 years. Although the 5-year cumulative survival in the PCI
arm of SoS (92.1%) was similar to the ARTS, ERACI-II, and
MASS-II trials (92.2%, 92.9%, and 86.3% respectively), the
survival in the CABG arm of SoS (95.5%) was remarkably
higher than in ARTS, ERACI-II, and MASS-II (92.6%,
88.5%, and 84.1%, respectively). The exact reason for this
superior survival rate remains puzzling, and a play of chance
cannot be excluded. A speculative reason for the heterogene-
ity might be the difference in the inclusion criteria and
procedural requirements in the different studies. In ARTS,
higher-risk patients were excluded; 67% of the patients had
2-vessel disease; and an equivalent revascularization rate was
required.9,32 Conversely, in MASS-II, almost 58% of the
patients had 3-vessel disease, and a proximal left anterior
descending artery lesion was required.12 Additionally, the
SoS trial protocol stated that the study was intended to be a
“pragmatic trial,” including enrollment of a wide range of
patients with minimal restriction on postrandomization pa-
tient management. However, both patient groups in SoS were
well matched, and it is unlikely that the pragmatic nature of
the trial was the reason for the unexpected difference in death
rates, which are not confirmed by the larger sample of this
meta-analysis.10
Coronary artery disease in diabetics has been shown to be
more aggressive and to be associated with an impaired
event-free survival after both CABG and PCI because of
smaller vessel sizes, longer lesion length, greater plaque
burden, and a possibly differently acting restenotic cascade
than in nondiabetics.33–38 Given this higher-risk profile,
which is most often associated with multivessel disease,
CABG was regarded as the preferred revascularization
method because of its ability to bypass this large amount of
plaque burden and to achieve more complete revasculariza-
tion rates, making the need for repeat revascularizations less
likely. Attempting to demonstrate the most optimal treatment
strategy for diabetics, a subgroup analysis of the randomized
BARI trial and a large observational registry demonstrated
significantly impaired survival among patients treated with
PCI compared with those treated with CABG.36,39 Interest-
ingly, in the BARI registry, all-cause survival was not
significantly different between both groups.40 Furthermore,
all the above-mentioned studies were performed in the
prestent era and may no longer be applicable in current
clinical practice. In the present analysis, using pooled patient-
level–based 5-year follow-up data from 4 randomized con-
trolled trials, we found no significant heterogeneity of the
Adjusted hazard ratio and 95% CI for death at 4Y
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Figure 2. HRs for each trial individually and the pooled estimate for all trials (corrected for between-trial outcome) for the end points of
all-cause mortality (A) and all-cause death, stroke, and MI (B).
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treatment effect in diabetics compared with nondiabetics,
although our analysis might have suffered from a lack of
power. The ongoing FREEDOM and CARDIA trials will
further address the relative safety and efficacy of CABG and
more contemporary PCI with drug-eluting stents in diabetics.
Two randomized controlled trials comparing PCI with
CABG, the Angina With Extremely Serious Operative Mortality
Evaluation (AWESOME) and a Randomized Comparison of
Stent Implantation and Off-Pump Bypass Surgery in Patients
Referred for Coronary Angioplasty (OCTOSTENT) trials,41,42
were excluded from the present meta-analysis. The AWESOME
trial (n454) included only high-risk patients with refractory
myocardial ischemia and a high risk of adverse outcomes,
generating a study population clearly different from the present
one. Moreover, 54% of the patients in AWESOME were treated
with balloon angioplasty only. The OCTOSTENT trial
(n280), with only 30% of the population having multives-
sel disease, was not yet published when the initial meta-
analysis by Mercado et al8 was performed. Of note, neither
AWESOME nor OCTOSTENT completed the 5-year follow-up
at the time of the present meta-analysis.
Pooling data from 4 multicenter randomized controlled
trials with diversity in inclusion and exclusion criteria re-
sulted in a diverse and high-risk patient population. However,
patients with severe 3-vessel disease presenting with an acute
coronary syndrome, left main lesions, previous coronary
interventions, heart failure, or renal disease were excluded in
all 4 trials. Although no heterogeneity in the treatment effect
was found among several high-risk subgroups in the present
analysis, the results of several large-scale, dedicated, random-
ized controlled trials are eagerly awaited to determine the
external validity of our findings. Until the relatively short-
term findings of these large trials are presented, the results
from the present meta-analysis constitute the highest amount
of clinical evidence regarding the relative long-term safety of
PCI using stents and CABG.
Conclusions
In this pooled analysis of 4 randomized trials, PCI was
associated with a long-term safety profile, expressed by
death, stroke, and MI, similar to that of CABG. However,
because of the persistently lower repeat revascularization
rates in the CABG patients, overall major adverse cardiac and
cerebrovascular event rates were significantly lower in the
CABG group at 5 years. Dedicated trial data on the impact of
drug-eluting stents, the relief of angina, and the role of PCI in
higher-risk patients are warranted.
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CLINICAL PERSPECTIVE
Randomized trials that studied clinical outcome after percutaneous coronary intervention (PCI) with bare metal stenting
versus coronary artery bypass grafting (CABG) are underpowered to properly assess safety end points like death, stroke,
and myocardial infarction. Pooling data from randomized controlled trials increases the statistical power and allows better
assessment of the treatment effect in high-risk subgroups. The present pooled analysis of 3051 patients in 4 randomized
trials evaluating the relative safety and efficacy of PCI with stenting and CABG for the treatment of multivessel coronary
artery disease demonstrates that both treatment modalities provided similar long-term safety profiles. At 5 years, the
cumulative incidence of death, myocardial infarction, and stroke was similar in patients randomized to PCI with stenting
versus CABG (16.7% versus 16.9%, respectively; hazard ratio, 1.04; 95% confidence interval, 0.86 to 1.27; P0.69).
Repeat revascularization, however, occurred significantly more frequently after PCI than CABG (29.0% versus 7.9%,
respectively; hazard ratio, 0.23; 95% confidence interval, 0.18 to 0.29; P0.001). Several large-scale randomized trials like
the Future Revascularization Evaluation in Patients With Diabetes: Optimal Management of Multivessel Disease, and
Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery are currently comparing the safety
and effectiveness of CABG and PCI with drug-eluting stents. Whether drug-eluting stents will tip the balance between
safety and efficacy of PCI and CABG is to be examined.
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Abstract
Aims: Late stent thrombosis has been documented in on- and off-label populations. Stent thrombosis is more
frequently in higher risk patients and there is still scarce data about the impact on late adverse cardiac events.
The aim therefore is to determine the 3-year safety and effectiveness of Sirolimus-Eluting Stent (SES) (Cypher®)
implantation in patients with multivessel disease and to compare outcomes with the historical results of the two
arms of the Arterial Revascularisation Therapies Study (ARTS-I).
Methods and results: ARTS-II is a 45 centre, 607 patient single-arm study. Three years outcomes were
compared to the outcome of the historical cohorts of ARTS-I using the same inclusion and exclusion criteria and
major adverse cardiac and cerebrovascular events (MACCE) definitions. Patients were stratified by clinical site
to ensure that at least 1/3 had 3-vessel disease to achieve a number of treated lesions per patient comparable
to ARTS-I. Stent thrombosis was re-adjudicated using the ARC definitions. An angiographic coronary score to
characterise lesion complexity was applied to allow the identification of patients who might benefit the most
from multivessel stenting.
In ARTS-II, 46.6% of the patients underwent 3-vessel treatment as compared to 18.0% in ARTS-I percutaneous
coronary intervention (PCI) (n=600) with bare metal stents (BMS). Diabetes was present in 26.2% in ARTS-II as
compared to 17.3% in ARTS-I. In ARTS-II, patients received on average 3.7 stents resulting in a mean total stented
length of 72.5 mm. The 3-year survival rate in ARTS-II was 97.0%, comparable to the 95.6% and 96.0% of the
historical surgical (n=605) and PCI cohorts of ARTS-I. The death/cerebrovascular accident (CVA)/myocardial infarction
(MI) event free survival rate in ARTS-II was 91.7%, versus 89.1% (p=0.1) and 87.2% (p=0.007) in ARTS-I coronary
artery bypass graft (CABG) and PCI cohorts, respectively. Freedom from revascularisation in ARTS-II was 85.5%,
lower than in ARTS-I CABG (93.4%; p<0.001) but higher than in ARTS-I PCI (73.7%; p<0.001) cohorts. MACCE
free survival was 80.6% in ARTS-II, comparable to ARTS-I CABG (83.8%; p=0.21) but superior to ARTS-I PCI
(66.0%; p<0.0001). The incidence of stent thrombosis (ARC any) in  ART-II was 6.4% (39/607 patients).
Conclusions: Despite the higher clinical and angiographic risk profile, the overall MACCE rate at three years was
lower in ARTS-II than in the ARTS-I PCI and comparable to ARTS-I CABG. However, the re-intervention rate in
ARTS-I CABG remained significantly lower than in ARTS-II.
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Introduction
In September 2001, the results of the pivotal randomised trial
comparing bare metal stents (BMS) and sirolimus-eluting stents
(SES) were presented at the scientific sessions of the European
Society of Cardiology and subsequently published in 2002.1 Shortly
after the commercialisation of this first drug-eluting stent (Cypher®)
in Europe in April 2002, European investigators requested the
manufacturer to sponsor a randomised comparison between bypass
surgery and stenting with SES for multivessel disease, using a similar
study design as in the Arterial Revascularisation Therapies Study
ARTS-I.2-4 However, the project was considered to be premature,
hazardous and expensive. As a surrogate, the ARTS-II registry was
designed applying the same inclusion and exclusion criteria, the
same protocol definitions and the same primary endpoint, in order to
make the registry as comparable as possible to the randomised
ARTS-I trial of coronary artery bypass surgery and BMS.5
Despite the non-randomized nature of the ARTS-II trial, the 3-year
results can be interpreted today in the context of the current concerns
raised about the long-term safety of SES, since the ARTS-II population is
so far one of the most complex populations of patient treated with SES.
Since the first seminal observation of very late stent thrombosis,
a large number of reports have raised concerns about the safety of
the treatment, particularly in off-label use.6-10 ARTS-II clearly
represents “off-label” use of SES with an average use of 3.7 stents
per patients resulting for a mean total stented length of 72.5 mm
per patient, a length of stenting unparalleled by any randomised
trial or current registry reported thus far. In the meantime, the
Academic Research Consortium (ARC), working with the FDA and
major stent manufacturers, created new definitions for the major
adverse clinical events, including stent thrombosis.11
In October 2006 the FDA requested that the events in the pivotal
Cypher and Taxus trials be re-adjudicated using these definitions.12-15 In
ARTS-II, events were re-adjudicated by a new independent critical event
committee, focusing on the incidence and timing of stent thrombosis.
The present study reports on the 3-year safety and effectiveness of
the SES in patients with multivessel disease compared to the
outcomes of the historical results of the two arms of ARTS-I applying
the ARC definition to determine the incidence of definite, probable
or possible stent thrombosis.
Methods
Study design
ARTS-II is a multicentre, non-randomised, open-label trial, designed to
compare the safety and efficacy of the SES in patients with de novo
multivessel coronary artery disease with the surgical group of ARTS-I
acting as a historical control.5 In order to obtain a population
comparable to ARTS-I, patients were stratified by clinical site in order to
ensure the inclusion of at least 1/3 of patients with three-vessel disease.
Patient selection
Patients were eligible for coronary revascularisations if they had either
stable angina (Canadian Cardiovascular Society class I-IV), unstable
angina (Braunwald class I-III B or C), or if they had silent ischaemia
and at least two lesions located in different major epicardial vessels
and/or their side branches (not including the left main coronary
artery) that were potentially amenable to stent implantation.16,17
Patients were required to have multivessel disease including
treatment of the left anterior descending (LAD) artery and at least one
other significant lesion (>50% diameter stenosis) in another major
epicardial coronary artery. The goal was to achieve complete
anatomic revascularisation.18 One totally occluded major epicardial
vessel or side branch could be included. The stenosis had to be
amenable to stenting using a SES with a diameter of 2.5 to 3.5 mm
and length of 13 to 33 mm, without restriction on the total implanted
stent length. Decisions to place stents in lesions with bifurcations,
fresh thrombus, calcification, diffuse disease, complex anatomy or
stenting of side branches were left to the discretion of the operators.
Patients with previous coronary intervention, left main coronary
disease, overt congestive heart failure or a left ventricular ejection
fraction of less than 30 percent were excluded. Additional exclusion
criteria were: history of a cerebrovascular accident, transmural
myocardial infarction in the preceding week, severe hepatic or renal
disease, neutropenia or thrombocytopenia, an intolerance or
contraindication to acetylsalicylic acid or thienopyridines, the need
for concomitant major surgery and life-limiting major concomitant
non-cardiac diseases. Written, informed consent was obtained from
each patient prior to enrolment. The study was approved by the
ethics committee of each participating site.
Study objectives
The primary objective of ARTS-II was to compare the safety and
effectiveness of coronary stent implantation using the SES with the
surgical arm of ARTS-I.19,20 Endpoints are measured in terms of
major adverse cardiac and cerebrovascular events (MACCE)
comprising all-cause death, any cerebrovascular event, non-fatal
MI, or any repeat revascularisation.
The secondary objectives of this study were to compare the ARTS-II
patients to both arms of ARTS-I with respect to MACCE at 30 days,
one, three and five years; the composite end point death, CVA and
myocardial infarction, and the itemised outcomes death, CVA,
myocardial infarction and repeat revascularisation; resource
utilisation at 30 days and one year; cost effectiveness at one year,
and quality of life at six months, and one, three and five years.21
Finally, the study aimed at describing the prognostic value of the
Syntax score on the MACCE rates in the ARTS-II population.
Endpoint definitions
Death was categorised as cardiac or non-cardiac. Cerebrovascular
events were divided into three main categories: stroke, transient
ischaemic attacks, and reversible ischaemic neurologic deficits. In
the first seven days after the intervention, a definite diagnosis of
myocardial infarction was made if there was documentation of new
abnormal Q-waves and either a ratio of serum creatine kinase MB
(CK-MB) isoenzyme to total cardiac enzyme that was greater than 0.1
or a CK-MB value that was five times the upper limit of normal22
Serum creatine kinase and CK-MB isoenzyme concentrations were
measured six, 12, and 18 hours after the intervention. Commencing
eight days after the intervention (the length of the hospital stay after
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surgery), either abnormal Q waves or enzymatic changes, as
described above, were sufficient for a diagnosis of myocardial
infarction. A myocardial infarction was confirmed only after the
relevant electrocardiograms had been analysed by the core laboratory
and adjudicated by the clinical-events committee. This two-part
method of defining myocardial infarction was developed for ARTS-I to
address the difficulty of diagnosing a myocardial infarction after
cardiac surgery.5 These definitions have been adopted by the ARC
Consortium and are applied whenever a comparison between DES
and surgery is performed.11 In the final report, the window of seven
days is not specifically mentioned and this window has been
maintained for the sake of comparison with the historical data from
ARTS-I. All repeat revascularisation procedures were recorded.
Secondary measures of efficacy were assessed by means of the EQ-
5D questionnaire, which allows patients to grade their general
health status.23
Endpoint measurement
In ARTS-II, the interventional procedure was performed within
48 hours of inclusion, while in ARTS-I patients were randomised
after informed consent had been obtained and then entered
a waiting list, with three deaths in the ARTS-I CABG arm occurring
whilst patients were awaiting revascularisation. To compensate for
the temporal difference since allocation between groups, events for
the present report were counted from the time of the procedure for
all three arms and not from the time of allocation as previously
published.3,4,24
In ARTS-I and ARTS-II, only data on subacute thrombotic occlusion
(<30 days) were collected in the case record form (CRF). In ARTS-II,
stent thrombosis was re-adjudicated according to the ARC definitions.11
In this process, all coronary angiograms, both procedure-related
(n=104) and non-procedure related (n=165) were reviewed by an
independent core laboratory and adjudicated by an independent
critical event committee. Thus far, no attempt has been made to
assess data on stent thrombosis in ARTS-I in a similar fashion.
In addition, a detailed coronary risk score which had been
previously published and tested in a subgroup of ARTS-II patients
with 3-vessel disease (the Syntax score) was used to characterise
the complexity of the coronary anatomy.25,26 In brief, each coronary
lesion producing > 50% luminal obstruction lumen in vessels
> 1.5 mm was separately scored and added to provide the overall
Syntax. The Syntax score was calculated using a dedicated software
that integrates the number of lesions with their specific weighting
factors based on the amount of myocardium distal to the lesion
according to the score of Leaman et al,27 and the morphologic
features of each single lesion, as previously reported26 (available at
http://www.europcronline.com/eurointervention/2nd_issue/36/).
This Syntax score is now available for the entire ARTS-II population
and its implications in terms of prognosis at three years are reported
in the present document.
Statistical analysis
The sample size justification was based on the comparison of 1-year
MACCE rates in the ARTS-II patients and the ARTS-I surgery patients
for the primary endpoint. A MACCE-free survival rate of 90.9% was
assumed in the ARTS-II trial, requiring a sample size of 600 patients
to guarantee a power of at least 90%.5,20 Binary variables are reported
as percentages, and the difference between groups was presented
with 95% confidence intervals. Time-to-event variables are presented
as Kaplan-Meier curves and incidences were compared using the
log-rank test. Safety data up to three years are presented as Kaplan-
Meier estimates, with relative risks and 95% confidence intervals. 
The final analyses will be performed at five years.
A separate multivariate regression analysis was performed to
determine independent predictors of MACCE and ST within the
ARTS-II population only. Baseline and procedural characteristics
listed in Table 1 were tested on a per patient basis by univariate
analysis to determine suitability for inclusion in the multivariate
model. Finally, a logistic regression model was built using the
significant univariate predictors (p<0.1).
Results
Baseline and procedural characteristics
Between April 1997 and June 1998 a total of 1,205 patients were
randomly assigned to PCI with BMS (n=600) or CABG (n=605) in 67
participating centres in the ARTS-I trial. Between February 2003 and
November 2003, 607 patients at 45 participating centres were
treated (Figure 1). Table 1 presents their baseline demographic and
angiographic characteristics. Patients treated in ARTS-II were
significantly older than those in ARTS-I. ARTS-II had a significantly
higher incidence of diabetes mellitus, hypertension, hypercho-
lesterolaemia and silent ischaemia, and a lower percentage of
current smokers or patients with a history of prior myocardial
infarction as compared to the ARTS-I CABG groups. Seven patients
did not receive any stents during the index procedure (four
underwent elective CABG, one required emergent CABG, one
underwent percutaneous treatment 35 days later and one remained
on medical therapy).
The percentage of percutaneous 3-vessel treatment was 46.6% in
ARTS-II versus 18.0% in ARTS-I PCI (p<0.001). The mean number of
Figure 1. Flowchart of ARTS-I and ARTS-II.
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significant lesions per patient was 3.6±1.3 in ARTS-II versus 2.8±1.0
in ARTS-I CABG (p<0.001) and 2.8±1.0 in ARTS-I PCI. ARTS-II
patients received 3.7±1.5 stents with average total stented length of
72±32 mm vs. 2.8±1.3 and 48±22 mm in ARTS-I PCI (p<0.001).
Post-procedure creatinine kinase (CK) release was within the
normal range (< 1 x Upper limit of normal (ULN)) in 81.7%
(496/607). Fourteen percent (85/607) of the patients had a CK
release of >1 and < 2 x ULN and only 4.3% (26/607) of the patients
had a post-procedure CK release of > 2 x ULN, thereby fulfilling the
ARC criteria for peri-procedural MI.
Three-year follow-up
MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS
The 3-year event rates are depicted in Table 2 and Figure 2. In
brief, the survival rate in ARTS-II was comparable to those of the
historical surgical and PCI cohorts of ARTS-I. The death/CVA/MI
Table 1. Baseline and procedural characteristics of ARTS II and ARTS I population (expressed per patient unless stated otherwise).
ARTS II ARTS I ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI
CABG (n=600) Difference Difference
(n=607) (n=605) (95% CI) (95% CI)
Baseline characteristics
Male gender (%) 77 76 77 0.6% (–4.2%, 5.4%) –0.4% (–5.2%, 4.4%)
Age (years±SD) 63±10 61±9 61±10 1.5 (0.4, 2.6) 2.1 (1.0, 3.2)
Body mass index±SD 27.5±4.1 27.4±3.7 27.2±3.7 0.2 (–0.3, 0.6) 0.3 (–0.1, 0.8)
Risk factors
Myocardial infarction (%) 34 42 44 –7.6% (–13.0%, –2.1%) –9.9% (–15.4%, –4.4%)
Diabetes (%) 26 16 19 10.3% (5.8%, 14.9%) 7.5% (2.8%, 12.2%)
Hypertension (%) 67 45 45 22.3% (16.8%, 27.7%) 22.5% (17.1%, 28.0%)
Hypercholesterolaemia (%) 74 58 58 16.4% (11.2%, 21.7%) 16.1% (10.8%, 21.4%)
Family history of MI 
or sudden death < 55 years (%) 36 42 39 –6.0% (–11.5%, –0.5%) –3.2% (–8.7%, 2.2%)
Current smoker (%) 19 26 28 –6.5% (–11.2%,–1.8) –8.7% (–13.4%, –3.9%)
Peripheral vascular disease (%) 7 5 6 1.8% (–0.9%, 4.5%) 1.4% (–1.3%, 4.2%)
Indication for treatment
Stable angina (%) 53 58 56 –4.8% (–10.4%, –0.8%) –3.1% (–8.7%, 2.5%)
Unstable angina (%) 36 37 38 –0.8% (–6.2%, 4.6%) –1.3% (–6.7%, 4.2%)
Silent ischaemia (%) 10 5 6 5.6% (2.6%, 8.5%) 4.4% (1.3%, 7.5%)
Angiographic characteristics
Ejection fraction (%) 60±12 60±13 61±12 –0.2 (–1.6, 1.3) –0.8 (–2.2, 0.7)
No. of lesions with stenosis > 50% 3.6±1.3 2.8±1.0 2.8±1.0 0.8 (0.6, 0.9) 0.8 (0.6, 0.9)
No. of diseased vessels (%)
1 0 4 4 –3.4% (–5.0%, –1.8%) –3.6% (–5.3%, –2.0%)
2 46 66 69 –20.1% (–25.6%, –14.6%) –22.4% (–27.9%, –17.0%)
3 54 30 27 23.5% (18.1%, 28.9%) 26.1% (20.7%, 31.4%)
Vessel territory with stenosis (% of lesions)
Right coronary artery 29 29 31 –0.4% (–3.3%, 2.5%) –2.1% (–5.0%, 0.9%)
Left main 0 0 0 –0.1% (–0.2%, 0.1%) –0.1% (–0.2%, 0.1%)
Left anterior descending 42 41 39 0.4% (–2.7%, 3.6%) 2.1% (–1.1%, 5.3%)
Left circumflex artery 29 29 29 0.0% (–2.9%, 3.0%) 0.0% (–2.9%, 3.0%)
Lesion length (visual) (% of lesions)
Discrete 61 68 66 –7.3% (–10.4%, –4.2%) –4.7% (–7.9%, –1.5%)
Tubular 27 25 27 2.0% (–0.9%, 4.9%) –0.1% (–3.0%, 2.8%)
Diffuse 12 7 7 5.3% (3.4%, 7.2%) 4.8% (2.9%, 6.7%)
Lesion classification (% of lesions)
Type A 7 7 6 0.0% (–1.6%, 1.6%) 0.9% (–0.7%, 2.5%)
Type B1 23 31 26 –7.9% (–10.8%, –5.1%) –3.0% (–5.8%, –0.2%)
Type B2 56 54 60 1.9% (–1.3%, 5.1%) –3.7% (–6.9%, –0.5%)
Type C 14 8 8 6.0% (4.0%, 8.0%) 5.9% (3.9%, 7.8%)
Procedural characteristics
Bifurcation requiring double wiring 34 32 35 2.2% (–0.9%, 5.3%) –0.6% (–3.7%, 2.6%)
Number of stents implanted±SD 3.7±1.5 – 2.8±1.3 – 0.9 (0.7, 1.0)
Total stent length (mm) 72.5±32.1 – 47.6±21.7 – 24.9 (21.8, 28.1)
Maximum dilatation pressure (atm±SD) 16.4±2.9 – 14.6±2.8 – 1.7 (1.4, 2.1)
Direct stenting (% of lesions) 34.6 – 3.3 – 31.3% (29.1%, 33.6%)
Duration of procedure (mins±SD) 85±43 193±67 99±50 –108.2 (–114.6, –101.8) –13.6 (–18.9, –8.3)
Post procedural hospital stay (days±SD) 3.4±2.7 9.6±4.9 3.9±3.7 –6.2 (–6.6, –5.8) –0.5 (–0.9, –0.2)
CI stands: confidence interval; SD: standard deviation; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft
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event free survival was 91.7% in ARTS-II, versus 89.1% (log rank
p=0.1) and the 87.2% (log rank p=0.007) in the ARTS-I CABG and
PCI cohorts, respectively. Freedom from revascularisation in ARTS-
II was 85.5%, which was lower than ARTS-I CABG (93.4%; log rank
p<0.0001) but higher than the ARTS-I PCI (73.3%; log rank
p<0.0001). The MACCE free survival was 80.6% in ARTS-II and did
not differ significantly from the MACCE event free survival rate of
83.8% in ARTS-I CABG (log rank p=0.21) but was superior to
ARTS-I PCI (66.0%; log rank p <0.0001).
STENT THROMBOSIS ACCORDING TO THE ARC
DEFINITIONS
In ARTS-II, a total of 39 patients (Table 3) experienced at least one
stent thrombotic event (definite, probable or possible). One patient
experienced two probable ST events (on day 331 and day 399), one
patient experienced a definite ST on day 1,020 and a probable ST on
day 1,079, one patient experienced definite ST on day 562 and day
984 and probable ST on day 983, and one patient experienced
probable ST on day 468 and possible ST on day 479 accounting for
44 ST events in total. The rate of stent thrombosis (definite or
probable or possible) in ARTS-II was 1.5% at 30 days, 3.1% at one
year, 4.4% at two years and 6.4% at three years, respectively. The
rate of definite stent thrombosis in our study rose from 1.0% at 30
days to 1.6% at one year, 2.1% at two years and 3.5% at three years.
By contrast, the rate of angiographically documented (definite) stent
thrombosis in the ARTS -I PCI cohort was 2.8% at 30 days.3
Among the 21 patients with definite ST, six were subacute (within
30 days), four late (within 30 days – one year) and 11 very late (after
one year). Four of the subacute thrombotic events occurred within
the first four days post procedure. Three of these were due to
suboptimal treatment, according to the independent CEC. No clear
cause for the thrombotic event in the remaining three patients could
be identified. Five of the subacute thrombotic events were treated
with repeat intervention (four PCI, one CABG) and one lesion was
left untreated. Two patients experienced a non-Q wave MI and four
patients experienced a Q wave MI. There were four late definite ST
(day 30-365). In one patient, the index procedure failed due to a wide
dissection and on day 40 the patient was admitted with angina (CCS 3)
and a total occlusion of the failed PCI was diagnosed. No increase 
in enzymes or appearance of a Q wave was documented. The three
remaining patients presented with in-stent restenosis and
(un)stable angina but an in-stent thrombus was diagnosed by the
CEC, who adjudicated the in-stent stenotic lesion as stent thrombosis.
Eleven very late definite stent thromboses occurred: three were
Table 2. Clinical endpoints at 3 years (hierarchical and non-hierarchical MACCE up to 1080 days, per patient) counted since date of procedure.
ARTS II ARTS I ARTS I ARTS II: I-CABG ARTS II: I-PCI
N=607 CABG PCI Difference (95% CI) Difference (95% CI)
N (%) N=602 * N=600 (%) (%)
N (%) N (%)
Hierarchical
Death 18 (3.0) 26 (4.3) 24 (4.0) –1.4 (–3.5, 0.8) –1.0 (–3.1, 1.0)
Cardiac 9 (1.5) 16 (2.7) 16 (2.7) –1.2 (–2.8, 0.4) –1.2 (–2.8, 0.4)
Non-cardiac 9 (1.5) 10 (1.7) 8 (1.3) –0.2 (–1.6, 1.2) 0.1 (–1.2, 1.5)
CVA 15 (2.5) 15 (2.5) 18 (3.0) 0.0 (–1.8, 1.7) –0.5 (–2.4, 1.3)
MI 17 (2.8) 24 (4.0) 35 (5.8) –1.2 (–3.2, 0.9) –3.0 (–5.3, –0.7)
MI Q-wave 10 (1.6) 22 (3.7) 30 (5.0) –2.0 (–3.8, –0.2) –3.4 (–5.4, –1.3)
MI non-Q-wave 7 (1.2) 2 (0.3) 5 (0.8) 0.8 (–0.1, 1.8) –0.3 (–0.8, 1.4)
Death / CVA / MI 50 (8.2) 65 (10.8) 77 (12.8) 2.6 (–5.9, 0.7) –4.6 (–8.1, –1.1)
Revascularisation 67 (11.0) 32 (5.3%) 127 (21.2) 5.7 (2.7, 8.8) –10.1 (–14.2, –6.0)
(re) CABG 13 (2.1) 5 (0.8) 40 (6.7) 1.3 (0.0, 2.7) –4.5 (–6.8, –2.2)
(re) PTCA 54 (8.9) 27 (4.5) 87 (14.5) 4.4 (1.6, 7.2) –5.6 (–9.2, –2.0)
Any MACCE 117 (19.3) 97 (16.1) 204 (34.0) 3.2 (–1.1, 7.5) –14.7 (–19.6, –9.8)
Non-hierarchical
CVA 17 (2.8) 19 (3.2) 20 (3.3) –0.4 (–2.3, 1.6) –0.5 (–2.5, 1.4)
MI 22 (3.6) 30 (5.0) 41 (6.8) –1.4 (–3.6, 0.9) –3.2 (–5.8, –0.7)
MI Q-wave 13 (2.1) 27 (4.5) 35 (5.8) –2.3 (–4.4, –0.3) –3.7 (–5.9, –1.5)
MI non-Q-wave 10 (1.6) 3 (0.5) 7 (1.2) 1.1 (0.0, 2.3) 0.5 (–0.8, 1.8)
Revascularisation 87 (14.3) 39 (6.5) 158 (26.3) 7.9 (4.4, 11.3) –12.0 (–16.5, –7.5)
(re) CABG 14 (2.3) 7 (1.2) 55 (9.2) 1.1 (–0.3, 2.6) –6.9 (–9.5, –4.3)
– Target lesion** 4 (0.7) 5 (0.8) 40 (6.7) –0.2 (–1.1, 0.8) –6.0 (–8.1, –3.9)
– Non target lesion 10 (1.6) 2 (0.3) 15 (2.5) 1.3 (0.2, 2.4) –0.9 (–2.5, 0.8)
(re) PTCA 75 (12.4) 36 (6.0) 118 (19.7) 6.4 (3.1, 9.6) –7.3 (–11.4, –3.2)
– Target lesion** 48 (7.9) 22 (3.7) 86 (14.3) 4.3 (1.6, 6.9) –6.4 (–10.0, –2.9)
– Non target lesion 37 (6.1) 15 (2.5) 42 (7.0) 3.6 (1.3, 5.9) –0.9 (–3.7, 1.9)
N stands: number of events
* Three patients died on the waiting list.
** In the ARTS-I PCI cohort, 12 out of 126 (8.7%) target lesion revascularisations were due to a myocardial infarction. In the ARTS-II cohort, 10 out of 52 (19.2%)
of the target lesion revascularisations were due to a myocardial infarction.
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described as restenoses with intrastent thrombus, eight as total
occlusion; four presented with unstable angina, seven as STEMI
with enzyme elevation and/or new Q-waves.
There was no relation between the use of periprocedural GP IIb/IIIa
inhibitors and ST. GP IIb/IIIa inhibitors were used in 197 out of 607
cases in ARTS-II. In this group, 9.1% (18 patients) experienced
stent thrombosis. In the group without IIb/IIIa inhibitor use (n=410),
5.1% (21 patients) experienced stent thrombosis (p=0.08). Early
stent thrombosis occurred in 1.2% (five patients) in the no GP
IIb/IIIa inhibitor group versus 2.0% (four patients) in the GP IIb/IIIa
inhibitor group (p=0.48).
Although clopidogrel was only recommended for three months,
a total of 266 were still using clopidogrel or thienopyridine at one
year. A stratified analysis revealed that the survival free of MACE
(79.2% vs. 80.7; log rank p=0.70) and ST (92.4% vs. 95.4%;
Logrank p=0.13) was identical between patients who were still on
clopidogrel or thienopyridine at one year versus those without.
The impact of stent thrombosis on the clinical event rates is
depicted in Figure 3a and b.
Including only pre-procedural risk factors, type B2 and C lesions
and the presence of an intracoronary thrombus at baseline on 
the diagnostic film emerged as independent predictors of stent
thrombosis. Including post-procedure risk factors, the presence 
of an intracoronary thrombus, maximum CK post-procedure and
stent length per 10 mm increase emerged as independent
predictors of stent thrombosis re-adjudicated according to the ARC
definitions.
Impact of Syntax score on clinical outcome
Multivariate analysis was performed on the ARTS-II population to
determine independent predictors of MACCE (Table 4). The Syntax
score proved to be among the strongest predictors of MACCE 
Figure 2. Kaplan-Meier curves out to three years in ARTS-I and ARTS-II; all-cause survival (A); freedom from all-cause death, cerebrovascular
accident (CVA) or myocardial infarction (MI) (B); freedom from repeat revascularisation (C) and freedom from all-cause death, CVA, myocardial
infarction or repeat revascularisation (MACCE) (D). Thick black line depicts the ARTS-II cohort. The thin black line depicts the ARTS-I PCI cohort
and the dotted line the ARTS-I CABG cohort. P-values are Log rank.
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RR 0.57, 95% CI 0.47 - 0.69; P < 0.0001
ARTS-II vs . ARTS-I CABG
RR1.20, 95% CI 0.94 -1.53; P=0.21
ARTS-I PCI
ARTS-II
ARTS-I CABG
ARTS-I PCI
ARTS-II
ARTS-I CABG
ARTS-I PCI
ARTS-II
ARTS-I CABG
ARTS-I PCI
ARTS-II
ARTS-I CABG
A.
D.C.
B.
Table 3. Stent thrombosis according to the ARC definitions.
Stent thrombosis defined by ARC ARTS-II Death up to 1080 days MI** up to 1080 days MI*** up to 1080 days
(Sub)acute 9 (23.1%) 0/9 (0.0%) 9/9 (100%) 5/9 (55.6%)
Late 10 (25.6%) 3/10 (30.0%) 4/10 (40.0%) 2/10 (20.0%)
Very late 20 (51.3%) 5/20 (25.0%) 13/20 (65.0%) 12/22 (54.5%)
Definite 21 (53.8%) 0/21 (0.0%) 15/21 (71.4%) 12/21 (57.1%)
Definite or probable 32 (82.1%) 1/32 (3.1%) 25/32 (78.1%) 19/32 (59.4%)
Definite, probable or possible* 39 (100%) 8/39 (20.5%) 25/39 (64.1%) 19/39 (48.7%)
* One patients experienced two probable ST events (on day 331 and day 399), one patient experienced a definite ST on day 1020 and a probable ST on day
1079, one patient experienced definite ST on day 562 and day 984 and probable ST on day 983, and one patient experienced probable ST on day 468 and
possible ST on day 479 accounting for 44 ST events in total; ** MI according to ARC definition; *** MI according to protocol
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Figure 3. Kaplan Meier survival curves for death; death or myocardial infarction (MI) and death, MI or repeat revascularisation (MACE), with
superimposed on the curves, individual hierarchical thrombotic event (definite or probable or possible stent thrombosis according to the ARC
definitions) (A); (B) shows the same Kaplan Meier curve, after removal of the individual clinical events related to stent thrombosis – resulting in
an upward shift of the three curves, reflecting higher event free rates.
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Table 4. Independent predictors of MACCE and stent thrombosis in the ARTS-II group.
Univariable predictors of MACCE at 3 years* Multivariable predictors of MACCE at 3 years*
Variable Odds ratio 95% confidence interval P-value Odds ratio 95% confidence interval P-value
Pre-procedure
Diabetes (%) 1.97 1.28-3.02 0.002 1.76 1.13-2.74 0.012
Syntax score (per group increase) 1.62 1.26-2.09 0.0002 1.43 1.08-1.90 0.014
Peripheral vascular disease (%) 2.01 1.01-3.99 0.047 1.76 0.86-3.60 0.12
Nr. of lesions type B2 or C 1.25 1.07-1.47 0.006 1.11 0.88-1.41 0.37
Nr. of lesions with stenosis >50% 1.20 1.03-1.40 0.018 1.01 0.80-1.26 0.95
Age (years±SD) 1.02 1.00-1.05 0.033 *** *** ***
Pre + peri-procedure
Nr. of lesions with direct stenting 0.81 0.67-0.98 0.032 0.80 0.65-0.99 0.037
Diabetes (%) 1.97 1.28-3.02 0.002 1.64 1.02-2.63 0.042
Max post proc CK 1.35 1.08-1.68 0.008 1.25 1.00-1.57 0.053
Syntax score (per group increase) 1.62 1.26-2.09 0.0002 1.34 0.98-1.83 0.06
Peripheral vascular disease (%) 2.01 1.01-3.99 0.047 1.79 0.85-3.78 0.13
Total stent length (mm) 1.09 1.03-1.16 0.006 1.03 0.94-1.13 0.48
Duration of procedure (mins±SD) 1.00 1.00-1.00 0.09 1.00 1.00-1.01 0.56
Nr. of lesions with stenosis >50% 1.20 1.03-1.40 0.018 1.05 0.80-1.36 0.74
Bifurcation requiring double wiring 1.19 0.98-1.44 0.08 1.05 0.82-1.33 0.72
Nr. of lesions type B2 or C 1.25 1.07-1.47 0.006 0.97 0.74-1.26 0.81
Complete revascularisation 0.67 0.45-1.01 0.055 0.98 0.59-1.62 0.93
Age (years±SD) 1.02 1.00-1.05 0.033 *** *** ***
Univariable predictors of stent thrombosis at 3 years** Multivariable predictors of stent thrombosis at at 3 years**
Variable Odds ratio 95% confidence interval P-value Odds ratio 95% confidence interval P-value
Pre-procedure
Total stent length (mm) 1.13 1.04-1.23 0.005 1.11 1.00-1.24 0.053
Nr. of lesions type B2 or C 1.44 1.13-1.84 0.004 1.40 0.94-2.08 0.095
Nr. of lesions with stenosis >50% 1.26 1.00-1.59 0.051 0.74 0.49-1.13 0.16
Syntax score (per group increase) 1.04 1.01-1.07 0.008 1.02 0.99-1.06 0.20
Pre + peri-procedure
Max post proc CK 1.47 1.15-1.88 0.002 1.36 1.06-1.74 0.016
Nr. of lesions type B2 or C 1.44 1.13-1.84 0.004 1.35 0.89-2.06 0.16
Total stent length (mm) 1.13 1.04-1.23 0.005 1.18 0.93-1.51 0.18
Nr. of lesions with stenosis >50% 1.26 1.00-1.59 0.051 0.79 0.51-1.23 0.29
Syntax score (per group increase) 1.04 1.01-1.07 0.008 1.01 0.98-1.05 0.53
Number of stents implanted ±SD 1.23 1.02-1.49 0.032 0.87 0.50-1.54 0.64
Bifurcation requiring double wiring 1.37 1.03-1.84 0.033 1.07 0.75-1.52 0.71
* Per protocol definitions; ** ARC definitions; *** Not included due to colinearity problems
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Figure 4. Kaplan-Meier curve of MACCE out to 3 years of the ARTS-II
population stratified to the Syntax score: <16 (n=209), > 16 and <24
(n=199) and > 24 (n=199).
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(OR 1.43, 95% CI 1.08 – 1.90; p=0.014) together with the presence
of diabetes mellitus (OR 1.76, 95% CI 1.13 – 2.74; p=0.012).
The entire population of ARTS-II was subdivided into patients with 
a Syntax score <16 (n=209), >=16 and < 24 (n=199) and > 24 (n=199).
The Kaplan Meier estimates of MACCE free survival (Figure 4) show
that the two subgroups with the highest Syntax score had
significantly worse prognosis than the subgroup with the lowest
Syntax score.
surgical or percutaneous re-intervention at three years increased
from 73.7% in ARTS-I PCI BMS era to 85.7% in the ARTS-II study
using SES. Furthermore, at three years, only 2.3% of patients in
ARTS-II required CABG as compared to 9.2% in the ARTS-I PCI
cohort treated with BMS.
A major criticism that could be levelled at the present report is that
a comparison with a cohort of patients treated surgically ten years
ago is inappropriate and potentially misleading considering the
progress in surgical techniques and post-operative management
over the past decade. The recently completed Syntax trial
comparing surgery to multivessel treatment using paclitaxel-eluting
stents has reported a rate of complete arterial revascularisation and
use of bilateral thoracic arteries of 18.6% and 26.9%,
respectively.29 Only a true randomised comparison in all-comers
can definitively address the the respective merits of surgery and PCI
with a particular type of stent for multivessel treatment.29
Nevertheless, the use of a comprehensive coronary score, recently
designed and tested in a subgroup of three vessel treatment cohort
in ARTS-II at one year is informative: testing this score anew on the
entire population and for a period of three years confirms our initial
observation that patients with a score of < 16 have a MACE-free
survival rate greater than 88% when treated with the SES, while
those with a score > 24 may potentially have better outcomes with
surgery, based on the population specifically included in ARTS-II.
Comparative assessment of MI per protocol and
according to the ARC definitions
Comparing the MI rates of the ARTS-II per protocol and according
to the ARC definitions revealed a difference of 5% (3.6% vs. 8.6%,
respectively). In ARTS-II, the criteria for an MI according to the
protocol (see methods) are those applied to ARTS-I which allows
comparison with the historical PCI and CABG cohorts of ARTS-I,
using less sensitive criteria for diagnosing a MI. Therefore, it may be
argued that the incidence of periprocedural and spontaneous MI in
ARTS-II is under-reported. However, this would likely also apply to
both cohorts of patients in ARTS-I. When assessing levels of enzyme
release in the peri-procedural period, it became apparent that 4.3%
of the ARTS-II patients had an enzyme release > 2 x ULN, the
threshold criterion used for the ARC definitions. This difference in
threshold alone explains the entire difference between the variation
in two incidences of MI rates at three years.
Stent thrombosis
Very late stent thrombosis, perceived as a safety issue, can
potentially result in an erosion of the long-term beneficial effect of
multivessel treatment with DES. ARTS-II is the first study to report
the impact of stent thrombosis on the long-term outcome in
a population with 2- and 3-vessel disease. The rate of stent
thrombosis (definite, probable or possible) in ARTS-II was 1.5% at
30 days, 3.1% at one year, 4.4% at two years and 6.4% at three
years, respectively. The rate of definite stent thrombosis in this study
increased from 1.0% at 30 days to 1.6% at one year, 2.1% at
2 years and 3.5% at three years; a steady increase comparable to
the rate reported in an all-comer population treated with DES.7
Quality of life
There were no differences in the quality of life as assessed by the
self-rated thermometer of the EQ-5D questionnaire at three years
among patients allocated to either CABG or PCI with bare-metal
stents or SES (78, 76 and 76 in the ARTS-I CABG, ARTS-I PCI and
ARTS-II respectively; p=0.1).
Discussion
Events per protocol
At three years, there was no significant difference in overall mortality
between the ARTS-II and the ARTS-I PCI and CABG cohorts, despite a
higher angiographic and clinical risk profile in the more contemporary
ARTS-II cohort. Although the present study might have been
underpowered to demonstrate any significant difference mortality, the
findings concur with the previously published 10-year follow-up of the
BARI study in which PCI was performed without coronary stents.28
The composite endpoint of death, CVA and MI was the lowest in the
ARTS-II group and was significantly better than in the ARTS-I PCI
cohort. When the MACCE rates in the three cohorts were compared,
the surgical group had the lowest MACCE rate, but the actual
difference in MACCE at three years between the ARTS-I CABG and
the ARTS-II group was 3.2%, which did not reach statistical
significance. When considering the rate of re-intervention over time
it became apparent that surgical revascularisation is more durable
than percutaneous revascularisation. The actual difference in
MACCE between ARTS-I CABG and ARTS-II increased progressively
from 4.2% at 1 year to 6.2% and 7.9% at two and three years
respectively. However, it is noteworthy that the freedom from
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However, the rates of overall death and MI at three years are
reassuring when one compares the rates of death (3.0% vs. 4.0%)
and MI (3.6% vs. 6.8%) in ARTS-II and ARTS-I PCI, respectively,
despite the higher baseline risk profile in ARTS-II. Despite the fact
that two third of these patients sustained an MI or underwent a
repeat revascularisation, none of the patients with definite
angiographic stent thrombosis died up to three years. While we
recognise that late and very late stent thromboses also occur with
bare metal stents, we are unable to quantify the number of these
events in ARTS-I PCI cohort for comparison at this time.
Figure 3 illustrates the fact that early, late and very late, as well as
definite, probable or possible stent thrombosis contributed to an
erosion of the treatment effect expressed as freedom from death,
death/MI and death/MI/repeat revascularisation. Out of the
127 patients who had a major adverse cardiac event (ARC definitions),
21 had a definite, 11 a probable and seven a possible thrombosis (total
39 or 30.7% of adverse events). If this incidence of stent thrombosis
could be reduced significantly, as a result of better stent implantation,
less thrombogenic devices, and more effective antithrombotic therapy,
up to 30% of the adverse events could potentially be prevented. In the
early days of bare metal stenting, more than a decade ago, we
suggested that bare metal stenting could reduce the impact of
restenosis in angioplasty if the early phenomenon of subacute
thrombosis could be adequately controlled. 30
Limitations
First, a five year time lag exists between the groups that are being
compared. Both PCI and CABG have improved with time. Second,
this study is non-randomised and thus the groups are not directly
comparable, precluding a formal non-inferiority comparison.
Furthermore, statistical adjustment was required to correct for the
differences versus the historical control group. Thirdly, while the
protocol required that the lesions in ARTS-II be potentially treatable
by CABG, the absence of dialogue with the surgeons prior to
intervention may have caused a selection bias. However, this is not
obvious considering that patients actually enrolled in ARTS-II were
more complex than those enrolled in ARTS-I. Finally, the incidence
and impact of stent thrombosis was not re-adjudicated according to
the ARC definitions in the ARTS-I study preventing the authors to
compare the results of ARTS-II to the historical PCI arm of ARTS-I.
Conclusion
At three years there was no significant difference in the incidence of
the irreversible hard clinical endpoints of death, CVA and MI between
the ARTS-II cohort and the ARTS-I PCI and CABG cohorts. Although
CABG remained more effective in reducing the need for repeat
revascularisation as compared to both PCI cohorts, the significant
improvement in the reintervention rates in the ARTS-II SES cohort as
compared to the bare metal ARTS-I PCI cohort resulted in a
comparable MACCE rate in the ARTS-II and ARTS-I CABG cohorts at
three years.
Addendum
In this study, one patient had a probable and definite stent
thrombosis triggered on two consecutive days. It is clear that they
may reflect the same event. As the current ARC definition does not
indicate how these triggers should be reported we counted them as
two separate events.
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Impact of Body Mass Index on the One-Year Clinical Outcome of
Patients Undergoing Multivessel Revascularization With
Sirolimus-Eluting Stents (from the Arterial Revascularization
Therapies Study Part II)†
Ahmed A. Khattab, MDa,*, Joost Daemen, MDb, Gert Richardt, MDa, Philippe Rioux, MDc,
Franz-Wolfgang Amann, MDd, Richard Levy, MDe, Ivan G. Horvath, MDf, Rui C. Teles, MDg,
Fath Ordoubadi, MDh, Magdaleen Pieters, MSci, Kristel Wittebols, MSci,
Hans-Peter Stoll, MDi, and Patrick W. Serruys, MD, PhDb
The differential safety and efficacy profiles of sirolimus-eluting stents when implanted in
patients with multivessel coronary artery disease who have increased body mass indexes
(BMIs) compared with those with normal BMIs are largely unknown. This study evaluated
the impact of BMI on 1-year outcomes in patients with multivessel coronary artery disease
treated with sirolimus-eluting stents as part of the Arterial Revascularization Therapies
Study Part II (ARTS II). From February to November 2003, 607 patients were included at
45 centers; 176 patients had normal BMIs (<25 kg/m2), 289 were overweight (>25 and <30
kg/m2), and 142 were obese (>30 kg/m2). At 30 days, the cumulative incidence of the
primary combined end point of death, myocardial infarction, cerebrovascular accident, and
repeat revascularization (major adverse cardiac and cerebrovascular events) was 3.4% in
the group with normal BMIs, 3.1% in overweight patients, and 2.8% in obese patients (p 
0.76). At 1 year, the cumulative incidence of major adverse cardiac and cerebrovascular
events was 10.8%, 11.8%, and 7.0% in the normal BMI, overweight, and obese groups,
respectively (p  0.31). In conclusion, BMI had no impact on 1-year clinical outcomes in
patients with multivessel coronary artery disease treated with sirolimus-eluting stents in
ARTS II. © 2008 Elsevier Inc. All rights reserved. (Am J Cardiol 2008;101:1550–1559)
The Arterial Revascularization Therapies Study Part II
(ARTS II) is a multicenter, European, open-label, nonran-
domized trial evaluating the safety and efficacy of siroli-
mus-eluting stents (SES) in patients with multivessel coro-
nary artery disease in comparison with the randomized
ARTS I trial.1 In the overall population, ARTS II has shown
a similar rate of major adverse cardiac and cerebrovascular
events (MACCEs) in patients treated with SES compared
with the surgical cohort of ARTS I.2
At present, overweight and obese individuals constitute
most of the population in industrialized countries. In the
United States, 64.5% of the population is classified as
overweight, of whom 30.5% are obese.3 Accordingly, this is
a study population of particular interest. The preferred
method of coronary revascularization for these patients
proved to be controversial. A subgroup analysis of the
ARTS I trial showed that patients treated with coronary
artery bypass grafting (CABG) had significantly lower
MACCE rates compared with those treated with bare-metal
stents.4 Furthermore, among patients who had been random-
ized to surgery, those with normal body mass indexes
(BMIs) had worse outcomes than overweight or obese pa-
tients, whereas BMI did not influence the overall outcomes
in patients randomized to stent implantation. This finding
was confirmed in the Bypass Angioplasty Revascularization
Investigation (BARI) trial and registry. However, unlike in
ARTS I, an increased BMI was associated with worse long-
term outcomes in patients who underwent CABG.5
In the present analysis, we evaluated the impact of BMI
on 1-year outcomes after multivessel SES implantation in
the 607 patients enrolled in ARTS II. Another objective of
this analysis was to compare the overweight and obese
patients in ARTS II with the respective cohorts in the 2 arms
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of ARTS I, investigating treatment with CABG versus bare-
metal stents.
Methods
ARTS II is a multicenter, nonrandomized, open-label trial
designed to compare the safety and efficacy of SES in
patients with de novo multivessel coronary artery disease,
with the surgical group of ARTS I as a historical control
group.2,6 To obtain a population comparable with that of
ARTS I, patients were stratified by clinical site to ensure the
inclusion of 1/3 of patients with 3-vessel disease.
Patients were eligible for coronary revascularization if
they had stable angina, unstable angina, or silent ischemia
and 2 de novo lesions amenable to stent implantation that
were located in different major epicardial vessels and/or
their side branches. Patients were required to have multives-
sel coronary artery disease with the need for treatment of the
left anterior descending artery and 1 other significant
lesion (50% diameter stenosis) in another major epicardial
coronary artery. One totally occluded major epicardial ves-
sel could be included. The lesion had to be amenable to
stenting using a stent with a diameter of 2.5 to 3.5 mm and
a length of 13 to 33 mm, without any restriction on the total
stent length implanted. Patients with any previous coronary
intervention, left main coronary disease, overt congestive
heart failure, or left ventricular ejection fractions 30%
were excluded. Additional exclusion criteria were a history
of any cerebrovascular accident or ST elevation myocardial
infarction (MI) in the preceding week, with persisting ele-
vation of creatine kinase. The parameters needed to calcu-
late BMI (weight and height) were documented, and written
informed consent was obtained from each patient before
enrolment. The study was approved by the ethics committee
of each participating site. All interventions were performed
according to current standard practice guidelines, and the
final interventional strategy, including the use of glycopro-
tein IIb/IIIa inhibitors, was left entirely to the discretion of
the operator, except for stent use. All patients were advised
to maintain aspirin lifelong. Clopidogrel 300 mg as a load-
ing dose, or ticlopidine 500 mg, was to be started24 hours
before the procedure. Postprocedural clopidogrel 75 mg/day
or ticlopidine 250 mg twice daily was recommended for2
months after revascularization.
The primary objective of this ARTS II post hoc suba-
nalysis was to compare the safety and effectiveness of
coronary stent implantation using SES in normal-weight,
overweight, and obese patients. The primary outcome mea-
sure was the incidence of the combined end point MACCEs
at 1 year, comprising all-cause death, any cerebrovascular
event, nonfatal MI, or any repeat revascularization (contem-
porary comparison).
The secondary objective of this study was to compare the
1-year MACCE rate in ARTS II patients, stratified accord-
Table 1
Baseline clinical characteristics of patients in the Arterial Revascularization Therapies Study Part II, stratified according to body mass index (n  607)
Variable BMI (kg/m2) p Value
(Trend)
25 25–30 30
(n  176) (n  289) (n  142)
Age (yrs) 64.2  10.1 (35–80) 62.9  9.3 (37–80) 61.1 9.6 (36–80) 0.004
Ejection fraction (%) 59.8  11.6 (35–85) 60.2  11.6 (30–97) 60.4 11.6 (30–88) 0.66
BMI (kg/m2) 23.2  1.6 (15–25) 27.3  1.4 (25–30) 33.3 2.8 (30–43) 0.001
Men 76.1% (134/176) 84.4% (244/289) 61.3% (87/142) 0.005
Diabetes mellitus 19.9% (35/176) 22.5% (65/289) 41.5% (59/142) 0.001
Insulin-dependent diabetics 4.5% (8/176) 2.8% (8/289) 8.5% (12/142) 0.14
Hypertension 57.4% (101/176) 70.2% (203/289) 73.2% (104/142) 0.002
Hypercholesterolemia (total cholesterol 250 mg/dl) 70.9% (124/175) 72.7% (210/289) 80.1% (113/141) 0.07
History of cerebrovascular accident 1.1% (2/176) 0.7% (2/289) 0.7% (1/141) 0.66
Family history of MI/sudden death aged 55 yrs 34.3% (60/175) 33.2% (96/289) 43.6% (61/140) 0.11
Peripheral vascular disease 11.4% (20/176) 6.6% (19/289) 2.1% (3/141) 0.001
Previous MI 37.5% (66/176) 33.2% (96/289) 33.1% (47/142) 0.39
Previous CABG 0.0% (0/176) 0.0% (0/289) 0.0% (0/142)
Previous percutaneous coronary intervention 0.6% (1/176) 0.7% (2/289) 0.0% (0/142) 0.50
Carotid surgery 1.1% (2/176) 1.4% (4/289) 1.4% (2/141) 0.82
Chronic obstructive pulmonary disease 4.5% (8/176) 3.5% (10/289) 2.8% (4/141) 0.41
Smokers
Previous 38.6% (68/176) 45.7% (132/289) 33.8% (48/142) 0.48
Current 22.2% (39/176) 20.1% (58/289) 14.1% (20/142) 0.08
Unstable angina pectoris 43.2% (76/176) 34.3% (99/289) 32.4% (46/142) 0.039
Stable angina pectoris 46.6% (82/176) 56.1% (162/289) 55.6% (79/142) 0.09
Silent ischemia 10.2% (18/176) 9.7% (28/289) 12.0% (17/142) 0.64
No. of narrowed coronary arteries
1 0.0% (0/176) 0.3% (1/289) 0.7% (1/142) 0.28
2 48.3% (85/176) 43.6% (126/289) 48.6% (69/142) 0.97
3 51.7% (91/176) 56.1% (162/289) 50.7% (72/142) 0.93
Glycoprotein IIb/IIIa inhibitors 29.5% (52/176) 32.5% (94/289) 35.9% (51/142) 0.23
Data are expressed as mean  SD (range) or as percentages.
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ing to BMI (normal, overweight, or obese) with that of
patients with similar BMI classifications who were random-
ized to either coronary stent implantation using bare-metal
stents or CABG in the ARTS I trial (historical comparison).
However, much weight cannot be given to this analysis,
given differences in treatment protocols and evolution in the
procedures for percutaneous coronary intervention and
CABG.
The National Heart, Lung, and Blood Institute and the
World Health Organization have introduced a weight clas-
sification for BMI that is calculated by dividing a patient’s
weight in kilograms by the patient’s height in meters
squared. According to this classification, a BMI of 18.5 to
24.9 kg/m2 is considered normal, a BMI of 25 to 30 kg/m2
is considered to represent overweight, and a BMI 30
kg/m2 is considered to represent obesity.7,8 Clinical and
angiographic data were analyzed and adjudicated by an
independent core laboratory (Cardialysis, Rotterdam, The
Netherlands) and a clinical-events committee.
All-cause death was reported, and CVAs included
strokes, transient ischemic attacks, and reversible ischemic
neurologic deficits. In the first 7 days after the intervention,
a definite diagnosis of MI was made if there was documen-
tation of new abnormal Q waves (according to the Minne-
sota code) and either a ratio of serum creatine kinase-MB to
total cardiac enzyme 0.1 or a creatine kinase-MB value
5 times the upper limit of normal.1,2,9 Serum creatine
kinase and creatine kinase-MB concentrations were mea-
sured 6, 12, and 18 hours after the intervention. Beginning
8 days after the intervention (the average length of hospi-
talization after surgery), either abnormal Q waves or enzy-
matic changes were sufficient for a diagnosis of MI. This
2-part method of defining MI was developed for ARTS I to
address the difficulty of diagnosing MI after surgery. All
repeat revascularization procedures were recorded. Events
were counted from the time of the initial procedure. Throm-
botic occlusions were defined by either angiographic docu-
mentation of a complete occlusion (Thrombolysis In Myo-
cardial Infarction [TIMI] flow grade 0 or 1) or angiographic
documentation of a flow-limiting thrombus (TIMI flow
grade 1 or 2).
Continuous variables were compared using Student’s
unpaired t test and are expressed as mean SD. Categorical
variables were compared using the chi-square test and are
expressed as percentages. Comparisons among the 3 groups
were performed using a general linear model. On the basis
of a selection criterion of p 0.1 when used in a univariate
post hoc analysis, the following baseline and procedural
variables were selected for inclusion in the multivariate
model: gender, current smoking, family history, previous
MI, peripheral vascular disease, diabetes mellitus, hyper-
cholesterolemia, hypertension, unstable angina, days to pro-
cedure, number of lesions with diameter stenosis 50%,
duration of procedure, number of type C lesions, number of
lesions with 100% occlusion, and number of lesions with
moderate to heavy calcification. For medical and statistical
reasons, it was decided to include age and the left ventric-
ular ejection fraction as binary variables, using their medi-
Table 2
Angiographic and procedural characteristics of patients in the Arterial Revascularization Therapies Study Part II stratified according to body mass index
(n  607 patients, n  2,160 lesions)
Variable BMI (kg/m2) p Value
(Trend)
25 25–30 30
(176 patients/625 lesions) (289 patients/1,040 lesions) (142 patients/495 lesions)
No. of stents implanted 3.7  1.4 (1–8) 3.7  1.6 (1–11) 3.7  1.4 (2–10) 0.93
Average stent length (mm) 19.3 3.4 (11–28) 19.6 3.7 (12–31) 19.7 3.2 (13–30) 0.42
Total stent length (mm) 71.7  30.2 (26–179) 72.9 33.7 (12–253) 72.6 31.3 (26–175) 0.77
Maximum dilatation pressure (atm) 16.2 3.0 (8–25) 16.4 2.7 (9–26) 16.6 3.0 (10–24) 0.23
Days in hospital since procedure 3.3  2.0 (1–18) 3.5 3.1 (1–31) 3.4  2.4 (1–13) 0.72
Duration of procedure (min) 84.0  41.6 (16–214) 84.7 42.9 (10–293) 87.4 46.0 (25–252) 0.50
No. of lesions 50% DS 3.6  1.3 (2–7) 3.6  1.2 (2–8) 3.5  1.4 (1–8) 0.69
No. of vessels with lesions 50% DS 2.5  0.5 (2–3) 2.6  0.5 (1–3) 2.5  0.5 (1–3) 0.83
No. of treated lesions: stented lesions 3.2 1.2 (1–7) 3.2  1.1 (0–7) 3.2  1.1 (0–8) 0.99
Coronary artery narrowed
Right 29.8% (186/625) 28.2% (293/1,040) 30.1% (149/495) 0.96
Left main 0.0% (0/625) 0.0% (0/1,040) 0.0% (0/495)
Left anterior descending 42.4% (265/625) 41.0% (426/1,040) 41.6% (206/495) 0.76
Left circumflex 27.8% (174/625) 30.9% (321/1,040) 28.3% (140/495) 0.78
Lesion length: diffuse 20 mm 12.6% (75/597) 11.0% (110/998) 12.7% (60/471) 1.00
Reference diameter 2.5 mm 91.5% (572/625) 91.0% (946/1,040) 89.5% (443/495) 0.26
Readily accessible segment 96.0% (572/596) 95.3% (948/995) 94.7% (446/471) 0.32
Ostial lesion 4.9% (29/597) 4.6% (46/997) 3.0% (14/471) 0.15
Calcification: moderate to heavy 36.2% (216/596) 28.1% (280/997) 31.3% (147/470) 0.049
Thrombus present 0.3% (2/607) 0.7% (7/1,010) 0.4% (2/482) 0.78
Total occlusion 2.7% (17/619) 2.3% (24/1,030) 2.4% (12/490) 0.73
Bifurcation requiring double guidewire 33.4% (199/596) 32.2% (321/998) 38.4% (181/471) 0.11
Type B2/C lesion 69.8% (432/619) 68.8% (709/1,030) 71.8% (352/490) 0.51
Data are expressed as mean  SD (range) or as percentages.
DS  diameter stenosis.
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ans as cutoff (age63 years and ejection fraction59). We
analyzed 3 treatment combinations: ARTS II versus ARTS
I CABG, ARTS II versus ARTS I bare-metal stents, and
ARTS I bare-metal stents versus CABG. In each of these
treatment groups, we tested for interactions between the
model parameters and the BMI groups. Survival curves
were generated using the Kaplan-Meier method, and sur-
vival among groups was compared using the log-rank test.
Table 4
Thirty-day clinical outcomes of patients in the Arterial Revascularization Therapies Study Part II stratified according to body mass index (n  607)
Complication BMI (kg/m2) P Value
(Trend)
25 25–30 30
(n  176) (n  289) (n  142)
Hierarchical complications
MACCEs 3.4% (6/176) 3.1% (9/289) 2.8% (4/142) 0.76
Death 0.0% (0/176) 0.0% (0/289) 0.0% (0/142)
Cerebrovascular accident without death 0.6% (1/176) 0.0% (0/289) 0.0% (0/142)
MI without death or cerebrovascular accident 2.3% (4/176) 0.0% (0/289) 0.7% (1/142)
Q-wave MI 2.3% (4/176) 0.0% (0/289) 0.7% (1/142)
Non-Q-wave MI 0.0% (0/176) 0.0% (0/289) 0.0% (0/142)
Revascularization without death or cerebrovascular accident or MI 0.6% (1/176) 3.1% (9/289) 2.1% (3/142)
CABG without death or cerebrovascular accident or MI 0.0% (0/176) 1.7% (5/289) 1.4% (2/142)
Repeat percutaneous coronary intervention without death or
cerebrovascular accident or MI or CABG
0.6% (1/176) 1.4% (4/289) 0.7% (1/142)
Free of MACCEs 96.6% (170/176) 96.9% (280/289) 97.2% (138/142) 0.76
Nonhierarchical complications
Death/cerebrovascular accident/MI 2.8% (5/176) 0.0% (0/289) 0.7% (1/142) 0.037
Death 0.0% (0/176) 0.0% (0/289) 0.0% (0/142)
Cerebrovascular accident 0.6% (1/176) 0.0% (0/289) 0.0% (0/142) 0.19
MI 2.3% (4/176) 0.0% (0/289) 0.7% (1/142) 0.09
Q-wave MI 2.3% (4/176) 0.0% (0/289) 0.7% (1/142) 0.09
Non-Q-wave MI 0.0% (0/176) 0.0% (0/289) 0.0% (0/142)
Revascularization 1.7% (3/176) 3.1% (9/289) 2.1% (3/142) 0.76
CABG 0.6% (1/176) 1.7% (5/289) 1.4% (2/142) 0.48
Repeat percutaneous coronary intervention 1.1% (2/176) 1.4% (4/289) 0.7% (1/142) 0.75
Subacute occlusion 1.1% (2/176) 0.7% (2/289) 0.7% (1/142) 0.65
Table 5
One-year clinical outcomes of patients in the Arterial Revascularization Therapies Study Part II stratified according to body mass index (n  607)
Complication BMI (kg/m2) p Value
(Trend)
25 25–30 30
(n  176) (n  289) (n  142)
Hierarchical complications
MACCEs 10.8% (19/176) 11.8% (34/289) 7.0% (10/142) 0.31
Death 1.1% (2/176) 0.7% (2/289) 1.4% (2/142)
Cerebrovascular accident without death 2.3% (4/176) 0.3% (1/289) 0.0% (0/142)
MI without death or cerebrovascular accident 2.3% (4/176) 0.7% (2/289) 0.7% (1/142)
Q-wave MI 2.3% (4/176) 0.0% (0/289) 0.7% (1/142)
Non-Q-wave MI 0.0% (0/176) 0.7% (2/289) 0.0% (0/142)
Revascularization without death or cerebrovascular accident or MI 5.1% (9/176) 10.0% (29/289) 4.9% (7/142)
CABG without death or cerebrovascular accident or MI 0.6% (1/176) 3.1% (9/289) 1.4% (2/142)
Repeat percutaneous coronary intervention without death or
cerebrovascular accident or MI or CABG
4.5% (8/176) 6.9% (20/289) 3.5% (5/142)
Free of MACCEs
Nonhierarchical complications
Death/cerebrovascular accident/MI 5.7% (10/176) 1.7% (5/289) 2.1% (3/142) 0.047
Death 1.1% (2/176) 0.7% (2/289) 1.4% (2/142) 0.85
Cerebrovascular accident 2.3% (4/176) 0.3% (1/289) 0.0% (0/142) 0.021
MI 2.8% (5/176) 0.7% (2/289) 0.7% (1/142) 0.08
Q-wave MI 2.3% (4/176) 0.0% (0/289) 0.7% (1/142) 0.09
Non-Q-wave MI 0.6% (1/176) 0.7% (2/289) 0.0% (0/142) 0.50
Revascularization 7.4% (13/176) 10.4% (30/289) 5.6% (8/142) 0.66
CABG 1.1% (2/176) 3.1% (9/289) 1.4% (2/142) 0.78
Repeat percutaneous coronary intervention 6.3% (11/176) 7.6% (22/289) 4.2% (6/142) 0.52
Subacute occlusion 0.6% (1/176) 0.0% (0/289) 0.7% (1/142) 0.91
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Proportional-hazards and Weibull models were used to as-
sess the risk reduction of adverse events. Probability was
significant at a p level of 0.05. All statistical tests were 2
tailed. Statistical analysis was performed using SAS version
8.02 (SAS Institute Inc., Cary, North Carolina).
Results
From February 2003 to November 2003, 607 patients were
included at 45 centers. A total of 176 patients had normal
BMIs, 289 were overweight, and 142 were obese. Table 1
lists the patients’ baseline demographic and clinical charac-
teristics on the basis of their BMIs. No significant differ-
ences in angiographic and procedural characteristics were
noted between the groups (Table 2). All baseline character-
istics of patients in ARTS II compared with ARTS I ac-
cording to BMI are listed in Table 3.
No deaths occurred in the first 30 days. There were no
significant differences among patients with normal BMIs,
overweight, and obesity regarding the cumulative incidence
of MACCEs during the first 30 days (3.4% in patients with
normal BMIs, 3.1% in overweight patients, and 2.8% in
obese patients, p  0.76). The power to detect a relative
difference of 25% at 30 days was 10%. The itemized
outcomes of MACCEs are listed in Table 4. A total of 5
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Figure 1. MACCE-free survival at 1 year for 607 patients treated with SES for multivessel coronary artery disease in ARTS II stratified according to BMI.
CI  confidence interval.
Table 6
One-year clinical outcomes of patients in the Arterial Revascularization Therapies Study Part II (n  607) versus patients in the Arterial
Revascularization Therapies Study Part I who underwent coronary artery bypass surgery (n  604) and patients in the Arterial Revascularization
Therapies Study Part I who received bare-metal stents (n  599) stratified according to body mass index (total n  1,810)
Outcome ARTS II ARTS I (BMS) RR (95% CI) p Value ARTS I (CABG) RR (95% CI) p Value
BMI 25 kg/m2 n  176 n  168 n 169
MACCEs 11.0% 23.8% 0.45 (0.27–0.75) 0.001 15.6% 0.69 (0.40–1.20) 0.17
Death/cerebrovascular accident/MI 5.8% 7.7% 0.73 (0.33–1.63) 0.46 9.6% 0.59 (0.28–1.27) 0.17
Death 1.1% 1.8% 0.64 (0.11–3.76) 0.62 2.4% 0.47 (0.09–2.56) 0.37
Repeat revascularization 7.5% 18.6% 0.40 (0.22–0.74) 0.002 6.1% 1.23 (0.56–2.74) 0.60
BMI 25–30 kg/m2 n  289 n  307 n  299
MACCEs 11.9% 28.3% 0.42 (0.29–0.60) 0.0001 12.1% 0.98 (0.63–1.51) 0.91
Death/cerebrovascular accident/MI 1.8% 10.4% 0.17 (0.07–0.42) 0.0001 8.0% 0.22 (0.08–0.56) 0.0005
Death 0.7% 2.9% 0.24 (0.05–1.08) 0.05 3.4% 0.21 (0.05–0.94) 0.03
Repeat revascularization 10.5% 22.8% 0.46 (0.31–0.69) 0.0001 4.7% 2.22 (1.20–4.09) 0.009
BMI 30 kg/m2 n  142 n  119 n  136
MACCEs 7.1% 25.8% 0.27 (0.14–0.53) 0.0001 5.9% 1.19 (0.48–2.92) 0.72
Death/cerebrovascular accident/MI 2.2% 9.7% 0.22 (0.06–0.76) 0.008 5.9% 0.36 (0.10–1.32) 0.1
Death 1.5% 3.2% 0.44 (0.08–2.34) 0.32 1.5% 0.21 (0.14–6.65) 0.96
Repeat revascularization 5.7% 21.4% 0.27 (0.13–0.57) 0.0001 0.8% 7.61 (0.96–60.0) 0.03
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Figure 2. MACCE-free survival at 1 year for ARTS II patients compared with ARTS I CABG and bare-metal stent (BMS) patients: (A) patients with normal
BMIs, (B) overweight patients, and (C) obese patients. CI  confidence interval.
Impact of BMI in ARTS-II | Chapter 27
293
angiographically documented subacute (24 hours to 30
days) thrombotic occlusions were reported: 2 in the nor-
mal and overweight groups and 1 in the obese group (p 
0.65).
Clinical outcomes at 1 year are listed in Table 5. At 1
year, the incidence of MACCEs was similar in the 3 BMI
groups (10.8%, 11.8%, and 7.0% in the normal, overweight,
and obese groups, respectively, p  0.31; Figure 1). The
power to detect a relative difference of 45% at 1 year was
85%. Normal-weight patients were at significantly higher
risk for the combined endpoint of death or cerebrovascular
accident and MI compared with overweight and obese pa-
tients (5.7% vs 1.7% and 2.1%, respectively).
The outcome of each treatment arm in the 3 BMI groups
is listed in Table 6 and shown in Figure 2. Compared with
the ARTS I bare-metal stent patients, ARTS II patients were
at significantly lower risk for MACCEs, irrespective of their
BMIs. It was notable that overweight and obese patients
from ARTS II were at significantly lower risk for death or
cerebrovascular accident and MI than ARTS I bare-metal
stent patients. The incidence of repeat revascularization was
significantly lower in ARTS II patients compared with
ARTS I bare-metal stent patients, a finding that was con-
sistent among the 3 BMI groups. Compared with ARTS I
CABG patients, conversely, the incidence of repeat revas-
cularization was significantly higher in ARTS II, a finding
that was mainly apparent in overweight and obese patients.
In the patients with normal BMIs, the difference in repeat
revascularization between ARTS II and ARTS I CABG
patients did not reach a statistically significant level.
After adjusting for covariates as reported in “Methods,”
no statistically significant interactions between the model
parameters and BMI could be detected (results of the overall
likelihood-ratio tests for interaction in BMI groups: ARTS
II vs ARTS I bare-metal stent p 0.083, ARTS II vs ARTS
I CABG p  0.71). However, when examining ARTS II
versus ARTS I bare-metal stent in greater detail (Figure 3),
we found that the confidence intervals of treatment in the
normal BMI group and the obese group were completely
disjunctive. Together with a clear trend in hazard ratio over
Figure 3. Heterogeneity of the treatment effect among the 3 BMI groups.
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the 3 BMI groups, an interaction between treatment and
BMI group in this population is very likely.
Discussion
Several reports have suggested that patients with increased
BMIs, when treated using mechanical revascularization for
atherosclerotic coronary artery disease, may have different
outcomes than patients with normal BMIs.1,5,10–12 The re-
sults of these studies are mixed, however, so that no solid
conclusion can be drawn with respect to the better method
of revascularization for such patients. Furthermore, only
very few data exist regarding the outcomes of these patients
after drug-eluting stent implantation. Because the distribu-
tion of Western populations has become almost equally
scattered across the different BMI classes,3 and drug-eluting
stent treatment is the most frequently applied coronary re-
vascularization procedure, it seems more important than
ever to investigate such a relation. The main finding of this
analysis is that the safety and effectiveness of multivessel
treatment using SES previously reported for the overall
population of ARTS II at 1 year are consistent across all
BMI classes. This is in concordance with ARTS I results, in
which BMI did not influence long-term outcomes after
multivessel percutaneous coronary intervention using bare-
metal stents.4 A subgroup analysis from TAXUS IV showed
that obesity was an important risk factor for restenosis and
major adverse cardiac events in patients who received bare-
metal stents, whereas paclitaxel-eluting stents attenuated
this increased risk so that the prognosis at 9 months was
independent of body weight in these patients.13
Acute and late outcomes after stent treatment are greatly
dependent on adequate clopidogrel therapy; this is particu-
larly true for drug-eluting stents.14 Ex vivo platelet aggre-
gometry data from 2 reports15,16 have postulated a weight
adjustment of the dose of clopidogrel for percutaneous cor-
onary intervention, with the need for higher doses in over-
weight and obese patients. In contrast, clinical data from
2,000 percutaneous coronary intervention patients from
the Clopidogrel for Reduction of Events During Observa-
tion (CREDO) study showed that increasing BMI was as-
sociated with better efficacy and bleeding outcomes at 1
year, with the standard dose of clopidogrel given in this
study.17 Diabetes mellitus and its precursor, insulin resis-
tance, have been repeatedly shown to be predictors of ad-
verse events after coronary artery revascularizations.18–22
This was also true for SES, revealing diabetes as a negative
predictor of angiographic restenosis23 and associated with
higher late mortality after such treatment.24 Manifest dia-
betes, undiagnosed diabetes, and insulin resistance are more
common in patients with increased BMIs.25 However, our
results suggest that these considerations are probably not of
clinical relevance.
Although the reduction in MACCEs in ARTS II com-
pared with ARTS I was consistent among the 3 BMI groups,
heterogeneity in the treatment effect could not be com-
pletely excluded. A clear trend was observed in a greater
benefit from SES compared with bare-metal stents with
increasing BMI. Compared with the ARTS I CABG cohort,
SES-treated patients from ARTS II when stratified accord-
ing to BMI had equivalent 1-year MACCE rates. This is in
contrast to the overweight and obese patients treated with
bare-metal stents from ARTS I, who had lower MACCE-
free survival compared with their surgically treated coun-
terparts, mainly because of a higher need for repeat revas-
cularization. A final remarkable finding of this study was
that overweight and obese patients from ARTS II were at
significantly lower risk for the combined end point of death
or cerebrovascular accident and MI compared with their
counterparts in the ARTS I bare-metal stent cohort.
The obesity paradox previously described for percu-
taneous coronary intervention,10,11 acute coronary syn-
dromes,26,27 clopidogrel safety and efficacy,17 and CABG4
was not observed for multivessel SES treatment in our series,
with similar MACCE rates for increased BMI as for normal
BMI at 1 year. However, it should be noted that the number of
patients in each group was relatively small, resulting in a small
number of adverse events. By its retrospective design, the
present study may have suffered from a lack of power to detect
statistically significant differences among the groups. Larger
randomized controlled trials are needed to validate our find-
ings. The trend toward a higher safety profile of SES use
compared with CABG in overweight patients should be seen
as hypothesis generating and should be confirmed by larger
scale randomized controlled trials.
ARTS II should be regarded as an intermediate step
before the fulfillment of the next era of randomized trials of
drug-eluting stent percutaneous coronary intervention ver-
sus CABG. When ARTS II was designed, the decision was
taken to use a historical control (ARTS I) to assess the
improvement in clinical outcomes when SES are implanted.
This decision precludes the possibility of adjusting for un-
measured confounders between the 2 groups of individuals
and entails the need to use previous definitions of primary
end points or patient classification. In this study, the anti-
platelet regimen was different from that in ARTS I because
of the recommended clopidogrel loading dose administered
24 hours before the intervention. This may have contrib-
uted, among other confounders, to the more favorable out-
come of ARTS II compared with the ARTS I bare-metal
stent arm. No data were available on the glycemic control of
patients with diabetes in ARTS II and ARTS I. It is un-
known whether this lack of information may have affected
the differences among the groups. Furthermore, it must be
noted that differences in MACCEs between treatments,
even when broken down by BMI group, may have origi-
nated from other (possibly unknown) factors not listed here.
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Objectives: To assess the 3-year relative safety and effectiveness of coronary artery bypass graft surgery (CABG) 
and percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients with and without 
diabetes with multivessel coronary artery disease. 
Methods: The Arterial Revascularization Therapies Study part-II (ARTS-II) is a 45-center single-arm study (n=607) 
including 159 diabetics treated with SES, whose 3-year clinical outcome was compared to the historical diabetic 
and non-diabetic arms of the randomized ARTS-I trial (n= 1205; including 96 diabetic patients in the CABG-arm 
and 112 in the PCI-arm).  
Results: At 3 years, in non-diabetics, the incidence of the primary composite of death, CVA, myocardial infarction 
(MI) and repeat revascularization (MACCE), was significantly lower in ARTS-II than in ARTS-I PCI (adjusted OR 
0.41, 95% CI 0.26-0.64) and similar to ARTS-I CABG (adjusted OR 0.83, 95% CI 0.56-1.23). Additionally, ARTS-II 
patients were at significantly lower risk for death/CVA/MI as compared to both ARTS-I PCI (adjusted OR 0.55, 
95% CI 0.34-0.91) and ARTS-I CABG (adjusted OR 0.56, 95% CI 0.35-0.92). In diabetics, the incidence of MACCE in 
ARTS-II was similar to both the ARTS-I PCI arm (adjusted OR 0.72, 95% CI 0.37-1.37) and ARTS-I CABG arm 
(adjusted OR 1.08, 95% 0.41-2.84). Conversely, the incidence of death/CVA/MI, was significantly lower in ARTS-II 
than in ARTS-I PCI (adjusted OR 0.67, 95% CI 0.27-1.65) and similar to ARTS-I CABG (adjusted OR 0.67, 95% CI 
0.29-1.57). 
Conclusion: At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and 
more efficacious than PCI using bare metal stents, irrespective of the diabetic status of the patient. PCI using SES 
appears to be a valuable alternative to CABG for both diabetic and non-diabetic patients. The results of 
dedicated large-scale randomized trials will help to further validate our findings.  
INTRODUCTION 
The optimal method of revascularization for 
diabetic patients with concomitant multivessel 
coronary artery disease remains in dispute. 
While several randomized controlled trials have 
demonstrated a similar safety profile for 
percutaneous coronary intervention (PCI and 
Coronary Artery Bypass graft (CABG) surgery up 
to 5 years, CABG was associated with a 
significantly lower risk for repeat 
revascularizations as compared to PCI with bare 
metal stents (BMS), a benefit that proved to be 
most apparent in diabetic patients.(1-6)  
However, when drug-eluting stents (DES) were 
shown to significantly reduce the need for 
repeat revascularizations, interventionalists 
quickly added DES treatment arms to the 
pivotal randomized PCI vs. CABG trials.(7,8) As a 
result, the 1-year results of the Arterial 
Revascularization Therapies Study (ARTS-II) and 
the Argentine randomized trial of coronary 
angioplasty with stenting versus coronary 
bypass surgery in patients with multiple vessel 
disease (ERACI-III) studies suggested that PCI 
using sirolimus-eluting stents (SES) was safe and 
effective and could be a viable alternative for 
the treatment of multivessel coronary artery 
disease.(7,8) Nevertheless, the higher 
susceptibility to repeat adverse cardiac events 
in diabetic patients makes extrapolation of 
these findings to this high-risk patient 
population uncertain. Diabetics are known to 
have an accelerated and more aggressive form 
of atherosclerosis with higher restenosis rates 
and less favourable long-term survival than non-
diabetics.(9-12) Furthermore, diabetes has been 
a strong and consistent predictor of (late) stent 
thrombosis in patients treated with DES. This 
has raised some concerns about a potential 
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erosion of the initial treatment benefit due to 
the occurrence of stent thrombosis, a finding 
that only became apparent after multiple years 
of follow-up.(13-15)  
The present study reports on the 3-year safety 
and effectiveness of the SES in diabetic patients 
with multivessel disease in ARTS-II compared to 
the outcomes of the historical results of the 
surgical and percutaneous arms of ARTS-I.  
METHODS 
ARTS-II STUDY DESIGN 
ARTS-II is a multicenter, non-randomized, open 
label trial designed to compare the safety and 
efficacy of SES in patients with de novo 
multivessel coronary artery disease with the 
surgical group of ARTS-I as a historical 
control.(16) In order to obtain a population 
comparable to ARTS-I, patients were stratified 
by clinical site in order to ensure the inclusion 
of at least 1/3 of patients with three-vessel 
disease. Patients were eligible for coronary 
revascularization if they had either stable 
angina (Canadian Cardiovascular Society class I-
IV), unstable angina (Braunwald class I-III B or 
C), or silent ischemia, and at least two lesions 
located in different major epicardial vessels 
including their sidebranches (except for the left 
main coronary artery) that were potentially 
amenable to stent implantation.(17,18) Patients 
were required to have multivessel disease 
including treatment of the left anterior 
descending (LAD) artery and at least one other 
significant lesion (>50% diameter stenosis) in 
another major epicardial coronary artery. The 
goal was to achieve complete anatomic 
revascularization.(19) One totally occluded 
major epicardial vessel or side branch could be 
included. The stenosis had to be amenable to 
stenting using a SES with a diameter of 2.5 to 
3.5mm and length of 13 to 33mm, without 
restriction on the total implanted stent length. 
Decisions to place stents in lesions with 
bifurcations, fresh thrombus, calcification, 
diffuse disease, complex anatomy or stenting of 
side branches were left to the discretion of the 
operators. Patients with previous coronary 
intervention, left main coronary disease, overt 
congestive heart failure or a left ventricular 
ejection fraction of less than 30 percent were 
excluded. Additional exclusion criteria were: 
history of a cerebrovascular accident, 
transmural myocardial infarction (MI) in the 
preceding week, severe hepatic or renal 
disease, neutropenia or thrombocytopenia, an 
intolerance or contraindication to acetylsalicylic 
acid or thienopyridines, the need for 
concomitant major surgery and life-limiting 
major concomitant non-cardiac diseases. 
Written, informed consent was obtained from 
each patient prior to enrollment. The study was 
approved by the ethics committee of each 
participating site. 
STUDY POPULATION 
Between April 1997 and June 1998 a total of 
1205 patients were randomly assigned to PCI 
with BMS (n=600) or CABG (n=605) in 67 
participating centers in the ARTS-I trial. 
Diabetes was present in 112 patients in the 
ARTS-I BMS arm and in 96 patients in the ARTS-I 
CABG arm. Between February 2003 and 
November 2003, 607 patients, of whom 159 
were diabetic, were treated at 45 participating 
centers in the ARTS-II study with SES.  
STUDY OBJECTIVES  
The primary objective of this study was to 
assess the safety and efficacy of SES in ARTS-II 
as compared to both the stent and surgical arms 
of ARTS-I in patients with or without diabetes. 
The primary safety endpoint was the composite 
endpoint of death, MI and CVA. The primary 
efficacy endpoint was MACCE, defined as the 
occurrence of major adverse cardiac and 
cerebrovascular accidents, death, stroke, MI 
and repeat revascularization. Secondary 
endpoints were the itemized outcome 
parameters death, CVA, MI, repeat 
revascularization and stent thrombosis in the 
ARTS-II population. 
BASELINE AND ENDPOINT DEFINITIONS 
Hypertension was defined as a blood pressure 
≥140 systolic or ≥90 mm Hg diastolic or based 
on the current use of antihypertensive 
treatment. Dyslipidemia was classified as a total 
serum cholesterol level ≥6.2mmol/l or the use 
of lipid lowering drugs. Death was categorized
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Table 1. Baseline Patient Demographics and Clinical Characteristics in non-diabetics.
Non-diabetics ARTS II ARTS I-CABG ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI 
Baseline Characteristics  
Male gender (%) 80.1 77.4 77.9 0.34 0.42 
Age (years r SD) 62.1±9.9 61.0±9.4 60.2±9.7 0.07 0.004 
Body Mass Index r SD 27.1±3.8 27.2±3.6 26.9±3.6 0.54 0.38 
Risk factors      
Hypertension (%)  62.7 42.8 40.2 <0.001 <0.001 
Hypercholesterolemia (%)  74.0 59.3 58.6 <0.001 <0.001 
Family history of MI or sudden death < 
55 (%) 
36.7  43.7 38.6 0.029 0.54 
Current smoker (%) 21.9 27.5 29.6 0.051 0.007 
Peripheral vascular disease (%) 6.5 4.7 5.5 0.26 0.58 
Previous myocardial infarction (%) 36.2 40.7 41.1 0.16 0.006 
Indication for Treatment  
Stable angina (%) 53.1 57.2 55.7 0.22 0.43 
Unstable angina (%) 37.9 37.9 37.7 1.00 0.95 
Silent ischemia (%) 8.9 4.9 6.6 0.015 0.18 
Angiographic Characteristics      
Ejection fraction (%) 60±12 60±13 61±12 0.94 0.45 
No. of lesions with stenosis > 50% 3.6±1.3 2.7±1.0 2.8±0.9 <0.001 <0.001 
No. of diseased vessels       
1 0.2 4.2 4.0 <0.001 <0.001 
2 45.1 66.7 69.3 <0.001 <0.001 
3 54.7 29.0 26.7 <0.001 <0.001 
Vessel territory with stenosis (% of 
lesions) 
     
Right coronary artery 29.3 29.6 31.3 0.87 0.24 
Left main 0.0 0.1 0.1 0.46 0.45 
Left anterior descending 41.8 41.2 40.1 0.74 0.36 
Left circumflex artery 28.9 29.2 28.5 0.90 0.84 
Lesion Length (visual)       
Discrete (<10mm) 63.2 67.4 67.0 0.023 0.041 
Tubular (10-20mm) 26.0 26.0 25.8 0.97 0.97 
Diffuse (>20mm) 10.8 6.6 7.2 <0.001 0.001 
Lesion Classification (% of lesions)  
Type A 6.9 6.8 6.5 0.88 0.65 
Type B1 24.4 31.8 26.4 <0.001 0.23 
Type B2 55.7 53.5 58.9 0.23 0.10 
Type C 12.9 7.9 8.2 <0.001 <0.001 
Procedural Characteristics      
Bifurcation requiring double wiring 34.7 30.8 35.0 0.029 0.90 
Number of stents implanted ±SD 3.7±1.5 - 2.7±1.2 - <0.001 
Total stent length (mm±SD) 72.0±32.1 - 46.4±20.6 - <0.001 
Maximum dilatation pressure (Atm±SD) 16.4±2.9 - 14.6±2.8 - <0.001 
Direct stenting (% of lesions) 36.0 - 3.4 - <0.001 
Duration of procedure (mins±SD) 86±44 191±67 98±50 <0.001 <0.001 
Post procedural Hospital stay (days±SD) 3.3±2.6 9.4±4.3 3.8±3.7 <0.001 0.031 
Numbers are % (counts/available field sample size) or mean ± 1 Standard Deviation; SD = Standard Deviation 
 as cardiac or non-cardiac. Cerebrovascular 
events were divided into three main categories: 
stroke, transient ischemic attacks, and 
reversible ischemic neurologic deficits. All 
repeat revascularization procedures were 
recorded. In the first 7 days after the 
intervention, a definite diagnosis of myocardial 
infarction was made if there was 
documentation of new abnormal Q-waves and 
either a ratio of serum creatine kinase MB (CK-
MB) isoenzyme to total cardiac enzyme that 
was greater than 0.1 or a CK-MB value that was 
5 times the upper limit of normal.(20) Serum 
creatine kinase and CK-MB isoenzyme 
concentrations were measured 6, 12, and 18 
hours after the intervention. Beginning 8 days 
after the intervention (the length of the hospital 
stay after surgery), either abnormal Q waves or 
enzymatic changes, as described above, were 
sufficient for a diagnosis of myocardial 
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infarction. A myocardial infarction was 
confirmed only after the relevant 
electrocardiograms had been analyzed by the 
core laboratory and adjudicated by the clinical-
events committee. This two-part method of 
defining myocardial infarction was developed 
for ARTS-I to address the difficulty of diagnosing 
a myocardial infarction after surgery.(16) These 
definitions have been adopted by the ARC 
Consortium and are applied whenever a 
comparison between DES and surgery is 
performed.(21)  
THREE YEAR CLINICAL FOLLOW-UP 
The study protocol required all patients to have 
clinical follow-up including registration of an 
ECG at 1 month, 6 months, 1 year, and 3 years. 
At each visit, physical examination, anginal 
status, and use of medications were assessed. 
Additional information was obtained by 
telephone interview or via the referring 
physician when needed. An independent 
committee adjudicated clinical events and ECGs. 
Quality of life (EuroQuol/SF 36) was assessed at 
1 month, 6 months, 1 year, and 3 years. Finally, 
complete 3-year follow-up was available for 
99% of the patients in all treatment arms.  
ENDPOINT MEASUREMENT  
In ARTS-II, the procedure was performed within 
48 hours after inclusion. In ARTS-I, patients 
were randomized after informed consent had 
been obtained and then entered onto a waiting 
list. Three deaths occurred in the ARTS I-CABG 
arm while these patients were still on the 
waiting list for surgery. To compensate for the 
temporal difference since allocation between 
groups, events for the present report were 
counted from time of procedure for all three 
arms and not from time of allocation as 
previously published.(3,22,23) 
In ARTS-I and ARTS-II, only data on subacute 
thrombotic occlusions (<30 days) were collected 
in the case record form (CRF). In ARTS-II, stent 
thrombosis was re-adjudicated according to the 
ARC definitions.(24) In this process, all coronary 
angiograms in ARTS-II, both procedure-related 
(n=104) and non-procedure related (n=165) 
were reviewed by an independent core 
laboratory and adjudicated by an independent 
critical event committee. Thus far, no attempt 
has been made to assess data on stent 
thrombosis in ARTS-I in a similar fashion. 
Statistical analysis 
Demographic and procedural characteristics of 
diabetic patients were compared between 
ARTS-II and ARTS-I (CABG and PCI). A similar 
comparison was performed for non-diabetic 
patients, and for diabetics vs. non-diabetics in 
ARTS-II. Continuous variables are expressed as 
mean ± standard deviation. Binary variables are 
reported as percentages, and the difference 
between groups was presented with 95% 
confidence intervals. The two group T-test for 
continuous variables and the Fisher’s exact test 
for categorical variables were used. (Itemized) 
MACCE rates at 3 years are presented as counts 
and percentages and were compared in terms 
of relative risks (ARTS-II vs. both ARTS-I arms) 
with 95% confidence intervals. Time-to-event 
variables are presented as Kaplan-Meier curves, 
and the overall incidence was tested using the 
log-rank test.  
A separate multivariate regression analysis was 
performed to further study treatment effects, 
considering potential confounders listed in 
Table 1. Baseline and procedural characteristics 
listed in Table 1 were tested on a per-patient 
basis by univariate analysis to determine 
suitability for inclusion in the multivariate 
model. Finally, a logistic regression model was 
built using the statistically significant univariate 
predictors (p<0.1).  
RESULTS 
NON-DIABETIC PATIENTS IN ARTS I AND ARTS II 
BASELINE CHARACTERISTICS  
Baseline and procedural characteristics of the 
non-diabetic patients from ARTS-II and ARTS-I 
are depicted in Table 1. In brief, the ARTS-II 
patients had significantly more often 
hypertension and hypercholesterolemia as 
compared to both the ARTS-I CABG and ARTS-I 
PCI cohorts. Patients from ARTS-II presented 
significantly more often with 3-vessel disease 
and Type C lesions as compared to both ARTS-I 
PCI and ARTS-I CABG. Finally, as compared to 
ARTS-I PCI, ARTS-II patients received 
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Table 2. Clinical endpoints at 3 years in non-diabetics (hierarchical and non-hierarchical MACCE up to 1080 days, per 
patient) counted since date of procedure. 
Up to 1080 days ARTS II ARTS I- ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI 
MACCE * 16.3% 15.8% 30.9% 1.03 [0.77, 1.38] 0.53 [0.41, 0.67] 
Death/CVA/MI * 7.8% 10.3% 11.5% 0.76 [0.50, 1.14] 0.68 [0.46, 1.02] 
Death/MI * 6.0% 8.5% 9.0% 0.71 [0.45, 1.13] 0.67 [0.42, 1.06] 
Death 2.2% 4.2% 3.3% 0.54 [0.26, 1.13] 0.68 [0.31, 1.48] 
- Cardiac Death 1.1% 2.4% 1.8% 0.47 [0.17, 1.33] 0.61 [0.20, 1.79] 
- Non-cardiac Death 1.1% 1.8% 1.4% 0.63 [0.21, 1.86] 0.78 [0.25, 2.43] 
CVA 2.5% 2.6% 2.9% 0.96 [0.43, 2.11] 0.86 [0.39, 1.87] 
Myocardial Infarction 4.0% 4.9% 6.1% 0.81 [0.45, 1.47] 0.65 [0.37, 1.16] 
- Q-wave 2.5% 4.5% 5.3% 0.54 [0.27, 1.10] 0.46 [0.23, 0.92] 
- Non Q-wave 1.8% 0.4% 1.0% 4.52 [0.96, 21.16] 1.74 [0.57, 5.29] 
Revascularization 11.8% 6.3% 23.6% 1.87 [1.23, 2.85] 0.50 [0.37, 0.68] 
CABG 1.8% 1.0% 8.2% 1.81 [0.60, 5.48] 0.22 [0.10, 0.46] 
- CABG TL 0.4% 0.8% 6.1% 0.56 [0.10, 3.07] 0.07 [0.02, 0.30] 
- CABG non TL 1.3% 0.2% 2.0% 6.78 [0.82, 56.07] 0.65 [0.24, 1.78] 
RPTCA 10.3% 5.9% 17.8% 1.73 [1.11, 2.69] 0.58 [0.41, 0.80] 
- RPTCA TL 5.8% 3.8% 13.1% 1.55 [0.87, 2.75] 0.44 [0.29, 0.69] 
- RPTCA non TL 5.8%  2.4%  6.4%  2.45 [1.25, 4.79] 0.91 [0.55, 1.51] 
* Hierarchical; TL - target lesion; CABG - Coronary Artery Bypass Graft; RPTCA - Repeat Percutaneous Transluminal Coronary
Angioplasty; MACCE - Major Adverse Cardiac Cerebrovascular Event (Death, CVA, Myocardial Infarction, Target Vessel CABG,
Target Vessel RPTCA); Death, CVA and Myocardial Infarction are adjudicated by the independent Clinical Event Committee 
 significantly more stents, which resulted in a 
significantly longer total stented length. 
Clinical endpoints at 3 years are depicted in 
Table 2. In brief, the MACCE rate in the non-
diabetic patients from ARTS-II was significantly 
lower than in the ARTS-I PCI and similar to the 
ARTS-I CABG arm. [Figure 1a] Adjustment for 
independent predictors of the combined 
endpoint of MACCE resulted in an OR of 0.41 
(95% CI 0.26 – 0.64) for ARTS-II vs. ARTS-I PCI 
and an OR of 0.83 (95% CI 0.56 – 1.23) for ARTS-
II vs. ARTS-I CABG.  There was a trend towards a 
lower incidence of the combined safety 
endpoint of death/CVA/MI in non-diabetic 
patients from ARTS-II as compared to both arms 
of the ARTS-I trial which reached statistical 
significance after adjustment for independent 
predictors [OR 0.56 (95% CI 0.35 – 0.92) for 
ARTS-II vs. ARTS-I CABG and an OR of 0.55 (95% 
CI 0.34 – 0.91) for ARTS-II vs. ARTS-I PCI] [Figure 
1b]. The need for repeat revascularizations in 
ARTS-II remained significantly higher than in 
ARTS-I CABG but was significantly lower than in 
ARTS-I PCI. Adjustment for independent 
predictors of the combined endpoint of 
revascularization resulted in an OR of 1.36 (95% 
CI 0.80 – 2.29) for ARTS-II vs. ARTS-I CABG and 
an OR of 0.43 (95% CI 0.27 – 0.69) for ARTS-II vs.
ARTS-I PCI. 
DIABETIC PATIENTS IN ARTS I AND ARTS II  
BASELINE CHARACTERISTICS  
Baseline clinical and procedural characteristics
of the diabetic patients are presented in Table
3. Similar to the non-diabetic population, the
ARTS-II diabetic patients had a significantly
higher rate of hypertension and
hypercholesterolemia as compared to both the
ARTS-I CABG and ARTS-I PCI cohorts. Patients
from ARTS-II presented significantly more often
with 3-vessel disease and Type C lesions
compared to both ARTS-I PCI and ARTS-I CABG
patients. Finally, as compared to ARTS-I PCI,
ARTS-II patients received significantly more
stents, which resulted in a significantly longer
total stented length.  
The 3-year results of the ARTS-II diabetic
patients, compared to both arms of the
randomized ARTS-I trial are depicted in Table 4.
In brief, the MACCE rate in ARTS-II was
significantly lower than in the ARTS-I PCI, and
similar to the ARTS-I CABG arm. [Figure 2a]
Adjustment for independent predictors of 
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Table 3. Baseline Patient Demographics and Clinical Characteristics in diabetics
Diabetics ARTS II ARTS I- ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI 
Baseline Characteristics  
Male gender (%) 66.7 68.8 73.2 0.78 0.29 
Age (years r SD) 64.5r8. 62.6r9. 62.5r9.1 0.09 0.08 
Body Mass Index r SD 28.9r4. 28.1r3. 28.7r3.7 0.16 0.78 
Risk factors      
Diabetes, insulin treated (%)  17.6 16.7 20.5 1.0 0.64 
Hypertension (%)  79.9 56.3 64.3 <0.001 0.005 
Hypercholesterolemia (%)  74.1 49.0 55.4 <0.001 0.002 
Family history of MI or sudden death < 55 (%) 33.8 32.6 41.4 0.89 0.20 
Current smoker (%) 11.9 16.7 20.5 0.35 0.06 
Peripheral vascular disease (%) 8.2 7.3 5.4 1.00 0.47 
Previous myocardial infarction (%) 29.6 49.0 41.4 0.002 0.053 
Indication for Treatment  
Stable angina (%) 53.5 62.5 58.9 0.19 0.39 
Unstable angina (%) 32.1 33.3 37.5 0.89 0.37 
Silent ischemia (%) 14.5 4.2 3.6 0.011 0.003 
Angiographic Characteristics      
Ejection fraction (%) 60r12 60r14 61r13 0.64 0.54 
No. of lesions with stenosis > 50% (nrSD) 3.6r1.3 3.0r1.1 2.9r1.2 0.001 <0.001 
No. of diseased vessels       
1 0.6 1.0 3.7 1.00 0.16 
2 49.1 63.5 65.4 0.028 0.012 
3 50.3 35.4 30.8 0.027 0.002 
Vessel territory with stenosis (% of lesions)      
Right coronary artery 28.5 29.0 30.4 0.94 0.59 
Left main 0.0 0.0 0.0 - - 
Left anterior descending 40.7 40.7 36.6 1.00 0.25 
Left circumflex artery 30.8 30.3 33.0 0.94 0.54 
Lesion Length (visual)       
Discrete (<10mm) 54.4 71.9 59.9 <0.001 0.13 
Tubular (10-20mm) 30.9 21.7 33.8 0.005 0.40 
Diffuse (>20mm) 14.7 6.4 6.4 <0.001 <0.001 
Lesion Classification (% of lesions)      
Type A 6.6 7.2 3.6 0.77 0.06 
Type B1 20.4 29.0 26.2 0.006 0.051 
Type B2 56.4 56.2 62.8 1.00 0.07 
Type C 16.7 7.6 7.4 <0,001 <0.001 
Procedural Characteristics      
Bifurcation requiring double wiring 31.9 36.3 32.6 0.21 0.88 
Number of stents implanted ±SD 3.6±1.5 - 3.0±1.5 - 0.002 
Total stent length (mm±SD) 73.9±31 - 52.7±25.6 - <0.001 
Maximum dilatation pressure (Atm±SD) 16.2±2. - 14.9±2.9 - <0.001 
Direct stenting (% of lesions) 30.6 - 2.6 - <0.001 
Duration of procedure (mins±SD) 83±40 201r64 104±51 <0.001 <0.001 
Post procedural Hospital stay (days±SD) 3.6±2.9 11.0r7. 4.6±3.4 <0.001 0.012 
Numbers are % (counts/available field sample size) or mean ± 1 Standard Deviation; SD = Standard Deviation; CI = Confidence 
Interval 
 
 MACCE resulted in an OR of 0.72 (95% CI 0.37 – 
1.37) for ARTS-II vs. ARTS-I PCI and an OR of 
1.08 (95% CI 0.41 – 2.84) for ARTS-II vs. ARTS-I 
CABG. The incidence of death/CVA/MI was 
significantly lower in ARTS-II than in ARTS-I PCI, 
but was observed at a similar rate in the ARTS-I 
CABG arm [Figure 2b]. Adjustment for 
independent predictors of the combined 
endpoint of death/CVA/MI resulted in an OR of 
0.67 (95% CI 0.27 – 1.65) for ARTS-II vs. ARTS-I 
PCI and an OR of 0.67 (95% CI 0.29 – 1.57) for 
ARTS-II vs. ARTS-I CABG.  
As expected, there was a higher MACCE rate in 
the diabetic patients on insulin therapy 
compared to those not receiving insulin 
treatment.[Figure 3]  The 23.6% difference in 
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TABLE 4. Clinical endpoints at 3 years in diabetics (hierarchical and non-hierarchical MACCE up to 1080 days, per patient) 
counted since date of procedure. 
Up to 1080 days ARTS II ARTS I-CABG ARTS I-PCI ARTS II:I-CABG ARTS II:I-PCI 
MACCE * 27.7% (44/159) 17.7% (17/96) 47.3% (53/112) 1.56 [0.95, 2.57] 0.58 [0.43, 0.80] 
Death/CVA/MI * 9.4% (15/159) 13.5% (13/96) 18.8% (21/112) 0.70 [0.35, 1.40] 0.50 [0.27, 0.93] 
Death/MI * 6.9% (11/159) 9.4% (9/96) 14.3% (16/112) 0.74 [0.32, 1.72] 0.48 [0.23, 1.00] 
Death 5.0% (8/159) 5.2% (5/96) 7.1% (8/112) 0.97 [0.33, 2.87] 0.70 [0.27, 1.82] 
- Cardiac Death 2.5% (4/159) 4.2% (4/96) 6.3% (7/112) 0.60 [0.15, 2.36] 0.40 [0.12, 1.34] 
- Non-cardiac Death 2.5% (4/159) 1.0% (1/96) 0.9% (1/112) 2.42 [0.27, 21.29] 2.82 [0.32, 24.87] 
CVA 3.8% (6/159) 6.3% (6/96) 5.4% (6/112) 0.60 [0.20, 1.82] 0.70 [0.23, 2.13] 
Myocardial 
Infarction 
2.5% (4/159) 5.2% (5/96) 9.8% (11/112) 0.48 [0.13, 1.75] 0.26 [0.08, 0.78] 
- Q-wave 1.3% (2/159) 4.2% (4/96) 8.0% (9/112) 0.30 [0.06, 1.62] 0.16 [0.03, 0.71] 
- Non Q-wave 1.3% (2/159) 1.0% (1/96) 1.8% (2/112) 1.21 [0.11, 13.14] 0.70 [0.10, 4.93] 
Revascularization 21.4% (34/159) 7.3% (7/96) 38.4% (43/112) 2.93 [1.35, 6.35] 0.56 [0.38, 0.81] 
CABG 3.8% (6/159) 2.1% (2/96) 13.4% (15/112) 1.81 [0.37, 8.79] 0.28 [0.11, 0.70] 
- CABG TL 1.3% (2/159) 1.0% (1/96) 8.9% (10/112) 1.21 [0.11, 13.14] 0.14 [0.03, 0.63] 
- CABG non TL 2.5% (4/159) 1.0% (1/96) 4.5% (5/112) 2.42 [0.27, 21.29] 0.56 [0.15, 2.05] 
RPTCA 18.2% (29/159) 6.3% (6/96) 27.7% (31/112) 2.92 [1.26, 6.77] 0.66 [0.42, 1.03] 
- RPTCA TL 13.8% (22/159) 3.1% (3/96) 19.6% (22/112) 4.43 [1.36, 14.40] 0.70 [0.41, 1.21] 
- RPTCA non TL 6.9% (11/159) 3.1% (3/96) 9.8% (11/112) 2.21 [0.63, 7.74] 0.70 [0.32, 1.57] 
* Hierarchical; TL - target lesion; CABG - Coronary Artery Bypass Graft; RPTCA - Repeat Percutaneous Transluminal Coronary 
Angioplasty; MACCE - Major Adverse Cardiac Cerebrovascular Event (Death, CVA, Myocardial Infarction; Target Vessel CABG; 
Target Vessel RPTCA). Death, CVA and Myocardial Infarction are adjudicated by the independent Clinical Event Committee.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Kaplan-Meier curve out to 3 years in ARTS-I and ARTS-II non-diabetics patients: freedom from major adverse cardiac 
and cerebrovascular events (MACCE) (A), the combined endpoint of all-cause death, cerebrovascular accident (CVA), myocardial 
infarction and repeat revascularization and death/CVA/MI (B). Figure 2: Kaplan-Meier curve out to 3 years in ARTS-I and ARTS-II 
diabetics patients: freedom from major adverse cardiac and cerebrovascular events (MACCE) (A), the combined endpoint of all-
cause death, cerebrovascular accident (CVA), myocardial infarction and repeat revascularization and death/CVA/MI (B).
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TABLE 5. Clinical endpoints of diabetics and non­diabetic patients at 3 years in ARTS­II. (hierarchical and non­
hierarchical MACCE up to 1080 days, per patient) counted since date of procedure. 
Up to 1080 days  Diabetics  Non­diabetics  Relative Risk (95% CI) 
MACCE *  27.7% (44/159) 16.3% (73/448) 1.70 [1.22, 2.36] 
Death/CVA/MI *  9.4% (15/159) 7.8% (35/448) 1.21 [0.68, 2.15] 
Death/MI *  6.9% (11/159) 6.0% (27/448) 1.15 [0.58, 2.26] 
Death  5.0% (8/159) 2.2% (10/448) 2.25 [0.91, 5.61] 
‐ Cardiac Death  2.5% (4/159) 1.1% (5/448) 2.25 [0.61, 8.29] 
‐ Non‐cardiac Death 2.5% (4/159) 1.1% (5/448) 2.25 [0.61, 8.29] 
CVA  3.8% (6/159) 2.5% (11/448) 1.54 [0.58, 4.09] 
Myocardial Infarction 2.5% (4/159) 4.0% (18/448) 0.63 [0.22, 1.82] 
‐ Q‐wave  1.3% (2/159) 2.5% (11/448) 0.51 [0.11, 2.29] 
‐ Non Q‐wave  1.3% (2/159) 1.8% (8/448) 0.70 [0.15, 3.28] 
Revascularization  21.4% (34/159) 11.8% (53/448) 1.81 [1.22, 2.67] 
CABG  3.8% (6/159) 1.8% (8/448) 2.11 [0.74, 6.00] 
‐ CABG TL  1.3% (2/159) 0.4% (2/448) 2.82 [0.40, 19.84] 
‐ CABG non TL  2.5% (4/159) 1.3% (6/448) 1.88 [0.54, 6.57] 
RPTCA  18.2% (29/159) 10.3% (46/448) 1.78 [1.16, 2.73] 
‐ RPTCA TL  13.8% (22/159) 5.8% (26/448) 2.38 [1.39, 4.08] 
‐ RPTCA non TL  6.9% (11/159) 5.8% (26/448) 1.19 [0.60, 2.36] 
* Hierarchical; TL - target lesion; CABG - Coronary Artery Bypass Graft, clinically driven; RPTCA - Repeat Percutaneous 
Transluminal Coronary Angioplasty, clinically driven; MACCE - Major Adverse Cardiac Cerebrovascular Event (Death, CVA, 
Myocardial Infarction, Target Vessel CABG, Target Vessel RPTCA); Death, CVA and Myocardial Infarction are adjudicated by the 
independent Clinical Event Committee. 
MACCE rates between the insulin- and non-
insulin treated diabetic patients in the CABG 
arm is worth noting. However, there were only 
16 insulin- treated diabetics in the ARTS-II CABG 
arm, a number which precludes any definitive 
statement about a difference in the relative 
treatment effect in insulin-treated diabetics. 
 
 
 
 
 
 
 
 
 
Figure 3: Kaplan-Meier curve out to 3 years in ARTS-I and 
ARTS-II insulin- versus non-insulin dependent diabetics 
patients: freedom from major adverse cardiac and 
cerebrovascular events (MACCE), the combined endpoint of 
all-cause death, cerebrovascular accident, myocardial 
infarction and repeat. IDDM stands for insulin-dependent 
diabetes mellitus; NIDDM stands for non-insulin dependent 
diabetes mellitus.  
THE IMPACT OF DIABETES IN ARTS-II  
After Adjustment for independent predictors, 
diabetes proved to be the strongest pre-
procedural predictor of MACCE in ARTS-II (OR 
1.76, 95% CI 1.13 – 2.74; p=0.012).(25) The 
clinical endpoints of the ARTS-II diabetics vs. 
non-diabetics are depicted in Table 5. In brief, 
the incidence of MACCE in diabetic patients was 
significantly higher than in non-diabetics. This 
difference was mainly driven by the significantly 
higher need for repeat revascularizations in the 
diabetic patients. At 3-years, the difference in 
the incidence of the combined safety endpoint 
of death/CVA/MI between diabetic and non-
diabetic patients did not reach statistical 
significance. 
Remarkably, the incidence of stent thrombosis 
(definite, probable or possible) at 3 years was 
similar in the ARTS-II diabetics as compared to 
the non-diabetics (6.9% (11/159) vs. 6.3% 
(28/448) respectively; p=0.85). Definite or 
probable stent thrombosis occurred in 5.0% 
(8/159) of the diabetics as compared to 5.4% 
(24/448) in the non-diabetics (p=1.00). There 
were no differences in the incidence of stent 
thrombosis between insulin and non-insulin 
treated diabetics. Definite or probable stent 
thrombosis occurred in 4.6% (6/131) of the non-
insulin treated diabetics vs. 7.1% (2/28) of the 
insulin treated diabetics (p=0.63). 
In the diabetic patients, out of the 44 patients 
who had a major adverse cardiac event (ARC 
definitions), 10 (22.7%) patients had a definite, 
probable or possible stent thrombosis. Out of 
the 83 non-diabetics patients in ARTS-II who 
Impact of diabetes in ARTS-II | Chapter 28
307
had a major adverse cardiac event, 28 patients 
(33.7%) had a definite, probable or possible 
stent thrombosis. More specifically, 5/26 
(19.2%) of the clinically driven percutaneous 
target lesion revascularizations in the non-
diabetics and 12/22 (54.5%) of the clinically 
driven percutaneous target lesion 
revascularizations in the diabetics were due to 
definite stent thrombosis. 
DISCUSSION 
The present study is the first to compare the 
long-term safety and efficacy of PCI using SES 
with CABG in diabetic and non-diabetic patients 
with multivessel coronary artery disease. In the 
total ARTS-II population we recently reported 
on the significantly lower incidence of 
death/CVA/MI in patients treated with SES 
(8.3%) as compared to the historical PCI arm of 
the ARTS-I (12.8%; Logrank p=0.007). 
Stratification of these results according to 
diabetic status revealed that when adjusting for 
independent predictors of outcome, the risk for 
death/CVA/MI in the non-diabetic patients was 
significantly lower in ARTS-II than in both arms 
of the ARTS-I. Conversely, in the diabetic cohort, 
the cumulative incidence of death/CVA/MI in 
ARTS-II was 9.2% lower than in the 
percutaneous arm of ARTS-I and 4.1% lower 
than in the ARTS-I CABG arm. However, these 
differences in the hard clinical endpoints did not 
reach statistical significance after adjusting for 
independent predictors of outcome. Thus far, 
no consensus has been reached about 
differences in hard clinical endpoints between 
PCI and CABG. In the pre-stent era, randomized 
trials and registries demonstrated higher 
survival rates following CABG than PCI, a 
difference that was most pronounced in 
diabetic patients.(12,26,27) Comparing PCI 
using BMS with CABG, a meta-analysis of the 
ARTS-I, SoS, ERACI-II and MASS-II trials 
demonstrated similar mortality rates following 
both treatment options in both the overall 
analysis as well as in the diabetic subset at 1-
year.(2) We observed a clear trend towards a 
lower incidence of death/CVA/MI in the 
patients treated with DES in the ARTS-II 
compared to the ARTS-I PCI population. 
Although the present study was underpowered 
to make definitive statements about a better 
survival following PCI using DES as compared to 
BMS, these findings are in agreement with the 
3-year results of the randomized DIABETES trial 
in which 6.4% of the patients treated with SES 
experienced  an MI and/or died of a cardiac 
cause versus 12.6% of the patients treated with 
BMS.(28) Furthermore, various large-scale 
registries have recently shown a small, but 
consistent long-term survival advantage when 
using DES versus BMS in all-comer 
populations.(29-33)  
CABG has been associated with a significantly 
lower risk for repeat revascularizations as 
compared to PCI with BMS, a benefit that 
proved to be most apparent in patients with 
multivessel disease often suffering from 
diabetes.(1-6) Although DES proved to tighten 
the gap between PCI and CABG, it remains 
unclear whether these findings can be 
extrapolated to diabetics. (7,8) Diabetics are 
known to have a smaller vessel size, longer 
lesion length, greater plaque burden and 
possibly a different restenotic cascade as 
compared to non-diabetics making them more 
susceptible to atherosclerosis and a higher need 
for repeat revascularizations.(9-12,34,35) This is 
confirmed by the 3-year revascularization rate 
in the ARTS-II diabetics, who had an 81% 
increased risk for repeat revascularization as 
compared to the non-diabetic patients. The use 
of CABG remains the most effective method for 
avoiding reinterventions in diabetics. When 
compared to the ARTS-I PCI population, the 
incidence of repeat revascularization was 31% 
lower following surgical revascularization 
(38.4% vs. 7.3% respectively). Although CABG 
remained significantly superior to PCI with DES 
in reducing the need for repeat 
revascularizations, the use of SES in this-high 
risk population resulted in a 44% decrease in 
the need for repeat revascularizations as 
compared to the ARTS-I PCI arm, despite the 
higher baseline and procedural risk profile of 
the ARTS-II patient population. In the non-
diabetics conversely these differences were 
substantially smaller. The difference was 17.0% 
between both arms of the ARTS-I, while the 
difference in repeat revascularization rates 
between ARTS-II and ARTS-I CABG was 5.5% 
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confirming the more pronounced efficacy of 
CABG in diabetics.  
Diabetes has been associated with enhanced 
platelet reactivity and reduced responsiveness 
to antiplatelet agents.(36,37) Abnormalities in 
neovascularization have also been recognized 
and are hypothesized to enhance 
atherosclerotic plaque destabilization.(38) The 
latter is reflected by the 70% higher relative risk 
of MACCE in diabetic as compared to non-
diabetic patients in ARTS-II. However, at three 
years, the incidence of definite or probable 
stent thrombosis(21) was similar in the ARTS-II 
diabetic and non-diabetic patients, a  finding 
that at first is not entirely consistent with  the 
current literature(13-15) but may  be partly 
explained by the relatively  small and specific 
patient population studied. Clinical and 
procedural risk factors are usually worse for 
diabetics as compared to non-diabetics. 
However, in ARTS-II, clinical presentation, lesion 
calcification, number of stents and total stented 
length were similar between the diabetics and 
non-diabetics. As a result, the impact of ST on 
the 3-year MACCE-rates in ARTS-II was similar in 
the diabetic and non-diabetic population.  
Although the present subset analysis of patients 
with diabetes was prespecified in the ARTS-II 
protocol, this non-randomized study has several 
limitations. First, a 5-year time lag exists 
between the groups that are being compared. 
Both PCI and CABG as well as concomitant 
medical therapy have improved with time. 
Secondly, despite the use of complex statistical 
adjustment methods, it remains unclear 
whether we were able to fully adjust for the 
differences between ARTS-II and ARTS-I studies. 
Third, while the protocol required that the 
lesions in ARTS II be potentially treatable by 
CABG, the absence of dialogue with the 
surgeons prior to intervention may have caused 
a selection bias. However, this is not obvious 
considering that patients actually enrolled in 
ARTS II were more complex than those enrolled 
in ARTS I. Finally, the incidence and impact of 
stent thrombosis was not readjudicated 
according to the ARC definitions in the ARTS-I 
study preventing the authors from comparing 
the results of ARTS-II to the historical PCI arm of 
ARTS-I. As a consequence, we were unable to 
verify the hypothesized increase in late stent 
thrombosis in diabetic patients treated with DES 
as compared to BMS. However, it was 
reassuring to note the trend towards a lower 
rate of death and a significantly lower rate of 
myocardial infarction, as well as Q-wave 
myocardial infarction, in the ARTS-II compared 
to the ARTS-I PCI population. .  
Several large-scale dedicated randomized 
controlled trials like Syntax (using the paclitaxel-
eluting stent), FREEDOM (using the PES and 
SES), and CARDia (comparing SES with CABG in 
diabetics) are ongoing to assess the relative 
safety and efficacy of PCI using DES and 
CABG.(39,40) However, until the long-term 
outcome data from these trials will be revealed, 
the results from the present study are unique in 
addressing the relative long-term safety and 
efficacy of PCI using SES for both diabetic and 
non-diabetic patients with multivessel coronary 
artery disease. The results of the randomized 
FREEDOM and CARDia trials are eagerly awaited 
to confirm the findings of this analysis.  
CONCLUSION 
At 3 years, PCI using SES for patients with 
multivessel coronary artery disease seems to be 
safer and more efficacious as compared to PCI 
using bare metal stents, irrespective of the 
diabetic status of the patient. Although superior 
to PCI with BMS, PCI using SES remains inferior 
to CABG in reducing the need for repeat 
revascularizations. However, we observed a 
clear trend towards a lower risk for 
death/CVA/MI in the ARTS-II patients as 
compared to both arms of the ARTS-I trial. 
These findings suggest that PCI using SES could 
be a genuine alternative to CABG. The results of 
dedicated large-scale randomized trials are 
eagerly awaited to validate our findings.  
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Abstract
Background: Health related quality-of-life (HRQL) beyond one year of treatment of multivessel coronary artery
disease with stenting or coronary artery bypass grafting (CABG) is yet unknown. The Arterial Revascularisation
Therapy Study (ARTS) was designed to compare CABG and stenting in multivessel disease.
Methods and results: HRQL was evaluated at baseline, at 1- month and at 6-, 12- and 36 months after
revascularisation using the Short Form Health Survey (SF-36) in patients randomised to stenting (n=483)
versus CABG (n=492). Both stenting and CABG resulted in significant improvement of HRQL and anginal
status. Although there was a trend for better HRQL after CABG up to one year, the disparity between the
two procedures decreased long-term. Most of the difference between the two procedures was attributed to
repeat interventions in the stent group; at three years, 19% of stent patients versus 13% of CABG patients
(p<0.0001) had undergone a repeat intervention. On most of the SF-36 scores, there was no difference
between diabetics and non-diabetics, with diabetic patients having a worse score only on general health
and physical functioning at all time points (p<0.0001).
Conclusions: Both stenting and CABG resulted in a significant improvement in HRQL especially up to one
year, but CABG was associated with less angina at all time points. There was a trend for better HRQL after
CABG, but this difference was mainly attributed to repeat revascularisation in the stent group. Based on
these findings, patients should select for themselves whether or not they would prefer the improved HRQL
benefits after CABG, or whether they would prefer more angina after PCI and avoid a major operation.
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bypass surgery, 
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Introduction
Multiple randomised studies have demonstrated similar mortality
rates for percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG). However, patients undergoing PCI
are much more likely to have recurrent ischaemia with subsequent
repeat interventions. When there is an absence of a clear advantage
for either CABG or PCI, revascularisation strategies are selected
based solely upon technical considerations and perceived
procedural risks. Because the elimination of ischaemia is more
complete with surgery, patients may derive a greater health related
quality-of-life (HRQL) benefit with CABG compared with PCI. In the
early 1990s, the pre-stent era, several clinical trials comparing
CABG with balloon angioplasty included HRQL and showed that
CABG patients had greater improvement in HRQL scores1-3. More
recently, the AWESOME investigators reported equivalent six-
months HRQL between PCI and CABG4. On the other hand, the
Stent or Surgery (SoS) study group reported a significant
improvement in angina-related health status at six months and at
one year after intervention5. Furthermore, a few observational
registries identified that over 12 months of follow-up health status
was more improved after CABG than after PCI, but this was
primarily driven by the adverse influence of restenosis after PCI6,7.
However, almost no data are available to describe the HRQL
recovery after revascularisation beyond one year. Only the Arterial
Revascularisation Therapy Study (ARTS) reported the HRQL,
assessed by the 5-item EuroQOL EQ-5D health status, at one and
three years8. ARTS was a randomised trial comparing stenting with
CABG in patients with multivessel disease9. At five years, there was
no difference in mortality, myocardial infarction or stroke between
the two procedures10. However, increased repeat revascularisation
was needed in the stent group.
Besides the EQ-5D, ARTS also evaluated the more well-known and
more detailed Short Form Healthy Survey (SF-36). The objective of
this study was to evaluate the SF-36 and anginal status at baseline,
at 1-month, and 6-, 12 and 36-months of patients enrolled in the
ARTS trial.
Methods
Population
Between April 1997 and June 1998, 1,205 patients who had
multivessel disease and considered equally treatable with the two
modalities were randomised to either stent implantation (n=600) or
CABG (n=605) at 67 participating centres worldwide as part of the
ARTS trial. Details of this study have been described previously11.
The indications for revascularisation included silent ischaemia,
stable or unstable angina pectoris, and the presence of at least two
de novo lesions located in different major epicardial coronary
arteries, potentially amenable to stent implantation. For each
patient, entry into the study required agreement from both the
surgeon and interventional cardiologist that an equivalent degree of
revascularisation could potentially be obtained using either
approach. Specific exclusion criteria from the randomised trial may
be summarised as follows: left ventricular ejection fraction <30%,
left main stenosis, history of cerebrovascular accident, transmural
myocardial infarction within the preceding week, severe hepatic or
renal disease and need for concomitant major surgery. All patients
gave written informed consent.
As the SF-36 questionnaire was not translated in all languages of
the participating centres, of the total 1,205 patients, 1,035 patients
were eligible to participate in this substudy. Of these eligible
patients, 975 (94%) agreed to participate. At respectively 1-, 6-, 12-
and 36 months follow-up six, 20, 24 and 43 patients had died
(equally divided among both treatment groups). The corresponding
participating rates were 100% at baseline and at one month, and
92% at 6-, 12- and 36 months.
Health-related quality of life and anginal status
The Short Form Health Survey (SF-36) is a generic measure of
HRQL that assesses eight domains, i.e. physical functioning, role
physical functioning, role emotional functioning, mental health,
vitality, social functioning, bodily pain, and general health12. Scale
scores are obtained by summing the items together within a
domain, dividing this outcome by the range of scores and then
transforming the raw scores to a scale from zero to 100. A higher
score on the SF-36 sub domains represents a better HRQL with a
high score on the bodily pain scale indicating freedom from pain.
The scale has good reliability with Cronbach’s alpha ranging from
.65 to .96 for all subscales12. The SF-36 was administered at
baseline, and at one, six, 12 and 36 months’ post-index procedure.
Anginal status was assessed by the Canadian Cardiovascular
Society (CCS) classification.
Statistical analysis
Comparisons between treatment groups were analysed according to
the intention-to-treat principle. Baseline characteristics were
compared by unpaired Student’s t test for continuous variables and
Fisher exact tests for categorical variables. Health status recorded
over follow-up time was analysed with repeated measures analysis
of variance with Bonferroni correction. All tests of statistical
significance were 2-tailed and a probability value of <0.05 was
considered significant. A pre-specified subgroup analysis was
performed in the stent group to investigate the effect of repeat
revascularisation on HRQL. Since the BARI investigators reported
better survival in diabetics after CABG, much attention has been
seen in this subgroup. Therefore, also, an analysis was performed
on patients with and without diabetes3.
Results
Baseline clinical and procedural characteristics of the 975 patients
who participated in this ARTS randomised HRQL substudy were
similar in both treatment groups (Table 1). Mean age was 61 years and
77% were male. There were no differences in baseline characteristics
between responders and non-responders on the SF-36.
The time course of recovery from the coronary intervention differed
by treatment strategy (Figure 1). Patients undergoing CABG
experienced a decrease in most SF-36 subscales in the first post-
operative month, whereas in the group of patients undergoing PCI
the HRQL immediately increased significantly. This improvement
varied between 10% to 64% at one month. Between one and six
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Figure 1. SF 36 subscales according to CABG and stenting at baseline, 1, 6, 12 and 36 months.
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months, most HRQL scores improved substantially, but the
strongest in the CABG group up to an equal or greater level than the
PCI group. Only bodily pain remained low in the first six months in
patients undergoing CABG. Between six and 12 months, the HRQL
sub domain scores for all stent and most CABG remained similar.
Physical and emotional role functioning further increased after
CABG, and bodily pain finally improved to the same stent level.
Ultimately, three of the SF-36 sub domain scores (physical
functioning, social functioning and general health) were significantly
higher in the CABG than in the stent group. During longer follow-up
up to three years, all sub-domain scores in both treatment groups
slightly decreased and converged to the same level.
To better explain differences in HRQL between CABG and stenting,
an additional analysis was performed to investigate the effect of
repeat revascularisation on the relative benefit of CABG versus
stenting. Although among those PCI patients who did not require
repeat revascularisation (73% of the stent patients), average HRQL
scores at six months and later were similar with the scores in the
CABG patients, whether or not these CABG patients had a repeat
intervention (Figure 2).
Anginal status
The incidence of angina after stenting and CABG is shown in
Figure 3. At all time points, angina was more prevalent in the stent
group, although the differences getting smaller with prolonged
follow-up. At three years, 19% of the stent patients and 13% of the
CABG patients had angina (p<0.0001). In the group of stent
patients in whom no repeat revascularisation was needed, the
prevalence of angina was lower compared with those stent patients
with a repeat revascularisation, but it was still higher than the CABG
group at all time points (p<0.0001).
Patients with diabetes
In the stent group there was no difference between diabetics and
non-diabetics in most of the SF-36 scores. Only on general health,
Table 1. Baseline characteristics.
Stent CABG P
(n=483) (n=492)
Age (years) 61 62 0.3
Range (years) 30-83 32-82
Male (%) 77 77 0.8
Diabetes (%) 19 16 0.3
Hypertension (%) 44 44 0.9
Hypercholesterolaemia (%) 56 56 0.9
Current smoker (%) 33 26 0.2
Previous myocardial infarction (%) 54 42 0.2
Unstable angina (%) 36 35 0.7
Ejection fraction (%) 61 60 0.2
Range 30-92 30-91
No of diseased vessels (%) 0.7
1 2 0
2 68 67
3 30 33
the diabetic patients scored significantly worse than the non-diabetic
patients at all time points (p<0.0001), and physical functioning
decreased gradually with longer follow-up among the diabetic stent
patients. Also in the CABG group, most SF-36 scores were similar
among the diabetics and non-diabetics. Only a trend in worse
emotional well-being was observed in the diabetics long-term.
Discussion
The main reason for treating patients with severe ischaemia is to
restore the patient to as normal a life as possible. As a
consequence, evidence of a meaningful benefit from the patient’s
perspective is an important consideration in the comparison of
treatment strategies. Both stenting and CABG resulted in significant
improvements in HRQL and anginal status. Although this
improvement was clear immediately following stenting, due to the
major surgery, at six months HRQL after CABG was at the same
level as after stenting. The first month assessment allowed us to
detect both the drop in both physical and mentally function with
CABG and the impact of repeat revascularisation on HRQL with
stenting. Between six months and 12 months patients who
underwent CABG had, in general, a better HRQL than those who
underwent PCI. However, most of this difference was attributed to
repeat interventions in the stent group. At one year, and up to three
years, HRQL of both groups converged to each other. Furthermore,
CABG surgery was associated with less angina at all time points, but
again much of this difference was due to the repeat
revascularisations after stenting. Therefore, with the recent
introduction of the drug-eluting stents, with subsequent substantial
reduction of restenosis, it is to be expected that HRQL after stenting
will converge to the same as CABG.
Recently, this study reported a HRQL measurement, by means of
the 5-item EuroQOL EQ-5D, beyond one year and up to three years
after the procedure8. At one year after the intervention the stent
group scored better on the subscales “mobility”, “anxiety and
depression” and “usual activity”, but at three years all differences
had diminished. However, it has been suggested that the EQ-5D is
not sensitive enough as disease specific instrument and that the
more well known and widely accepted 36-item SF-36 more
adequately discriminates HRQL13. A limitation of this study is the
lack of a disease-specific health status survey. Disease specific
surveys have multiple advantages over generic surveys such as the
SF-36, especially when comparing interventions within a disease
state. A survey such as the MacNEW or SAQ would have captured
domains most relevant to the question at hand, and could have
added much to the results.
Multiple clinical trials have reported and demonstrated improvement
in HRQL for both stenting and CABG1-3. However, all these studies
date from the pre-stent era. Only the AWESOME and SoS investigators
have reported HRQL after stenting and CABG4,5. The AWESOME trial
found equivalent HRQL outcomes at 6-months and the SoS study
reported improved HRQL up to 12 months after CABG.
In the diabetic subgroup of this study (n=208), no difference in 5-
year mortality was found10. In general, no difference in HRQL was
found between patients with and without diabetes in both the stent
and CABG groups.
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Figure 2. SF 36 subscales according to CABG and stenting with or without repeat revascularisation at baseline, 1, 6, 12 and 36 months.
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Figure 3. Anginal status according to CABG and stenting with or with-
out repeat revascularisation at baseline, 1, 6, 12 and 36 months.
The present study has shown improved health status after either
stenting or CABG, especially in the stent patients who didn’t undergo
a repeat intervention. Many patients may refuse to undergo the
greater initial suffering of CABG compared to PCI in order to achieve
only similar HRQL on the long-term. Therefore, from a HRQL point of
view, there seems no reason to believe that CABG should be the first
choice. All the more in this drug-eluting stent era, the need of repeat
of revascularisation after stenting is decreasing rapidly.
Conclusion
Both stenting and CABG resulted in a significant improvement in
HRQL especially up to one year, but CABG was associated with less
angina at all time points. There was a trend for better HRQL after
CABG, but this difference was mainly attributed to repeat
revascularisation in the stent group. Although, based purely on HRQL
outcomes, there seems little reason to prefer CABG to stenting in
order to provide long-term pain relief. However, the decision should
be made on an individual patient basis, including balancing the larger
‘upfront’ risks of CABG with the risk of repeat revascularisation and
residual angina with PCI. Furthermore, based on these findings,
patients should select for themselves whether or not they would prefer
the improved HRQL benefits after CABG, or whether they would
prefer more angina after PCI and avoid a major operation.
References
1. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB 3rd.
A comparison of the costs of and quality of life after coronary angioplasty
or coronary surgery for multivessel coronary artery disease. Results from
the Emory Angioplasty Versus Surgery Trial (EAST). Circulation
1995;92:2831-40.
2. Pocock SJ, Henderson RA, Seed P, Treasure T, Hampton JR.
Quality of life, employment status, and anginal symptoms after coronary
angioplasty or bypass surgery. 3-year follow-up in the Randomized
Intervention Treatment of Angina (RITA) Trial. Circulation 1996;94:135-42.
3. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt
B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical
care costs and quality of life after randomization to coronary angioplasty
or coronary bypass surgery. Bypass Angioplasty Revascularization
Investigation (BARI) Investigators. N Engl J Med 1997;336:92-9.
4. Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W,
Hlatky M, Sethi G, Morrison DA; Department of Veterans Affairs Angina
With Extremely Serious Operative Mortality (AWESOME) Investigators.
Health-related quality of life after percutaneous coronary intervention ver-
sus coronary bypass surgery in high-risk patients with medically refractory
ischemia. J Am Coll Cardiol 2003;41:1732-8.
5. Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA,
Weintraub WS. Disease-specific health status after stent-assisted percuta-
neous coronary intervention and coronary artery bypass surgery: one-year
results from the Stent or Surgery trial. Circulation 2003;108:1694-700.
6. Borkon AM, Muehlebach GF, House J, Marso SP, Spertus JA.
A comparison of the recovery of health status after percutaneous coronary
intervention and coronary artery bypass. Ann Thorac Surg 2002;74:1526-30.
7. Spertus JA, Nerella R, Kettlekamp R, House J, Marso S, Borkon AM,
Rumsfeld JS. Risk of restenosis and health status outcomes for patients
undergoing percutaneous coronary intervention versus coronary artery
bypass graft surgery. Circulation 2005;111:768-73.
8. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC,
Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM,
Neves JP, Lindeboom W, Backx B; Arterial Revascularization Therapy
Study (ARTS) Investigators. Three-year outcome after coronary stenting
versus bypass surgery for the treatment of multivessel disease. Circulation
2004;109:1114-20.
9. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ,
Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden
LA, Morel MA, van Hout BA; Arterial Revascularization Therapies Study
Group. Comparison of coronary-artery bypass surgery and stenting for the
treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
10. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A,
Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B,
Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary
stenting versus bypass surgery for the treatment of multivessel disease:
the final analysis of the Arterial Revascularization Therapies Study (ARTS)
randomized trial. J Am Coll Cardiol 2005;46:575-81.
11. Serruys PW, Unger F, van Hout BA, van den Brand MJ, van
Herwerden LA, van Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A,
Santoli C, Vandormael M, Marshall PR, Madonna O, Firth BG, Breeman A,
Morel MA, Hugenholtz PG. The ARTS study (Arterial Revascularization
Therapies Study). Semin Interv Cardiol 1999;4:209-19.
12. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health
Survey (SF-36). Medical Care 1993:30:473-483.
13. Nordlund A, Ekberg K, Kristenson M. EQ-5D in a general popula-
tion survey—a description of the most commonly reported EQ-5D health
states using the SF-36. Qual Life Res 2005;14:1099-109.
HRQL in ARTS-II
318
Chapter 30
Cost-eff ecti veness of the unrestricted use of sirolimus-
eluti ng stents vs. bare metal stents at 1 and 2-year 
follow-up: results from the RESEARCH Registry 
Ong AT, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, 
Serruys PW
Eur Heart J. 2006;27(24):2996-3003 

Cost-effectiveness of the unrestricted use of
sirolimus-eluting stents vs. bare metal stents at 1 and
2-year follow-up: results from the RESEARCH Registry{
Andrew T.L. Ong, Joost Daemen, Ben A. van Hout, Pedro A. Lemos, Johanna L. Bosch,
Ron T. van Domburg, and Patrick W. Serruys*
Thoraxcenter, Erasmus Medical Center, Ba-583, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Received 12 January 2006; revised 6 October 2006; accepted 12 October 2006; online publish-ahead-of-print 17 November 2006
Aims To assess the cost-effectiveness of sirolimus-eluting stents (SESs) compared with bare metal stents
(BMSs) as the default strategy in unselected patients treated in the Rapamycin Eluting Stent Evaluated
At Rotterdam Cardiology Hospital (RESEARCH) Registry at 1 and 2-years following the procedure.
Methods and results A total of 508 consecutive patients with de novo lesions exclusively treated with
SES were compared with 450 patients treated with BMS from the immediate preceding period. Resource
use and costs of the index procedure, and clinical outcomes were prospectively recorded over a 2-year
follow-up period. Follow-up costs were measured as unit costs per patient based on the incidence of
clinically driven target vessel revascularization (TVR), to obtain cumulative costs at 1 and 2-years. Cost-
effectiveness was measured as the incremental cost-effectiveness ratio (ICER) per TVR avoided.
The use of SES cost E3036 more per patient at the index procedure, driven by the price of SES.
Follow-up costs after 1-year were E1,089 less with SES when compared with BMS, due to less TVR,
resulting in a net excess cost of E1968 per patient in the SES group, and reduced by a further E100
per patient in the second year. The incidence of death or myocardial infarction between groups was
similar at 1 and 2 years. Rates of TVR in the SES and BMS groups were 3.7% vs. 10.4%, P, 0.01 at
1 year, respectively; and 6.4% vs. 14.7%, P, 0.001 at 2 years. The ICER per TVR avoided was
E29 373 at 1 year, and E22 267 at 2 years.
Conclusion The use of SES, while significantly beneficial in reducing the need for repeat revasculariza-
tion, was more expensive and not cost-effective in the RESEARCH registry at either 1 or 2-years when
compared with BMS. On the basis of these results, in an unselected population with 1 year of follow-up,
the unit price of SES would have to be E1023 in order to be cost-neutral.
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Introduction
Drug-eluting stents have revolutionized the treatment of
coronary artery stenosis by systemically reducing the need
for re-intervention following stent implantation.1 The
pivotal European randomized trial comparing
sirolimus-eluting stents (SESs) with bare metal stents
(BMSs), RAVEL,2 paved the way for the definitive trial,
SIRIUS,3 conducted in the United States. These respective
trials led to its commercialization in Europe in 2002 and in
the United States in 2003. Confirmation of the efficacy of
SES over BMSs in a diverse unselected population was
made in the Rapamycin Eluting Stent Evaluated At Rotter-
dam Cardiology Hospital (RESEARCH) Registry with 14 and
2-year follow-up.5 More recently, the randomized BASKET
trial with 6 months follow-up concurred with the results of
RESEARCH.6
The market price of drug-eluting stents has almost unan-
imously been perceived as the major limitation for a more
widespread use of SES worldwide.7 On the other hand, the
striking decrease in the incidence of cardiac events with
the use of SES is theoretically associated with a reduction
in resource utilization, and therefore costs, during
follow-up. In the RAVEL trial, the treatment of a single
native de novo coronary lesion with SES was associated
with an increased procedural cost of E1286 over BMS,
which was reduced to an additional cost of E54 after
1 year of follow-up, mainly because of the lower frequency
of repeat revascularizations among SES-treated patients.8
Correspondingly, in the SIRIUS randomized trial, patients
treated with SES cost US$2881 more than BMS patients. At
1 year, aggregate costs narrowed but were still US$ 309
higher in SES patients.9 The incremental cost-effectiveness
ratio (ICER) for SES was US$1650 per repeat revasculariza-
tion avoided.
* Corresponding author. Tel: þ31 10 463 5260; fax: þ31 10 436 9154.
E-mail address: p.w.j.c.serruys@erasmusmc.nl
{ The results reported in this manuscript have been presented in part at the
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Although the cost-effectiveness profile of SES has been
assessed in the context of randomized trials,8,9 there is
limited information on the balance between costs and
effects of SES in the real world. In the present study, we per-
formed a prospective resource utilization and economic
evaluation during a 2-year follow-up period of the patients
treated in the RESEARCH registry.
Methods
Patient population and treatment strategy
The RESEARCH registry is a single-centre registry conducted with
the main purpose of evaluating the safety and efficacy of SES
implantation for patients treated in daily practice. Its study
design has been previously published.10 Briefly, since 16 April
2002, our institution has adopted a policy of using SES (Cypher;
Johnson & Johnson-Cordis unit, Cordis Europa, NV, USA) as the
default stent for every percutaneous coronary intervention. In the
first 6 months of enrolment, 508 patients with de novo lesions
were treated exclusively with SES (SES group) and compared with
a group of 450 consecutive patients treated with BMS for de novo
lesions in the preceding 6 months (pre-SES group). The total study
population thus comprised 958 patients divided into two sequential
cohorts, primarily distinguished by the interventional strategy
applied (BMS or SES implantation, respectively). This protocol was
approved by the hospital Ethics Committee and is in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from every patient.
All interventions were performed according to current standard
guidelines with the final interventional strategy (including use of
periprocedural glycoprotein IIb/IIIa inhibitors) at the operator’s dis-
cretion. All patients were advised to maintain lifelong aspirin. At
least 1-month clopidogrel treatment (75 mg/d) was recommended
for patients treated in the pre-SES phase. For patients treated
with SES, clopidogrel was prescribed for at least 3 months, unless
one of the following was present (in which case clopidogrel was
maintained for at least 6 months): multiple SES implantation (.3
stents), total stented length .36 mm, chronic total occlusion, and
bifurcations.
Determination of costs
For each index procedure, detailed resource use and costs were
recorded on a dedicated electronic database, together with the
actual costs for 2001 and 2002 and calculated on the basis of
equipment opened during the angioplasty, irrespective of its
actual use in the patient. With respect to costs, the analysis was
limited to direct medical costs. The actual price paid for per SES
was E1929 euros, while the average weighted price of a bare
stent in the study period was E692. Medication costs were
obtained for glycoprotein IIb/IIIa inhibitors and contrast, while
for the others, a reasonable assumption of E150 per patient was
made to cover the costs of other intra-procedural medications
(e.g. heparin, nitrates, saline, beta-blockers, etc.). The cost of
post-procedural clopidogrel in both groups was calculated on the
basis of duration of prescription determined at the completion of
the index procedure.
Lengths of hospital stay were calculated by querying the hospi-
tal’s admission and discharge database, which records the date of
admission and discharge, into and out of individual wards.
Consequently, admissions to a particular type of ward are con-
sidered on a per day basis. As this hospital is a tertiary referral
centre, the majority of discharges are to referring or peripheral hos-
pitals. Length of stay was calculated from the time of the procedure
up to the point of discharge from this hospital. Unit costs were esti-
mated on the basis of detailed information from our institution
following an approach similar to that reported previously.8
Follow-up costs were estimated according to the need for repeat
revascularization. As the incidence of death and myocardial infarc-
tion (MI) between both groups did not differ, they were not
costed.4,5 A re-intervention was defined as any target-vessel revas-
cularization (TVR) (percutaneous or surgical). Costs of
re-intervention were estimated as the product of the event multi-
plied by the cost per event taken from the RAVEL study, adjusted
for inflation.11 The costs of outpatient visits, related work-up, and
other ongoing medications were not tracked.
Determination of effectiveness and
cost-effectiveness analysis
Major adverse cardiac events were defined as (1) death, (2) non-
fatal MI, or (3) TVR. An MI was diagnosed by a rise in the creatine
kinase-MB fraction of more than three times the upper limit of
normal. A TVR was defined as a repeat intervention (surgical or per-
cutaneous) driven by any lesion located in the same epicardial
vessel(s) as the treated lesion(s). The results of both the 1 and
2-year clinical follow-up have been published.4,5
For the purposes of the cost-effectiveness analysis, the following
assumptions were required. The incidence of repeat revasculariza-
tion is given as whole numbers and the proportion estimated
according to the Kaplan–Meier method. There were a dispropor-
tionate number of post-procedural coronary angiograms performed
in the SES period, due to the repeat angiography mandated in
‘complex’ patients, typically with SES implanted in bifurcations,
left main coronary, chronic total occlusions, very small vessels,
long stented length (.36 mm), and acute MI.4 Because of the well-
known effect of angiographic re-evaluation in increasing the inci-
dence of repeat revascularization,12 all re-interventions in the
first year were retrospectively adjudicated and classified as clini-
cally driven or non-clinically driven by a group of clinicians not
involved in the treatment of the particular patient analysed.4
Clinically driven repeat revascularizations were defined as any
intervention motivated by a significant luminal stenosis (.50%
diameter stenosis) in the presence of anginal symptoms and/or
proven myocardial ischaemia in the target-vessel territory by
non-invasive testing. No mandated angiographic re-study was
performed in the pre-SES group.
In order to correct for the excess additional costs related to the
mandatory angiographic studies in the SES group, it was assumed
that the actual number of clinically driven restudies would be pro-
portionate to the number of clinically driven re-interventions.
Therefore, the number of patients that would have had clinically
driven angiography could be calculated from the figures found in
the pre-SES phase. As clinically driven re-interventions in the SES
phase were less frequent than in the pre-SES by a factor of 0.356,
the number of patients who would have undergone clinically
driven re-study in the absence of mandatory angiographic follow-up
was calculated as 0.356 proportion of patients in pre-SES group
with angiography  number of patients in SES group. From this, it
was estimated that 24 patients would have had a re-study in the
SES group.
Statistical analysis
Continuous variables are presented as mean+ SD and were com-
pared by means of the Student unpaired t-test. Categorical vari-
ables are presented as counts and percentages and compared by
means of the Fisher exact test. Resource use is reported on a per
patient basis. Cost data are reported as both mean and median
values and compared by t-tests. All statistical and cost-
effectiveness analysis were performed on an intention-to-treat prin-
ciple. All statistical tests were two-tailed.
The uncertainty surrounding the differences in costs and effects
were estimated using the bootstrapping technique. With bootstrap-
ping, average costs and effects were repeated 1000 times. Each
bootstrap provides a new estimate of average costs and average
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effects with the resulting 1000 estimates summarized in terms of a
distribution. Truncating the upper and lower 2.5% of the distribution
provides the 95% confidence intervals which are then demonstrated
visually. This is a useful method when the distribution cannot be
obtained in a classic way.13 Furthermore, additional graphical rep-
resentation of the bootstrapping results are presented with 5%,
50%, and 95% probability ellipses, to describe their degree of
uncertainty.
Cost-effectiveness was measured as the ICER per repeat revascu-
larization avoided. It is obtained by dividing the difference in
medical costs expended by our institution at the end of one and
2 years for the two treatment groups by the difference in repeat
revascularization rates over the same time frames.9
Results
Baseline and procedural characteristics
The RESEARCH registry was a real-world study into
drug-eluting stent use, and enrolled all-comers. The base-
line and procedural characteristics in Table 1 reflect the
complex patient demographics typically seen in a tertiary
referral centre for PCI. Both groups were reasonably well
matched for baseline characteristics, with the exception
of previous MI being more common in the pre-SES group.
Over half of the patients presented with an acute coronary
syndrome, and an acute MI was the reason for intervention
in 18% of patients.
Major adverse cardiac events
The 1 and 2-year results of the RESEARCH registry have been
published.4,5 Briefly, the combined outcome of death or MI
was similar and the difference in major adverse cardiac
events was driven by the reduction in the need for repeat
revascularization, defined as TVR in the SES group.
Similarly, at 2 years, the reduction in major adverse
cardiac events was again due to the reduction in TVR in
the SES group.
At the end of 1 year, less patients underwent a re-
intervention procedure in the SES group (3.65% in the SES
group as compared with 10.4% in the pre-SES group,
P , 0.001; Table 4, Figure 1). During the first year of
follow-up, because of mandated angiographic re-study, sig-
nificantly more patients underwent coronary angiography
in the SES period compared with the BMS period, 175 vs.
59, P, 0.001). At 2 years, the difference in re-intervention
Table 1 Baseline and procedural characteristics
Pre-SES group (n ¼ 450) SES group (n ¼ 508) P-value
Male, n (%) 317 (72) 345 (68) 0.4
Age, years+ SD 61+ 11 61+ 11 0.7
Diabetes, n (%) 67 (15) 90 (18) 0.3
Non-insulin-dependent, n (%) 49 (11) 60 (12) 0.7
Insulin-dependent, n (%) 18 (4) 30 (6) 0.2
Hypertension, n (%) 169 (48) 210 (41) 0.2
Hypercholesterolaemia, n (%) 249 (55) 282 (56) 1.0
Current smoking, n (%) 153 (34) 156 (31) 0.3
Previous MI, n (%) 176 (40) 152 (30) 0.002
Previous angioplasty, n (%) 81 (18) 95 (19) 0.8
Previous coronary bypass surgery, n (%) 36 (8) 47 (9) 0.5
Single-vessel disease, n (%) 235 (52) 232 (46) 0.05
Multivessel disease, n (%) 215 (48) 275 (54) 0.05
Clinical presentation — — 0.8
Stable angina, n (%) 214 (48) 227 (45) —
Unstable angina, n (%) 156 (35) 189 (37) —
Acute MI, n (%) 80 (18) 92 (18) —
Cardiogenic shock, n (%)a 9 (12) 9 (10) 0.7
Treated vessel
Left anterior descending, n (%) 267 (59) 298 (59) 0.8
Left circumflex, n (%) 149 (33) 161 (32) 0.7
Right coronary artery, n (%) 153 (34) 196 (39) 0.2
Left main coronary, n (%) 10 (2) 15 (3) 0.6
Bypass graft, n (%) 9 (2) 17 (3) 0.2
Lesion type
Type A, n (%) 88 (20) 111 (22) 0.4
Type B1, n (%) 143 (32) 156 (31) 0.7
Type B2, n (%) 223 (50) 247 (49) 0.8
Type C, n (%) 134 (30) 216 (43) 0.000
Bifurcation stenting, n (%) 35 (8) 80 (16) 0.000
Number of stented segments+ SD 1.8+ 0.9 2.0+ 1.0 0.000
Individual stent length 33 mm, n (%) 44 (10) 178 (35) 0.000
Total stented length per patient, mm+ SD 30.1+ 19.6 38.7+ 28.7 0.000
Nominal stent diameter 2.5 mm, n (%) 102 (23) 183 (36) 0.000
Post-dilatation with a balloon 0.5 mm larger, n (%) 85 (19) 249 (49) 0.000
Angiographic success of all lesions, n (%) 438 (97) 494 (97) 1.0
aRelative to acute MI.
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rates widened from 6.75 to 8.3%. (a cumulative incidence of
6.4 vs. 14.7% respectively, P, 0.001).
Resource use at index procedure
The procedural equipment use is listed in Table 2 with the
results expressed as mean number of items consumed per
patient. On a per patient basis, significantly more guiding
catheters, coronary wires, balloons, and contrast were
used, and more stents were implanted resulting in a
longer procedural time in the SES phase compared with
the pre-SES phase. This reflects the increased complexity
of cases seen in the SES phase. Post-procedurally, total
in-hospital stay at our institution was similar, 2.6 days in
the pre-SES phase and 2.0 days in the SES group, P ¼ 0.15.
Costs of index procedure
The overall average per patient cost of the index procedure
was E6887 in the pre-SES group and E9924 in the SES group,
an excess of E3036 in the SES group (Table 3), driven by the
difference of E2925 due to the price premium of SES.
Costs at follow-up
At 1-year follow-up, the difference in costs had narrowed
from E3036 to E1968 due to the reduction in
re-interventions (Table 4). At the end of 2 years following
the index procedure, this difference further narrowed to
E1869, due to a non-significantly fewer number of events
in the SES group in the second year of follow-up.
Cost effectiveness
Figures 2 and 3 depict the estimated differences in costs and
effectiveness of SES vs. BMS, at 1 and 2 years. All estimates
lie in the right-upper quadrant, indicating that SES are
clearly more effective but also more costly than BMS. Note
that the ellipse in Figure 4 is shifted downwards and out-
wards in the 2-year follow-up, as compared with the
1-year follow-up, although not significantly.
On the basis of costs and results obtained from the
RESEARCH registry, the ICER was then calculated. In the
1-year analysis, the ICER for SES was calculated at E29 373
per repeat revascularization avoided; while at the end of
2 years, this number had decreased to E22 627 per repeat
revascularization avoided (Table 4).
From this ratio, a straight-line relationship exists between
the unit price of a new device vs. the ICER at a given unit
price of the old device (Figure 4). Thus, at a price of E692
per bare stent for the bare stent group (the actual
average weighted price of BMSs in this registry), the calcu-
lated cost neutral price for the DES would be E1023 with
the 1-year result of this registry, while at the maximum
acceptable threshold of E10 000 per repeat revasculariza-
tion avoided,9 the highest price would be E1336 per DES.
At 2 years, the cost neutral price and the cost at the
E10 000 threshold declined slightly (E1069 and E1452,
respectively) due to the non-significant reduction in events
in the second year.
Discussion
The primary finding of this analysis of the RESEARCH registry
is that based on the price of E1929 per SES paid by our insti-
tution in April 2002, the unrestricted use of SES was not
cost-effective to our institution, at either 1 or 2 years,
using the acceptable maximum threshold of E10 000 per
repeat revascularization avoided. Using 1-year costs and
effects, the calculated cost-neutral price for SES was
E1023; while at the acceptable threshold of E10 000 per
repeat revascularization avoided, the calculated price was
E1336 per SES. With the inclusion of second year costs, in
association with a further non-significant reduction in
events in the second year, the cost neutral price was
E1069 or E1452 at the E10 000 threshold.
Specific features of this study
As a tertiary referral centre with a feeder population of 14
peripheral hospitals, our institution has a policy of returning
stable patients to their referral hospital or to the hospital in
their catchment area. Unstable patients and patients from
our catchment area are treated at our institution until
such time that they are suitable for discharge home or dis-
charge to their local hospital. In the combined population,
only 4.1% of patients were admitted for longer than 10
days at our institution.
The introduction of SES in the second period of the
RESEARCH registry created a real-world imbalance. Despite
similar presenting symptoms and clinical characteristics,
more segments were treated, resulting in longer stented
lengths and the use of more stents. Although this resulted
in higher costs to the SES group, it reflects daily practice
outside of clinical trials, where the introduction of DES has
resulted in the implantation of more stents. Furthermore,
the ongoing use of DES at our institution resulted in the treat-
ment of more complex patients, with even longer stented
lengths implanted in the following year.14
Costs outside randomized trials
Cost-effectiveness studies from the randomized RAVEL and
SIRIUS trials have been published. In both these studies,
use of SES resulted in additional 1-year costs of E166 and
US$309 in the SES groups, respectively (NB E1  US$1.30
April 2005). The additional cost of DES was effectively
negated by the decreased follow-up costs resulting from a
decrease in the need for repeat intervention. In this
present study, the reduction in follow-up costs were insuffi-
cient to compensate for the elevated index cost, when
Figure 1 Clinically driven re-intervention (TVR) in the RESEARCH Registry
at 2-year follow-up.
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measured at the end of either 1 or 2 years. The respective
excess cost in the SES group were E1968 and E1869,
respectively, much higher than that reported from the ran-
domized trials. This reflects the results of DES use outside
of trials.
Acceptable cost of DES outside randomized trials
The results of RAVEL and SIRIUS would suggest that the
prices of DES of E2000 and US$2900 are reasonably cost-
effective. At the time this registry was conducted, the
price of DES paid for by our institution was E1929 while
the price of bare stents was E692, reflecting the prices of
April 2002. Since that time, paclitaxel-eluting stents
(Boston Scientific Corporation) have been introduced, and
zotarolimus-eluting stents (Medtronic Corporation) have
recently received CE mark certification. This increased com-
petition, together with an increasing market share of DES,
will serve to bring down prices of DES to that judged as cost-
effective in our model. Correspondingly, as the market share
of BMSs shrink, their prices will also fall, thus necessitating
that the price of DES fall even further than that predicted.
Given a not unreasonable bare stent price of E400 today, a
DES would have to fall to E779 to be cost-neutral within the
framework of the model presented here.
Comparison with other ‘real-world’ trials
The BASKET ‘real-world’ randomized study demonstrated
that at 6 months, DES were on average, E905 more
Table 2 Resource use at index procedure
Index procedure BMS (n ¼ 450) SES (n ¼ 508) Difference (95% CI) P-value
Equipment use during the index
procedure, expressed as units used
per patient unless stated otherwise
Basic diagnostic packet (includes 0.035 in. wire) 1.00 1.01 0.00 (20.01; 0.01) 0.5
Diagnostic catheter, n 0.63 0.50 0.13 (0.01; 0.25) 0.03
Guiding catheter, n 1.43 1.59 20.16 (20.27; 20.05) 0.003
Additional 0.035 in. wire, n 0.16 0.19 20.03 (20.09; 0.03) 0.3
0.014 in. coronary wire, n 1.62 2.07 20.45 (20.63; 20.28) ,0.001
Coronary balloon, n 1.30 1.81 20.50 (20.68; 20.32) ,0.001
Multifunctional probing catheter, n 0.08 0.06 0.02 (20.01; 0.05) 0.3
Pressure/Flow/Doppler wire, n 0.08 0.07 0.10 (20.03; 0.05) 0.6
IVUS catheter, n 0.15 0.18 20.02 (20.08; 0.03) 0.4
Atherectomy catheter, n 0.01 0.01 0.00 (20.01; 0.01) 0.9
Cutting balloon, n 0.03 0.02 0.01 (20.01; 0.03) 0.3
Thrombectomy catheter, n 0.00 0.01 20.01 (20.02; 0.01) 0.4
Distal protection device, n 0.01 0.01 0.00 (20.02; 0.01) 0.5
Swan Ganz catheter, n 0.02 0.04 20.01 (20.03; 0.01) 0.3
Temporary pacing wire, n 0.02 0.02 20.01 (20.02; 0.01) 0.5
Intra-aortic balloon pump, n 0.02 0.02 0.01 (20.01; 0.02) 0.5
Femoral artery closure device, n 0.47 0.53 20.06 (20.13; 0.01) 0.08
Bare stent, n 1.81 —
Covered stent, n 0.01 —
Drug-eluting stent, n — 2.16
Contrast volume, mL+ SD 253+ 118 284+ 137 231 (249; 212) 0.001
Abciximab use, % 33 19 14 (8; 20) ,0.001
Clopidogrel prescription, months+SD 2.9+ 2.0 4.0+ 2.0 21.1 (21.4; 1.0) ,0.01
Procedure time, mins+ SD 92+ 43 107+ 48 215 (221;2 9) ,0.001
Post-procedural hospital stay
ICU, days 0.06+ 0.75 0.01+ 0.11 0.05 (20.01;0.12) 0.12
CCU, days 0.56+ 1.87 0.54+ 2.14 0.02 (20.24;0.28) 0.9
General ward, days 2.27+ 4.76 1.56+ 4.1 0.71 (0.15;1.27) 0.01
Table 3 Costs at index procedure, expressed on a per patient basis
Index procedure BMS SES Difference (95% CI of the difference) P-value
Cost of stents, E+ SD 1266+ 771 4192+ 2791 22925 (23192; 22659) 0.000
Cost of consumables (excluding stents),
E+ SD
1575+ 772 1819+ 938 2244 (2353; 2134) 0.000
Medication, E+ SD 765+ 529 685+ 473 79 (15; 143) 0.015
Laboratory cost, E+ SD 1790+ 841 2078+ 937 2288 (2401; 2174) 0.000
Post-procedural hospital stay, E+ SD 1491+ 3323 1150+ 3350 341 (283; 2765) 0.11
Total cost at index, E+ SD 6887+ 3962 9924+ 5734 23036 (23669; 22403) 0.000
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expensive per patient when compared with BMS. In that
study, the price difference between DES and BMS were con-
siderably less than in this study, resulting in a calculated
ICER of less than E20 000 per major event avoided, as
opposed to the E29 373 at 1 year, and E22 627 at 2 years
per repeat revascularization avoided in our series. Despite
the smaller difference, the results of the present study are
in concordance with their findings, and has the advantage
of extended follow-up out to 2 years.
Implications of prolonged follow-up
A specific feature of this report is the prolonged follow-up
out to 2 years. The non-significant widening of the treat-
ment effect from the first to the second year resulted in low-
ering of the ICER by almost E7000, but not sufficient to
make the finding cost-effective. It remains to be seen if pro-
longed follow-up out to 5 years will equalize the groups,
however, most cost-effectiveness studies are generally
limited to short-term follow-ups of 1 year.
Applicability to other drug-eluting stent systems
and to newer bare-stent systems
This study was a specific comparison between SES and BMS,
and since both pricing and efficacy of the different DES
systems in the market today vary, the results of this study
may not be totally generalizable to other systems.
However, given the ongoing price premium and better out-
comes of DES, this study may therefore be used as a guide.
Similarly, there are now newer generation BMS, such as
those incorporating non-drug-eluting coatings (e.g. carbon-,
titanium oxide-, and CD34 antibody-coated stents),15,16
which have demonstrated better restenosis rates than con-
ventional BMS used in this study and consequently, the possi-
bility exists that the differential benefit of DES may be
reduced when compared against these newer BMS devices.
Limitations
By design, the costs in this study specifically reflect pro-
cedural and follow-up costs directly impacting on our insti-
tution. It is therefore an institutional as opposed to a
Figure 2 Estimates of differences in cost and effects after bootstrapping
analysis based on the normal distributions surrounding the estimates of the
relative risks at one (top panel) and 2 years (bottom panel), respectively.
All points reside in the top-right quadrant, signifying that SESs are more
effective, but more expensive than BMSs, both at 1 and at 2 years following
implantation.
Table 4 Costs, effectiveness, differences in costs and effectiveness at the end of 1 and 2 years, expressed on a per patient basis
Follow-up events BMS
events, n
BMS
events, %
BMS
cost, E
SES
events, n
SES
events, %
SES
cost, E
Difference,
(95% CI)a
First year of follow-up
Clinically driven
repeat revascularization
45 10.4b 18 3.65b 6.75 (3.0;9.4)
Re-PCI 35 8.1 695 16 3.3 279
CABG 10 2.3 393 2 0.4 69
Total coronary angiography 59 13.1 506 175 3.45 177
Total follow-up cost 1594 525c
Total cost at 1 year 8481 10 449 2E1968 (2E2854;
2E1212) ICER ¼ 29 373
(14 659; 83 884)
Second year of follow-up
Repeat revascularization 18 4.3 13 2.75 8.3 (3.8;11.4)
Re-PCI 16 3.8 331 11 2.3 203
CABG 2 0.5 82 2 0.4 73
Coronary angiography 17 3.8 148 24 4.7 185
Total follow-up cost 561 461
Total cost at 2 years 9042 10 911 2E1869 (E2796;
E1080) ICER ¼ 22 627
(10 737; 65 978)
a95% confidence intervals calculated using the bootstrap method. The comparison of costs and effectiveness are presented in Figures 3 and 4.
bEvent rate derived from Kaplan–Meier estimates.
cCorrection factor of 0.35 applied to coronary angiograms in the SES phase relative to the BMS phase.
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societal analysis, and therefore underestimates the true
overall societal cost by not accounting for total length of
stay in other hospitals nor costs associated with follow-up
visits and work-up for recurrent symptoms. This was a
necessary limitation, given the tertiary referral nature of
our practice and the multiple complex co-morbidities seen
in this ‘real-world’ population.
Conclusion
The lower differential effect in real-world outcomes,
together with increased material use compared with ran-
domized trials combine to reduce the cost-effectiveness of
SESs compared with BMSs. On the basis of our findings,
prices of SES need to be further reduced in order to
become cost-effective.
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Abstract
Objective: Vital exhaustion is associated with the pathogenesis
of cardiovascular disease (CVD), but its prevalence after percuta-
neous coronary intervention (PCI) with drug-eluting stent implan-
tation, as well as the impact of personality on exhaustion, is not
known. In PCI patients, we examined (a) the prevalence of
exhaustion, (b) the impact of type-D personality on exhaustion
over time, and (c) the clinical significance of type-D personality
compared with gender and age as predictors of exhaustion.
Methods: Consecutive patients (n=419) with stable or unstable
angina treated with PCI with drug-eluting stent implantation
completed the Type-D Scale (DS14) at baseline and the Maastricht
Questionnaire (which assesses exhaustion) at baseline and at 1 year.
Results: Of all patients, 53% were exhausted at baseline and at
1 year, with 41% experiencing chronic symptoms. Type-D patients
[F(1, 417)=98.688; Pb.001] had significantly higher exhaustion
levels than non type-D patients both at the time of the index PCI
and at 1 year. There was a general improvement in symptoms of
exhaustion over time [F(1, 417)=5.005; P=.03], but type-D
exerted a stable effect on exhaustion (P=.06). In multivariable
analysis, type-D (OR=3.53; 95% CI=1.88–6.64) remained an
independent predictor of exhaustion at 1 year, adjusting for
demographic and clinical risk factors and exhaustion at baseline.
The impact of type-D on exhaustion was large compared with a
small effect for gender and age, as measured by Cohen’s effect
size index. Conclusions: Symptoms of exhaustion were still
highly prevalent in PCI patients 1 year post-PCI despite treatment
with the latest technique in interventional cardiology. Type-D
exerted a large and stable effect on exhaustion compared with
that of gender and age. CVD research and clinical practice may
benefit by adopting a personality approach in order to identify
high-risk patients.
D 2007 Elsevier Inc. All rights reserved.
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Introduction
Vital exhaustion is a mental state characterized by
unusual fatigue, demoralization, and increased irritability
[1]. Exhaustion is an etiological risk factor for ischemic heart
disease and all-cause mortality in healthy individuals [2] and
a prognostic risk factor for adverse health outcomes in
patients following percutaneous coronary intervention (PCI)
and myocardial infarction (MI) [3–6]. The risk associated
with exhaustion in patients with established cardiovascular
disease (CVD) ranges from two- to three-fold [3,5], making it
a risk factor on par with traditional biomedical risk factors
[6,7]. Of note, exhaustion is not merely a marker of
subclinical CVD but a risk factor in its own right [3].
Symptoms of exhaustion have been linked to inflamma-
tion [8,9], cytomegalovirus, Chlamydia pneumoniae [9,10],
lower levels of cortisol and adrenocorticotropic hormones
[11,12], impaired fibrinolysis [13], and low vagal tone [14],
4 Corresponding author. CoRPS, Department of Medical Psychology,
Room P503a, Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE
Tilburg, The Netherlands. Tel.: +31 13 466 2503; fax: +31 13 466 2370.
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all of which have been associated with the pathogenesis of
CVD. Conceptually, exhaustion shares several features with
depression, and results are conflicting as to their independ-
ence [15,16]. Hence, this is the subject of an ongoing
debate. To fuel the debate, a recent study found that
exhaustion and self-rated health, but not depression, were
associated with increased inflammation in women with
CVD [17].
The recent Exhaustion Intervention Trial (EXIT) showed
that although symptoms of exhaustion were reduced by 55%
following a behavioral intervention, this benefit was only
seen in patients without a previous history of CVD [18].
Similarly, only patients without a previous history of CVD
experienced a 60% reduction in the risk of adverse health
outcomes, whereas the intervention did not lead to overall
enhanced survival at 2 years follow-up [18].
Although the EXIT increases our knowledge of factors
that may impede changes in exhaustion and subsequent
benefits to survival, little is known about the impact of
personality on exhaustion. Knowledge of the predictors of
exhaustion may lead to more successful intervention trials in
the future. In addition, focus on patient-centered outcomes,
such as exhaustion and its determinants, may bridge the gap
between research and clinical practice [19].
In a previous study conducted in the pre-drug-eluting
stent era, we identified type-D personality as a predictor of
exhaustion in a mixed group of cardiac patients pre- and
post-treatment with PCI, coronary artery bypass graft
(CABG) surgery, or conservative treatment [20]. Type-D
is defined as the tendency to experience increased negative
emotions paired with the non-expression of these emotions
in social interactions [21]. Type-D is an emerging risk factor
in CVD that has been associated with an increased risk of
adverse prognosis [22–26]. However, given that the use of
drug-eluting stents has been associated with a significant
decrease in the risk of restenosis and the need for repeat
revascularization [27] and that exhaustion plays a role in the
etiology of restenosis post-PCI, it is not clear whether
exhaustion remains a problem in the drug-eluting stent era.
The current study was conducted in a series of consec-
utive PCI patients treated with the paclitaxel-eluting stent
(PES) as the default stent. The aims were to (a) evaluate the
prevalence of symptoms of exhaustion, (b) examine the
impact of type-D personality on exhaustion at the time of
the index PCI and at 1 year, and (c) compare the clinical
significance of type-D personality with gender and age as
predictors of exhaustion.
Materials and methods
Study design and participants
Consecutive patients with stable or unstable angina,
treated with PCI at the Erasmus Medical Center Rotterdam
using PES as the default strategy between July 1, 2003, and
July 1, 2004, qualified for inclusion in the current study. Of
the 845 patients treated during this period, 19 patients died
within the first month and 116 were excluded due to
insufficient knowledge of the Dutch language. The remain-
ing 710 patients were approached and asked to complete a
number of psychological questionnaires 4 weeks post-PCI,
of whom 536 (75%) agreed. In the remainder of the article,
we will refer to this assessment as baseline. Although
assessment at 4 weeks was adapted for logistic reasons,
preliminary evidence suggests that psychological assess-
ment at the time of PCI may be less optimal than 1 month
post-procedure [28].
Given that we used a prospective design, analyses are
based on 419 patients, who had a score on the relevant
psychological questionnaires both at baseline and at follow-
up. See Fig. 1 for a flowchart of the patient selection for the
current study.
The study was approved by the local medical ethics
committee and conducted in accordance with the Helsinki
Declaration. Written informed consent was provided by
all patients.
Materials
Socio-demographic and clinical variables
Socio-demographic variables included gender and age.
Information on clinical variables, that is, indication for PCI
(stable or unstable angina), stent type (PES, sirolimus-
eluting stent, or other), multivessel disease, previous cardiac
history (i.e., MI, PCI, or CABG prior to the index PCI),
hypertension, dyslipidemia, diabetes mellitus, smoking, and
cardiac medication (aspirin, beta-blockers, diuretics, ACE
inhibitors, and statins), was obtained from the patients’
medical records.
Fig. 1. Flowchart of patient selection.
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Type-D personality
We used the Type-D Scale (DS14) to assess the
distressed (type-D) personality [21]. The scale consists of
14 items that are answered on a five-point Likert scale from
0 (false) to 4 (true). Seven items tap negative affectivity,
and seven items tap social inhibition (score range, 0–28 for
each subscale). Type-D caseness is defined by a high score
on both subscales, as determined by a standardized cut-off
score z10 [21]. The DS14 is a valid and reliable scale with
Cronbach’s a=.88/.86 and 3-month test–retest reliability
(r)=.72/.82 for the negative affectivity and social inhibition
subscales, respectively [21]. Type-D personality is more
than negative affect, as it also takes into account how
patients deal with this affect through the inclusion of the
social inhibition component [21,22]. The DS14 was
administered at baseline.
Vital exhaustion
The Maastricht Questionnaire (MQ) was used to assess
symptoms of exhaustion [1]. The questionnaire consists of
21 items that are answered on a three-point scale (0=no;
1=?; 2=yes), with a score range of 0–42. We used a
standardized cutoff score z14 to identify patients who were
exhausted [18,29]. The reliability of the scale, as measured
by Cronbach’s a, is .89 [1]. The MQ was administered both
at baseline and at 1 year post-PCI. Patients were asked to
complete the MQ items with regard to how they felt at the
time of completing the questionnaire; hence, answers were
not prone to recall bias.
Statistical analyses
Discrete variables were compared with the chi-square
test (Fisher’s exact test when appropriate), whereas
continuous variables were compared with Student’s t test
for independent samples. Analysis of variance (ANOVA)
for repeated measures was used to examine whether the
impact of type-D was stable over time. Univariable and
multivariable logistic regression analyses were used to
examine the impact of type-D personality on exhaustion at
1 year. Prior to analyses, we dichotomized vital exhaustion
using a standardized cutoff, with a score z14 indicating
those who are exhausted [18,28]. Exhaustion scores were
dichotomized to be able to compare results with previous
research and to enhance clinical interpretability, as advo-
cated by others [30,31]. In multivariable analyses, we
entered type-D personality, baseline exhaustion, gender,
age, indication for PCI, stent type, multivessel disease,
previous cardiac history (defined as MI, PCI, or CABG
prior to the index PCI), hypertension, dyslipidemia,
diabetes, and smoking. Cohen’s effect size index was used
to evaluate the clinical significance of type-D personality
compared with gender and age as predictors of exhaustion
[32]. An effect size of 0.20, 0.50, and z0.80 is considered
small, moderate, and large, respectively. We used a P value
b .05 to indicate statistical significance. Odds ratios (ORs)
with 95% confidence intervals (CIs) are reported.
All statistical analyses were performed using SPSS 12.0.1
for Windows (SPSS, Chicago, IL, USA).
Results
Differences between responders and non-responders on
baseline characteristics
Excluded patients and non-responders on psychological
questionnaires were more likely to smoke (22% vs. 14%;
P=.003) but less likely to suffer from dyslipidemia (63% vs.
74%; P=.001) than responders. No other differences
were found between excluded patients/non-responders
and responders on baseline characteristics, including
cardiac medication.
Patient baseline characteristics stratified by personality
Of the 419 patients, 104 (25%) had a type-D personality.
Baseline characteristics stratified by personality type are
shown in Table 1. Except for type-D patients being more
likely to be prescribed diuretics compared with non type-D
patients (5% vs. 1%; P=.02), no differences were found on
baseline characteristics between the two personality types.
Both at baseline and at 1 year post-PCI, 53% of the
patients were exhausted according to the predetermined cut-
off score z14. Of the 419 patients, 173 (41%) experienced
chronic symptoms, that is, a score z14 on the MQ both at
baseline and at 1 year. Exhaustion at 1 year could not be
Table 1
Baseline characteristics stratified by personality type
Type-D
(n=104)
Non type-D
(n=315) P
Demographics
Males 79 (76) 235 (75) .88
Age, mean (S.D.) 62 (10) 63 (11) .30
Indication for PCI
Unstable angina 55 (53) 137 (44) .12
Stent type
PES 91 (88) 284 (90) .56
Clinical variables
Multivessel disease 58 (56) 193 (61) .38
Previous cardiac historya 55 (53) 174 (55) .76
Hypertension 51 (49) 151 (48) .94
Dyslipidemia 82 (79) 237 (75) .54
Diabetes mellitus 23 (22) 57 (18) .45
Current smoking 12 (12) 39 (12) .96
Cardiac medication
Aspirin 100 (96) 302 (96) 1.00
Beta-blockers 23 (22) 71 (23) 1.00
Diuretics 5 (5) 2 (1) .024
ACE inhibitors 13 (13) 25 (8) .23
Statins 74 (71) 239 (76) .41
Values are expressed as n (%) unless otherwise specified.
a MI, PCI, or CABG prior to the index PCI.
4 Pb.05.
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attributed to a cardiac event (i.e., MI, PCI, or CABG) during
follow-up (12% vs. 7%; P=.07).
Impact of type-D personality on exhaustion
As indicated in Fig. 2, ANOVA for repeated measures
showed that type-D patients [F(1, 417)=98.688; Pb.001]
had significantly higher mean exhaustion scores compared
with non type-D patients both at the time of the index PCI
and at 1 year. The within-subjects effect for time was also
significant [F(1, 417)=5.005; P=.03], indicating a general
decline in symptoms of exhaustion over time. The type-
Dtime interaction effect was not significant [F(1,
417)=3.702; P=.06], showing that type-D exerted a stable
effect on exhaustion over time.
Patients with chronic exhaustion, defined as exhaustion
both at baseline and at 1 year, were more likely to have a
type-D personality compared with patients with exhaustion
at either baseline or follow-up alone or exhaustion at neither
time points, with patients in the no-exhaustion group having
the lowest prevalence of type-D [v2(3, N=419)=58.822;
Pb.001] (Fig. 3).
In univariable analyses, type-D was associated with a
five-fold increased risk of exhaustion at 1 year post-PCI
(OR=5.53; 95% CI=3.23–9.45; Pb.001).
Independent predictors of exhaustion at 1 year
In multivariable analysis, type-D (OR=3.53; 95% CI=
1.88–6.64; Pb.001) remained an independent predictor of
exhaustion at 1 year with a three-fold increased risk,
adjusting for demographic (gender and age) and clinical
risk factors (unstable angina, stent type, multi-vessel
disease, cardiac history, hypertension, dyslipidemia, diabe-
tes, and smoking) and exhaustion at baseline (Table 2).
Exhaustion at baseline (OR=9.33; 95% CI=5.73–15.19;
Pb.001) was also an independent predictor of exhaustion
at follow-up.
Clinical significance of type-D personality versus gender
and age
Given that gender and age are individual difference
variables routinely included in CVD research, we wanted to
evaluate the clinical significance of type-D compared with
gender and age z60 in relation to exhaustion, using Cohen’s
effect size index. We found that the effect of type-D on
symptoms of exhaustion was large both at baseline and at
1 year, whereas the effect of gender was small and that of
age was negligible at both time points (Fig. 4). In other
words, although the effects of gender, age, and type-D on
exhaustion were stable over the 1-year period, they had a
significantly differential effect on exhaustion.
Fig. 2. Exhaustion (mean scores) stratified by type-D personality at baseline
and at 1 year post-PCI. Mean scores (F standard deviations) are presented
on top of bars.
Fig. 3. Prevalence of type-D personality stratified by chronicity of
exhaustion.
Table 2
Predictors of exhaustion at 1 year (multivariable analysis)
OR 95% CI P
Type-D personality 3.53 1.88–6.64 b.0014
Exhaustion at baseline 9.33 5.73–15.19 b.0014
Males 0.81 0.45–1.43 .46
Age 1.01 0.99–1.04 .39
Unstable angina 0.96 0.59–1.56 .86
PES 2.12 0.94–4.76 .07
Multivessel disease 0.97 0.58–1.62 .92
Previous cardiac historya 1.48 0.90–2.43 .13
Hypertension 0.66 0.40–1.10 .11
Dyslipidemia 0.72 0.41–1.28 .26
Diabetes mellitus 1.64 0.87–3.11 .13
Current smoking 0.78 0.36–1.69 .53
a Previous MI, PCI, or CABG.
4 Pb.001.
Fig. 4. Clinical relevance of type-D personality versus age and gender as
determinants of exhaustion at baseline and at 1 year.
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Discussion
This is the first study to examine levels of exhaustion and
the impact of personality on exhaustion in PCI patients
treated in the drug-eluting stent era. The prevalence of
exhaustion at the time of the index procedure and at 1 year
was 53%, with 41% experiencing chronic symptoms. This
indicates that exhaustion is also highly prevalent in the
drug-eluting stent era. Patients with a type-D personality
experienced significantly higher levels of exhaustion both at
baseline and at 1 year, with type-D exerting a stable effect
over time. Type-D was also an independent predictor of
exhaustion 1 year post-PCI and was associated with a three-
fold increased risk, adjusting for demographic and clinical
baseline characteristics and exhaustion at baseline.
Despite treatment with PCI with drug-eluting stents, we
found that exhaustion is still highly prevalent, with 41%
being exhausted at both time points and, hence, experienc-
ing chronic, persistent exhaustion. This suggests that, once
present, exhaustion remains relatively stable and may not
abate with time. Similar prevalence rates have been found in
studies conducted in the pre-drug-eluting stent era in PCI
patients [29] and mixed cardiac patients [20]. In the latter
study, the prevalence of exhausted patients decreased from
75% at baseline to 59% following treatment [20]. However,
it should be noted that the baseline assessment took place
prior to PCI, CABG, or conservative treatment and that
these prevalences were point prevalence rates and do not
reflect levels of chronic symptoms.
Type-D personality was shown to exert a stable effect on
exhaustion during the 1-year follow-up period. In addition,
type-D was an independent predictor of exhaustion at 1 year
post-PCI, even when adjusting for demographic and clinical
characteristics and exhaustion at baseline, with the risk
being three-fold. This finding is at odds with a prospective
study on personality predictors of chronic fatigue in a
sample of working men and women, which found that the
impact of personality is negligible when adjusting for
baseline fatigue [33]. However, the latter study investigated
the impact of single personality traits rather than the
combination of traits, used fatigue as the outcome measure
rather than the broader construct of exhaustion, and was
conducted in a healthy population rather than in CVD
patients. In a previous study of a mixed group of cardiac
patients in the pre-drug-eluting stent era, we also found that
type-D personality was an independent predictor of exhaus-
tion at baseline and at follow-up, but in this study, we did
not adjust for baseline scores of exhaustion [20].
The results of the current study have implications for
research and clinical practice. Symptoms of exhaustion are
still highly prevalent in the drug-eluting stent era, with
future studies needing to investigate whether exhaustion is
also related to adverse clinical outcome in this era. More
importantly, these symptoms persisted over time, which
has also been shown by others, both in CVD patients
[18,20] and in a healthy sample [34]. Although the EXIT
trial demonstrated that a behavioral intervention can
successfully alleviate symptoms of exhaustion leading to
improved prognosis, this benefit was only seen in patients
without a previous cardiac history [18]. In other words, we
still have no means by which to reduce exhaustion in
patients with a previous cardiac history and enhance their
survival, although several suggestions have been put
forward in a recent substudy of the EXIT trial that examined
the impact of the intervention on quality of life and other
secondary outcomes [35]. These suggestions comprise the
targeting of inhibition and hostility in future intervention
trials and to be aware of potential limiting factors, such as
chronic, painful comorbidities (e.g., rheumatism).
Future studies also need to examine the potential
interrelationship between exhaustion and depression.
Exhaustion and depression conceptually share several
features, and to date, results as to their independence have
been conflicting [15,16]. This knowledge is important to
reduce the burden to patients and for epidemiological
research, given the limited number of questionnaires that
can usually be included in a study design.
The current study pointed to type-D personality as an
important predictor of exhaustion, with type-D exerting a
stable and clinically significant effect compared with the
effect of gender and age. Gender and age are routinely
included in CVD research, whereas, to a large extent, a
personality approach has been abandoned since inconsistent
results in relation to the type-A Behavior Pattern were
reported [36]. The findings of the current study and other
studies [23–26] indicate that a personality approach may be
advantageous in terms of identifying high-risk patients.
However, the ensuing question is that if type-D personality
is an all-important predictor of exhaustion, how do we
modify its impact on exhaustion and other health outcomes?
Undoubtedly, it will be important to teach type-D patients to
cope with stress in a different way, which can be done by
means of a combination of cognitive behavioral therapy,
psychotherapy, and relaxation therapy. However, designing
an intervention trial targeting type-D at this point in time is
somewhat premature, as we know very little about the
moderators and mechanisms that may relate type-D to
adverse health outcome, be they physiological or behavioral
or a combination thereof. In other words, attention should
now be focused on research into these moderators and
mechanisms, which may, on the long term, lead to the
designing of more successful intervention trials.
The results of the current study should be interpreted
with some caution. First, the response rate was 75%, with
non-responders/excluded patients being more likely to
smoke but less likely to suffer from dyslipidemia than
responders. Second, we only included patients with stable or
unstable angina, and the results may not generalize to
patients, who had an acute MI as indication for PCI.
Nevertheless, the studying of patients with angina is
important since psychosocial factors have also been shown
to predict mortality in these patients [37]. Third, we had no
Vital exhausti on in a PCI populati on | Chapter 31
335
information on participation in cardiac rehabilitation and the
use of psychotropic medication, such as antidepressants,
which could potentially influence levels of exhaustion.
Fourth, there is evidence to suggest that the Maastricht
Interview for Vital Exhaustion may have better predictive
validity concerning future cardiac events than the self-report
MQ [38], which was used in the current study. However, the
MQ has also been shown to predict future adverse clinical
events [3,5] and is a more feasible instrument to use in
clinical research and practice. An advantage of the current
study was its prospective design with the assessment of
exhaustion at two time points.
In conclusion, the results of the current study show that
exhaustion is still highly prevalent in PCI patients treated in
the drug-eluting stent era and that symptoms remain
relatively stable over a 1-year period. Type-D personality
exerted a three-fold increased risk even when adjusting for
baseline exhaustion in addition to demographic and clinical
characteristics. When comparing the clinical relevance of
type-D with gender and age, two characteristics that are
routinely included in CVD research, a large effect was
found for type-D, whereas small effects were found for
gender and age. CVD research and clinical practice may
benefit by adopting a personality approach in order to
identify high-risk patients.
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Abstract
Objective: We investigated the relative effects of fatigue,
depressive symptoms, and hopelessness on prognosis at 2-year
follow-up in percutaneous coronary intervention (PCI) patients.
Methods: Consecutively admitted PCI patients (n=534) treated
with paclitaxel-eluting stent as the default strategy completed the
Maastricht Questionnaire (MQ) at baseline. Apart from an
overall vital exhaustion score, the MQ also assesses fatigue
(seven items; Cronbach’s a=.87) and depressive symptoms
(seven items; Cronbach’s a=.83), with hopelessness (one item)
comprised in the depressive symptom items. Patients were
followed up for adverse clinical events (mortality and nonfatal
myocardial infarction) at 2 years. Results: At 2-year follow-up,
there were 31 clinical events. In univariable analyses, overall
vital exhaustion and depressive symptoms, but not fatigue, were
associated with adverse prognosis; in multivariable analysis,
depressive symptoms [hazard ratio (HR)=2.69; 95% confidence
interval (95% CI)=1.31–5.55] remained the only predictor of
clinical outcome. Among the depressive symptoms, hopelessness
(HR=3.44; 95% CI=1.65–7.19) was the most cardiotoxic
symptom. The incidence of clinical events was higher in the
high-hopelessness patients (11% vs. 3%; P=.001) than in the
low-hopelessness patients. Hopelessness (HR=3.36; 95%
CI=1.58–7.14; P=.002) remained an independent predictor of
clinical outcome at 2 years in adjusted analysis. Conclusion:
Symptoms of depression, but not fatigue, predicted adverse
clinical events. Hopelessness was the most cardiotoxic symptom,
associated with a more than three-fold risk of clinical events
2 years post-PCI. Screening for hopelessness may lead to the
identification of high-risk patients.
D 2007 Elsevier Inc. All rights reserved.
Keywords: Coronary artery disease; Depressive symptoms; Fatigue; Hopelessness; Percutaneous coronary intervention; Prognosis
Introduction
In the context of coronary artery disease (CAD), there is
an ongoing debate as to whether depressive symptoms
reflect actual depression or symptoms of underlying disease,
given the overlap between depression and somatic symp-
toms, such as fatigue, trouble sleeping, and so on [1,2].
Fatigue [3–6], depression [1], and hopelessness [7,8] have
all been associated with CAD. Fatigue is a frequently
reported symptom in patients with cardiac conditions, with
prevalence rates ranging from 59% to 75% [9]. Fatigue has
been shown to precede the onset of myocardial infarction
(MI) [3] and to be a risk factor for ischemic heart disease
and mortality in healthy individuals [4]. In CAD patients,
fatigue or exhaustion confers a two-fold to three-fold
increased risk of morbidity and mortality, adjusting for
clinical risk factors including disease severity [5,6].
B No conflict of interest exists.
4 Corresponding author. CoRPS, Department of Medical Psychology,
Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE Tilburg,
The Netherlands. Tel.: +31 13 466 2503; fax: +31 13 466 2370.
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Fatigue in patients with cardiac conditions has primarily
been assessed with the Maastricht Questionnaire (MQ),
which taps symptoms of exhaustion, demoralization, and
increased irritability [10]. However, evidence suggests that
the MQ assesses not only symptoms of fatigue but also
symptoms of depression [11,12]. Given that depression is a
risk factor for adverse clinical outcome in CAD [1,2,13], it
is possible that depressive symptoms, as assessed by the
MQ, may predict prognosis above and beyond fatigue.
Previous attempts addressing this issue have primarily been
performed at a conceptual level and have yielded incon-
sistent results [11,12,14–16].
Knowledge of the nature of depressive symptoms is
important for secondary prevention in order to optimize risk
stratification in clinical practice. Hence, there is a quest for
the identification of the core and most cardiotoxic depres-
sive symptoms. In epidemiological studies, hopelessness
has been associated with the progression of carotid
atherosclerosis [17,18], risk of mortality, and incidence
of MI and cancer [7,19]. Although hopelessness may
be considered a feature of depression, the strength of
association with established depression scales is weak,
suggesting that this psychological symptom should be
studied in its own right [19]. To our knowledge, only one
study has examined the role of hopelessness in the clinical
course of CAD in patients with established disease and has
found hopelessness to be associated with reduced survival
[8]. However, this study did not compare the influence of
fatigue relative to the influence of depressive symptoms
and hopelessness.
Hence, in the current study, we investigated the relative
effect of fatigue, depressive symptoms, and hopelessness on
prognosis in patients treated with percutaneous coronary
intervention (PCI).
Materials and methods
Participants and study design
Consecutively admitted patients presenting with stable or
unstable angina, treated with PCI at the Erasmus Medical
Center Rotterdam (Rotterdam, The Netherlands) between
July 1, 2003, and July 1, 2004, qualified for inclusion in the
current study. Implantation with paclitaxel-eluting stent
comprised the default strategy. During this period, 845
patients were treated; patients who died within the first
4 weeks after the index procedure (n=19) or who were not
sufficiently proficient in the Dutch language to complete a
psychological questionnaire (n=116) were excluded. The
remaining surviving patients (n=710) were approached in
writing and asked to complete the MQ 4 weeks post-PCI,
which, in the remainder of the article, will be referred to as
baseline; 536 (response rate, 75%) agreed to participate.
Patients were followed up for clinical adverse events for
2 years.
Excluded patients and nonresponders on the MQ were
more likely to smoke (22% vs. 14%; P=.003) but were less
likely to suffer from dyslipidemia (63% vs. 74%; P=.001)
than responders. No other differences were found between
excluded/nonresponders and responders on baseline char-
acteristics, including cardiac medication.
The hospital medical ethics committee approved the
protocol. All patients provided written informed consent,
and the study was carried out to conform with the
Helsinki Declaration.
Demographic and clinical variables
Demographic variables comprised sex and age. Informa-
tion on clinical variables, [i.e., indication for PCI (stable or
unstable angina), previous MI, previous coronary artery
bypass graft (CABG) surgery, previous PCI, stent type
(paclitaxel-eluting stent or other), multivessel disease,
hypertension, dyslipidemia, diabetes mellitus, smoking,
and cardiac medications such as aspirin, angiotensin-
converting enzyme (ACE) inhibitors, h-blockers, diuretics,
and statins] was obtained from medical records.
Fatigue, depressive symptoms, and hopelessness
The 21-item MQ, administered at baseline, was used to
evaluate overall vital exhaustion and symptoms of fatigue,
depression, and hopelessness [10]. Items were answered on
a 3-point scale (0=no, 1=?, 2=yes), with the total score
ranging from 0 to 42. The reliability of the total scale is
good (Cronbach’s a=.89) [5]. Research suggests that the
MQ predominantly assesses two symptom dimensions:
fatigue and depression [11]. We could replicate these findings
in the current study (Table 1). A principal components
analysis (varimax rotation with scree plot criterion to
determine the number of factors to extract) indicated two
dominant dimensions, and both scales had good internal
consistency, as measured by Cronbach’s a: (I) fatigue (seven
items; Cronbach’s a=.87; variance=36.4%) and (II) depres-
sive symptoms (seven items; Cronbach’s a=.83; var-
iance=8.0%). Hopelessness was assessed with Item 10 of
the MQ (i.e., bHave you experienced a feeling of hope-
lessness recently?Q). Previous studies have also used one or
two items to assess hopelessness as a risk factor for the onset
of CAD [7,8,17,18].
Clinical end point
The end point was defined as a clinical adverse event
(all-cause mortality or nonfatal MI) 2 years post-PCI.
Statistical analysis
Comparisons of baseline characteristics stratified by
hopelessness (using the highest tertile to indicate a high
score) were performed using chi-square test (Fisher’s exact
test, when appropriate) for nominal variables and Student’s
t test for independent samples for continuous variables.
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Univariable and multivariable Cox regression analyses were
used to examine the predictive value of the total MQ scale
(21 items) and the MQ subscales fatigue (seven items) and
depressive symptoms (seven items), using both continuous
and dichotomized scores. When using dichotomized scores,
we used the standardized cutoff of z14 for the total MQ
[20] and the highest tertile to indicate clinically manifest
symptoms on the separate fatigue and depressive symptom
dimensions, respectively. In all multivariable analyses, we
adjusted for sex, age, multivessel disease, previous cardiac
history, hypertension, dyslipidemia, diabetes, and smoking.
Hazard ratios (HRs) with 95% confidence intervals (CIs) are
reported. Pb.05 was used to indicate statistical significance.
All tests were two-tailed. All analyses were performed using
SPSS 12.0.1.
Results
Of the 536 patients, two patients did not have a score on
the hopelessness item of the MQ and were therefore
excluded from further analyses.
Baseline characteristics
Baseline characteristics stratified by hopelessness are
shown in Table 2. Patients who scored high on hopelessness
were younger, were more likely to have had a previous
cardiac history, and were more likely to have been
prescribed ACE inhibitors. No other differences on demo-
graphic and clinical characteristics were found between
high-hopelessness patients and low-hopelessness patients.
Fatigue, depressive symptoms, and clinical events
At 2-year follow-up, there were 31 (21 deaths and
10 nonfatal MIs) clinical events.
In univariable analyses using dichotomized scores,
depressive symptoms, but not fatigue, were significantly
associated with the incidence of death and nonfatal MI at
2-year follow-up (Fig. 1). Subjecting these subscales and the
original MQ scale (assessing vital exhaustion, cutoff of
z14) to a multivariable Cox regression analysis using a
stepwise procedure, depressive symptoms (HR=2.69; 95%
CI=1.31–5.55; P=.007), but not fatigue and vital exhaus-
tion, were associated with clinical outcome (Table 3). A
stepwise procedure was chosen in order to extract
the component(s) that exerted the most toxic influence
on prognosis.
Table 1
Symptoms of fatigue and depression, as assessed by the MQ
Item
Factor
analysis Reliabilitya
MQ item
number
Fatigue (Factor I)
1. Do you often feel tired? .76 0.69 1
2. Do you have a feeling that you
have not been accomplishing
much lately?
.75 0.69 5
3. Do you feel weak all over? .71 0.69 4
4. I feel fine (reverse). .71 0.68 14
5. Do you feel more listless
lately than before?
.68 0.67 8
6. Do you have a feeling these
days that you just do not
have what it takes any more?
.65 0.58 17
7. Do you sometimes feel that
your body is like a battery
that is losing its power?
.63 0.58 15
Cronbach’s
a=.87
Depressive symptoms (Factor II)
1. Would you want to be
dead at times?
.76 0.57 16
2. Do you feel you want
to give up trying?
.72 0.59 13
3. Do you feel dejected? .68 0.66 18
4. Do you believe that you have
come to a bdead endQ?
.66 0.66 7
5. Do you feel like crying sometimes? .60 0.50 19
6. Have you experienced a feeling
of hopelessness recently?
.56 0.57 10
7. Do you ever wake up with
feelings of exhaustion and fatigue?
.49 0.46 20
Cronbach’s
a=.83
Factor loadings are presented in italics.
a Corrected item–total correlations (Cronbach’s a=estimate of internal
consistency).
Table 2
Baseline characteristics stratified by hopelessness
High
hopelessness
(n=187)
Low
hopelessness
(n=347) P
Demographic characteristics
Male (%) 68 74 .20
Age in years
[mean (S.D.)]
61 (11) 64 (11) .00244
Married/partner (%) 81 81 1.00
Clinical variables (%)
Paclitaxel-eluting stenta 90 88 .53
Multivessel disease 60 60 1.00
Cardiac historyb 62 52 .044
Hypertension 45 50 .35
Dyslipidemia 73 74 .87
Diabetes mellitus 24 18 .12
Smoking 18 12 .06
Cardiac medication (%)
Aspirin 93 96 .15
ACE inhibitors 16 6 b .001444
h-Blockers 25 21 .26
Diuretics 2 1 .81
Statins 77 73 .39
a Paclitaxel-eluting stent was used as the default stent (i.e., in 89% of
the total sample). The other stents used were sirolimus-eluting stent (4%),
both paclitaxel-eluting stent and sirolimus-eluting stent (1%), or bare-metal
stent/balloon dilation (6%).
b MI, PCI, or CABG prior to the index event.
4 Pb.05.
44 Pb.01.
444 Pb.001.
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Hopelessness and clinical events
Given the possibility that the predictive value of
depressive symptomatology might be attributed to specific
symptoms such as hopelessness, we performed a series of
univariable analyses using continuous scores of the items.
Only the symptoms bhopelessnessQ and bwanting to be
deadQ were significant predictors of death/MI (Table 4). In a
multivariable analysis with a stepwise procedure subjecting
all depressive symptom items as continuous scores, the
only symptom that was retained was bhopelessnessQ (MQ
10; HR=1.93; 95% CI=1.33–2.80; P=.001). Since
bhopelessnessQ and bwanting to be deadQ (i.e., the only
two items that were significant predictors in univariable
analyses) could potentially be equally important cardiotoxic
depressive symptoms, we entered both in a multivariable
analysis, together with baseline characteristics. However,
only hopelessness (HR=1.91; 95% CI=1.28–2.86; P=.02),
but not bwanting to be deadQ (HR=0.97; 95% CI=0.62–
1.48; P=.88), was associated with adverse clinical events
on follow-up. After dichotomizing the hopelessness symp-
tom, with the highest tertile representing clinically manifest
symptomatology, the incidence of clinical events was 11%
(20 of 187) in high-hopelessness patients versus 3% (11 of
347) in low-hopelessness patients (P=.001). Hopelessness
was associated with a more than three-fold risk (HR=3.44;
95% CI=1.65–7.19; P=.001) of adverse clinical outcome in
univariable analysis (Fig. 2).
Entering the hopelessness symptom together with the rest
of the subscale comprising the six other depression symptoms
showed that hopelessness was an independent predictor
of clinical events (HR=4.07; 95% CI=1.76–9.43; P=.001),
whereas the six-item depression score was no longer
associated with death/MI (HR=0.73; 95% CI=0.32–1.63;
P=.44). In multivariable analysis, hopelessness (HR=3.36;
95% CI=1.58–7.14; P=.002) remained an independent
predictor of death/MI and was associated with a more than
three-fold increased risk, adjusting for sex, age, multivessel
disease, previous cardiac history, hypertension, dyslipidemia,
diabetes, and smoking.
In the final analysis, we investigated whether the addition
of hopelessness to a multivariable model, comprising
demographic and clinical baseline characteristics, improved
the level of prediction of death and MI on follow-up. As
indicated by the 2 log likelihood function, the level of
Fig. 1. Death/MI stratified by fatigue and depressive symptoms. *Numbers
are presented on top of bars.
Table 3
Baseline symptoms and death/MI (31 events) at 2 years post-PCI
HR [95% CI] P
(A) Univariable analysis
Subscale scores
Fatigue 1.35 [0.67–2.74] .40
Depressive symptoms 2.69 [1.31–5.55] .00744
Total MQ score
Vital exhaustion 2.73 [1.17–6.33] .024
(B) Multivariable analysisa
Significant
Depressive symptoms 2.69 [1.31–5.55] .007**
Nonsignificant
Fatigue .42
Vital exhaustion .29
a Stepwise procedure.
4 Pb.05.
44 Pb.01.
Table 4
Predictive value of specific depressive items in relation to death/MI at
2 years post-PCIa
HR [95% CI] P
1. Hopelessness (MQ 10) 1.89 [1.31–2.74] .00144
2. Wanting to be dead (MQ 16) 1.59 [1.07–2.37] .024
3. Feeling dejected (MQ 18) 1.24 [0.83–1.85] .30
4. Feeling like crying (MQ 19) 1.19 [0.81–1.75] .38
5. Waking up exhausted (MQ 20) 1.16 [0.80–1.69] .43
6. Wanting to give up trying (MQ 13) 1.15 [0.77–1.71] .50
7. Coming to a bdead endQ (MQ 7) 1.07 [0.71–1.62] .75
a Univariable analyses, using continuous scores for depressive items.
4 Pb.05.
44 Pb.01.
Fig. 2. Death/MI stratified by hopelessness. *Numbers are presented on top
of bars.
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prediction of the model improved with the addition of
hopelessness [v2=10.420 (df=1), P=.001].
Discussion
To our knowledge, this is one of the first studies to
have examined the relative effects of fatigue, depressive
symptoms, and hopelessness on clinical events in patients
with established CAD. In PCI patients treated with
paclitaxel-eluting stents, we found that depressive symp-
toms, but not fatigue, were associated with adverse clinical
outcomes, with the most cardiotoxic depressive symptom
being hopelessness. Hopelessness was associated with a
three-fold increased risk of death/nonfatal MI at 2 years in
adjusted analyses.
The last decade has witnessed a surge in research on
depression as a risk factor for CAD, leading to a call for the
recognition of depression as an established risk factor [13].
Despite extensive research, we still know little about the
nature of depressive symptoms and those that are most toxic
in terms of predicting clinical outcomes. Hence, identifica-
tion of the core and most toxic symptoms of depression is
now receiving increased attention [1,2,21]. However,
studies to date have been rather heterogeneous in their
focus, ranging from deriving subscales from the Beck
Depression Inventory (BDI) and relating them to clinical
outcome [1], to comparing the predictive validity of
instruments (BDI vs. the depression subscale of the Hospital
Anxiety and Depression Scale) [2], to assessing whether
depressive cognitions comprise an underpinning of depres-
sion in post-MI patients [21].
In the current study, we identified hopelessness as the
depressive symptom that was most salient in predicting
prognosis. PCI patients who scored high on hopelessness, as
measured by one item on the MQ, had a more than three-
fold increased risk of mortality and nonfatal MI 2 years
postprocedure, independent of baseline demographic and
clinical characteristics. Previous epidemiological studies
also found that hopelessness was associated with the
progression of carotid atherosclerosis [17,18], morbidity,
and mortality [7,19], but to our knowledge, only one study
has examined the impact of hopelessness as a risk factor in
patients with established CAD [8]. In the latter study,
hopelessness was also associated with decreased survival
and was shown to exert an independent effect on prognosis
relative to depressive symptoms. However, the study did not
compare the influence of fatigue relative to depressive
symptoms and hopelessness.
Physiological pathways through which hopelessness
may exert its deleterious effect on health include decreased
heart rate variability (particularly reduced vagal tone or
parasympathetic activity) [22], impaired fibrinolysis [23],
and inflammation [17]. In the latter study, plasma
fibrinogen, a marker of systemic inflammation, was shown
to mediate the relationship between hopelessness and
progression of carotid atherosclerosis. Compliance may
comprise a behavioral pathway, given that depression has
been shown to have a negative influence on adherence to
cardiac rehabilitation [24] and medication [25]. However,
whether these results extend to hopelessness needs to be
confirmed in future studies.
Given the relatively high prevalence of fatigue and its
deleterious effects on health [3–5,9], it is surprising that
fatigue has not received more attention in the cardiovascular
literature. Although we were not able to confirm that fatigue
was associated with adverse prognosis in the current study,
it is too premature to write off fatigue as a risk factor in
CAD. The reason for the nonsignificant result may be due to
the relatively small number of events in the current study, as
the incidence of death and nonfatal MI was larger in
fatigued patients than in nonfatigued patients. As voiced by
others, there is an urgent need to develop measures of
fatigue that tap these symptoms in patients with cardiac
conditions without the confounding of related symptoma-
tology [11]. With the availability of such measures, it will be
possible to establish the salience of fatigue as a predictor of
clinical events in CAD.
The findings of the current study have implications for
research and clinical practice. Given that there is an inverse
relationship between the length of a questionnaire and the
response rate [26], when collating a test battery, it may be
important to prioritize the inclusion of a measure of
hopelessness if there is no room for a more lengthy measure
of depressive symptoms. A two-item measure of depressive
symptoms [i.e., the Patient Health Questionnaire (PHQ-2)],
which includes hopelessness, has previously been shown to
have good sensitivity and specificity, compared with the
gold standard of a clinical diagnosis of depression, and to be
sensitive to change [27]. The recent four-item Symptoms of
mixed Anxiety–Depression Index (SAD4) also includes
hopelessness [28] and has been shown to predict a clinical
diagnosis of depression even when adjusting for depressive
symptomatology, as measured by the BDI. However, neither
the PHQ-2 nor the SAD4 has yet been used as a potential
predictor of clinical outcome in CAD. In terms of clinical
practice, screening for hopelessness is feasible and can be
incorporated into the daily routine of practicing cardiolo-
gists. PCI patients suffering from hopelessness need to be
identified early on and to be followed more closely
throughout in order to motivate them to participate in
cardiac rehabilitation, as they may be more inclined to
refuse participation or to drop out from rehabilitation
programs [24]. In terms of intervention, it may be possible
to reduce feelings of hopelessness using a cognitive–
behavioral approach either on its own or in combination
with pharmacotherapy, as hopelessness is predominantly
considered a cognitive symptom of depression [29,30].
The current study has some limitations. First, for 42%
of the patients, we had no information on left ventricular
ejection fraction; therefore, in multivariable analyses, we
were not able to adjust for measures of disease severity
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but only for a measure of the extent of disease, as assessed
by multivessel disease. Second, results may not be
generalizable to MI patients, since only patients with
stable or unstable angina as an indication for PCI were
included. Nevertheless, the results of this study show that
the assessment of psychosocial risk factors is also
important in more low-risk patients, such as patients with
angina, given their impact on adverse clinical events.
Third, 25% of patients declined to participate. However,
nonresponders and excluded patients (excluded due to lack
of language proficiency) did not differ from responders on
demographic and clinical baseline characteristics, except
for nonresponders/excluded patients being more likely to
smoke and less likely to suffer from dyslipidemia. Fourth,
our multivariable model was overfitted given the number
of adverse clinical events. Fifth, hopelessness was assessed
by one item, but other studies have also used a one-item
measure of hopelessness and have shown that hopelessness
is a predictor of adverse clinical outcome [8]. Finally,
although it may seem contrary to expectations that the
item bDo you ever wake up with a feeling of exhaustion
and fatigue?Q loaded on the depression factor rather than
on the fatigue factor, insomnia and fatigue both form part
of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition diagnostic criteria for a major
depressive disorder.
In conclusion, we found that depressive symptoms, but
not fatigue, were associated with adverse clinical outcome
in PCI patients treated with paclitaxel-eluting stents. More
specifically, hopelessness proved to be the most cardiotoxic
component and was associated with a more than three-fold
increased risk of death and nonfatal MI at 2 years, after
adjusting for demographic and clinical baseline character-
istics. It is feasible to include the assessment of hopelessness
in research protocols and clinical practice. Future studies
that replicate these findings are warranted, given that few
studies have examined the impact of hopelessness on
patients with established CAD.
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Objective. Emotional distress has been related to clini-
cal events in patients with coronary artery disease, but
the influence of positive affect (i.e. mood states such
as activity, joy and cheerfulness) has received little
attention. Therefore, we wanted to investigate the role
of positive affect on clinical outcome after percutane-
ous coronary intervention (PCI) with stent implanta-
tion in these patients.
Design. Prospective follow-up study. At baseline,
patients from the Rapamycin-Eluting Stent Evaluated
At Rotterdam Cardiology Hospital (RESEARCH) reg-
istry completed measures of positive affect, depression
and anxiety post-PCI. Patients with reduced positive
affect scored 1 SD below the mean score.
Setting. University Hospital; Thoraxcenter of the
Department of Cardiology.
Subjects. 874 patients (72% men; 62.2 ± 10.9 years)
from the RESEARCH registry.
Main outcome measure. Death or myocardial infarction
(MI) 2 years post-PCI.
Results. At follow-up, there were 52 clinical events
(deaths n = 27, MIs n = 25). Reduced positive affect
and depression ⁄ anxiety were associated with poor
prognosis, but reduced positive affect was the only
independent predictor of events. The incidence of
death ⁄MI in adequate versus reduced positive affect
patients was 4% (29 ⁄663) vs. 11% (23 ⁄211);
HR = 2.55 (95% CI 1.46–4.34, P = 0.001), adjusting
for clinical variables. Reduced positive affect and dia-
betes were independent prognostic factors, and
patients with one (HR = 2.84, 95% CI 1.58–5.10) or
both (HR = 5.61, 95% CI 2.25–13.99) of these factors
had a higher risk when compared with nondiabetic
patients with adequate positive affect, P £ 0.003.
Conclusions. Reduced positive affect independently pre-
dicted death ⁄MI following stent implantation, and
improved risk stratification above and beyond diabetes.
Keywords: coronary artery disease, diabetes, depres-
sion, positive affect, anhedonia.
Introduction
Symptoms of psychosocial distress have been associ-
ated with an increased risk of cardiac events [1–4].
However, little is known about the impact of posi-
tive affect. Positive affect refers to mood states such
as joy, activity and cheerfulness [5]. Positive affect
is not merely the opposite of negative affect [6], as
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people can experience positive and negative emo-
tions at the same time [7]. Epidemiological research
in middle-aged adults [8] and patients with coronary
artery disease (CAD) [9] has confirmed that these
emotions are relatively independent mood dimen-
sions.
Positive affect may enhance immune function [10]
and one’s ability to achieve successful outcomes in
life [11], and dampen physiologic reactivity to stress
[12]. Reduced positive affect has also been associ-
ated with an increased risk of mortality [13] and
stroke [14] in community-based studies of older
adults. By contrast, there is a paucity of research on
the role of positive affect in surviving serious illness
[5]. Positive affect may benefit survival in AIDS
[15] and surgery [16] patients, but more research is
needed on the effect of adequate versus reduced
positive affect in cardiac patients. An advantage of
studying positive affect is that CAD patients are not
likely to describe themselves in terms of negative
emotions alone. Accordingly, positive affect scales
may be especially responsive to the effect of inter-
vention [17].
The current study investigated the role of positive affect
in the clinical course of CAD patients who received
percutaneous coronary intervention (PCI) with either a
sirolimus-eluting stent (SES) or a bare metal stent
(BMS) implantation, as part of the Rapamycin-Eluting
Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) registry [18]. The aim of this study was
to compare the impact of positive versus negative affect
on the risk of clinical events at 2-year follow-up of
these patients.
Methods
Participants
The RESEARCH registry population comprised con-
secutive patients with CAD treated with PCI with
either SES or BMS implantation between October
2001 and October 2002 [18]. This registry was
designed to evaluate the efficacy and safety of SES
implantation in patients treated with PCI in the ‘real
world’ of interventional cardiology; no patients were
excluded based on anatomical ⁄ clinical presentations,
and 68% of the RESEARCH registry patients would
not qualify for inclusion in clinical trials [19]. At
6 months post-PCI, all living patients were asked to
complete a psychological questionnaire; 874 (71%)
returned this questionnaire [20]. Nonresponders were
younger, more likely to have a history of MI, to have
diabetes and to be treated with ACE inhibitors, but
less likely to have renal impairment or to be treated
with b-blockers and aspirin than responders (all
P < 0.05). The mean age of the present sample of
875 patients was 62.2 ± 10.9 years, and 72%
(n = 629) were men; 41% (n = 358) were treated with
SES. The study was approved by the local hospital
ethics committee, and every patient provided written
informed consent.
Symptoms of anxiety and depression
The two seven-item scales of the Hospital Anxiety
and Depression Scale (HADS) were administered
6 months post-PCI to assess anxiety and depression
symptoms [21].
The HADS has been related to mortality in patients
referred for exercise testing; a cut-off score ‡8 yields
a good balance between sensitivity and specificity for
both scales and was used to indicate probable anxiety
and depression caseness [22, 23].
Assessment of positive affect
Self-report depression ⁄ anxiety scales not only tap a
broad range of negative affects in CAD patients but
also (the absence of) positive affect [9]. Previous
research in myocardial infarction patients showed that
the HADS comprised three distinct factors, and found
support for the use of a subscale to assess (the
absence of) positive affect [24]. Accordingly, we also
used exploratory factor analysis (i.e. principal compo-
nents analysis with varimax rotation) to examine the
notion that positive affect was distinctly different from
negative affect in the present study. The scree-plot
was used as a criterion for the number of underlying
factors to extract.
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This analysis yielded two dominant affect factors that
were assessed by the HADS measure, and a third,
smaller factor. Four items of the HADS reflected a
positive affect dimension as indicated by high load-
ings on factor I; i.e. being cheerful, looking forward
with enjoyment to things, being still able to enjoy
things and seeing funny side of things (Table 1). Cor-
rected item–total correlations ranging between
0.69 ⁄0.72 and Cronbach’s a = 0.86 indicated a high
internal consistency of this four-item factor. Previous
research supports the use of a factor analytically
derived HADS subscale to assess positive affect [24];
by analogy, these four items were summed to com-
prise a Positive Affect score (range 0–12, mean 9.4,
SD 2.9) in this study.
Factor II represented the negative affect dimensions
of mood, and was also defined by four items: i.e.
fears something awful will happen (item 3; factor
loading 0.84), feelings of panic (item 13; loading
0.83), frequently worries (item 5; loading 0.75) and
feels tense (item 1; loading 0.62). Factor III com-
prised three items reflecting relaxation; i.e. not both-
ered by restlessness (item 11; loading 0.80), feels
relaxed (item 7; loading 0.69) and enjoys a good
book or radio ⁄TV program (item 14; loading 0.67).
These items were summed to comprise Negative
Affect (mean 3.1 ± 2.8; a = 0.85) and Relaxed
Affect (mean 6.5 ± 2.1; a = 0.69) scores respec-
tively.
Two of the three remaining HADS items loaded on
the Positive Affect (items 8 and 10) and one on
the Negative Affect (item 9) factor. These items had
relatively lower item–total correlations, did not add
significantly to the internal consistency of the corre-
sponding scales and therefore were not included in
the new affect subscales. Overall, we replicated the
three-factor model of the HADS, but the Positive
Affect subscale that we derived included four items,
and not seven as previously described [24].
Endpoint
The endpoint was a composite of death and MI
2 years post-PCI. Events occurring between PCI and
psychological assessment were excluded as an end-
point from analyses. MI was diagnosed by a rise in
the creatine kinase-MB level to more than three times
the upper normal limit [25].
Demographic, clinical variables and medication
Demographic variables included age and sex. Infor-
mation on clinical variables was obtained from the
patients’ medical records at the time of psychologi-
cal assessment. Clinical variables included stent
type, multi-vessel disease (52%, n = 458), MI (37%,
n = 327), coronary artery bypass graft (CABG) sur-
gery (12%, n = 101) or PCI (25%, n = 219) prior
to index event, hypercholesterolaemia (81%,
n = 709), hypertension (39%, n = 339), smoking
(31%, n = 273), renal impairment (creatinine
£60 ml ⁄min, 30%, n = 265) and diabetes (15%,
n = 127). More than 95% of the patients were trea-
ted with b-blockers (n = 856), aspirin (n = 840) and
clopidogrel (n = 830); statins (67%), calcium antag-
onists (47%) and ACE-inhibitors (26%) were also
included.
Statistical analyses
Cox regression analyses were performed to investigate
continuous scores on the positive affect, negative
Table 1 Positive affect scale (n = 874)
Item no.
Factor
analysis
factor I
Reliabilitya
Cronbach’s
a ¼ 0.86 HADS item
1. Looks forward with
enjoyment to things
0.80 0.69 HADS #12
2. Still enjoys things
he ⁄ she used to enjoy
0.79 0.72 HADS #2
3. He ⁄ she can laugh
and see funny side
0.77 0.72 HADS #4
4. Feels cheerful 0.74 0.69 HADS #6
HADS, Hospital Anxiety and Depression Scale [21–23]. Factor
loadings are presented in bold.
aCorrected item–total correlations; Cronbach’s a = estimate of inter-
nal consistency.
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affect, depression and anxiety scales as predictors of
clinical events. To enhance the clinical interpretability
of findings on the role of affect measures in progno-
sis, similar analyses were used to examine the effect
of a 1 SD decrease in positive affect on the clinical
course following implantation of coronary stents.
Hence, a score £7 (i.e. 1 SD below the mean Positive
Affect score) was used to identify patients with anhe-
donia, which refers to markedly reduced positive
affect [24]. In multivariable analyses, we adjusted for
age, gender and clinical variables. All variables,
including reduced positive affect, were entered simul-
taneously in the multivariable models. In post hoc
analyses, diabetes and reduced positive affect were
used to stratify patients by four risk groups. All statis-
tical tests were two-tailed; P < 0.05 was used to indi-
cate statistical significance. Hazard ratios (HR) with
95% confidence intervals (CI) are reported. Analyses
were performed using spss (SPSS Inc., Chicago, IL,
USA) for Windows version 12.0.
Results
Positive affect, depression, anxiety and clinical events
At 2-year follow-up, there were 52 clinical events
(death n = 27, MI n = 25). In univariable analyses,
higher scores of positive affect and relaxed affect were
associated with a lower risk of clinical events
(HR = 0.86 and 0.87 respectively), while higher scores
of negative affect (HR = 1.14), depression
(HR = 1.10) and anxiety (HR = 1.10) were associated
with a higher risk of events (Table 2, top). However, a
multivariable regression analysis indicated that positive
affect (HR = 0.85), older age (HR = 1.94) and male
sex (HR = 2.81) were the only independent predictors
of clinical events, and that symptoms of depression,
anxiety or other affect measures did not add signifi-
cantly to this prediction model (Table 2, bottom).
Individual positive affect items and clinical events
To better understand which characteristics of positive
affect were responsible for the observed health effect,
we examined the relation between individual items and
prognosis. The items being still able to enjoy things
(HR = 0.51, 95% CI 0.40–0.66, P < 0.0001), being
cheerful (HR = 0.62, 95% CI 0.47–0.80, P < 0.0001)
and looking forward with enjoyment to things
(HR = 0.66, 95% CI 0.51–0.86, P = 0.002) were sig-
nificantly related to prognosis, adjusting for age and
sex. There was a trend for the item seeing funny side
of things (HR = 0.74, 95% CI 0.55–1.00, P = 0.053).
Reduced positive affect and clinical events
Using a score £7 (i.e. 1 SD below the mean) as a
cut-off, 211 patients (24%) were classified as
experiencing reduced positive affect. These patients
had a significantly increased rate of 2-year clinical
events (23 ⁄211 = 11%) when compared with patients
with an adequate positive affect (29 ⁄663 = 4%);
OR=2.84, 95% CI 1.59–5.07, P < 0.0001, adjusted
for age and sex. Conversely, a high positive affect
score (i.e. 1 SD above the mean) was associated with
a decreased risk of clinical events (OR = 0.33, 95%
CI 0.15–0.72, P = 0.005). However, a multivariable
model only retained reduced positive affect as
Table 2 Baseline emotions and death ⁄MI post-PCI
(n = 52 ⁄ 874)
Hazard ratio [95% CI] P
Univariable analysis
Affect measures
Positive affect 0.86 [0.79–0.93] 0.0001
Relaxed affect 0.87 [0.77–0.98] 0.021
Negative affect 1.14 [1.05–1.24] 0.002
HADS Scales
Depression 1.10 [1.04–1.17] 0.001
Anxiety 1.10 [1.04–1.18] 0.002
Multivariable analysis
Significant
Positive affect 0.85 [0.78–0.92] 0.0001
Age ‡60 years 1.94 [1.07–3.54] 0.03
Male sex 2.81 [1.33–5.91] 0.007
Not significant
Relaxed affect 0.54
Negative affect 0.06
Depression 0.81
Anxiety 0.06
MI, myocardial infarction; PCI, percutaneous coronary intervention.
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independent predictor of events (P < 0.0001). There
was a trend for high positive affect (P = 0.064).
Demographic and clinical predictors
In univariable analysis, multi-vessel disease
(P = 0.045), previous CABG (P = 0.005), diabetes
mellitus (P = 0.008) and ACE-inhibitor therapy
(P = 0.032) were significantly related to an increased
risk of death ⁄MI at 2-years follow-up (Table 3, top).
There was also a trend for age ‡60 years (P = 0.055),
male sex (P = 0.069) and previous MI (P = 0.069). In
multivariable analysis, diabetes mellitus (HR = 2.42),
previous CABG (HR = 2.36), male sex (HR = 2.28)
and age ‡60 (HR = 2.03) emerged as independent
predictors of prognosis (Table 3, bottom); there was a
trend for smoking (P = 0.057). These variables were
included in the following analyses.
The prevalence of reduced positive affect was differ-
ent as a function of demographic characteristics; i.e.
this prevalence was significantly lower in men when
compared with women (Table 4). There was also a
trend for older age to be associated with reduced posi-
tive affect (P = 0.081). However, reduced positive
affect was not significantly associated with smoking,
previous CABG or diabetes.
Independent predictors of cardiac events
To determine whether reduced positive affect and the
clinical variables that emerged from previous analyses
were independent predictors of prognosis, we entered
these factors in a multivariable regression model. The
final Cox regression model indicated that reduced
positive affect was associated with a more than 150%
increase in risk of clinical events, adjusting for clini-
cal and demographic variables (Table 5). Diabetes,
previous CABG, male sex and older age (all with an
increase in risk >100%) were also independent predic-
tors of events in this regression model.
Diabetes and reduced positive affect subgroups
Because diabetes and reduced positive affect
emerged as two independent predictors of clinical
Table 3 Baseline characteristics and death ⁄MI post-PCI (n =
52 ⁄ 874)
Hazard ratio [95% CI] P
(a) Univariable analysis
Demographics
Age ‡60 years 1.78 [0.99–3.21] 0.055
Male sex 1.95 [0.95–4.00] 0.069
Clinical factors
Sirolimus-eluting stent 1.50 [0.83–2.70] 0.18
Multi-vessel disease 1.80 [1.01–3.18] 0.045
Previous MI 1.66 [0.96–2.85] 0.069
Previous CABG 2.54 [1.33–4.83] 0.005
Previous PCI 1.55 [0.87–2.77] 0.014
Hypercholesterolemia 0.84 [0.43–1.63] 0.60
Hypertension 1.17 [0.68–2.03] 0.58
Smoking 1.38 [0.79–2.41] 0.26
Diabetes mellitus 2.29 [1.24–4.24] 0.008
Renal impairment 1.22 [0.69–2.14] 0.50
Beta-blockers 1.10 [0.15–7.96] 0.93
Aspirin 1.04 [0.25–4.29] 0.95
Clopidogrel 2.92 [0.40–21.09] 0.29
Statins 1.06 [0.59–1.92] 0.84
Calcium antagonists 1.28 [0.74–2.22] 0.37
ACE-inhibitors 1.85 [1.06–3.23] 0.032
(b) Multivariable analysis
Age ‡60 years 2.03 [1.10–3.78] 0.024
Male sex 2.28 [1.10–4.73] 0.027
Previous CABG 2.36 [1.21–4.58] 0.011
Smoking 1.76 [0.98–3.15] 0.057
Diabetes mellitus 2.42 [1.31–4.49] 0.005
Previous, prior to index event; MI, myocardial infarction; CABG,
coronary artery bypass surgery; PCI, percutaneous coronary inter-
vention.
Table 4 Association between baseline characteristics and
reduced positive affect
Adequate
positive affect
(n = 663)
Reduced
positive affect
(n = 211) P-value
Age ‡60 years 54% (360) 61% (129) 0.081
Male sex 74% (490) 66% (139) 0.024
Previous CABG 11% (72) 14% (29) 0.25
Smoking 30% (199) 35% (74) 0.17
Diabetes mellitus 14% (91) 17% (36) 0.23
Number of subjects appears within parentheses.
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events, we examined the combination of these fac-
tors in relation to prognosis in post hoc analyses.
Patients were stratified by four subgroups: no diabe-
tes and adequate positive affect (n = 572), diabetes
but adequate positive affect (n = 91), reduced posi-
tive affect but no diabetes (n = 175) and both dia-
betes and reduced positive affect (n = 36). Patients
with no diabetes but reduced positive affect had a
similar risk of clinical events when compared with
patients with diabetes but adequate positive affect
(P = 0.81); the effect of reduced positive affect on
prognosis was equal to that of diabetes (Fig. 1).
Patients with either diabetes or reduced positive
affect had a higher risk when compared with nondi-
abetic patients with adequate positive affect
(HR = 2.84, 95% CI 1.58–5.10). Those with both
diabetes and reduced positive affect were in the
highest risk group (HR = 5.61, 95% CI 2.25–
13.99).
Discussion
The impact of negative emotions has been studied
extensively in the context of CAD. By contrast, the
potential role of positive emotions on clinical outcome
has been neglected. In the current study, we found
that the incidence of death ⁄MI 2-year post-PCI was
significantly higher in patients with reduced positive
affect, with the risk being more than twofold adjust-
ing for demographic and clinical factors. Of note,
reduced positive affect was a risk factor on par with
diabetes, an established, biomedical risk factor. Strati-
fication of patients by reduced positive affect and dia-
betes showed that patients with both risk factors had
a significantly higher risk compared with the presence
of one or neither of these risk factors.
Unresolved issues in coronary-artery stenting include
the adverse effect of diabetes on the clinical course
post-PCI [26]. The present findings confirm this, but
also suggest that markedly reduced positive affect
may have an adverse effect as well. Constructs that
are related to positive affect such as positive
self-perceptions [27] and emotional well-being [28]
have previously been associated with increased
longevity in older community-dwelling individuals,
and optimism has been related to a significantly
reduced risk for cardiac events [29]. There is also
some evidence to suggest that the relative lack of
positive emotions may be a better predictor of clinical
outcomes than negative emotions [13, 14, 28].
Accordingly, we also found that the presence of nega-
tive emotions, in addition to reduced positive affect,
Table 5 Multivariable predictors of death ⁄MI post-PCI (n =
52 ⁄ 874)
Hazard ratio [95% CI] P
Demographics
Age ‡60 years 2.04 [1.09–3.82] 0.026
Male sex 2.53 [1.21–5.30] 0.014
Clinical factors
Previous CABG 2.15 [1.11–4.19] 0.024
Smoking 1.62 [0.90–2.91] 0.11
Diabetes mellitus 2.32 [1.25–4.30] 0.008
Psychological status
Reduced positive affecta 2.55 [1.46–4.34] 0.001
Previous, prior to index event; MI, myocardial infarction; CABG,
coronary artery bypass surgery; PCI, percutaneous coronary inter-
vention.
aScore £7 on the Positive Affect Scale coded as 1.
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did not increase the level of prediction of clinical
events. These findings suggest that future research
should focus more on the role of anhedonia, as indi-
cated by the relative inability to enjoy things or to be
cheerful, in the prognosis of CAD patients.
CAD patients may be more likely to recognize them-
selves by means of a combination of negative and
positive emotions rather than negative emotions alone.
Positive affect is not merely the opposite of negative
affect [6]; rather there seems to be a relative indepen-
dence of positive and negative affect in CAD patients
[8, 10], which the factor analysis of the HADS in the
present study also confirmed. Hence, positive affect
needs to be assessed in its own right. For example,
future randomized trials may benefit from the assess-
ment of basal positive affect levels.
There are several potential pathways through which
positive affect could influence health, although at this
point they remain speculative as they are yet to be
tested empirically. One pathway is health-related
behaviours, that is the adoption of more health-pro-
moting practices, such as exercising or getting suffi-
cient sleep [5]. The autonomic nervous system
comprises another mechanism, with positive affect
probably altering the activity of the sympathetic ner-
vous system in turn leading to decreases in heart rate
and blood pressure [5, 12]. The hypothalamus–pit-
uitary–adrenal axis may also be involved, as induction
of positive mood states has been shown to lead to
reduction in cortisol levels [5]. In turn, cortisol regu-
lation is important in immune functioning. In a recent
study, Steptoe et al. showed that happiness was inver-
sely related to inflammation, heart rate (although in
men only) and cortisol levels [10]. These factors have
all been associated with cardiovascular prognosis.
This study has several limitations regarding the
causality and conclusiveness of its findings. First, the
psychological questionnaires were administered
6 months after stenting because of logistic reasons
[20]. This may have biased our results; i.e. there may
have been a number of high positive affect individuals
who died in the first months post-PCI, before the
assessment of positive affect took place. It is also pos-
sible that patients who reported more positive affect
at this time point were doing so because they had less
recurrence of angina or other health problems follow-
ing successful PCI. However, the study did not
include a measure of symptoms at 6 months after
stenting, making it impossible to control for the effect
of cardiac symptoms at this point in time. Secondly,
nonresponders differed from responders on baseline
characteristics, and therefore the results may not be
generalizable to the total sample. Thirdly, we did not
have information on the cause of death, and the com-
bined endpoint included MI as well as all types of
death. Fourthly, we had no information on health-
related behaviours, apart from smoking, that poten-
tially may explain the relation between affect and
health outcome.
Finally, the scale used in this study may not be a
typical measure of positive affect; i.e. it includes one
affective item (cheerful), two items reflecting the
ability to enjoy things (or lack of anhedonia) and
one on humour. Nevertheless, the technique that we
used to construct a positive affect measure has also
been used by others in studies that have factor
analysed the Center for Epidemiologic Studies
Depression Scale (CES-D) to derive a positive affect
component.
This study also has a number of strengths, including
its prospective design and use of psychometrically
sound measures of self-reported symptoms of depres-
sion and anxiety. Moreover, this study was conducted
in the ‘real world’ of interventional cardiology, repre-
senting patients seen in daily clinical practice [19].
Research conducted in the ‘real world’ has been pro-
posed as a means by which to close the gap between
research and clinical practice [30]. Finally, given the
paucity of research on positive affect and coronary
health, the findings of the present study add to our
understanding of the influence of emotions on cardio-
vascular health.
In conclusion, we found that reduced positive affect
was a significant independent predictor of adverse
clinical events, adjusting for demographic and clini-
cal risk factors. Of note, negative emotions did not
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add to the level of prediction of clinical events
above and beyond positive emotions and demo-
graphic and clinical risk factors. In addition,
reduced positive affect was a risk factor on par
with diabetes, with patients with both risk factors
forming a high-risk group. The present results high-
light the importance of looking beyond depression
and other negative emotions and also focusing on
the relative lack of positive emotions in CAD
research and clinical practice. The results also sug-
gest that subgroups of patients, such as those with
diabetes and reduced positive affect, may not bene-
fit from coronary-artery stent implantation on par
with other patients. Finally, this points to a new tar-
get for behavioural interventions, namely focusing
on enhancing positive affect.
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Pivotal randomized controlled trials and registries 
showed that both sirolimus-eluti ng stents (SES) 
and paclitaxel-eluti ng stents (PES) proved to be 
superior to bare metal stents (BMS) at 1-year of 
follow-up in selected pati ents. The present thesis 
aims to provide insights into the long-term safety, 
effi  cacy and caveats of drug-eluti ng stents (DES).
The all-comer populati on
The Thoraxcenter was one of the few centers 
worldwide that pursued an unrestricted DES use 
from the moment of the commercial introducti on 
of the Cypher stent in April 2002. By extending 
the follow-up of the RESEARCH and T-SEARCH 
registries (in which SES and PES respecti vely were 
used in an unrestricted manner), we were the fi rst 
to demonstrate that SES remained signifi cantly 
superior to BMS at 2, 3 and 4 years of follow-
up (Chapters 5 and 6).  The use of SES proved 
to decrease major adverse cardiac event rates 
with 27% and 43% at 3 and 4 years respecti vely 
as compared to BMS. These lower event rates 
were mainly due to a persistent and signifi cant 
decrease in target vessel revascularizati on rates 
along with similar rates of death and myocardial 
infarcti on. Additi onally, we demonstrated that 
there was no stati sti cally signifi cant diff erence in 
safety and effi  cacy endpoints between SES and 
PES (Chapter 4). 
The performance of DES in specifi c 
pati ent and lesion subsets
Following all pati ents treated in our center 
between January 2000 and December 2005 
allowed us to assess the parti cular performance 
of DES in high-risk pati ent and lesion subsets. 
Recognizing the detrimental impact of renal 
impairment on the long-term outcome of pati ents 
treated with PCI, we demonstrated that in a 
cohort of 10 pati ents on haemodialysis, no cases 
of death, myocardial infarcti on or target lesion 
revascularizati on occurred up to 1 year (Chapter 
7). In Chapter 8, we looked for the performance of 
DES in pati ents presenti ng with acute myocardial 
infarcti on, a subset of pati ents that had been 
rarely studied in randomized controlled trials. 
While the use of SES proved to be superior to BMS 
at 1 year in reducing repeat revascularizati on, we 
demonstrated that at 3-years, the use of both 
SES and PES was no longer superior to BMS in 
reducing major adverse cardiac events in pati ents 
presenti ng with ST-segment elevati on myocardial 
infarcti on. Additi onally, we demonstrated that 
PES were not superior to BMS in reducing the 
incidence of adverse cardiac events at 1-, 2- and 3 
years of follow-up. Chapter 8 demonstrates that 
this laƩ er fi nding could be due to the increased 
rates of stent thrombosis in both DES groups as 
compared to the BMS group. 
Moreover, the growing subset of pati ents from 
diabeti cs was studied. With an accelerated 
and more aggressive form of atherosclerosis 
and subsequently higher rates of restenosis 
as compared with non-diabeti cs, diabetes is 
inherently linked to a smaller vessel size, longer 
lesion length, greater plaque burden and a 
possibly diff erently acti ng restenoti c cascade as 
compared to non-diabeti cs. Given their superior 
anti restenoti c properti es, DES were hypothesized 
to be a parti cular interesti ng opti on in these high-
risk pati ents. In Chapters 9 we demonstrate that 
in 708 consecuti ve diabeti c pati ents, at 2 years, 
there was a trend towards a more favorable 
outcome associated with the use of PES over 
BMS. There was no signifi cant diff erence between 
SES and PES in each of the clinical endpoints, 
and neither in the NIDDM pati ents, which are 
hypothesized to be beƩ er off  with PES. Aft er 
propensity analyses we found that none of the 
diff erences in any of the clinical endpoints in SES 
or PES as compared to BMS reached stati sti cal 
signifi cance. We hypothesized that part of this 
non-superiority was due to the high rate of stent 
thrombosis in both DES cohorts (4.4% in the SES 
group vs. 2.4% in the PES group) as compared to 
the BMS group (0.8%). Following these pati ents 
for another more year (Chapter 10) revealed 
that the trend toward a superior outcome with 
PES became stati sti cally signifi cant, whereas the 
diff erences between SES and BMS did not. Aft er 
multi variate adjustment, risks of TVR and MACE 
(all-cause mortality, any myocardial infarcti on or 
TVR) in PES were lower than in BMS (Hazard rati o 
[HR] 0.50 [95%CI: 0.33-0.75] for TVR, HR 0.65 
[95%CI: 0.48-0.87] for MACE), but these risks in 
SES were comparable with BMS (HR 0.75 [95%CI: 
Summary and Conclusions
Summary and conclusions | Part IX
363
0.46-1.24] for TVR, HR 0.77 [95%CI: 0.52-1.13] for 
MACE).
Focussing more specifi cally on the performance 
of DES in specifi c lesion types, we started by 
evaluati ng the long-term safety and effi  cacy of 
DES in bifurcati ons lesions. SES proved to be safe 
and effi  cacious despite the challenging clinical 
seƫ  ng of the bifurcati on lesion by using either 
the Crush or CuloƩ e technique (Chapter 11). With 
the growing confi dence in the superiority of DES, 
the clinical indicati ons for their use expanded 
despite the lack of long-term data. Physicians 
started to stent smaller vessels, longer lesions 
and used more stents. In Chapter 12 we assessed 
the relati vely effi  cacy of SES and PES in vessels 
with a diameter of 2.25mm or less, a clinical 
seƫ  ng which would have resulted in exclusion 
of the pati ent in pivotal randomized controlled 
trials. At 2 years, the cumulati ve incidence of 
major adverse cardiac events (MACE) in the 
SES group was signifi cantly lower than in the 
PES group (10.3% vs. 23.3%, P = 0.02). Another 
challenging clinical seƫ  ng which would without 
any doubt have been treated with bypass 
surgery several years ago is the chronic total 
occlusions. In Chapter 13 we demonstrated that 
SES where associated with a similar safety profi le 
as compared to BMS up to 3 years of follow-up. 
However, the crude diff erence in TVR was only 
3.5% (12.7% in the BMS group vs. 9.2% in the SES 
group). Respecti ng the limited size of the study 
populati on (n=147), we concluded that the use of 
SES in pati ents with chronic total occlusions did 
not appear to be signifi cantly superior to BMS at 
3 years of follow-up. 
Percutaneous treatment of stenoses involving 
aorto-osti al lesions is a technically demanding 
procedure for interventi onalists and has been 
associated with lower procedural success, and 
poorer clinical and angiographic outcomes when 
compared with treatment of non-osti al lesion, 
however data on the effi  cacy of DES for osti al 
lesions are sti ll limited. In Chapter 14 we examined 
the 7-months angiographic and 2-year clinical 
outcome of 76 consecuti ve pati ents treated with 
PES for aorto-osti al lesions. At 7-months the late 
lumen loss was 0.48mm, which resulted in a TVR 
rate of 14.5% along with a total MACE rate of 
31.6% at 2 years. We concluded that although 
the use of PES was feasible, the gradual increase 
in late adverse events makes that PCI for aorta-
osti al lesions remains problemati c. 
Finally, we analyzed the 4-year outcome of SES 
and PES versus BMS aft er concerns were raised 
on the long-term safety of DES for saphenous 
vein graft  disease. In a cohort of 250 pati ents 
with vein graft  disease, the cumulati ve survival 
rate in the DES group was 80.5% versus 77.5% in 
the BMS group (adjusted HR 1.09; 95% CI 0.63 – 
1.90) along with a higher event free survival of 
clinically driven target vessel revascularizati on 
in the DES group as compared to the BMS group 
(81.6% vs. 69.0%; adjusted HR 0.53; 95% CI 0.27 
– 1.05).
Disputi ng the safety concerns 
In September 2006, several proceedings from 
the European Society and world congress of 
Cardiology tempered the success of DES (Chapter 
16). As compared to BMS, DES would be associated 
with a higher rate of late stent thrombosis as 
compared to BMS. A concern that had already 
been acknowledged for several high-risk pati ent 
subsets (Chapter 8,9 and 10) was hypothesized 
to be also associated with a detrimental eff ect 
on the long-term hard clinical safety endpoints. 
By having followed a cohort of more than 4000 
pati ents treated with DES, we decided to test and 
strengthen our observati ons by pooling our data 
with the data collected by the University medical 
center of Bern Switzerland, at which a similar 
unrestricted use of DES was applied from the 
moment of the commercial introducti on of the 
SES in April 2002. Scruti nizing the 3-year follow-
up of over 8000 pati ents treated with either SES 
or PES demonstrated that stent thrombosis (>30 
days) occurred with an incidence of 0.6%/year 
(Chapter 17), a rate that had never been published 
before. Additi onally, we were the fi rst to report 
the cumulati ve incidence of angiographic stent 
thrombosis in an all-comer pati ent populati on up 
to 3 years, which appeared to be 2.9%. In Chapter 
18 we verifi ed these fi ndings by analyzing the 
4-year data of this cohort and found that the 
incidence of stent thrombosis steadily accrued 
instead of decreasing aft er 3 years. In Chapter 
19 we assessed the impact of thrombus burden 
on the clinical outcome of 812 consecuti ve 
pati ents presenti ng with STEMI treated with 
DES. Intracoronary thrombus burden was 
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angiographically esti mated and categorized as 
large thrombus burden (LTB), defi ned as thrombus 
burden ≥2 vessel diameters, and small thrombus 
burden (STB) to predict clinical outcomes. At a 
mean follow-up of 18 months, we demonstrated 
that LTB was an independent predictor of mortality 
(hazard rati o [HR] 1.76, p= 0.023) and MACE (HR 
1.88, p<0.001). The cumulati ve angiographic 
infarct related artery stent thrombosis was 1.1% 
at 30 days and 3.2% at 2 years, and conti nued 
to augment beyond 2 years. It was signifi cantly 
higher in the LTB compared with the STB group 
(8.2% vs. 1.3% at 2 years, respecti vely, p<0.001). 
Signifi cant independent predictors for infarct 
related artery stent thrombosis were LTB (HR 
8.73, p<0.001), stent thrombosis at presentati on 
(HR 6.24, p<0.001), bifurcati on stenti ng (HR 4.06, 
p=0.002), age (HR 0.55, p=0.003), and rheolyti c 
thrombectomy (HR 0.11, p=0.03).
Following the worrying fi ndings presented at 
the European Society of Cardiology conference 
in Barcelona 2006, physicians were challenged 
by reports showing a detrimental eff ect on long-
term outcome in pati ents treated with DES. In 
brief, DES would increase the risk of death and 
myocardial infarcti on as compared to BMS. As 
a reacti on to these accusati ons, we pooled the 
individual pati ent level data from the pivotal 
randomized controlled Cypher and Taxus trials 
to specifi cally assess the long-term safety of 
DES. In Chapters 20 and 21 we demonstrate 
that, at least for on-label indicati ons, there are 
no signifi cant diff erences in the rates of death, 
myocardial infarcti on and stent thrombosis in 
DES as compared to BMS. However, the highly 
selected pati ents in these pivotal randomized 
trials consti tute only ~25% of the daily clinical 
practi ce. For this reason the board of directors 
of the Erasmus Medical Center requested a 
reassessment of the Thoraxcenter policy of an 
unrestricted DES use, and more specifi cally, 
that the extensive analysis of the RESEARCH 
and T-SEARCH registries be complemented by a 
retrospecti ve analysis of an equally sized cohort 
of pati ents treated with BMS. Therefore, the 
long-term survival of 3 sequenti al cohorts of all-
comers treated with either BMS, SES and PES in 
our center was analyzed by our cardiovascular 
epidemiological department. In this real world 
pati ent populati on, aft er 4 years, the overall 
use of DES was associated with similar all-cause 
mortality rates and a signifi cantly reduced risk for 
post-operati ve MI and TVR as compared to BMS 
(Chapter 22). 
As together with our data more reports were 
published on the long-term safety and effi  cacy 
of DES, the European Society of Cardiology got 
triggered and felt responsible for bringing out a 
European consensus on the use of DES in daily 
clinical practi ce. Chapter 23 contains the offi  cial 
meeti ng report of the ESC forum on DES. 
DES for multi vessel coronary artery 
disease
The superior anti restenoti c properti es of DES 
suddenly made PCI a more appealing opti on 
for pati ents with multi vessel coronary artery 
disease (MVD). While coronary artery bypass 
surgery (CABG) proved to be superior to PCI 
with BMS in avoiding repeat revascularizati ons, 
the introducti on of DES changed the effi  cacy 
equati on. At fi rst, we were able to demonstrate 
in a pati ent level based data meta-analysis that 
PCI with BMS resulted in similar rates of death, 
stroke and myocardial infarcti on as compared to 
CABG. An important conclusion that could thus 
far not be drawn based on the individual trials 
randomizing pati ents to either PCI with BMS 
or CABG (Chapter 25). Following the interest 
in the long-term safety and effi  cacy of DES as 
compared to CABG, we used the data from 
the Arterial Revascularizati on Therapies Study 
part II (ARTS-II) and showed that at 3 years, the 
use of SES was associated with a survival free 
of death/Cerebrovascular accident CVA/MI of 
91.7%, versus 89.1% (p=0.1) and 87.2% (p=0.007) 
in ARTS-I CABG and PCI cohorts, respecti vely. 
Freedom from revascularizati on in ARTS-II was 
85.5%, lower than in ARTS-I CABG (93.4%; 
p<0.001) but higher than in ARTS-I PCI (73.7%; 
p<0.001) cohorts.  In additi on we specifi cally 
studied the performance of overweight (BMI 
≥25 and ≤30kg/m2)and obese (BMI >30kg/m2) 
pati ents (Chapter 27) with MVD who make up 
the majority of the populati on in industrialized 
countries (in the United States, at least 64.5% 
is classifi ed as overweight, versus 40% in the 
Netherlands). The preferred method of coronary 
revascularizati on for these pati ents proved to be 
controversial. At fi rst, we demonstrated that BMI 
had no impact on the 1-year clinical outcome 
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in pati ents with multi vessel CAD treated with 
SES in ARTS II. Additi onally, as compared to the 
ARTS-I CABG cohort, SES treated pati ents from 
ARTS II when strati fi ed according to their BMI 
had equivalent 1-year MACCE rates. This is in 
contrast to the BMS treated overweight and 
obese pati ents from ARTS I who had a lower 
MACCE-free survival as compared to their 
surgically treated counterparts, mainly due to 
a higher need for repeat revascularizati on. In 
Chapter 28 we studied the effi  cacy of PCI with 
SES in diabeti cs with concomitant multi vessel 
coronary artery disease in which the opti mal 
method of revascularizati on remains in dispute. 
At 3 years, PCI using SES for pati ents with 
multi vessel coronary artery disease seems to be 
safer and more effi  cacious than PCI using BMS, 
irrespecti ve of the diabeti c status of the pati ent. 
PCI using SES appears to be a valuable alternati ve 
to CABG for both diabeti c and non-diabeti c 
pati ents. Of note, in the diabeti c cohort, the 
cumulati ve incidence of death/CVA/MI in ARTS-II 
was 9.2% lower than in the percutaneous arm of 
ARTS-I and 4.1% lower than in the ARTS-I CABG 
arm. Finally, we used the ARTS-II data to assess 
the short- and long-term health related quality 
of life and anginal status in pati ents treated for 
of multi vessel coronary artery disease in ARTS-II. 
At 3 years, both stenti ng and CABG resulted in 
a signifi cant improvement in HRQL and angina. 
HRQL aft er SES was signifi cantly improved as 
compared with BMS and was similar to CABG. 
Cost-eff ecti veness of DES 
In Chapter 31 we assessed the cost-eff ecti veness 
of DES based on the 2-year follow-up of the 
RESEARCH registry. The use of SES cost €3,036 
more per pati ent at the index procedure, driven 
by the price of SES. Follow-up costs aft er 1-year 
were €1,089 less with SES when compared with 
BMS, due to less TVR, resulti ng in a net excess 
cost of €1,968 per pati ent in the SES group, 
and reduced by a further €100 per pati ent in 
the second year. The ICER (calculated as the 
diff erence in costs devided by the diff erence in 
eff ecti veness) per TVR avoided was €29 373 at 1 
year, and €22,267 at 2 years.
Beyond the conventi onal riskfactors
Type-D is defi ned as the tendency to experience 
increased negati ve emoti ons paired with the 
non-expression of these emoti ons in social 
interacti ons. Type-D is an emerging risk 
factor in cardiovascular disease that has been 
associated with an increased risk of adverse 
prognosis. However, given that the use of DES 
has been associated with a signifi cant decrease 
in the risk of restenosis and the need for repeat 
revascularizati on and that exhausti on plays a role 
in the eti ology of restenosis post-PCI, it is not 
clear whether exhausti on remains a problem in 
the DES era. In Chapter 31 we demonstrated that 
Type-D personality was an independent predictor 
of exhausti on at 1 year. The impact of type-D on 
exhausti on was large compared with a small eff ect 
for gender and age. CVD research and clinical 
practi ce may benefi t by adopti ng a personality 
approach in order to identi fy high-risk pati ents. 
In additi on to these fi ndings we addressed the 
relati ve eff ects of fati gue, depressive symptoms 
and hopelessness on the 2-year outcome 
of pati ents treated with DES. Correcti ng for 
independent predictors, depressive symptoms 
appeared to have a negati ve eff ect on the 2-year 
outcome following PCI. Moreover, hopelessness 
was associated with a more than 3-fold higher risk 
for clinical events. Finally, we assessed the role of 
positi ve aff ect on clinical outcome aft er PCI with 
DES implantati on. The incidence of death⁄MI in 
adequate versus reduced positi ve aff ect pati ents 
was 4% vs. 11% (HR 2.55; 95% CI 1.46–4.34, P = 
0.001), adjusti ng for clinical variables. Reduced 
positi ve aff ect and diabetes were independent 
prognosti c factors, and pati ents with one (HR 
2.84, 95% CI 1.58–5.10) or both (HR 5.61, 95% 
CI 2.25–13.99) of these factors had a higher risk 
when compared with nondiabeti c pati ents with 
adequate positi ve aff ect, P < 0.003.
Conclusion
Probably the most important fi nding of this thesis 
was that both SES and PES were associated with 
a similar risk of death and myocardial infarcti on 
as compared to BMS up to 4 years, irrespecti ve 
of the baseline or procedural characteristi cs of 
the pati ent. This laƩ er fi nding remained valid 
despite the higher risk for late stent thrombosis 
following SES and PES implantati on. A second 
important observati on was that when looking at 
the long-term effi  cacy of both DES, baseline and 
procedural pati ent characteristi cs did seem to be 
of parti cular importance. We demonstrated that 
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in several high risk pati ent subsets, there was no 
more than a persistent trend towards lower repeat 
revascularizati on rates. However, if the price of 
DES would lower, liƩ le to no contraindicati ons 
would remain to restrict their use. Finally, given 
their emerging role in predicti ng adverse events, 
psychological risk factors will become of parti cular 
interest in future studies.  
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Samenvatti  ng en conclusies
Initi ële gerandomiseerde studies en registrati es 
toonden dat zowel sirolimus-eluti ng stents (SES) 
als paclitaxel-eluti ng stents (PES) superieur 
waren ten opzichte van niet gecoate bare-metal 
stents (BMS) 1 jaar na stent implantati e in strict 
geselecteerde pati ënten. Dit proefschrift  heeft 
als doel inzicht te verschaff en in de lange termijn 
resultaten alsmede de valkuilen te belichten van 
het ongelimiteerde gebruik van drug-eluti ng 
stents (DES). 
Een studiegroep zonder exclusie 
criteria
Het Thoraxcentrum was een van de eerste 
centra wereldwijd dat vanaf het moment van de 
commercialisering van de Cypher stent in April 
2002 een ongelimiteerd drug-eluti ng stent beleid 
voerde. Door de follow-up van de RESEARCH en 
T-SEARCH registrati es (in welke zowel SES als PES 
ongelimiteerd gebruikt werden) uit te breiden, 
waren wij een van de eerste die konden aantonen 
dat het gebruik van SES tot signifi cant  betere 
resultaten leidde in vergelijking tot BMS na 2, 3, en 
4 jaar follow-up (Hoofdstuk 5 en 6). Het gebruikt 
van SES resulteerde in een vermindering van de 
incidenti e van het gecombineerde eindpunt dood, 
myocard infarct en herinterventi e van het initi eel 
behandelde bloedvat (MACE), van respecti evelijk 
27% en 43% op 3 en 4 jaar in vergelijking tot BMS. 
Deze signifi cante reducti e was met name het 
gevolg van de signifi cant lagere revascularizati es 
van het ti jdens de index procedure behandelde 
bloedvat, zonder verschillen in de incidenti e van 
dood of myocard infarct. Aanvullend vonden 
wij geen verschillen in de relati eve veiligheid 
en eff ecti viteit van SES in vergelijking tot PES 
(Hoofdstuk 4).
De veiligheid en eff ecti viteit van drug-
eluti ng stents in specifi eke pati ënten 
en laesies
Door alle pati ënten die tussen 2000 en 2005 
in ons centrum behandeld waren te volgen 
waren we in staat om de prestati es van DES in 
specifi eke pati ënten en laesies te bestuderen. 
Nierinsuffi  ciënti e staat reeds lang bekend als 
een factor die de lange termijn resultaten 
van PTCA negati ef kan beïnvloeden. Om deze 
reden analyseerden wij de uitkomsten van 10 
dialysepati ënten behandeld met DES. Een jaar 
na follow-up waren allen nog in leven, en waren 
er geen myocard infarcten danwel nieuwe 
revascularizati es gerapporteerd (Hoofdstuk 7). 
In Hoofdstuk 8 keken we naar de eff ecti viteit 
van DES in pati ënten die zich presenteerde met 
een acuut myocard infarct, een subgroep van 
pati ënten die slechts in zeer beperkte mate 
door gerandomiseerde studies was bestudeerd. 
Ondanks dat het gebruik van SES tot een 
signifi cant lager aantal revascularizati es leidde op 
1-jaar na implantati e, lieten wij zien dat na 3 jaar, 
zowel SES als PES niet in staat waren het aantal 
cardiale events (inclusief revascularizati es) te 
verminderen in vergelijking tot BMS in pati ënten 
die zich presenteerden met een acuut myocard 
infarct. Bovendien lieten we zien dat PES-gebruik 
in deze populati e niet tot signifi cant betere 
resultaten leidde in vergelijking tot BMS op zowel 
1, 2 als 3 jaar. Hoofdstuk 8 laat zien dat dit gebrek 
aan superioriteit gedeeltelijk verklaard kan 
worden door de verhoogde incidenti e van late 
stent trombose in beide DES groepen. Vervolgens 
werd de alsmaar groter wordende groep van 
diabeten bestudeerd. Met een versnelde en 
agressievere atherosclerose progressie en als 
gevolg meer restenose in vergelijking tot niet-
diabeten, is diabetes onlosmakelijk verbonden 
met een kleine coronaire diameter, langere 
laesies, een grotere plaque belasti ng en een 
restenose cascade die mogelijk anders werkt 
dan bij niet-diabeten. Gezien hun superieure 
anti -restenoti sche eigenschappen werden DES 
als snel geacht bij uitstek geschikt te zijn in deze 
hoog-risico pati ënten. In Hoofdstuk 9 lieten 
wij zien dat na 2 jaar, in 708 opeenvolgende 
pati ënten met diabetes er een trend was naar 
een betere uitkomst in de met PES behandelde 
groep in vergelijking tot de BMS groep. Verder 
werd er geen verschil gevonden tussen de 
relati eve eff ecti viteit van SES en PES in elk van de 
individuele eindpunten (dood, myocard infarct, 
revascularizati e van het initi eel behandelde vat), 
alsmede in niet insuline aĬ ankelijke diabeten die 
geacht werden een betere prognose te hebben 
wanneer ze behandeld werden met PES. Na 
propensity analyse vonden we dat geen van de 
verschillen in elk van de klinische eindpunten 
na SES of PES in vergelijking tot BMS stati sti sch 
signifi cant bleken te zijn. We maakten de 
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hypothese dat ook hier een deel van deze niet 
superioriteit verklaard kon worden door de 
hogere incidenti e van stent trombose in beide 
DES groepen (4.4% in de SES groep versus 2.4% 
in de PES groep) in vergelijking tot de BMS groep 
(0.8%). Wanneer we deze pati ënten nog een 
jaar langer volgden (Hoofdstuk 10) bleek dat de 
trend tot een betere uitkomst met PES stati sti sch 
signifi cant werd, terwijl SES niet signifi cant beter 
was dan BMS. Na multi variate analyse waren 
de risicos voor revascularizati e van het initi eel 
behandelde bloedvat (TVR) en het gecombineerde 
eindpunt van dood, infarct en revascularisati e 
(MACE) in pati ënten behandeld met PES lager 
dan na BMS (Hazard rati o [HR] 0.50 [95%CI: 0.33-
0.75] voor TVR, HR 0.65 [95%CI: 0.48-0.87] voor 
MACE). De risicos in pati ënten behandeld met 
SES waren vergelijkbaar met (HR 0.75 [95%CI: 
0.46-1.24] voor TVR, HR 0.77 [95%CI: 0.52-1.13] 
voor MACE).
Vervolgens richƩ en wij ons meer specifi ek op de 
prestati es van DES in specifi eke laesies. Als een van 
de eerste bekeken wij de lange termijn veiligheid 
en eff ecti viteit van DES in bifurcati e laesies. Het 
gebruik van SES bleek veilig en eff ecti ef ondanks 
deze klinische uitdagende seƫ  ng waarin zowel 
de Crush als de CuloƩ e techniek gebruikt werden 
(Hoofdstuk 11). Met het groeiende enthousiasme 
in de superioriteit van DES groeiden ondanks het 
gebrek aan lange termijn resultaten, het aantal 
klinische indicati es . Interventi e cardiologen 
gingen kleinere en langere laesies stenten en 
gebruikten meer en meer stents. In Hoofdstuk 12 
bekeken we de relati eve eff ecti viteit van SES en 
PES in vaten met een diameter van ≤2.25mm, een 
klinische seƫ  ng welke zeker zou geleid hebben 
tot exclusie in gerandomiseerde studies. Na 2 
jaar, was de cumulati eve incidenti e van MACE in 
de SES groep signifi cant lager dan in de PES groep 
(10.3% vs. 23.3%, p=0.02). Vervolgens keken we 
naar de eff ecti viteit van DES in chronisch totale 
occlusies, een klinische seƫ  ng die tot dusver 
vaak leidde tot een chirurgische interventi e. 
In Hoofdstuk 13 toonden we dat na 2 jaar, SES 
even veilig waren als BMS. Het verschil in TVR 
bleek echter niet meer te zijn 3.5% (12.7% in de 
BMS groep vs. 9.2% in de SES groep). Ondanks 
het beperkt aantal studiepati ënten (147), 
concludeerden we dat het gebruik van SES en 
pati ënten met chronisch total occlusies niet tot 
signifi cant betere resultaten leidde van BMS na 3 
jaar van follow-up.
De percutane behandeling van stenoses in aorta-
osti ale laesies is een technisch ingewikkelde 
procedure en wordt gekenmerkt door lagere 
procedurele succes percentages en een 
slechtere klinische en angiografi sche prognose in 
vergelijking tot laesies verder van het osti um. Tot 
dusver waren de gegevens over de eff ecti viteit 
van DES in deze laesies echter zeer beperkt. In 
Hoofdstuk 14 analyseerden we de 7-maanden 
angiografi sche en 2-jaar klinische uitkomsten 
van 76 opeenvolgende pati ënten behandeld met 
PES voor aorta-osti ale laesies. Na 7 maanden 
bleek de late lumen loss 0.48mm te zijn, wat 
resulteerde in een TVR incidenti e van 14.5% met 
een incidenti e van MACE van 31.6% na  2 jaar. We 
concludeerden dat ondanks dat het gebruik van 
PES zeer wel mogelijk was, PTCA van aorta-osti ale 
laesies problemati sch blijft  dankzij het lineair 
toenemende risico op MACE. 
Tot slot analyseerden we de 4-jaar resultaten van 
het gebruik van SES en PES in vergelijking tot BMS 
in veneuze bypass graft s waar recent ernsti ge 
waarschuwingen voor waren uitgesproken met 
betrekking tot hun veiligheid. In een cohort van 
250 post-bypass chirurgie pati ënten met stenoses 
in veneuze bypass graft s, was de cumulati eve 
overleving in de DES groep 80.5% in vergelijking 
tot 77.5% in de BMS groep (adjusted HR 1.09; 95% 
CI 0.63-1.90) in combinati e met een hogere TVR 
vrije overleving in de DES groep in vergelijking 
tot de BMS groep (81.6% vs. 69.0%, adjusted HR 
0.53; 95% CI 0.27 - 1.05).
De waarschuwingen omtrent 
veiligheid aan de tand gevoeld
In September 2006, werd het succes van DES 
bruusk de kop ingedrukt door een trio van 
presentati es op het congres van de European 
Society and World Congres of Cardiology 
(Hoofdstuk 16). In vergelijking tot BMS, zouden 
DES geassocieerd zijn met hogere incidenti e 
van late stent trombose in vergelijking tot BMS. 
Een zorg die reeds eerder geopperd was in 
hoog-risico pati ënten (Hoofdstuk 8, 9 en 10) 
bleek mogelijk te leiden tot hogere incidenti e 
van sterft e en myocard infarct. Doordat we 
een cohort van meer dan 4000 DES pati ënten 
hadden gevolgd, besloten we onze bevindingen 
te testen en te versterken door onze data te 
poolen met vergelijkbare data die was verzameld 
door het Universitair Medisch Centrum in 
Bern, Zwitserland alwaar een vergelijkbaar 
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ongelimiteerd DES beleid was gevoerd vanaf het 
moment van de commerciële introducti e van 
de SES in april 2002. We onderzochten in groot 
detail de 3-jaar follow-up van meer dan 8000 
pati ënten behandeld met SES en PES en vonden 
dat de incidenti e van late stent trombose (>30 
dagen na implantati e) 0.6% per jaar bedroeg 
(Hoofdstuk 17). Een incidenti e die nooit eerder 
gepubliceerd was. Bovendien waren we de eerste 
die rapporteerden dat 3 jaar na implantati e, de 
totale incidenti e van agiografi sch bewezen stent 
trombose in een all-comer pati ënten populati e 
2.9% bleek te zijn. In Hoofdstuk 18 verifi eerden 
we deze bevindingen door ook de 4-jaar follow-
up van dit cohort te bestuderen en vonden dat 
de incidenti e van stent trombose langzaam met 
dezelfde trend verder steeg in plaats van af te 
nemen na 3 jaar. In Hoofdstuk 19 keken we meer 
specifi ek naar de impact van trombus last op de 
klinische uitkomsten van 812 opeenvolgende 
pati ënten behandeld met DES in de seƫ  ng van 
een ST-elevati e myocard infarct. Intracoronaire 
trombus last was angiografi sch geschat en 
gecategoriseerd als grote trombus last (LTB) en 
was gedefi nieerd als een trombus last van ≥2x 
de coronair diameter en kleine trombus last 
(STB) om klinische uitkomsten te voorspellen. Na 
18 maanden van follow-up toonden we aan dat 
LTB een onaĬ ankelijke voorspeller bleek te zijn 
van mortaliteit (HR 1.76, p=0.023) en MACE (HR 
1.88, p<0.001). De cumulati eve incidenti e van 
angiografi sche infarct arterie gerelateerde stent 
trombose was 1.1% na 30 dagen en 3.2% na 2 jaar, 
en liep nog verder op na 2 jaar. Deze incidenti e 
bleek signifi cant hoger in de LTB groep dan in de 
STB groep (respecti evelijk 8.2% vs. 1.3% na 2 jaar, 
p<0.001). Signifi cante onaĬ ankelijke voorspellers 
van infarct arterie gerelateerde stent trombose 
waren LTB (HR 8.73, p<0.001), presentati e met 
stent trombose (HR 6.24, p<0.001), bifurcati e 
stenten (HR 4.06, p=0.002), leeft ijd (HR 0.55, 
p=0.003) en rheolyti c trombectomie (HR 0.11, 
p=0.03). 
In navolging van de verontrustende bevindingen 
die werden gepresenteerd op het European 
Society of Cardiology congres in Barcelona 
2006 werden artsen geconfronteerd met tal van 
waarschuwingen omtrent veiligheid jaren na DES 
implantati e. Vergeleken met BMS zouden DES 
het risico op dood en myocard infarct vergroten. 
Als reacti e hierop besloten we de individuele 
pati ënten data uit de initi ële gerandomiseerde 
Cypher en TAXUS studies te poolen om specifi ek 
te kijken naar de lange-termijn veiligheid van 
DES. In Hoofdstuk 20 en 21 toonden we aan 
dat, ten minste voor on-label indicati es, er 
geen verschillen was in de incidenti e van dood, 
myocard infarct en stent trombose in pati ënten 
behandeld met DES in vergelijking tot BMS. Een 
kanƩ ekening moet gemaakt worden over het 
feit dat deze pati ënten slechts representati ef 
zijn voor zon 25% van de dagelijkse populati e in 
een modern cathlab. Om deze reden werden we 
door de raad van bestuur van het Erasmus MC 
dringen verzocht het ongelimiteerde DES beleid 
van het Thoraxcentrum opnieuw te beoordelen 
en meer specifi ek, de RESEARCH en T-SEARCH 
populati es te vergelijken met een retrospecti eve 
analyse van een qua grooƩ e vergelijkbaar 
cohort van BMS pati ënten. Stati sti sche analyses 
werden uitgevoerd door de afdeling klinische 
epidemiologie van het Thoraxcentrum. Vier jaar 
na implantati e bleek het ongelimiteerd gebruik 
van DES niet te leidden tot een verhoogd risico op 
sterft e maar wel te resulteren in een signifi cant 
lager risico op post-operati ef myocard infarct en 
TVR in vergelijking tot BMS (Hoofdstuk 22). 
In dezelfde ti jd werden meerdere vergelijkbare 
studies gedaan en gepubliceerd en de European 
Society of Cardiologie voelden zich geroepen een 
Europees consensus paper uit te brengen over 
het gebruik van DES in de dagelijkse klinische 
prakti jk. Hoofdstuk 23 bevat het offi  ciële meeti ng 
rapport van het ESC forum over DES. 
DES voor meervatslijden
Door de signifi cant lagere behoeft e aan nieuwe 
revascularizati es werd PTCA plots een interessante 
opti e voor pati ënten met meervatslijden. Ondanks 
dat coronaire bypass chirurgie (CABG) bewezen 
had eff ecti ever te zijn dan PTCA met BMS gebruik 
veranderde DES deze eff ecti viteitverhouding. Om 
te beginnen toonden we in een meta-analyse 
aan dat PTCA met BMS resulteerde in dezelfde 
incidenti e van dood, beroertes en myocard 
infarct in vergelijking tot CABG. Een belangrijke 
bevinding die tot dusver niet met zekerheid 
gesteld kon worden gezien de beperkte stati sche 
power van de individuele gerandomiseerde 
PTCA (met BMS) vs. CABG studies (Hoofdstuk 
25). In navolging aan de interesse in de lange 
termijn veiligheid van DES in vergelijking tot 
CABG gebruikten we de data van de Arterial 
Revascularizati on Therapies Study part II (ARTS-II) 
studie en toonden aan dat na 3 jaar, het gebruik 
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van SES geassocieerd was met een overleving 
vrij van dood, beroerte of myocard infarct van 
91.7%, versus 89.1 (p=0.1) en 87.2% (p=0.007) in 
respecti evelijk de ARTS-I CABG en PTCA cohorten. 
Overleving vrij van nieuwe revascularizati e in 
ARTS-II was 85.5%, welke lager bleek dan in 
ARTS-I CABG (93.4%; p<0.001) maar hoger dan 
in het ARTS-I PTCA cohort (73.7%; o<0.001). 
Bovendien bestudeerden we meer specifi ek de 
uitkomsten van pati ënten met overgewicht (BMI 
≥25 and ≤30kg/m2) en obesitas (BMI >30kg/
m2) die in de geïndustrialiseerde landen de 
meerderheid van de populati e bedragen (in de VS 
lijdt >64.5% aan overgewicht versus 40% in NL). 
De opti male revascularizati e methode voor deze 
pati ënten blijft  echter controversieel. We vonden 
dat BMI geen impact had op de 1-jaar klinische 
prognose in pati ënten behandeld met SES voor 
meervatslijden in ARTS-II. In vergelijking tot het 
ARTS-I CABG cohort waren er geen signifi cante 
verschillen in pati ënten behandeld met SES 
in ARTS-II gestrati fi ceerd naar hun BMI in de 
incidenti e van het gecombineerde eindpunt dood, 
infarct, beroerte en revascularizati e. Dit laatste 
gold niet voor pati ënten met overgewicht en 
obesitas die behandeld waren met BMS in ARTS-I. 
Deze pati ënten hadden een signifi cant hogere 
incidenti e van het gecombineerde eindpunt 
in vergelijking tot de ARTS-I CABG pati ënten, 
met name door het signifi cant hoger aantal 
revascularizati es. In Hoofdstuk 28 bestudeerden 
we de eff ecti viteit van PTCA met SES in diabeten 
met meervatslijden, een cohort van pati ënten 
waarin de opti male behandelingsmethode 
controversieel blijft . Drie jaar na stent implantati e 
bleek PTCA met DES veiliger en eff ecti ever in 
vergelijking tot PTCA met BMS, onaĬ ankelijk van 
het hebben van diabetes. Vervolgens bleek PTCA 
met SES een waardevol alternati ef voor CABG in 
zowel diabeten als niet diabeten. De cumulati eve 
incidenti e van dood, beroerte of myocard infarct 
in ARTS-II was 9.2% lager dan in de percutane 
arm van ARTS-I en 4.1% lager dan in de ARTS-I 
CABG arm. Tot slot gebruikten we de ARTS-II 
data om de korte- en lange-termijn gezondheid 
gerelateerde kwaliteit van leven en angina status 
te onderzoeken in pati ënten met meervatslijden. 
Na 3 jaar bleken zowel PTCA als CABG tot een 
signifi cante verbeteringen te leiden in kwaliteit 
van leven en angina pectoris klachten. Kwaliteit 
van leven na SES bleek signifi cant beter dan na 
BMS en vergelijkbaar met CABG. 
De kosteneff ecti viteit van DES 
In Hoofdstuk 33 beoordeelden we de 
kosteneff ecti viteit van DES gebaseerd op de 
2-jaar follow-up van de RESEARCH registrati e. 
Het gebruik van SES was €3036,- duurder dan 
het gebruik van BMS ti jdens de indexprocedure, 
bepaald door de hogere prijs van SES. Follow-
up kosten 1 jaar na implantati e waren €1089,- 
minder in de SES groep dan in de BMS groep 
door de lagere incidenti e van herinterventi e, 
wat resulteerde in een neƩ o kosten overschot 
van €1968,- per pati ënt in de SES groep. Deze 
kosten verminderde met €100,- in het tweede 
jaar. We berekenden dat de ICER (uitgedrukt in 
het verschil in kosten gedeeld door het verschil in 
eff ecti viteit) per te vermijden TVR €29373,- was 
na 1 jaar, en €22267,- euro na 2 jaar. 
De conventi onele risicofactoren voorbij
Type-D persoonlijkheid is gedefi nieerd als de 
neiging tot het overmati g ervaren van negati eve 
emoti es tezamen met het niet in staat zijn deze 
emoti es tot expressie te brengen ti jdens sociale 
contacten. Type-D is een opkomende risicofactor 
in cardiovasculaire ziekte waarvan is aangetoond 
te leiden tot een slechtere prognose. Gezien het 
gebruik van DES leidt tot een signifi cante reducti e 
van restenose en de noodzaak tot herinterventi e, 
tezamen met het feit dat uitpuƫ  ng een rol 
speelt in de eti ologie van restenose na PTCA, 
blijft  het onduidelijk of uitpuƫ  ng een probleem 
blijft  in de DES periode. In Hoofdstuk 31 tonen 
we aan dat een Type-D persoonlijkheid een 
onaĬ ankelijk voorspeller is van uitpuƫ  ng 1 
jaar na stent implantati e. De impact van Type-D 
op uitpuƫ  ng bleek groot in vergelijking tot de 
relati ef kleine impact van leeft ijd en geslacht. 
Cardiovasculair onderzoek alsmede de klinische 
prakti jk zouden kunnen profi teren van een 
psychologische benadering om pati ënten met 
een slechtere prognose te identi fi ceren. Bovenop 
deze bevindingen keken we naar de relati eve 
eff ecten van uitpuƫ  ng, depressieve symptomen 
en hulpeloosheid 2 jaar na DES implantati e. 
Wanneer we corrigeerden voor onaĬ ankelijke 
voorspellers, bleken depressieve symptomen een 
negati ef eff ect te hebben op de 2-jaar uitkomsten 
na PTCA. Hulpeloosheid bleek te leiden tot een 
3x verhoogd risico op klinische events. Tot slot 
bestudeerden we de rol van verminderd positi ef 
aff ect op de klinische uitkomsten na PTCA met 
DES gebruik. De incidenti e van dood en myocard 
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infarct in pati ënten met een adequaat versus een 
verminderd positi ef aff ect waren respecti evelijk 
4% en 11% (HR 2.55;  95% CI 1.46-4.34, P = 
0.001), gecorrigeerd voor klinische variabelen. 
Verminderd positi ef aff ect en diabetes waren 
onaĬ ankelijke prognosti sche factoren en 
pati ënten met 1 (HR = 2.84, 95% CI 1.58-
5.10) of beide (HR = 5.61, 95% CI 2.25-13.99) 
risico factoren hadden een verhoogd risico in 
vergelijking tot niet diabeti sch pati ënten met een 
adequaat positi ef aff ect (p<0.003).
Conclusie
Misschien wel de belangrijkste bevinding van dit 
proefschrift  is dat zowel SES als PES geassocieerd 
zijn met een vergelijkbaar risico op dood en infarct 
in vergelijking tot BMS tot 4 jaar na implantati e, 
onaĬ ankelijk van de klinische of procedurele 
pati ënten karakteristi eken. Deze bevinding bleef 
geldig ondanks het verhoogd risico op late stent 
trombose na zowel SES als PES implantati e. Een 
tweede belangrijke bevinding was dat als we 
keken naar de lange termijn eff ecti viteit van 
beide DES, klinische en procedurele pati ënten 
karakteristi eken wel degelijk van invloed 
bleken. We toonden aan dat in multi pele hoog 
risico cohorten, enkel een persisterende trend 
werd gezien richti ng een lagere herinterventi e 
incidenti e. DesalnieƩ emin, als de prijs van de 
DES zou zakken, zouden er weinig tot geen 
contra-indicati es zijn welke hun gebruik zouden 
limiteren. Tot slot, gegeven hun opkomende 
prognosti sche waarde, zullen psychologische 
risicofactoren meer een meer een rol gaan spelen 
in toekomsti ge studies. 
Samenvaƫ  ng en conclusies
372
It must have been somewhere at the end of 2002 
when I started looking for a research topic to fi nal-
ize my doctoral exam in medicine. Thinking about 
the future and my personal interests I decided to 
contact the head of the surgical cardiothoracic 
department. Having seen several presentati ons 
on minimal invasive cardiothoracic surgery I ap-
plied for a research positi on on the topic. Merely 
one week later, my request was turned down. 
Although they were interested in my request, 
there was nobody who had the ti me to supervise 
me. I had to say, I was disappointed. Neverthe-
less, a few days later I told a fellow student about 
what happened. Without arguing he directed me 
to “somebody on the fourth fl oor who was quit 
successful in doing something with new metal 
tubes called stents”. Being a complete lay in the 
fi eld of interventi onal cardiology I started looking 
for some background informati on. Soon I found 
out, the person upstairs was called prof. Patrick 
Serruys who just started a novel project on the 
use of sirolimus-eluti ng stents. Having caught my 
aƩ enti on I decided to send a leƩ er. A couple of 
weeks later I was invited for an interview. Tues-
day January 2003, 4pm. Nicely on ti me I knocked 
the door on the fourth fl oor where a secretary 
told me he was sti ll in “the lab”. Aft er having been 
waiti ng for more than an hour I decided to ask a 
guy in the room next to the lab whether he could 
tell me where prof. Serruys was and whether 
there was a chance I was going to meet him. The 
guy couldn’t help me but reassured me that pro-
fessor would show up soon. Another hour later a 
man stepped outside the lab, completely ignoring 
the young guy siƫ  ng on the chair in front of the 
door. Although I had no idea whether this man 
was prof. Serruys, I approached him and told him 
who I was. I was lucky! He took me to his offi  ce 
where he told me he was ti red from a day in the 
lab and that he just came back from a trip to the 
US. The interview took no more than 2 minutes, 
however, I was welcome and a guy called Pedro 
(apparently the guy in the room next to the lab 
I spoke to a liƩ le bit earlier) would take care of 
me. From that moment on things changed. I had 
just entered the rollercoaster called “Thoraxcen-
ter”.  Although I was sti ll a 4th year med-school 
student, from July unti l November 2003 I learned 
incredibly lot on many things going on in the 
Thoraxcenter. Being embraced by the ongoing 
RESEARCH study project I left  the Thoraxcenter in 
November 2003 for two years to do my rotati ons 
with already a few small publicati ons. From that 
moment on I was sure about my future plans. It 
had to be cardiology with a parti cular interest in 
the fi eld of interventi onal cardiology. No more 
than 1 year later I applied for an offi  cial PhD posi-
ti on in the group of prof. Serruys. However, this 
would have never happened without the super-
vision of Pedro Lemos, a fellow from Brazil who 
appeared to be one of the most intelligent and 
friendly people I have ever met. Pedro, I’m sti ll 
convinced that I would have never come this far 
without the enormous amount of ti me you in-
vested to help me, teach me, and involve me in 
many projects going on during the ti me I spent 
in the Thoraxcenter as a student. It’s a true hon-
our to have you in my PhD commiƩ ee! The sec-
ond person I have to thank in parti cular at this 
moment is Ron van Domburg, my co-promoter. 
Ron, your enthusiasm and help in working with 
the databases, your lessons in stati sti cs, data col-
lecti on and management, clinical follow-up and 
writi ng were of excepti onal value. I will never for-
get the many moments we spent together from 
the fi rst day as a student in July 2003. Complet-
ing the rest of my training in the Thoraxcenter, 
I look forward to conti nue working with you.
In November 2005 when I started my PhD project 
it had already been two and a half years since the 
fi rst drug-eluti ng stent was introduced. For this 
reason we decided to start focussing on the long-
term follow-up of the drug-eluti ng stent. When I 
started, the group of internati onal fellows I was 
used to work with had changed. Pedro had left  
the Thoraxcenter in 2003, and was followed-up by 
Andrew Ong, an Australian fellow, with Malaysian 
roots. To be honest, I was afraid when I started in 
November 2005 and was supposed to follow-up 
Andrew, who was fi nishing his thesis. Both An-
drew and Pedro had left  enormous footprints in 
the Thoraxcenter. Andrew, each ti me we meet 
again during internati onal conferences I need to 
think about the moments you thought me many 
ti ps and tricks to survive in the Thoraxcenter 
jungle. Thereby, your lessons in how to manage 
the database, contact journals and industry part-
ners, and most importantly, how to survive under 
the 24hour non-stop pressure of the department 
were unforgeƩ able. From the moment you left  I 
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tried to handle things without your conti nuous 
supervision. At the same ti me it was Ron who in-
troduced me to a variety of medical students who 
were all interested in helping us to complete the 
follow-up. What Ron discovered already way ear-
lier was that without them, we would have never 
come this far. Although many students came and 
left , I have to thank two people in parti cular. At 
fi rst Giulio Stefanini, an Italian student who ap-
peared when I just started. Giulio, I’m grateful for 
all your help and I will never forget the headache 
I had aft er having fi nished a full boƩ le of your 
homemade limoncello. Secondly, Piet Hein van 
Twisk, the tall guy. Piet Hein, your incredible en-
thusiasm and understanding for everything going 
on was unforgeƩ able. The many evenings and 
weekends we spent together on the 14th fl oor 
were defi nitely worth the eff ort. I’m confi dent 
you both will have a fantasti c future ahead of you. 
At this moment I also have to menti on all the 
many fellows from all over the world I worked 
with during the past years. Francesco Saia, Marco 
Valgimigli, Muzaff er Degertekin, Angela Hoye, 
Neville Kukreja, Yoshi Onuma, Keiichi Tsuchida, 
Shuzou Tanimoto, Jiro Aoki, Masato Otsuka, 
Steve Ramcharitar, Emanuel Meliga, Sophia Vai-
na, Hector Garcia-Garcia, Nieves Gonzalo. It 
was a great pleasure to work with each of you! 
I truly hope we can keep in contact in the future. 
The longer I worked in the Thoraxcenter I started 
recognizing the importance of the people in the 
lab. Not a single paper would have been pub-
lished without the marvelous acti viti es of the 
interventi onal cardiologists; Evelyn Regar, Erik 
Duckers, Robert Jan van Geuns, Georgios Sianos, 
Carlos van Mieghem, Marti n vd Ent, Prof. Wim vd 
Giessen, Prof. Pim de Feyter. In parti cular I have 
to name and thank Peter de Jaegere, an incredibly 
smart and friendly person. Peter, I have to be hon-
est. In the beginning when I asked you to review a 
manuscript, I could hardly recognize my work due 
to all the correcti ons you made. However, it was 
a great pleasure working with you and very soon 
I realized that your clear and concise way of writ-
ing impacted my skills in a positi ve way. Finally, 
Prof. Maarten Simoons, head of the department. 
Although we had liƩ le contact in the beginning 
of the PhD project, it was a great honor to ac-
cept your invitati on to parti cipate in the ESC DES 
Taskforce meeti ng in Nice 2007 and to work with 
you on the meeti ng report - a task which fi nally 
proved to be one of the most challenging ever.
Only several months aft er having started my PhD 
project I experienced that 36 hour working weeks 
belonged to the past. Weekly working hours 
quickly increased to up to 60 hours per week. At 
the same ti me I realized that the people I worked 
with became more than colleagues. At fi rst Bob 
Meijboom, who was doing a PhD at the cardio-
vascular imaging department. While not working 
together on a regular basis, we went to many 
conferences together. In parti cular the weeks in 
Barcelona 2006 and Florida early 2007 I will never 
forget. Although I could write a full acknowledge-
ment on our adventures, I believe it’s beƩ er for 
the both of us to keep this between you and me. 
Nevertheless, it’s a great pleasure to conti nue 
the cardiology training in parallel with you and 
it’s an honor to have you as a paranymf. A spe-
cial thanks as well to Gerrit-Anne, Marie-Angele, 
Marco, Dick, Tessa and the other people from 
Cardialysis. Thanks to the many meeti ngs in your 
offi  ce I started appreciati ng the many aspects of 
a core-lab which turned out to be of crucial im-
portance while raising the quality level of a study. 
When long-term safety and effi  cacy data of the 
drug-eluti ng stent became available, several ca-
veats emerged. As a consequence, single center 
experiences were no longer suffi  cient and our 
network of fellow researchers expanded bey-
ond the Dutch borders. A fantasti c collaborati on 
arose with Stephan Windecker, Peter Wenawe-
ser and Peter Jüni from the University Hospital 
Medical Center in Bern, Switzerland. Dear all, 
I enjoyed every minute we worked together on 
the Bern RoƩ erdam study! I truly hope we can 
conti nue our collaborati on in the future. Finally, 
Stephan, it’s a great honor to have you as a mem-
ber of the PhD commiƩ ee. A second collabora-
ti on I will never forget is with Christi an Spaulding 
from Cochin Hospital in Paris, France. Christi an, 
the memorable moments we spent together dis-
cussing with the editors form the New England 
Journal of Medicine and the meeti ng with John 
Jarcho were unforgeƩ able. It was only aft er these 
experiences that I started to recognize the true 
and excepti onally high level of such a Journal. Be-
sides that, it was a great pleasure working with 
you and many thanks for being a member of the 
PhD commiƩ ee. Another word of thanks goes to 
Susanne Pedersen, with whom I got in contact as 
early as 2004. Although I have to admit I was so-
mewhat skepti cal in accepti ng the psychological 
aspects in PCI studies, your persistent enthusi-
asm about the topic made that I got more and 
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more interested in these new risk factors in car-
diovascular disease. It was a great pleasure wor-
king with you in the many psychological studies 
we did. Finally, Paul Cummins. Paul, I learned to 
know you as probably the most colorful guy in 
the Thoraxcenter. Your humor and enthusiasm 
made my long working hours and evening acti vi-
ti es during internati onal conferences a lot more 
fun. Furthermore, it was a great pleasure to ac-
cept the invitati on to become an associate editor 
for Euro Interventi on, the journal that is sti ll gro-
wing thanks to all your work as a managing editor. 
At this moment, it´s ti me to thank the man who 
made it all happen, my boss, my promotor, my 
mentor, Prof.dr. Patrick W. Serruys. The enthusi-
asm with which you launched new projects and 
ideas on a daily basis and the millions of oppor-
tuniti es you off ered me are unforgeƩ able. The 
diffi  culti es I experienced in the beginning soon 
belonged to the past when I fi gured out Andrew 
and Pedro were right. The wide diversity of proj-
ects in which you involved your fellows were 
overwhelming and there was no way to manage 
or to stay involved in all of them. Instead, I had 
to learn to make choices and prioriti es. This re-
sulted in many phone calls during the day (please 
note, day means 24hours), evenings and week-
ends in your house. Arriving in the aƫ  c, aft er 
having been welcomed by you incredible wife, I 
have to think back on the many anecdotes you 
told me. More importantly, you taught me how 
to write, and whereas it took months to fi nalize 
my fi rst manuscripts, it was incredible to see that 
at the end, we wrote editorials in merely 2 eve-
nings. You gave me the opportunity to get in con-
tact with people from all over the world, rang-
ing from the editorial board of EuroInterventi on, 
the people from Cardialysis, Stephan Windecker, 
Christi an Spaulding, and even Eugene Braun-
wald (the legend). In a certain way I always felt 
proud to be one of your fellows whenever you 
received a new internati onal Award and the lon-
ger worked with you, the more I understood why. 
Given your habit of carefully selecti ng top clinical 
and research fellows from all over the world, rec-
ommended by key-opinion leaders in the fi eld, 
I’m sti ll curious to see what drove you to accept 
a 24 year student with a zero knowledge of car-
diology for a PhD positi on at the end of 2005?! 
I hope I didn’t disappoint you and regret that I 
will probably not be able to do my clinical train-
ing under your supervision. Instead I hope that 
we will keep in close contact in the years your 
sti ll in the Thoraxcenter. Thanks for everything!
Dan miscchien wel de belangrijkste mensen in 
mijn leven, mijn familie en vrienden. Mijn ou-
ders, papa en mama, en mijn zusje Francine, zon-
der jullie oneindige steun en liefde zou ik nooit 
zover zijn gekomen. Jullie leerden mij zaken in 
perspecti ef te plaatsen en te genieten van de vele 
mooie dingen van het leven die alleen nog maar 
mooier bleken nadat er hard gewerkt was. En dan 
Lisanne, alles verandere toen jij je in mijn leven 
nestelde. Ondanks dat mijn werkti jden er zeker in 
het begin niet langer op werden werkte ik in de 
resterende ti jd met nog meer plezier. Jouw on-
ophoudelijke vrolijkheid en enthousiasme gaven 
mijn leven meer kleur. Ik wil je nooit meer kwijt! 
Vervolgens mijn vrienden: Vincent, Ly, Sebasti -
aan, Guido, Emiel, BriƩ a, Jan Jaap, Oscar, Elisa, 
Hans, Annefl oor, Marc, Bart, John, Robert Jan 
en Anouk. Zonder jullie zou mijn leven er zeker 
weten anders uit hebben gezien. Ondanks dat 
de frequenti e van onze talrijke etentjes en stap-
avonden zeker is afgenomen dankzij onze hecti -
sche levens weet ik zeker dat we nog vele mooie 
jaren tegemoet gaan. In het bijzonder Henk-Jan, 
mijn paranymf. Bedant voor al je hulp om van 
14 november een onvergetelijke dag te maken! 
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